﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Ben-Arye, E
   Paller, CJ
   Lopez, AM
   White, S
   Pendleton, E
   Kienle, GS
   Samuels, N
   Abbawaajii, N
   Balneaves, LG
AF Ben-Arye, Eran
   Paller, Channing J.
   Lopez, Ana Maria
   White, Shelley
   Pendleton, Eva
   Kienle, Gunver S.
   Samuels, Noah
   Abbawaajii, Nuria
   Balneaves, Lynda G.
TI The Society for Integrative Oncology Practice Recommendations for online
   consultation and treatment during the COVID-19 pandemic
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Integrative oncology; Telemedicine; Practice guidelines; Supportive
   care; Doctor-patient communication
ID CLINICAL-PRACTICE GUIDELINES; CANCER-RELATED FATIGUE; BREAST-CANCER;
   CONTROLLED-TRIAL; ACUPUNCTURE; MINDFULNESS; INTERVENTIONS; THERAPIES;
   PROGRAM; PAIN
AB Objective The Society for Integrative Oncology (SIO) Online Task Force was created in response to the challenges facing continuity of integrative oncology care resulting from the COVID-19 pandemic. The Task Force set out to guide integrative oncology practitioners in providing effective and safe online consultations and treatments for quality-of-life-concerns and symptom management. Online treatments include manual, acupuncture, movement, mind-body, herbal, and expressive art therapies. Methods The SIO Online Practice Recommendations employed a four-phase consensus process: (1) literature review and discussion among an international panel of SIO members, identifying key elements essential in an integrative oncology visit; (2) development, testing, and refinement of a questionnaire defining challenges and strategies; (3) refinement input from integrative oncology experts from 19 countries; and (4) SIO Executive Committee review identifying the most high-priority challenges and strategies. Results The SIO Online Practice Recommendations address ten challenges, providing practical suggestions for online treatment/consultation. These include overcoming unfamiliarity, addressing resistance among patients and healthcare practitioners to online consultation/treatment, exploring ethical and medical-legal aspects, solving technological issues, preparing the online treatment setting, starting the online treatment session, maintaining effective communication, promoting specific treatment effects, involving the caregiver, concluding the session, and ensuring continuity of care. Conclusions The SIO Online Practice Recommendations are relevant for ensuring continuity of care beyond the present pandemic. They can be implemented for patients with limited accessibility to integrative oncology treatments due to geographic constraints, financial difficulties, physical disability, or an unsupportive caregiver. These recommendations require further study in practice settings.
C1 [Ben-Arye, Eran] Clalit Hlth Serv, Integrat Oncol Program, Lin Med Ctr, 35 Rothschild St, Haifa, Israel.
   [Ben-Arye, Eran] Clalit Hlth Serv, Integrat Oncol Program, Zebulon Med Ctr, 35 Rothschild St, Haifa, Israel.
   [Ben-Arye, Eran] Clalit Hlth Serv, Integrat Oncol Program, Carmel Med Ctr, 35 Rothschild St, Haifa, Israel.
   [Ben-Arye, Eran] Technion Israel Inst Technol, Fac Med, 35 Rothschild St, Haifa, Israel.
   [Paller, Channing J.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   [Lopez, Ana Maria] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA.
   [White, Shelley] Univ Utah, Huntsman Canc Inst, Wellness & Integrat Hlth Ctr, Salt Lake City, UT USA.
   [Pendleton, Eva] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
   [Kienle, Gunver S.] Univ Freiburg, Fac Med, Inst Infect Prevent & Hosp Epidemiol, Ctr Complementary Med,Med Ctr, Freiburg, Germany.
   [Kienle, Gunver S.] Univ Witten Herdecke, Inst Appl Epistemol & Med Methodol, Freiburg, Germany.
   [Samuels, Noah] Shaarei Zedek Med Ctr, Ctr Integrat Complementary Med, Jerusalem, Israel.
   [Samuels, Noah] Tel Aviv Univ, Fac Med, Tel Aviv, Israel.
   [Abbawaajii, Nuria; Balneaves, Lynda G.] Univ Manitoba, Coll Nursing, Winnipeg, MB, Canada.
C3 Clalit Health Services; Clalit Health Services; Clalit Health Services;
   Carmel Medical Center; Technion Israel Institute of Technology;
   Rappaport Faculty of Medicine; Johns Hopkins University; Thomas
   Jefferson University; Utah System of Higher Education; University of
   Utah; Huntsman Cancer Institute; Memorial Sloan Kettering Cancer Center;
   University of Freiburg; Witten Herdecke University; Hebrew University of
   Jerusalem; Shaare Zedek Medical Center; Tel Aviv University; University
   of Manitoba
RP Ben-Arye, E (corresponding author), Clalit Hlth Serv, Integrat Oncol Program, Lin Med Ctr, 35 Rothschild St, Haifa, Israel.; Ben-Arye, E (corresponding author), Clalit Hlth Serv, Integrat Oncol Program, Zebulon Med Ctr, 35 Rothschild St, Haifa, Israel.; Ben-Arye, E (corresponding author), Clalit Hlth Serv, Integrat Oncol Program, Carmel Med Ctr, 35 Rothschild St, Haifa, Israel.; Ben-Arye, E (corresponding author), Technion Israel Inst Technol, Fac Med, 35 Rothschild St, Haifa, Israel.
EM eranben@netvision.net.il
RI Balneaves, Lynda/AAG-9383-2021; López, Ana/KII-1580-2024
OI Balneaves, Lynda/0000-0002-6535-2096; White,
   Shelley/0000-0003-2315-9498; 
CR Al-Shamsi HO, 2020, ONCOLOGIST, V25, pE936, DOI 10.1634/theoncologist.2020-0213
   American Society of Clinical Oncology, 2020, ASCO 2020 CANC OPINI
   [Anonymous], 2014, WHO handbook for guideline development, V2nd
   [Anonymous], 2018, Web Content Accessibility Guidelines 2.1 (WCAG 2.1)
   [Anonymous], 2018, License CC BY-NC-SA 3.0 IGO
   Archer S, 2020, PSYCHO-ONCOLOGY, V29, P1430, DOI 10.1002/pon.5486
   Ben-Arye E, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0511-1
   BENARYE E, 2021, SUPPORT CARE CANCER
   Brouwers MC, 2010, CAN MED ASSOC J, V182, pE839, DOI 10.1503/cmaj.090449
   Cassileth BR, 2007, CHEST, V132, p340S, DOI 10.1378/chest.07-1389
   Chung WW, 2018, COMPUT BIOL MED, V101, P146, DOI 10.1016/j.compbiomed.2018.08.014
   Floyd D, TELE HLTH ACCESSIBIL
   Freeman LW, 2015, PSYCHO-ONCOLOGY, V24, P910, DOI 10.1002/pon.3656
   Goode AD, 2015, J CANCER SURVIV, V9, P660, DOI 10.1007/s11764-015-0442-2
   Gorin SS, 2012, J CLIN ONCOL, V30, P539, DOI 10.1200/JCO.2011.37.0437
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Grégoire C, 2020, PSYCHO-ONCOLOGY, V29, P1165, DOI 10.1002/pon.5395
   Huberty J, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2530-8
   Hwang NK, 2020, HEALTHCARE-BASEL, V8, DOI 10.3390/healthcare8040355
   Kelleher SA, 2019, PSYCHO-ONCOLOGY, V28, P1671, DOI 10.1002/pon.5141
   Kubo A, 2019, INTEGR CANCER THER, V18, DOI 10.1177/1534735419850634
   Kutikov A, 2020, ANN INTERN MED, V172, P756, DOI 10.7326/M20-1133
   Lesi G, 2016, J CLIN ONCOL, V34, P1795, DOI 10.1200/JCO.2015.63.2893
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Mikolasek M, 2018, INT J BEHAV MED, V25, P1, DOI 10.1007/s12529-017-9679-7
   Molassiotis A, 2013, ANN ONCOL, V24, P1645, DOI 10.1093/annonc/mdt034
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Murphy MK., 1998, HEALTH TECHNOL ASSES, V2, P1
   Narayanan S, 2021, INTEGR CANCER THER, V20, DOI 10.1177/1534735421999101
   Newton RU, 2020, JCO ONCOL PRACT, V16, P656, DOI 10.1200/OP.20.00210
   Ng DWL, 2020, PSYCHO-ONCOLOGY, V29, P1380, DOI 10.1002/pon.5437
   Passaro A, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2019-000598
   Rithirangsriroj K, 2015, GYNECOL ONCOL, V136, P82, DOI 10.1016/j.ygyno.2014.10.025
   Russell L, 2019, SUPPORT CARE CANCER, V27, P2735, DOI 10.1007/s00520-018-4574-6
   Shankar A, 2020, Asian Pacific Journal of Cancer Prevention, V21, P569, DOI [10.31557/apjcp.2020.21.3.569, DOI 10.31557/APJCP.2020.21.3.569, 10.31557/APJCP.2020.21.3.569, DOI 10.1200/OP.20.00167]
   Sierpina V, 2006, EXPLORE-NY, V2, P368, DOI 10.1016/j.explore.2006.05.018
   Sutherland AE, 2020, BMJ SUPPORT PALLIAT, V10, P271, DOI 10.1136/bmjspcare-2020-002326
   WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1
   Witt Claudia M., 2017, Journal of the National Cancer Institute Monographs, P3, DOI [10.1093/jncimonographs/lgx012, 10.1093/jncimonographs/lgx012]
   World Health Organization, 2019, Licence: CC BY-NC-SA 3.0 IGO
   Zernicke KA, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-34
   Zick SM, 2018, JNCI CANCER SPECT, V2, DOI 10.1093/jncics/pky064
NR 42
TC 27
Z9 29
U1 1
U2 12
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD OCT
PY 2021
VL 29
IS 10
BP 6155
EP 6165
DI 10.1007/s00520-021-06205-w
EA APR 2021
PG 11
WC Oncology; Health Care Sciences & Services; Rehabilitation
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA UL1DT
UT WOS:000640131900003
PM 33852088
OA Green Submitted, hybrid
DA 2026-01-16
ER

PT J
AU Yuan, Y
   Li, P
AF Yuan, Yong
   Li, Ping
TI Effect of warm needle therapy guided by ultrasound on pain relief and
   improvement of physical function in patients with knee osteoarthritis
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Knee osteoarthritis (KOA); warm needle therapy; ultrasound guidance;
   meloxicam; pain relief; knee; function; patient satisfaction;
   inflammatory factor
ID ACUPUNCTURE
AB Background: Conventional treatments for knee osteoarthritis (KOA) often fall short in providing optimal outcomes. Objective: To evaluate the effect of warm needle therapy guided by ultrasound on pain relief and physical function in patients with KOA. Methods: In this retrospective study, the clinical records of patients with KOA undergoing either meloxicam alone or meloxicam combined with warm needle therapy were reviewed. Various parameters, including pain evaluations, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores, range of motion for knee flexion, knee society scores, quality of life scores, inflammatory factor levels, and patient satisfaction were comparatively analyzed. Results: A total of 140 patients were included, including 68 patients treated by Meloxicam and 72 patients treated by Meloxicam and warm needle therapy. Following treatment, the meloxicam combined with warm needle therapy group exhibited lower pain scores (3.62 +/- 1.98 vs. 4.38 +/- 1.95, P=0.023), improved WOMAC scores (27.82 +/- 8.75 vs. 31.25 +/- 8.82, P=0.022), increased range of motion (136.82 degrees +/- 8.58 degrees vs. 133.43 degrees +/- 8.86 degrees, P=0.023), higher knee society scores (93.32 +/- 7.21 vs. 90.21 +/- 7.78, P=0.016), and superior Short Form-36 Health Survey (SF-36) scores (81.24 +/- 6.33 vs. 78.43 +/- 6.85, P=0.013). Furthermore, a significant reduction in inflammatory factors including interleukin-8 (IL-8), matrix metalloproteinase-3 (MMP-3), Interleukin-1 beta (IL-1 beta), Tumor Necrosis Factor-alpha (TNF-alpha), and cyclooxygenase-2 (COX-2) levels was observed in the meloxicam combined with warm needle therapy group compared to the meloxicam alone group (all P<0.05). Patient satisfaction was likewise notably higher in the meloxicam combined with warm needle therapy group (8.43 +/- 2.15 vs. 7.58 +/- 2.24, P=0.024), with a greater proportion of patients willing to recommend the treatment (81.94% vs. 64.71%, P=0.034). Conclusion: Warm needle therapy guided by ultrasound, in combination with meloxicam, significantly improves pain relief, physical function, inflammatory modulation, and patient satisfaction in KOA patients.
C1 [Yuan, Yong] Henan Vocat Univ Sci & Technol, Med Coll, 6 East Sect Wenchang Ave, Zhoukou 466000, Henan, Peoples R China.
   [Li, Ping] Zhoukou City Sixth Peoples Hosp, Tradit Chinese Med Dept, Zhoukou 466000, Henan, Peoples R China.
RP Yuan, Y (corresponding author), Henan Vocat Univ Sci & Technol, Med Coll, 6 East Sect Wenchang Ave, Zhoukou 466000, Henan, Peoples R China.
EM yxy408@126.com
CR Allaeys C, 2020, ACTA ORTHOP BELG, V86, P412
   Benner RW, 2019, ORTHOP CLIN N AM, V50, P425, DOI 10.1016/j.ocl.2019.05.001
   Brophy RH, 2022, J AM ACAD ORTHOP SUR, V30, pE721, DOI 10.5435/JAAOS-D-21-01233
   Chen YD, 2024, PANMINERVA MED, DOI 10.23736/S0031-0808.24.05176-0
   Clark GP, 2023, JAAPA-J AM ACAD PHYS, V36, DOI 10.1097/01.JAA.0000979536.73946.98
   Giorgino R, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24076405
   Han R, 2024, MEDICINE, V103, DOI 10.1097/MD.0000000000038325
   Huang JF, 2021, GLOB SPINE J, V11, P1248, DOI 10.1177/2192568220962440
   Jang S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052619
   Jokar N, 2021, CLIN NUCL MED, V46, pE410, DOI 10.1097/RLU.0000000000003678
   Jun JH, 2023, FRONT MED-LAUSANNE, V10, DOI 10.3389/fmed.2023.971147
   Jun JH, 2022, PHYTOMEDICINE, V106, DOI 10.1016/j.phymed.2022.154388
   Kolasinski SL, 2020, ARTHRITIS RHEUMATOL, V72, P220, DOI [10.1002/art.41142, 10.1002/acr.24131]
   Lee IS, 2022, J ACUPUNCT MERIDIAN, V15, P157, DOI 10.51507/j.jams.2022.15.3.157
   Li J, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016301
   Liew JW, 2023, OSTEOARTHR CARTILAGE, V31, P1234, DOI 10.1016/j.joca.2023.04.015
   Liu W, 2021, J PAIN RES, V14, P2209, DOI 10.2147/JPR.S315956
   Lynning M, 2021, J ALTERN COMPLEM MED, V27, P832, DOI 10.1089/acm.2020.0510
   Ma XL, 2022, ORTHOP SURG, V14, P789, DOI 10.1111/os.13281
   Mavaddat N, 2019, AM J HUM GENET, V104, P21, DOI 10.1016/j.ajhg.2018.11.002
   Michelfelder AJ, 2022, FAM MED, V54, P240, DOI 10.22454/FamMed.2022.867513
   Mirahmadi A, 2023, J ORTHOP SURG RES, V18, DOI 10.1186/s13018-023-04347-7
   Mou JJ, 2024, EXPLORE-NY, V20, P562, DOI 10.1016/j.explore.2023.12.015
   Murakami E, 2023, J NEUROIMMUNOL, V382, DOI 10.1016/j.jneuroim.2023.578165
   Nakarmi S, 2019, INT J RHEUM DIS, V22, P1877, DOI 10.1111/1756-185X.13690
   Naunheim MR, 2020, LARYNGOSCOPE INVEST, V5, P90, DOI 10.1002/lio2.333
   Primorac D, 2020, GENES-BASEL, V11, DOI 10.3390/genes11080854
   Shah S, 2022, CURR PAIN HEADACHE R, V26, P453, DOI 10.1007/s11916-022-01048-4
   Shao G, 2022, AGING DIS, V13, P1030, DOI 10.14336/AD.2022.0115
   Sharma L, 2021, NEW ENGL J MED, V384, P51, DOI 10.1056/NEJMcp1903768
   Shimizu H, 2022, CLIN RHEUMATOL, V41, P2625, DOI 10.1007/s10067-022-06150-x
   Somaiya KJ, 2024, CUREUS J MED SCIENCE, V16, DOI 10.7759/cureus.56817
   Song GQ, 2019, INFLAMM BOWEL DIS, V25, P1129, DOI 10.1093/ibd/izy371
   Sun DP, 2023, ALTERN THER HEALTH M, V29, P271
   Sun Hui, 2021, Zhen Ci Yan Jiu, V46, P592, DOI [10.13702/j.1000-0607.200647, 10.13702/j.1000-0607.200647]
   Trinh K, 2022, MED ACUPUNCT, V34, P34, DOI 10.1089/acu.2021.0046
   Tsokanos A, 2021, MEDICINA-LITHUANIA, V57, DOI 10.3390/medicina57070696
   Tu JF, 2021, ARTHRITIS RHEUMATOL, V73, P448, DOI 10.1002/art.41584
   van Doormaal MCM, 2020, MUSCULOSKELET CARE, V18, P575, DOI 10.1002/msc.1492
   Wen JY, 2021, AM J CHINESE MED, V49, P1, DOI 10.1142/S0192415X21500014
   Werner DM, 2022, RHEUM DIS CLIN N AM, V48, P907, DOI 10.1016/j.rdc.2022.06.010
   Wu QM, 2023, MEDICINE, V102, DOI 10.1097/MD.0000000000033979
   Zhang D, 2022, COMPUT MATH METHOD M, V2022, DOI 10.1155/2022/5315619
   Zhao HM, 2025, EUR RADIOL, V35, P327, DOI 10.1007/s00330-024-10928-9
NR 44
TC 1
Z9 1
U1 0
U2 5
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2024
VL 16
IS 12
BP 7467
EP 7479
DI 10.62347/KFNE8547
PG 13
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA R1C3O
UT WOS:001388915000019
PM 39822505
OA Green Submitted, Bronze
DA 2026-01-16
ER

PT J
AU Pintas, S
   Zhang, AN
   James, KJ
   Lee, RM
   Shubov, A
AF Pintas, Stephanie
   Zhang, Annie
   James, Kevin J.
   Lee, Roger M.
   Shubov, Andrew
TI Effect of Inpatient Integrative Medicine Consultation on 30-Day
   Readmission Rates: A Retrospective Observational Study at a Major US
   Academic Hospital
SO JOURNAL OF INTEGRATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
DE acupuncture; cost effectiveness; East Asian Medicine; integrative
   medicine; pain management
ID LOW-BACK-PAIN; COST SAVINGS; ACUPUNCTURE; CARE; ONCOLOGY; EFFICACY;
   OPIOIDS; TRIALS
AB Objectives: The prevalence of inpatient integrative medicine (IM) consult services is increasing among academic health care institutions. The diversity of services between institutions, as well as the novel nature of such interventions, makes it challenging for health care administrators to determine the cost/benefit of adding such a program to their institution. The main purpose of this study was to examine the performance of the new University of California, Los Angeles (UCLA) East-West (EW) consult service as measured by 30-day readmission rates and lengths of stay.Design: This is a retrospective observational case-control study with participants matched to themselves.Setting: UCLA Santa Monica Hospital, a 281-bed academic tertiary care hospital near Los Angeles, California.Subjects: Patients who had received an EW consultation during the inaugural 20 months of the program (2018-2020), and who had been hospitalized in the prior 2 years from the date of their first EW consult.Intervention: Inpatient East-West consultation, which may include counseling, acupuncture and/or trigger point injections depending on medical necessity.Outcome Measures: Thirty-day readmission rates and lengths of hospital admission were compared between the hospitalization that included an EW consult (which included the use of acupuncture and/or trigger point injections when appropriate) and any prior admissions during the 2 years before that EW consult. Secondary outcomes included quantitative analysis of average number of treatments and qualitative assessment of integrative treatment(s) received, conditions treated, and reasons that EW treatment may have been deferred during a consult.Results: One hundred sixty-five unique patients met the study criteria. The EW consultation was associated with clinically relevant, statistically significant decreased 30-day readmission rates (33.0% vs. 4.6%, p < 0.001, odds ratio [OR] 0.10, 95% confidence interval [CI] 0.06-0.17). This effect was similar when limiting the analysis to pain-related admissions (32.3% vs. 3.4%, p < 0.001, OR = 0.07, 95% CI 0.03-0.16). Hospital admissions with EW consults were found to have a statistically significant increased length of stay (7.03 days vs. 5.40 days, p < 0.001).Conclusion: The EW medicine, an example of IM, correlates with a reduced risk of 30-day readmission and with modestly increased lengths of stay.
C1 [Pintas, Stephanie; Zhang, Annie; James, Kevin J.; Lee, Roger M.; Shubov, Andrew] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
   [Zhang, Annie; Lee, Roger M.; Shubov, Andrew] UCLA Santa Mon Hosp, Dept Med, Santa Monica, CA USA.
   [Zhang, Annie; Shubov, Andrew] UCLA Ctr East West Med, Dept Med, Los Angeles, CA USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA
RP Shubov, A (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Ctr East West Med, Dept Med, 200 Med Plaza,Suite 420, Los Angeles, CA 90095 USA.
EM ashubov@mednet.ucla.edu
OI Pintas, Stephanie/0000-0002-0230-8012
CR Alvarez DJ, 2002, AM FAM PHYSICIAN, V65, P653
   Ballantyne JC, 2008, CLIN J PAIN, V24, P469, DOI 10.1097/AJP.0b013e31816b2f26
   Barnett ML, 2017, NEW ENGL J MED, V376, P663, DOI 10.1056/NEJMsa1610524
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Brinkhaus B, 2006, ARCH INTERN MED, V166, P450
   Bron C, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-8
   Cheong KB, 2014, COMPLEMENT THER MED, V22, P767, DOI 10.1016/j.ctim.2014.05.002
   Chien Tsai-Ju, 2013, J Tradit Complement Med, V3, P234, DOI 10.4103/2225-4110.119733
   Chiu HY, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12457
   Crespin DJ, 2015, PAIN MED, V16, P1195, DOI 10.1111/pme.12685
   Dagenais S, 2008, SPINE J, V8, P8, DOI 10.1016/j.spinee.2007.10.005
   Dorsher PT, 2009, J PAIN, V10, P723, DOI 10.1016/j.jpain.2008.12.010
   Dueñas M, 2016, J PAIN RES, V9, P457, DOI 10.2147/JPR.S105892
   Dusek JA, 2018, J ALTERN COMPLEM MED, V24, P557, DOI 10.1089/acm.2017.0203
   Dusek Jeffery A, 2010, J Patient Saf, V6, P48, DOI 10.1097/PTS.0b013e3181d10ad5
   Estores IM, 2018, EXPLORE-NY, V14, P212, DOI 10.1016/j.explore.2018.02.002
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   GARVEY TA, 1989, SPINE, V14, P962, DOI 10.1097/00007632-198909000-00008
   Gomes T, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.0217
   Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892
   Herman Patricia M, 2013, Glob Adv Health Med, V2, P56, DOI 10.7453/gahmj.2013.002
   Herman PM, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001046
   Herzig SJ, 2014, J HOSP MED, V9, P73, DOI 10.1002/jhm.2102
   Johnson JR, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-486
   Johnson Jill R., 2014, Journal of the National Cancer Institute Monographs, P330, DOI 10.1093/jncimonographs/lgu030
   Kim SY, 2012, ACUPUNCT MED, V30, P273, DOI 10.1136/acupmed-2012-010178
   Kligler B, 2011, AM J MANAG CARE, V17, P779
   Lacy BE, 2018, J CLIN GASTROENTEROL, V52, P20, DOI 10.1097/MCG.0000000000000728
   Lee JH, 2013, CLIN J PAIN, V29, P172, DOI 10.1097/AJP.0b013e31824909f9
   Leibing E, 2002, PAIN, V96, P189, DOI 10.1016/S0304-3959(01)00444-4
   Madsen MV, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a3115
   Maizes V, 2009, EXPLORE-NY, V5, P277, DOI 10.1016/j.explore.2009.06.008
   Manheimer E, 2012, AM J GASTROENTEROL, V107, P835, DOI 10.1038/ajg.2012.66
   Nate KC, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/394040
   Osler W., 1892, PRINCIPLES PRACTICE, P282
   Ratcliffe J, 2006, BRIT MED J, V333, P626, DOI 10.1136/bmj.38932.806134.7C
   Reinecke H, 2015, BRIT J PHARMACOL, V172, P324, DOI 10.1111/bph.12634
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Wadhwa V, 2017, WORLD J GASTROENTERO, V23, P4428, DOI 10.3748/wjg.v23.i24.4428
   Wu MS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150367
   Yang MX, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-311
   Zhang AN, 2021, J ALTERN COMPLEM MED, V27, P803, DOI 10.1089/acm.2021.0087
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
NR 43
TC 2
Z9 2
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2768-3605
EI 2768-3613
J9 J INTEGR COMPLEMENT
JI J. Integr. Complement. Med.
PD MAR 1
PY 2022
VL 28
IS 3
BP 241
EP 249
DI 10.1089/jicm.2021.0155
EA JAN 2022
PG 9
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA 8M4QR
UT WOS:000839254200001
PM 35294299
DA 2026-01-16
ER

PT J
AU Romeiser, JL
   Chen, Z
   Nanavati, K
   Williams, AA
AF Romeiser, Jamie L.
   Chen, Zhi
   Nanavati, Kaushal
   Williams, Augusta A.
TI Correlates and patterns of using complementary health approaches among
   individuals with recent and longer-term cancer diagnoses: a US national
   cross-sectional study
SO JOURNAL OF CANCER SURVIVORSHIP
LA English
DT Article; Early Access
DE Complementary health approaches; Complementary and integrative health;
   Integrative medicine; Complementary therapies; Cancer; Survivorship;
   Prevalence; Mind and body therapies
ID ALTERNATIVE MEDICINE USE; SELF-CARE COMPLEMENTARY; QUALITY-OF-LIFE;
   INTEGRATIVE MEDICINE; CHRONIC PAIN; THERAPY USE; SURVIVORS; MANAGEMENT;
   EFFICACY
AB Purpose To (1) describe and compare the prevalence of using of complementary health approaches, focusing on mind and body practices, and reasons for use among cancer survivors, and (2) examine characteristics associated with use among those with a recent and non-recent diagnosis of cancer compared to those without a previous cancer diagnosis. Methods Using data from the 2022 US National Health Interview Survey, prevalence estimates were derived for using any complementary health approach, by category (manipulative body-based [chiropractor, acupuncture, massage], creative [music therapy, art therapy], and mind-body [meditation, guided imagery, yoga]), and reasons for use. Regression models identified correlates of use among all participants and within cancer diagnosis subgroups. Results Among 26,523 adult participants, overall prevalence of using any complementary approach was similar amongst individuals with recent cancer (40.17%), non-recent cancer (37.75%), and no cancer diagnosis (37.93%). However, odds of use were higher amongst recent (OR = 1.37) and relatively long term (OR = 1.14) cancer survivors compared to those without a history of cancer in adjusted models (both p < 0.05). In cancer survivors, mind-body approaches were mostly used for general health purposes, whereas manipulative approaches were used for general health and pain management. Female sex, younger age, higher education and income were among the prominent variables associated with using complementary approaches. Conclusion We present an important snapshot of the landscape of using complementary approaches, specifically mind and body practices, in adult cancer survivors in the US. Inequalities in access to these therapies may exist, as use remains highest amongst those with higher socioeconomic conditions.
C1 [Romeiser, Jamie L.; Chen, Zhi; Williams, Augusta A.] Upstate Med Univ, Dept Publ Hlth & Prevent Med, Syracuse, NY 13210 USA.
   [Nanavati, Kaushal] Upstate Med Univ, Upstate Canc Ctr, Syracuse, NY USA.
   [Nanavati, Kaushal] Upstate Med Univ, Dept Family Med, Syracuse, NY USA.
C3 State University of New York (SUNY) System; SUNY Upstate Medical
   University; State University of New York (SUNY) System; SUNY Upstate
   Medical University; State University of New York (SUNY) System; SUNY
   Upstate Medical University
RP Romeiser, JL (corresponding author), Upstate Med Univ, Dept Publ Hlth & Prevent Med, Syracuse, NY 13210 USA.
EM RomeiseJ@upstate.edu
RI Williams, Augusta/MGW-6935-2025; Romeiser, Jamie/HPH-9911-2023
OI Romeiser, Jamie/0000-0003-0281-8933; Chen, Zhi/0009-0002-4952-8239
CR [Anonymous], Cancer and complementary health approaches: What you need to know
   [Anonymous], 2021, Complementary, alternative, or integrative health: What's in a name?
   Archie P, 2013, SUPPORT CARE CANCER, V21, P2609, DOI 10.1007/s00520-013-1841-4
   Boyd C, 2016, PAIN MED, V17, P1553, DOI 10.1093/pm/pnw100
   Bradt J, 2021, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006911.pub4
   Campo RA, 2016, SUPPORT CARE CANCER, V24, P3783, DOI 10.1007/s00520-016-3200-8
   Clarke TC, 2018, J ALTERN COMPLEM MED, V24, P139, DOI 10.1089/acm.2016.0182
   Clarke Tainya C, 2015, Natl Health Stat Report, P1
   Crawford C, 2014, PAIN MED, V15, pS86, DOI 10.1111/pme.12407
   Delgado R, 2014, PAIN MED, V15, pS9, DOI 10.1111/pme.12412
   Dyer NL, 2022, J INTEGR COMPLEMENT, V28, P618, DOI 10.1089/jicm.2021.0413
   Harrington CB, 2010, INT J PSYCHIAT MED, V40, P163, DOI 10.2190/PM.40.2.c
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Huebner J, 2017, MED PRIN PRACT, V26, P41, DOI 10.1159/000450645
   John GM, 2016, J CANCER SURVIV, V10, P850, DOI 10.1007/s11764-016-0530-y
   Källman M, 2023, BMC COMPLEMENT MED, V23, DOI 10.1186/s12906-023-03876-2
   King N, 2015, INTEGR CANCER THER, V14, P515, DOI 10.1177/1534735415589984
   Kligler B, 2016, AM FAM PHYSICIAN, V94, P369
   Kristoffersen AE, 2021, BMC COMPLEMENT MED, V21, DOI 10.1186/s12906-021-03258-6
   Lapen K., 2023, JCO Oncol Pract, V19, P25, DOI [10.1200/OP.2023.19.11suppl.25, DOI 10.1200/OP.2023.19.11SUPPL.25]
   Lin PJ, 2023, J NATL COMPR CANC NE, V21, P153, DOI 10.6004/jnccn.2022.7080
   Lin WF, 2019, CANCER MANAG RES, V11, P6663, DOI 10.2147/CMAR.S195935
   Mao JJ, 2011, J CANCER SURVIV, V5, P8, DOI 10.1007/s11764-010-0153-7
   Boccolini PDM, 2022, BMC COMPLEMENT MED, V22, DOI 10.1186/s12906-022-03687-x
   Miller KD, 2022, CA-CANCER J CLIN, V72, P409, DOI 10.3322/caac.21731
   Nahin RL, 2024, JAMA-J AM MED ASSOC, V331, P613, DOI 10.1001/jama.2023.26775
   National Center for Complementary and Integrative Health, National health interview survey 2017 Internet. Natl Cent Complement Integr Health
   Ojukwu M, 2015, INTEGR CANCER THER, V14, P503, DOI 10.1177/1534735415589347
   Reid R, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1143-8
   Saper Robert, 2016, Glob Adv Health Med, V5, P5, DOI [10.7453/gahmj.2015.133, 10.7453/gahmj.2015.133]
   Schwartz Malaika R, 2021, Glob Adv Health Med, V10, p21649561211023377, DOI [10.1177/21649561211023377, 10.1177/21649561211023377]
   Shah AQ, 2023, BMC COMPLEMENT MED, V23, DOI 10.1186/s12906-023-04100-x
   Sohl SJ, 2015, CANCER-AM CANCER SOC, V121, P900, DOI 10.1002/cncr.29138
   Sohl SJ, 2014, SUPPORT CARE CANCER, V22, P927, DOI 10.1007/s00520-013-2040-z
   Wong CHL, 2021, SUPPORT CARE CANCER, V29, P271, DOI 10.1007/s00520-020-05494-x
   Yao CJ, 2021, EVID-BASED COMPL ALT, V2021, DOI 10.1155/2021/6678184
   Yun Hyeongjun, 2017, Journal of the National Cancer Institute Monographs, P29, DOI [10.1093/jncimonographs/lgx004, 10.1093/jncimonographs/lgx004]
   Zetzl T, 2021, SUPPORT CARE CANCER, V29, P2973, DOI 10.1007/s00520-020-05794-2
NR 38
TC 1
Z9 1
U1 1
U2 6
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1932-2259
EI 1932-2267
J9 J CANCER SURVIV
JI J. Cancer Surviv.-Res. Pract.
PD 2024 SEP 9
PY 2024
DI 10.1007/s11764-024-01665-5
EA SEP 2024
PG 10
WC Oncology; Social Sciences, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Oncology; Biomedical Social Sciences
GA F4B2A
UT WOS:001309280900001
PM 39249689
DA 2026-01-16
ER

PT J
AU Kennedy, L
   Gonzales, E
   Corbin, L
AF Kennedy, Laura
   Gonzales, Erin
   Corbin, Lisa
TI THE EFFECT OF CURANDERISMO ON CHRONIC NON-MALIGNANT PAIN: A CASE
   REPORT
SO EXPLORE-THE JOURNAL OF SCIENCE AND HEALING
LA English
DT Article
DE curanderismo; indigenous medicine; complementary medicine; chronic pain
ID LOW-BACK-PAIN; COMPLEMENTARY; ACUPUNCTURE; MASSAGE; THERAPY; FOLK
AB This case study describes the effects of the use of curanderismo, an indigenous healing modality combining techniques in massage, sound, and aromatherapy, on a patient with chronic pain. Despite being a commonly used health practice in certain populations, little is reported in the medical literature about the use of curanderismo. Case report as part of a larger randomized trial of curanderismo for chronic pain. Setting was a community-based hospital affiliated primary care clinic. An adult patient with chronic, opioid dependent back pain following an injury, and subsequent spinal fusion was treated. Intervention was the patient received 33 curanderismo treatment sessions over 10 months in addition to ongoing conventional treatment at a community-based chronic pain management clinic. Main outcomes measures were self-reported assessments of pain, functional ability, mood, insomnia, and narcotic usage. Secondary outcome measure was qualitative interview. Although there was no change in quantitative self-reported pain measures, the patient reported improved function, mood, and sleep as well as decreased narcotic usage. Curanderismo, in addition to conventional pain management, improved patient reported symptoms and functional ability, led to healthy lifestyle changes, and decreased narcotic usage. Controlled studies are needed to confirm the benefit of curanderismo as safe, non-interventional, and cost-effective adjunct for chronic pain management.
C1 [Kennedy, Laura; Gonzales, Erin] Univ Colorado, Sch Med, Anschutz Med Campus,Bldg 500-13001,E 17th Pl, Aurora, CO 80045 USA.
   [Corbin, Lisa] Univ Colorado Hosp, Ctr Integrat Med, 3055 Rosyln St,Suite 250, Denver, CO 80238 USA.
   [Corbin, Lisa] Univ Colorado, Dept Internal Med, Div Gen Internal Med, Sch Med,Acad Off 1, Anschutz Med Campus,8th Floor,Mailstop B180, Aurora, CO 80045 USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus; University of Colorado System; University of Colorado Hospital;
   University of Colorado System; University of Colorado Anschutz Medical
   Campus
RP Corbin, L (corresponding author), Univ Colorado Hosp, Ctr Integrat Med, 3055 Rosyln St,Suite 250, Denver, CO 80238 USA.; Corbin, L (corresponding author), Univ Colorado, Dept Internal Med, Div Gen Internal Med, Sch Med,Acad Off 1, Anschutz Med Campus,8th Floor,Mailstop B180, Aurora, CO 80045 USA.
EM lisa.corbin@ucdenver.edu
OI Corbin, Lisa/0000-0003-0363-8598
FU AlterMed Research Foundation
FX AlterMed Research Foundation provided a $2500 USD grant to offset the
   cost of conducting this study. The (under had no role in the
   preparation, review, or approval of the article.
CR [Anonymous], REL PAIN AM BLUEPR T
   APPLEWHITE SL, 1995, HEALTH SOC WORK, V20, P247, DOI 10.1093/hsw/20.4.247
   Cambron JA, 2007, J ALTERN COMPLEM MED, V13, P793, DOI 10.1089/acm.2006.6401
   Chavez-Hilton Sofia, 2015, COMMUNICATION
   Cherkin DC, 2001, ARCH INTERN MED, V161, P1081, DOI 10.1001/archinte.161.8.1081
   Chou R, 2015, ANN INTERN MED, V162, P276, DOI 10.7326/M14-2559
   Cohen M, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-241
   DeBellonia RR, 2008, PEDIATR EMERG CARE, V24, P228, DOI 10.1097/PEC.0b013e31816b7a92
   Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569
   Ferraresi M, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-129
   Gonzalez-Stuart A, 2008, USE HERBAL MED MEXIC, P130
   Gore M, 2012, SPINE, V37, pE668, DOI 10.1097/BRS.0b013e318241e5de
   Herman Carla J, 2006, Prev Chronic Dis, V3, pA80
   Hunt R, 2013, ANESTH ANALG, V117, P597, DOI 10.1213/ANE.0b013e31824a0b1c
   Luna Elaine, 2003, J Holist Nurs, V21, P326, DOI 10.1177/0898010103258574
   Manheimer E, 2005, ANN INTERN MED, V142, P651, DOI 10.7326/0003-4819-142-8-200504190-00014
   Martinez LN, 2009, HISPANIC J BEHAV SCI, V31, P128, DOI 10.1177/0739986308328513
   Ou MC, 2012, J OBSTET GYNAECOL RE, V38, P817, DOI 10.1111/j.1447-0756.2011.01802.x
   Padilla R, 2001, ARCH INTERN MED, V161, P1336, DOI 10.1001/archinte.161.10.1336
   Salazar CL, 2013, EXPLORE-NY, V9, P150, DOI 10.1016/j.explore.2013.02.003
   Sañudo B, 2012, J ALTERN COMPLEM MED, V18, P158, DOI 10.1089/acm.2010.0881
   Smith BW, 2008, EXPLORE-NY, V4, P359, DOI 10.1016/j.explore.2008.08.001
   Thomas K J., 2005, Health Technol Assess, P1, DOI DOI 10.3310/HTA9320
   Tiran D, 1996, Complement Ther Nurs Midwifery, V2, P88, DOI 10.1016/S1353-6117(96)80081-3
   Titus SKF, 2014, J HOLIST NURS, V32, P189, DOI 10.1177/0898010113512560
   Trotter Robert T, 2011, CURANDERISMO MEXICAN
   Turk DC, 2002, CLIN J PAIN, V18, P355, DOI 10.1097/00002508-200211000-00003
   Vega W A, 2001, J Immigr Health, V3, P133, DOI 10.1023/A:1011385004913
NR 28
TC 6
Z9 9
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1550-8307
EI 1878-7541
J9 EXPLORE-NY
JI Explore-J Sci. Heal.
PD JUL-AUG
PY 2016
VL 12
IS 4
BP 263
EP 267
DI 10.1016/j.explore.2016.04.006
PG 5
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA DQ1RC
UT WOS:000378977100015
PM 27198039
DA 2026-01-16
ER

PT J
AU Huang, HY
   Wang, BQ
   Chen, SJ
   Fang, JY
   Wang, XH
   Chen, LC
   Jiang, Y
   Zhang, HZ
   Chen, JC
   Lin, ZG
AF Huang, Hongye
   Wang, Bingqian
   Chen, Shuijin
   Fang, Jiayu
   Wang, Xiaohua
   Chen, Lechun
   Jiang, Yu
   Zhang, Huanzhen
   Chen, Jincheng
   Lin, Zhigang
TI Chinese Tuina remodels the synaptic structure in neuropathic pain rats
   by downregulating the expression of N-methyl D- aspartate receptor
   subtype 2B and postsynaptic density protein-95 in the spinal cord dorsal
   horn
SO JOURNAL OF TRADITIONAL CHINESE MEDICINE
LA English
DT Article
DE neuralgia; spinal cord dorsal horn; receptors; N-Methyl-D-aspartate;
   disks large homolog 4 protein; neuronal plasticity; Chinese Tuina
ID GLUTAMATE RELEASE; PLASTICITY; INJURY; NR2B; ELECTROACUPUNCTURE;
   INTERLEUKIN-1-BETA; HYPERSENSITIVITY; MECHANISMS; SENSATION; INCREASE
AB OBJECTIVE: To investigate whether the Chinese massage system, Tuina, exerts analgesic effects in a rat model of chronic constriction injury (CCI) by remodeling the synaptic structure in the spinal cord dorsal horn (SCDH). METHODS: Sixty-nine male Sprague-Dawley rats were randomly and evenly divided into the normal group, sham group, CCI group, CCI + Tuina group, CCI + MK-801 [an N-methyl D-aspartate receptor subtype 2B (NR2B) antagonist] group, and CCI + MK-801 + Tuina group. The neuropathic pain model was established using CCI with right sciatic nerve ligation. Tuina was administered 4 d after CCI surgery, using pressing manipulation for 10 min, once daily. Motor function was observed with the inclined plate test, and pain behaviors were observed by the Von Frey test and acetone spray test. At 19 d after surgery, the L3-L5 spinal cord segments were removed. Glutamate, interleukin 1 & beta; (IL-1 & beta;), and tumor necrosis factor-& alpha; (TNF-& alpha;) levels were detected by enzyme-linked immunosorbent assay. The protein expression levels of NR2B and postsynaptic density protein-95 (PSD-95) were detected by Western blot, and the synaptic structure was observed by transmission electron microscopy (TEM). RESULTS: CCI reduced motor function and caused mechanical and cold allodynia in rats, increased glutamate concentration and TNF-& alpha; and IL-1 & beta; levels, and increased expression of synapse-related proteins NR2B and PSD-95 in the SCDH. TEM revealed that the synaptic structure of SCDH neurons was altered. Most of these disease-induced changes were reversed by Tuina and intrathecal injection of MK-801 (P < 0.05 or < 0.01). For the majority of experiments, no significant differences were found between the CCI + MK-801 and CCI + MK 801 + Tuina groups. CONCLUSIONS: Chinese Tuina can alleviate pain by remodeling the synaptic structure, and NR2B and PSD95 receptors in the SCDH may be among its targets. & COPY; 2023 JTCM. All rights reserved.
C1 [Huang, Hongye; Fang, Jiayu; Wang, Xiaohua] Fujian Univ Tradit Chinese Med, Coll Rehabil Med, Fuzhou 350122, Peoples R China.
   [Chen, Shuijin; Chen, Lechun; Jiang, Yu; Zhang, Huanzhen; Chen, Jincheng; Lin, Zhigang] Fujian Univ Tradit Chinese Med, Subsidiary Rehabil Hosp, Fuzhou 350003, Peoples R China.
   [Chen, Shuijin; Chen, Lechun; Jiang, Yu; Zhang, Huanzhen; Chen, Jincheng; Lin, Zhigang] Fujian Prov Key Lab Rehabil Technol, Fuzhou 350003, Peoples R China.
   [Wang, Bingqian] Peking Univ, Int Hosp, Beijing 102206, Peoples R China.
C3 Fujian University of Traditional Chinese Medicine; Fujian University of
   Traditional Chinese Medicine; Peking University
RP Lin, ZG (corresponding author), Fujian Univ Tradit Chinese Med, Subsidiary Rehabil Hosp, Fuzhou 350003, Peoples R China.
EM linzhigang@fjtcm.edu.cn
RI Fang, Jiayu/AFR-1898-2022
FU Effects of Tuina Point Press on AMPA/NMDA Receptor Scaffold Protein and
   Synaptic Plasticity in Spinal Dorsal Horn of Rats with Neuropathic Pain
   [2020CXA052] Funding Source: Medline; Study on Analgesic Mechanism of
   Tuina on Neuropathic Pain in Spinal Dorsal Horn/ACC Brain Region based
   on PKA-NMDA-NR2B Pathway [2020J01758] Funding Source: Medline; Natural
   Science Foundation-funded Project: Study on the Mechanism of Tuina and
   Tuina in Regulating the Synaptic Plasticity of Spinal Dorsal Horn in
   Lumbar Disc Herniation Based on LncRNA-HOTAIR/miR-219 Mediated NMDAR
   Pathway [82174523] Funding Source: Medline; Natural Science Foundation
   of Fujian Province: Study on the Mechanism of Tuina Regulating the
   Synaptic Plasticity of Spinal Dorsal Horn in Lumbar Disc Herniation
   based on NMDAR-CAMK2-CREB Pathway [2020J01757] Funding Source: Medline;
   Fujian Health Science and Technology Program: Study on the Analgesic
   Mechanism of Tuina Manipulation On Lumbar Disc Herniation from the
   Efficacy of miR-219/NR2B Mediated Synaptic Transmission [2020GGA070]
   Funding Source: Medline
CR Ai J, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000019332
   Alomar SY, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14040307
   BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6
   Berger JV, 2011, BRAIN RES REV, V67, P282, DOI 10.1016/j.brainresrev.2011.03.003
   Bittar A, 2017, PAIN, V158, P2137, DOI 10.1097/j.pain.0000000000001014
   Borja GB, 2021, METHODS MOL BIOL, V2191, P109, DOI 10.1007/978-1-0716-0830-2_8
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9
   Chen J, 2011, PAIN, V152, P1165, DOI 10.1016/j.pain.2011.01.049
   Chen LC, 2020, FU JIAN YI KE XUE XU, V54, P291
   D'Mello R, 2011, MOL THER, V19, P1780, DOI 10.1038/mt.2011.42
   Deng MC, 2019, CELL MOL LIFE SCI, V76, P1889, DOI 10.1007/s00018-019-03047-y
   Duarte RV, 2020, PAIN, V161, P24, DOI 10.1097/j.pain.0000000000001689
   Gao Yong-Hui, 2009, Zhen Ci Yan Jiu, V34, P376
   Gui XW, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00405-3
   GULDNER FH, 1980, NEUROSCI LETT, V17, P27, DOI 10.1016/0304-3940(80)90056-7
   Guo W, 2007, J NEUROSCI, V27, P6006, DOI 10.1523/JNEUROSCI.0176-07.2007
   Huang LE, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26209-7
   Jiang HL, 2016, J TRADIT CHIN MED, V36, P85
   JONES DG, 1978, BRAIN RES, V147, P47, DOI 10.1016/0006-8993(78)90771-0
   Kawasaki Y, 2008, J NEUROSCI, V28, P5189, DOI 10.1523/JNEUROSCI.3338-07.2008
   Kuner R, 2017, NAT REV NEUROSCI, V18, P20, DOI 10.1038/nrn.2016.162
   Li MJ, 2017, PAIN, V158, P717, DOI 10.1097/j.pain.0000000000000827
   Li S, 2011, J NEUROSCI RES, V89, P1869, DOI 10.1002/jnr.22719
   Liang F, 2017, SAUDI PHARM J, V25, P649, DOI 10.1016/j.jsps.2017.04.039
   Liao WT, 2020, BRAIN RES BULL, V164, P307, DOI 10.1016/j.brainresbull.2020.09.005
   Lin TB, 2015, ANESTHESIOLOGY, V123, P909, DOI 10.1097/ALN.0000000000000809
   [林志刚 Lin Zhigang], 2020, [中华中医药杂志, China Journal of Traditional Chinese Medicine and Pharmacy], V35, P927
   Loftis JM, 2003, PHARMACOL THERAPEUT, V97, P55, DOI 10.1016/S0163-7258(02)00302-9
   Lu LJ, 2017, J MOL CELL BIOL, V9, P132, DOI 10.1093/jmcb/mjw043
   Luo HB, 2019, CHIN HERB MED, V11, P438, DOI 10.1016/j.chmed.2019.03.005
   Osikowicz M, 2013, EXP PHYSIOL, V98, P372, DOI 10.1113/expphysiol.2012.069922
   Park Chang Hyun, 2016, [Applied Microscopy, 한국현미경학회지], V46, P188, DOI 10.9729/am.2016.46.4.188
   Peng B, 2010, NEUROSCI LETT, V486, P24, DOI 10.1016/j.neulet.2010.09.037
   Peterson CD, 2021, MOL PAIN, V17, DOI 10.1177/17448069211029171
   Qu XX, 2009, EXP NEUROL, V215, P298, DOI 10.1016/j.expneurol.2008.10.018
   RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577
   Roh DH, 2010, EXP NEUROL, V224, P123, DOI 10.1016/j.expneurol.2010.03.002
   Smith BH, 2020, PAIN, V161, pS127, DOI 10.1097/j.pain.0000000000001824
   Sung BK, 2003, J NEUROSCI, V23, P2899
   Vissers K, 2005, ANESTH ANALG, V101, P457, DOI 10.1213/01.ANE.0000158471.41575.F0
   Wang J, 2017, MOL PAIN, V13, DOI 10.1177/1744806917746564
   Wang XY, 2018, J HEADACHE PAIN, V19, DOI 10.1186/s10194-018-0935-2
   Wang ZF, 2019, J CEREBR BLOOD F MET, V39, P1588, DOI 10.1177/0271678X18762637
   Wu QY, 2021, MOL PAIN, V17, DOI 10.1177/1744806921997654
   Wu ZW, 2019, TRIALS, V20, DOI 10.1186/s13063-018-3096-3
   Xu FX, 2017, NEUROREPORT, V28, P856, DOI 10.1097/WNR.0000000000000849
   Xu QL, 2012, NEURAL REGEN RES, V7, P1378, DOI 10.3969/j.issn.1673-5374.2012.18.003
   Yan XS, 2013, J BIOL CHEM, V288, P30544, DOI 10.1074/jbc.M113.495465
   Yu TY, 2012, ANMO TUINA XUE, V3rd, P3
   Zhang SP, 2020, TRIALS, V21, DOI 10.1186/s13063-020-4198-2
NR 50
TC 8
Z9 13
U1 3
U2 20
PU JOURNAL TRADITIONAL CHINESE MED
PI BEIJING
PA 16 NANXIAOJIE, DONGZHIMEN NEI, BEIJING, 100700, PEOPLES R CHINA
SN 0255-2922
EI 1577-7014
J9 J TRADIT CHIN MED
JI J. Tradit. Chin. Med.
PD AUG
PY 2023
VL 43
IS 4
BP 715
EP 724
DI 10.19852/j.cnki.jtcm.20221214.002
PG 10
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA M8DJ6
UT WOS:001032463500001
PM 37454256
DA 2026-01-16
ER

PT J
AU Xu, YM
   Wu, JZ
   Jiang, QQ
   Lv, YY
   Zhou, J
   Wang, ZY
   Zhao, H
   Du, DP
AF Xu, Yongming
   Wu, Junzhen
   Jiang, Qingqing
   Lv, Yingying
   Zhou, Jin
   Wang, Zhiyu
   Zhao, Hui
   Du, Dongping
TI Efficacy of Transcutaneous Electrical Acupoint Stimulation on Modulating
   Upper Extremity Sympathetic Skin Response in Alleviating Cancer
   Survivors With Chemotherapy-Induced Peripheral Neuropathy: A Propensity
   Score-Matched Cohort Study
SO JOURNAL OF PAIN RESEARCH
LA English
DT Article
DE transcutaneous electrical acupoint stimulation; chemotherapy-induced
   peripheral neuropathy; sympathetic skin response; cancer survivors;
   neuropathic pain
ID PAIN; PACLITAXEL; ACUPUNCTURE
AB Objective: Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of chemotherapy and it is currently intractable We compared the efficacy of transcutaneous electrical acupoint stimulation (TEAS) against non-TEAS groups and investigated the variables that predict effective relief of upper extremity pain in cancer survivors with CIPN.<br /> Methods: We retrospectively collected data of cancer survivors who developed CIPN between May 2017 to March 2022. All eligible CIPN patients were divided into TEAS group (received TEAS) and non-TEAS group (did not receive TEAS) in our department. A 1:1 ratio propensity score matching (PSM) was used to balance the baseline features. The change of numerical rating scale (NRS), Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2), and sympathetic skin response (SSR) parameters are all assessed after treatment. The procedure was considered a clinically effective relief if the patients' NRS scores were reduced by 50% or more, and overall patients with effective relief were all counted after treatment. Furthermore, a multivariable logistic regression model was utilized to evaluate the predictors of effective relief following CIPN treatment.<br /> Results: : A total of 102 cancer survivors with CIPN were analyzed after PSM (51 in each group). The change of NRS, SF-MPQ-2, SSR latency and SSR amplitude in TEAS group were significantly higher than those in non-TEAS group at 3 weeks after therapy (all P< 0.01). In addition, the effective relief rate was significantly higher in TEAS group than in non-TEAS group (P=0.026). Multivariate logistic regression on the total study cohort showed that TEAS group (OR 2.783, P = 0.025) and the baseline SSR amplitude of the upper extremity < 1265 mu V (OR 12.191, P = 0.000) were independent predictive factors for the clinical efficacy.<br /> Conclusions: : TEAS significantly decreased the severity of CIPN. TEAS group and baseline SSR amplitude of the upper extremity < 1265 mu V were the independent predictive factors for the clinical efficacy after treatment.
C1 [Xu, Yongming; Wu, Junzhen; Lv, Yingying; Zhou, Jin; Du, Dongping] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Pain Management Ctr, Sch Med, Shanghai, Peoples R China.
   [Jiang, Qingqing] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Neurol, Sch Med, Shanghai, Peoples R China.
   [Wang, Zhiyu; Zhao, Hui] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Internal Oncol, Sch Med, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University
RP Du, DP (corresponding author), Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Pain Management Ctr, Shanghai, Peoples R China.; Zhao, H (corresponding author), Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Neurol, 600 Yishan Rd, Shanghai 200233, Peoples R China.
EM zhao-hui@sjtu.edu.cn; dudp@sjtu.edu.cn
RI jiang, qingqing/NWH-3264-2025
OI Wu, Junzhen/0000-0001-5295-6133
FU National Natural Science Foundation of China [82271250]; Science
   Technology Department of School of Medicine, Shanghai Jiaotong
   University [TM202111]
FX This research was funded by the National Natural Science Foundation of
   China (82271250) and the Science Technology Department of School of
   Medicine, Shanghai Jiaotong University (NO. TM202111) .
CR Argyriou AA, 2005, EUR J NEUROL, V12, P858, DOI 10.1111/j.1468-1331.2005.01086.x
   ARUNODAYA GR, 1995, J NEUROL SCI, V129, P81, DOI 10.1016/0022-510X(94)00265-P
   Bao T, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.0681
   Ben-Arye E, 2022, CANCER-AM CANCER SOC, V128, P3641, DOI 10.1002/cncr.34422
   Brewer JR, 2016, GYNECOL ONCOL, V140, P176, DOI 10.1016/j.ygyno.2015.11.011
   Bulls HW, 2019, GYNECOL ONCOL, V152, P310, DOI 10.1016/j.ygyno.2018.12.002
   Chen S, 2024, PAIN THER, V13, P269, DOI 10.1007/s40122-024-00580-y
   Cheng Y, 2020, J CONTROL RELEASE, V318, P38, DOI 10.1016/j.jconrel.2019.12.011
   Cui X, 2023, J PAIN RES, V16, P2997, DOI 10.2147/JPR.S424841
   Cui X, 2022, FRONT NEUROSCI-SWITZ, V16, DOI 10.3389/fnins.2022.822436
   D'Alessandro EG, 2022, BMJ SUPPORT PALLIAT, V12, P64, DOI 10.1136/bmjspcare-2018-001542
   D'Souza RS, 2023, CURR PAIN HEADACHE R, V27, P99, DOI 10.1007/s11916-023-01107-4
   Desforges AD, 2022, BIOMED PHARMACOTHER, V147, DOI 10.1016/j.biopha.2022.112671
   Fabry V, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00342
   Fukuda Y, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00481
   Gao X, 2015, NEUROGASTROENT MOTIL, V27, P1817, DOI 10.1111/nmo.12694
   Gewandter JS, 2019, SUPPORT CARE CANCER, V27, P1765, DOI 10.1007/s00520-018-4424-6
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Hou S, 2018, PAIN PHYSICIAN, V21, P571, DOI 10.36076/ppj.2018.6.571
   Huang MC, 2023, ONCOLOGIST, V28, pE436, DOI 10.1093/oncolo/oyad065
   Idiaquez J, 2023, NEUROPHYSIOL CLIN, V53, DOI 10.1016/j.neucli.2022.102840
   Kang LM, 2021, J NEUROL, V268, P3269, DOI 10.1007/s00415-020-09942-w
   Karsidag S, 2005, DIABETES RES CLIN PR, V67, P211, DOI 10.1016/j.diabres.2004.07.017
   Kim DH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14359-z
   Lipov EG, 2009, MED HYPOTHESES, V72, P657, DOI 10.1016/j.mehy.2009.01.009
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Lyu Z, 2024, SUPPORT CARE CANCER, V32, DOI 10.1007/s00520-023-08240-1
   Ma QF, 2022, CURR OPIN NEUROBIOL, V76, DOI 10.1016/j.conb.2022.102602
   McCrary JM, 2019, SUPPORT CARE CANCER, V27, P3849, DOI 10.1007/s00520-019-04680-w
   Ng DQ, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.604688
   Noguchi Y, 2018, BIOL PHARM BULL, V41, P1694, DOI 10.1248/bpb.b18-00444
   On AY, 2022, KOREAN J PAIN, V35, P327, DOI 10.3344/kjp.2022.35.3.327
   Saad M, 2014, CURR OPIN ONCOL, V26, P634, DOI 10.1097/CCO.0000000000000139
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Staff NP, 2019, J PERIPHER NERV SYST, V24, pS26, DOI 10.1111/jns.12335
   Timmins HC, 2020, SUPPORT CARE CANCER, V28, P4459, DOI 10.1007/s00520-020-05299-y
   Vetrugno R, 2003, CLIN AUTON RES, V13, P256, DOI 10.1007/s10286-003-0107-5
   von Bischhoffshausen S, 2017, BRAIN, V140, P1238, DOI 10.1093/brain/awx069
   Wang YL, 2023, NEURAL PLAST, V2023, DOI 10.1155/2023/9303419
   Westerhaus MJ, 2001, BRAIN RES, V903, P117, DOI 10.1016/S0006-8993(01)02453-2
   Xu YM, 2023, PAIN THER, V12, P785, DOI 10.1007/s40122-023-00499-w
   Yan WL, 2023, PAIN THER, V12, P631, DOI 10.1007/s40122-023-00496-z
   Zhi WI, 2018, INTEGR CANCER THER, V17, P1079, DOI 10.1177/1534735418788667
   Zhou X, 2021, CANCER MANAG RES, V13, P1449, DOI 10.2147/CMAR.S292325
   Zhu XY, 2022, PAIN, V163, pE106, DOI 10.1097/j.pain.0000000000002321
   Zucker NA, 2017, PAIN MED, V18, P1582, DOI 10.1093/pm/pnx001
NR 46
TC 0
Z9 0
U1 5
U2 10
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-7090
J9 J PAIN RES
JI J. Pain Res.
PY 2025
VL 18
BP 293
EP 303
DI 10.2147/JPR.S500717
PG 11
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA T3D6R
UT WOS:001403861000001
PM 39867541
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Childress, MA
   Stuek, SJ
AF Childress, Marc A.
   Stuek, Samantha Jayne
TI Neck Pain: Initial Evaluation and Management
SO AMERICAN FAMILY PHYSICIAN
LA English
DT Article
ID LOW-BACK-PAIN; CERVICAL RADICULOPATHY; DIAGNOSTIC-ACCURACY;
   EPIDEMIOLOGY; MYELOPATHY; POPULATION; PLACEBO; TESTS
AB Neck pain is a common presenting symptom in the primary care setting and causes significant disability. The broad differential diagnosis requires an efficient but global assessment; therefore, emphasis is typically placed on red flags that can assist in the early recognition and treatment of more concerning diagnoses, such as traumatic injuries, infection, malignancy, vascular emergencies, and other inflammatory conditions. The critical element in appropriate diagnosis and management of these conditions is an accurate patient history. Physical examination findings complement and refine diagnostic cues from the history but often lack the specificity to be of value independently. Diagnostic tools such as imaging and electrodiagnostic tests have variable utility, especially in chronic or degenerative conditions. Treatment of mechanical or nonneuropathic neck pain includes short-term use of medications and possibly injections. However, long-term data for these interventions are limited. Acupuncture and other complementary and alternative therapies may be helpful in some cases. Advanced imaging and surgical evaluation may be warranted for patients with worsening neurologic function or persistent pain. (Copyright (C) 2020 American Academy of Family Physicians.)
C1 [Childress, Marc A.; Stuek, Samantha Jayne] Virginia Commonwealth Univ Fairfax Family Practic, 3650 Joseph Siewick Dr,Ste 400, Fairfax, VA 22033 USA.
RP Childress, MA (corresponding author), Virginia Commonwealth Univ Fairfax Family Practic, 3650 Joseph Siewick Dr,Ste 400, Fairfax, VA 22033 USA.
EM mchildress@ffpcs.com
CR American College of Radiology, ACR APPR CRIT CERV N
   Bono CM, 2011, SPINE J, V11, P64, DOI 10.1016/j.spinee.2010.10.023
   Bronfort G, 2012, ANN INTERN MED, V156, P1, DOI 10.7326/0003-4819-156-1-201201030-00002
   Childress MA, 2016, AM FAM PHYSICIAN, V93, P746
   Chou R, 2009, LANCET, V373, P463, DOI 10.1016/S0140-6736(09)60172-0
   Cohen SP, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j3221
   Cohen SP, 2015, MAYO CLIN PROC, V90, P284, DOI 10.1016/j.mayocp.2014.09.008
   Cook C, 2009, J ORTHOP SPORT PHYS, V39, P172, DOI 10.2519/jospt.2009.2938
   Davies BM, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.k186
   Duehmke RM, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003726.pub4
   Finnerup NB, 2015, LANCET NEUROL, V14, P162, DOI 10.1016/S1474-4422(14)70251-0
   Friedman BW, 2015, JAMA-J AM MED ASSOC, V314, P1572, DOI 10.1001/jama.2015.13043
   Gattie ER, 2017, JMIR RES PROTOC, V6, DOI 10.2196/resprot.7980
   Ghasemi M, 2013, J RES MED SCI, V18, pS43
   Grijalva RA, 2015, SPINE, V40, P475, DOI 10.1097/BRS.0000000000000794
   Gross A, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004249.pub4
   HONET JC, 1976, ARCH PHYS MED REHAB, V57, P12
   Kroeling P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004251.pub5
   Laiho K, 2002, CLIN RHEUMATOL, V21, P227, DOI 10.1007/PL00011222
   Langevin P, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008626.pub2
   Lazennec JY, 2015, ORTHOP TRAUMATOL-SUR, V101, P507, DOI 10.1016/j.otsr.2015.02.005
   Liu R, 2017, REGION ANESTH PAIN M, V42, P52, DOI 10.1097/AAP.0000000000000505
   Malmivaara A., 2003, Cochrane Database Syst Rev, DOI DOI 10.1002/14651858.CD004058
   Manchikanti L, 2015, PAIN PHYSICIAN, V18, pE535, DOI 10.36076/ppj.2015/18/e535
   Matsumoto M, 1998, J BONE JOINT SURG BR, V80B, P19, DOI 10.1302/0301-620X.80B1.7929
   Murray CJL, 2013, JAMA-J AM MED ASSOC, V310, P591, DOI 10.1001/jama.2013.13805
   Nouri A, 2015, SPINE, V40, pE675, DOI 10.1097/BRS.0000000000000913
   RADHAKRISHNAN K, 1994, BRAIN, V117, P325, DOI 10.1093/brain/117.2.325
   Räsänen P, 2006, J NEUROSURG-SPINE, V5, P204, DOI 10.3171/spi.2006.5.3.204
   Rubinstein SM, 2007, EUR SPINE J, V16, P307, DOI 10.1007/s00586-006-0225-6
   Smith AD, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-313
   Stenneberg MS, 2017, ARCH PHYS MED REHAB, V98, P1407, DOI 10.1016/j.apmr.2016.10.003
   Trinh K, 2016, COCHRANE DATABASE SY
   Vasseljen O, 2013, PAIN, V154, P1237, DOI 10.1016/j.pain.2013.03.032
   Young WF, 2000, AM FAM PHYSICIAN, V62, P1064
   Young WF, 2001, AM FAM PHYSICIAN, V63, P1916
NR 36
TC 31
Z9 41
U1 0
U2 8
PU AMER ACAD FAMILY PHYSICIANS
PI KANSAS CITY
PA 8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA
SN 0002-838X
EI 1532-0650
J9 AM FAM PHYSICIAN
JI Am. Fam. Physician
PD AUG 1
PY 2020
VL 102
IS 3
BP 150
EP 156
PG 7
WC Primary Health Care; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA NM3GN
UT WOS:000567988500007
PM 32735440
DA 2026-01-16
ER

PT J
AU Dhingra, L
   Ahmed, E
   Shin, J
   Scharaga, E
   Magun, M
AF Dhingra, Lara
   Ahmed, Ebtesam
   Shin, Jae
   Scharaga, Elyssa
   Magun, Maximilian
TI Cognitive Effects and Sedation
SO PAIN MEDICINE
LA English
DT Review
DE Opioid Therapy; Chronic Pain; Adverse Events; Cognitive Impairment;
   Psychomotor Dysfunction; Sedation
ID OPIOID-INDUCED SEDATION; CHRONIC NONCANCER PAIN; LOW-BACK-PAIN;
   NONMALIGNANT PAIN; RELEASE MORPHINE; MANAGEMENT; CANCER; PERFORMANCE;
   ANALGESICS; DELIRIUM
AB ObjectiveCognitive effects and sedation (CES) are prevalent in chronic nonmalignant pain populations receiving long-term opioid therapy and are among the most common reasons patients discontinue opioid use. In this narrative review, we describe the phenomenology, epidemiology, mechanisms, assessment, and management of opioid-related CES.
   DesignWe reviewed the empirical and theoretical literature on CES in opioid-treated populations with chronic pain. Data on long-term opioid therapy (3 months in duration) in chronic nonmalignant pain patients were sought.
   ResultsThe phenomenology of CES includes: inattention, concentration difficulties, memory deficits, psychomotor dysfunction, perceptual distortions, and executive dysfunction and somnolence, sleep disorders, and lethargy. Deficits may be caused by unrelieved pain or opioid therapy alone, or from a combination of these and other factors. Mechanisms include central nervous system effects, for example, direct toxic effects on neurons resulting in decreased consciousness; direct effects on processing and reaction resulting in cognitive or psychomotor impairment, and inhibitory effects on cholinergic activity. Pharmacological management approaches may include opioid dose reduction and rotation or psychostimulant use. Nonpharmacological approaches may include cognitive-behavioral therapy, mindfulness-based stress reduction, acupuncture, exercise, and yoga.
   ConclusionsThe most prevalent CES include: memory deficits (73-81%), sleep disturbance (35-57%), and fatigue (10%). At its most severe, extreme cognitive dysfunction can result in frank delirium and decreased alertness can result in coma. Emotional distress, sleep disorders, and other comorbidities and treatments can worsen CES, particularly among the elderly. Conclusions about the neuropsychological domains affected by opioids are limited due to the heterogeneity of studies and methodological issues.
C1 [Dhingra, Lara; Ahmed, Ebtesam] MJHS Inst Innovat Palliat Care, New York, NY 10006 USA.
   [Ahmed, Ebtesam; Magun, Maximilian] St Johns Univ, Coll Pharm & Hlth Sci, New York, NY USA.
   [Shin, Jae] Calif Pacific Med Ctr, Div Hepatol, San Francisco, CA USA.
   [Scharaga, Elyssa] Yeshiva Univ, Ferkauf Grad Sch Psychol, Bronx, NY USA.
C3 St. John's University; California Pacific Medical Center; Yeshiva
   University
RP Dhingra, L (corresponding author), MJHS Inst Innovat Palliat Care, 39 Broadway,3rd Floor, New York, NY 10006 USA.
EM LDhingra@mjhs.org
FU American Cancer Society [117416-RSGT-09-201-01-PC]; Pfizer's Office of
   Independent Grants for Learning and Change [8408357]; Cystic Fibrosis
   Foundation Therapeutics, Inc. [PORTEN13AO]
FX Supported by the American Cancer Society 117416-RSGT-09-201-01-PC,
   Pfizer's Office of Independent Grants for Learning and Change 8408357,
   and Cystic Fibrosis Foundation Therapeutics, Inc. PORTEN13AO.
CR [Anonymous], J CANC PAIN SYMPTOM
   [Anonymous], 2013, CLIN GERIATR
   Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008
   Dagtekin O, 2007, ANESTH ANALG, V105, P1442, DOI 10.1213/01.ane.0000281078.65585.1e
   Dimsdale JE, 2007, J CLIN SLEEP MED, V3, P33
   Dworkin RH, 2010, MAYO CLIN PROC, V85, pS3, DOI 10.4065/mcp.2009.0649
   Eccleston C, 1999, PSYCHOL BULL, V125, P356, DOI 10.1037/0033-2909.125.3.356
   Ersek Mary, 2004, Pain Manag Nurs, V5, P75, DOI 10.1016/j.pmn.2003.11.002
   Fredheim OMS, 2006, PALLIATIVE MED, V20, P35, DOI 10.1191/0269216306pm1099oa
   Gagnon B, 2005, J PSYCHIATR NEUROSCI, V30, P100
   Gallagher R, 2007, CAN FAM PHYSICIAN, V53, P426
   Hart RP, 2000, NEUROPSYCHOL REV, V10, P131, DOI 10.1023/A:1009020914358
   Jarzyna D, 2011, PAIN MANAG NURS, V12, P118, DOI 10.1016/j.pmn.2011.06.008
   Jorge LL, 2009, EUR J PHYS REHAB MED, V45, P469
   Kendall SE, 2010, PAIN, V150, P225, DOI 10.1016/j.pain.2010.05.012
   Knotkova H, 2009, J PAIN SYMPTOM MANAG, V38, P426, DOI 10.1016/j.jpainsymman.2009.06.001
   Kurita GP, 2012, ACTA ANAESTH SCAND, V56, P1257, DOI 10.1111/j.1399-6576.2012.02760.x
   Lavretsky Helen, 2009, Aging health, V5, P61, DOI 10.2217/1745509X.5.1.61
   Lawlor PG, 2002, CANCER-AM CANCER SOC, V94, P1836, DOI 10.1002/cncr.10389
   Leung L, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007650
   Liu XH, 2014, ACTA NEUROPSYCHIATR, V26, P195, DOI 10.1017/neu.2013.47
   Mailis-Gagnon A, 2012, CLIN J PAIN, V28, P542, DOI 10.1097/AJP.0b013e3182385332
   Mandala Mario, 2006, Ther Clin Risk Manag, V2, P447, DOI 10.2147/tcrm.2006.2.4.447
   Mao JR, 2002, J NEUROSCI, V22, P7650
   McCracken LM, 2001, J PAIN SYMPTOM MANAG, V21, P392, DOI 10.1016/S0885-3924(01)00267-6
   McNicol E, 2003, J PAIN, V4, P231, DOI 10.1016/S1526-5900(03)00556-X
   Mercadante S, 2001, J PAIN SYMPTOM MANAG, V21, P144, DOI 10.1016/S0885-3924(00)00228-1
   Moriarty O, 2011, PROG NEUROBIOL, V93, P385, DOI 10.1016/j.pneurobio.2011.01.002
   Morrison RS, 2003, J GERONTOL A-BIOL, V58, P76
   Nisbet AT, 2009, PAIN MANAG NURS, V10, P154, DOI 10.1016/j.pmn.2009.03.001
   Noble M, 2008, J PAIN SYMPTOM MANAG, V35, P214, DOI 10.1016/j.jpainsymman.2007.03.015
   O'Neil CK, 2012, AM J GERIATR PHARMAC, V10, P331, DOI 10.1016/j.amjopharm.2012.09.004
   Pasero C, 2007, AM J NURS, V107, P52, DOI 10.1097/00000446-200702000-00023
   Puustinen J, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-70
   Raja SN, 2002, NEUROLOGY, V59, P1015, DOI 10.1212/WNL.59.7.1015
   Reissig JE, 2005, ANN PHARMACOTHER, V39, P727, DOI 10.1345/aph.1E309
   Roth RS, 2005, ARCH PHYS MED REHAB, V86, P1147, DOI 10.1016/j.apmr.2004.10.041
   Sabatowski R, 2014, PAIN THER, V3, P17, DOI 10.1007/s40122-014-0025-3
   Schiltenwolf M, 2014, PAIN PHYSICIAN, V17, P9
   Slatkin NE, 2001, J PAIN SYMPTOM MANAG, V21, P425, DOI 10.1016/S0885-3924(01)00270-6
   Slatkin Neal E, 2003, J Support Oncol, V1, P53
   Smith HS, 2014, J PAIN RES, V7, P589, DOI 10.2147/JPR.S55782
   Smith Howard S, 2007, Anesthesiol Clin, V25, P809, DOI 10.1016/j.anclin.2007.07.005
   Stone P, 2011, PALLIATIVE MED, V25, P431, DOI 10.1177/0269216310380763
   Swegle JM, 2006, AM FAM PHYSICIAN, V74, P1347
   Tassain V, 2003, PAIN, V104, P389, DOI 10.1016/S0304-3959(03)00047-2
   Wang D, 2007, SLEEP MED REV, V11, P35, DOI 10.1016/j.smrv.2006.03.006
   Webster L, 2003, PAIN MED, V4, P135, DOI 10.1046/j.1526-4637.2003.03014.x
   Wheeler M, 2002, J PAIN, V3, P159, DOI 10.1054/jpai.2002.123652
   Won A, 2006, J GERONTOL A-BIOL, V61, P165, DOI 10.1093/gerona/61.2.165
   Young J, 2007, BMJ-BRIT MED J, V334, P842, DOI 10.1136/bmj.39169.706574.AD
   Yue HJ, 2010, MED CLIN N AM, V94, P435, DOI 10.1016/j.mcna.2010.02.007
NR 52
TC 41
Z9 46
U1 0
U2 20
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1526-2375
EI 1526-4637
J9 PAIN MED
JI Pain Med.
PD OCT
PY 2015
VL 16
SU 1
BP S37
EP S43
DI 10.1111/pme.12912
PG 7
WC Anesthesiology; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Anesthesiology; General & Internal Medicine
GA CT7AB
UT WOS:000362964300008
PM 26461075
DA 2026-01-16
ER

PT J
AU Zhou, LL
   Zhu, SG
   Fang, Y
   Huang, SS
   Huang, JF
   Hu, ZD
   Chen, JY
   Zhang, X
   Wang, JY
AF Zhou, Li-Li
   Zhu, Shi-Guo
   Fang, Yuan
   Huang, Shi-Shi
   Huang, Jie-Fan
   Hu, Ze-Di
   Chen, Jin-Yu
   Zhang, Xiong
   Wang, Jian-Yong
TI Neck pain and absence of cranial nerve symptom are clues of cervical
   myelopathy mimicking stroke: Two case reports
SO WORLD JOURNAL OF CLINICAL CASES
LA English
DT Article
DE Cervical cord; Spinal cord diseases; Stroke; Neck pain; Cranial nerves;
   Hematoma; epidural; spinal; Neoplasm metastasis; Case report
ID SPINAL-EPIDURAL-HEMATOMA; TISSUE-PLASMINOGEN ACTIVATOR; CLINICAL
   CHARACTERISTICS; HEMIPARESIS; THROMBOLYSIS; ACUPUNCTURE; MANAGEMENT;
   DIAGNOSIS
AB BACKGROUND Cervical myelopathy is a potential stroke imitator, for which intravenous thrombolysis would be catastrophic. CASE SUMMARY We herein present two cases of cervical myelopathy. The first patient presented with acute onset of right hemiparesis and urinary incontinence, and the second patient presented with sudden-onset right leg monoplegia. The initial diagnoses for both of them were ischemic stroke. However, both of them lacked cranial nerve symptom and suffered neck pain at the beginning of onset. Their cervical spinal cord lesions were finally confirmed by cervical computed tomography. A literature review showed that neck pain and absence of cranial nerve symptom are clues of cervical myelopathy. CONCLUSION The current report and the review remind us to pay more attention to these two clues in suspected stroke patients, especially those within the thrombolytic time window.
C1 [Zhou, Li-Li; Zhu, Shi-Guo; Fang, Yuan; Huang, Shi-Shi; Huang, Jie-Fan; Hu, Ze-Di; Chen, Jin-Yu; Zhang, Xiong; Wang, Jian-Yong] Wenzhou Med Univ, Affiliated Hosp 2, Inst Geriatr Neurol, Dept Neurol, Wenzhou 325027, Zhejiang, Peoples R China.
   [Zhou, Li-Li; Zhu, Shi-Guo; Fang, Yuan; Huang, Shi-Shi; Huang, Jie-Fan; Hu, Ze-Di; Chen, Jin-Yu; Zhang, Xiong; Wang, Jian-Yong] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou 325027, Zhejiang, Peoples R China.
   [Wang, Jian-Yong] Wenzhou Med Univ, Affiliated Hosp 2, Inst Geriatr Neurol, Dept Neurol, B305-B307 Biomed Res Bldg, Wenzhou 325027, Zhejiang, Peoples R China.
   [Wang, Jian-Yong] Wenzhou Med Univ, Yuying Childrens Hosp, B305-B307 Biomed Res Bldg, Wenzhou 325027, Zhejiang, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical
   University; Wenzhou Medical University
RP Wang, JY (corresponding author), Wenzhou Med Univ, Affiliated Hosp 2, Inst Geriatr Neurol, Dept Neurol, B305-B307 Biomed Res Bldg, Wenzhou 325027, Zhejiang, Peoples R China.; Wang, JY (corresponding author), Wenzhou Med Univ, Yuying Childrens Hosp, B305-B307 Biomed Res Bldg, Wenzhou 325027, Zhejiang, Peoples R China.
EM wangjianyong2020@126.com
RI zhou, lili/HZI-5623-2023; Fang, Yuanjian/AAH-1971-2020; Wang,
   Jian-Yong/HGC-1081-2022
OI Wang, Jian-Yong/0000-0003-4695-4806; Zhang, Xiong/0009-0007-5359-2029
FU Wenzhou Municipal Science and Technology Bureau [Y2020065]; Education
   Foundation of Zhejiang [Y202044311]; Fundamental Research Funds for
   Wenzhou Medical University [KYYW202030]
FX Supported by the Wenzhou Municipal Science and Technology Bureau, No.
   Y2020065; Education Foundation of Zhejiang, No. Y202044311; and
   Fundamental Research Funds for Wenzhou Medical University, No.
   KYYW202030.
CR Adamson DC, 2004, SURG NEUROL, V62, P156, DOI 10.1016/j.surneu.2003.10.040
   Al Khathaami AM, 2020, NEUROSCIENCES, V25, P38, DOI 10.17712/nsj.2020.1.20190096
   Bailey KC, 2012, J NEURORADIOLOGY, V39, P132, DOI 10.1016/j.neurad.2011.03.001
   Brihaye J, 1988, Adv Tech Stand Neurosurg, V16, P121
   Buyukgol H, 2015, AM J EMERG MED, V33, DOI 10.1016/j.ajem.2015.01.018
   Chen CL, 2020, J EMERG MED, V58, pE185, DOI 10.1016/j.jemermed.2020.01.009
   CONSTANS JP, 1983, J NEUROSURG, V59, P111, DOI 10.3171/jns.1983.59.1.0111
   D'Souza M, 2008, CEREBROVASC DIS, V26, P665, DOI 10.1159/000172974
   Domenicucci M, 2017, J NEUROSURG-SPINE, V27, P198, DOI 10.3171/2016.12.SPINE15475
   Emamhadi Mohammadreza, 2019, Asian J Neurosurg, V14, P286, DOI [10.4103/ajns.ajns_333_17, 10.4103/ajns.AJNS_333_17]
   Feigin VL, 2017, CIRC RES, V120, P439, DOI 10.1161/CIRCRESAHA.116.308413
   Gibson LM, 2013, J ROY COLL PHYS EDIN, V43, P114, DOI 10.4997/JRCPE.2013.205
   Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656
   Holtas S, 1996, RADIOLOGY, V199, P409, DOI 10.1148/radiology.199.2.8668786
   Hsieh CF, 2006, EUR J EMERG MED, V13, P36, DOI 10.1097/00063110-200602000-00009
   Huang DW, 2020, NEUROSCIENCES, V25, P316, DOI 10.17712/nsj.2020.4.20200027
   Inatomi Y, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.105030
   Ishikawa E, 2008, NEUROL INDIA, V56, P98, DOI 10.4103/0028-3886.39332
   Keselman B, 2019, EUR J NEUROL, V26, P1091, DOI 10.1111/ene.13944
   LAWTON MT, 1995, J NEUROSURG, V83, P1, DOI 10.3171/jns.1995.83.1.0001
   Lee JH, 2011, SPINE, V36, pE891, DOI 10.1097/BRS.0b013e3181fc1e38
   Lemmens R, 2012, ACTA NEUROL BELG, V112, P291, DOI 10.1007/s13760-012-0079-0
   Lin IY, 2004, ANN EMERG MED, V44, P183, DOI 10.1016/j.annemergmed.2004.02.041
   Liou KC, 2012, AM J EMERG MED, V30, DOI 10.1016/j.ajem.2011.06.018
   LOBITZ B, 1995, SOUTHERN MED J, V88, P580, DOI 10.1097/00007611-199505000-00015
   Marinella MA, 1996, ANN EMERG MED, V27, P514
   MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401
   Matsumoto H, 2012, J SPINAL CORD MED, V35, P262, DOI 10.1179/2045772312Y.0000000014
   Mesfin A, 2015, J AM ACAD ORTHOP SUR, V23, P38, DOI 10.5435/JAAOS-23-01-38
   Morimoto T, 2016, SPINE, V41, pE437, DOI 10.1097/BRS.0000000000001243
   Moulin S, 2019, CURR OPIN NEUROL, V32, P54, DOI 10.1097/WCO.0000000000000620
   Nakanishi K, 2011, ADV ORTHOP, V2011, DOI 10.4061/2011/516382
   Nguyen PL, 2015, J EMERG MED, V49, P244, DOI 10.1016/j.jemermed.2014.12.072
   OBRIEN PA, 1987, AGE AGEING, V16, P319, DOI 10.1093/ageing/16.5.319
   Ofluloglu E, 2009, TURK NEUROSURG, V19, P99
   Park J, 2013, SPINE J, V13, pE59, DOI 10.1016/j.spinee.2013.06.024
   Patel Ravish, 2018, BMJ Case Rep, V2018, DOI [10.1136/bcr-2017-222686, 10.1136/bcr-2017-222686]
   Rahangdale R, 2020, NEUROLOGY, V95, P496, DOI 10.1212/WNL.0000000000010511
   Rao R, 2002, J BONE JOINT SURG AM, V84A, P1872, DOI 10.2106/00004623-200210000-00021
   Romaniuc A, 2020, ACTA NEUROL BELG, V120, P495, DOI 10.1007/s13760-018-0939-3
   Sakamoto N, 2003, ARCH NEUROL-CHICAGO, V60, P783, DOI 10.1001/archneur.60.5.783
   Schmidley James W, 2013, Acute Med, V12, P30
   Sequeira D, 2016, PREHOSP EMERG CARE, V20, P723, DOI 10.3109/10903127.2016.1168889
   Shima H, 2012, NAGOYA J MED SCI, V74, P207
   Son S, 2012, NEUROLOGIST, V18, P41, DOI 10.1097/NRL.0b013e31823d7ade
   Szeto CLC, 2022, CEREBROVASC DIS, V51, P265, DOI 10.1159/000518525
   Tay MRJ, 2021, AM J PHYS MED REHAB, V100, pE133, DOI 10.1097/PHM.0000000000001655
   Teles Pedro, 2020, Surg Neurol Int, V11, P157, DOI [10.25259/sni_161_2020, 10.25259/SNI_161_2020]
   Terabe S, 2015, JPN J CLIN ONCOL, V45, P584, DOI 10.1093/jjco/hyv034
   Toledano M, 2013, NEUROL CLIN, V31, P287, DOI 10.1016/j.ncl.2012.09.003
   Tsou A, 2019, AM J EMERG MED, V37, DOI 10.1016/j.ajem.2019.03.044
   Wang CC, 2009, EUR SPINE J, V18, pS210, DOI 10.1007/s00586-008-0819-2
   Winkler DT, 2009, STROKE, V40, P1522, DOI 10.1161/STROKEAHA.108.530352
NR 53
TC 2
Z9 3
U1 0
U2 3
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 2307-8960
J9 WORLD J CLIN CASES
JI World J. Clin. Cases
PD NOV 16
PY 2022
VL 10
IS 32
BP 11835
EP 11844
DI 10.12998/wjcc.v10.i32.11835
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 6J2ZY
UT WOS:000886696700015
PM 36405285
OA Green Accepted, gold
DA 2026-01-16
ER

PT J
AU Wilson, KL
   Grewelle, RE
   Gupta, T
   Kim, SH
   Katsumoto, TR
AF Wilson, Kalin L.
   Grewelle, Richard E.
   Gupta, Tanya
   Kim, Sun H.
   Katsumoto, Tamiko R.
TI Aromatase inhibitor-induced arthralgia ameliorated by Mediterranean diet
   and active lifestyle guided by continuous glucose monitoring: a case
   report and review of the literature
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE hormone receptor-positive breast cancer; aromatase inhibitor-induced
   arthralgia; continuous glucose monitoring; Mediterranean diet; lifestyle
   medicine
ID INDUCED MUSCULOSKELETAL SYMPTOMS; EARLY BREAST-CANCER; PHASE-II;
   CLINICAL-TRIAL; DOUBLE-BLIND; PLACEBO; PAIN; OMEGA-3-FATTY-ACIDS;
   INTERVENTIONS; MULTICENTER
AB Aromatase inhibitors (AIs) are a cornerstone adjuvant treatment of many hormone receptor-positive breast cancers, and nearly half of women taking aromatase inhibitors suffer from AI-induced arthralgia (AIA), also known as AI-associated musculoskeletal syndrome (AIMSS), for which there are limited evidence-based treatments. Pharmacologic management and complementary methods including supplements, exercise, physical therapy, yoga, acupuncture, and massage have all shown mixed results. Comprehensive diet and lifestyle strategies are understudied in AIA/AIMSS despite their disease-modifying effects across many chronic conditions. Here we report a case of a woman with stage 2 estrogen and progesterone receptor-positive invasive ductal carcinoma on adjuvant anastrozole whose AI-induced arthralgia was durably controlled through a Mediterranean plant-forward diet and daily physical activity guided by continuous glucose monitoring. We posit that diet and a lifestyle inclusive of daily physical activity constitute a low-cost, low-risk, and potentially high-reward strategy for controlling common AI-induced musculoskeletal symptoms and that more investigation in this arena, including well-designed randomized trials, is warranted.
C1 [Wilson, Kalin L.] Stanford Univ, Sch Med, Dept Med, Stanford, CA USA.
   [Grewelle, Richard E.] Stanford Univ, Dept Biol, Stanford, CA USA.
   [Grewelle, Richard E.] Stanford Univ, Sch Med, Dept Genet, Stanford, CA USA.
   [Gupta, Tanya] Stanford Univ, Sch Med, Dept Med, Div Oncol ,Stanford Canc Inst, Stanford, CA USA.
   [Kim, Sun H.] Stanford Univ, Sch Med, Dept Med, Div Endocrinol, Stanford, CA USA.
   [Katsumoto, Tamiko R.] Stanford Univ, Sch Med, Dept Med, Div Immunol & Rheumatol, Stanford, CA 94305 USA.
C3 Stanford University; Stanford University; Stanford University; Stanford
   Cancer Institute; Stanford University; Stanford University; Stanford
   University
RP Katsumoto, TR (corresponding author), Stanford Univ, Sch Med, Dept Med, Div Immunol & Rheumatol, Stanford, CA 94305 USA.
EM tkatsum@stanford.edu
RI Gupta, Tanya/LDG-1869-2024; Katsumoto, Tamiko/V-4086-2019
OI Katsumoto, Tamiko/0000-0002-7978-0315; Kim, Sun/0000-0003-0895-7491;
   Grewelle, Richard/0000-0002-6432-1423
CR Bae K, 2023, CRIT REV ONCOL HEMAT, V181, DOI 10.1016/j.critrevonc.2022.103898
   Beckwée D, 2017, SUPPORT CARE CANCER, V25, P1673, DOI 10.1007/s00520-017-3613-z
   Birrell S, 2009, CANCER RES, V69, DOI [10.1158/0008-5472.SABCS-09-804, DOI 10.1158/0008-5472.SABCS-09-804]
   Boszkiewicz K, 2022, J CLIN MED, V11, DOI 10.3390/jcm11113133
   Carpenter CL., Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors
   Cathcart-Rake E, 2021, SUPPORT CARE CANCER, V29, P387, DOI 10.1007/s00520-020-05473-2
   Chan A, 2017, SUPPORT CARE CANCER, V25, P3785, DOI 10.1007/s00520-017-3810-9
   Harbeck N, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572-019-0122-z, 10.1038/s41572-019-0111-2, 10.1038/s41572-019-0122-z]
   Henry NL, 2008, BREAST CANCER RES TR, V111, P365, DOI 10.1007/s10549-007-9774-6
   Henry NL, 2019, CANCER-AM CANCER SOC, V125, P2123, DOI 10.1002/cncr.32024
   Henry NL, 2018, J CLIN ONCOL, V36, P326, DOI 10.1200/JCO.2017.74.6651
   Hershman DL, 2015, J CLIN ONCOL, V33, P1910, DOI 10.1200/JCO.2014.59.5595
   Islami F, 2021, JNCI-J NATL CANCER I, V113, P1648, DOI 10.1093/jnci/djab131
   Khan QJ, 2017, BREAST CANCER RES TR, V166, P491, DOI 10.1007/s10549-017-4429-8
   Kubo M, 2012, ANTICANCER RES, V32, P2331
   Li YF, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/2478565
   Liu P, 2014, GENET MOL RES, V13, P5285, DOI 10.4238/2014.July.24.7
   Lustberg MB, 2018, BREAST CANCER RES TR, V167, P709, DOI 10.1007/s10549-017-4559-z
   Mieog JSD, 2012, LANCET ONCOL, V13, P420, DOI 10.1016/S1470-2045(11)70328-X
   Morales L, 2007, BREAST CANCER RES TR, V104, P87, DOI 10.1007/s10549-006-9394-6
   Morze J, 2021, EUR J NUTR, V60, P1561, DOI 10.1007/s00394-020-02346-6
   Niravath P, 2013, ANN ONCOL, V24, P1443, DOI 10.1093/annonc/mdt037
   Niravath P, 2019, BREAST CANCER RES TR, V177, P427, DOI 10.1007/s10549-019-05319-4
   Peng N, 2018, BREAST, V37, P18, DOI 10.1016/j.breast.2017.08.003
   Rastelli AL, 2011, BREAST CANCER RES TR, V129, P107, DOI 10.1007/s10549-011-1644-6
   Roberts K, 2017, CRIT REV ONCOL HEMAT, V111, P66, DOI 10.1016/j.critrevonc.2017.01.010
   Roberts KE, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012988.pub2
   Roberts KE, 2018, Cochrane Database Syst Rev, DOI [10.1002/14651858.CD013167, DOI 10.1002/14651858.CD013167]
   Rosati MS, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.533
   Schoenenberger KA, 2021, NUTRIENTS, V13, DOI 10.3390/nu13124221
   Sestak I, 2008, LANCET ONCOL, V9, P866, DOI 10.1016/S1470-2045(08)70182-7
   Sestak I, 2009, J CLIN ONCOL, V27, P4961, DOI 10.1200/JCO.2009.22.0236
   Shapiro AC, 2016, BREAST CANCER RES TR, V155, P501, DOI 10.1007/s10549-016-3710-6
   Shenouda M, 2022, CLIN BREAST CANCER, V22, pE30, DOI 10.1016/j.clbc.2021.06.007
   Sordi Renan, 2019, Journal of Natural Remedies, V19, P24, DOI [10.18311/jnr/2019/22867, 10.18311/jnr/2019/22867]
   Widmer RJ, 2015, AM J MED, V128, P229, DOI 10.1016/j.amjmed.2014.10.014
   Yang GS, 2017, CANCER NURS, V40, pE26, DOI 10.1097/NCC.0000000000000409
   Younge JO, 2015, INT J EPIDEMIOL, V44, P2006, DOI 10.1093/ije/dyv183
NR 38
TC 0
Z9 1
U1 2
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD FEB 1
PY 2024
VL 14
AR 1189287
DI 10.3389/fonc.2024.1189287
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HS4T1
UT WOS:001161488600001
PM 38361780
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Park, SH
   Knobf, MT
   Sutton, KM
AF Park, So-Hyun
   Knobf, M. Tish
   Sutton, Karen M.
TI Etiology, Assessment, and Management of Aromatase Inhibitor-Related
   Musculoskeletal Symptoms
SO CLINICAL JOURNAL OF ONCOLOGY NURSING
LA English
DT Article
ID ESTROGEN REPLACEMENT THERAPY; EARLY BREAST-CANCER; POSTMENOPAUSAL WOMEN;
   TENOSYNOVIAL CHANGES; JOINT SYMPTOMS; ACUPUNCTURE; ARTHRALGIA; KNEE;
   PAIN; TRIAL
AB Aromatase inhibitors (AIs) are recommended as adjuvant endocrine therapy for postmenopausal women with hormone-responsive breast cancer. With the widespread use of AI adjuvant endocrine therapy, a significant profile of musculoskeletal symptoms has emerged. Moderate to severe musculoskeletal symptoms have led some women to discontinue therapy, compromising the survival benefit. The etiology of AI-related musculoskeletal symptoms is poorly understood, which challenges development of effective management strategies. The purpose of this article is to describe AI-related musculoskeletal symptoms, review possible causes, provide assessment guidelines, and recommend management strategies based on the best available evidence. Little evidence exists for effective management strategies of AI-related musculoskeletal symptoms, and randomized clinical trials are needed to establish effective interventions. A thorough musculoskeletal assessment can help guide clinical decision making for the best individual management approach. Providers need to manage symptoms with the best available evidence to minimize symptom distress and maximize adherence to AI therapy.
C1 [Park, So-Hyun; Knobf, M. Tish] Yale Univ, Sch Nursing, New Haven, CT 06536 USA.
   [Sutton, Karen M.] Yale Univ, Dept Orthoped Surg & Rehabil, New Haven, CT 06536 USA.
C3 Yale University; Yale University
RP Park, SH (corresponding author), Yale Univ, Sch Nursing, New Haven, CT 06536 USA.
EM so-hyun.park@yale.edu
CR Briot K, 2010, BREAST CANCER RES TR, V120, P127, DOI 10.1007/s10549-009-0692-7
   Burstein HJ, 2010, J CLIN ONCOL, V28, P3784, DOI 10.1200/JOP.000082
   CHRISTENSEN BV, 1992, ACTA ANAESTH SCAND, V36, P519, DOI 10.1111/j.1399-6576.1992.tb03511.x
   Crew Katherine D, 2007, J Cancer Surviv, V1, P283, DOI 10.1007/s11764-007-0034-x
   Crew KD, 2007, J CLIN ONCOL, V25, P3877, DOI 10.1200/JCO.2007.10.7573
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Dent SF, 2011, BREAST CANCER RES TR, V126, P295, DOI 10.1007/s10549-011-1351-3
   Dietrich W, 2006, J SOC GYNECOL INVEST, V13, P512, DOI 10.1016/j.jsgi.2006.07.002
   Din OS, 2010, BREAST CANCER RES TR, V120, P525, DOI 10.1007/s10549-010-0757-7
   Dizdar O, 2009, J CLIN ONCOL, V27, P4955, DOI 10.1200/JCO.2008.20.5435
   Dowsett M, 2010, J CLIN ONCOL, V28, P509, DOI 10.1200/JCO.2009.23.1274
   Ernst E, 2011, PAIN, V152, P755, DOI 10.1016/j.pain.2010.11.004
   Ezzo J, 2001, ARTHRITIS RHEUM, V44, P819, DOI 10.1002/1529-0131(200104)44:4<819::AID-ANR138>3.3.CO;2-G
   Fernihough JK, 1999, ARTHRITIS RHEUM, V42, P2103, DOI 10.1002/1529-0131(199910)42:10<2103::AID-ANR10>3.0.CO;2-S
   Freedman RA, 2010, BREAST, V19, P69, DOI 10.1016/j.breast.2009.11.009
   Guise TA, 2010, CURR MED RES OPIN, V26, P6
   Hall H, 2011, PAIN, V152, P711, DOI 10.1016/j.pain.2011.01.039
   Henry NL, 2008, BREAST CANCER RES TR, V111, P365, DOI 10.1007/s10549-007-9774-6
   Henry NL, 2012, J CLIN ONCOL, V30, P936, DOI 10.1200/JCO.2011.38.0261
   Henry NL, 2011, BREAST CANCER RES TR, V125, P751, DOI 10.1007/s10549-010-1206-3
   Ingle JN, 2010, J CLIN ONCOL, V28, P4674, DOI 10.1200/JCO.2010.28.5064
   Jones SE, 2007, J CLIN ONCOL, V25, P4765, DOI 10.1200/JCO.2007.10.8274
   Josefsson ML, 2010, BREAST, V19, P76, DOI 10.1016/j.breast.2009.12.010
   Khan QJ, 2010, BREAST CANCER RES TR, V119, P111, DOI 10.1007/s10549-009-0495-x
   Mao JJ, 2009, CANCER, V115, P3631, DOI 10.1002/cncr.24419
   Miaskowski C, 2008, CLIN J ONCOL NURS, V12, P213, DOI 10.1188/08.CJON.213-221
   Millar A., 2009, ACSMS RESOURCES MANU, P661
   Morales L, 2008, J CLIN ONCOL, V26, P3147, DOI 10.1200/JCO.2007.15.4005
   Morales L, 2007, BREAST CANCER RES TR, V104, P87, DOI 10.1007/s10549-006-9394-6
   Offit K, 2010, J CLIN ONCOL, V28, P4665, DOI 10.1200/JCO.2010.31.2926
   Presant CA, 2007, CLIN BREAST CANCER, V7, P775, DOI 10.3816/CBC.2007.n.038
   Prieto-Alhambra D, 2011, BREAST CANCER RES TR, V125, P869, DOI 10.1007/s10549-010-1075-9
   Sugamata N, 1999, INT J ONCOL, V14, P259
   Takeda W, 1994, Arthritis Care Res, V7, P118, DOI 10.1002/art.1790070304
   Vanderschueren D, 1997, ENDOCRINOLOGY, V138, P2301, DOI 10.1210/en.138.6.2301
   Waltman NL, 2009, CANCER NURS, V32, P143, DOI 10.1097/01.NCC.0000339262.44560.92
   Zhang YQ, 1998, ARTHRITIS RHEUM, V41, P1867, DOI 10.1002/1529-0131(199810)41:10<1867::AID-ART20>3.3.CO;2-N
NR 37
TC 10
Z9 12
U1 0
U2 8
PU ONCOLOGY NURSING SOC
PI PITTSBURGH
PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA
SN 1092-1095
EI 1538-067X
J9 CLIN J ONCOL NURS
JI Clin. J. Oncol. Nurs.
PD JUN
PY 2012
VL 16
IS 3
BP 260
EP 266
DI 10.1188/12.CJON.260-266
PG 7
WC Oncology; Nursing
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Oncology; Nursing
GA 953BI
UT WOS:000304841500007
PM 22641317
DA 2026-01-16
ER

PT J
AU Naughton, MJ
   Zahrieh, DM
   Gnant, M
   Zdenkowski, N
   Lemieux, J
   Mao, JJ
   Bjelic-Radisic, V
   Shinn, E
   Balic, M
   Thomssen, C
   Meisel, JL
   Ruiz, GM
   Loibl, S
   Isaacs, C
   Cameron, D
   Henao-Carrasco, FM
   Goetz, MP
   Singer, CF
   Werutsky, G
   Rugo, HS
   Vetter, M
   Tseng, LM
   Miller, K
   Fitzal, F
   Gil, JMG
   Park, H
   Linderholm, B
   Bajetta, E
   Dayao, Z
   Prat, A
   Ehrhardt, K
   Metzger, O
   Arahmani, A
   Law, EH
   Partridge, AH
   Carey, LA
   Zoroufy, A
   Dueck, AC
   O'Brien, P
   Hlauschek, D
   Demichele, A
   Mayer, EL
AF Naughton, M. J.
   Zahrieh, D. M.
   Gnant, M.
   Zdenkowski, N.
   Lemieux, J.
   Mao, J. J.
   Bjelic-Radisic, V.
   Shinn, E.
   Balic, M.
   Thomssen, C.
   Meisel, J. L.
   Ruiz, G. M.
   Loibl, S.
   Isaacs, C.
   Cameron, D.
   Henao-Carrasco, F. M.
   Goetz, M. P.
   Singer, C. F.
   Werutsky, G.
   Rugo, H. S.
   Vetter, M.
   Tseng, L. -m.
   Miller, K.
   Fitzal, F.
   Gil, J. M. Gil
   Park, H.
   Linderholm, B.
   Bajetta, E.
   Dayao, Z.
   Prat, A.
   Ehrhardt, K.
   Metzger, O.
   Arahmani, A.
   Law, E. H.
   Partridge, A. H.
   Carey, L. A.
   Zoroufy, A.
   Dueck, A. C.
   O'Brien, P.
   Hlauschek, D.
   Demichele, A.
   Mayer, E. L.
TI Quality-of-life and symptom severity in the PALLAS randomized trial of
   palbociclib with adjuvant endocrine therapy in early breast cancer
   (AFT-05, ABCSG-42, BIG-14-03, PrE0109)
SO ESMO OPEN
LA English
DT Article
DE breast cancer; quality of life; symptoms; palbociclib; adjuvant
   endocrine therapy; PALLAS
ID INHIBITOR-RELATED ARTHRALGIA; RISK; ELECTROACUPUNCTURE; VALIDITY; MODEL
AB Background: The PALLAS phase III, randomized trial investigated whether the addition of 2 years of palbociclib to adjuvant endocrine therapy (ET) improved invasive disease-free survival (iDFS) over adjuvant ET alone. This study reports the patient-reported outcomes (PROs) by treatment arm. Patients and methods: A total of 4688 of 5796 PALLAS patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, stage II-III breast cancer completed PRO measures. Patients were randomly assigned (1 : 1) to either 2 years of palbociclib (125 mg/day, 3 weeks on 1 week off) plus ongoing provider or patient-choice adjuvant ET (palbociclib + ET) versus ongoing ET alone. Eight PRO endpoints were measured serially (i.e. day 1 of each monthly cycle for the first 3 months, then every 3 months for 2 years, and once at 3 years). These endpoints were the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) global health status/quality-of-life (QoL) score, the Brief Fatigue Inventory (BFI) score, the modified Brief Pain Inventory (mBFI) severity and pain interference scores, the EORTC Core Quality of Life Questionaire-Breast 23 (QLQ-BR23) alopecia score, and the Breast Cancer Prevention Trial (BCPT) hot flash symptoms, vaginal problems, and musculoskeletal pain scores. Treatment with palbociclib stopped after the second interim analysis (May 2020) due to futility, and patients transitioned to follow-up. Results: After adjustment for baseline covariates, on average, no significant differences between arms were observed on any of the eight endpoints over the study period. However, there were differences by treatment regimen in the worsening of symptoms over time, and by race and ethnicity. These findings have important implications for the management of symptoms in HR-positive/HER2-negative breast cancer survivors receiving endocrine and/or other therapies long term. Conclusions: No clinically significant differences in patient-reported QoL or symptom severity were found by treatment arm. However, the results of the PRO analyses may inform patient-centered communication and adherence efforts regarding treatment toxicity in subgroups of survivors.
C1 [Naughton, M. J.] Ohio State Univ, Columbus, OH USA.
   [Zahrieh, D. M.; Goetz, M. P.; Zoroufy, A.] Mayo Clin, Alliance Fdn Trials Stat, Rochester, MN USA.
   [Zahrieh, D. M.; Goetz, M. P.; Zoroufy, A.] Mayo Clin, Data Ctr, Rochester, MN USA.
   [Gnant, M.; Fitzal, F.] Med Univ Vienna AT, Vienna, Austria.
   [Gnant, M.; Fitzal, F.; Prat, A.; Ehrhardt, K.; Hlauschek, D.] Austrian Breast & Colorectal Canc Study Grp ABCSG, Vienna, Austria.
   [Zdenkowski, N.] Univ Newcastle, Callagan, Australia.
   [Lemieux, J.] Univ Laval, Ctr Hosp Univ Quebec, Quebec City, PQ, Canada.
   [Mao, J. J.] Mem Sloan Kettering Canc Ctr, New York, NY USA.
   [Bjelic-Radisic, V.] Univ Witten Herdecke, Wuppertal, Germany.
   [Shinn, E.] MD Anderson Canc Ctr, Houston, TX USA.
   [Balic, M.] Med Univ Graz, Graz, Austria.
   [Thomssen, C.] Universitatsfrauenklin Halle, Wittenberg, Germany.
   [Meisel, J. L.] Emory Univ, Atlanta, GA USA.
   [Ruiz, G. M.] European Med Ctr, Moscow, Russia.
   [Loibl, S.] German Breast Grp, Neu Isenburg, Germany.
   [Isaacs, C.] Georgetown Univ, Washington, DC USA.
   [Cameron, D.] Canc Res UK Edinburgh Ctr, Edinburgh, Scotland.
   [Henao-Carrasco, F. M.] Hosp Virgen Macarena Sevilla, Seville, Spain.
   [Henao-Carrasco, F. M.] GEICAM Collaborat Grp, Seville, Spain.
   [Goetz, M. P.] Mayo Clin, Rochester, MN USA.
   [Singer, C. F.] Breast Ctr, Sankt Veit An Der Glan, Austria.
   [Werutsky, G.] Latin Amer Cooperat Oncol Grp LACOG, Porto Alegre, Brazil.
   [Rugo, H. S.] Univ Calif San Francisco, San Francisco, CA USA.
   [Vetter, M.] Univ Hosp Basel, Basel, Switzerland.
   [Tseng, L. -m.] Taipei Vet Gen Hosp, Taipei, Taiwan.
   [Miller, K.] Indiana Univ, Simon Canc Ctr, Indianapolis, IN USA.
   [Gil, J. M. Gil] Catalan Inst Oncol, Barcelona, Spain.
   [Park, H.] Washington Univ, Sch Med, St Louis, MO USA.
   [Linderholm, B.] Karolinska Inst, Solna, Sweden.
   [Bajetta, E.] Polyclin Hosp, Inst Oncol, Monza, Italy.
   [Dayao, Z.] Univ New Mexico Hosp, Albuquerque, NM USA.
   [Prat, A.] Hosp Clin Barcelona, Barcelona, Spain.
   [Metzger, O.; Mayer, E. L.] Dana Farber Canc Inst, Boston, MA USA.
   [Arahmani, A.] Breast Int Grp, Brussels, Belgium.
   [Law, E. H.] Pfizer Inc, New York, NY USA.
   [Carey, L. A.] Univ North Carolina, Chapel Hill, NC USA.
   [Dueck, A. C.; O'Brien, P.] Mayo Clin, Alliance Fdn Trials Stat, Phoenix, AZ USA.
   [Dueck, A. C.; O'Brien, P.] Mayo Clin, Data Ctr, Phoenix, AZ USA.
   [Demichele, A.] Univ Penn, Philadelphia, PA USA.
C3 University System of Ohio; Ohio State University; Mayo Clinic; Mayo
   Clinic; University of Newcastle; Laval University; Laval University
   Hospital; Memorial Sloan Kettering Cancer Center; Witten Herdecke
   University; University of Texas System; UTMD Anderson Cancer Center;
   Medical University of Graz; Emory University; German Breast Group;
   Georgetown University; Mayo Clinic; University of California System;
   University of California San Francisco; University of Basel; Taipei
   Veterans General Hospital; Indiana University System; Indiana University
   Indianapolis; Institut Catala d'Oncologia; Washington University
   (WUSTL); Karolinska Institutet; University of New Mexico; University of
   Barcelona; Hospital Clinic de Barcelona; Harvard University; Harvard
   University Medical Affiliates; Dana-Farber Cancer Institute; Breast
   International Group; Pfizer; Pfizer USA; University of North Carolina;
   University of North Carolina Chapel Hill; Mayo Clinic; Mayo Clinic
   Phoenix; Mayo Clinic; Mayo Clinic Phoenix; University of Pennsylvania
RP Naughton, MJ (corresponding author), Ohio State Univ, Dept Internal Med, Div Canc Prevent & Control, 3650 Olentangy River Rd,Suite 200, Columbus, OH 43214 USA.
EM Michelle.Naughton@osumc.edu
RI Gnant, Michael/AAN-7054-2020; Thomssen, Christoph/ABC-3102-2021; Rugo,
   Hope S./NRX-7907-2025; Naughton, Michelle/OUJ-5515-2025; Balic,
   Marija/LPQ-3522-2024
OI Gnant, Michael/0000-0003-1002-2118; Mao, Jun/0000-0001-9229-0380; Balic,
   Marija/0000-0001-9482-9191; Shinn, Eileen/0000-0002-3220-7423
FU Austrian Breast and Colorectal Cancer Study Group; Alliance Foundation
   Trials, LLC; PrECOG, LLC; NSABP Foundation, Inc.; German Breast Group;
   Breast International Group; Pfizer
FX This work was supported in part by the Austrian Breast and Colorectal
   Cancer Study Group (https:// www.abcsg.com , no grant number) and the
   Alliance Foundation Trials, LLC
   (https://acknowledgments.alliancefound.org, no grant number) , in
   collaboration with the PrECOG, LLC, the NSABP Foundation, Inc, the
   German Breast Group, and the Breast International Group, also supported
   in part by Pfizer (no grant number) . The content of this manuscript is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the Alliance Foundation Trials, LLC.
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Austin PC, 2017, STAT MED, V36, P4391, DOI 10.1002/sim.7501
   Brady MJ, 1997, J CLIN ONCOL, V15, P974, DOI 10.1200/JCO.1997.15.3.974
   Burstein HJ, 2019, J CLIN ONCOL, V37, P423, DOI 10.1200/JCO.18.01160
   Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129
   Fitzmaurice C, 2019, JAMA ONCOL, V5, P1749, DOI 10.1001/jamaoncol.2019.2996
   Gnant M, 2022, J CLIN ONCOL, V40, P282, DOI 10.1200/JCO.21.02554
   GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951
   Gundy CM, 2012, QUAL LIFE RES, V21, P1607, DOI 10.1007/s11136-011-0082-6
   Kieffer JM, 2014, QUAL LIFE RES, V23, P24
   Mao JJ, 2009, INTEGR CANCER THER, V8, P123, DOI 10.1177/1534735409332903
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Mao JJ, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2813
   Mao JJ, 2009, CANCER, V115, P3631, DOI 10.1002/cncr.24419
   Mayer EL, 2022, J CLIN ONCOL, V40, P449, DOI 10.1200/JCO.21.01918
   Mayer EL, 2021, LANCET ONCOL, V22, P212, DOI 10.1016/S1470-2045(20)30642-2
   Mendoza TR, 1999, CANCER-AM CANCER SOC, V85, P1186, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N
   Naughton MJ, 2021, CANCER-AM CANCER SOC, V127, P300, DOI 10.1002/cncr.33184
   Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004
   Pan HC, 2017, NEW ENGL J MED, V377, P1836, DOI 10.1056/NEJMoa1701830
   Rugo HS, 2022, ANN ONCOL, V33, P616, DOI 10.1016/j.annonc.2022.03.006
   Rugo HS, 2019, BREAST CANCER RES TR, V174, P719, DOI 10.1007/s10549-018-05125-4
   Rugo HS, 2018, ANN ONCOL, V29, P888, DOI 10.1093/annonc/mdy012
   Sloan J., 2003, J Cancer Integr Med, V1, P41
   Spring LM, 2020, LANCET, V395, P817, DOI 10.1016/S0140-6736(20)30165-3
   Stanton AL, 2005, JNCI-J NATL CANCER I, V97, P448, DOI 10.1093/jnci/dji069
   Tolaney SM, 2024, EUR J CANCER, V199, DOI 10.1016/j.ejca.2024.113555
   Wheeler SB, 2019, JNCI-J NATL CANCER I, V111, P498, DOI 10.1093/jnci/djy136
   Wyrwich KW, 2005, QUAL LIFE RES, V14, P285, DOI 10.1007/s11136-004-0705-2
NR 29
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2059-7029
J9 ESMO OPEN
JI ESMO Open
PD JUN
PY 2025
VL 10
IS 6
AR 105120
DI 10.1016/j.esmoop.2025.105120
EA JUN 2025
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 3SS3U
UT WOS:001508099600003
PM 40472660
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Shen, Q
   Zhu, YW
   Xu, WH
   Tang, MY
   Xie, HJ
   Chen, JDZ
   Wu, GJ
AF Shen, Qin
   Zhu, Ying-wei
   Xu, Wen-hui
   Tang, Ming-yu
   Xie, Hong-jun
   Chen, Jiande D. Z.
   Wu, Gao-jue
TI Integrative Effects of Transcutaneous Electrical Acustimulation and
   Autonomic-Endocrine Mechanisms on Postprocedural Recovery in Patients
   With Endoscopic Retrograde Cholangio-Pancreatography
SO NEUROMODULATION
LA English
DT Article
DE Autonomic function; endoscopic retrograde cholangio-pancreatography
   (ERCP); gastrointestinal motility; ghrelin; transcutaneous electrical
   acustimulation
ID NERVE-STIMULATION; PAIN; ERCP
AB Objectives: This study aimed to investigate the integrative effects and mechanisms of transcutaneous electrical acustimulation (TEA) on postprocedural recovery from endoscopic retrograde cholangio-pancreatography (ERCP). Materials and Methods: A total of 86 patients for elective ERCP were randomly ordered to receive TEA (n = 43) at acupoints PC6 and ST36 or Sham-TEA (n = 43) at sham points from 24 hours before ERCP (pre-ERCP) to 24 hours after ERCP (PE24). Scores of gastrointestinal (GI) motility-related symptoms and abdominal pain, gastric slow waves, and autonomic functions were recorded through the spectral analysis of heart rate variability; meanwhile, circulatory levels of inflammation cytokines of tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-10 and GI hormones of motilin, ghrelin, cholecystokinin (CCK), and vasoactive intestinal peptide (VIP) were assessed by enzyme-linked immunosorbent assay. Results: 1) TEA, but not Sham-TEA, decreased the post-ERCP GI motility-related symptom score (2.4 +/- 2.6 vs 7.9 +/- 4.6, p < 0.001) and abdominal pain score (0.5 +/- 0.7 vs 4.1 +/- 2.7, p < 0.001) at PE24, and decreased the post-ERCP hospital day by 20.0% (p < 0.05 vs Sham-TEA); 2) TEA improved the average gastric percentage of normal slow waves and dominant frequency by 34.6% and 33.3% at PE24, respectively (both p < 0.001 vs Sham-TEA); 3) TEA, but not Sham-TEA, reversed the ERCP-induced increase of TNF alpha but not IL-10 at PE24, reflected as a significantly lower level of TNF-alpha in the TEA group than in the Sham-TEA group (1.6 +/- 0.5 pg/mL vs 2.1 +/- 0.9 pg/mL, p < 0.01); 4) compared with Sham-TEA, TEA increased vagal activity by 37.5% (p < 0.001); and 5) TEA caused a significantly higher plasma level of ghrelin (1.5 +/- 0.8 ng/ml vs 1.1 +/- 0.7 ng/ml, p < 0.05) but not motilin, VIP, or CCK than did Sham-TEA at PE24. Conclusion: TEA at PC6 and ST36 accelerates the post-ERCP recovery, reflected as the improvement in GI motility and amelioration of abdominal pain, and suppression of the inflammatory cytokine TNF-alpha may mediate through both autonomic and ghrelin-related mechanisms.
C1 [Shen, Qin; Zhu, Ying-wei; Xu, Wen-hui; Tang, Ming-yu; Xie, Hong-jun; Wu, Gao-jue] Jiangnan Univ, Wuxi 2 Peoples Hosp, Dept Gastroenterol, Med Ctr, 68 Zhongshan Rd, Wuxi 214002, Jiangsu Provinc, Peoples R China.
   [Shen, Qin; Zhu, Ying-wei; Tang, Ming-yu; Wu, Gao-jue] Jiangnan Univ, Wuxi Sch Med, Wuxi, Jiangsu Provinc, Peoples R China.
   [Chen, Jiande D. Z.] Univ Michigan, Div Gastroenterol & Hepatol, Ann Arbor, MI USA.
C3 Jiangnan University; Jiangnan University; University of Michigan System;
   University of Michigan
RP Wu, GJ (corresponding author), Jiangnan Univ, Wuxi 2 Peoples Hosp, Dept Gastroenterol, Med Ctr, 68 Zhongshan Rd, Wuxi 214002, Jiangsu Provinc, Peoples R China.
EM wugaojue@aliyun.com
RI Tang, Mingyu/JHU-6766-2023
OI Wu, Gaojue/0000-0003-4680-2685; Zhu, Yingwei/0009-0001-7865-6806
FU Top Talent Support Program for young and middle-aged people of Wuxi
   Health Committee [BJ2023031]; Science and Technology Bureau of Wuxi City
   [Y20212028]; Wuxi City, Jiangsu Province, China
FX Source (s) of financial support: This study was supported by Top Talent
   Support Program for young and middle-aged people of Wuxi Health
   Committee (Gaojue Wu: Grant ID: BJ2023031) and "Light of Taihu Lake"
   science and technology research project sponsored by Science and
   Technology Bureau of Wuxi City (Gao-jue Wu: Grant ID: Y20212028) , Wuxi
   City, Jiangsu Province, China.
CR Alam MJ, 2023, DIAGNOSTICS, V13, DOI 10.3390/diagnostics13040627
   Bansal V, 2012, INFLAMMATION, V35, P214, DOI 10.1007/s10753-011-9307-7
   Boeckxstaens GE, 2009, GUT, V58, P1300, DOI 10.1136/gut.2008.169250
   Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070
   CHEN JD, 1993, IEEE T BIO-MED ENG, V40, P128, DOI 10.1109/10.212066
   Chen MJ, 2022, HEPATOB PANCREAT DIS, V21, P285, DOI 10.1016/j.hbpd.2021.12.002
   Davis EA, 2020, CURR BIOL, V30, DOI 10.1016/j.cub.2020.08.069
   Dumonceau JM, 2020, ENDOSCOPY, V52, P127, DOI 10.1055/a-1075-4080
   Harrison E, 2013, FRONTLINE GASTROENTE, V4, P282, DOI 10.1136/flgastro-2013-100309
   Huang ZH, 2022, AM J GASTROENTEROL, V117, P1491, DOI 10.14309/ajg.0000000000001882
   Jiao ZT, 2022, NUTRIENTS, V14, DOI 10.3390/nu14194191
   Jin HF, 2019, NEUROGASTROENT MOTIL, V31, DOI 10.1111/nmo.13615
   Kitazawa T, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00278
   KRAUSE AW, 1987, PHYS THER, V67, P507, DOI 10.1093/ptj/67.4.507
   Lee A, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003281.pub4
   Liu S, 2008, NEUROGASTROENT MOTIL, V20, P1204, DOI 10.1111/j.1365-2982.2008.01164.x
   Lu ZK, 2012, MOL BIOL REP, V39, P3557, DOI 10.1007/s11033-011-1129-z
   Maple JT, 2009, GASTROINTEST ENDOSC, V70, P278, DOI 10.1016/j.gie.2008.12.050
   Matsushita M, 2017, GASTROINTEST ENDOSC, V86, P747, DOI 10.1016/j.gie.2017.05.007
   Niu F, 2019, VIDEOSURGERY MINIINV, V14, P394, DOI 10.5114/wiitm.2019.82871
   Ouyang H, 2004, ALIMENT PHARM THER, V20, P831, DOI 10.1111/j.1365-2036.2004.02196.x
   Petrov MS, 2017, SCAND J GASTROENTERO, V52, P615, DOI 10.1080/00365521.2017.1296182
   Priebe HJ, 2016, BEST PRACT RES-CLIN, V30, P171, DOI 10.1016/j.bpa.2016.03.001
   Prodam F, 2014, ARCH IMMUNOL THER EX, V62, P369, DOI 10.1007/s00005-014-0287-9
   Qi DB, 2016, LIFE SCI, V160, P64, DOI 10.1016/j.lfs.2016.06.025
   Shrestha YB, 2009, PEPTIDES, V30, P1187, DOI 10.1016/j.peptides.2009.02.001
   Su Yang-Shuai, 2022, Zhen Ci Yan Jiu, V47, P1, DOI 10.13702/j.1000-0607.20211341
   Tolentino Bento da Silva M, 2021, PHYSIOL BEHAV, V233, DOI 10.1016/j.physbeh.2021.113355
   Traut U, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004930.pub3
   Wang HW, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110343
   Wu JN, 2017, EXP THER MED, V14, P4655, DOI 10.3892/etm.2017.5159
   Xiao Y, 2022, CLIN TRANSL GASTROEN, V13, DOI 10.14309/ctg.0000000000000485
   Xuan JL, 2022, NEUROGASTROENT MOTIL, V34, DOI 10.1111/nmo.14249
   Yin JY, 2023, EXPERT REV GASTROENT, V17, P1221, DOI 10.1080/17474124.2023.2288156
   Yin JY, 2013, J NEUROGASTROENTEROL, V19, P5, DOI 10.5056/jnm.2013.19.1.5
   Zhang B, 2021, AM J GASTROENTEROL, V116, P1495, DOI 10.14309/ajg.0000000000001203
   Zhang B, 2019, NEUROMODULATION, V22, P546, DOI 10.1111/ner.12856
   Zhang B, 2018, AM J GASTROENTEROL, V113, P1026, DOI 10.1038/s41395-018-0156-y
   Zhang RY, 2020, ARQ NEURO-PSIQUIAT, V78, P617, DOI [10.1590/0004-282X20200078, 10.1590/0004-282x20200078]
NR 39
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1094-7159
EI 1525-1403
J9 NEUROMODULATION
JI Neuromodulation
PD JAN
PY 2025
VL 28
IS 1
BP 174
EP 184
DI 10.1016/j.neurom.2024.06.503
EA JAN 2025
PG 11
WC Medicine, Research & Experimental; Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Neurosciences & Neurology
GA S7T7U
UT WOS:001400206700001
PM 39115505
DA 2026-01-16
ER

PT J
AU Chen, Q
   Feng, JM
   Liu, ZD
   An, DY
   Li, YD
   Zhou, SH
   Weng, ZW
AF Chen, Qi
   Feng, Jiaming
   Liu, Zhidan
   An, Dongyang
   Li, Yadan
   Zhou, Shaohu
   Weng, Zhiwei
TI Research trends of prostatitis over past 20 years: A bibliometric
   analysis
SO ANDROLOGIA
LA English
DT Article
DE bibliographic item co-occurrence matrix builder; bibliometric analysis;
   prostatitis; research trends; VOSviewer
ID PELVIC PAIN SYNDROME; OXIDATIVE STRESS; H-INDEX; SYMPTOMS; MEN;
   EPIDEMIOLOGY; HEALTH
AB In the past two decades, thousands of documents in the field of prostatitis have been published. This bibliometric analysis aimed to assess the characteristics, hotspots and frontiers trend of global scientific output on prostatitis. With the trend of moderate growth, altogether 2,423 papers were reviewed. The leading role of the United States in global prostatitis research was obvious, while China had developed rapidly in recent years. Queen's University and JOURNAL OF UROLOGY were the most prolific affiliation and journal respectively. Nickel, J. C made the greatest contribution to the field of prostatitis. Five hotspots have been confirmed: (a) male infertility associated with prostatitis and the molecular mechanisms; (b) diagnosis and treatment of prostatitis; (c) inflammation, pain and bladder irritation symptoms; (d) relationship between chronic prostatitis/chronic pelvic pain syndrome, benign prostatic hyperplasia and prostate cancer; (e) epidemiology, complications of prostatitis and improvement of acupuncture. This bibliometric analysis reveals that the international cooperation was becoming more and more close. Hotspot analysis shows that the molecular mechanism of prostatitis will be a hotspot in the future, mainly focussing on inflammatory immunity and oxidative stress.
C1 [Chen, Qi; Feng, Jiaming; Liu, Zhidan; An, Dongyang; Li, Yadan; Zhou, Shaohu; Weng, Zhiwei] Guangzhou Univ Chinese Med, Clin Med Sch 1, Guangzhou, Peoples R China.
   [Chen, Qi; Feng, Jiaming] Guangzhou Univ Chinese Med, Lingnan Med Res Ctr, Guangzhou, Peoples R China.
   [Zhou, Shaohu; Weng, Zhiwei] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou 510400, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine; Guangzhou University of Chinese Medicine
RP Weng, ZW (corresponding author), Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou 510400, Peoples R China.
EM lcwzw@126.com
RI Wen, Zhiwei/S-9645-2019; Chen, Qi/KEI-0452-2024
OI CHEN, QI/0000-0001-5960-0826; An, Dongyang/0000-0003-0207-8082
FU State Administration of Traditional Chinese Medicine of Guangdong
   Province [20181097]; Research Development Project of Guangzhou
   University of Chinese Medicine [2021xk64]; Youth Research Fund of the
   First Affiliated Hospital of Guangzhou University of Chinese Medicine
   [2019QN30]
FX This work was supported by grants from the State Administration of
   Traditional Chinese Medicine of Guangdong Province (20181097), the
   Research Development Project of Guangzhou University of Chinese Medicine
   (2021xk64)) and Youth Research Fund of the First Affiliated Hospital of
   Guangzhou University of Chinese Medicine (2019QN30)
CR Alexander RB, 2004, ANN INTERN MED, V141, P581, DOI 10.7326/0003-4819-141-8-200410190-00005
   Alshahrani S, 2013, J REPROD IMMUNOL, V100, P30, DOI 10.1016/j.jri.2013.05.004
   Bertoli-Barsotti L, 2017, SCIENTOMETRICS, V111, P1415, DOI 10.1007/s11192-017-2351-9
   Brown T, 2019, SCAND J OCCUP THER, V26, P475, DOI 10.1080/11038128.2018.1473489
   Chen R, 2003, UROLOGY, V61, P1156, DOI 10.1016/S0090-4295(03)00141-9
   Cooper ID, 2015, J MED LIBR ASSOC, V103, P217, DOI 10.3163/1536-5050.103.4.013
   Delongchamps NB, 2008, J UROLOGY, V179, P1736, DOI 10.1016/j.juro.2008.01.034
   Dennis LK, 2002, UROLOGY, V60, P78, DOI 10.1016/S0090-4295(02)01637-0
   Devos P, 2019, J HYPERTENS, V37, P2116, DOI 10.1097/HJH.0000000000002143
   Durieux V, 2010, RADIOLOGY, V255, P342, DOI 10.1148/radiol.09090626
   Garfield E, 1999, CAN MED ASSOC J, V161, P979
   Glander Hans-Jurgen, 2007, J Dtsch Dermatol Ges, V5, P924, DOI 10.1111/j.1610-0387.2007.06526.x
   Huang TJ, 2020, SPINE, V45, pE721, DOI 10.1097/BRS.0000000000003381
   Hui JL, 2020, INT J IMPOT RES, V32, P409, DOI 10.1038/s41443-019-0161-8
   Ihsan AU, 2018, BIOMED PHARMACOTHER, V106, P714, DOI 10.1016/j.biopha.2018.06.139
   Ioannidis JPA, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000918
   Khan FU, 2017, BIOMED PHARMACOTHER, V94, P1064, DOI 10.1016/j.biopha.2017.08.016
   Krieger JN, 2008, INT J ANTIMICROB AG, V31, pS85, DOI 10.1016/j.ijantimicag.2007.08.028
   Liang CZ, 2009, J UROLOGY, V182, P558, DOI 10.1016/j.juro.2009.04.011
   Magistro G, 2016, EUR UROL, V69, P286, DOI 10.1016/j.eururo.2015.08.061
   Magri V, 2018, ARCH ITAL UROL ANDRO, V90, P227, DOI 10.4081/aiua.2018.4.227
   Mandar R, 2020, ANDROLOGY-US, V8, P101, DOI 10.1111/andr.12647
   Meng LQ, 2018, PROSTATE, V78, P790, DOI 10.1002/pros.23536
   Motrich RD, 2020, BJU INT, V126, P379, DOI 10.1111/bju.15117
   Nickel JC, 2001, J UROLOGY, V165, P842, DOI 10.1016/S0022-5347(05)66541-X
   Nowak JK, 2018, CROAT MED J, V59, P25, DOI 10.3325/cmj.2018.59.25
   Paulis G, 2018, RES REP UROL, V10, P75, DOI 10.2147/RRU.S170400
   Polackwich AS, 2016, PROSTATE CANCER P D, V19, P132, DOI 10.1038/pcan.2016.8
   RASMUSSEN M, 2004, TR04021 UMNCS
   Rees J, 2015, BJU INT, V116, P509, DOI 10.1111/bju.13101
   Sahin S, 2015, PROSTATE CANCER P D, V18, P249, DOI 10.1038/pcan.2015.13
   Schaeffer AJ, 2003, ANDROLOGIA, V35, P252, DOI 10.1046/j.1439-0272.2003.00584.x
   Schagdarsurengin U, 2017, UROL INT, V98, P89, DOI 10.1159/000452251
   Schoeb DS, 2017, WORLD J UROL, V35, P1659, DOI 10.1007/s00345-017-2054-0
   Schoor Richard A, 2002, Curr Urol Rep, V3, P324, DOI 10.1007/s11934-002-0058-8
   Shoskes DA, 2013, WORLD J UROL, V31, P755, DOI 10.1007/s00345-013-1075-6
   Tao L, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.02.67
   van Eck NJ, 2010, SCIENTOMETRICS, V84, P523, DOI 10.1007/s11192-009-0146-3
   Wang CY, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.665912
   Wiygul Regula Doggweiler, 2005, Curr Urol Rep, V6, P282, DOI 10.1007/s11934-005-0025-2
   Zhang LG, 2020, PROSTATE, V80, P1394, DOI 10.1002/pros.24065
   Zhao QX, 2020, ANDROLOGY-US, V8, P747, DOI 10.1111/andr.12747
   Zhu DF, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/3473796
NR 43
TC 9
Z9 12
U1 0
U2 40
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0303-4569
EI 1439-0272
J9 ANDROLOGIA
JI Andrologia
PD NOV
PY 2021
VL 53
IS 10
AR e14206
DI 10.1111/and.14206
EA AUG 2021
PG 13
WC Andrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA UZ8ZF
UT WOS:000682605500001
PM 34365673
DA 2026-01-16
ER

PT J
AU Schlaeger, JM
   Cai, HY
   Xu, NG
   Steffens, AD
   Wang, L
   Wilkie, DJ
AF Schlaeger, Judith M.
   Cai, Hui Yan
   Xu Nenggui
   Steffens, Alana D.
   Wang Lin
   Wilkie, Diana J.
TI Do Vulvodynia TCM Patterns Differ by Pain Types? Beginning Evidence
   Supporting the Concept
SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
DE vulvodynia; acupuncture; Traditional Chinese Medicine; pain
ID VULVAR VESTIBULITIS SYNDROME; CHRONIC PELVIC PAIN; NEUROPATHIC PAIN;
   LUNG-CANCER; WOMEN; QUESTIONNAIRE; CLASSIFICATION; DESCRIPTORS;
   THRESHOLDS; DIAGNOSIS
AB Introduction: Vulvodynia affects a maximum of 14 million U.S. women; however, it has not been adequately characterized. Traditional Chinese Medicine (TCM) offers pattern diagnoses that may be considered vulvodynia phenotypes and may guide the development of more targeted treatments.
   Objectives: In women with vulvodynia, to explore relationships between the TCM patterns and pain.
   Design/Methods: In an exploratory study, 36 women diagnosed with vulvodynia had a TCM assessment and completed the Short Form McGill Pain Questionnaire (SF-MPQ).
   Results: All 36 women were diagnosed with one of the two TCM patterns (excess heat [n = 28] or excess cold [n = 8]). Although not statistically significant, (1) the excess heat pattern group had a higher mean sensory score (14.4 +/- 6.0) and mean affective pain score (4.1 +/- 2.8) (more pain) compared with the mean sensory score (13.3 +/- 5.9) and mean affective score (3.3 +/- 1.8) of the excess cold pattern group; (2) there was a higher mean score for neuropathic sensory descriptors in the excess heat pattern group (1.55 +/-.58) compared with the excess cold pattern group (1.16 +/- 0.72); and (3) there was a higher mean score for nociceptive sensory descriptors in the excess cold pattern group (1.23 +/- 0.45) compared with the excess heat pattern group (1.14 +/- 0.62). The difference in the hotburning mean score between the two TCM pattern groups was statistically significant (t [34] = 6.55, p < 0.0001).
   Conclusion: Intriguing trends were observed in the pain scores for the two TCM pattern groups. The possibility that TCM pattern groups have different types of pain (neuropathic vs. nociceptive) deserves further research in larger samples. If these exploratory findings are confirmed, the characterization of TCM patterns could lead to new treatments for vulvodynia.
C1 [Schlaeger, Judith M.] Univ Illinois, Coll Nursing, Dept Women Children & Family Hlth Sci, 840 S Damen Ave, Chicago, IL 60612 USA.
   [Cai, Hui Yan] Natl Univ Hlth Sci, Dept Acupuncture & Oriental Med, Lombard, IL USA.
   [Xu Nenggui; Wang Lin] Guangzhou Univ Chinese Med, Dept Acupuncture, Guangzhou, Guangdong, Peoples R China.
   [Steffens, Alana D.] Univ Illinois, Coll Nursing, Off Res Facilitat, Chicago, IL USA.
   [Wilkie, Diana J.] Univ Florida, Coll Nursing, Dept Biobehav Nursing Sci, Gainesville, FL 32611 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; Guangzhou University of Chinese
   Medicine; University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; State University System of
   Florida; University of Florida
RP Schlaeger, JM (corresponding author), Univ Illinois, Coll Nursing, Dept Women Children & Family Hlth Sci, 840 S Damen Ave, Chicago, IL 60612 USA.
EM jschlaeg@uic.edu
RI schlaeger, judith/N-4482-2017; Wilkie, Diana J/ABG-5417-2021
OI Wilkie, Diana J/0000-0002-3954-8933
CR Bohm-Starke N, 1999, GYNECOL OBSTET INVES, V48, P270, DOI 10.1159/000010198
   Bornstein J, 2016, J SEX MED, V13, P607, DOI 10.1016/j.jsxm.2016.02.167
   BOUREAU F, 1990, PAIN, V42, P145, DOI 10.1016/0304-3959(90)91158-F
   Chen JK, 2009, CHINES HERBAL FORMUL
   Cherny N. I., 1994, Annals Academy of Medicine Singapore, V23, P139
   Deadman P, 2007, US J CHINESE MED PUB
   Dobratz MC, 2008, AM J HOSP PALLIAT ME, V25, P469, DOI 10.1177/1049909108322293
   Epstein JB, 2009, HEAD NECK ONCOL, V1, DOI 10.1186/1758-3284-1-26
   Farmer MA, 2013, PAIN, V154, P2277, DOI 10.1016/j.pain.2013.05.028
   Fitzgerald CM, 2011, J REPROD MED, V56, P117
   Giesecke J, 2004, OBSTET GYNECOL, V104, P126, DOI 10.1097/01.AOG.0000129238.49397.4e
   Granot M, 2002, BJOG-INT J OBSTET GY, V109, P863, DOI 10.1111/j.1471-0528.2002.01416.x
   Haefner Hope K, 2005, J Low Genit Tract Dis, V9, P40, DOI 10.1097/00128360-200501000-00009
   Loving S, 2014, EUR J PAIN, V18, P1259, DOI 10.1002/j.1532-2149.2014.485.x
   Lowenstein L, 2004, PAIN, V107, P47, DOI 10.1016/j.pain.2003.09.012
   Martin LA, 1997, J PAIN SYMPTOM MANAG, V14, P99, DOI 10.1016/S0885-3924(97)00009-2
   MASSON EA, 1989, PAIN, V38, P25, DOI 10.1016/0304-3959(89)90068-7
   MELZACK R, 1986, PAIN, V27, P297, DOI 10.1016/0304-3959(86)90157-0
   MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5
   MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8
   Neville CE, 2012, J BODYW MOV THER, V16, P50, DOI 10.1016/j.jbmt.2011.06.002
   PAYNE R, 1989, CANCER, V63, P2266, DOI 10.1002/1097-0142(19890601)63:11<2266::AID-CNCR2820631135>3.0.CO;2-5
   Portenoy R K, 1997, Semin Oncol Nurs, V13, P25, DOI 10.1016/S0749-2081(97)80046-0
   Pukall CF, 2002, PAIN, V96, P163, DOI 10.1016/S0304-3959(01)00442-0
   Schlaeger JM, 2015, J SEX MED, V12, P1019, DOI 10.1111/jsm.12830
   Stockdale CK, 2014, J LOW GENIT TRACT DI, V18, P93, DOI 10.1097/LGT.0000000000000021
   Tu FF, 2008, CLIN J PAIN, V24, P45, DOI 10.1097/AJP.0b013e318156db13
   Tu FF, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.09.002
   Twycross R, 1997, ACTA ANAESTH SCAND, V41, P141, DOI 10.1111/j.1399-6576.1997.tb04628.x
   Wilkie DJ, 2010, J NATL MED ASSOC, V102, P18, DOI 10.1016/S0027-9684(15)30471-5
   WILKIE DJ, 1991, CLIN J PAIN, V7, P292, DOI 10.1097/00002508-199112000-00007
   Wilkie DJ, 2001, J PAIN SYMPTOM MANAG, V22, P899, DOI 10.1016/S0885-3924(01)00351-7
   Zhang Z, 2011, CLIN J PAIN, V27, P755, DOI 10.1097/AJP.0b013e31821c98ec
NR 33
TC 1
Z9 2
U1 0
U2 10
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1075-5535
EI 1557-7708
J9 J ALTERN COMPLEM MED
JI J. Altern. Complement Med.
PD MAY
PY 2017
VL 23
IS 5
BP 380
EP 384
DI 10.1089/acm.2015.0353
PG 5
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA EV0UM
UT WOS:000401460900012
PM 28294632
DA 2026-01-16
ER

PT J
AU Marcondes, L
   Ferreira, PM
   Sawada, NO
   Chianca, TCM
   Felix, JVC
   Guimaraes, PRB
   Kalinke, LP
AF Marcondes, Larissa
   Ferreira, Poliana Martins
   Sawada, Namie Okino
   Chianca, Tania Couto Machado
   Felix, Jorge Vinicius Cestari
   Guimaraes, Paulo Ricardo Bittencourt
   Kalinke, Luciana Puchalski
TI Effect of Laser Auriculotherapy on Quality of Life, Fatigue, and Anxiety
   in Women with Advanced Breast Cancer: Randomized Clinical Trial
SO HEALTHCARE
LA English
DT Article
DE auriculotherapy; breast cancer; complementary therapies; oncology
   nursing; quality of life
ID ACUPUNCTURE; PAIN
AB Objective: To evaluate the effect of laser auriculotherapy on health-related quality of life, cancer-related fatigue, and anxiety in women with advanced breast cancer undergoing palliative chemotherapy. Method: A randomized, parallel, single-blind, single-center clinical trial was conducted in a Brazilian oncology referral hospital. A total of 123 women were randomly divided into groups: 41 in the experimental group (10 weekly laser auriculotherapy sessions), 40 in the sham group (10 weekly sham sessions), and 42 in the control group. Outcomes were assessed at baseline, 5th week, and 11th week, using the Quality of Life Questionnaire Core-30, Functional Assessment of Cancer Therapy: Fatigue and State-Trait Anxiety Inventory. Statistical analyses included Kruskal-Wallis, Mann-Whitney, and Friedman tests. Results: The experimental group exhibited the highest mean overall quality of life, with a significant increase (p < 0.000001) between the second and third evaluations and a significant improvement in fatigue between the second and third evaluations (p = 0.00001). Conversely, women in the sham and control groups experienced a decline and worsening in both their quality of life and fatigue. Women in all three groups showed reduction an anxiety. Changes in anxiety in these women were not statistically significant. Conclusions: reduction improvement in health-related quality of life and a reduction in cancer-related fatigue in the experimental group. These results show a positive effect of auriculotherapy on cancer-related fatigue, demonstrating potential for application in clinical practice in women with advanced breast cancer and in palliative chemotherapy. Brazilian Registry of Clinical Trials: RBR-6hxffx4.
C1 [Marcondes, Larissa; Felix, Jorge Vinicius Cestari; Kalinke, Luciana Puchalski] Fed Univ Parana UFPR, Dept Nursing, BR-81210170 Curitiba, Brazil.
   [Ferreira, Poliana Martins; Sawada, Namie Okino] Fed Univ Alfenas UNIFAL, Dept Nursing, BR-37130001 Alfenas, Brazil.
   [Chianca, Tania Couto Machado] Univ Fed Minas Gerais, Dept Nursing, BR-30130100 Belo Horizonte, Brazil.
   [Guimaraes, Paulo Ricardo Bittencourt] Fed Univ Parana UFPR, Dept Stat, BR-81531990 Curitiba, Brazil.
C3 Universidade Federal de Alfenas; Universidade Federal de Minas Gerais
RP Marcondes, L (corresponding author), Fed Univ Parana UFPR, Dept Nursing, BR-81210170 Curitiba, Brazil.
EM marcondes.lari@gmail.com; poliana.martins@sou.unifal-mg.edu.br;
   namie.sawada@unifal-mg.edu.br; taniachianca@gmail.com;
   jvcfelix@hotmail.com; guimaraes.prb@gmail.com; kalinkeluciana@gmail.com
RI ; kalinke, luciana/GNH-3175-2022; Marcondes, Larissa/HZH-4393-2023;
   Sawada, Namie Okino/C-6112-2012; Chianca, Tania/ABI-1404-2020
OI Martins Ferreira, Poliana/0000-0002-9780-8633; kalinke,
   luciana/0000-0003-4868-8193; Chianca, Tania/0000-0002-8313-2791;
   Marcondes, Larissa/0000-0002-8745-6486; Bittencourt Guimarães, Paulo
   Ricardo/0000-0002-9852-6777; Sawada, Namie Okino/0000-0002-1874-3481; 
CR ae Kang Mi, 2019, [The Korean Journal of Health Service Management, 보건의료산업학회지], V13, P81, DOI 10.12811/kshsm.2019.13.3.081
   Vallim ETA, 2019, REV ESC ENFERM USP, V53, DOI 10.1590/S1980-220X2018043603525
   [Anonymous], 2004, TABLE DAVID BOHM DIA
   Bao T, 2023, CANCER RES, V83, DOI 10.1158/1538-7445.SABCS22-PD8-05
   Baxter GD, 2008, J ACUPUNCT MERIDIAN, V1, P65, DOI 10.1016/S2005-2901(09)60026-1
   Biaggio A.M.B., 1979, Manual para o Inventrio de Ansiedade Trao-Estado (IDATE)
   Choi TY, 2022, CANCERS, V14, DOI 10.3390/cancers14184419
   Chu YR, 2023, INTEGR CANCER THER, V22, DOI 10.1177/15347354221150907
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   European Organization For Research and Treatment Of Cancer (EORTC), 1995, Functional Assessment of Cancer Therapy: Fatigue (FACT-F)Verso 3.0
   FACIT Group, FACIT Measures & Searchable Library
   Filler K, 2016, SUPPORT CARE CANCER, V24, P5, DOI 10.1007/s00520-015-2965-5
   Fonseca A.A., 2017, Rev. Eletrnica Acervo Sade, V5, ps222
   Gori L, 2007, EVID-BASED COMPL ALT, V4, P13, DOI 10.1093/ecam/nem106
   Guo YQ, 2023, BMC NURS, V22, DOI 10.1186/s12912-023-01184-1
   Hiensch AE, 2022, TRIALS, V23, DOI 10.1186/s13063-022-06556-7
   Höxtermann MD, 2021, CANCERS, V13, DOI 10.3390/cancers13164082
   Ishikawa NM, 2010, SUPPORT CARE CANCER, V18, P481, DOI 10.1007/s00520-009-0697-0
   Kumar JVR, 2015, Asian Journal of Nursing Education and Research, V5, P513, DOI [10.5958/2349-2996.2015.00105.6, 10.5958/2349-2996.2015.00105.6, DOI 10.5958/2349-2996.2015.00105.6]
   Habimorad PHL, 2020, CIENC SAUDE COLETIVA, V25, P395, DOI 10.1590/1413-81232020252.11332018
   Li MJ, 2022, BMJ OPEN, V12, DOI 10.1136/bmjopen-2022-062407
   Lin L, 2021, BMJ SUPPORT PALLIAT, V11, P32, DOI 10.1136/bmjspcare-2019-001937
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Ministrio da Sade do Brasil, 2022, Estimativa 2023: incidncia de cncer no Brasil
   National Cancer Institute, 2021, Palliative care in cancer
   Nogier P.M.F, 1983, From Auriculotherapy to Auriculomedicine-Hardcover
   Riggio AI, 2021, BRIT J CANCER, V124, P13, DOI 10.1038/s41416-020-01161-4
   Rodrigues MD, 2019, COMPLEMENT THER MED, V42, P340, DOI 10.1016/j.ctim.2018.12.010
   Round R, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/984763
   Saligan LN, 2015, SUPPORT CARE CANCER, V23, P2853, DOI 10.1007/s00520-015-2815-5
   Sampaio H, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1540-9
   Silvrio-Lopes S.S., 2020, Atlas de Auriculoterapia de A a Z, V4th
   Soliman N, 1999, Phys Med Rehabil Clin N Am, V10, P547
   Spielberger C.D., 1970, MANUAL STATE TRAIT A
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tsao Y, 2019, SUPPORT CARE CANCER, V27, P4155, DOI 10.1007/s00520-019-04682-8
   Xi Y, 2020, Frontiers of Nursing, V7, P9, DOI [10.2478/fon-2020-0008, 10.2478/fon-2020-0008, DOI 10.2478/FON-2020-0008, 10.2478/FON-2020-0008]
   Yang EM, 2022, J INTEGR COMPLEMENT, V28, P427, DOI 10.1089/jicm.2021.0256
   Yeh CH, 2016, CANCER NURS, V39, P402, DOI 10.1097/NCC.0000000000000303
   Zhang JL, 2021, INTEGR CANCER THER, V20, DOI 10.1177/15347354211019103
NR 40
TC 3
Z9 3
U1 3
U2 7
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
EI 2227-9032
J9 HEALTHCARE-BASEL
JI Healthcare
PD JAN
PY 2025
VL 13
IS 2
AR 166
DI 10.3390/healthcare13020166
PG 20
WC Health Care Sciences & Services; Health Policy & Services
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services
GA T5X2Z
UT WOS:001405723400001
PM 39857193
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Rocha, ALL
   Reis, FM
   Petraglia, F
AF Rocha, Ana Luiza L.
   Reis, Fernando M.
   Petraglia, Felice
TI New trends for the medical treatment of endometriosis
SO EXPERT OPINION ON INVESTIGATIONAL DRUGS
LA English
DT Review
DE acupuncture; antiangiogenic therapy; antioxidant therapy; endometriosis;
   natural extracts; new treatment; omega-3; selective estrogen receptor
   modulator; statins; thiazolinedione; vitamins
ID ENDOTHELIAL GROWTH-FACTOR; CHRONIC PELVIC PAIN; PROGESTERONE-RECEPTOR
   MODULATOR; SIMVASTATIN INDUCES APOPTOSIS; GAMMA AGONIST ROSIGLITAZONE;
   CANCER CELL-PROLIFERATION; CB1 CANNABINOID RECEPTOR; NUDE-MOUSE MODEL;
   STROMAL CELLS; IN-VITRO
AB Introduction: Endometriosis is a benign sex hormone-dependent gynecological disease, characterized by the presence and growth of endometrial tissue outside the uterus; it affects 10% of women of reproductive age and is associated with infertility and pain. Treatment of endometriosis involves conservative or radical surgery, or medical therapies. The goals for endometriosis treatment may be the relief of pain and/or a successful pregnancy achievement in infertile patients. Treatment must be individualized with a multidisciplinary approach. The classical treatments carry adverse side effects and in some cases a negative impact on quality of life. New agents promise a distinct perspective in endometriosis treatment.
   Areas covered: The aim of this paper is to systematically review the literature evidence of new medical treatments for endometriosis, defined as pharmacological treatments not yet commonly available and currently under investigation.
   Expert opinion: These new medical therapies would be used associated with surgical treatment and, in the future, will render possible the association of hormone therapy with non-hormonal treatment for endometriosis.
C1 [Rocha, Ana Luiza L.; Petraglia, Felice] Univ Siena, Dept Pediat Obstet & Reprod Med, Policlin Santa Maria alle Scotte, I-53100 Siena, Italy.
   [Rocha, Ana Luiza L.; Reis, Fernando M.] Univ Fed Minas Gerais, Dept Obstet & Gynecol, Belo Horizonte, MG, Brazil.
   [Rocha, Ana Luiza L.; Reis, Fernando M.] Natl Inst Hormones & Womens Hlth, Belo Horizonte, MG, Brazil.
C3 University of Siena; Universidade Federal de Minas Gerais
RP Petraglia, F (corresponding author), Univ Siena, Dept Pediat Obstet & Reprod Med, Policlin Santa Maria alle Scotte, Viale Bracci, I-53100 Siena, Italy.
EM petraglia@unisi.it
RI Rocha, Ana/B-1645-2014; PETRAGLIA, Felice/D-4373-2019; Reis, Fernando
   M/E-5930-2013
OI Rocha, Ana/0000-0002-4717-9541; PETRAGLIA, Felice/0000-0002-8851-625X;
   Reis, Fernando M/0000-0002-9258-7472
CR Ailawadi RK, 2004, FERTIL STERIL, V81, P290, DOI 10.1016/j.fertnstert.2003.09.029
   Akhmetshina A, 2009, ARTHRITIS RHEUM-US, V60, P1129, DOI 10.1002/art.24395
   Al Kadri H, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005997.pub2
   Altintas D, 2010, EUR J OBSTET GYN R B, V150, P84, DOI 10.1016/j.ejogrb.2010.02.004
   Amsterdam LL, 2005, FERTIL STERIL, V84, P300, DOI 10.1016/j.fertnstert.2005.02.018
   Anthony M, 2001, ANN NY ACAD SCI, V949, P261
   ARUMUGAM K, 1995, FERTIL STERIL, V63, P198, DOI 10.1016/S0015-0282(16)57320-8
   Aytan H, 2007, AUST NZ J OBSTET GYN, V47, P321, DOI 10.1111/j.1479-828X.2007.00744.x
   Baarine M, 2011, GENES NUTR, V6, P161, DOI 10.1007/s12263-011-0232-z
   Bahamondes L, 2007, CONTRACEPTION, V75, pS134, DOI 10.1016/j.contraception.2006.12.008
   Becker CM, 2011, AM J PATHOL, V178, P1782, DOI 10.1016/j.ajpath.2010.12.037
   Beretta P, 1998, FERTIL STERIL, V70, P1176, DOI 10.1016/S0015-0282(98)00385-9
   Berkley KJ, 2005, SCIENCE, V308, P1587, DOI 10.1126/science.1111445
   Berkley KJ, 2010, ENDOCRINOLOGY, P2356
   BOUABOULA M, 1995, BIOCHEM J, V312, P637, DOI 10.1042/bj3120637
   Boucher A, 2001, BIOL REPROD, V65, P890, DOI 10.1095/biolreprod65.3.890
   Bruner-Tran KL, 2011, BIOL REPROD, V84, P106, DOI 10.1095/biolreprod.110.086744
   Bruner-Tran KL, 2009, J CLIN ENDOCR METAB, V94, P2489, DOI 10.1210/jc.2008-2802
   Bulun SE, 2009, NEW ENGL J MED, V360, P268, DOI 10.1056/NEJMra0804690
   Carli C, 2009, ENDOCRINOLOGY, V150, P3128, DOI 10.1210/en.2008-1088
   Carr B, 2011, 11 WORLD C END, P176
   Chabbert-Buffet N, 2005, HUM REPROD UPDATE, V11, P293, DOI 10.1093/humupd/dmi002
   Chapron C, 2002, HUM REPROD UPDATE, V8, P591, DOI 10.1093/humupd/8.6.591
   Chegini N, 1999, MOL HUM REPROD, V5, P459, DOI 10.1093/molehr/5.5.459
   CHEN DB, 1995, HUM REPROD, V10, P2773, DOI 10.1093/oxfordjournals.humrep.a135790
   Chishima F, 2002, AM J REPROD IMMUNOL, V48, P50, DOI 10.1034/j.1600-0897.2002.01101.x
   Cho SJ, 2008, INT J CANCER, V123, P951, DOI 10.1002/ijc.23593
   Chwalisz K, 2005, ENDOCR REV, V26, P423, DOI 10.1210/er.2005-0001
   Chwalisz K, 2004, FERTIL STERIL, V82, pS83, DOI 10.1016/j.fertnstert.2004.07.212
   Chwalisz K, 2002, ANN NY ACAD SCI, V955, P373, DOI 10.1111/j.1749-6632.2002.tb02798.x
   Cobellis L, 2004, EUR J OBSTET GYN R B, V116, P100, DOI 10.1016/j.ejogrb.2004.02.007
   Collins NH, 2009, BIOL REPROD, V80, P375, DOI 10.1095/biolreprod.107.065375
   Cosín R, 2009, FERTIL STERIL, V92, P1214, DOI 10.1016/j.fertnstert.2008.08.079
   COVENS AL, 1988, FERTIL STERIL, V49, P698
   Critchley HOD, 2006, ENDOCRINOLOGY, V147, P744, DOI 10.1210/en.2005-1153
   De Petrocellis L, 1998, P NATL ACAD SCI USA, V95, P8375, DOI 10.1073/pnas.95.14.8375
   Defer N, 2009, FASEB J, V23, P2120, DOI 10.1096/fj.09-129478
   del Pulgar TG, 2002, BIOCHEM J, V363, P183, DOI 10.1042/0264-6021:3630183
   Delgado-Rosas F, 2011, REPRODUCTION, V142, P745, DOI 10.1530/REP-11-0223
   Delmas D, 2004, ONCOGENE, V23, P8979, DOI 10.1038/sj.onc.1208086
   Delmas D, 2003, J BIOL CHEM, V278, P41482, DOI 10.1074/jbc.M304896200
   Delmas D, 2002, INT J MOL MED, V10, P193
   Delmas D, 2000, ONCOL REP, V7, P847
   Demirturk F, 2006, J SOC GYNECOL INVEST, V13, P58, DOI 10.1016/j.jsgi.2005.10.002
   Donnez J, 2002, GYNECOL OBSTET INVES, V54, P52, DOI 10.1159/000066295
   Dousset B, 2010, ANN SURG, V251, P887, DOI 10.1097/SLA.0b013e3181d9722d
   Ebert AD, 2005, EUR J OBSTET GYN R B, V122, P144, DOI 10.1016/j.ejogrb.2005.04.017
   Elden H, 2005, BMJ-BRIT MED J, V330, P761, DOI 10.1136/bmj.38397.507014.E0
   Esfandiari N, 2007, FERTIL STERIL, V87, P257, DOI 10.1016/j.fertnstert.2006.06.040
   Fauconnier A, 2005, HUM REPROD UPDATE, V11, P595, DOI 10.1093/humupd/dmi029
   Ferrero S, 2009, HUM REPROD, V24, P3033, DOI 10.1093/humrep/dep302
   Ferrero S, 2011, REPROD BIOL ENDOCRIN, V9, DOI 10.1186/1477-7827-9-89
   Foyouzi N, 2004, FERTIL STERIL, V82, P1019, DOI 10.1016/j.fertnstert.2004.02.133
   Franzoni F, 2003, INT J CARDIOL, V90, P317, DOI 10.1016/S0167-5273(02)00577-6
   French L, 2005, AM FAM PHYSICIAN, V71, P285
   French Linda, 2008, Paediatr Drugs, V10, P1, DOI 10.2165/00148581-200810010-00001
   Furman C, 2004, ATHEROSCLEROSIS, V174, P93, DOI 10.1016/j.atherosclerosis.2004.01.009
   Ricci AG, 2011, REPROD SCI, V18, P614, DOI 10.1177/1933719110395406
   Garcia-Gonzalez E, 2009, RHEUMATOLOGY, V48, P1050, DOI 10.1093/rheumatology/kep189
   Gazvani MR, 2001, FERTIL STERIL, V76, P717, DOI 10.1016/S0015-0282(01)01991-4
   GERHARD I, 1992, GYNECOL ENDOCRINOL, V6, P171
   Giudice LC, 2004, LANCET, V364, P1789, DOI 10.1016/S0140-6736(04)17403-5
   Giudice LC, 2010, NEW ENGL J MED, V362, P2389, DOI 10.1056/NEJMcp1000274
   Grow DR, 1996, J CLIN ENDOCR METAB, V81, P1933, DOI 10.1210/jc.81.5.1933
   Guindon J, 2008, BRIT J PHARMACOL, V153, P319, DOI 10.1038/sj.bjp.0707531
   Harel Z, 1996, AM J OBSTET GYNECOL, V174, P1335, DOI 10.1016/S0002-9378(96)70681-6
   Hefler LA, 2005, FERTIL STERIL, V84, P1033, DOI 10.1016/j.fertnstert.2005.04.059
   HELMS JM, 1987, OBSTET GYNECOL, V69, P51
   Herington JL, 2011, FERTIL STERIL, V95, P1295, DOI 10.1016/j.fertnstert.2010.09.017
   Highfield ES, 2006, J ALTERN COMPLEM MED, V12, P317, DOI 10.1089/acm.2006.12.317
   HODGEN GD, 1994, HUM REPROD, V9, P77, DOI 10.1093/humrep/9.suppl_1.77
   Howard FM, 2009, J MINIM INVAS GYN, V16, P540, DOI 10.1016/j.jmig.2009.06.017
   Huang Hong-Yuan, 2008, Chang Gung Med J, V31, P431
   Hudelist G, 2007, REPROD SCI, V14, P798, DOI 10.1177/1933719107309120
   Huirne JAF, 2001, LANCET, V358, P1793, DOI 10.1016/S0140-6736(01)06797-6
   Hull ML, 2005, HUM REPROD, V20, P350, DOI 10.1093/humrep/deh611
   Imesch P, 2011, FERTIL STERIL, V95, P1579, DOI 10.1016/j.fertnstert.2010.12.058
   Jackson LW, 2005, HUM REPROD, V20, P2014, DOI 10.1093/humrep/dei001
   Julien B, 2005, GASTROENTEROLOGY, V128, P742, DOI 10.1053/j.gastro.2004.12.050
   KAUPPILA A, 1979, PROSTAG OTH LIPID M, V18, P655, DOI 10.1016/0090-6980(79)90033-9
   KAUPPILA A, 1985, OBSTET GYNECOL, V65, P379
   Kennedy S, 2005, HUM REPROD, V20, P2698, DOI 10.1093/humrep/dei135
   Kitawaki J, 1997, BIOL REPROD, V57, P514, DOI 10.1095/biolreprod57.3.514
   Kitawaki J, 1999, FERTIL STERIL, V72, P1100, DOI 10.1016/S0015-0282(99)00424-0
   Klein TW, 2005, NAT REV IMMUNOL, V5, P400, DOI 10.1038/nri1602
   Kulak Jr J, 2011, ENDOCRINOLOGY
   Lançon A, 2004, BIOCHEM BIOPH RES CO, V316, P1132, DOI 10.1016/j.bbrc.2004.02.164
   Lancon A, 2007, DRUG METAB DISPOS, V35, P699, DOI 10.1124/dmd.106.013664
   Laschke MW, 2006, BRIT J PHARMACOL, V149, P137, DOI 10.1038/sj.bjp.0706857
   Laschke MW, 2008, HUM REPROD, V23, P2308, DOI 10.1093/humrep/den245
   Laschke MW, 2007, HUM REPROD UPDATE, V13, P331, DOI 10.1093/humupd/dmm006
   Laschke MW, 2006, HUM REPROD, V21, P262, DOI 10.1093/humrep/dei308
   Lazzeri L, 2011, 11 WORLD C END, P181
   Lebovic DI, 2007, FERTIL STERIL, V88, P1108, DOI 10.1016/j.fertnstert.2006.12.072
   Lebovic DI, 2010, ENDOCRINOLOGY, V151, P1846, DOI 10.1210/en.2009-1076
   Lebovic DI, 2004, FERTIL STERIL, V82, P1008, DOI 10.1016/j.fertnstert.2004.02.148
   Lian F, 2007, CHIN J INTEGR MED, V13, P109, DOI 10.1007/s11655-007-0109-6
   Lossl K, 2009, EUR J OBSTET GYN R B, V144, P48, DOI 10.1016/j.ejogrb.2009.02.001
   Luisi S, 2009, GYNECOL ENDOCRINOL, V25, P734, DOI 10.3109/09513590903159664
   Lund I, 2006, ACTA OBSTET GYN SCAN, V85, P12, DOI 10.1080/00016340500317153
   Machado DE, 2008, FERTIL STERIL, V90, P148, DOI 10.1016/j.fertnstert.2007.05.076
   Machado DE, 2010, FERTIL STERIL, V93, P2674, DOI 10.1016/j.fertnstert.2009.11.037
   Madauss KP, 2007, MOL ENDOCRINOL, V21, P1066, DOI 10.1210/me.2006-0524
   Marel AK, 2008, MOL NUTR FOOD RES, V52, P538, DOI 10.1002/mnfr.200700185
   Mckinnon BD, 2011, 11 WORLD C END, P182
   McLaren J, 2000, HUM REPROD UPDATE, V6, P45, DOI 10.1093/humupd/6.1.45
   Melck D, 2000, ENDOCRINOLOGY, V141, P118, DOI 10.1210/en.141.1.118
   Meresman GF, 2005, FERTIL STERIL, V84, P459, DOI 10.1016/j.fertnstert.2005.01.137
   Michalski CW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001701
   Mier-Cabrera J, 2008, INT J GYNECOL OBSTET, V100, P252, DOI 10.1016/j.ijgo.2007.08.018
   Mier-Cabrera J, 2009, REPROD BIOL ENDOCRIN, V7, DOI 10.1186/1477-7827-7-54
   Mier-Cabrera J, 2011, BJOG-INT J OBSTET GY, V118, P6, DOI 10.1111/j.1471-0528.2010.02777.x
   Milingos S, 2003, ANN NY ACAD SCI, V997, P269, DOI 10.1196/annals.1290.030
   MOORE J., 2004, the Cochrane Library
   Moravek MB, 2009, GYNECOL OBSTET INVES, V68, P167, DOI 10.1159/000230713
   Muñoz-Luque J, 2008, J PHARMACOL EXP THER, V324, P475, DOI 10.1124/jpet.107.131896
   Murphy AA, 1998, FERTIL STERIL, V69, P1092, DOI 10.1016/S0015-0282(98)00087-9
   Nap AW, 2004, HUM REPROD, V19, P2180, DOI 10.1093/humrep/deh408
   Nasu K, 2001, MOL HUM REPROD, V7, P741, DOI 10.1093/molehr/7.8.741
   Netsu S, 2008, FERTIL STERIL, V90, P1496, DOI 10.1016/j.fertnstert.2007.08.014
   Noble LS, 1996, J CLIN ENDOCR METAB, V81, P174, DOI 10.1210/jc.81.1.174
   Novella-Maestre E, 2009, HUM REPROD, V24, P1025, DOI 10.1093/humrep/den499
   Novembri R, 2011, J ENDOMETR PELVIC PA, V3, P34, DOI 10.5301/JE.2011.8331
   Oktem M, 2007, HUM REPROD, V22, P1474, DOI 10.1093/humrep/del505
   Olivares C, 2011, FERTIL STERIL, V96, P428, DOI 10.1016/j.fertnstert.2011.05.063
   Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2
   Panina P, 2011, 11 WORLD C END, P188
   Pezzuto JM, 2011, ANN NY ACAD SCI, V1215, P123, DOI 10.1111/j.1749-6632.2010.05849.x
   Piotrowski PC, 2006, BIOL REPROD, V75, P107, DOI 10.1095/biolreprod.106.051763
   Pouresmail Zahra, 2002, J Tradit Chin Med, V22, P205
   Prentice A, 2004, COCHRANE LIB
   Ramón LA, 2011, HUM REPROD, V26, P1082, DOI 10.1093/humrep/der025
   Razzi S, 2004, BJOG-INT J OBSTET GY, V111, P182, DOI 10.1046/j.1471-0528.2003.00038.x
   Remorgida V, 2007, FERTIL STERIL, V88, P724, DOI 10.1016/j.fertnstert.2006.12.027
   Remorgida V, 2007, AUST NZ J OBSTET GYN, V47, P222, DOI 10.1111/j.1479-828X.2007.00722.x
   Rossi M, 2005, REPRODUCTION, V130, P721, DOI 10.1530/rep.1.00688
   Rubi-Klein K, 2010, EUR J OBSTET GYN R B, V153, P90, DOI 10.1016/j.ejogrb.2010.06.023
   Rueda D, 2000, MOL PHARMACOL, V58, P814, DOI 10.1124/mol.58.4.814
   Saito T, 2003, ARZNEIMITTEL-FORSCH, V53, P507
   SELAK V., 2004, The Cochrane library
   Sesti F, 2009, EUR J OBSTET GYN R B, V147, P72, DOI 10.1016/j.ejogrb.2009.07.003
   Sharma I, 2011, FERTIL STERIL, V95, P829, DOI 10.1016/j.fertnstert.2010.09.008
   Slayden OD, 1998, HUM REPROD, V13, P269, DOI 10.1093/humrep/13.2.269
   Smuc T, 2009, MOL CELL ENDOCRINOL, V301, P59, DOI 10.1016/j.mce.2008.07.020
   Sokalska A, 2010, J CLIN ENDOCR METAB, V95, P3453, DOI 10.1210/jc.2010-0072
   Soysal S, 2004, HUM REPROD, V19, P160, DOI 10.1093/humrep/deh035
   Spitz IM, 2010, CONTRACEPTION, V82, P442, DOI 10.1016/j.contraception.2009.12.012
   Stratton P, 2008, OBSTET GYNECOL, V111, P88, DOI 10.1097/01.AOG.0000297307.35024.b5
   Struthers RS, 2009, J CLIN ENDOCR METAB, V94, P545, DOI 10.1210/jc.2008-1695
   Stygar Denis, 2003, Reprod Biol Endocrinol, V1, P40
   Szekeres T, 2011, ANN NY ACAD SCI, V1215, P89, DOI 10.1111/j.1749-6632.2010.05864.x
   Tan XJ, 2002, FERTIL STERIL, V78, P148, DOI 10.1016/S0015-0282(02)03187-4
   Teixeira-Clerc F, 2006, NAT MED, V12, P671, DOI 10.1038/nm1421
   Tokushige N, 2006, HUM REPROD, V21, P3001, DOI 10.1093/humrep/del260
   Tsou K, 1996, NEUROSCIENCE, V70, P791, DOI 10.1016/S0306-4522(96)83015-6
   Van Langendonckt A, 2008, MOL HUM REPROD, V14, P259, DOI 10.1093/molehr/gan019
   Velasco I, 2006, MOL HUM REPROD, V12, P377, DOI 10.1093/molehr/gal041
   Vercellini P, 2003, AM J OBSTET GYNECOL, V188, P606, DOI 10.1067/mob.2003.7
   Vercellini P, 2008, BEST PRACT RES CL OB, V22, P275, DOI 10.1016/j.bpobgyn.2007.10.001
   Viganò P, 2006, J MOL ENDOCRINOL, V36, P415, DOI 10.1677/jme.1.01946
   Wassmann S, 2002, ARTERIOSCL THROM VAS, V22, P300, DOI 10.1161/hq0202.104081
   Wieser F, 2005, FERTIL STERIL, V84, pS192, DOI 10.1016/j.fertnstert.2005.07.480
   Wieser F, 2007, HUM REPROD UPDATE, V13, P487, DOI 10.1093/humupd/dmm015
   Wieser F, 2009, BIOL REPROD, V81, P371, DOI 10.1095/biolreprod.108.075069
   Wilson WRW, 2005, EUR J VASC ENDOVASC, V30, P259, DOI 10.1016/j.ejvs.2005.02.044
   WOLF JP, 1989, FERTIL STERIL, V52, P1055
   Wölfler MM, 2005, HUM REPROD, V20, P1702, DOI 10.1093/humrep/deh796
   Xu H, 2009, HUM REPROD, V24, P608, DOI 10.1093/humrep/den417
   Yang Dong-xia, 2006, Chin J Integr Med, V12, P218
   Yao Z, 2005, J INVEST SURG, V18, P177, DOI 10.1080/08941930591004412
   Yavuz E, 2007, FERTIL STERIL, V88, P1129, DOI 10.1016/j.fertnstert.2007.01.010
NR 171
TC 47
Z9 52
U1 1
U2 43
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1354-3784
EI 1744-7658
J9 EXPERT OPIN INV DRUG
JI Expert Opin. Investig. Drugs
PD JUL
PY 2012
VL 21
IS 7
BP 905
EP 919
DI 10.1517/13543784.2012.683783
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 958ND
UT WOS:000305244600002
PM 22568855
DA 2026-01-16
ER

PT J
AU Almeida, TCD
   Zatta, SM
   Paiva, LD
   de Carvalho, LEW
   Schoueri, J
   de Abreu, LC
   Fonseca, FLA
   Adami, F
AF do Carmo Almeida, Tabata Cristina
   Zatta, Simone Meneghette
   da Silva Paiva, Laercio
   de Carvalho, Luis Eduardo Werneck
   Schoueri, Jean
   de Abreu, Luiz Carlos
   Fonseca, Fernando Luiz Affonso
   Adami, Fernando
TI Reduction on Proinflammatory Cytokines after Application of
   Transcutaneous Electrical Nerve Stimulation (TENS) in Patients with a
   Breast Cancer: A Nonrandomized, Open, and Single-Arm Study Protocol with
   Paired Analysis
SO MEDIATORS OF INFLAMMATION
LA English
DT Article
ID POSTOPERATIVE PAIN MANAGEMENT; INFLAMMATION; ELECTROACUPUNCTURE; BLOOD
AB Background. Transcutaneous electrical nerve stimulation (TENS) has been used as analgesic therapy in many diseases. It is already known that studies that have observed the relationship between pain and cytokines have found that patients who report less severe pain have less production of proinflammatory cytokines. However, one another accepted mechanism is that decreasing proinflammatory cytokines results in decreased pain intensity. Analyzing the literature, the authors describe that, in addition to the analgesic effect, TENS has shown systemic effects, and clinically, the reduction of proinflammatory cytokines could be a protective factor against inflammation. To test the inflammatory effect of TENS, we researched the literature for clinical conditions that suggest that proinflammatory cytokines are one of the main mediators of the disease process. Chronic inflammation is one of the risk factors mentioned for the development of a new cancer; at the same time, it is indicated as an indicator of the worst prognosis. Studies also suggest that the worst prognosis of breast cancer, one of the types with the highest incidence in the world, may be related to increased inflammatory activity. Considering that inflammation is increased in breast cancer and that TENS can reduce proinflammatory cytokines even without blocking the pain pathway, our hypothesis is that the anti-inflammatory effect of TENS can bring benefits to these patients. The aim of this study will be to evaluate the effect of TENS on blood reduction of proinflammatory cytokines in breast cancer patients. Methods. This study will evaluate at least 59 patients, over 18 years of age, diagnosed with breast cancer, but who have not yet started any treatment. All patients will be submitted to TENS intervention (Ibramed, Model Neurodyn III, parameters: VIF-turn on, frequency-2-247 Hz, pulse size-50-500 mu s, and intensity (mA)-maximum tolerated by the patient), and the data will be analyzed in the pre- and postintervention of each patient. The application has a total duration of 30 minutes, and 8 ml of blood will be collected before and after the intervention. Proinflammatory (IL-1, IL-2, IL-6, IL-7, and TNF-alpha) and anti-inflammatory (IL-4, IL-10, IL-13, and FTC beta) cytokines will be analyzed. As a primary endpoint, we will analyze the reduction in blood concentration of proinflammatory cytokines, and as secondary endpoints, we will analyze the size of the effect according to each type of proinflammatory cytokine, describe the effect size of the reduction according to the breast cancer immunohistochemistry, and analyze the effect of TENS on anti-inflammatory cytokines. This study is approved by the Research Ethics Committee (Centro Universitario FMABC, Brazil) and registered in the Brazilian Clinical Trials (Search text: RBR-10jbwh47).
C1 [do Carmo Almeida, Tabata Cristina; da Silva Paiva, Laercio; de Carvalho, Luis Eduardo Werneck; Schoueri, Jean; Adami, Fernando] Ctr Univ FMABC, Lab Epidemiol & Analise Dados, Av Lauro Gomes 2000, BR-09060870 Santo Andre, SP, Brazil.
   [Zatta, Simone Meneghette] Clin Res, Pesquisare Saude, Av Dom Pedro 2,Room 53, BR-09060110 Santo Andre, SP, Brazil.
   [de Carvalho, Luis Eduardo Werneck] Oncol Brasil Ensino & Pesquisa, Av Visc de Souza Franco 570, BR-66053000 Belem, Para, Brazil.
   [de Abreu, Luiz Carlos] Ctr Univ FMABC, Lab Delineamento Estudos & Escrita Cient, Av Lauro Gomes 2000, BR-09060870 Santo Andre, SP, Brazil.
   [Fonseca, Fernando Luiz Affonso] Ctr Univ FMABC, Lab Anal Clin, Av Lauro Gomes 2000, BR-09060870 Santo Andre, SP, Brazil.
   [Fonseca, Fernando Luiz Affonso] Univ Fed Sao Paulo UNIFESP, Dept Ciencias Farmaceut, Sao Paulo, SP, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP)
RP Almeida, TCD (corresponding author), Ctr Univ FMABC, Lab Epidemiol & Analise Dados, Av Lauro Gomes 2000, BR-09060870 Santo Andre, SP, Brazil.
EM tabatacristina@yahoo.com.br; szatta50@gmail.com; laercio.paiva@fmabc.br;
   dreduardocarvalho@oncologicadobrasil.com.br; jean.schoueri@gmail.com;
   luiz.abreu@fmabc.br; profferfonseca@gmail.com; fernando.adami@fmabc.br
RI do Carmo Almeida, Tábata Cristina/N-1039-2017; de Abreu,
   Luiz/B-7873-2012; Schoueri, Jean/X-7806-2018
OI do Carmo Almeida, Tábata Cristina/0000-0001-7069-8772; 
CR Atsumi T, 2014, CANCER RES, V74, P8, DOI 10.1158/0008-5472.CAN-13-2322
   de Oliveira CMB, 2011, REV BRAS ANESTESIOL, V61, P255, DOI 10.1016/S0034-7094(11)70029-0
   Beilin B, 2003, ANESTH ANALG, V97, P822, DOI 10.1213/01.ANE.0000078586.82810.3B
   Beilin B, 2003, ANESTHESIOLOGY, V98, P151, DOI 10.1097/00000542-200301000-00024
   Ben-Baruch A, 2003, BREAST CANCER RES, V5, P31, DOI 10.1186/bcr554
   Bray F, 2012, LANCET ONCOL, V13, P790, DOI 10.1016/S1470-2045(12)70211-5
   Chan AW, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.e7586
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Cramp AFL, 2000, CLIN PHYSIOL, V20, P150
   Cruz F.M., 2013, REV BRASILEIRA ONCOL, V9
   DeSantis C, 2014, CA-CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203
   Almeida TCD, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/1094352
   Figueiredo Cláudia Roberta L. V., 2019, J. Bras. Patol. Med. Lab., V55, P321, DOI [10.5935/1676-2444.20190029, 10.5935/1676-2444.20190029]
   Fiorelli A, 2016, EUR J CARDIO-THORAC, V49, P339, DOI 10.1093/ejcts/ezv097
   Fiorelli A, 2012, EUR J CARDIO-THORAC, V41, P861, DOI 10.1093/ejcts/ezr108
   Gonçalves João, 2014, Arq Med, V28, P08
   Igwea SE, 2016, COMPLEMENT THER CLIN, V24, P86, DOI 10.1016/j.ctcp.2016.05.001
   Jauregui Julio J, 2016, Surg Technol Int, V28, P296
   Jemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI 10.3322/caac.20107
   Johnson M.I., 2016, COCHRANE LIB, V2015
   Kavoussi B, 2007, INTEGR CANCER THER, V6, P251, DOI 10.1177/1534735407305892
   Kim SK, 2010, AUTON NEUROSCI-BASIC, V157, P38, DOI 10.1016/j.autneu.2010.03.010
   Kozlowski L, 2003, Rocz Akad Med Bialymst, V48, P82
   Kraychete Durval Campos, 2006, Rev. Bras. Reumatol., V46, P199
   Martin L, 2010, J CLIN ONCOL, V28, P4376, DOI 10.1200/JCO.2009.27.1916
   Moran F, 2011, J PAIN, V12, P929, DOI 10.1016/j.jpain.2011.02.352
   Ngai SPC, 2010, RESP PHYSIOL NEUROBI, V173, P29, DOI 10.1016/j.resp.2010.06.005
   Ouyang BS, 2011, CHIN J INTEGR MED, V17, P505, DOI 10.1007/s11655-011-0783-2
   Ouyang Ba-Si, 2010, Zhongguo Zhen Jiu, V30, P840
   Pantaleao MA, 2011, J PAIN, V12, P581, DOI 10.1016/j.jpain.2010.11.001
   Polyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295
   Schleder Juliana Carvalho, 2017, Rev. dor, V18, P316, DOI [10.5935/1806-0013.20170122, 10.5935/1806-0013.20170122]
   Sharma Nidhi, 2017, J Midlife Health, V8, P36, DOI 10.4103/jmh.JMH_60_16
   Shavit Y, 2006, J NEUROIMMUNE PHARM, V1, P443, DOI 10.1007/s11481-006-9043-1
   Sommer C, 2004, NEUROSCI LETT, V361, P184, DOI 10.1016/j.neulet.2003.12.007
   Song C, 2009, PHARMACOPSYCHIATRY, V42, P182, DOI 10.1055/s-0029-1202263
   Vance CGT, 2014, PAIN MANAG, V4, P197, DOI [10.2217/PMT.14.13, 10.2217/pmt.14.13]
   Viechtbauer W, 2015, J CLIN EPIDEMIOL, V68, P1375, DOI 10.1016/j.jclinepi.2015.04.014
   Wang Jun-lu, 2008, Zhen Ci Yan Jiu, V33, P26
   Yan L, 2006, EUR J CANCER, V42, P793, DOI 10.1016/j.ejca.2006.01.013
   Zhang JM, 2007, INT ANESTHESIOL CLIN, V45, P27, DOI 10.1097/AIA.0b013e318034194e
NR 41
TC 3
Z9 3
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0962-9351
EI 1466-1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PD FEB 18
PY 2022
VL 2022
AR 1350813
DI 10.1155/2022/1350813
PG 8
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA ZR1LK
UT WOS:000767553500001
PM 35241969
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Zeng, JC
   Lu, YQ
   Chu, H
   Lu, LM
   Chen, YX
   Ji, KS
   Lin, YZ
   Li, JJ
   Wang, SX
AF Zeng, Jingchun
   Lu, Yiqian
   Chu, Hui
   Lu, Liming
   Chen, Yuexuan
   Ji, Kaisong
   Lin, Yeze
   Li, Jingjing
   Wang, Shuxin
TI Research trends and frontier hotspots of TRPV1 based on bibliometric and
   visualization analyses
SO HELIYON
LA English
DT Review
DE TRPV1; Bibliometrics; Visualization analyses; Research hotspots;
   CiteSpace
ID POTENTIAL VANILLOID 1; CANCER-CELLS INVOLVEMENT; CAPSAICIN-RECEPTOR;
   CHANNEL CONTRIBUTES; OXIDATIVE STRESS; ION-CHANNEL; SPINAL-CORD;
   ACTIVATION; EXPRESSION; BRAIN
AB Background: Transient receptor potential vanilloid type1 (TRPV1) is a non-selective cation channel with multiple activation mechanisms, which has received increasing attention since it was first cloned in 1997. Methods: We used bibliometric and visualization analyses to evaluate the theme trends and knowledge structure of TRPV1 research-papers on TRPV1 from 2002 to 2022 obtained from the Web of Science Core Collection. VOSviewer and CiteSpace were used to analyze authors, institutions, countries, co-cited references, and keywords. Results: A total of 7413 papers were included. The main research area of TRPV1 was neuroscience; the most published country was the United States, and the University of California, San Francisco, had the highest centrality. Two major collaborative sub-networks were formed between the authors. The distribution of keywords shows that TRPV1 was initially studied extensively, and the recent studies focused on TRPV1 structure and diseases. "Oxidative stress," "TRPV1 structure," "cancer," and "model" have been the research hotspots in recent years. Conclusions: This research provides valuable information for the study of TRPV1. Disease research was focused on pain, cancer, and neurodegenerative diseases. Both agonists and antagonists of TRPV1 are gradually being used in clinical practice, and acupuncture was effective in treating TRPV1-mediated inflammatory pain. TRPV1 is involved in classical endogenous cannabis system signaling, and new signaling pathways continue to be revealed.
C1 [Zeng, Jingchun; Lin, Yeze; Wang, Shuxin] Guangzhou Univ Chinese Med, Rehabil Ctr, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
   [Lu, Yiqian; Chu, Hui; Chen, Yuexuan; Ji, Kaisong] Guangzhou Univ Chinese Med, Clin Med Coll 1, Guangzhou, Guangdong, Peoples R China.
   [Lu, Liming] Guangzhou Univ Chinese Med, Med Coll Acu Moxi & Rehabil, South China Res Ctr Acupuncture & Moxibust, Clin Res & Data Ctr, Guangzhou, Guangdong, Peoples R China.
   [Li, Jingjing] Guangzhou Univ Tradit Chinese Med, Baoan Tradit Chinese Med Hosp, Clin Med Coll 7, Shenzhen, Guangdong, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou
   University of Chinese Medicine
RP Wang, SX (corresponding author), Guangzhou Univ Chinese Med, Rehabil Ctr, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.; Li, JJ (corresponding author), Guangzhou Univ Tradit Chinese Med, Baoan Tradit Chinese Med Hosp, Clin Med Coll 7, Shenzhen, Guangdong, Peoples R China.
EM lijingjing85@gzucm.edu.cn; widiot@126.com
RI ; Chen, Yuexuan/OGQ-5217-2025
OI Wang, Shuxin/0000-0002-8320-7685; 
FU Traditional Chinese Medicine Bureau of Guangdong Province [20211128];
   Guangzhou Municipal Science and Technology Bureau [202201011206]; Basic
   and Applied Research Fund of Guangdong Province [2019A1515110371]
FX This study was supported by the Traditional Chinese Medicine Bureau of
   Guangdong Province (20211128) ; Guangzhou Municipal Science and
   Technology Bureau (202201011206) ; and the Basic and Applied Research
   Fund of Guangdong Province (2019A1515110371) . These Funding
   organizations had no role in the study design, collection, analysis, and
   interpretation of data, writing the manuscript, or the decision to
   submit the paper for publication.
CR Abbas MA, 2020, CHEM-BIOL INTERACT, V330, DOI 10.1016/j.cbi.2020.109178
   Akiba Y, 2004, BIOCHEM BIOPH RES CO, V321, P219, DOI 10.1016/j.bbrc.2004.06.149
   Akopian AN, 2009, TRENDS PHARMACOL SCI, V30, P79, DOI 10.1016/j.tips.2008.10.008
   Alawi K, 2010, PHARMACOL THERAPEUT, V125, P181, DOI 10.1016/j.pharmthera.2009.10.005
   Basith S, 2016, MOLECULES, V21, DOI 10.3390/molecules21080966
   Bert J., 2016, INT MED REV, V124, P1
   BEVAN S, 1992, BRIT J PHARMACOL, V107, P544, DOI 10.1111/j.1476-5381.1992.tb12781.x
   Bhaskaran MD, 2010, EXP NEUROL, V223, P529, DOI 10.1016/j.expneurol.2010.01.021
   Birder LA, 2002, NAT NEUROSCI, V5, P856, DOI 10.1038/nn902
   Boudes M, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00130
   Brown BS, 2010, BIOORG MED CHEM LETT, V20, P3291, DOI 10.1016/j.bmcl.2010.04.047
   Carrasco C, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00095
   Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807
   Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906
   Cavanaugh DJ, 2011, J NEUROSCI, V31, P5067, DOI 10.1523/JNEUROSCI.6451-10.2011
   Çetin ES, 2017, J RECEPT SIG TRANSD, V37, P84, DOI 10.3109/10799893.2016.1160931
   Chen L, 2017, J ALZHEIMERS DIS, V59, P683, DOI 10.3233/JAD-170337
   Chen SJ, 2014, J BIOL CHEM, V289, P36284, DOI 10.1074/jbc.M114.620922
   Chen Y, 2011, NEUROSCIENCE, V193, P440, DOI 10.1016/j.neuroscience.2011.06.085
   Chung MK, 2016, PHARMACEUTICALS-BASE, V9, DOI 10.3390/ph9040066
   Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196
   Czifra G, 2009, J CANCER RES CLIN, V135, P507, DOI 10.1007/s00432-008-0482-3
   Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076
   Di Marzo V, 2002, CURR OPIN NEUROBIOL, V12, P372, DOI 10.1016/S0959-4388(02)00340-9
   Du YH, 2020, AGING CELL, V19, DOI 10.1111/acel.13113
   Ertilav K, 2021, BIOL TRACE ELEM RES, V199, P1469, DOI 10.1007/s12011-020-02250-4
   Fernández-Carvajal A, 2022, FRONT MOL NEUROSCI, V15, DOI 10.3389/fnmol.2022.930964
   Fischbach T, 2007, J NEUROPHYSIOL, V98, P929, DOI 10.1152/jn.01096.2006
   Fischer D, 2008, MOL CELL NEUROSCI, V37, P471, DOI 10.1016/j.mcn.2007.11.002
   Fonseca BM, 2018, J PHYSIOL BIOCHEM, V74, P261, DOI 10.1007/s13105-018-0611-7
   Gao MK, 2021, EXPERT OPIN THER PAT, V31, P169, DOI 10.1080/13543776.2021.1854225
   Garami A, 2020, PHARMACOL THERAPEUT, V208, DOI 10.1016/j.pharmthera.2020.107474
   Gonzales CB, 2014, ORAL ONCOL, V50, P437, DOI 10.1016/j.oraloncology.2013.12.023
   Hartel M, 2006, GUT, V55, P519, DOI 10.1136/gut.2005.073205
   Hassan S, 2014, BRIT J PHARMACOL, V171, P2426, DOI 10.1111/bph.12615
   Helliwell RJA, 1998, NEUROSCI LETT, V250, P177, DOI 10.1016/S0304-3940(98)00475-3
   Hind WH, 2015, BRIT J PHARMACOL, V172, P3015, DOI 10.1111/bph.13106
   Ho KW, 2014, GLIA, V62, P1435, DOI 10.1002/glia.22691
   Howlett AC, 2002, PROSTAG OTH LIPID M, V68-9, P619, DOI 10.1016/S0090-6980(02)00060-6
   Huang JJ, 2006, SEMIN CELL DEV BIOL, V17, P638, DOI 10.1016/j.semcdb.2006.11.002
   Huang SM, 2002, P NATL ACAD SCI USA, V99, P8400, DOI 10.1073/pnas.122196999
   Iannotti FA, 2014, ACS CHEM NEUROSCI, V5, P1131, DOI 10.1021/cn5000524
   Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497
   Kato S, 2003, BIOCHEM PHARMACOL, V66, P1115, DOI 10.1016/S0006-2952(03)00461-1
   Kim J, 2020, HUM MOL GENET, V29, P228, DOI 10.1093/hmg/ddz276
   Komiya H, 2018, J DENT RES, V97, P467, DOI 10.1177/0022034517741253
   Kong WL, 2017, BRAIN BEHAV IMMUN, V64, P354, DOI 10.1016/j.bbi.2017.03.007
   Kumar R, 2017, FASEB J, V31, P1238, DOI 10.1096/fj.201601132R
   Lee GR, 2013, OBESITY, V21, P115, DOI 10.1002/oby.20246
   Lee Y, 2015, EXPERT OPIN THER PAT, V25, P291, DOI 10.1517/13543776.2015.1008449
   Li L, 2021, INT J BIOL SCI, V17, P2034, DOI 10.7150/ijbs.59918
   Liao HY, 2017, SCI REP-UK, V7, DOI 10.1038/srep42531
   Lishko PV, 2007, NEURON, V54, P905, DOI 10.1016/j.neuron.2007.05.027
   Liu T, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2831-y
   Liu YJ, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/9102107
   Lu KW, 2016, SCI REP-UK, V6, DOI 10.1038/srep22123
   Martins D, 2014, NEUROPHARMACOLOGY, V85, P151, DOI 10.1016/j.neuropharm.2014.05.034
   Masuoka T, 2020, BRIT J PHARMACOL, V177, P4223, DOI 10.1111/bph.15176
   McDonald JL, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/591796
   Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002
   Miyake T, 2015, GLIA, V63, P1870, DOI 10.1002/glia.22854
   Nakanishi M, 2016, EXP CELL RES, V345, P180, DOI 10.1016/j.yexcr.2016.06.006
   Nam JH, 2015, BRAIN, V138, P3610, DOI 10.1093/brain/awv297
   Öz A, 2022, METAB BRAIN DIS, V37, P2291, DOI 10.1007/s11011-022-01037-x
   Punzo F, 2018, PHARMACOL RES, V137, P25, DOI 10.1016/j.phrs.2018.09.017
   Razavi R, 2006, CELL, V127, P1123, DOI 10.1016/j.cell.2006.10.038
   Razavinasab M, 2013, FUND CLIN PHARMACOL, V27, P632, DOI 10.1111/fcp.12015
   Reilly CA, 2003, TOXICOL SCI, V73, P170, DOI 10.1093/toxsci/kfg044
   Santello M, 2019, NAT NEUROSCI, V22, P154, DOI 10.1038/s41593-018-0325-8
   Serafini M, 2018, J MED CHEM, V61, P4436, DOI 10.1021/acs.jmedchem.8b00109
   Singh R, 2021, EXPERT OPIN THER TAR, V25, P529, DOI 10.1080/14728222.2021.1956464
   Soliman E, 2016, MOL CARCINOGEN, V55, P1807, DOI 10.1002/mc.22429
   Southall MD, 2003, J PHARMACOL EXP THER, V304, P217, DOI 10.1124/jpet.102.040675
   Stock K, 2012, NAT MED, V18, P1232, DOI 10.1038/nm.2827
   Szallasi A, 1995, BRAIN RES, V703, P175, DOI 10.1016/0006-8993(95)01094-7
   Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4
   Tsumura M, 2012, CELL CALCIUM, V52, P124, DOI 10.1016/j.ceca.2012.05.002
   Uguz AC, 2012, J PINEAL RES, V53, P91, DOI 10.1111/j.1600-079X.2012.00974.x
   van Eck NJ, 2010, SCIENTOMETRICS, V84, P523, DOI 10.1007/s11192-009-0146-3
   Venkatachalam K, 2007, ANNU REV BIOCHEM, V76, P387, DOI 10.1146/annurev.biochem.75.103004.142819
   [王鑫栋 Wang Xindong], 2021, [中国皮肤性病学杂志, The Chinese Journal of Dermatovenereology], V35, P684
   Weber LV, 2016, BREAST CANCER-TARGET, V8, P243, DOI 10.2147/BCTT.S121610
   Weil A, 2005, MOL PHARMACOL, V68, P518, DOI 10.1124/mol.105.012146
   Wu ZZ, 2013, PAIN, V154, P2130, DOI 10.1016/j.pain.2013.06.040
   Xie YK, 2022, SCI TRANSL MED, V14, DOI 10.1126/scitranslmed.abh2557
   Xu SC, 2018, FOOD FUNCT, V9, P344, DOI 10.1039/c7fo01295k
   Yang J, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/5068347
   Yu W, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.004971
   Zhang LL, 2007, CIRC RES, V100, P1063, DOI 10.1161/01.RES.0000262653.84850.8b
   Zhang Xuejun C, 2022, Biophys Rep, V8, P205, DOI [10.52601/bpr.2022.220012, 10.52601/bpr.2022.220012]
   Zhu K, 2023, EUR J MED CHEM, V261, DOI 10.1016/j.ejmech.2023.115806
   Zhu YF, 2019, THORAC CANCER, V10, P988, DOI 10.1111/1759-7714.13042
   Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761
NR 93
TC 9
Z9 10
U1 2
U2 31
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2405-8440
J9 HELIYON
JI Heliyon
PD JAN 5
PY 2024
VL 10
IS 2
AR e24153
DI 10.1016/j.heliyon.2024.e24153
EA JAN 2024
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA IB8B0
UT WOS:001163942600001
PM 38293347
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Geagea, D
   Tyack, Z
   Kimble, R
   Polito, V
   Ayoub, B
   Terhune, DB
   Griffin, B
AF Geagea, Dali
   Tyack, Zephanie
   Kimble, Roy
   Polito, Vince
   Ayoub, Bassel
   Terhune, Devin B.
   Griffin, Bronwyn
TI Clinical Hypnosis for Procedural Pain and Distress in Children: A
   Scoping Review
SO PAIN MEDICINE
LA English
DT Review
DE Procedural Pain; Distress; Clinical Hypnosis; Children; Scoping Review
ID PEDIATRIC CANCER-PATIENTS; SYSTEMATIC REVIEWS; VIRTUAL-REALITY;
   SELF-HYPNOSIS; BURN PAIN; REDUCTION; ANXIETY; ADOLESCENTS; MANAGEMENT;
   ANALGESIA
AB Objective Pain and distress are common in children undergoing medical procedures, exposing them to acute and chronic biopsychosocial impairments if inadequately treated. Clinical hypnosis has emerged as a potentially beneficial treatment for children's procedural pain and distress due to evidence of effectiveness and potential superiority to other psychological interventions. However, systematic reviews of clinical hypnosis for children's procedural pain and distress have been predominantly conducted in children undergoing oncology and needle procedures and are lacking in broader pediatric contexts. This scoping review maps the evidence of clinical hypnosis for children's procedural pain and distress across broad pediatric contexts while highlighting knowledge gaps and areas requiring further investigation. Methods Published databases (PubMed, Cochrane Library, PsycINFO, Embase, CINAHL, Scopus, and Web of Science) and grey literature were searched in addition to hand-searching reference lists and key journals (up to May 2022). Two independent reviewers screened the titles and abstracts of search results followed by a full-text review against eligibility criteria. Articles were included if they involved a clinical hypnosis intervention comprising an induction followed by therapeutic suggestions for pain and distress in children undergoing medical procedures. This review followed the Arksey and O'Malley (2005) methodology and incorporated additional scoping review recommendations by the Joanna Briggs Institute and Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Results A total of 38 eligible studies involving 2,205 children were included after 4,775 articles were screened. Research on clinical hypnosis for children's procedural pain and distress was marked by a lack of fidelity measures and qualitative data as well as by inadequate intervention reporting and high attrition rates. Evidence regarding the safety of clinical hypnosis, pain unpleasantness outcomes, factors influencing outcomes, as well as barriers and facilitators to implementing hypnosis and study procedures was also lacking. Clinical hypnosis has potential benefits for children's procedural pain and distress based on evidence of superiority to control conditions and nonpharmacological interventions (e.g., distraction, acupressure) with moderate to large effect sizes as reported in 76% of studies. However, heterogeneous interventions, contexts, study designs, and populations were identified, and the certainty of the evidence was not evaluated. Conclusions The review suggests potential benefits of clinical hypnosis for children's procedural pain and distress and thus provides a precursor for further systematic reviews and trials investigating the effectiveness of clinical hypnosis. The review also indicates the need to further explore the feasibility, acceptability, implementation, and safety of clinical hypnosis in children undergoing painful procedures. Based on the review, researchers implementing clinical hypnosis should adequately report interventions or use treatment manuals, follow recommended research guidelines, and assess the fidelity of intervention delivery to promote replicating and comparing interventions. The review also highlights common methodological shortcomings of published trials to avoid, such as the lack of implementation frameworks, small sample sizes, inadequate reporting of standard care or control conditions, and limited evidence on pain unpleasantness outcomes.
C1 [Geagea, Dali; Tyack, Zephanie] Univ Queensland, Child Hlth Res Ctr, Ctr Childrens Burns & Trauma Res, Brisbane, Australia.
   [Tyack, Zephanie] Queensland Univ Technol, Australian Ctr Hlth Serv Innovat, Brisbane, Australia.
   [Tyack, Zephanie] Queensland Univ Technol, Ctr Healthcare Transformat, Sch Publ Hlth & Social Work, Brisbane, Australia.
   [Kimble, Roy] Univ Queensland, Queensland Childrens Hosp, Ctr Childrens Burns & Trauma Res, Brisbane, Australia.
   [Polito, Vince] Macquarie Univ, Sch Psychol Sci, Sydney, Australia.
   [Ayoub, Bassel] Queensland Univ Technol, Fac Hlth, Brisbane, Australia.
   [Terhune, Devin B.] Goldsmiths Univ London, Dept Psychol, London, England.
   [Terhune, Devin B.] Kings Coll London, Inst Psychiat, Dept Psychol, Psychol & Neurosci, London, England.
   [Griffin, Bronwyn] Griffith Univ, Sch Nursing & Midwifery, Nathan, Qld, Australia.
   [Geagea, Dali] Ctr Childrens Hlth Res, Level 7,62 Graham St, South Brisbane, Qld 4101, Australia.
C3 University of Queensland; Queensland University of Technology (QUT);
   Queensland University of Technology (QUT); University of Queensland;
   Childrens Health Queensland Hospital & Health Service; Queensland
   Childrens Hospital; Macquarie University; Queensland University of
   Technology (QUT); University of London; Goldsmiths University London;
   University of London; King's College London; Griffith University
RP Geagea, D (corresponding author), Ctr Childrens Hlth Res, Level 7,62 Graham St, South Brisbane, Qld 4101, Australia.
EM d.geagea@uq.net.au
RI Terhune, Devin/GNM-6644-2022; Tyack, Zephanie/Z-4135-2019; Griffin,
   Bronwyn/AEB-6299-2022; Geagea, Daly/AFO-4985-2022; Ayoub,
   Bassel/HJY-9150-2023; Kimble, Roy/B-4160-2011; Polito, Vince/A-7348-2011
OI Terhune, Devin/0000-0002-6792-4975; Tyack, Zephanie/0000-0003-3376-5731;
   Griffin, Bronwyn/0000-0002-6182-9125; Geagea, Daly/0000-0002-9289-7809;
   Polito, Vince/0000-0003-3242-9074
CR Accardi MC, 2009, J BEHAV MED, V32, P328, DOI 10.1007/s10865-009-9207-6
   AMBUEL B, 1992, J PEDIATR PSYCHOL, V17, P95, DOI 10.1093/jpepsy/17.1.95
   Arksey H., 2005, INT J SOC RES METHOD, V8, P19, DOI [10.1080/1364557032000119616, DOI 10.1080/1364557032000119616]
   Axelrad ABD., 2009, KAPLAN SADOCKS COMPR, V9th, P2804
   Baaleman DF, 2022, J NEUROGASTROENTEROL, V28, P312, DOI 10.5056/jnm20274
   Babineau J, 2014, J CAN HEALTH LIBRARI, V35, P68, DOI 10.5596/c14-016
   Barlow D H., 1988, Anxiety and Its Disorders: The Nature and Treatment of Anxiety Panic
   Bayat A, 2010, EXPERT REV NEUROTHER, V10, P1747, DOI [10.1586/ern.10.158, 10.1586/ERN.10.158]
   Birnie KA, 2014, J PEDIATR PSYCHOL, V39, P783, DOI 10.1093/jpepsy/jsu029
   Blount R.L., 2009, Handbook of Pediatric Psychology, V4th, P171
   Boggia B, 2020, HAEMOPHILIA, V26, P117
   Brennan F, 2007, ANESTH ANALG, V105, P205, DOI 10.1213/01.ane.0000268145.52345.55
   Brown EA, 2018, CLIN CHILD FAM PSYCH, V21, P224, DOI 10.1007/s10567-017-0252-3
   Brown NJ, 2014, BURNS, V40, P751, DOI 10.1016/j.burns.2013.09.027
   Brown NJ, 2014, BURNS, V40, P204, DOI 10.1016/j.burns.2013.11.024
   Brydges CR, 2019, INNOV AGING, V3, DOI 10.1093/geroni/igz036
   Butler LD, 2005, PEDIATRICS, V115, pE77, DOI 10.1542/peds.2004-0818
   Calipel S, 2005, PEDIATR ANESTH, V15, P275, DOI 10.1111/j.1460-9592.2004.01514.x
   Centre for Musculoskeletal Outcomes Research (CMOR) Dunedin School of Medicine University of Otago Dunedin New Zealand, 2020, OBM Integrative and Complementary Medicine, V5, DOI [10.21926/obm.icm.2001005, 10.21926/obm.icm.2001005, DOI 10.21926/OBM.ICM.2001005]
   Cheseaux N, 2014, INT J CLIN EXP HYP, V62, P399, DOI 10.1080/00207144.2014.931170
   Chester SJ, 2018, PAIN, V159, P1790, DOI 10.1097/j.pain.0000000000001276
   Christian LM, 2006, NEUROIMMUNOMODULAT, V13, P337, DOI 10.1159/000104862
   Cohen LL, 2008, J PEDIATR PSYCHOL, V33, P939, DOI 10.1093/jpepsy/jsm103
   Colquhoun HL, 2014, J CLIN EPIDEMIOL, V67, P1291, DOI 10.1016/j.jclinepi.2014.03.013
   Craig P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1655
   CRAWFORD AH, 1976, ANESTH ANALG, V55, P42
   Duparc-Alegria N, 2018, J CLIN NURS, V27, P86, DOI 10.1111/jocn.13848
   Elkins G, 2005, PSYCHOTHERAPY, V42, P232, DOI 10.1037/0033-3204.42.2.232
   Elkins GR, 2015, INT J CLIN EXP HYP, V63, P1, DOI 10.1080/00207144.2014.961870
   ENQVIST B, 1995, STRESS MEDICINE, V11, P229, DOI 10.1002/smi.2460110138
   Erappa Umadevi, 2021, Int J Clin Pediatr Dent, V14, pS186, DOI [10.5005/jp-journals-10005-2113, 10.5005/jp-journals-10005-2113]
   FRICTON JR, 1985, AM J CLIN HYPN, V27, P226, DOI 10.1080/00029157.1985.10402612
   Gagnier JJ, 2013, DTSCH ARZTEBL INT, V110, P603, DOI [10.1186/1752-1947-7-223, 10.1111/head.12246, 10.7453/gahmj.2013.008, 10.3238/arztebl.2013.0603, 10.1136/bcr-2013-201554]
   Geagea D, 2021, PAIN MED, V22, P2818, DOI 10.1093/pm/pnab038
   Gillum M, 2022, J BURN CARE RES, V43, P368, DOI 10.1093/jbcr/irab167
   GOKLI MA, 1994, J DENT CHILD, V61, P272
   Goodenough B, 1999, EUR J PAIN, V3, P301, DOI 10.1016/S1090-3801(99)90012-5
   Gough D, 2012, SYST REV-LONDON, V1, DOI 10.1186/2046-4053-1-28
   Hawkins P.J., 1998, CONT HYPNOSIS, V15, P199, DOI [DOI 10.1002/CH.135, 10.1002/ch.135]
   Hilgard E.R., 1965, Hypnotic susceptibility
   HILGARD JR, 1982, INT J CLIN EXP HYP, V30, P417, DOI 10.1080/00207148208407277
   Hodel TV., 1983, HYPNOSIS RELIEF PAIN
   Duedahl TH, 2007, PEDIATR ANESTH, V17, P756, DOI 10.1111/j.1460-9592.2007.02213.x
   Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]
   Huet A, 2011, INT J CLIN EXP HYP, V59, P424, DOI 10.1080/00207144.2011.594740
   Iserson KV, 2014, J EMERG MED, V46, P588, DOI 10.1016/j.jemermed.2013.09.024
   Maria PPJ, 2021, CHILDREN-BASEL, V8, DOI 10.3390/children8121195
   Kain ZN, 1996, ARCH PEDIAT ADOL MED, V150, P1238, DOI 10.1001/archpedi.1996.02170370016002
   Kashlak NL, 2012, The Acceptability of Imagery-Hypnosis for Management of Pain, Anxiety, and Distress Related to Needle Procedures in Pediatric OncologyHematology Patients
   KATZ ER, 1987, J PEDIATR PSYCHOL, V12, P379, DOI 10.1093/jpepsy/12.3.379
   Kekecs Z, 2022, INT J CLIN EXP HYP, V70, P104, DOI 10.1080/00207144.2022.2049446
   KELLERMAN J, 1983, J ADOLESCENT HEALTH, V4, P85, DOI 10.1016/S0197-0070(83)80024-2
   KOHEN DP, 1984, J DEV BEHAV PEDIATR, V5, P21
   Kohen DP., 2011, Hypnosis and Hypnotherapy With Children, V4th edition
   KUTTNER L, 1988, J DEV BEHAV PEDIATR, V9, P374
   Kuttner L, 2012, PEDIATR ANESTH, V22, P573, DOI 10.1111/j.1460-9592.2012.03860.x
   Lambert SA, 1996, J DEV BEHAV PEDIATR, V17, P307, DOI 10.1097/00004703-199610000-00003
   Lee GY, 2014, PEDIATRICS, V133, P500, DOI 10.1542/peds.2013-2744
   LETHEM J, 1983, BEHAV RES THER, V21, P401, DOI 10.1016/0005-7967(83)90009-8
   Liossi C, 1999, INT J CLIN EXP HYP, V47, P104, DOI 10.1080/00207149908410025
   Liossi C, 2003, INT J CLIN EXP HYP, V51, P4, DOI 10.1076/iceh.51.1.4.14064
   Liossi C, 2006, HEALTH PSYCHOL, V25, P307, DOI 10.1037/0278-6133.25.3.307
   Liossi C, 2009, PAIN, V142, P255, DOI 10.1016/j.pain.2009.01.017
   Lobe TE, 2006, J LAPAROENDOSC ADV S, V16, P639, DOI 10.1089/lap.2006.16.639
   Loncar Z, 2006, COLLEGIUM ANTROPOL, V30, P319
   Mahood Q, 2014, RES SYNTH METHODS, V5, P221, DOI 10.1002/jrsm.1106
   Manworren RCB, 2015, Journal of Pediatric Surgical Nursing, V4, P60, DOI [10.1097/jps.0000000000000061, 10.1097/JPS.0000000000000061, DOI 10.1097/JPS.0000000000000061]
   Manworren RCB, 2018, J LAPAROENDOSC ADV S, V28, P1234, DOI 10.1089/lap.2017.0699
   McGrath PJ, 1996, CLIN J PAIN, V12, P135, DOI 10.1097/00002508-199606000-00009
   McKittrick ML, 2022, PAIN MED, V23, P1015, DOI 10.1093/pm/pnab320
   Meller S T, 1994, Drugs, V47 Suppl 5, P10, DOI 10.2165/00003495-199400475-00004
   Milling LS, 2000, INT J CLIN EXP HYP, V48, P113, DOI 10.1080/00207140008410044
   Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005
   Montgomery GH, 2000, INT J CLIN EXP HYP, V48, P138, DOI 10.1080/00207140008410045
   MORGAN AH, 1973, INT J CLIN EXP HYP, V21, P78, DOI 10.1080/00207147308409308
   Munn Z, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-017-0468-4
   Nelson KL, 2010, ANESTH ANALG, V110, P754, DOI 10.1213/ANE.0b013e3181ca749c
   Nelson S, 2019, EUR J PAIN, V23, P421, DOI 10.1002/ejp.1319
   Oberoi J, 2016, PEDIATR DENT, V38, P112
   Ogez D, 2021, BRIT J PAIN, V15, P147, DOI 10.1177/2049463720932949
   Okur kavak EK., 2020, CRIT CARE, V24, P72, DOI [10.1186/s13054-020-2772-3, DOI 10.1186/S13054-020-2772-3]
   Orne M T., 1996, Introducing psychological research, DOI DOI 10.1007/978-1-349-24483-6_59
   Patterson DR, 2010, INT J CLIN EXP HYP, V58, P288, DOI 10.1080/00207141003760595
   Patterson DR, 2006, INT J CLIN EXP HYP, V54, P130, DOI 10.1080/00207140500528182
   Peters M., 2015, The Joanna Briggs Institute Reviewers manual 2015, P3, DOI DOI 10.1017/CBO9781107415324.004
   Polito V., 2014, J MIND-BODY REGUL, V2, P118
   Raja SN, 2020, PAIN, V161, P1976, DOI 10.1097/j.pain.0000000000001939
   Ramírez-Carrasco A, 2017, PAIN RES MANAG, V2017, DOI 10.1155/2017/1434015
   Richardson J, 2006, J PAIN SYMPTOM MANAG, V31, P70, DOI 10.1016/j.jpainsymman.2005.06.010
   Rienhoff S, 2022, CHILDREN-BASEL, V9, DOI 10.3390/children9050611
   Rocco T.S., 2009, HUM RESOUR DEV REV, V8, P120, DOI DOI 10.1177/1534484309332617
   Rycroft-Malone J, 2004, J NURS CARE QUAL, V19, P297, DOI 10.1097/00001786-200410000-00002
   Rycroft-Malone J, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-28
   Sabherwal P, 2021, EUR ARCH PAEDIATR DE, V22, P823, DOI 10.1007/s40368-021-00619-0
   Saxe G, 2001, J AM ACAD CHILD PSY, V40, P915, DOI 10.1097/00004583-200108000-00013
   Schnee AD., 1995, Ph.D. Thesis
   Schnur Julie B, 2008, Contemp Hypn, V25, P114, DOI 10.1002/ch.364
   Sheridan RL, 2014, J TRAUMA ACUTE CARE, V76, P828, DOI 10.1097/TA.0b013e3182ab111c
   Smith JT, 1996, J COUNS PSYCHOL, V43, P187, DOI 10.1037/0022-0167.43.2.187
   Stinson J, 2008, PAIN RES MANAG, V13, P51, DOI 10.1155/2008/465891
   Stoddard FJ, 2002, J BURN CARE REHABIL, V23, P135, DOI 10.1097/00004630-200203000-00012
   Terhune DB, 2016, AM J CLIN HYPN, V59, P155, DOI 10.1080/00029157.2016.1201454
   Thompson T, 2019, NEUROSCI BIOBEHAV R, V99, P298, DOI 10.1016/j.neubiorev.2019.02.013
   Tomé-Pires C, 2012, INT J CLIN EXP HYP, V60, P432, DOI 10.1080/00207144.2012.701092
   Tran LC, 2021, FRONT PEDIATR, V9, DOI 10.3389/fped.2021.719626
   Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850
   Turk D., 2019, PAIN TERMS TAXONOMIE, V5th
   Uman LS, 2006, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD005179.pub3, 10.1002/14651858.CD005179]
   Uman LS, 2008, J PEDIATR PSYCHOL, V33, P842, DOI 10.1093/jpepsy/jsn031
   Vanhaudenhuyse A, 2014, NEUROPHYSIOL CLIN, V44, P343, DOI 10.1016/j.neucli.2013.09.006
   WALL VJ, 1989, AM J CLIN HYPN, V31, P181, DOI 10.1080/00029157.1989.10402887
   Weisman SJ, 1998, ARCH PEDIAT ADOL MED, V152, P147
   Widgerow AD, 2012, BURNS, V38, P951, DOI 10.1016/j.burns.2012.05.024
   Wild MR, 2004, J DEV BEHAV PEDIATR, V25, P207, DOI 10.1097/00004703-200406000-00010
   Williams J, 2013, UNITED NATIONS CONVENTION ON THE RIGHTS OF THE CHILD IN WALES, P1
   Yeh Vivian M, 2014, Psychol Conscious (Wash D C), V1, P213
   Young KD, 2005, ANN EMERG MED, V45, P160, DOI 10.1016/j.annemergmed.2004.09.019
   ZELTZER L, 1982, J PEDIATR-US, V101, P1032
   ZELTZER LK, 1991, PEDIATRICS, V88, P34
   Zielinski J, 2020, ADV CLIN EXP MED, V29, P365, DOI 10.17219/acem/112600
NR 120
TC 21
Z9 21
U1 3
U2 26
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1526-2375
EI 1526-4637
J9 PAIN MED
JI Pain Med.
PD JUN 1
PY 2023
VL 24
IS 6
BP 661
EP 702
DI 10.1093/pm/pnac186
EA JAN 2023
PG 42
WC Anesthesiology; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Anesthesiology; General & Internal Medicine
GA H7AP5
UT WOS:000905659900001
PM 36448690
OA Green Submitted, Bronze
DA 2026-01-16
ER

PT J
AU Bae, K
   Song, SY
AF Bae, Kyeore
   Song, Si Yeon
TI Comparison of the clinical effectiveness of treatments for aromatase
   inhibitor-induced arthralgia in breast cancer patients: a protocol for a
   systematic review and network meta-analysis
SO BMJ OPEN
LA English
DT Article
ID CONTROLLED-TRIAL; RISK-FACTORS; JOINT PAIN; THERAPY; PLACEBO;
   MULTICENTER; ANASTROZOLE; SYMPTOMS; OMEGA-3-FATTY-ACIDS; ACUPUNCTURE
AB Introduction Aromatase inhibitor-induced arthralgia (AIA) is a major adverse event of aromatase inhibitors (AIs) and leads to premature discontinuation of AI therapy in breast cancer patients. The objective of this protocol for a systematic review and network meta-analysis (NMA) is to provide the methodology to compare the change in pain intensity between different AIA treatments and demonstrate the rank probabilities for different treatments by combining all available direct and indirect evidence.
   Methods and analysis PubMed, the Cochrane Controlled Register of Trials (CENTRAL), EMBASE, Web of Science and ClinicalTrials.gov will be searched to identify publications in English from inception to November 2019. We will include randomised controlled trials (RCTs) assessing the effects of different treatments for AIA in postmenopausal women with stage 0-III hormone receptor-positive breast cancer. The primary endpoints will be the change in patient-reported pain intensity from baseline to post-treatment. The number of adverse events will be presented as a secondary outcome.
   Both pairwise meta-analysis and NMA with the Frequentist approach will be conducted. We will demonstrate summary estimates with forest plots in meta-analysis and direct and mixed evidence with a ranking of the treatments as the P-score in NMA. The revised Cochrane risk-of-bias tool for randomised trials will be used to assess the methodological quality within individual RCTs. The quality of evidence will be assessed.
   Ethics and dissemination As this review does not involve individual patients, ethical approval is not required. The results of this systematic review and NMA will be published in a peer-reviewed journal. This review will provide valuable information on AIA therapeutic options for clinicians, health practitioners and breast cancer survivors.
C1 [Bae, Kyeore] Kwanghye Hosp, Ctr Immun & Pain, Dept Integrat Med, Seoul, South Korea.
   [Song, Si Yeon] Daejeon Univ, East West Canc Ctr, Dunsan Korean Med Hosp, Daejeon, South Korea.
C3 Daejeon University
RP Bae, K (corresponding author), Kwanghye Hosp, Ctr Immun & Pain, Dept Integrat Med, Seoul, South Korea.
EM kyeorebae@gmail.com
OI Bae, Kyeore/0000-0002-8596-8293
FU  [MIMIC2019-RS07]
FX This research is supported by a grant of the Research Supporting
   Programme, MIMICUS Inc. (MIMIC2019-RS07). The funders had no role in
   development of the protocol, decision to publish or preparation of the
   manuscript.
CR Aydiner A, 2013, BREAST, V22, P121, DOI 10.1016/j.breast.2013.01.014
   Beckwée D, 2017, SUPPORT CARE CANCER, V25, P1673, DOI 10.1007/s00520-017-3613-z
   Borenstein M., 2009, Introduction to meta-analysis, P221, DOI [DOI 10.1002/9780470743386.CH23, DOI 10.1002/9780470743386.CH1]
   Breivik H, 2008, BRIT J ANAESTH, V101, P17, DOI 10.1093/bja/aen103
   Burstein HJ, 2019, J CLIN ONCOL, V37, P423, DOI 10.1200/JCO.18.01160
   Burstein HJ, 2010, J CLIN ONCOL, V28, P3784, DOI 10.1200/JOP.000082
   Coleman RE, 2008, CANCER TREAT REV, V34, P275, DOI 10.1016/j.ctrv.2007.10.004
   Egawa C, 2016, INT J CLIN ONCOL, V21, P262, DOI 10.1007/s10147-015-0905-5
   Ferlay J, 2018, EUR J CANCER, V103, P356, DOI 10.1016/j.ejca.2018.07.005
   FOLLMANN D, 1992, J CLIN EPIDEMIOL, V45, P769, DOI 10.1016/0895-4356(92)90054-Q
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Hadji P, 2014, ANN ONCOL, V25, P372, DOI 10.1093/annonc/mdt513
   Han JS, 2011, NEUROSCI BIOBEHAV R, V35, P680, DOI 10.1016/j.neubiorev.2010.08.006
   Henry NL, 2018, J CLIN ONCOL, V36, P326, DOI 10.1200/JCO.2017.74.6651
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hershman DL, 2015, J CLIN ONCOL, V33, P1910, DOI 10.1200/JCO.2014.59.5595
   Hershman DL, 2010, J CLIN ONCOL, V28, P4120, DOI 10.1200/JCO.2009.25.9655
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Hozo S., 2005, BMC MED RES METHODOL, V5, P13, DOI [DOI 10.1186/1471-2288-5-13, 10.1186/1471-2288-5-13, DOI 10.1186/1471-2288-5-13)]
   International Agency for Research on Cancer, 2019, IARC CANC MORT DAT
   Jansen JP, 2014, VALUE HEALTH, V17, P157, DOI 10.1016/j.jval.2014.01.004
   Jung KW, 2019, CANCER RES TREAT, V51, P431, DOI 10.4143/crt.2019.139
   Kadic AJ, 2016, J CLIN EPIDEMIOL, V74, P119, DOI 10.1016/j.jclinepi.2016.01.002
   Kanematsu M, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-436
   Karmakar M, 2017, BREAST CANCER-BASIC, V11, P1, DOI 10.1177/1178223417694520
   Kim TH, 2018, MATURITAS, V118, P29, DOI 10.1016/j.maturitas.2018.09.005
   Langevin HM, 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1155/2011/180805
   Li YF, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/2478565
   Linde K, 2010, FORSCH KOMPLEMENTMED, V17, P259, DOI 10.1159/000320374
   Lopez-Lopez JA, 2018, RES SYNTH METHODS, V9, P336, DOI [DOI 10.1002/jrsm.1310, DOI 10.1002/JRSM.1310]
   Lu G, 2004, STAT MED, V23, P3105, DOI 10.1002/sim.1875
   Lustberg MB, 2018, BREAST CANCER RES TR, V167, P709, DOI 10.1007/s10549-017-4559-z
   Mao JJ, 2009, CANCER, V115, P3631, DOI 10.1002/cncr.24419
   Menas Pamela, 2012, J Oncol Pharm Pract, V18, P387, DOI 10.1177/1078155211434853
   Moxley G, 2010, CLIN BREAST CANCER, V10, P144, DOI 10.3816/CBC.2010.n.019
   Nahm Nicole, 2018, Asia Pac J Clin Oncol, V14, P374, DOI 10.1111/ajco.12845
   Nasser Mona, 2020, AM J PUBLIC HEALTH, V110, P753, DOI [10.2105/AJPH.2020.305609, DOI 10.2105/AJPH.2020.305609]
   Paley CA, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007753.pub3
   Polanin JR, 2016, CAMPBELL METHODS POL
   Puhan MA, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5630
   Roberts K, 2017, CRIT REV ONCOL HEMAT, V111, P66, DOI 10.1016/j.critrevonc.2017.01.010
   Rucker G, 2019, R package version 1.0-1
   Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g7647
   Shi QL, 2013, J PAIN, V14, P290, DOI 10.1016/j.jpain.2012.11.010
   Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898
   Wan X, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-135
   White P, 2012, PAIN, V153, P455, DOI 10.1016/j.pain.2011.11.007
   Yang GS, 2017, CANCER NURS, V40, pE26, DOI 10.1097/NCC.0000000000000409
   Youlden Danny R., 2014, Cancer Biology Medicine, V11, P101, DOI 10.7497/j.issn.2095-3941.2014.02.005
   Zorzela L, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i157
NR 50
TC 4
Z9 4
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD MAY
PY 2020
VL 10
IS 5
AR e033461
DI 10.1136/bmjopen-2019-033461
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA VK5WH
UT WOS:000738373200027
PM 32371507
OA Green Submitted, Green Accepted, gold
DA 2026-01-16
ER

PT J
AU Deng, GE
   Rausch, SM
   Jones, LW
   Gulati, A
   Kumar, NB
   Greenlee, H
   Pietanza, MC
   Cassileth, BR
AF Deng, Gary E.
   Rausch, Sarah M.
   Jones, Lee W.
   Gulati, Amitabh
   Kumar, Nagi B.
   Greenlee, Heather
   Pietanza, M. Catherine
   Cassileth, Barrie R.
TI Complementary Therapies and Integrative Medicine in Lung Cancer
   Diagnosis and Management of Lung Cancer, 3rd ed: American College of
   Chest Physicians Evidence-Based Clinical Practice Guidelines
SO CHEST
LA English
DT Article
ID QUALITY-OF-LIFE; CHEMOTHERAPY-INDUCED NAUSEA; PREOPERATIVE PULMONARY
   REHABILITATION; CRUCIFEROUS VEGETABLE INTAKE; BRIEF HYPNOSIS
   INTERVENTION; TAI-CHI-CHUAN; BREAST-CANCER; ALTERNATIVE MEDICINE;
   PALLIATIVE CARE; NUTRITIONAL SUPPORT
AB Background: Physicians are often asked about complementary therapies by patients with cancer, and data show that the interest in and use of these therapies among patients with cancer is common. Therefore, it is important to assess the current evidence base on the benefits and risks of complementary therapies (modalities not historically used in modern Western medicine).
   Methods: A systematic literature review was carried out and recommendations were made according to the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines development methodology.
   Results: A large number of randomized controlled trials, systematic reviews, and meta-analyses, as well as a number of prospective cohort studies, met the predetermined inclusion criteria. These trials addressed many different issues pertaining to patients with lung cancer, such as symptoms of anxiety, mood disturbance, pain, quality of life, and treatment-related side effects. The available data cover a variety of interventions, including acupuncture, nutrition, mind-body therapies, exercise, and massage. The body of evidence supports a series of recommendations. An evidenced-based approach to modern cancer care should integrate complementary therapies with standard cancer therapies such as surgery, radiation, chemotherapy, and best supportive care measures.
   Conclusions: Several complementary therapy modalities can be helpful in improving the overall care of patients with lung cancer.
C1 [Deng, Gary E.; Gulati, Amitabh; Pietanza, M. Catherine; Cassileth, Barrie R.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
   [Rausch, Sarah M.] Univ Florida, Coll Med, Jacksonville, FL USA.
   [Kumar, Nagi B.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
   [Jones, Lee W.] Duke Canc Inst, Durham, NC USA.
   [Greenlee, Heather] Columbia Univ, New York, NY USA.
C3 Memorial Sloan Kettering Cancer Center; State University System of
   Florida; University of Florida; H Lee Moffitt Cancer Center & Research
   Institute; Duke University; Columbia University
RP Deng, GE (corresponding author), Mem Sloan Kettering Canc Ctr, 1429 First Ave, New York, NY 10021 USA.
EM dengg@mskcc.org
RI Kumar, Nagi/AGI-6573-2022
OI Kumar, Nagi/0000-0002-6121-2627
FU Lung Cancer Research Foundation; Boehringer Ingelheim Pharmaceuticals,
   Inc.
FX The overall process for the development of these guidelines, including
   matters pertaining to funding and conflicts of interest, are described
   in the methodology article. 1 The development of this guideline was
   supported primarily by the American College of Chest Physicians. The
   lung cancer guidelines conference was supported in part by a grant from
   the Lung Cancer Research Foundation. The publication and dissemination
   of the guidelines was supported in part by a 2009 independent
   educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. COI
   Grids reflecting the conflicts of interest that were current as of the
   date of the conference and voting are posted in the online supplementary
   materials.
CR Adams D, 2011, PEDIATRICS, V128, pE1575, DOI 10.1542/peds.2011-1091
   Adams J, 2003, MED J AUSTRALIA, V179, P297, DOI 10.5694/j.1326-5377.2003.tb05551.x
   Albanes D, 1996, J NATL CANCER I, V88, P1560, DOI 10.1093/jnci/88.21.1560
   Amin M, 2010, EUR ARCH OTO-RHINO-L, V267, P1291, DOI 10.1007/s00405-010-1223-1
   [Anonymous], NATL HLTH STAT REPOR
   [Anonymous], 2008, INT J YOGA, DOI DOI 10.4103/0973-6131.36789
   Arbane G, 2011, LUNG CANCER, V71, P229, DOI 10.1016/j.lungcan.2010.04.025
   Arthur HM, 2000, ANN INTERN MED, V133, P253, DOI 10.7326/0003-4819-133-4-200008150-00007
   Astin JA, 2004, CLIN J PAIN, V20, P27, DOI 10.1097/00002508-200401000-00006
   Aune D, 2009, ASIAN PAC J CANCER P, V10, P429
   Baldwin C, 2011, J HUM NUTR DIET, V24, P431, DOI 10.1111/j.1365-277X.2011.01189.x
   Banasik J, 2011, J AM ACAD NURSE PRAC, V23, P135, DOI 10.1111/j.1745-7599.2010.00573.x
   Bao T, 2011, PAIN RES TREAT, V2011, DOI 10.1155/2011/920807
   Barnes PM., 2008, NATL HLTH STAT REPOR, DOI DOI 10.1037/E623942009-001
   Bobbio A, 2008, EUR J CARDIO-THORAC, V33, P95, DOI 10.1016/j.ejcts.2007.10.003
   Boffetta P, 2010, JNCI-J NATL CANCER I, V102, P529, DOI 10.1093/jnci/djq072
   Bonadonna Ramita, 2003, Holist Nurs Pract, V17, P309
   Bor MV, 2010, AM J CLIN NUTR, V91, P571, DOI 10.3945/ajcn.2009.28082
   Bosaeus I, 2008, SUPPORT CARE CANCER, V16, P447, DOI 10.1007/s00520-007-0388-7
   Bruera E, 1997, BRIT MED J, V315, P1219, DOI 10.1136/bmj.315.7117.1219
   Büchner FL, 2010, CANCER EPIDEM BIOMAR, V19, P2278, DOI 10.1158/1055-9965.EPI-10-0489
   Carpenter CL, 2009, NUTR CANCER, V61, P492, DOI 10.1080/01635580902752270
   Carson JW, 2007, J PAIN SYMPTOM MANAG, V33, P331, DOI 10.1016/j.jpainsymman.2006.08.009
   Cassileth BR, 2007, CHEST, V132, p340S, DOI 10.1378/chest.07-1389
   Cassileth BR, 2004, ONCOLOGIST, V9, P80, DOI 10.1634/theoncologist.9-1-80
   Cesario A, 2007, LUNG CANCER, V57, P175, DOI 10.1016/j.lungcan.2007.02.017
   Cesario A, 2007, LUNG CANCER, V57, P118, DOI 10.1016/j.lungcan.2007.03.022
   Chan CLW, 2012, SUPPORT CARE CANCER, V20, P1121, DOI 10.1007/s00520-011-1378-3
   Chandwani Kavita D, 2010, J Soc Integr Oncol, V8, P43
   Chen Zhong-jie, 2008, Zhongguo Zhen Jiu, V28, P251
   Cherkin DC, 2003, ANN INTERN MED, V138, P898, DOI 10.7326/0003-4819-138-11-200306030-00011
   Chrystal Kathryn, 2003, N Z Med J, V116, pU296
   Corbin Lisa, 2005, Cancer Control, V12, P158
   Couch M, 2007, HEAD NECK-J SCI SPEC, V29, P401, DOI 10.1002/hed.20447
   Crew Katherine D, 2007, J Cancer Surviv, V1, P283, DOI 10.1007/s11764-007-0034-x
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Cross AJ, 2007, PLOS MED, V4, P1973, DOI 10.1371/journal.pmed.0040325
   Dale HL, 2010, PSYCHO-ONCOLOGY, V19, P227, DOI 10.1002/pon.1598
   Dean-Clower E, 2010, INTEGR CANCER THER, V9, P158, DOI 10.1177/1534735409360666
   Deng G, 2008, J THORAC CARDIOV SUR, V136, P1464, DOI 10.1016/j.jtcvs.2008.07.053
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Dosil-Díaz O, 2008, NUTRITION, V24, P407, DOI 10.1016/j.nut.2008.01.005
   Druss BG, 1999, JAMA-J AM MED ASSOC, V282, P651, DOI 10.1001/jama.282.7.651
   Enblom A, 2012, ANN ONCOL, V23, P1353, DOI 10.1093/annonc/mdr402
   EPPLEY KR, 1989, J CLIN PSYCHOL, V45, P957, DOI 10.1002/1097-4679(198911)45:6<957::AID-JCLP2270450622>3.0.CO;2-Q
   Ernst E, 2011, PAIN, V152, P755, DOI 10.1016/j.pain.2010.11.004
   Ernst E, 2003, RHEUMATOLOGY, V42, P1101, DOI 10.1093/rheumatology/keg306
   Ernst E, 2009, SUPPORT CARE CANCER, V17, P333, DOI 10.1007/s00520-008-0569-z
   Ernst E, 2001, AM J MED, V110, P481, DOI 10.1016/S0002-9343(01)00651-9
   Ezzo JM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002285.pub2
   Fearon KCH, 2003, GUT, V52, P1479, DOI 10.1136/gut.52.10.1479
   Fearon KCH, 2006, J CLIN ONCOL, V24, P3401, DOI 10.1200/JCO.2005.04.5724
   Fjorback LO, 2011, ACTA PSYCHIAT SCAND, V124, P102, DOI 10.1111/j.1600-0447.2011.01704.x
   Gansler T, 2008, CANCER-AM CANCER SOC, V113, P1048, DOI 10.1002/cncr.23659
   Gardani G, 2007, Minerva Med, V98, P665
   Gonzalez CA, 2006, PUBLIC HEALTH NUTR, V9, P124, DOI 10.1079/PHN2005934
   Gottschling S, 2008, KLIN PADIATR, V220, P365, DOI 10.1055/s-0028-1086039
   Granger CL, 2011, LUNG CANCER, V72, P139, DOI 10.1016/j.lungcan.2011.01.006
   Guo R, 1995, J Tradit Chin Med, V15, P262
   Hamerman D, 2002, J GERONTOL A-BIOL, V57, pM511, DOI 10.1093/gerona/57.8.M511
   He J. P., 1999, Clinical and Experimental Obstetrics and Gynecology, V26, P81
   Higdon JV, 2007, PHARMACOL RES, V55, P224, DOI 10.1016/j.phrs.2007.01.009
   Hilliard RE, 2005, EVID-BASED COMPL ALT, V2, P173, DOI 10.1093/ecam/neh076
   Hyodo I, 2005, J CLIN ONCOL, V23, P2645, DOI 10.1200/JCO.2005.04.126
   Ito Y, 2005, J EPIDEMIOL, V15, pS140, DOI 10.2188/jea.15.S140
   Jindal V, 2008, J PEDIAT HEMATOL ONC, V30, P431, DOI 10.1097/MPH.0b013e318165b2cc
   Jones LW, 2007, CANCER-AM CANCER SOC, V110, P590, DOI 10.1002/cncr.22830
   Jones LW, 2008, CANCER-AM CANCER SOC, V113, P3430, DOI 10.1002/cncr.23967
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010
   Kaufer D, 2009, NEUROLOGY, V73, P2052, DOI 10.1212/WNL.0b013e3181c6784a
   Kumar NB, 2010, CURR TREAT OPTION ON, V11, P107, DOI 10.1007/s11864-010-0127-z
   Kwekkeboom KL, 2010, J PAIN SYMPTOM MANAG, V39, P126, DOI 10.1016/j.jpainsymman.2009.05.022
   Lam TK, 2010, CANCER EPIDEM BIOMAR, V19, P2534, DOI 10.1158/1055-9965.EPI-10-0475
   Lang EV, 2008, J VASC INTERV RADIOL, V19, P897, DOI 10.1016/j.jvir.2008.01.027
   Lao LX, 2003, ALTERN THER HEALTH M, V9, P72
   Ledesma D, 2009, PSYCHO-ONCOLOGY, V18, P571, DOI 10.1002/pon.1400
   Lewis SZ, 2013, CHEST, V143, p41S, DOI 10.1378/chest.12-2344
   LI QS, 1994, CHINESE MED J-PEKING, V107, P289
   Lim WY, 2011, NUTR CANCER, V63, P850, DOI 10.1080/01635581.2011.589961
   Lin KY, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/659876
   Linseisen J, 2007, INT J CANCER, V121, P1103, DOI 10.1002/ijc.22807
   Littman AJ, 2012, SUPPORT CARE CANCER, V20, P267, DOI 10.1007/s00520-010-1066-8
   Lu WD, 2010, INTEGR CANCER THER, V9, P284, DOI 10.1177/1534735410378856
   Maciver I, 1996, INFECT IMMUN, V64, P4618, DOI 10.1128/IAI.64.11.4618-4629.1996
   MacPherson H, 2001, Acupunct Med, V19, P93
   Mansky P, 2006, INTEGR CANCER THER, V5, P192, DOI 10.1177/1534735406291590
   MARTIN GP, 1981, NEW ZEAL MED J, V93, P421
   Matchim Y, 2007, ONCOL NURS FORUM, V34, P1059, DOI 10.1188/07.ONF.1059-1066
   McCulloch M, 2006, J CLIN ONCOL, V24, P419, DOI 10.1200/JCO.2005.03.6392
   Molassiotis A, 2005, ANN ONCOL, V16, P655, DOI 10.1093/annonc/mdi110
   Montbriand MJ, 1998, CANCER NURS, V21, P36, DOI 10.1097/00002820-199802000-00005
   Montgomery GH, 2002, ANESTH ANALG, V94, P1639, DOI 10.1097/00000539-200206000-00052
   Montgomery GH, 2007, JNCI-J NATL CANCER I, V99, P1304, DOI 10.1093/jnci/djm106
   Montgomery GH, 2010, J CONSULT CLIN PSYCH, V78, P80, DOI 10.1037/a0017392
   Montgomery GH, 2009, HEALTH PSYCHOL, V28, P317, DOI 10.1037/a0013582
   Murphy RA, 2010, J NUTR, V140, P1602, DOI 10.3945/jn.110.123521
   Mustian Karen M, 2006, J Support Oncol, V4, P139
   Mustian KM, 2004, SUPPORT CARE CANCER, V12, P871, DOI 10.1007/s00520-004-0682-6
   *NAT I HLTH NAT CT, WHAT IS COMPL ALT ME
   Navo MA, 2004, J CLIN ONCOL, V22, P671, DOI 10.1200/JCO.2004.04.162
   Neuhouser ML, 2003, CANCER EPIDEM BIOMAR, V12, P350
   Nilsson U, 2003, ANAESTHESIA, V58, P699, DOI 10.1046/j.1365-2044.2003.03189_4.x
   Nystrom E, 2008, ACUPUNCT MED, V26, P27, DOI 10.1136/aim.26.1.27
   Omenn GS, 1996, J NATL CANCER I, V88, P1550, DOI 10.1093/jnci/88.21.1550
   Osborn RL, 2006, INT J PSYCHIAT MED, V36, P13, DOI 10.2190/EUFN-RV1K-Y3TR-FK0L
   Paley CA, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq020
   Perkins P, 2008, PALLIATIVE MED, V22, P193, DOI 10.1177/0269216307087144
   Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860
   Quist M, 2012, LUNG CANCER, V75, P203, DOI 10.1016/j.lungcan.2011.07.006
   Raghavendra RM, 2007, EUR J CANCER CARE, V16, P462, DOI 10.1111/j.1365-2354.2006.00739.x
   Raiasekaran M, 2005, PALLIATIVE MED, V19, P418, DOI 10.1191/0269216305pm1030oa
   Remen RN, 2008, HEMATOL ONCOL CLIN N, V22, P767, DOI 10.1016/j.hoc.2008.04.001
   Richardson J, 2007, EUR J CANCER CARE, V16, P402, DOI 10.1111/j.1365-2354.2006.00736.x
   Riesenberg H, 2010, SUPPORT CARE CANCER, V18, P877, DOI 10.1007/s00520-009-0727-y
   Rivadeneira DE, 1998, CA-CANCER J CLIN, V48, P69, DOI 10.3322/canjclin.48.2.69
   Satia JA, 2009, CANCER EPIDEM BIOMAR, V18, P1419, DOI 10.1158/1055-9965.EPI-09-0038
   Schmidt K, 2004, ANN ONCOL, V15, P733, DOI 10.1093/annonc/mdh174
   Schmidt K, 2002, COMPLEMENT THER MED, V10, P179, DOI 10.1016/S0965229902000742
   Schnur JB, 2008, ANESTH ANALG, V106, P440, DOI 10.1213/ane.0b013e31815edb13
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Shennan C, 2011, PSYCHO-ONCOLOGY, V20, P681, DOI 10.1002/pon.1819
   Shumay D M, 2001, J Fam Pract, V50, P1067
   Sima Lei, 2009, Zhongguo Zhen Jiu, V29, P3
   Smith JE, 2005, J ADV NURS, V52, P315, DOI 10.1111/j.1365-2648.2005.03592.x
   Smith KB, 2009, PSYCHO-ONCOLOGY, V18, P465, DOI 10.1002/pon.1411
   Speed-Andrews AE, 2010, CANCER NURS, V33, P369, DOI 10.1097/NCC.0b013e3181cfb55a
   Spruit MA, 2006, LUNG CANCER, V52, P257, DOI 10.1016/j.lungcan.2006.01.003
   Stalpers LJA, 2005, INT J RADIAT ONCOL, V61, P499, DOI 10.1016/j.ijrobp.2004.06.005
   Streitberger K, 2006, AUTON NEUROSCI-BASIC, V129, P107, DOI 10.1016/j.autneu.2006.07.015
   Struijker-Boudier HAJ, 2008, HYPERTENSION, V51, P821, DOI 10.1161/HYPERTENSIONAHA.107.103234
   Szabo E, 2013, CHEST, V143, pE40, DOI 10.1378/chest.12-2348
   Tang L, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-162
   Tang NP, 2009, JPN J CLIN ONCOL, V39, P352, DOI 10.1093/jjco/hyp028
   Tasevska N, 2011, INT J CANCER, V128, P402, DOI 10.1002/ijc.25327
   Tasevska N, 2009, AM J CLIN NUTR, V89, P1884, DOI 10.3945/ajcn.2008.27272
   Taspinar A, 2010, EUR J ONCOL NURS, V14, P49, DOI 10.1016/j.ejon.2009.07.006
   Temel JS, 2009, J THORAC ONCOL, V4, P595, DOI 10.1097/JTO.0b013e31819d18e5
   Vadiraja HS, 2009, COMPLEMENT THER MED, V17, P274, DOI 10.1016/j.ctim.2009.06.004
   van der Meij BS, 2010, J NUTR, V140, P1774, DOI 10.3945/jn.110.121202
   Vapiwala N, 2006, CANCER J, V12, P467, DOI 10.1097/00130404-200611000-00006
   Verhoef Marja J, 2005, Integr Cancer Ther, V4, P274, DOI 10.1177/1534735405282361
   Vickers Andrew J, 2006, BMC Anesthesiol, V6, P5, DOI 10.1186/1471-2253-6-5
   Vojacek J, 2010, J CARDIAC SURG, V25, P72, DOI 10.1111/j.1540-8191.2009.00938.x
   Weiger WA, 2002, ANN INTERN MED, V137, P889, DOI 10.7326/0003-4819-137-11-200212030-00010
   Wells M, 2007, CANCER NURS, V30, P45, DOI 10.1097/00002820-200701000-00008
   White Adrian, 2004, Acupunct Med, V22, P122
   White Margaret A, 2003, Integr Cancer Ther, V2, P217, DOI 10.1177/1534735403256411
   Wilkinson S, 2008, J ADV NURS, V63, P430, DOI 10.1111/j.1365-2648.2008.04712.x
   Wong Raimond, 2006, Acupunct Med, V24, P87
   Wong RHL, 2006, ANN THORAC SURG, V81, P2031, DOI 10.1016/j.athoracsur.2005.12.064
   Wu XA, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-269
   Xu S, 1995, J Tradit Chin Med, V15, P189
   Xu Wei-Ru, 2010, Zhongguo Zhen Jiu, V30, P457
   Yamashita H, 1999, J ALTERN COMPLEM MED, V5, P229, DOI 10.1089/acm.1999.5.229
   Yamashita H, 2001, COMPLEMENT THER MED, V9, P98, DOI 10.1054/ctim.2001.0446
   Yang WS, 2011, AM J CLIN NUTR, V94, P1575, DOI 10.3945/ajcn.111.020966
   Yang Yan, 2009, Zhongguo Zhen Jiu, V29, P955
   Yin Shi, 2006, Zhonghua Zhongliu Zazhi, V28, P840
   You Q, 2009, INT J GYNECOL CANCER, V19, P567, DOI 10.1111/IGC.0b013e31819d8b48
NR 159
TC 120
Z9 142
U1 1
U2 58
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0012-3692
EI 1931-3543
J9 CHEST
JI Chest
PD MAY
PY 2013
VL 143
IS 5
SU S
BP E420
EP E436
DI 10.1378/chest.12-2364
PG 17
WC Critical Care Medicine; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Respiratory System
GA AB1HL
UT WOS:000331542000019
PM 23649450
DA 2026-01-16
ER

PT J
AU Ben-Arye, E
   Samuels, N
   Schiff, E
   Raz, OG
   Sharabi, IS
   Lavie, O
AF Ben-Arye, Eran
   Samuels, Noah
   Schiff, Elad
   Raz, Orit Gressel
   Sharabi, Ilanit Shalom
   Lavie, Ofer
TI Quality-of-life outcomes in patients with gynecologic cancer referred to
   integrative oncology treatment during chemotherapy
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Integrative medicine; Gynecologic oncology; Quality of life;
   Chemotherapy; Complementary medicine
ID OVARIAN-CANCER; COMPLEMENTARY MEDICINE; ALTERNATIVE MEDICINE; CARE;
   ACUPUNCTURE; PACLITAXEL; SERVICE
AB Integrative oncology incorporates complementary medicine (CM) therapies in patients with cancer. We explored the impact of an integrative oncology therapeutic regimen on quality-of-life (QOL) outcomes in women with gynecological cancer undergoing chemotherapy.
   A prospective preference study examined patients referred by oncology health care practitioners (HCPs) to an integrative physician (IP) consultation and CM treatments. QOL and chemotherapy-related toxicities were evaluated using the Edmonton Symptom Assessment Scale (ESAS) and Measure Yourself Concerns and Wellbeing (MYCAW) questionnaire, at baseline and at a 6-12-week follow-up assessment. Adherence to the integrative care (AIC) program was defined as a parts per thousand yen4 CM treatments, with a parts per thousand currency sign30 days between each session.
   Of 128 patients referred by their HCP, 102 underwent IP consultation and subsequent CM treatments. The main concerns expressed by patients were fatigue (79.8 %), gastrointestinal symptoms (64.6 %), pain and neuropathy (54.5 %), and emotional distress (45.5 %). Patients in both AIC (n = 68) and non-AIC (n = 28) groups shared similar demographic, treatment, and cancer-related characteristics. ESAS fatigue scores improved by a mean of 1.97 points in the AIC group on a scale of 0-10 and worsened by a mean of 0.27 points in the non-AIC group (p = 0.033). In the AIC group, MYCAW scores improved significantly (p < 0.0001) for each of the leading concerns as well as for well-being, a finding which was not apparent in the non-AIC group.
   An IP-guided CM treatment regimen provided to patients with gynecological cancer during chemotherapy may reduce cancer-related fatigue and improve other QOL outcomes.
C1 [Ben-Arye, Eran; Samuels, Noah; Raz, Orit Gressel; Sharabi, Ilanit Shalom] Clalit Hlth Serv, Oncol Serv, Lin Kou Med Ctr, Integrat Oncol Program, Haifa, Israel.
   [Ben-Arye, Eran] Technion Israel Inst Technol, Complementary & Tradit Med Unit, Dept Family Med, Fac Med, Haifa, Israel.
   [Samuels, Noah] Chaim Sheba Med Ctr, Tal Ctr Integrat Med, Inst Oncol, IL-52621 Tel Hashomer, Israel.
   [Schiff, Elad] Bnai Zion Hosp, Dept Internal Med, Haifa, Israel.
   [Schiff, Elad] Bnai Zion Hosp, Integrat Surg Serv, Haifa, Israel.
   [Lavie, Ofer] Carmel Hosp, Dept Obstet & Gynecol, Gynecol Oncol Serv, Haifa, Israel.
C3 Clalit Health Services; Technion Israel Institute of Technology;
   Rappaport Faculty of Medicine; Tel Aviv University; Chaim Sheba Medical
   Center; Bnai Zion Medical Center; Bnai Zion Medical Center; Clalit
   Health Services; Carmel Medical Center
RP Ben-Arye, E (corresponding author), Technion Israel Inst Technol, Complementary & Tradit Med Unit, Dept Family Med, Fac Med, Haifa, Israel.
EM eranben@netvision.net.il
CR Abouzeid AH, 2014, INT J PHARMACEUT, V464, P178, DOI 10.1016/j.ijpharm.2014.01.009
   Ahn WS, 2004, INT J GYNECOL CANCER, V14, P589, DOI 10.1111/j.1048-891X.2004.14403.x
   Andersen MR, 2012, GYNECOL ONCOL, V124, P465, DOI 10.1016/j.ygyno.2011.10.029
   Ben-Arye E, 2014, SUPPORT CARE CANCER, V22, P627, DOI 10.1007/s00520-013-2016-z
   Ben-Arye E, 2012, PATIENT EDUC COUNS, V89, P423, DOI 10.1016/j.pec.2012.02.011
   Ben-Arye E, 2012, INT J GYNECOL CANCER, V22, P146, DOI 10.1097/IGC.0b013e318226c614
   Danhauer Suzanne C, 2008, J Soc Integr Oncol, V6, P47
   Delia P, 2007, WORLD J GASTROENTERO, V13, P912, DOI 10.3748/wjg.v13.i6.912
   Deng G, 2008, CURR ONCOL S, V15
   Deng Gary E, 2009, J Soc Integr Oncol, V7, P85
   Etheridge Amy S., 2009, Journal of Dietary Supplements, V6, P104, DOI 10.1080/19390210902861817
   Frenkel M, 2010, INTEGR CANCER THER, V9, P276, DOI 10.1177/1534735410378663
   Gross AH, 2013, CANCER NURS, V36, P256, DOI 10.1097/NCC.0b013e31826f3bc4
   Helpman L, 2011, INT J GYNECOL CANCER, V21, P587, DOI 10.1097/IGC.0b013e31820fa24a
   King MT, 2014, INT J GYNECOL CANCER, V24, P865, DOI 10.1097/IGC.0000000000000167
   León-Pizarro C, 2007, PSYCHO-ONCOLOGY, V16, P971, DOI 10.1002/pon.1171
   Lu WD, 2009, J ALTERN COMPLEM MED, V15, P745, DOI 10.1089/acm.2008.0589
   Nazik E, 2012, ASIAN PAC J CANCER P, V13, P21, DOI 10.7314/APJCP.2012.13.1.021
   Oldenmenger WH, 2013, J PAIN SYMPTOM MANAG, V45, P1083, DOI 10.1016/j.jpainsymman.2012.06.007
   Paterson C, 2007, COMPLEMENT THER MED, V15, P38, DOI 10.1016/j.ctim.2006.03.006
   Rhode JM, 2008, INT J GYNECOL OBSTET, V103, P111, DOI 10.1016/j.ijgo.2008.06.001
   Sieja K, 2004, GYNECOL ONCOL, V93, P320, DOI 10.1016/j.ygyno.2003.12.013
   von Gruenigen VE, 2006, GYNECOL ONCOL, V103, P120, DOI 10.1016/j.ygyno.2006.01.059
   You Q, 2009, INT J GYNECOL CANCER, V19, P567, DOI 10.1111/IGC.0b013e31819d8b48
NR 24
TC 31
Z9 36
U1 0
U2 18
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD DEC
PY 2015
VL 23
IS 12
BP 3411
EP 3419
DI 10.1007/s00520-015-2690-0
PG 9
WC Oncology; Health Care Sciences & Services; Rehabilitation
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA CV1PN
UT WOS:000364030600007
PM 25752885
OA Bronze
DA 2026-01-16
ER

PT J
AU Tan, SY
   Jiang, H
   Ma, Q
   Ye, X
   Fu, X
   Ren, YF
   You, FM
AF Tan, Shi-Yan
   Jiang, Hua
   Ma, Qiong
   Ye, Xin
   Fu, Xi
   Ren, Yi-Feng
   You, Feng-Ming
TI Effects of transcutaneous electrical acupoint stimulation on early
   postoperative pain and recovery: a comprehensive systematic review and
   meta-analysis of randomized controlled trials
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE transcutaneous electrical acupoint stimulation; surgery; pain; recovery;
   meta-analysis
ID CLINICALLY IMPORTANT DIFFERENCE; ZUSANLI ST 36; NERVE-STIMULATION;
   ACUPUNCTURE STIMULATION; LIPOSOMAL BUPIVACAINE; GENERAL-ANESTHESIA;
   SURGERY; QUALITY; ANALGESIA; CANCER
AB Background Previous studies have indicated beneficial outcomes of transcutaneous electrical acupoint stimulation (TEAS), but high-quality and comprehensive meta-analyses are lacking. The aim was to quantitatively analyze the efficacy and safety of perioperative TEAS on postoperative pain and recovery. Methods PubMed, Web of Science, EMBASE, and the Cochrane Library were searched through July 2022. Randomized controlled trials (RCTs) that examined the perioperative application of TEAS in adults compared with sham-TEAS and/or non-TEAS were eligible. Cumulative analgesic consumption within 24 h and rest pain scores at 2, 6, 12, and 24 h postoperatively were the two co-primary outcomes. Results Seventy-six RCTs (n = 9,665 patients) were included. Patients treated with TEAS experienced a reduction in clinical importance in cumulative analgesic (morphine equivalent) consumption (WMD: -14.60 mg, 97.5% CI: -23.60 to -5.60; p < 0.001) and a reduction in statistical importance in rest pain scores at multiple time points within the first 24 postoperative hours. The secondary outcome analysis also identified clinically significant recovery benefits to TEAS during the first 24 h after surgery. Furthermore, TEAS could effectively reduce opioid-related side effects and did not increase serious side effects. Conclusion This article describes current evidence about TEAS intervention on early postoperative pain and recovery. The results support the effectiveness of TEAS, but more high-quality evidence of clinical applicability is also needed.
C1 [Tan, Shi-Yan; Jiang, Hua; Ma, Qiong; Ye, Xin; Fu, Xi; Ren, Yi-Feng; You, Feng-Ming] Hosp Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan Provinc, Peoples R China.
   [Fu, Xi; Ren, Yi-Feng; You, Feng-Ming] Hosp Chengdu Univ Tradit Chinese Med, TCM Regulating Metab Dis Key Lab Sichuan Prov, Chengdu, Sichuan Provinc, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Chengdu University
   of Traditional Chinese Medicine
RP Ren, YF; You, FM (corresponding author), Hosp Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan Provinc, Peoples R China.; Ren, YF; You, FM (corresponding author), Hosp Chengdu Univ Tradit Chinese Med, TCM Regulating Metab Dis Key Lab Sichuan Prov, Chengdu, Sichuan Provinc, Peoples R China.
EM ryftcm.dr@yahoo.com; yfmdoc@163.com
RI ; Ma, Qiong/NOE-7809-2025
OI Ren, Yifeng/0000-0003-2976-4250; 
CR Ao L, 2021, EXP THER MED, V21, DOI 10.3892/etm.2021.9615
   Bai WY, 2018, J NEUROSURG ANESTH, V30, P337, DOI 10.1097/ANA.0000000000000460
   Chen JB, 2020, INT J SURG, V73, P57, DOI 10.1016/j.ijsu.2019.10.036
   Chen JH, 2020, THORAC CANCER, V11, P928, DOI 10.1111/1759-7714.13343
   Chen L, 1998, ANESTH ANALG, V87, P1129, DOI 10.1097/00000539-199811000-00028
   Chiu JH, 1999, DIS COLON RECTUM, V42, P180, DOI 10.1007/BF02237124
   Clarke H, 2019, BRIT J ANAESTH, V122, pE90, DOI 10.1016/j.bja.2019.02.015
   Deng G, 2019, PAIN MED, V20, P207, DOI 10.1093/pm/pny258
   Feng R, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0382-1
   Gan TJ, 2017, J PAIN RES, V10, P2287, DOI 10.2147/JPR.S144066
   Gan TJ, 2014, CURR MED RES OPIN, V30, P149, DOI 10.1185/03007995.2013.860019
   Gao Peng, 2020, Zhongguo Zhen Jiu, V40, P829, DOI 10.13703/j.0255-2930.20190729-k0001
   Gao W, 2022, FRONT MED-LAUSANNE, V9, DOI 10.3389/fmed.2022.766244
   Gao W, 2021, SURGERY, V170, P1618, DOI 10.1016/j.surg.2021.08.007
   Ge Mei, 2021, Zhongguo Gu Shang, V34, P750, DOI [10.12200/j.issn.1003-0034.2021.08.011, 10.12200/j.issn.1003-0034.2021.08.011]
   Gheibi S, 2019, INT J ENDOCRINOL MET, V17, DOI 10.5812/ijem.95216
   Gu SH, 2019, EUR J INTEGR MED, V26, P11, DOI 10.1016/j.eujim.2019.01.001
   Guo Jun, 2018, Zhongguo Zhen Jiu, V38, P1043, DOI 10.13703/j.0255-2930.2018.10.004
   Guyatt GH, 2008, BMJ-BRIT MED J, V336, P1049, DOI 10.1136/bmj.39493.646875.AE
   Huang LP, 2017, TURK J MED SCI, V47, P1267, DOI 10.3906/sag-1611-35
   Huang W, 2019, J TRADIT CHIN MED, V39, P433
   Huang Wei, 2018, Zhen Ci Yan Jiu, V43, P611, DOI 10.13702/j.1000-0607.180005
   Hussain N, 2021, REGION ANESTH PAIN M, V46, P61, DOI 10.1136/rapm-2020-101995
   Hussain N, 2021, REGION ANESTH PAIN M, V46, P3, DOI 10.1136/rapm-2020-101917
   Hussain N, 2021, ANESTHESIOLOGY, V134, P147, DOI 10.1097/ALN.0000000000003651
   Jang JH, 2017, CHIN J INTEGR MED, V23, P215, DOI 10.1007/s11655-016-2609-8
   Jin D, 2022, J PAIN RES, V15, P745, DOI 10.2147/JPR.S356150
   JPT H J T, 2022, Cochrane Handbook for Systematic Reviews of Interventions version 6.3
   Lan F, 2012, MINERVA ANESTESIOL, V78, P887
   Lee A, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003281.pub4
   Li MM, 2020, NEUROMODULATION, V23, P838, DOI 10.1111/ner.13178
   Liu X, 2015, ACUPUNCT MED, V33, P270, DOI 10.1136/acupmed-2014-010749
   Lu ZH, 2021, J CLIN ANESTH, V74, DOI 10.1016/j.jclinane.2021.110453
   Meng D, 2022, EVID-BASED COMPL ALT, V2022, DOI 10.1155/2022/9922879
   Mi Zhihua, 2018, Zhongguo Zhen Jiu, V38, P256, DOI 10.13703/j.0255-2930.2018.03.007
   Myles PS, 2020, ANAESTHESIA, V75, pE143, DOI 10.1111/anae.14786
   Myles PS, 2017, BRIT J ANAESTH, V118, P424, DOI 10.1093/bja/aew466
   Myles PS, 2016, ANESTHESIOLOGY, V125, P39, DOI 10.1097/ALN.0000000000001158
   Oh JE, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.813748
   Oztas B, 2019, CONTEMP NURSE, V55, P122, DOI 10.1080/10376178.2019.1628650
   Page MJ, 2021, BMJ-BRIT MED J, V372, DOI [10.1136/bmj.n160, 10.1136/bmj.n71, 10.1038/nchembio.2180, 10.1186/s40900-023-00424-7, 10.3390/jpm13020373]
   Page MJ., 2022, Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022)
   Que B, 2021, EVID-BASED COMPL ALT, V2021, DOI 10.1155/2021/5909956
   Shaheen PE, 2009, J PAIN SYMPTOM MANAG, V38, P409, DOI 10.1016/j.jpainsymman.2009.06.004
   Sharififar S, 2018, ANN PHYS REHABIL MED, V61, P339, DOI 10.1016/j.rehab.2018.06.005
   Song BJ, 2020, NAT SCI SLEEP, V12, P809, DOI 10.2147/NSS.S270739
   Szmit M, 2021, J CLIN MED, V10, DOI 10.3390/jcm10010146
   Tao HM, 2018, J HEADACHE PAIN, V19, DOI 10.1186/s10194-018-0868-9
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Wang BG, 1997, ANESTH ANALG, V85, P406, DOI 10.1097/00000539-199708000-00029
   Wang Dongdong, 2017, Zhongguo Zhen Jiu, V37, P701, DOI 10.13703/j.0255-2930.2017.07.005
   Wang Jun-lu, 2008, Zhen Ci Yan Jiu, V33, P26
   Wu CL, 2005, REGION ANESTH PAIN M, V30, P516, DOI 10.1016/j.rapm.2005.07.190
   Wu HX, 2016, EXP THER MED, V11, P495, DOI 10.3892/etm.2015.2913
   Wu MS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150367
   Xiong QJ, 2021, OBES SURG, V31, P1912, DOI 10.1007/s11695-020-05205-9
   Yang XY, 2015, BRIT J ANAESTH, V115, P883, DOI 10.1093/bja/aev352
   Yao YS, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/324360
   Yeh ML, 2011, INT J NURS STUD, V48, P703, DOI 10.1016/j.ijnurstu.2010.10.009
   Yeh ML, 2010, ALTERN THER HEALTH M, V16, P10
   Yin Xiu-qi, 2013, Zhen Ci Yan Jiu, V38, P431
   Yu XD, 2020, TRIALS, V21, DOI 10.1186/s13063-019-3892-4
   Yu Z, 2020, WORLD J GASTROENTERO, V26, DOI 10.3748/wjg.v26.i23.3182
   Zárate E, 2001, ANESTH ANALG, V92, P629
   Zhan WF, 2020, EUR J INTEGR MED, V35, DOI 10.1016/j.eujim.2020.101087
   Zhang B, 2019, NEUROMODULATION, V22, P546, DOI 10.1111/ner.12856
   Zhang B, 2018, AM J GASTROENTEROL, V113, P1026, DOI 10.1038/s41395-018-0156-y
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhao Fang-Chao, 2021, Zhen Ci Yan Jiu, V46, P684, DOI [10.13702/j.1000-0607.200784, 10.13702/j.1000-0607.200784]
   Zhao FC, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/9018701
   Zhou DD, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/7341920
   Zhou X, 2021, CANCER MANAG RES, V13, P1449, DOI 10.2147/CMAR.S292325
NR 72
TC 3
Z9 3
U1 7
U2 16
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD APR 29
PY 2024
VL 11
AR 1302057
DI 10.3389/fmed.2024.1302057
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA QP5N6
UT WOS:001222088500001
PM 38745738
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Wang, M
   Pei, ZW
   Molassiotis, A
AF Wang, Mian
   Pei, Ziwen
   Molassiotis, Alex
TI Recent advances in managing chemotherapy-induced peripheral neuropathy:
   A systematic review
SO EUROPEAN JOURNAL OF ONCOLOGY NURSING
LA English
DT Review
DE Cancer; Chemotherapy-induced peripheral neuropathy; Pain; Symptom
   management; Systematic review
ID INDUCED SENSORY NEUROPATHY; QUALITY-OF-LIFE; BREAST-CANCER;
   RANDOMIZED-TRIAL; THERAPY; DULOXETINE; PREVALENCE; PREVENTION;
   PREGABALIN; MANAGEMENT
AB Purpose: The aim in this review was to explore recent advances in chemotherapy-induced peripheral neuropathy (CIPN) management interventions and to identify the implications for practice and future research.Methods: A comprehensive search through seven electronic databases (AMED, CINAHL, Cochrane Library, EMBASE, PEDro, PubMed, and Web of Science) was conducted for studies published between January 1, 2013 and August 3, 2019. An updated search for subsequently published studies was made through PubMed on February 15, 2022. Randomized controlled trials (RCTs) involving either pharmacological or non pharmacological interventions were considered eligible. The Cochrane Risk of Bias tool version 2.0 (RoB 2.0) was used to appraise the methodological risk of bias. Data extracted from the included RCTs were synthesized in a narrative approach.Results: Forty-two RCTs involving a total of 3393 participants were included. Overall, a high risk of bias was found in most of the included RCTs. The results further confirmed the analgesic effect of duloxetine on pain related to CIPN. Exercise-based interventions, acupuncture, and several non-invasive neuromodulation techniques showed promise for managing CIPN.Conclusions: The effects of most pharmacological and non-pharmacological interventions on CIPN are inconclusive due to methodological issues. Duloxetine remains the only pharmacological intervention recommended for managing pain related to CIPN. Although definitive recommendations cannot be made based on current research evidence, non-pharmacological interventions, especially non-invasive neuromodulation techniques, warrant future research.
C1 [Wang, Mian; Molassiotis, Alex] Hong Kong Polytech Univ, Sch Nursing, Hong Kong, Peoples R China.
   [Pei, Ziwen] Wuhan Hosp Tradit Chinese & Western Med, Dept Rehabil Med, Wuhan, Hubei, Peoples R China.
C3 Hong Kong Polytechnic University
RP Molassiotis, A (corresponding author), Hong Kong Polytech Univ, Sch Nursing, Hong Kong, Peoples R China.
EM alex.molasiotis@polyu.edu.hk
RI ; Molassiotis, Alex/MDS-6695-2025
OI Pei, Ziwen/0000-0001-9423-1114; Wang, Mian/0000-0002-8935-5021;
   Molassiotis, Alex/0000-0001-6351-9991
CR Akyuz G, 2014, AM J PHYS MED REHAB, V93, P253, DOI 10.1097/PHM.0000000000000037
   Al Onazi MM, 2021, J PAIN SYMPTOM MANAG, V61, P1127, DOI 10.1016/j.jpainsymman.2020.10.028
   Argenta PA, 2017, GYNECOL ONCOL, V144, P159, DOI 10.1016/j.ygyno.2016.11.013
   Argyriou AA, 2020, EXPERT REV NEUROTHER, V20, P1005, DOI 10.1080/14737175.2020.1796639
   Avan R, 2018, J RES MED SCI, V23, DOI 10.4103/jrms.JRMS_1068_17
   Bao T, 2021, ONCOLOGIST, V26, pE2070, DOI 10.1002/onco.13933
   Bao T, 2020, JNCI CANCER SPECT, V4, DOI 10.1093/jncics/pkaa048
   Bao T, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.0681
   Bao T, 2016, BREAST CANCER RES TR, V159, P327, DOI 10.1007/s10549-016-3939-0
   Bonhof CS, 2021, J CANCER SURVIV, V15, P190, DOI 10.1007/s11764-020-00923-6
   Bozorgi H, 2021, J ETHNOPHARMACOL, V281, DOI 10.1016/j.jep.2021.114511
   Childs DS, 2021, J PAIN SYMPTOM MANAG, V61, P1247, DOI 10.1016/j.jpainsymman.2020.11.025
   Chu SH, 2015, SUPPORT CARE CANCER, V23, P513, DOI 10.1007/s00520-014-2408-8
   Chung KH, 2022, CANCERS, V14, DOI 10.3390/cancers14051224
   D'Alessandro EG, 2022, BMJ SUPPORT PALLIAT, V12, P64, DOI 10.1136/bmjspcare-2018-001542
   Dhawan S, 2020, CANCER NURS, V43, P269, DOI 10.1097/NCC.0000000000000693
   Dorsey SG, 2019, JNCI-J NATL CANCER I, V111, P531, DOI 10.1093/jnci/djz011
   Drossman DA, 2018, GASTROENTEROLOGY, V154, P1140, DOI 10.1053/j.gastro.2017.11.279
   Emine K.E., 2021, IN PRESS, DOI [10.1016/j.explore.2021.07.002.S1550-8307(21)00144-0, DOI 10.1016/J.EXPLORE.2021.07.002.S1550-8307(21)00144-0]
   Farshchian N, 2018, CANCER CHEMOTH PHARM, V82, P787, DOI 10.1007/s00280-018-3664-y
   Forstenpointner J, 2018, PAIN, V159, P569, DOI 10.1097/j.pain.0000000000001088
   Gewandter JS, 2014, SUPPORT CARE CANCER, V22, P1807, DOI 10.1007/s00520-014-2158-7
   Han XY, 2017, BMC CANCER, V17, DOI 10.1186/s12885-016-3037-z
   Hershman DL, 2018, JNCI-J NATL CANCER I, V110, P669, DOI 10.1093/jnci/djx259
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Hincker A, 2019, PAIN, V160, P1835, DOI 10.1097/j.pain.0000000000001577
   Hirayama Y, 2015, INT J CLIN ONCOL, V20, P866, DOI 10.1007/s10147-015-0810-y
   Hou S, 2018, PAIN PHYSICIAN, V21, P571, DOI 10.36076/ppj.2018.6.571
   Huang CC, 2021, J CLIN MED, V10, DOI 10.3390/jcm10163694
   Husebo AML, 2015, J CLIN NURS, V24, P500, DOI 10.1111/jocn.12633
   Iravani S., 2020, PAIN
   Izgu N, 2019, CANCER NURS, V42, P139, DOI 10.1097/NCC.0000000000000577
   Jones KF, 2022, J PALLIAT MED, V25, P964, DOI 10.1089/jpm.2021.0512
   Jordan B, 2020, ANN ONCOL, V31, P1306, DOI 10.1016/j.annonc.2020.07.003
   Kneis S, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5522-7
   Knoerl R, 2022, J CANCER SURVIV, V16, P882, DOI 10.1007/s11764-021-01081-z
   Knoerl R, 2018, J PAIN, V19, P382, DOI 10.1016/j.jpain.2017.11.009
   Knotkova H, 2021, LANCET, V397, P2111, DOI 10.1016/S0140-6736(21)00794-7
   Kolb NA, 2016, JAMA NEUROL, V73, P860, DOI 10.1001/jamaneurol.2016.0383
   Kurt S, 2018, EUR J ONCOL NURS, V32, P12, DOI 10.1016/j.ejon.2017.11.001
   Leen AJ, 2022, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.763229
   Lin WL, 2021, SUPPORT CARE CANCER, V29, P5303, DOI 10.1007/s00520-021-06082-3
   Lindblad K, 2016, SUPPORT CARE CANCER, V24, P2523, DOI 10.1007/s00520-015-3060-7
   Loprinzi C, 2020, SUPPORT CARE CANCER, V28, P1183, DOI 10.1007/s00520-019-04881-3
   Loprinzi CL, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01399
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Lynch ME, 2014, J PAIN SYMPTOM MANAG, V47, P166, DOI 10.1016/j.jpainsymman.2013.02.018
   Mariano TY, 2021, J TELEMED TELECARE, V27, P195, DOI 10.1177/1357633X19871746
   McGuinness LA, 2021, RES SYNTH METHODS, V12, P55, DOI 10.1002/jrsm.1411
   Molassiotis A., INTEGR CANCER THER
   Molassiotis A, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5302-4
   Noh GO, 2019, EUR J ONCOL NURS, V42, P82, DOI 10.1016/j.ejon.2019.08.007
   Noh H, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/6194184
   Page Matthew J., [No title captured]
   Prinsloo S, 2018, J PAIN SYMPTOM MANAG, V55, P1276, DOI 10.1016/j.jpainsymman.2018.01.010
   Prinsloo S, 2017, CANCER-AM CANCER SOC, V123, P1989, DOI 10.1002/cncr.30649
   Rick O, 2017, BIOELECTROMAGNETICS, V38, P85, DOI 10.1002/bem.22005
   Rostami N, 2019, PHYTOTHER RES, V33, P2685, DOI 10.1002/ptr.6442
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/349653
   Salehifar E, 2020, CLIN DRUG INVEST, V40, P249, DOI 10.1007/s40261-019-00882-6
   Schloss JM, 2013, CLIN NUTR, V32, P888, DOI 10.1016/j.clnu.2013.04.007
   Schönsteiner SS, 2017, EXP HEMATOL ONCOL, V5, DOI 10.1186/s40164-017-0065-6
   Schwenk M, 2016, GERONTOLOGY, V62, P553, DOI 10.1159/000442253
   Selvy M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082400
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Simon NB, 2017, QUAL LIFE RES, V26, P2763, DOI 10.1007/s11136-017-1635-0
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Smith TJ, 2020, J PALLIAT CARE, V35, P53, DOI 10.1177/0825859719827589
   Song SY, 2020, INTEGR CANCER THER, V19, DOI 10.1177/1534735420925519
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898
   Streckmann F, 2019, SUPPORT CARE CANCER, V27, P2471, DOI 10.1007/s00520-018-4531-4
   Sun YJ, 2016, EXP THER MED, V12, P4017, DOI 10.3892/etm.2016.3871
   Tamburin S, 2022, CRIT REV ONCOL HEMAT, V171, DOI 10.1016/j.critrevonc.2021.103575
   Tonezzer Tania, 2017, J Phys Ther Sci, V29, P685, DOI [10.1589/jpts.29.685, 10.1589/jpts.29.685]
   Xiong ZF, 2016, WORLD J ACUPUNCT-MOX, V26, P20, DOI 10.1016/S1003-5257(17)30005-3
   Zhi WI, 2021, CANCER MED-US, V10, P5456, DOI 10.1002/cam4.4098
   Zhou LK, 2021, ECLINICALMEDICINE, V41, DOI 10.1016/j.eclinm.2021.101157
NR 78
TC 9
Z9 12
U1 1
U2 18
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1462-3889
EI 1532-2122
J9 EUR J ONCOL NURS
JI Eur. J. Oncol. Nurs.
PD JUN
PY 2022
VL 58
AR 102134
DI 10.1016/j.ejon.2022.102134
EA APR 2022
PG 23
WC Oncology; Nursing
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Oncology; Nursing
GA 1G2WH
UT WOS:000795712900002
PM 35421796
DA 2026-01-16
ER

PT J
AU Lee, JH
   Kim, B
   Ko, SG
   Kim, W
AF Lee, Ji Hwan
   Kim, Bonglee
   Ko, Seong-Gyu
   Kim, Woojin
TI Analgesic Effect of SH003 and Trichosanthes kirilowii Maximowicz
   in Paclitaxel-Induced Neuropathic Pain in Mice
SO CURRENT ISSUES IN MOLECULAR BIOLOGY
LA English
DT Article
DE Allodynia; chemotherapy-induced neuropathic pain; Cucurbitacin D;
   Paclitaxel; Trichosanthes kirilowii Maximowicz
ID INDUCED PERIPHERAL NEUROPATHY; SUBSTANTIA-GELATINOSA; SPINAL-CORD;
   SYSTEM; ACUPUNCTURE; BEVACIZUMAB; INVOLVEMENT; INHIBITION; DULOXETINE;
   MANAGEMENT
AB Pacliatxel is a taxol-based chemotherapeutic drug that is widely used to treat cancer. However, it can also induce peripheral neuropathy, which limits its use. Although several drugs are prescribed to attenuate neuropathies, no optimal treatment is available. Thus, in our study, we analyzed whether SH003 and its sub-components could alleviate paclitaxel-induced neuropathic pain. Multiple paclitaxel injections (cumulative dose 8 mg/kg, i.p.) induced cold and mechanical allodynia from day 10 to day 21 after the first injection in mice. Oral administration of SH003, an herbal mixture extract of Astragalus membranaceus, Angelica gigas, and Trichosanthes kirilowii Maximowicz (Tk), dose-dependently attenuated both allodynia. However, when administered separately only Tk decreased both allodynia. The effect of Tk was shown to be mediated by the spinal noradrenergic system as intrathecal pretreatment with alpha(1)- and alpha(2)-adrenergic-receptor antagonists (prazosin and idazoxan), but not 5-HT1/2, and 5-HT3-receptor antagonists (methysergide and MDL-72222) blocked the effect of Tk. The spinal noradrenaline levels were also upregulated. Among the phytochemicals of Tk, cucurbitacin D was shown to play a major role, as 0.025 mg/kg (i.p.) of cucurbitacin D alleviated allodynia similar to 500 mg/kg of SH003. These results suggest that Tk should be considered when treating paclitaxel-induced neuropathic pain.
C1 [Lee, Ji Hwan; Kim, Woojin] Kyung Hee Univ, Dept Physiol, Coll Korean Med, Seoul 02447, South Korea.
   [Lee, Ji Hwan; Kim, Bonglee; Ko, Seong-Gyu; Kim, Woojin] Kyung Hee Univ, Coll Korean Med, Korean Med Based Drug Repositioning Canc Res Ctr, Seoul 02447, South Korea.
C3 Kyung Hee University; Kyung Hee University
RP Kim, W (corresponding author), Kyung Hee Univ, Dept Physiol, Coll Korean Med, Seoul 02447, South Korea.; Kim, W (corresponding author), Kyung Hee Univ, Coll Korean Med, Korean Med Based Drug Repositioning Canc Res Ctr, Seoul 02447, South Korea.
EM mibdna@khu.ac.kr; bongleekim@khu.ac.kr; epiko@khu.ac.kr; wjkim@khu.ac.kr
RI Kim, Bonglee/AAH-9077-2020; Kim, Woojin/AAK-2464-2020
OI Kim, Bonglee/0000-0002-8678-156X; Kim, Woojin/0000-0001-8494-4524; Lee,
   Ji Hwan/0000-0001-9572-6864
FU National Research Foundation of Korea (NRF) - Korea government (MSIT)
   [2020R1A5A2019413, 2020R1F1A1070512]
FX FundingThis work was supported by the National Research Foundation of
   Korea (NRF) grant funded by the Korea government (MSIT) No.
   2020R1A5A2019413 and No. 2020R1F1A1070512.
CR Argyriou AA, 2008, CRIT REV ONCOL HEMAT, V66, P218, DOI 10.1016/j.critrevonc.2008.01.008
   Armstrong DK, 2006, NEW ENGL J MED, V354, P34, DOI 10.1056/NEJMoa052985
   Baba H, 2000, ANESTHESIOLOGY, V92, P485, DOI 10.1097/00000542-200002000-00031
   Battaglini E, 2018, CONTEMP CLIN TRIALS, V70, P135, DOI 10.1016/j.cct.2018.04.011
   Caraceni A, 2004, J CLIN ONCOL, V22, P2909, DOI 10.1200/jco.2004.08.141
   Carozzi VA, 2015, NEUROSCI LETT, V596, P90, DOI 10.1016/j.neulet.2014.10.014
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9
   Chen T, 2020, AM J CHINESE MED, V48, P793, DOI 10.1142/S0192415X20500408
   Cheon C, 2020, INTEGR CANCER THER, V19, DOI 10.1177/1534735420911442
   Cheon C, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019502
   Choi HS, 2017, MOL CELL BIOCHEM, V426, P1, DOI 10.1007/s11010-016-2875-y
   Choi J, 2017, TOXINS, V9, DOI 10.3390/toxins9110351
   Choi S, 2017, J PHYSIOL SCI, V67, P431, DOI 10.1007/s12576-016-0505-9
   Choi YK, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/492173
   Choi YK, 2017, ONCOTARGET, V8, P88386, DOI 10.18632/oncotarget.11393
   Choi YJ, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1490-5
   Corbett A, 2014, BRIT MED BULL, V111, P139, DOI 10.1093/bmb/ldu023
   DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301
   Dougherty PM, 2004, PAIN, V109, P132, DOI 10.1016/j.pain.2004.01.021
   Dutta S, 2016, LIFE SCI, V152, P244, DOI 10.1016/j.lfs.2015.10.025
   Efferth T, 2011, CURR DRUG TARGETS, V12, P122, DOI 10.2174/138945011793591626
   Finnerup NB, 2015, LANCET NEUROL, V14, P162, DOI 10.1016/S1474-4422(14)70251-0
   Ge WZ, 2018, MOLECULES, V23, DOI 10.3390/molecules23123345
   Giovannini S, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11040613
   Golden JP, 2004, DRUG DISCOV TODAY, V1, P186, DOI [10.1016/j.ddmod.2004.09.005, DOI 10.1016/J.DDMOD.2004.09.005]
   Hayashida K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040822
   Hickey L, 2014, J NEUROSCI, V34, P4148, DOI 10.1523/JNEUROSCI.4835-13.2014
   Hirayama Y, 2015, INT J CLIN ONCOL, V20, P866, DOI 10.1007/s10147-015-0810-y
   Huang Luqi, 1995, Zhongguo Zhongyao Zazhi, V20, P195
   Iyengar S, 2004, J PHARMACOL EXP THER, V311, P576, DOI 10.1124/jpet.104.070656
   Jeong MS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168405
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim MJ, 2017, KOREAN J PHYSIOL PHA, V21, P657, DOI 10.4196/kjpp.2017.21.6.657
   Kim MS, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/6571674
   Kim W, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122626
   Kim W, 2016, TOXINS, V8, DOI 10.3390/toxins8020033
   KITAJIMA J, 1989, YAKUGAKU ZASSHI, V109, P250, DOI 10.1248/yakushi1947.109.4_250
   KUMAZAWA T, 1978, J COMP NEUROL, V177, P417, DOI 10.1002/cne.901770305
   Lee JH, 2021, PHARMACOL RES PERSPE, V9, DOI 10.1002/prp2.819
   Lee JH, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168811
   Lee JH, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9080970
   Lee JH, 2021, MOLECULES, V26, DOI 10.3390/molecules26030548
   Lee JH, 2016, KOREAN J PHYSIOL PHA, V20, P407, DOI 10.4196/kjpp.2016.20.4.407
   Lee K, 2021, EVID-BASED COMPL ALT, V2021, DOI 10.1155/2021/4120334
   Lee YA, 2021, BEHAV BRAIN RES, V409, DOI 10.1016/j.bbr.2021.113316
   Li DX, 2020, TOXINS, V12, DOI 10.3390/toxins12100620
   Li DX, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071652
   Loprinzi CL, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01399
   Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113
   Munro G, 2012, PHARMACOL BIOCHEM BE, V101, P465, DOI 10.1016/j.pbb.2012.02.008
   Obata H, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112483
   Pachman DR, 2011, CLIN PHARMACOL THER, V90, P377, DOI 10.1038/clpt.2011.115
   Patel R, 2022, POSTGRAD MED, V134, P245, DOI 10.1080/00325481.2021.1985351
   Pertovaara A, 2013, EUR J PHARMACOL, V716, P2, DOI 10.1016/j.ejphar.2013.01.067
   Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884
   Song SY, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000018653
   Staff NP, 2020, EXP NEUROL, V324, DOI 10.1016/j.expneurol.2019.113121
   Suebsakwong P, 2019, ACS MED CHEM LETT, V10, P1400, DOI 10.1021/acsmedchemlett.9b00161
   TAKESHIGE C, 1992, BRAIN RES BULL, V29, P617, DOI 10.1016/0361-9230(92)90131-G
   VERWEIJ J, 1994, ANN ONCOL, V5, P495, DOI 10.1093/oxfordjournals.annonc.a058903
   Wang D, 2021, INVEST NEW DRUG, V39, P122, DOI 10.1007/s10637-020-00997-0
   WESTLUND KN, 1982, PROG BRAIN RES, V57, P219, DOI 10.1016/S0079-6123(08)64131-X
   White MC, 2014, AM J PREV MED, V46, pS7, DOI 10.1016/j.amepre.2013.10.029
   Woo SM, 2016, PHYTOTHER RES, V30, P1817, DOI 10.1002/ptr.5687
   Xie QF, 2012, J ETHNOPHARMACOL, V144, P567, DOI 10.1016/j.jep.2012.09.041
   Yu XK, 2018, J ETHNOPHARMACOL, V224, P177, DOI 10.1016/j.jep.2018.05.034
   Zhang HQ, 2019, J PHARMACEUT BIOMED, V167, P114, DOI 10.1016/j.jpba.2019.02.003
   Zhang SM, 2021, SEMIN ONCOL, V48, P193, DOI 10.1053/j.seminoncol.2021.09.004
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
NR 69
TC 19
Z9 21
U1 3
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1467-3037
EI 1467-3045
J9 CURR ISSUES MOL BIOL
JI Curr. Issues Mol. Biol.
PD FEB
PY 2022
VL 44
IS 2
BP 718
EP 730
DI 10.3390/cimb44020050
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA ZL1RY
UT WOS:000763459800001
PM 35723335
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Jones, KF
   Wechsler, S
   Zulewski, D
   Wood, L
AF Jones, Katie Fitzgerald
   Wechsler, Stephen
   Zulewski, David
   Wood, Lisa
TI Pharmacological and Nonpharmacological Management of
   Chemotherapy-Induced Peripheral Neuropathy: A Scoping Review of
   Randomized Controlled Trials
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Review
DE chemotherapy-induced neuropathy; chronic pain; neuropathic pain;
   peripheral neuropathy
ID CANCER-RELATED LYMPHEDEMA; LEVEL LASER THERAPY; QUALITY-OF-LIFE; INDUCED
   POLYNEUROPATHY; SURVIVORS; BALANCE; IMPACT; SYMPTOMS; EXERCISE; FALLS
AB Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating side effect of cancer treatment with no effective preventative strategy or definitive treatment.Purpose: To synthesize empiric literature from randomized controlled trials (RCTs) of pharmacological and nonpharmacological management of CIPN.Data Sources: Articles published between January 1, 2010, and February 28, 2021, were identified using keywords searching Medline, PubMed, CINAHL, Web of Science, Cochrane Library, and Embase.Study Selection: RCTs that recruited individuals who were post-chemotherapy and experienced persistent CIPN symptoms.Data Extraction and Synthesis: Three independent reviewers screened a total of 2023 abstracts. After screening, full-text review, and quality appraisal, 22 articles were included in this review. Data related to study design, participant characteristics, interventions, controls, outcome measures, and relevant findings were extracted from full texts. Descriptive quantitative summaries were calculated and narrative analysis was performed.Results: Of the 22 studies, 4 investigated pharmacologic treatments, 2 compared acupuncture to pharmacologic treatments, and 16 studies examined nonpharmacologic treatments. Pharmacologic studies reported mixed results with evidence of participant response varying by history of chemotherapeutic agent. Acupuncture, exercise/physical therapy, and neurofeedback appear to be effective treatments for CIPN. Evidence regarding biophysical agents and cognitive-behavioral therapy is equivocal. Scrambler therapy is not supported.Limitations: Studies included in this review share several limitations, including widely variable outcome measures, small and demographically homogenous samples, and nonstandardized treatment protocols.Conclusion: This scoping review summarized the current body of high-quality RCTs investigating treatment for CIPN. The majority of studies in this review reports benefits of pharmacologic and nonpharmacologic interventions, although management may require a multipronged approach and should be tailored to the individual. Clinical implications are proposed and suggestions made for future research include implementation of standardized intervention protocols, use of outcome measures representative of the spectrum of CIPN symptoms, and stratification by the chemotherapeutic agent.
C1 [Jones, Katie Fitzgerald; Zulewski, David; Wood, Lisa] Boston Coll, William F Connell Sch Nursing, 140 Commonwealth Ave, Chestnut Hill, MA 02467 USA.
   [Wechsler, Stephen] Massachusetts Gen Hosp, Inst Hlth Professionals, Sch Rehabil Sci, Boston, MA 02114 USA.
C3 Boston College; Harvard University; Harvard University Medical
   Affiliates; Massachusetts General Hospital
RP Jones, KF (corresponding author), Boston Coll, William F Connell Sch Nursing, 140 Commonwealth Ave, Chestnut Hill, MA 02467 USA.
EM jonesafq@bc.edu
OI Jones, Katie/0000-0002-0825-8394; Wechsler, Stephen/0000-0003-4753-0212;
   Wood Magee, Lisa/0000-0003-1145-3649
FU National Institute of Nursing Research [F31NR019929] Funding Source: NIH
   RePORTER; NINR NIH HHS [F31 NR019929] Funding Source: Medline
CR Argenta PA, 2017, GYNECOL ONCOL, V144, P159, DOI 10.1016/j.ygyno.2016.11.013
   Arksey H., 2005, INT J SOC RES METHOD, V8, P19, DOI [DOI 10.1080/1364557032000119616, 10.1080/1364557032000119616, DOI 10.1080/136.455.7032000119616]
   Avan R, 2018, J RES MED SCI, V23, DOI 10.4103/jrms.JRMS_1068_17
   Bao T, 2020, JNCI CANCER SPECT, V4, DOI 10.1093/jncics/pkaa048
   Bao T, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.0681
   Bao T, 2016, BREAST CANCER RES TR, V159, P327, DOI 10.1007/s10549-016-3939-0
   Beijers AJM, 2020, ANN ONCOL, V31, P131, DOI 10.1016/j.annonc.2019.09.006
   Brice R, CASP CHECKLISTS CASP
   Bulls HW, 2021, ANN BEHAV MED, V55, P844, DOI 10.1093/abm/kaaa101
   Cammisuli S, 2016, EUR J PHYS REHAB MED, V52, P479
   Cancer.Net, 2011, CANC SURV GUID
   Chien TJ, 2019, INTEGR CANCER THER, V18, DOI 10.1177/1534735419866910
   Childs DS, 2021, J PAIN SYMPTOM MANAG, V61, P1247, DOI 10.1016/j.jpainsymman.2020.11.025
   Covidence, Covidence Systematic Review Software
   D'Alessandro EG, 2022, BMJ SUPPORT PALLIAT, V12, P64, DOI 10.1136/bmjspcare-2018-001542
   Dimitrova A, 2017, MED ACUPUNCT, V29, P352, DOI 10.1089/acu.2017.1242
   Eckhoff L, 2015, EUR J CANCER, V51, P292, DOI 10.1016/j.ejca.2014.11.024
   Finlayson CS, 2015, J PALLIAT MED, V18, P176, DOI 10.1089/jpm.2014.0222
   Fu MR, 2014, CLIN J ONCOL NURS, V18, P68, DOI 10.1188/14.CJON.S3.68-79
   Fu MR, 2013, PSYCHO-ONCOLOGY, V22, P1466, DOI 10.1002/pon.3201
   Galantino ML, 2019, INTEGR CANCER THER, V18, DOI 10.1177/1534735419850627
   Galantino ML, 2019, INT J YOGA THER, V30, P49
   Geiger G, 2015, BIOELECTROMAGNETICS, V36, P251, DOI 10.1002/bem.21897
   Gewandter JS, 2013, SUPPORT CARE CANCER, V21, P2059, DOI 10.1007/s00520-013-1766-y
   Gewandter JS, 2017, NEUROLOGY, V89, P859, DOI 10.1212/WNL.0000000000004272
   Gewandter JS, 2014, SUPPORT CARE CANCER, V22, P1807, DOI 10.1007/s00520-014-2158-7
   Goto Y, 2020, J CLIN NEUROSCI, V73, P101, DOI 10.1016/j.jocn.2020.01.020
   Han XY, 2017, BMC CANCER, V17, DOI 10.1186/s12885-016-3037-z
   Hile ES, 2010, PHYS THER, V90, P1649, DOI 10.2522/ptj.20090405
   Hincker A, 2019, PAIN, V160, P1835, DOI 10.1097/j.pain.0000000000001577
   Hou S, 2018, PAIN PHYSICIAN, V21, P571, DOI 10.36076/ppj.2018.6.571
   Hsieh YL, 2016, SUPPORT CARE CANCER, V24, P233, DOI 10.1007/s00520-015-2773-y
   Hsieh YL, 2016, ACUPUNCT MED, V34, P398, DOI 10.1136/acupmed-2016-011112
   Huang MH, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208573
   Iravani S, 2020, PAIN RES MANAG, V2020, DOI 10.1155/2020/2504674
   Kandula T, 2018, JAMA NEUROL, V75, P980, DOI 10.1001/jamaneurol.2018.0963
   Kerckhove N, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00086
   Kleckner IR, 2018, SUPPORT CARE CANCER, V26, P1019, DOI 10.1007/s00520-017-4013-0
   Kneis S, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5522-7
   Knoerl R, 2018, J PAIN, V19, P382, DOI 10.1016/j.jpain.2017.11.009
   Kolb NA, 2016, JAMA NEUROL, V73, P860, DOI 10.1001/jamaneurol.2016.0383
   Lindblad K, 2016, SUPPORT CARE CANCER, V24, P2523, DOI 10.1007/s00520-015-3060-7
   Liou KT, 2019, PAIN MED, V20, P2060, DOI 10.1093/pm/pnz087
   Lopes-Souza P, 2018, DRUG DISCOV THER, V12, P239, DOI 10.5582/ddt.2018.01039
   Loprinzi C, 2020, SUPPORT CARE CANCER, V28, P1183, DOI 10.1007/s00520-019-04881-3
   Loprinzi CL, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01399
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Ludwick A, 2020, PAIN MANAG NURS, V21, P142, DOI 10.1016/j.pmn.2019.08.005
   Lynch ME, 2014, J PAIN SYMPTOM MANAG, V47, P166, DOI 10.1016/j.jpainsymman.2013.02.018
   McCrary JM, 2019, SUPPORT CARE CANCER, V27, P3849, DOI 10.1007/s00520-019-04680-w
   Monfort SM, 2017, BREAST CANCER RES TR, V164, P69, DOI 10.1007/s10549-017-4230-8
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Prinsloo S, 2018, J PAIN SYMPTOM MANAG, V55, P1276, DOI 10.1016/j.jpainsymman.2018.01.010
   Prinsloo S, 2017, CANCER-AM CANCER SOC, V123, P1989, DOI 10.1002/cncr.30649
   Rick O, 2017, BIOELECTROMAGNETICS, V38, P85, DOI 10.1002/bem.22005
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/349653
   Schönsteiner SS, 2017, EXP HEMATOL ONCOL, V5, DOI 10.1186/s40164-017-0065-6
   Schwenk M, 2016, GERONTOLOGY, V62, P553, DOI 10.1159/000442253
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Smith TJ, 2020, J PALLIAT CARE, V35, P53, DOI 10.1177/0825859719827589
   Smoot B, 2015, J CANCER SURVIV, V9, P287, DOI 10.1007/s11764-014-0411-1
   Song SY, 2020, INTEGR CANCER THER, V19, DOI 10.1177/1534735420925519
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Streckmann F, 2019, SUPPORT CARE CANCER, V27, P2471, DOI 10.1007/s00520-018-4531-4
   Sun YJ, 2016, EXP THER MED, V12, P4017, DOI 10.3892/etm.2016.3871
   Tanay MA, 2019, EUR J CANCER CARE, V28, DOI 10.1111/ecc.13011
   Tofthagen C, 2012, SUPPORT CARE CANCER, V20, P583, DOI 10.1007/s00520-011-1127-7
   Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850
   van den Beuken-van Everdingen MH, 2016, J PAIN SYMPTOM MANAG, V51
   Verhulst ALJ, 2015, ONCOL REV, V9, DOI 10.4081/oncol.2015.263
   Wechsler S, 2021, REHABIL ONCOL, V39, P6, DOI 10.1097/01.REO.0000000000000238
   Winters-Stone KM, 2017, J CLIN ONCOL, V35, P2604, DOI 10.1200/JCO.2016.71.3552
   Zanville NR, 2016, SUPPORT CARE CANCER, V24, P4779, DOI 10.1007/s00520-016-3329-5
   Zimmer P, 2018, SUPPORT CARE CANCER, V26, P615, DOI 10.1007/s00520-017-3875-5
NR 75
TC 16
Z9 22
U1 2
U2 18
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
EI 1557-7740
J9 J PALLIAT MED
JI J. Palliat. Med.
PD JUN
PY 2022
VL 25
IS 6
BP 964
EP 995
DI 10.1089/jpm.2021.0512
EA FEB 2022
PG 32
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services
GA 3S9TI
UT WOS:000751990300001
PM 35128938
OA Green Submitted
DA 2026-01-16
ER

PT J
AU Wasserman, AM
AF Wasserman, Amy M.
TI Diagnosis and Management of Rheumatoid Arthritis
SO AMERICAN FAMILY PHYSICIAN
LA English
DT Article
ID MODIFYING ANTIRHEUMATIC DRUGS; AMERICAN-COLLEGE; RISK-FACTORS; DISEASE;
   SUSCEPTIBILITY; ACUPUNCTURE; PREDICTORS; DISABILITY; OUTCOMES; ADULTS
AB Rheumatoid arthritis is the most commonly diagnosed systemic inflammatory arthritis. Women, smokers, and those with a family history of the disease are most often affected. Criteria for diagnosis include having at least one joint with definite swelling that is not explained by another disease. The likelihood of a rheumatoid arthritis diagnosis increases with the number of small joints involved. In a patient with inflammatory arthritis, the presence of a rheumatoid factor or anti-citrullinated protein antibody, or elevated C-reactive protein level or erythrocyte sedimentation rate suggests a diagnosis of rheumatoid arthritis. Initial laboratory evaluation should also include complete blood count with differential and assessment of renal and hepatic function. Patients taking biologic agents should be tested for hepatitis B, hepatitis C, and tuberculosis. Earlier diagnosis of rheumatoid arthritis allows for earlier treatment with disease-modifying antirheumatic agents. Combinations of medications are often used to control the disease. Methotrexate is typically the first-line drug for rheumatoid arthritis. Biologic agents, such as tumor necrosis factor inhibitors, are generally considered second-line agents or can be added for dual therapy. The goals of treatment include minimization of joint pain and swelling, prevention of radiographic damage and visible deformity, and continuation of work and personal activities. Joint replacement is indicated for patients with severe joint damage whose symptoms are poorly controlled by medical management. (Am Fam Physician. 2011;84(11):1245-1252. Copyright (C) 2011 American Academy of Family Physicians.)
C1 Boston Univ, Sch Med, Boston, MA 02118 USA.
C3 Boston University
RP Wasserman, AM (corresponding author), Boston Univ, Sch Med, 72 E Concord St,Evans 501, Boston, MA 02118 USA.
EM amywass@bu.edu
CR AHRQ, 2008, CHOOS MED RHEUM ARTH
   Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI [10.1136/ard.2010.138461, 10.1002/art.27584]
   Allaire S, 2009, ARTHRIT RHEUM-ARTHR, V61, P321, DOI 10.1002/art.24281
   [Anonymous], 2002, Cochrane Database Syst Rev, DOI [DOI 10.1002/14651858, DOI 10.1002/14651858.CD002826]
   [Anonymous], 2004, **DROPPED REF**
   Atzeni F, 2010, AUTOIMMUN REV, V9, P835, DOI 10.1016/j.autrev.2010.07.018
   Baecklund E, 2006, ARTHRITIS RHEUM, V54, P692, DOI 10.1002/art.21675
   Baillet A, 2009, RHEUMATOLOGY, V48, P410, DOI 10.1093/rheumatology/ken511
   Balsa A, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2975
   Bang SY, 2010, ARTHRITIS RHEUM-US, V62, P369, DOI 10.1002/art.27272
   Brodin N, 2008, ARTHRIT RHEUM-ARTHR, V59, P325, DOI 10.1002/art.23327
   Cameron M, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002948.pub2
   Casimiro L, 2002, Cochrane Database Syst Rev, pCD003787
   Choy EHS, 2005, RHEUMATOLOGY, V44, P1414, DOI 10.1093/rheumatology/kei031
   Costenbader KH, 2006, AM J MED, V119, P503, DOI 10.1016/j.amjmed.2005.09.053
   Deighton C, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b702
   Evans S, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-19
   Firestein G.S., 2009, Kelly's Textbook of Rheumatology, P1035, DOI [10.1016/B978-0-323-31696-5.00069-3, DOI 10.1016/B978-0-323-31696-5.00069-3, 10.1016/B978-1-4160-3285-4.10065-8]
   Friedewald VE, 2010, AM J CARDIOL, V106, P442, DOI 10.1016/j.amjcard.2010.04.005
   Guthrie KA, 2010, ARTHRITIS RHEUM-US, V62, P1842, DOI 10.1002/art.27459
   Hagen KB, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006400.pub2
   Hurkmans E, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006853.pub2
   Kaaja RJ, 2005, JAMA-J AM MED ASSOC, V294, P2751, DOI 10.1001/jama.294.21.2751
   Karlson EW, 2008, ARTHRIT RHEUM-ARTHR, V59, P1589, DOI 10.1002/art.24194
   Karlson EW, 2004, ARTHRITIS RHEUM-US, V50, P3458, DOI 10.1002/art.20621
   Katchamart W, 2010, ARTHRIT CARE RES, V62, P1128, DOI 10.1002/acr.20188
   Kelly RB, 2009, AM FAM PHYSICIAN, V80, P481
   MacGregor AJ, 2000, ARTHRITIS RHEUM, V43, P30, DOI 10.1002/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B
   McClure A, 2009, RHEUMATOLOGY, V48, P1369, DOI 10.1093/rheumatology/kep272
   Mochan E, 2008, AM FAM PHYSICIAN, V77, P1451
   Orozco G, 2010, EXPERT REV CLIN IMMU, V6, P61, DOI 10.1586/ECI.09.72
   Ravelli A, 2005, ARTHRITIS RHEUM, V52, P826, DOI 10.1002/art.20945
   Saag KG, 2008, ARTHRIT RHEUM-ARTHR, V59, P762, DOI 10.1002/art.23721
   Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140-6736(10)60826-4
   Smedslund G, 2010, J AM DIET ASSOC, V110, P727, DOI 10.1016/j.jada.2010.02.010
   Tehlirian C V., 2008, Primer on the rheumatic disease, V13th, P114
   van der Helm-van Mil AHM, 2007, ARTHRITIS RHEUM-US, V56, P433, DOI 10.1002/art.22380
   Wang CC, 2008, ARTHRIT RHEUM-ARTHR, V59, P1249, DOI 10.1002/art.24009
   WILDER RL, 1991, CLIN ORTHOP RELAT R, P36
   Wilson A, 2004, AM J MED, V116, P50, DOI 10.1016/j.amjmed.2003.12.012
   Wolfe F, 1998, ARTHRITIS RHEUM, V41, P1072, DOI 10.1002/1529-0131(199806)41:6<1072::AID-ART14>3.0.CO;2-G
NR 41
TC 230
Z9 278
U1 0
U2 26
PU AMER ACAD FAMILY PHYSICIANS
PI KANSAS CITY
PA 8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA
SN 0002-838X
EI 1532-0650
J9 AM FAM PHYSICIAN
JI Am. Fam. Physician
PD DEC 1
PY 2011
VL 84
IS 11
BP 1245
EP 1252
PG 8
WC Primary Health Care; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 980AP
UT WOS:000306866300010
PM 22150658
DA 2026-01-16
ER

PT J
AU Liu, ZC
   Qiao, F
   Liu, DJ
   Kong, XZ
   Liu, KW
   Gu, HW
   Zhang, YQ
   Meng, QB
   Cheng, L
AF Liu, Zhenchuan
   Qiao, Fei
   Liu, Dejian
   Kong, Xiangzhen
   Liu, Kaiwen
   Gu, Hanwen
   Zhang, Yuanqiang
   Meng, Qunbo
   Cheng, Lei
TI Periplocin targets LRP4 to regulate metabolic homeostasis and
   anti-inflammation for the treatment of IVDD
SO PHYTOMEDICINE
LA English
DT Article
DE Intervertebral disc degeneration; Periplocin; TNF-alpha; inflammation;
   LRP4; Molecular docking
ID INTERVERTEBRAL DISC DEGENERATION; LOW-BACK-PAIN; KAPPA-B; ALPHA
AB Background: Intervertebral disc degeneration (IVDD) is characterized by deteriorating intervertebral discs, leading primarily to low back pain and leg pain. Most current treatments for IVDD primarily address symptoms without targeting the underlying degenerative process. Moreover, tumor necrosis factor-alpha (TNF-alpha)-mediated inflammation and degradation of the nucleus pulposus (NP) extracellular matrix (ECM) influence this pathological process. Periplocin, a cardiotonic steroid extracted from periplocin forrestii, has demonstrated a wide range of medical benefits, including cardiotonic, anticancer, anti-inflammatory, and wound healing properties. Nevertheless, the effects of periplocin on IVDD remain unexplored. Objective: Our study explores the mechanism of action and the potential target of periplocin in mitigating IVDD pathology. Methods: Rat models of IVDD were established using acupuncture, and the affected discs underwent analysis via Safranin O-Fast Green (S-O) and Hematoxylin and Eosin (H&E) staining. Nucleus pulposus cells (NPCs) were harvested from IVDD patients and experimental animals for examination. A variety of techniques, including Western blot analysis, quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) assay, immunofluorescence staining, Alcian Blue staining and Immunohistochemistry (IHC) staining, were utilized to evaluate inflammationrelated proteins, mRNAs and the ECM metabolism. In order to ascertain the potential protein targets of periplocin, the binding site of periplocin to LRP4 was elucidated through the utilisation of molecular docking experiments. Subsequently, the expression of low-density lipoprotein receptor-related protein 4 (LRP4) in NPCs was modified through the use of small interfering RNA (siRNA) knockdown and overexpression vectors, which were employed for the purposes of target validation. Results: We conclude from the present study that periplocin alleviates the progression of IVDD mainly through the following aspects: periplocin inhibits TNF-alpha-induced inflammatory; periplocin reduces matrix degradation; periplocin promotes matrix anabolism and regulates metabolic homeostasis. Moreover, the present study demonstrates that LRP4 is involved as a potential target in the multiple pathways mentioned above to protect the intervertebral disc. Conclusion: Our research suggests that periplocin may serve as a promising treatment for IVDD, offering antiinflammatory benefits, preventing ECM degradation, and promoting ECM anabolism.
C1 [Liu, Zhenchuan; Qiao, Fei; Liu, Dejian; Kong, Xiangzhen; Liu, Kaiwen; Gu, Hanwen; Zhang, Yuanqiang; Meng, Qunbo; Cheng, Lei] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Orthoped Surg, Jinan 250012, Shandong, Peoples R China.
   [Qiao, Fei] Dalian Women & Childrens Med Ctr Grp, Dept Pediat Orthoped, Dalian 116012, Liaoning, Peoples R China.
C3 Shandong University
RP Zhang, YQ; Meng, QB; Cheng, L (corresponding author), Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Orthoped Surg, Jinan 250012, Shandong, Peoples R China.
EM drzhyq@126.com; mengqunbo@126.com; chenglei@email.sdu.edu.cn
RI Sui, Jing/B-3455-2018; liu, kaiwen/GVS-5259-2022; Gu,
   Hanwen/JBJ-4790-2023
OI Gu, Hanwen/0000-0002-2716-9055; Qunbo, Meng/0009-0007-5774-339X
FU National Natural Science Foundation of China [82272548]; Natural Science
   Foundation of Shandong Province, China [ZR2023MH194]
FX Funding for the study included the National Natural Science Foundation
   of China (82272548) and the Natural Science Foundation of Shandong
   Province, China (ZR2023MH194) .
CR Asai N, 2014, BIOCHEM BIOPH RES CO, V451, P302, DOI 10.1016/j.bbrc.2014.07.125
   Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5
   Chai Q, 2023, CARTILAGE, V14, P506, DOI 10.1177/19476035231157341
   Chang HY, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03990-4
   Chen JX, 2023, ADV SCI, V10, DOI 10.1002/advs.202206306
   Chen L, 2021, J ETHNOPHARMACOL, V271, DOI 10.1016/j.jep.2021.113892
   Duan L, 2015, AM J TRANSL RES, V7, P194
   Fijalkowski I, 2016, J BONE MINER RES, V31, P874, DOI 10.1002/jbmr.2782
   Francisco V, 2022, NAT REV RHEUMATOL, V18, P47, DOI 10.1038/s41584-021-00713-z
   Gawri R, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4449
   Han B, 2008, SPINE, V33, P1925, DOI 10.1097/BRS.0b013e31817c64a9
   Hao JM, 2023, J CARDIOVASC TRANSL, V16, P127, DOI 10.1007/s12265-022-10277-2
   Hayashi S, 2008, SPINE, V33, P1542, DOI 10.1097/BRS.0b013e318178e5ea
   He ZL, 2018, BIOCHEM BIOPH RES CO, V506, P94, DOI 10.1016/j.bbrc.2018.10.069
   Jha R, 2023, J CLIN MED, V12, DOI 10.3390/jcm12216907
   Jiang XJ, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01709-5
   Knezevic NN, 2021, LANCET, V398, P78, DOI 10.1016/S0140-6736(21)00733-9
   Koneczny I, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8070671
   Lara-Castillo N, 2015, REV ENDOCR METAB DIS, V16, P141, DOI 10.1007/s11154-015-9315-2
   Lin RG, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658-019-0167-8
   Liu KW, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.687024
   Ma HW, 2022, CELL DEATH DISCOV, V8, DOI 10.1038/s41420-022-01002-8
   Molinos M, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2014.1191
   Molladavoodi S, 2020, CELL TISSUE RES, V379, P429, DOI 10.1007/s00441-019-03136-1
   Ni WY, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.579658
   Ogata N, 2000, CARDIOVASC RES, V45, P513, DOI 10.1016/S0008-6363(99)00364-8
   Qiu XJ, 2022, INT J BIOL SCI, V18, P2202, DOI 10.7150/ijbs.65973
   Rim Dae Cheol, 2016, Korean J Spine, V13, P1, DOI [10.14245/kjs.2016.13.1.1, 10.14245/kjs.2016.13.1.1]
   Risbud MV, 2014, NAT REV RHEUMATOL, V10, P44, DOI 10.1038/nrrheum.2013.160
   Séguin CA, 2005, SPINE, V30, P1940, DOI 10.1097/01.brs.0000176188.40263.f9
   Shang P, 2020, J CELL MOL MED, V24, P3701, DOI 10.1111/jcmm.15074
   Shao Z, 2021, OSTEOARTHR CARTILAGE, V29, P413, DOI 10.1016/j.joca.2020.11.006
   Sun J, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms241813695
   Sun K, 2020, OSTEOARTHR CARTILAGE, V28, P400, DOI 10.1016/j.joca.2020.02.027
   Vo NV, 2013, SPINE J, V13, P331, DOI 10.1016/j.spinee.2012.02.027
   Vos T, 2013, LANCET, V381, P628
   Wallwork SB, 2024, CAN MED ASSOC J, V196, pE29, DOI 10.1503/cmaj.230542
   Wang KD, 2022, ANN RHEUM DIS, V81, P544, DOI 10.1136/annrheumdis-2021-221380
   Zhang GZ, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.13057
   Zhang P, 2023, BIOMED PHARMACOTHER, V165, DOI 10.1016/j.biopha.2023.115252
   Zhang XD, 2023, BIOCHEM PHARMACOL, V211, DOI 10.1016/j.bcp.2023.115516
   Zhang Y, 2008, INT J BIOL SCI, V4, P283
   Zhao YP, 2020, THERANOSTICS, V10, P7015, DOI 10.7150/thno.45359
   Zhou MH, 2024, JOR SPINE, V7, DOI 10.1002/jsp2.1289
NR 44
TC 3
Z9 3
U1 9
U2 11
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944-7113
EI 1618-095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD JUL 25
PY 2025
VL 143
AR 156885
DI 10.1016/j.phymed.2025.156885
EA MAY 2025
PG 15
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 3IK7W
UT WOS:001501105100002
PM 40440911
DA 2026-01-16
ER

PT J
AU Pysarevska, S
   Plotycya, S
   Dubenska, L
AF Pysarevska, Solomiya
   Plotycya, Serhiy
   Dubenska, Liliya
TI Voltammetry of local anesthetics: theoretical and practical aspects
SO CRITICAL REVIEWS IN ANALYTICAL CHEMISTRY
LA English
DT Review
DE Chemically modified electrodes; electrochemical oxidation; local
   anesthetics; voltammetry
ID NANOTUBE MODIFIED ELECTRODE; GLASSY-CARBON ELECTRODES;
   PHARMACEUTICAL-PREPARATIONS; LIQUID-CHROMATOGRAPHY; PASTE ELECTRODE;
   SENSITIVE DETERMINATION; PROCAINE HYDROCHLORIDE; HUMAN SERUM; LIDOCAINE;
   BENZOCAINE
AB Local anesthetics (LAs) are widely used in anesthesiology, ophthalmology, and otolaryngology as well as for treatment of chronic and oncological pain. However, anesthetics can cause adverse effects up to lethal ones. In this work, we cited reviews on chromatographic and spectroscopic methods of local anesthetics determination published earlier, and the main purpose was to review the possibilities and advantages of voltammetric methods used for the LAs determination. The electrochemical behavior, mechanism of LAs transformation on the various working electrodes and analytical parameters of voltammetric methods used for their determination were reviewed in the work. Vast majority of these methods were developed for the most widely used anesthetics in medicine like benzocaine, lidocaine and procaine. Special attention was paid to possible mechanisms of electrochemical oxidation and in some cases reduction of LAs or their derivatives. Voltammetry is used for the determination of LAs in pharmaceutical formulations and in biological fluids. The analytical characteristics in terms of sensitivity, selectivity, reproducibility also were discussed in the article.
C1 [Pysarevska, Solomiya] Ivan Franko Natl Univ Lviv, Life Safety Dept, Doroshenko 41, UA-79000 Lvov, Ukraine.
   [Plotycya, Serhiy; Dubenska, Liliya] Ivan Franko Natl Univ Lviv, Analyt Chem Dept, Lvov, Ukraine.
   [Plotycya, Serhiy] State Sci Res Control Inst Vet Med Prod & Feed Ad, Lvov, Ukraine.
C3 Ministry of Education & Science of Ukraine; Ivan Franko National
   University Lviv; Ministry of Education & Science of Ukraine; Ivan Franko
   National University Lviv; Institute of Veterinary Medicinal Products &
   Feed Additives
RP Pysarevska, S (corresponding author), Ivan Franko Natl Univ Lviv, Life Safety Dept, Doroshenko 41, UA-79000 Lvov, Ukraine.
EM solomiya.pysarevska@lnu.edu.ua
RI ; Pysarevska, Solomiya/E-8268-2019; Dubenska, Liliya/K-9195-2017
OI Plotytsia, Serhiy/0000-0002-2258-7012; Pysarevska,
   Solomiya/0000-0003-4043-1692; 
CR Adamova EM, 2016, J ANAL CHEM+, V71, P1169, DOI 10.1134/S1061934816120029
   Ahmadi M, 2018, J CHROMATOGR B, V1095, P177, DOI 10.1016/j.jchromb.2018.07.036
   Al Nebaihi HM, 2017, PHARMACEUTICS, V9, DOI 10.3390/pharmaceutics9040052
   [Anonymous], 2016, The International Encyclopedia of Adverse Drug Reactions and Interactions
   Attia A. K., 2017, INSIGHTS ANAL ELECTR, V3, P1, DOI DOI 10.21767/2470-9867.100018
   Baniceru M, 2004, J PHARMACEUT BIOMED, V35, P593, DOI 10.1016/j.jpba.2004.02.012
   Baniceru M, 2011, J PHARMACEUT BIOMED, V54, P1, DOI 10.1016/j.jpba.2010.07.013
   Becker Daniel E, 2012, Anesth Prog, V59, P90, DOI 10.2344/0003-3006-59.2.90
   Bergamini MF, 2007, J PHARMACEUT BIOMED, V43, P315, DOI 10.1016/j.jpba.2006.06.001
   Cavalheiro E.T.G., 2012, Bioanal. Rev, V4, P31, DOI DOI 10.1007/S12566-012-0027-8
   Dejmkova H, 2011, ELECTROANAL, V23, P662, DOI 10.1002/elan.201000646
   Demir E, 2018, ANAL SCI, V34, P771, DOI 10.2116/analsci.17P589
   Doménech-Carbó A, 2014, REV ANAL CHEM, V33, P173, DOI 10.1515/revac-2013-0027
   DONG S, 1984, J ELECTROCHEM SOC, V131, P813, DOI 10.1149/1.2115705
   Dong S., 1985, CHIN J APPL CHEM, V2, P34
   DONG SJ, 1985, ACTA CHIM SINICA, V43, P712
   Dubenska L., 2017, VISNYK LVIV U C, V58, P231
   Dubenska L., 2018, VOPROSY KHIM KHIM TE, V5, P12
   Dubenska LO, 2017, METHODS OBJECTS CHEM, V12, P61, DOI 10.17721/moca.2017.61-75
   Dubenska L. O., 2016, 15 UKR POL S THEOR E
   de Lima RMF, 2018, ELECTROANAL, V30, P283, DOI 10.1002/elan.201700554
   Ganzberg Steven, 2010, Dent Clin North Am, V54, P601, DOI 10.1016/j.cden.2010.06.001
   Guan XW, 2016, ELECTROANAL, V28, P2007, DOI 10.1002/elan.201600007
   Guo W, 2013, INT J ELECTROCHEM SC, V8, P5369
   Gupta VK, 2011, ANAL BIOCHEM, V408, P179, DOI 10.1016/j.ab.2010.09.027
   Jadach M, 2012, ACTA POL PHARM, V69, P397
   2019, Chemical Science Transactions, V8, DOI [10.7598/cst2019.1527, 10.7598/cst2019.1527, DOI 10.7598/CST2019.1527]
   Kachoosangi RT, 2008, ELECTROANAL, V20, P2495, DOI 10.1002/elan.200804385
   Koehler A, 2005, J CHROMATOGR A, V1088, P126, DOI 10.1016/j.chroma.2005.03.071
   Komorsky-Lovric S, 2003, ELECTROANAL, V15, P544, DOI 10.1002/elan.200390067
   Li NB, 2003, ANAL SCI, V19, P1587, DOI 10.2116/analsci.19.1587
   Lirk P, 2018, ANESTH ANALG, V126, P1381, DOI 10.1213/ANE.0000000000002665
   Liu AL, 2012, J SOLID STATE ELECTR, V16, P1343, DOI 10.1007/s10008-011-1517-2
   Lu Q, 2008, BIOSENS BIOELECTRON, V24, P767, DOI 10.1016/j.bios.2008.06.056
   Lund Henning., 1991, Organic Electrochemistry: An Introduction and a Guide
   Matos CRS, 2017, MICROCHIM ACTA, V184, P1755, DOI 10.1007/s00604-017-2165-8
   Mekassa B, 2017, SENS BIO-SENS RES, V16, P46, DOI [10.1016/j.sbsr.2017.11.002, 10.1016/j.sbsr.2017.11.002, DOI 10.1016/J.SBSR.2017.11.002]
   MELICHAREK M, 1970, J ELECTROANAL CHEM, V26, P201, DOI 10.1016/S0022-0728(70)80304-7
   Merkoçi A, 2006, MICROCHIM ACTA, V152, P157, DOI 10.1007/s00604-005-0439-z
   Muzyka K, 2019, ANAL METHODS-UK, V11, P397, DOI 10.1039/c8ay02197j
   Norouzi P, 2007, ANAL CHIM ACTA, V590, P74, DOI 10.1016/j.aca.2007.03.019
   Oliveira RTS, 2007, ELECTROANAL, V19, P1189, DOI 10.1002/elan.200603840
   Pinar PT, 2020, DIAM RELAT MATER, V101, DOI 10.1016/j.diamond.2019.107649
   Plotycya S., 2016, VISNYK LVIV U C, V57, P203
   Plotycya S, 2018, INT J ELECTROCHEM, V2018, DOI 10.1155/2018/1376231
   Plotycya S, 2016, ELECTROANAL, V28, P2575, DOI 10.1002/elan.201600134
   Pysarevska S, 2018, SENSOR ACTUAT B-CHEM, V270, P9, DOI 10.1016/j.snb.2018.05.012
   Rahbar N, 2015, JUNDISHAPUR J NAT PH, V10
   Rahbar N, 2016, CHINESE CHEM LETT, V27, P837, DOI 10.1016/j.cclet.2016.04.017
   Reddy TM, 2006, CROAT CHEM ACTA, V79, P253
   Saad AS, 2019, J ELECTROCHEM SOC, V166, pB103, DOI 10.1149/2.0921902jes
   Siddiqui MR, 2017, ARAB J CHEM, V10, pS1409, DOI 10.1016/j.arabjc.2013.04.016
   Sivakumar V, 2014, J MATER SCI-MATER EL, V25, P1485, DOI 10.1007/s10854-014-1757-x
   Song J, 2011, MICROCHIM ACTA, V172, P117, DOI 10.1007/s00604-010-0470-6
   Sousa CP, 2019, CHEMELECTROCHEM, V6, P2350, DOI 10.1002/celc.201801742
   SUZUKI O, 2005, HDB PRACTICAL ANAL
   Taguchi J, 2003, J ELECTROANAL CHEM, V557, P91, DOI 10.1016/S0022-0728(03)00351-6
   Tan G, 2012, TURK J CHEM, V36, P593, DOI 10.3906/kim-1112-6
   Tonooka K, 2016, FORENSIC SCI INT, V265, P182, DOI 10.1016/j.forsciint.2016.02.044
   Uslu B, 2007, ANAL LETT, V40, P817, DOI 10.1080/00032710701242121
   Wang CY, 2002, J PHARMACEUT BIOMED, V30, P131, DOI 10.1016/S0731-7085(02)00204-2
   Wang J., 1988, Electroanalytical Techniques in Clinical Chemistry and Laboratory Medicine
   Wang YR, 2008, CHINESE J ANAL CHEM, V36, P1011, DOI 10.1016/S1872-2040(08)60052-3
   Wei M, 2008, ELECTROANAL, V20, P137, DOI 10.1002/elan.200704024
   Wu KB, 2006, BIOELECTROCHEMISTRY, V68, P144, DOI 10.1016/j.bioelechem.2005.05.002
   Xu Q, 2009, CURR PHARM ANAL, V5, P144, DOI 10.2174/157341209788172889
   Yang GM, 2014, J MATER CHEM C, V2, P10201, DOI 10.1039/c4tc02039a
   Zhang JJ, 2018, MICROCHIM ACTA, V185, DOI 10.1007/s00604-017-2551-2
   Zhang XH, 2010, MICROCHIM ACTA, V169, P153, DOI 10.1007/s00604-010-0330-4
   ZHOU JX, 1993, ELECTROANAL, V5, P295, DOI 10.1002/elan.1140050406
   Zyiatdinova G. K., 2013, SERIES PROBLEMS ANAL
NR 71
TC 12
Z9 14
U1 0
U2 32
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1040-8347
EI 1547-6510
J9 CRIT REV ANAL CHEM
JI Crit. Rev. Anal. Chem.
PD JUN 15
PY 2021
VL 51
IS 4
BP 339
EP 352
DI 10.1080/10408347.2020.1729691
EA FEB 2020
PG 14
WC Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA SW2EK
UT WOS:000516671400001
PM 32096424
DA 2026-01-16
ER

PT J
AU Jang, CE
   Jung, MS
   Sohn, EH
   Kim, M
   Yoo, HS
   Bae, K
   Kim, JR
   Lee, JS
AF Jang, Chang Eun
   Jung, Mi Sook
   Sohn, Eun Hee
   Kim, Mijung
   Yoo, Hwa-Seung
   Bae, Kyeore
   Kim, Je Ryong
   Lee, Jin Sun
TI The evaluation of changes in peripheral neuropathy and quality-of-life
   using low-frequency electrostimulation in patients treated with
   chemotherapy for breast cancer: a study protocol
SO TRIALS
LA English
DT Article
DE Chemotherapy-induced peripheral neuropathy; Health-related quality of
   life; Low-frequency electrostimulation device; Breast cancer
ID FUNCTIONAL-ASSESSMENT; SYMPTOM MANAGEMENT; SCRAMBLER THERAPY; FACT-B;
   PAIN; ACUPUNCTURE; VALIDITY; NEUROTOXICITY; RELIABILITY; VALIDATION
AB Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a progressive, enduring, and sometimes irreversible neurotoxic symptom that occurs in 30-40% of chemotherapy-treated cancer patients. CIPN negatively affects both the patient's abilities to perform daily activities and their health-related quality of life (HRQOL) after chemotherapy treatment. Although this neuropathy has been treated with duloxetine and/or gabapentin, limited therapeutic benefits have been reported, thereby necessitating the development of an integrated approach that combines pharmacological management and complementary methods such as acupuncture and electric nerve stimulation. Therefore, this study is designed to examine the effect of a portable, low-frequency electrostimulation (ES) device on CIPN symptoms and HRQOL of female patients diagnosed with CIPN immediately after chemotherapy for breast cancer.
   Methods: This study is a single-center, randomized, placebo-controlled trial with two parallel groups and a 2-week follow-up. We will enroll 80 breast cancer patients who are newly diagnosed with CIPN after chemotherapy. Duloxetine or pregabalin will be prescribed to all participants from the initial assessment. Half of the patients will be assigned into the experimental group and the other half to the control group. The CarebandR (Piomed Inc., Seoul, Korea), a wearable wristband that generates low-frequency electrostimulation, will be administered only to the experimental group. Electrostimulation will be administered on the unilateral PC6 acupoint. A numerical rating scale will be used to assess the overall intensity of CIPN symptoms. The key secondary outcome variables include patient-reported CIPN symptom distress tested by a self-rated questionnaire, physician-rated symptom severity assessed by the Total Neuropathy Score, and HRQOL.
   Discussion: It is expected that the combination of a low-frequency electrostimulation device and pharmacological intervention (duloxetine or pregabalin) will produce synergistic effects in breast cancer patients with CIPN after treatment. To our knowledge, this is the first study to investigate the beneficial effect of a new integrated approach for CIPN management after breast cancer treatment. The study findings can expand our knowledge and understanding of the occurrence of CIPN and the efficacy of integrated intervention efforts to ameliorate CIPN symptoms.
C1 [Jang, Chang Eun] Yonsei Univ, Coll Med, Dept Surg, Seoul, South Korea.
   [Jung, Mi Sook; Kim, Mijung] Chungnam Natl Univ, Coll Nursing, Daejeon, South Korea.
   [Sohn, Eun Hee] Chungnam Natl Univ Hosp, Dept Neurol, Daejeon, South Korea.
   [Yoo, Hwa-Seung; Bae, Kyeore] Daejeon Univ, East West Canc Ctr, Dunsan Korean Med Hosp, Daejeon, South Korea.
   [Kim, Je Ryong; Lee, Jin Sun] Chungnam Natl Univ, Coll Med, Dept Surg, 33 Munwha Ro, Daejeon, South Korea.
   [Kim, Je Ryong; Lee, Jin Sun] Chungnam Natl Univ, Coll Med, Res Inst Med Sci, 33 Munwha Ro, Daejeon, South Korea.
C3 Yonsei University; Yonsei University Health System; Chungnam National
   University; Chungnam National University; Chungnam National University
   Hospital; Daejeon University; Chungnam National University; Chungnam
   National University
RP Lee, JS (corresponding author), Chungnam Natl Univ, Coll Med, Dept Surg, 33 Munwha Ro, Daejeon, South Korea.; Lee, JS (corresponding author), Chungnam Natl Univ, Coll Med, Res Inst Med Sci, 33 Munwha Ro, Daejeon, South Korea.
EM leejin123@hanmail.net
OI Bae, Kyeore/0000-0002-8596-8293; Jung, Mi Sook/0000-0002-5895-8954
FU Ministry of Health and Welfare, Republic of Korea [HI15C0007]
FX Funded by the Ministry of Health and Welfare, Republic of Korea (grant
   number: HI15C0007).
CR Avis NE, 2005, J CLIN ONCOL, V23, P3322, DOI 10.1200/JCO.2005.05.130
   Bandla A, 2016, ACTA ONCOL, V55, P430, DOI 10.3109/0284186X.2015.1075664
   Brady MJ, 1997, J CLIN ONCOL, V15, P974, DOI 10.1200/JCO.1997.15.3.974
   Breanna L, 2014, J CLIN ONCOL, V32, P5
   Carlson K, 2011, CLIN BREAST CANCER, V11, P73, DOI 10.1016/j.clbc.2011.03.006
   Cavaletti G, 2006, J PERIPHER NERV SYST, V11, P135, DOI 10.1111/j.1085-9489.2006.00078.x
   Cavaletti G, 2003, NEUROLOGY, V61, P1297, DOI 10.1212/01.WNL.0000092015.03923.19
   Cavaletti G, 2007, J PERIPHER NERV SYST, V12, P210, DOI 10.1111/j.1529-8027.2007.00141.x
   CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570
   Choi JW, 2015, AM J CHINESE MED, V43, P57, DOI 10.1142/S0192415X15500044
   Cornblath DR, 1999, NEUROLOGY, V53, P1660, DOI 10.1212/WNL.53.8.1660
   Coyne Patrick J, 2013, J Pain Palliat Care Pharmacother, V27, P359, DOI 10.3109/15360288.2013.847519
   Deirdre R, 2012, J CLIN ONCOL S, V30, P9075, DOI [10.1200/jco.2012.30.15_suppl.9075, DOI 10.1200/JCO.2012.30.15_SUPPL.9075]
   Feeley N, 2009, CAN J NURS RES, V41, P84
   Franconi G, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/516916
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Hammes M, 2010, HDB ACPUNCTURE
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Hertzog MA, 2008, RES NURS HEALTH, V31, P180, DOI 10.1002/nur.20247
   Howard-Anderson J, 2012, JNCI-J NATL CANCER I, V104, P386, DOI 10.1093/jnci/djr541
   Hsieh YL, 2016, ACUPUNCT MED, V34, P398, DOI 10.1136/acupmed-2016-011112
   Irvin W, 2011, ONCOLOGIST, V16, P1203, DOI 10.1634/theoncologist.2011-0159
   Jensen MP, 2003, J PAIN, V4, P2, DOI 10.1054/jpai.2003.1
   Kim HY, 2014, J KOREAN ACAD NURS, V44, P735, DOI 10.4040/jkan.2014.44.6.735
   Kim Z, 2015, J BREAST CANCER, V18, P103, DOI 10.4048/jbc.2015.18.2.103
   Korean Breast Cancer Society, 2017, BREAST CANC FACTS FI
   Kukkar A, 2013, ARCH PHARM RES, V36, P237, DOI 10.1007/s12272-013-0057-y
   Manji H, 2011, CURR OPIN NEUROL, V24, P484, DOI 10.1097/WCO.0b013e32834a94b6
   Miltenburg NC, 2014, CANCER TREAT REV, V40, P872, DOI 10.1016/j.ctrv.2014.04.004
   Moore RA, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007076.pub2
   Murphy BA, 2009, CURR OPIN ONCOL, V21, P242, DOI 10.1097/CCO.0b013e32832a230c
   Oh CM, 2016, CANCER RES TREAT, V48, P436, DOI 10.4143/crt.2016.089
   Pachman DR, 2015, SUPPORT CARE CANCER, V23, P943, DOI 10.1007/s00520-014-2424-8
   Paice JA, 1997, CANCER NURS, V20, P88, DOI 10.1097/00002820-199704000-00002
   Pandey Manoj, 2005, World J Surg Oncol, V3, P63, DOI 10.1186/1477-7819-3-63
   Park HS, 2013, KOREAN J PAIN, V26, P65, DOI 10.3344/kjp.2013.26.1.65
   Park Ji Hye, 2015, [Journal of Korean Traditional Oncology, 대한암한의학회지], V20, P1, DOI 10.15432/jkto.2015.20.1.001
   Park Ji Hye, 2016, [The Journal of Korean Oriental Internal Medicine, 대한한방내과학회지], V37, P77
   Park Ji Hye, 2016, [The Journal of Korean Oriental Internal Medicine, 대한한방내과학회지], V37, P631, DOI 10.22246/jikm.2016.37.4.631
   Park SB, 2013, CA-CANCER J CLIN, V63, P419, DOI 10.3322/caac.21204
   Postma TJ, 2005, EUR J CANCER, V41, P1135, DOI 10.1016/j.ejca.2005.02.012
   Rao RD, 2007, CANCER-AM CANCER SOC, V110, P2110, DOI 10.1002/cncr.23008
   Ng R, 2012, BREAST CANCER RES TR, V131, P619, DOI 10.1007/s10549-011-1764-z
   Ricci M, 2012, SUPPORT CARE CANCER, V20, P405, DOI 10.1007/s00520-011-1128-6
   Rivera DR, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx140
   Schneider BP, 2012, J CLIN ONCOL, V30, P3051, DOI 10.1200/JCO.2011.39.8446
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Smith EML, 2013, QUAL LIFE RES, V22, P2787, DOI 10.1007/s11136-013-0379-8
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Smith TJ, 2010, J PAIN SYMPTOM MANAG, V40, P883, DOI 10.1016/j.jpainsymman.2010.03.022
   Verstappen CCP, 2003, DRUGS, V63, P1549, DOI 10.2165/00003495-200363150-00003
   Wolf SL, 2012, SUPPORT CARE CANCER, V20, P625, DOI 10.1007/s00520-011-1141-9
   Wong R, 2016, INTEGR CANCER THER, V15, P153, DOI 10.1177/1534735415627926
   Yoo HJ, 2005, QUAL LIFE RES, V14, P1627, DOI 10.1007/s11136-004-7712-1
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
NR 55
TC 8
Z9 10
U1 1
U2 20
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD SEP 29
PY 2018
VL 19
AR 526
DI 10.1186/s13063-018-2874-2
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Research & Experimental Medicine
GA GV2MI
UT WOS:000445923700001
PM 30268158
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Choi, S
   Chae, HK
   Heo, H
   Hahm, DH
   Kim, W
   Kim, SK
AF Choi, Seunghwan
   Chae, Hyeon Kyeong
   Heo, Ho
   Hahm, Dae-Hyun
   Kim, Woojin
   Kim, Sun Kwang
TI Analgesic Effect of Melittin on Oxaliplatin-Induced Peripheral
   Neuropathy in Rats
SO TOXINS
LA English
DT Article
DE chemotherapy; cold allodynia; mechanical allodynia; melittin;
   neuropathic pain; oxaliplatin
ID DILUTED BEE VENOM; ACUPOINT STIMULATION; COLD ALLODYNIA; PAIN;
   ELECTROACUPUNCTURE; MODEL; MECHANISMS; FLUOROURACIL; LEUCOVORIN;
   RECEPTORS
AB Oxaliplatin is a chemotherapeutic agent used for metastatic colon and other advanced cancers. Most common side effect of oxaliplatin is peripheral neuropathy, manifested in mechanical and cold allodynia. Although the analgesic effect of bee venom has been proven to be effective against oxaliplatin-induced peripheral neuropathy, the effect of its major component; melittin has not been studied yet. Thus, in this study, we investigated whether melittin has an analgesic effect on oxaliplatin-induced allodynia. Intraperitoneal single injection of oxaliplatin (6 mg /kg) induced mechanical and cold allodynia, resulting in increased withdrawal behavior in response to von Frey filaments and acetone drop on hind paw. Subcutaneous melittin injection on acupoint ST36 (0.5 mg /kg) alleviated oxaliplatin-induced mechanical and cold allodynia. In electrophysiological study, using spinal in vivo extracellular recording, it was shown that oxaliplatin-induced hyperexcitation of spinal wide dynamic range neurons in response to peripheral stimuli, and melittin administration inhibited this neuronal activity. In behavioral assessment, analgesic effect of melittin was blocked by intrathecal alpha(1)- and alpha(2)-adrenergic receptor antagonists administration. Based on these results, we suggest that melittin could be used as an analgesic on oxaliplatin-induced peripheral neuropathy, and that its effect is mediated by activating the spinal alpha(1)-and alpha(2)-adrenergic receptors.
C1 [Choi, Seunghwan; Kim, Woojin; Kim, Sun Kwang] Kyung Hee Univ, Grad Sch, Dept East West Med, Seoul 02447, South Korea.
   [Chae, Hyeon Kyeong; Kim, Sun Kwang] Kyung Hee Univ, Grad Sch, Dept Sci Korean Med, Seoul 02447, South Korea.
   [Heo, Ho] Anapn Korean Tradit Med Clin, 11 Seongnae Ro, Seoul 05392, South Korea.
   [Hahm, Dae-Hyun] Kyung Hee Univ, Sch Med, Dept Physiol, Seoul 02447, South Korea.
   [Kim, Woojin; Kim, Sun Kwang] Kyung Hee Univ, Coll Korean Med, Dept Physiol, Seoul 02447, South Korea.
C3 Kyung Hee University; Kyung Hee University; Kyung Hee University; Kyung
   Hee University
RP Kim, W; Kim, SK (corresponding author), Kyung Hee Univ, Grad Sch, Dept East West Med, Seoul 02447, South Korea.; Kim, SK (corresponding author), Kyung Hee Univ, Grad Sch, Dept Sci Korean Med, Seoul 02447, South Korea.; Kim, W; Kim, SK (corresponding author), Kyung Hee Univ, Coll Korean Med, Dept Physiol, Seoul 02447, South Korea.
EM wjkim@khu.ac.kr; skkim77@khu.ac.kr
RI Choi, Seunghwan/LTY-8958-2024; Kim, Sun Kwang/AAM-1289-2020; Kim,
   Woojin/AAK-2464-2020
OI Choi, Seunghwan/0000-0002-0665-190X; Kim, Sun Kwang/0000-0002-2649-6652;
   Kim, Woojin/0000-0001-8494-4524
FU National Research Foundation of Korea (NRF) - Korea government
   [NRF-2017M3A9E4057926]; Immune and Pain Society
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (NRF-2017M3A9E4057926), and
   by a grant from the Immune and Pain Society.
CR Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709
   Argyriou AA, 2015, TOXICS, V3, P187, DOI 10.3390/toxics3020187
   Chae HK, 2019, NUTRIENTS, V11, DOI 10.3390/nu11020432
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9
   Chen HS, 2010, BRAIN RES, V1355, P61, DOI 10.1016/j.brainres.2010.08.002
   Chen J, 2016, NEUROSCI BULL, V32, P265, DOI 10.1007/s12264-016-0024-y
   Choi J, 2017, TOXINS, V9, DOI 10.3390/toxins9110351
   Choi S, 2017, J PHYSIOL SCI, V67, P431, DOI 10.1007/s12576-016-0505-9
   CHOI Y, 1994, PAIN, V59, P369, DOI 10.1016/0304-3959(94)90023-X
   Cunningham D, 2008, NEW ENGL J MED, V358, P36, DOI 10.1056/NEJMoa073149
   Dault R, 2016, CURR ONCOL, V23, pE65, DOI 10.3747/co.23.2780
   de Medeiros MA, 2003, BRAIN RES, V973, P196, DOI 10.1016/S0006-8993(03)02479-X
   DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X
   DIXON WJ, 1965, J AM STAT ASSOC, V60, P967, DOI 10.2307/2283398
   Flatters SJL, 2004, PAIN, V109, P150, DOI 10.1016/j.pain.2004.01.029
   Fradkin M, 2019, CURR MED CHEM
   Graham J, 2004, NAT REV DRUG DISCOV, V3, P11, DOI 10.1038/nrd1287
   Huh JE, 2018, ALTERN THER HEALTH M, V24, P28
   Kidwell KM, 2012, CANCER-AM CANCER SOC, V118, P5614, DOI 10.1002/cncr.27593
   Kim W, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122626
   Kim W, 2016, TOXINS, V8, DOI 10.3390/toxins8020033
   Lee C, 2017, ONCOTARGET, V8, P54951, DOI 10.18632/oncotarget.18627
   LEE G, 2016, MOLECULES BASEL SWIT, V21, DOI DOI 10.3390/MOLECULES21050616
   Lee JH, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-471
   Li D, 2015, TOXINS, V7, P2422, DOI 10.3390/toxins7072422
   Li JH, 2010, AM J CHINESE MED, V38, P1039, DOI 10.1142/S0192415X10008457
   Li KC, 2004, NEUROSCIENCE, V126, P753, DOI 10.1016/j.neuroscience.2004.03.050
   Lim BS, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/369324
   LIU X, 1986, PAIN, V24, P383, DOI 10.1016/0304-3959(86)90124-7
   Lu KW, 2016, SCI REP-UK, V6, DOI 10.1038/srep22123
   Pachman DR, 2015, J CLIN ONCOL, V33, P3416, DOI 10.1200/JCO.2014.58.8533
   Park JW, 2012, INTEGR CANCER THER, V11, P166, DOI 10.1177/1534735411413265
   Park JH, 2009, J PHYSIOL SCI, V59, P291, DOI 10.1007/s12576-009-0035-9
   Park SB, 2011, ONCOLOGIST, V16, P708, DOI 10.1634/theoncologist.2010-0248
   Rady I, 2017, CANCER LETT, V402, P16, DOI 10.1016/j.canlet.2017.05.010
   Ryu HK, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/191347
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Suker M, 2016, LANCET ONCOL, V17, P801, DOI 10.1016/S1470-2045(16)00172-8
   Yang J, 2006, BRAIN RES BULL, V68, P453, DOI 10.1016/j.brainresbull.2005.10.002
   Yeo JH, 2016, J PAIN, V17, P298, DOI 10.1016/j.jpain.2015.10.018
   Yoon H, 2015, BIOL PHARM BULL, V38, P710, DOI 10.1248/bpb.b14-00797
   Yoon SY, 2009, J PAIN, V10, P253, DOI 10.1016/j.jpain.2008.09.002
   Yoshimura M, 2006, J PHARMACOL SCI, V101, P107, DOI 10.1254/jphs.CRJ06008X
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
NR 45
TC 31
Z9 33
U1 1
U2 12
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6651
J9 TOXINS
JI Toxins
PD JUL
PY 2019
VL 11
IS 7
AR 396
DI 10.3390/toxins11070396
PG 10
WC Food Science & Technology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Toxicology
GA IS4FW
UT WOS:000482110000026
PM 31288453
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Cao, YL
   Jing, F
   Jiang, LY
   Tian, MT
   Qiu, JJ
   Tang, LC
   Hu, Y
AF Cao, Yuling
   Jing, Feng
   Jiang, Lingyun
   Tian, Maoting
   Qiu, Jiajia
   Tang, Lichen
   Hu, Yan
TI The experience of musculoskeletal symptoms among patients with breast
   cancer during aromatase inhibitor therapy: A qualitative study
SO ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING
LA English
DT Article
DE Breast cancer; Aromatase inhibitor therapy; Musculoskeletal symptoms;
   Qualitative study; Symptom experience; Symptom management
ID ADJUVANT ENDOCRINE THERAPY; SOCIAL SUPPORT; OF-LIFE; CHINESE;
   MANAGEMENT; ADHERENCE; SURVIVORS; WOMEN
AB Objective: To examine the musculoskeletal symptom experiences of Chinese patients with breast cancer receiving aromatase inhibitor (AI) therapy and identify patient-centered strategies for symptom management. Methods: A descriptive qualitative study was conducted from June to August 2023 at a tertiary hospital in Shanghai, China. Using purposive sampling with maximum variation, 37 women with hormone receptor-positive (HR+) breast cancer (stages I-III) undergoing AI therapy participated in semi-structured telephone interviews. Data were audio-recorded, transcribed verbatim, and analyzed thematically. Results: Four themes were identified: (1) Symptom burden-persistent joint pain, stiffness, and fatigue interfered with daily activities; (2) Emotional impact-symptoms provoked anxiety, frustration, and reduced well-being; (3) Social challenges-decreased participation in social and family life led to feelings of isolation; and (4) Coping strategies-pharmacological measures (e.g., calcium and vitamin D supplementation) and nonpharmacological interventions (e.g., exercise, acupuncture) were adopted, though access to reliable information and professional guidance was often inadequate. Conclusions: Musculoskeletal symptoms related to AI therapy impose considerable physical, emotional, and social burdens on Chinese patients with breast cancer, potentially undermining treatment adherence. Culturally appropriate, patient-centered management incorporating both pharmacological and non-pharmacological interventions is essential to optimize symptom control and quality of life.
C1 [Cao, Yuling; Jing, Feng; Jiang, Lingyun; Tian, Maoting; Hu, Yan] Fudan Univ, Sch Nursing, Shanghai, Peoples R China.
   [Jing, Feng; Qiu, Jiajia; Tang, Lichen] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China.
C3 Fudan University; Fudan University
RP Hu, Y (corresponding author), Fudan Univ, Sch Nursing, Shanghai, Peoples R China.
EM huyan@fudan.edu.cn
OI Hu, Yan/0000-0001-6506-0694; Cao, Yuling/0009-0003-8818-5897
FU National Natural Science Foundation of China (NSFC) [(1) 2023 JBI, (2)
   2023];  [2023-82272922]
FX This research is supported by two research grants: (1) 2023 JBI Bright
   Future Grant; (2) 2023 National Natural Science Foundation of China
   (NSFC) , Grant No. 2023-82272922. The funders had no role in considering
   the study design or in the collection, analysis, interpretation of data,
   writing of the report, or decision to submit the article for
   publication.
CR Alizadeh Saeedeh, 2018, Asian Pac J Cancer Prev, V19, P2469
   Armstrong Terri S, 2003, Oncol Nurs Forum, V30, P601, DOI 10.1188/03.ONF.601-606
   Beckwée D, 2017, SUPPORT CARE CANCER, V25, P1673, DOI 10.1007/s00520-017-3613-z
   Berkowitz MJ, 2021, J CANCER SURVIV, V15, P29, DOI 10.1007/s11764-020-00908-5
   Bevers TB, 2018, J NATL COMPR CANC NE, V16, P1362, DOI 10.6004/jnccn.2018.0083
   Chan CWH, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17082950
   Clancy C, 2020, EUR J ONCOL NURS, V44, DOI 10.1016/j.ejon.2019.101706
   Dowsett M, 2015, LANCET, V386, P1341, DOI 10.1016/S0140-6736(15)61074-1
   Firouzbakht M, 2020, INT HEALTH, V12, P354, DOI [10.1093/inthealth/ihz108, 10.1093/inthealth/ihaa013]
   Harrow A, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005285
   Hata K, 2020, PSYCHO-ONCOLOGY, V29, P663, DOI 10.1002/pon.5303
   Henry NL, 2012, J CLIN ONCOL, V30, P936, DOI 10.1200/JCO.2011.38.0261
   Holz SC, 2023, CURR ONCOL REP, V25, P825, DOI 10.1007/s11912-023-01413-5
   Hyder T, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.713700
   Jacobs JM, 2022, CANCER-AM CANCER SOC, V128, P3541, DOI 10.1002/cncr.34409
   Jacobs JM, 2020, INT J BEHAV MED, V27, P687, DOI 10.1007/s12529-020-09908-2
   Kim MS, 1999, HEALTH COMMUN, V11, P249, DOI 10.1207/S15327027HC110307
   Kroenke CH, 2013, BREAST CANCER RES TR, V139, P515, DOI 10.1007/s10549-013-2477-2
   Laroche F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187165
   Lee EY, 2023, CANCER RES TREAT, V55, P1065, DOI 10.4143/crt.2023.846
   Li YL, 2019, CANCER RES TREAT, V51, P1098, DOI 10.4143/crt.2018.386
   Liu BS, 2021, NURS OPEN, V8, P1981, DOI 10.1002/nop2.876
   Lu XY, 2023, J MED INTERNET RES, V25, DOI 10.2196/38848
   Luckett T, 2011, LANCET ONCOL, V12, P1240, DOI 10.1016/S1470-2045(11)70212-1
   Lund-Jacobsen T, 2024, JMIR RES PROTOC, V13, DOI 10.2196/49549
   Luo AJ, 2022, J MED INTERNET RES, V24, DOI 10.2196/23354
   Ma Y, 2024, ASIA-PAC J ONCOL NUR, V11, DOI 10.1016/j.apjon.2023.100364
   Macía P, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0252075
   Macía P, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236572
   Mellado BH, 2016, INT J GYNECOL OBSTET, V133, P199, DOI 10.1016/j.ijgo.2015.08.024
   Meng H, 2022, MEDICINE, V101, DOI 10.1097/MD.0000000000028982
   Milbury K, 2017, SUPPORT CARE CANCER, V25, P2103, DOI 10.1007/s00520-017-3612-0
   Qing SS, 2020, J CHINESE SOCIOL, V7, DOI 10.1186/s40711-020-00123-w
   Roberts K, 2017, CRIT REV ONCOL HEMAT, V111, P66, DOI 10.1016/j.critrevonc.2017.01.010
   Roberts KE, 2022, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013167.pub2
   Song Y, 2014, INT J EQUITY HEALTH, V13, DOI 10.1186/1475-9276-13-8
   Taiwong A, 2024, BELITUNG NURS J, V10, P252, DOI 10.33546/bnj.3343
   Toivonen KI, 2021, CURR ONCOL, V28, P2496, DOI 10.3390/curroncol28040227
   Wagner LI, 2018, BREAST CANCER RES TR, V169, P537, DOI 10.1007/s10549-018-4713-2
   Wang LJ, 2023, BMJ OPEN, V13, DOI 10.1136/bmjopen-2023-073915
   Wang LJ, 2020, SUPPORT CARE CANCER, V28, P3259, DOI 10.1007/s00520-019-05161-w
   Wang XS, 2010, JNCI-J NATL CANCER I, V102, P732, DOI 10.1093/jnci/djq097
   Wells KJ, 2016, SUPPORT CARE CANCER, V24, P4123, DOI 10.1007/s00520-016-3229-8
   Wheeler SB, 2024, PATIENT EDUC COUNS, V127, DOI 10.1016/j.pec.2024.108349
   Xu XF, 2018, PALLIAT SUPPORT CARE, V16, P785, DOI 10.1017/S1478951517001171
   Yang EJ, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245987
   Yeung NCY, 2018, CANCER NURS, V41, P53, DOI 10.1097/NCC.0000000000000422
   You J, 2017, J GLOB ONCOL, V4, DOI 10.1200/JGO.2016.008763
   Zhang XT, 2017, BMC MED INFORM DECIS, V17, DOI 10.1186/s12911-017-0470-0
   Zhu JM, 2018, JMIR MHEALTH UHEALTH, V6, DOI 10.2196/mhealth.9438
   Zhu JM, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3276-7
NR 51
TC 0
Z9 0
U1 7
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 2347-5625
EI 2349-6673
J9 ASIA-PAC J ONCOL NUR
JI Asia-Pac. J. Oncol. Nurs.
PD DEC
PY 2025
VL 12
AR 100784
DI 10.1016/j.apjon.2025.100784
EA SEP 2025
PG 10
WC Nursing
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Nursing
GA 7SO4D
UT WOS:001578654700001
PM 41048407
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Machi, A
   Patel, A
   Ottestad, E
AF Machi, Anthony
   Patel, Ankur
   Ottestad, Einar
TI Nerve stimulation and neuromodulation for painful nerves: a narrative
   review
SO INTERNATIONAL ORTHOPAEDICS
LA English
DT Review
DE Transcutaneous electrical nerve stimulation; Percutaneous electrical
   nerve stimulation; Peripheral nerve stimulation; Neuromodulation;
   Neuropathic pain; Axon regeneration
ID ELECTRICAL-STIMULATION; NEUROPATHIC PAIN; TENS; METAANALYSIS;
   INHIBITION; MANAGEMENT; EFFICACY
AB Nerve injury primarily leads to neuropathic pain but may also have overlapping elements of nociplastic pain or ongoing nociceptive pain. Electrical stimulation is particularly effective in the treatment of neuropathic pain and may be effective for nociplastic and nociceptive pain. While multiple mechanisms contribute to the analgesic effect of electrical stimulation, the most widely accepted theory for the predominant effect is that of Melzack and Wall's gate control theory. According to this theory, non-painful sensory input carried by low-threshold large-diameter A beta fibres disrupt the transmission of pain signals in small pain fibers (A delta and C fibres). This occurs through the activation of inhibitory interneurons in the dorsal horn, which ultimately blocks pain signal transmission.This theory has been employed for different forms of stimulation, including transcutaneous electrical nerve stimulation (TENS), percutaneous electrical nerve stimulation (PENS), and peripheral nerve stimulation (PNS). Each of these methods offers a different approach to localized stimulation and neuromodulation for the treatment of pain. TENS is a non-invasive technique, that delivers electrical currents via surface electrodes placed on the skin. PENS, in contrast, is a minimally invasive method that applies electrical currents through small needles inserted near a target muscle or neural structure. PNS involves the implantation of temporary or permanent electrodes to deliver electrical stimulation directly to peripheral nerves. These modalities are widely used to manage various pain conditions including non-malignant, chronic musculoskeletal and neuropathic pain, such as chronic low back pain, neck pain, neuropathic pain, myofascial pain, and post-operative pain. TENS is particularly notable as a non-invasive device that is affordable, over-the-counter, self-administered, and nonpharmacological option that does not pose the risk of toxicity or overdose. PENS stands out for its ability to integrate electrical stimulation therapy with electroacupuncture through a minimally invasive technique. PNS, on the other hand, is unique in its capacity to precisely target specific nerves and provide a range of stimulation options for extended treatment durations.This article provides a narrative overview of TENS, PENS and PNS with a particular focus on their application for neuropathic pain management and for athletes. We will review mechanisms of action, indications, diagnostic and treatment algorithms, as well as complications and limitations. The overview concludes with a complex case study demonstrating the use of various electrical stimulation therapies, ultimately to successful pain resolution for the patient.
C1 [Machi, Anthony; Ottestad, Einar] Stanford Univ, Stanford, CA 94305 USA.
   [Patel, Ankur] Novant Hlth Spine Specialists, Winston Salem, NC USA.
C3 Stanford University
RP Machi, A (corresponding author), Stanford Univ, Stanford, CA 94305 USA.
EM amachi@stanford.edu; patel.ankur.anil@gmail.com; ottestad@stanford.edu
CR [Anonymous], 2022, NALU PRODUCT CATALOG
   [Anonymous], 2023, NEUROMODULATION NEUR
   [Anonymous], 2023, SYSTEM SPRINTPNS
   Astokorki AHY, 2017, EUR J APPL PHYSIOL, V117, P483, DOI 10.1007/s00421-016-3532-6
   Bjordal JM, 2003, EUR J PAIN, V7, P181, DOI 10.1016/S1090-3801(02)00098-8
   Bouhassira D, 2018, PAIN, V159, P576, DOI 10.1097/j.pain.0000000000001136
   Chakravarthy KV, 2019, NEUROMODULATION, V22, P235, DOI 10.1111/ner.12859
   Chow RM, 2023, CURR PAIN HEADACHE R, V27, P321, DOI 10.1007/s11916-023-01143-0
   CHUNG JM, 1984, PAIN, V19, P277, DOI 10.1016/0304-3959(84)90005-8
   Deer TR, 2019, BRAIN SCI, V9, DOI 10.3390/brainsci9020023
   Eldabe S, 2016, PAIN MED, V17, P325, DOI 10.1093/pm/pnv025
   Finnerup Nanna B, 2015, Lancet Neurol, V14, P162, DOI 10.1016/S1474-4422(14)70251-0
   Fitzcharles MA, 2022, PAIN REP, V7, DOI 10.1097/PR9.0000000000001024
   Fitzcharles MA, 2021, LANCET, V397, P2098, DOI 10.1016/S0140-6736(21)00392-5
   Gallego-Sendarrubias GM, 2021, J CLIN MED, V10, DOI 10.3390/jcm10040690
   García-Collado A, 2022, J CLIN MED, V11, DOI 10.3390/jcm11133753
   Ghoname ESA, 1999, JAMA-J AM MED ASSOC, V281, P818, DOI 10.1001/jama.281.9.818
   Gilmore CA, 2021, PAIN PRACT, V21, P877, DOI 10.1111/papr.13055
   Gordon T, 2010, EXP NEUROL, V223, P192, DOI 10.1016/j.expneurol.2009.09.020
   Heidland August, 2013, Clin Nephrol, V79 Suppl 1, pS12
   Helm S, 2021, PAIN THER, V10, P985, DOI 10.1007/s40122-021-00306-4
   Jensen TS, 2011, PAIN, V152, P2204, DOI 10.1016/j.pain.2011.06.017
   Johnson Mark, 2007, Rev Pain, V1, P7, DOI 10.1177/204946370700100103
   Johnson MI, 2017, PAIN MANAG, V7, P1, DOI 10.2217/pmt-2016-0030
   Johnson MI, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006142.pub3
   Johnson M, 2007, PAIN, V130, P157, DOI 10.1016/j.pain.2007.02.007
   Juckett L, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12121856
   Keane GC, 2022, HAND-AM ASSOC HAND S, V17, P540, DOI 10.1177/1558944720939200
   Kosek E, 2016, PAIN, V157, P1382, DOI 10.1097/j.pain.0000000000000507
   Kupers R, 2011, EUR J PAIN, V15, DOI 10.1016/j.ejpain.2010.06.015
   Hernandez JVL, 2021, PAIN PHYSICIAN, V24, P135, DOI 10.36076/ppj.2021.24.135-143
   Lin T, 2020, PAIN MED, V21, pS6, DOI 10.1093/pm/pnaa164
   Manchikanti Laxmaiah, 2024, PAIN PHYSICIAN, V27
   MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971
   Meyer-Friessem CH, 2019, CLIN J PAIN, V35, P111, DOI 10.1097/AJP.0000000000000661
   Plaza-Manzano G, 2020, EUR J PAIN, V24, P1023, DOI 10.1002/ejp.1559
   Power HA, 2020, NEUROSURGERY, V86, P769, DOI 10.1093/neuros/nyz322
   Sawant A, 2015, MULT SCLER RELAT DIS, V4, P219, DOI 10.1016/j.msard.2015.03.006
   StimRouter, 2022, STIMROUTER PNS PRODU
   Strand N, 2022, J PAIN RES, V15, P2483, DOI 10.2147/JPR.S362204
   Strand NH, 2021, CURR PAIN HEADACHE R, V25, DOI 10.1007/s11916-021-00962-3
   TOREBJORK HE, 1974, J NEUROL NEUROSUR PS, V37, P653, DOI 10.1136/jnnp.37.6.653
   Udina E, 2008, EXP NEUROL, V210, P238, DOI 10.1016/j.expneurol.2007.11.007
   van Hecke O, 2014, PAIN, V155, P654, DOI 10.1016/j.pain.2013.11.013
   Vance CGT, 2014, PAIN MANAG, V4, P197, DOI [10.2217/PMT.14.13, 10.2217/pmt.14.13]
   WALL PD, 1974, NATURE, V248, P740, DOI 10.1038/248740a0
   WALL PD, 1967, SCIENCE, V155, P108, DOI 10.1126/science.155.3758.108
   Woolf CJ, 2011, PAIN, V152, pS2, DOI 10.1016/j.pain.2010.09.030
   Xu JJ, 2021, PAIN PHYSICIAN, V24, pE131, DOI 10.36076/ppj.2021.24.e131-e152
   Yang F, 2014, EUR J PAIN, V18, P978, DOI 10.1002/j.1532-2149.2013.00443.x
   Yokoyama M, 2004, ANESTH ANALG, V98, P1552, DOI 10.1213/01.ANE.0000112312.94043.DF
NR 51
TC 4
Z9 4
U1 7
U2 10
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0341-2695
EI 1432-5195
J9 INT ORTHOP
JI Int. Orthop.
PD MAY
PY 2025
VL 49
IS 5
BP 989
EP 996
DI 10.1007/s00264-025-06498-0
EA MAR 2025
PG 8
WC Orthopedics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Orthopedics
GA 3YI7C
UT WOS:001467600600001
PM 40111452
DA 2026-01-16
ER

PT J
AU Cope, DG
AF Cope, Diane G.
TI Clinical Updates in Nausea and Vomiting
SO SEMINARS IN ONCOLOGY NURSING
LA English
DT Article
DE Chemotherapy-induced nausea and vomiting; Nausea; Vomiting; Antiemetics;
   Drug therapy; Quality of life
ID CHEMOTHERAPY-INDUCED NAUSEA; CANCER; ACUPUNCTURE; PREVENTION;
   GUIDELINES; EFFICACY; EMESIS
AB Objective: To review recent updated antiemetic guidelines from national cancer organizations and its impact on chemotherapy-induced nausea and vomiting (CINV) in the prevention and delayed phase of therapy. This article will also describe assessment and nursing strategies for individualized care and timely side effect management.Data Sources: Data sources include peer-reviewed articles sourced in electronic databases. Conclusion: CINV is a persistent problem for a large percentage of patients undergoing chemotherapy treatment despite advances in antiemetic therapy and increased use of targeted therapies. CINV management should be based on patient-focused assessment and adherence to national antiemetic guidelines. Ongoing assessment and follow-up are critical to ensure optimum management of side effects to optimized quality of life.Implications for Nursing Practice: Awareness of national antiemetic guidelines is important in caring for patients undergoing chemotherapy. CINV can have a significant impact on patients, causing physical effects, treatment delays, and diminished quality of life. Oncology nurses play a key role in assessment of patient related risk factors, education of patients and caregivers regarding pain medications, side effects, and oral adherence and continued follow-up for early recognition and intervention for uncontrolled CINV.(c) 2022 Elsevier Inc. All rights reserved.
C1 [Cope, Diane G.] Florida Canc Specialists & Res Inst, Nursing, Ft Myers, FL 33919 USA.
C3 Florida Cancer Specialists
RP Cope, DG (corresponding author), Florida Canc Specialists & Res Inst, 605 Astarias Circle, Ft Myers, FL 33919 USA.
EM dgcope@comcast.net
CR Cheng PY, 2020, INT J CLIN EXP MED, V13, P7965
   Clark-Snow R, 2018, SUPPORT CARE CANCER, V26, P557, DOI 10.1007/s00520-017-3866-6
   Crichton M, 2019, J ACAD NUTR DIET, V119, P2055, DOI 10.1016/j.jand.2019.06.009
   Das S, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0805-8
   Dranitsaris G, 2017, ANN ONCOL, V28, P1260, DOI 10.1093/annonc/mdx100
   Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Gupta Kush, 2021, Cancer Treat Res Commun, V26, P100278, DOI [10.1016/j.ctarc.2020.100278, 10.1016/j.ctarc.2020.100278]
   Hesketh PJ, 2020, J CLIN ONCOL, V38, P2782, DOI 10.1200/JCO.20.01296
   Ilyas AB, 2020, CUREUS J MED SCIENCE, V12, DOI 10.7759/cureus.12038
   Janowitz T, 2021, ONCOLOGIST, V26, P269, DOI 10.1002/onco.13680
   Kapogiannis A, 2018, EXPLORE-NY, V14, P137, DOI 10.1016/j.explore.2017.10.008
   Li QW, 2020, CHIN MED-UK, V15, DOI 10.1186/s13020-020-00333-x
   Mahidin EIB, 2019, ANN ONCOL, V30, P128, DOI 10.1093/annonc/mdz343.046
   Marx WM, 2013, NUTR REV, V71, P245, DOI 10.1111/nure.12016
   Mosa AM, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00329
   National Comprehensive Cancer Network (NCCN), ANT VERS 1 2021
   Navari RM, 2016, NEW ENGL J MED, V374, P1356, DOI 10.1056/NEJMra1515442
   Paz-Ares L, 2018, NEW ENGL J MED, V379, P2040, DOI 10.1056/NEJMoa1810865
   Raghavendra RM, 2007, EUR J CANCER CARE, V16, P462, DOI 10.1111/j.1365-2354.2006.00739.x
   Rapoport BL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00019
   Roila F, 2006, ANN ONCOL, V17, P20, DOI 10.1093/annonc/mdj078
   Roila F, 2016, ANN ONCOL, V27, pv119, DOI 10.1093/annonc/mdw270
   Shankar Abhishek, 2015, Asian Pac J Cancer Prev, V16, P6207, DOI 10.7314/apjcp.2015.16.15.6207
   Singh P, 2016, THER ADV GASTROENTER, V9, P98, DOI 10.1177/1756283X15618131
   Smith C, 2020, CANCER NURS, V43, pE217, DOI 10.1097/NCC.0000000000000694
   Sommariva S, 2016, CRIT REV ONCOL HEMAT, V99, P13, DOI 10.1016/j.critrevonc.2015.12.001
   Totmaj AS, 2019, PHYTOTHER RES, V33, P1957, DOI 10.1002/ptr.6377
   U.S. Department of Veterans Affairs, MAN CHEM IND NAUS VO
   Underhill ML, 2015, CLIN J ONCOL NURS, V19, P38, DOI 10.1188/15.CJON.38-40
   Wei TT, 2020, SUPPORT CARE CANCER, V28, P4031, DOI 10.1007/s00520-020-05409-w
NR 31
TC 12
Z9 16
U1 1
U2 27
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0749-2081
EI 1878-3449
J9 SEMIN ONCOL NURS
JI Semin. Oncol. Nurs.
PD FEB
PY 2022
VL 38
IS 1
SI SI
AR 151249
DI 10.1016/j.soncn.2022.151249
PG 5
WC Oncology; Nursing
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Oncology; Nursing
GA 1C1UC
UT WOS:000792911800007
PM 35219568
DA 2026-01-16
ER

PT J
AU Mora, DC
   Kristoffersen, AE
   Overvåg, G
   Jong, MC
   Mentink, M
   Liu, JP
   Stub, T
AF Mora, Dana C.
   Kristoffersen, Agnete E.
   Overvag, Grete
   Jong, Miek C.
   Mentink, Marit
   Liu, Jianping
   Stub, Trine
TI Safety of Complementary and Alternative Medicine (CAM) treatment among
   children and young adults who suffer from adverse effects of
   conventional cancer treatment: A systematic review
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Review
DE systematic review; observational studies; qualitative studies;
   complementary and alternative medicine; risk; patient safety
ID QUALITY-OF-LIFE; YOGA INTERVENTION; PEDIATRIC CANCER; ART-THERAPY;
   MUSIC-THERAPY; ACUPUNCTURE; RISK; CHEMOTHERAPY; METAANALYSIS;
   FEASIBILITY
AB Background: Complementary and Alternative Medicine (CAM) is widely used around the world to treat adverse effects derived from cancer treatment among children and young adults. Parents often seek CAM to restore and maintain the child's physical and emotional condition during and after cancer treatment. Objectives: The objectives of this review were (i) to identify literature that investigates CAM use for treating adverse effects of conventional cancer treatment, (ii) to investigate the safety of the included CAM modalities, and (iii) to evaluate the quality of included studies. Methods: Five scientific research databases were used to identify observational, quasi-experimental, and qualitative studies from January 1990 to May 2021. Included studies investigated the use of CAM to treat adverse effects of cancer treatment in childhood cancer. Results: Fifteen studies were included in this review. Ten quasi-experimental, 3 observational studies (longitudinal/prospective), 2 qualitative studies, and 1 study with a quasi-experimental and qualitative arm were identified. Less than half (n = 6; 40%) of the studies included reported adverse effects for the CAM modality being studied. Among the studies that reported adverse effects, they were mostly considered as direct risk, as 13% reported mainly bleeding and bruising upon acupuncture treatment, and dizziness with yoga treatment. All adverse effects were assessed as minor and transient. CAM modalities identified for treating adverse effects of cancer treatment were alternative medical systems, manipulative and body-based therapies, biologically-based therapies, and mind-body therapies. CAM modalities were used to alleviate anxiety, pain, toxicity, prevent trauma, and improve health-related quality of life, functional mobility, and physical activity levels. All studies assessed scored 70% or above according to the Joanna Briggs Institute critical appraisal for study quality checklists. Conclusion: Most of the studies (58.3%) included in this review did not report adverse effects from CAM modalities used to treat adverse effects of cancer treatment in children and young adults. This lack of safety information is of concern because parents need to know whether the modality represents an extra burden or harm to the child. To improve awareness about safety in the field, a universal and uniform reporting system for adverse effects in CAM research is needed.
C1 [Mora, Dana C.; Kristoffersen, Agnete E.; Overvag, Grete; Stub, Trine] UiT Arctic Univ Norway, Tromso, Norway.
   [Mentink, Marit] Netherlands Inst Hlth Serv Res, Utrecht, Netherlands.
   [Liu, Jianping] Beijing Univ Chinese Med & Pharmacol, Beijing, Peoples R China.
C3 UiT The Arctic University of Tromso; Netherlands Institute for Health
   Services Research; Beijing University of Chinese Medicine
RP Mora, DC (corresponding author), UiT Arctic Univ Norway, Natl Res Ctr Complementary & Alternat Med NAFKAM, Dept Community Med, Fac Hlth Sci, POB 6050, N-9037 Tromso, Norway.
EM dana.c.mora@uit.no
RI Mora, Dana C/HZH-9849-2023; Kristoffersen, Agnete
   Egilsdatter/J-3018-2019
OI Mora, Dana C/0000-0003-1209-3526; Mentink, Marit/0000-0002-1278-9665;
   Stub, Trine/0000-0002-7053-509X; Kristoffersen, Agnete
   Egilsdatter/0000-0003-4642-0310
FU Ekhagastiftelsen [2020-76]; NAFKAM - UIT The Arctic University of Norway
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This study
   was funded by Ekhagastiftelsen (2020-76) and NAFKAM. The publication
   charges for this article have been funded by UIT The Arctic University
   of Norway.
CR Abdulah DM, 2018, COMPLEMENT THER MED, V41, P180, DOI 10.1016/j.ctim.2018.09.020
   Adams D, 2011, PEDIATRICS, V128, pE1575, DOI 10.1542/peds.2011-1091
   Aguilar BA, 2017, J PEDIATR NURS, V36, P173, DOI 10.1016/j.pedn.2017.06.015
   [Anonymous], 2005, COMPL ALT MED US
   Barnekreftforeningen, 2021, CHILDH CANC
   Barrera ME, 2002, PSYCHO-ONCOL, V11, P379, DOI 10.1002/pon.589
   Bhakta N, 2019, LANCET ONCOL, V20, pE42, DOI 10.1016/S1470-2045(18)30761-7
   Birdee GS, 2009, ACAD PEDIATR, V9, P212, DOI 10.1016/j.acap.2009.04.002
   Bishop FL, 2010, PEDIATRICS, V125, P768, DOI 10.1542/peds.2009-1775
   Bond Mason C, 2006, Paediatr Child Health, V11, P148
   Bottomley Sarah J, 2003, J Pediatr Nurs, V18, P126, DOI 10.1053/jpdn.2003.13
   Chokshi SK, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26424
   Chotsampancharoen T, 2018, ACTA HAEMATOL-BASEL, V140, P203, DOI 10.1159/000493417
   Clerici CA, 2021, TUMORI J, V107, P171, DOI 10.1177/0300891620967750
   Cohen L, 2004, CANCER-AM CANCER SOC, V100, P2253, DOI 10.1002/cncr.20236
   Concato John, 2004, NeuroRx, V1, P341, DOI 10.1602/neurorx.1.3.341
   Deng Gary E, 2009, J Soc Integr Oncol, V7, P85
   Diorio C, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28324
   Diorio C, 2017, J GLOB ONCOL, V3, P791, DOI 10.1200/JGO.2016.005587
   Diorio C, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0529-3
   Facchini M, 2021, COMPLEMENT THER CLIN, V42, DOI 10.1016/j.ctcp.2020.101289
   Favara-Scacco C, 2001, MED PEDIATR ONCOL, V36, P474, DOI 10.1002/mpo.1112
   Flank J, 2016, PEDIATR BLOOD CANCER, V63, P1144, DOI 10.1002/pbc.25955
   Fonnebo V, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-7
   Gagnier JJ, 2006, ANN INTERN MED, V144, P364, DOI 10.7326/0003-4819-144-5-200603070-00013
   Galantino Mary Lou, 2008, Pediatr Phys Ther, V20, P66, DOI 10.1097/PEP.0b013e31815f1208
   Geyer R, 2011, PEDIATR PHYS THER, V23, P375, DOI 10.1097/PEP.0b013e318235628c
   Govardhan H., 2019, Oncol Radiother, V1, P34
   Hedén L, 2013, J PAIN SYMPTOM MANAG, V46, P366, DOI 10.1016/j.jpainsymman.2012.09.012
   Helsedirektoratet. The Norwegian Directorate of Health, 2021, NATL GUIDELINES GYNA
   Higgins J., 2008, COCHRANE HDB SYSTEMA
   Hooke MC, 2016, J PEDIATR ONCOL NURS, V33, P64, DOI 10.1177/1043454214563936
   Hu H., 2019, GLOB ADV HLTH MED, V8
   Jindal V, 2008, J PEDIAT HEMATOL ONC, V30, P431, DOI 10.1097/MPH.0b013e318165b2cc
   Joseph PD, 2015, BRIT J CLIN PHARMACO, V79, P357, DOI 10.1111/bcp.12305
   Juangpanich U., 2012, J NURSESASSOC THAILA, V30, P46
   Kanitz JL, 2013, COMPLEMENT THER MED, V21, pS20, DOI 10.1016/j.ctim.2012.02.001
   Karkhaneh M, 2020, BMJ PAEDIATR OPEN, V4, DOI 10.1136/bmjpo-2019-000584
   Kennedy DD, 2004, AM J CLIN NUTR, V79, P1029
   Kim HJ, 2005, CANCER NURS, V28, P270
   Kuttner Leora, 2006, Pain Res Manag, V11, P217
   Ladas EJ, 2004, J CLIN ONCOL, V22, P517, DOI 10.1200/JCO.2004.03.086
   Ladas EJ, 2018, J ALTERN COMPLEM MED, V24, P910, DOI 10.1089/acm.2018.0224
   Lewis RW, 2021, SUPPORT CARE CANCER, V29, P8077, DOI 10.1007/s00520-021-06332-4
   Lissauer TCGP., 2016, ENGLISH PEDRIATRICS
   Lopes LC, 2016, EUR J CANCER CARE, V25, P921, DOI 10.1111/ecc.12381
   Lopes LC Jr, 2020, CANCER NURS, V43, P290, DOI 10.1097/NCC.0000000000000690
   Lopes LC Jr, 2021, REV ESC ENFERM USP, V55, DOI 10.1590/S1980-220X2020025103709
   Lowrance WW, 1976, ACCEPTABLE RISK SCI, DOI DOI 10.1149/1.2132690
   Lüthi E, 2021, BMC COMPLEMENT MED, V21, DOI 10.1186/s12906-021-03271-9
   MacLennan AH, 2006, MED J AUSTRALIA, V184, P27, DOI 10.5694/j.1326-5377.2006.tb00092.x
   MacPherson H, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000261
   Mallen C, 2006, J CLIN EPIDEMIOL, V59, P765, DOI 10.1016/j.jclinepi.2005.12.010
   Mandanmohan, 2003, Indian Journal of Physiology and Pharmacology, V47, P387
   Medina Cordoba CA., 2019, INDEX ENFERMER A, V28, P46
   Michalsen A, 2005, MED SCI MONITOR, V11, pCR555
   Mora DC, 2022, BMC COMPLEMENT MED, V22, DOI 10.1186/s12906-022-03537-w
   Mustian KM, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.9013
   Myers SP, 2004, MED J AUSTRALIA, V181, P222, DOI 10.5694/j.1326-5377.2004.tb06244.x
   National Center for Complementary and Integrative Health National Institutes of Health, 2021, COMPLEMENTARY ALTERN
   Nilsson S, 2009, EUR J ONCOL NURS, V13, P102, DOI 10.1016/j.ejon.2009.01.003
   O'Regan D, 2010, AUTON NEUROSCI-BASIC, V157, P96, DOI 10.1016/j.autneu.2010.05.001
   Orsey AD, 2017, REHABIL ONCOL, V35, P15, DOI 10.1097/01.REO.0000000000000052
   Ouzzani M, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0384-4
   Page MJ, 2021, BMJ-BRIT MED J, V372, DOI [10.1136/bmj.n160, 10.1136/bmj.n71, 10.1038/nchembio.2180, 10.1186/s40900-023-00424-7, 10.3390/jpm13020373]
   Papanikolaou PN, 2006, CAN MED ASSOC J, V174, P635, DOI 10.1503/cmaj.050873
   Piper C, 2019, J MED LIBR ASSOC, V107, DOI [10.5195/jmla.2019.790, 10.5195/jmla.2019.790, DOI 10.5195/JMLA.2019.790]
   Rheingans JI, 2007, J PEDIATR ONCOL NURS, V24, P81, DOI 10.1177/1043454206298837
   Nunes MDR, 2018, J CHILD HEALTH CARE, V22, P186, DOI 10.1177/1367493517752498
   Shamliyan T, 2010, J CLIN EPIDEMIOL, V63, P1061, DOI 10.1016/j.jclinepi.2010.04.014
   Stub T., 2013, THESIS ARCTIC U NORW
   Stub T, 2022, EXPLORE-NY, V18, P114, DOI 10.1016/j.explore.2020.11.008
   Stub T, 2021, BMC COMPLEMENT MED, V21, DOI 10.1186/s12906-021-03253-x
   Stub T, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906-020-02882-y
   Stub T, 2016, COMPLEMENT THER MED, V26, P146, DOI 10.1016/j.ctim.2016.03.013
   Stub T, 2015, FORSCH KOMPLEMENTMED, V22, P30, DOI 10.1159/000377644
   Thanh NN, 2010, J PEDIATR ONCOL NURS, V27, P146, DOI 10.1177/1043454209355983
   The Norwegian Cancer Society, 2021, SENSK ENGL LAT EFF N
   Thygeson MV, 2010, J PEDIATR ONCOL NURS, V27, P276, DOI 10.1177/1043454210363478
   Tsukinoki R., 2013, EUR J EPIDEMIOL, V28, P1
   Turner LA, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-67
   Vandenbroucke JP, 2004, LANCET, V363, P1728, DOI 10.1016/S0140-6736(04)16261-2
   Velez-Florez G, 2018, CURR PSYCHIAT REP, V20, DOI 10.1007/s11920-018-0927-6
   von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI 10.2471/BLT.07.045120
   Waddington H, 2017, J CLIN EPIDEMIOL, V89, P43, DOI 10.1016/j.jclinepi.2017.02.015
   WHO, WHO CHILDH CANC
   Witt Claudia M., 2017, Journal of the National Cancer Institute Monographs, P3, DOI [10.1093/jncimonographs/lgx012, 10.1093/jncimonographs/lgx012]
   Wurz A, 2014, PEDIATR BLOOD CANCER, V61, P1828, DOI 10.1002/pbc.25096
   Zhang JH, 2015, NEW ENGL J MED, V373, P2336, DOI 10.1056/NEJMoa1508054
   Zuzak TJ, 2013, COMPLEMENT THER MED, V21, pS34, DOI 10.1016/j.ctim.2012.01.001
NR 90
TC 17
Z9 21
U1 4
U2 14
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD JUN
PY 2022
VL 21
AR 15347354221105563
DI 10.1177/15347354221105563
PG 22
WC Oncology; Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Integrative & Complementary Medicine
GA 2H6ZI
UT WOS:000814440100001
PM 35726681
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Luna, AL
   González, JA
   Guardo, LL
   Castro, NP
AF Luna, Alma Luz
   Gonzalez, Jaime Andres
   Guardo, Linda Lucia
   Castro, Nerlis Pajaro
TI CyberKnife Radiosurgery for refractory bilateral trigeminal neuralgia.
   Case report
SO COLOMBIA MEDICA
LA English
DT Article
DE Radiosurgery; rhizotomy; microvascular decompression surgery;
   microsurgery; robotic surgical procedures; intractable pain; trigeminal
   neuralgia
ID MICROVASCULAR DECOMPRESSION
AB Case description: A case of a 37-year-old female patient suffering from refractory bilateral trigeminal neuralgia is presented, who underwent various interventions such as acupuncture, block therapies and even microvascular decompression without effective pain relief.Clinical findings: Paresthesias and shooting-like twinges of pain intensity 10/10 in bilateral maxillary and mandibular branches of the trigeminal nerve, with nasal and intraoral triggers that made eating impossible, becoming increasingly severe since refractoriness to microvascular decompression and carbamazepine, triggering the twinges even during sleep, generating somnolence, depressive mood and social isolation.Treatment and results: The patient was evaluated by an interdisciplinary neuro-oncology team, where, in accordance with the analysis of the brain magnetic resonance imaging and the patient's history, it was indicated to perform Cyberknife (R) radiosurgery in monofraction on the left trigeminal and subsequently treat the contralateral trigeminal. When treated with Cyberknife (R) radiosurgery, the patient reported absolute improvement in her pain for 2 years.Clinical relevance: Radiosurgery by CyberKnife is not yet the first line of management in trigeminal neuralgia, however, it should be considered since several studies have managed to demonstrate an increase in the quality of life of patients and pain relief in refractory or severe cases. of said pathology.
C1 [Luna, Alma Luz; Gonzalez, Jaime Andres; Guardo, Linda Lucia; Castro, Nerlis Pajaro] Univ Sucre, Fac Ciencias Salud, Grp Ciencias Med & Farmaceut, Sincelejo, Colombia.
   [Luna, Alma Luz] Clin Las Penitas, Sincelejo, Colombia.
   [Gonzalez, Jaime Andres] Clin Santa Maria, Sincelejo, Colombia.
   [Guardo, Linda Lucia] Clin FOSCAL Int, Floridablanca, Colombia.
RP Castro, NP (corresponding author), Univ Sucre, Fac Ciencias Salud, Grp Ciencias Med & Farmaceut, Sincelejo, Colombia.
EM nerlis.pajaro@unisucre.edu.co
OI González Vega, Jaime Andrés/0000-0001-5405-7246; Guardo,
   Linda/0000-0002-1498-6187; Pajaro Castro, Nerlis/0000-0002-9831-9663
CR Alcantara Montero A, 2016, Semergen, V42, P244, DOI [10.1016/j.semerg.2015.09.007, 10.1016/j.semerg.2015.09.007]
   Arnold M., 2018, CEPHALALGIA, V38, P1, DOI [DOI 10.1177/0333102417738202, 10.1177/0333102417738202]
   Berti A, 2018, CUREUS J MED SCIENCE, V10, DOI 10.7759/cureus.2598
   Calcerrada N, 2005, EFECTIVIDAD SEGURID, V1st
   Campero Alvaro, 2014, Surg Neurol Int, V5, pS441, DOI 10.4103/2152-7806.142794
   Chumpitaz CV, 2014, ODONTOL SANMARQUINA, V16, P44, DOI [10.15381/os.v16i1.5379, DOI 10.15381/OS.V16I1.5379]
   Fleetwood IG, 2001, J NEUROSURG, V95, P513, DOI 10.3171/jns.2001.95.3.0513
   Chaves JPG, 2021, ARQ NEURO-PSIQUIAT, V79, P51, DOI [10.1590/0004-282X-anp-2020-0115, 10.1590/0004-282x-anp-2020-0115]
   Green TH, 2019, J PAIN PALLIAT CARE, V33, P32, DOI 10.1080/15360288.2019.1624676
   Ho CC, 2020, NEURALGIA TRIGEMINA
   Lakshman Vijay Bhaskar, 2019, Asian J Neurosurg, V14, P978, DOI [10.4103/ajns.ajns_53_18, 10.4103/ajns.AJNS_53_18]
   Li Y, 2019, J PAIN RES, V12, P1937, DOI 10.2147/JPR.S203141
   Liao JJ, 1997, SURG NEUROL, V47, P562, DOI 10.1016/S0090-3019(96)00250-9
   Merskey H., 1994, CLASSIFICATION CHRON, V2nd
   Mora Díaz I., 2013, Rev. Soc. Esp. Dolor, V20, P161, DOI 10.4321/s1134-80462013000400003
   Romanelli P, 2019, CUREUS J MED SCIENCE, V11, DOI 10.7759/cureus.6014
   Sanchez Arriaran Shery Lane, 2020, Gac Med Bol, V43, P67, DOI 10.47993/gmb.v43i1.21
   Serrano-Rubio AA, 2014, REV NEUROLOGIA, V59, P249, DOI 10.33588/rn.5906.2014177
   Tavakol S, 2020, OPER NEUROSURG, V18, P571, DOI 10.1093/ons/opz311
   Tian CL, 2020, NEUROSURGERY, V86, pE353, DOI 10.1093/neuros/nyz461
NR 20
TC 0
Z9 0
U1 0
U2 4
PU CORPORACION EDITORA MEDICA VALLE
PI CALI
PA UNIV VALLE, BLDG 118 FACULTY HEALTH, CALLE 4B 36-00, CALI, 00000,
   COLOMBIA
SN 1657-9534
J9 COLOMB MEDICA
JI Colomb. Medica
PY 2022
VL 53
IS 4
AR e5005283
DI 10.25100/cm.v53i4.5283
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA G9ZM8
UT WOS:000992652100001
PM 37287585
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Yoon, SY
   Yeo, JH
   Han, SD
   Bong, DJ
   Oh, B
   Roh, DH
AF Yoon, Seo-Yeon
   Yeo, Ji-Hee
   Han, Seung-Dae
   Bong, Dong-Jun
   Oh, Beomsoo
   Roh, Dae-Hyun
TI Diluted Bee Venom Injection Reduces Ipsilateral Mechanical Allodynia in
   Oxaliplatin-Induced Neuropathic Mice
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE bee venom; oxaliplatin; mechanical allodynia; alpha-2 adrenoceptor
ID ACUPOINT STIMULATION; FORMALIN TEST; PERIPHERAL NEUROPATHY; ACUPUNCTURE
   POINT; COLORECTAL-CANCER; PAIN MODEL; APIPUNCTURE; ACTIVATION;
   HYPERALGESIA; INVOLVEMENT
AB Oxaliplatin, which is used as one of anti-cancer drugs, commonly induces peripheral neuropathic pain. We have previously reported that an injection of diluted bee venom (DBV) produced a significant anti-nociceptive effects in several pain models of mice or rats. In this study, we evaluated time- and dose-dependent development of oxaliplatin-induced mechanical allodynia in bilateral hind paws of mice, and investigated the effect of DBV injection on this mechanical allodynia. DBV (0.1 mg/kg) was subcutaneously injected into the Zusanli acupoint 2 weeks after oxaliplatin (10 mg/kg) injection. One hour after DBV injection, we observed a significant reduction of mechanical allodynia in the ipsilateral hind paw, but not in the contralateral hind paw to DBV injection site. We subsequently examined whether this effect of DBV was related to the activation of peripheral nerves in DBV injected site, and then whether it was mediated by the activation of spinal cord alpha-2 adrenoceptors or opioid receptors. Subcutaneous pre-injection of 2% lidocaine (40 mg/kg) into the Zusanli acupoint completely blocked the anti-allodynic effect of DBV. Intrathecal pretreatment with yohimbine (25 mu g/mouse), an alpha-2 adrenoceptor antagonist, also prevented the anti-allodynic effect of DBV, whereas pretreatment with naloxone (20 mu g/mouse), an opioid receptor antagonist, did not block the effect of DBV. Taken together, these findings demonstrate that DBV injection into the Zusanli acupoint significantly reduces ipsilateral mechanical allodynia generated by oxaliplatin in mice, and also suggest that this anti-allodynic effect is dependent on the peripheral nerve activation in injected site and spinal cord alpha-2 adrenoceptors.
C1 [Yoon, Seo-Yeon] Korea Inst Sci & Technol, Ctr Neural Sci, Lab Mol Signal Transduct, Seoul 136791, South Korea.
   [Yeo, Ji-Hee; Han, Seung-Dae; Bong, Dong-Jun; Oh, Beomsoo; Roh, Dae-Hyun] Kyung Hee Univ, Sch Dent, Dept Maxillofacial Tissue Regenerat, Seoul 130701, South Korea.
   [Yeo, Ji-Hee; Han, Seung-Dae; Bong, Dong-Jun; Oh, Beomsoo; Roh, Dae-Hyun] Kyung Hee Univ, Sch Dent, Res Ctr Tooth & Periodontal Tissue Regenerat, Seoul 130701, South Korea.
C3 Korea Institute of Science & Technology (KIST); Kyung Hee University;
   Kyung Hee University
RP Roh, DH (corresponding author), Kyung Hee Univ, Sch Dent, Dept Maxillofacial Tissue Regenerat, Seoul 130701, South Korea.
EM dbroh@khu.ac.kr
RI Roh, Dae-Hyun/HPE-3599-2023
OI Roh, Dae-Hyun/0000-0002-5139-5458; Yeo, Jihee/0000-0001-7171-3786
FU Kyung Hee University [KHU-20120484]
FX This work was supported by a Grant from the Kyung Hee University in 2012
   (KHU-20120484).
CR Argyriou AA, 2008, CANCER TREAT REV, V34, P368, DOI 10.1016/j.ctrv.2008.01.003
   Attal N, 2009, PAIN, V144, P245, DOI 10.1016/j.pain.2009.03.024
   Binder A, 2007, EUR J CANCER, V43, P2658, DOI 10.1016/j.ejca.2007.07.030
   Chao Hui-Lin, 2013, Oncol Nurs Forum, V40, pE61, DOI 10.1188/13.ONF.E61-E68
   Farquhar-Smith Paul, 2011, Curr Opin Support Palliat Care, V5, P1, DOI 10.1097/SPC.0b013e328342f9cc
   Fu S, 2006, INT J GYNECOL CANCER, V16, P1717, DOI 10.1111/j.1525-1438.2006.00654.x
   Gao YH, 2013, NEUROCHEM RES, V38, P1467, DOI 10.1007/s11064-013-1047-7
   Gokin AP, 2001, ANESTHESIOLOGY, V95, P1441, DOI 10.1097/00000542-200112000-00025
   Grothey A, 2010, ONCOLOGY-BASEL, V79, P389, DOI 10.1159/000323491
   Kaley TJ, 2009, BRIT J HAEMATOL, V145, P3, DOI 10.1111/j.1365-2141.2008.07558.x
   Kang SY, 2012, J PAIN, V13, P155, DOI 10.1016/j.jpain.2011.10.012
   Kang SY, 2011, BRAIN RES BULL, V86, P412, DOI 10.1016/j.brainresbull.2011.08.012
   Kim HW, 2005, PHARMACOL RES, V51, P183, DOI 10.1016/j.phrs.2004.07.011
   Kroin JS, 2010, REGION ANESTH PAIN M, V35, P343, DOI 10.1097/AAP.0b013e3181e82df0
   Kwon YB, 2004, MOL CELLS, V17, P329
   Kwon YB, 2001, NEUROSCI LETT, V308, P133, DOI 10.1016/S0304-3940(01)01989-9
   Kwon YB, 2001, PAIN, V90, P271, DOI 10.1016/S0304-3959(00)00412-7
   Kwon YB, 2006, NEUROSCI RES, V55, P197, DOI 10.1016/j.neures.2006.03.003
   Lee JH, 2001, J VET MED SCI, V63, P251, DOI 10.1292/jvms.63.251
   Paice Judith A, 2009, Semin Oncol Nurs, V25, pS8, DOI 10.1016/j.soncn.2009.03.013
   Raez LE, 2010, CLIN LUNG CANCER, V11, P18, DOI 10.3816/CLC.2010.n.003
   Roh DH, 2006, J PAIN, V7, P500, DOI 10.1016/j.jpain.2006.02.002
   Roh DH, 2004, J PAIN, V5, P297, DOI 10.1016/j.jpain.2004.05.003
   SOMERFIELD SD, 1988, J RHEUMATOL, V15, P1878
   Stein A, 2012, EXPERT OPIN PHARMACO, V13, P125, DOI 10.1517/14656566.2012.643870
   Tofthagen C, 2011, CLIN J ONCOL NURS, V15, P182, DOI 10.1188/11.CJON.182-188
   Windebank AJ, 2008, J PERIPHER NERV SYST, V13, P27, DOI 10.1111/j.1529-8027.2008.00156.x
   Yajiri Y, 1997, NEUROSCIENCE, V76, P673, DOI 10.1016/S0306-4522(96)00291-6
   Yoon SY, 2012, NEUROSCIENCE, V221, P214, DOI 10.1016/j.neuroscience.2012.06.024
   Yoon SY, 2008, NEUROSCI LETT, V430, P163, DOI 10.1016/j.neulet.2007.10.035
   Yoon SY, 2013, J PAIN, V14, P205, DOI 10.1016/j.jpain.2012.11.002
   Yoon SY, 2009, J PAIN, V10, P253, DOI 10.1016/j.jpain.2008.09.002
NR 32
TC 17
Z9 20
U1 1
U2 12
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN
SN 0918-6158
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD NOV
PY 2013
VL 36
IS 11
BP 1787
EP 1793
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 244AQ
UT WOS:000326359900022
PM 23985901
OA gold
DA 2026-01-16
ER

PT J
AU Xu, YY
   Wu, GR
   Zhang, GM
   Li, DX
   Zhang, LY
   Yang, W
AF Xu, Yuanyuan
   Wu, Guangrong
   Zhang, Guomin
   Li, Dongxue
   Zhang, Lunyou
   Yang, Wei
TI Rare Emphysematous Osteomyelitis of the Femoral Head: A Case Report and
   Literature Review
SO INFECTION AND DRUG RESISTANCE
LA English
DT Review
DE emphysematous osteomyelitis; MRI; CT; acupotomy; diabetes
ID BONE
AB Emphysematous osteomyelitis (EO) is a perilous infection of the femoral head. In this case, we present a 66-year-old male patient of Han ethnicity, who had lumbar disc herniation and type 2 diabetes mellitus. The patient reported severe pain in his lower back and right lower limb, which had worsened over the past 20 days. Despite undergoing invasive procedures such as regional anesthetic blocks and other traditional Chinese medical methods such as acupuncture and acupotomy, his condition deteriorated. Pain in the lumbar region was not relieved, and there was a new onset of pain in the right hip, groin, and thighs. Preliminary medical evaluation revealed normal body temperature but elevated levels of the inflammatory marker high-sensitivity C-reactive protein (hsCRP). In the imaging tests, computed tomography revealed air bubbles within the right femoral head, corresponding to the EO. Diabetes mellitus and malignant neoplasms have been well-established as predominant risk factors for EO, while iatrogenic interventions may serve as potential precipitating factors in disease pathogenesis. Our report underlines the critical role of radiologists in identifying EO through distinctive imaging features, such as the "pumice stone" sign. This highlights the need for further research to enhance our understanding, diagnosis, and management of EO.
C1 [Xu, Yuanyuan; Wu, Guangrong; Zhang, Guomin; Li, Dongxue; Yang, Wei] Zunyi Med Univ, Peoples Hosp Zunyi 1, Affiliated Hosp 3, Dept Radiol, Zunyi, Guizhou, Peoples R China.
   [Zhang, Lunyou] Zunyi Med Univ, Peoples Hosp Zunyi 1, Affiliated Hosp 3, Dept Pathol, Zunyi, Guizhou, Peoples R China.
C3 Zunyi Medical University; Zunyi Medical University
RP Yang, W (corresponding author), Zunyi Med Univ, Peoples Hosp Zunyi 1, Affiliated Hosp 3, Dept Radiol, Zunyi, Guizhou, Peoples R China.
EM coxsackie@163.com
CR Berbudi A, 2020, CURR DIABETES REV, V16, P442, DOI 10.2174/1573399815666191024085838
   Campoccia D, 2010, BIOMATERIALS, V31, P6363, DOI 10.1016/j.biomaterials.2010.05.005
   Chang MK, 2008, J IMMUNOL, V181, P1232, DOI 10.4049/jimmunol.181.2.1232
   Charles JF, 2014, CURR OSTEOPOROS REP, V12, P1, DOI 10.1007/s11914-014-0195-2
   Chen JLY, 2016, QJM-INT J MED, V109, P427, DOI 10.1093/qjmed/hcw030
   Di Stasi Martina, 2020, Radiol Case Rep, V15, P1552, DOI [10.1016/j.radcr.2020.05.078, 10.1016/j.radcr.2020.05.078]
   Fang H, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4255-1
   Khan UH, 2024, J Clin Infect Dis, P77, DOI [10.4103/cids.cids6223, DOI 10.4103/CIDS.CIDS6223]
   Kim YK, 2018, INFECT CHEMOTHER, V50, P268, DOI 10.3947/ic.2018.50.3.268
   Kosai K, 2008, INTERNAL MED, V47, P1121, DOI 10.2169/internalmedicine.47.0937
   Larsen J, 2015, LANCET INFECT DIS, V15, P486, DOI 10.1016/S1473-3099(14)71017-5
   Lauer MF, 2019, ORTHOPEDICS, V42, pE128, DOI 10.3928/01477447-20181023-08
   Lee J, 2017, INFECT CHEMOTHER, V49, P151, DOI 10.3947/ic.2017.49.2.151
   Loomans CJM, 2009, MOL MED, V15, P152, DOI 10.2119/molmed.2009.00032
   Luey C, 2012, INT J INFECT DIS, V16, pE216, DOI 10.1016/j.ijid.2011.11.007
   Masters EA, 2022, NAT REV MICROBIOL, V20, P385, DOI 10.1038/s41579-022-00686-0
   Mautone Marcela, 2014, Case Rep Radiol, V2014, P616184, DOI 10.1155/2014/616184
   Moon TJ, 2023, JAAOS GLOB RES REV, V7, DOI 10.5435/JAAOSGlobal-D-21-00088
   Ono R, 2018, INTERNAL MED, V57, P2081, DOI 10.2169/internalmedicine.0219-17
   Potocki J, 2003, SKELETAL RADIOL, V32, P46, DOI 10.1007/s00256-002-0567-z
   Qin X, 2022, J HEALTHC ENG, V2022, DOI 10.1155/2022/1076112
   RAM PC, 1981, AM J ROENTGENOL, V137, P721, DOI 10.2214/ajr.137.4.721
   Sachdev IS, 2021, CUREUS J MED SCIENCE, V13, DOI 10.7759/cureus.16782
   Sax AJ, 2020, SKELETAL RADIOL, V49, P1487, DOI 10.1007/s00256-020-03470-4
   Schierenbeck M, 2023, DIAGNOSTICS, V13, DOI 10.3390/diagnostics13172745
   Small JE, 2022, CURR PROBL DIAGN RAD, V51, P666, DOI 10.1067/j.cpradiol.2018.05.008
   Sulyma Vadym, 2020, Ortop Traumatol Rehabil, V22, P153, DOI [10.5604/01.3001.0014.3231, 10.5604/01.3001.0014.3231]
NR 27
TC 1
Z9 1
U1 3
U2 3
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6973
J9 INFECT DRUG RESIST
JI Infect. Drug Resistance
PY 2025
VL 18
BP 1279
EP 1285
DI 10.2147/IDR.S479261
PG 7
WC Infectious Diseases; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Infectious Diseases; Pharmacology & Pharmacy
GA Z2U8A
UT WOS:001437529900001
PM 40059938
OA gold
DA 2026-01-16
ER

PT J
AU Lustberg, M
   Fan-Havard, P
   Wong, FL
   Hill, K
   Phelps, MA
   Herrera, KW
   Tsai, NC
   Synold, T
   Feng, Y
   Kalu, C
   Sedrak, MS
   Yee, LD
AF Lustberg, Maryam
   Fan-Havard, Patty
   Wong, F. Lennie
   Hill, Kasey
   Phelps, Mitch A.
   Herrera, Kevin W.
   Tsai, Ni-Chun
   Synold, Timothy
   Feng, Ye
   Kalu, Chidimma
   Sedrak, Mina S.
   Yee, Lisa D.
TI Randomized placebo-controlled, double-blind clinical trial of
   nanoemulsion curcumin in women with aromatase inhibitor-induced
   arthropathy: an Alliance/NCORP pilot trial
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Nanoemulsion curcumin; Aromatase inhibitors-induced joint arthropathy;
   Postmenopausal women; Plasma curcumin levels; Plasma estrone and
   estradiol levels
ID STAGE BREAST-CANCER; ADJUVANT THERAPY; SYMPTOMS; EFFICACY; PAIN;
   PHARMACOKINETICS; OSTEOARTHRITIS; ACUPUNCTURE; MULTICENTER; COMBINATION
AB Purpose Aromatase inhibitor (AI) therapy reduces risk of recurrence and death for postmenopausal women with breast cancer (BC); however, AI-induced arthralgia (AIIA) can lead to discontinuation of treatment. Curcumin, a bioactive polyphenolic substance, may help ameliorate inflammation-related conditions including osteoarthritis and pain. Methods We conducted a multisite randomized placebo-controlled, double-blind pilot trial (Alliance A22_Pilot9) to evaluate the effects of nanoemulsion curcumin (NEC, 200 mg/day) in postmenopausal women experiencing AIIA for >= 3 months. The primary objective was to determine the feasibility of using Functional Assessment of Cancer Treatment-Endocrine Symptoms (FACT-ES) to detect changes from 0 (T0) to 3 months (T3) of NEC treatment in AI-induced symptoms and well-being; secondary objectives included evaluation of changes in Disabilities of the Shoulder, Arm, and Hand (DASH), Brief Pain Inventory-short form (BPI-SF), grip strength, and biomarkers at T0 and T3. Results Forty-two patients were randomized to NEC or placebo; 34 women completed the 3-month study. Patient-reported outcome measures (PROMs: FACT-ES, DASH, BPI-SF) and biospecimens were collected at T0-T3 in > 80% of participants. Adherence was >= 90% for both arms. PROMs and grip strength did not differ significantly by treatment arm. Plasma curcumin was detected only in NEC arm participants. Serum estradiol and estrone levels were below detection or low on study agent. Gastrointestinal adverse effects were commonly reported in both arms. Conclusion NEC versus placebo in a multisite randomized trial is feasible and well-tolerated. Additional studies with larger sample size are needed to further evaluate the efficacy and safety of NEC in treatment of AIIA.ClinicalTrials.gov Identifier: NCT03865992, first posted March 7, 2019.
C1 [Lustberg, Maryam] Yale Canc Ctr, New Haven, CT USA.
   [Fan-Havard, Patty] Kaweah Hlth Care Dist, Visalia, CA USA.
   [Wong, F. Lennie; Herrera, Kevin W.; Tsai, Ni-Chun; Synold, Timothy; Feng, Ye; Kalu, Chidimma; Yee, Lisa D.] City Hope Comprehens Canc Ctr, Duarte, CA 91010 USA.
   [Hill, Kasey; Phelps, Mitch A.] Ohio State Univ, Wexner Med Ctr, Comprehens Canc Ctr, Columbus, OH USA.
   [Hill, Kasey; Phelps, Mitch A.] James Canc Hosp, Columbus, OH USA.
   [Sedrak, Mina S.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA.
   [Yee, Lisa D.] City Hope Comprehens Canc Ctr, Dept Surg, 1500 East Duarte Rd, Duarte, CA 91010 USA.
C3 Yale University; Yale New Haven Hospital; City of Hope; James Cancer
   Hospital & Solove Research Institute; University System of Ohio; Ohio
   State University; University System of Ohio; Ohio State University;
   James Cancer Hospital & Solove Research Institute; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA; City of Hope
RP Yee, LD (corresponding author), City Hope Comprehens Canc Ctr, Duarte, CA 91010 USA.; Yee, LD (corresponding author), City Hope Comprehens Canc Ctr, Dept Surg, 1500 East Duarte Rd, Duarte, CA 91010 USA.
EM lyee@coh.org
RI Phelps, Mitch/H-3941-2013
FU National Cancer Institute [UG1 CA189823-04]; Alliance NCORP Research
   Base - pilot project
FX We thank all the study participants, clinicians, clinic staff, and
   clinical trial teams involved in the study. This pilot project was
   funded by the Alliance NCORP Research Base - pilot project pilot grant
   award UG1 CA189823-04 (LDY, ML).
CR Belcaro G, 2010, PANMINERVA MED, V52, P269
   Belcaro G, 2010, ALTERN MED REV, V15, P337
   Bergman J, 2013, CLIN NEUROPHARMACOL, V36, P73, DOI 10.1097/WNF.0b013e31828ef969
   Bertelsen BE, 2020, J ENDOCR SOC, V4, DOI 10.1210/jendso/bvaa047
   Brier MJ, 2015, CANCER-AM CANCER SOC, V121, P2808, DOI 10.1002/cncr.29407
   Chen W, 2012, J CHROMATOGR B, V900, P89, DOI 10.1016/j.jchromb.2012.05.026
   Chuengsamarn S, 2012, DIABETES CARE, V35, P2121, DOI 10.2337/dc12-0116
   Cox KHM, 2020, NUTRIENTS, V12, DOI 10.3390/nu12061678
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Daily JW, 2016, J MED FOOD, V19, P717, DOI 10.1089/jmf.2016.3705
   DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4
   Dressman JB, 2000, EUR J PHARM SCI, V11, pS73, DOI 10.1016/S0928-0987(00)00181-0
   Fallowfield LJ, 1999, BREAST CANCER RES TR, V55, P189
   Goss PE, 2016, NEW ENGL J MED, V375, P209, DOI 10.1056/NEJMoa1604700
   Goss PE, 2003, NEW ENGL J MED, V349, P1793, DOI 10.1056/NEJMoa032312
   Goss PE, 2005, JNCI-J NATL CANCER I, V97, P1262, DOI 10.1093/jnci/dji250
   Henry NL, 2021, JNCI CANCER SPECT, V5, DOI 10.1093/jncics/pkab087
   Henry NL, 2018, J CLIN ONCOL, V36, P326, DOI 10.1200/JCO.2017.74.6651
   Henry NL, 2012, J CLIN ONCOL, V30, P936, DOI 10.1200/JCO.2011.38.0261
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hershman DL, 2015, J CLIN ONCOL, V33, P1910, DOI 10.1200/JCO.2014.59.5595
   Hróbjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106
   Hudak PL, 1996, AM J IND MED, V29, P602, DOI 10.1002/(SICI)1097-0274(199606)29:6<602::AID-AJIM4>3.0.CO;2-L
   Irwin ML, 2015, J CLIN ONCOL, V33, P1104, DOI 10.1200/JCO.2014.57.1547
   Liu ZF, 2012, CANCER CHEMOTH PHARM, V69, P679, DOI 10.1007/s00280-011-1749-y
   Lombard JM, 2016, SUPPORT CARE CANCER, V24, P2139, DOI 10.1007/s00520-015-3001-5
   Lopresti AL, 2017, J AFFECT DISORDERS, V207, P188, DOI 10.1016/j.jad.2016.09.047
   Menon VP, 2007, ADV EXP MED BIOL, V595, P105
   Nakagawa Y, 2014, J ORTHOP SCI, V19, P933, DOI 10.1007/s00776-014-0633-0
   Panahi Y, 2014, COMPLEMENT THER MED, V22, P851, DOI 10.1016/j.ctim.2014.07.006
   Pouton CW, 2000, EUR J PHARM SCI, V11, pS93, DOI 10.1016/S0928-0987(00)00167-6
   Shen S, 2018, BREAST CANCER RES TR, V172, P603, DOI 10.1007/s10549-018-4946-0
   Small GW, 2018, AM J GERIAT PSYCHIAT, V26, P266, DOI 10.1016/j.jagp.2017.10.010
   Tsai IC, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14121235
   Vareed SK, 2008, CANCER EPIDEM BIOMAR, V17, P1411, DOI 10.1158/1055-9965.EPI-07-2693
   Young NA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111559
   Zeng LT, 2021, BIOSCIENCE REP, V41, DOI 10.1042/BSR20210817
NR 37
TC 7
Z9 8
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD MAY
PY 2024
VL 205
IS 1
BP 61
EP 73
DI 10.1007/s10549-023-07223-4
EA JAN 2024
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA UA8F2
UT WOS:001150541000001
PM 38280052
OA Green Submitted, hybrid
DA 2026-01-16
ER

PT J
AU Raybin, JL
   Montgomery, K
   Janosy, N
   Mist, S
   Franklin, H
   Dieckmann, NF
   Hendricks-Ferguson, VL
   Jankowski, CM
AF Raybin, Jennifer L.
   Montgomery, Kathleen
   Janosy, Norah
   Mist, Scott
   Franklin, Heather
   Dieckmann, Nathan F.
   Hendricks-Ferguson, Verna L.
   Jankowski, Catherine M.
TI Study of Complementary and Integrative Interventions in Pediatric
   Patients With Serious Illness
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE Integrative; complementary; quality of life; symptoms; childhood cancer
ID QUALITY-OF-LIFE; CREATIVE ARTS THERAPY; ACUTE LYMPHOBLASTIC-LEUKEMIA;
   ALTERNATIVE MEDICINE; SYMPTOM CLUSTERS; CHILDREN; ONCOLOGY; CANCER;
   PAIN; MANAGEMENT
AB Context. Pediatric patients report using complementary and integrative health interventions (CHI) for symptom management. Objective. Feasibility and initial effect sizes of CHI with patients at two children's hospitals. Methods. Using convenience sampling at two academic centers and accepting the wide age range of patients traditionally treated in children's hospitals, we examined feasibility of CHI and outcomes of quality of life (QOL) and symptoms with validated surveys and two physiologic measures. A priori feasibility thresholds were 90% accrual rate and 60% completion of at least two surveys and one CHI session. Results. Over 18 months we accrued 100 participants (Site 1, n = 34; Site 2, n = 66) who completed 811 assessments. Participants were aged 2-29 years (M = 13.5, SD = 5.6), 65% female, 23% from underrepresented populations, 52% with cancer versus other serious illness. Accrual rate was 94%, completion rate was 87%, acceptability was 96%. Ninety-nine participants received 191 total CHI sessions: acupuncture (39%), aromatherapy (35%), creative arts (20%), massage therapy (5%) and hypnosis (1%). After CHI heart rate decreased and symptom scores improved for anxiety, fatigue, nausea, pain, and sadness (Cohen's d effect sizes 0.22-0.99). Adjusted mixed-effects models suggested that the Faces Scale scores improved over time (b = 0.19, P< 0.01). Conclusion. Prospective two-site data collection in relationship to CHI exceeded feasibility thresholds and was acceptable. When given the choice, CHI were popular and may have contributed to improved QOL immediately and longitudinally. These preliminary findings support further study of CHI for targeted symptoms in distinct populations with rigor. (c) 2025 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
C1 [Jankowski, Catherine M.] Univ Colorado, Coll Nursing, Auroroa, CO USA.
   [Jankowski, Catherine M.] Univ Colorad, Sch Med, Auroroa, CO USA.
   [Hendricks-Ferguson, Verna L.] St Louis Univ, Sch Nursing, St Louis, MO USA.
   [Raybin, Jennifer L.; Mist, Scott; Franklin, Heather; Dieckmann, Nathan F.] Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97239 USA.
   [Raybin, Jennifer L.; Mist, Scott; Franklin, Heather; Dieckmann, Nathan F.] Oregon Hlth & Sci Univ, Sch Med, Portland, OR USA.
   [Montgomery, Kathleen] Univ Wisconsin Madison, Sch Nursing, Madison, WI USA.
C3 Saint Louis University; Oregon Health & Science University; Oregon
   Health & Science University; University of Wisconsin System; University
   of Wisconsin Madison
RP Raybin, JL (corresponding author), Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97239 USA.; Raybin, JL (corresponding author), Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97239 USA.
EM raybin@ohsu.edu
RI Mist, Scott/O-7629-2019
OI franklin, heather/0000-0002-4256-3579; Dieckmann,
   Nathan/0000-0001-5061-9889; Montgomery, Kathleen/0000-0001-7662-0247;
   Janosy, Norah/0000-0001-7343-9450
FU Children ' s Oncology Group National Clinical Trials Network Operations
   Grant; University of Colorado Center for Integrative Medicine CAMPUS
   Award; Oregon Clinical and Translational Research Institute (OCTRI);
   National Center for Advancing Translational Sciences (NCATS)
   [UL1TR002369]; National Institutes of Health (NIH); NIH Roadmap for
   Medical Research;  [U10CA180886]
FX This work was supported by the Children ' s Oncology Group National
   Clinical Trials Network Operations Grant (U10CA180886, PI: Hawkins) -
   Nursing Discipline Research Award and the University of Colorado Center
   for Integrative Medicine CAMPUS Award. This publication was made
   possible with support from the Oregon Clinical and Translational
   Research Institute (OCTRI) , grant number UL1TR002369 from the National
   Center for Advancing Translational Sciences (NCATS) , a component of the
   National Institutes of Health (NIH) , and NIH Roadmap for Medical
   Research. Soothing Scents Aromatherapy (c) donated the aromatherapy
   pods. We thank the Children ' s Healing Art Project (CHAP) , a nonpro fi
   t hospital arts program, for allowing us to ask patients to answer
   surveys before and after they participated in CHAP art sessions. We are
   grateful to the participants for their time and enthusiasm in joining
   the study. The authors have no disclosures or con fl icts of interest to
   report.
CR Aguilar BA, 2017, J PEDIATR NURS, V36, P173, DOI 10.1016/j.pedn.2017.06.015
   Ahmadipour S, 2024, AM J PERINAT, V41, pe3420, DOI 10.1055/s-0039-1685493
   Azadinia F, 2014, J SPINAL DISORD TECH, V27, pE212
   Barrett E, 2018, PHYSIOTHER THEOR PR, V34, P301, DOI 10.1080/09593985.2017.1394411
   Barrett E, 2013, REHABIL RES PRACT, V2013, DOI 10.1155/2013/475870
   Breau LM, 2001, CLIN J PAIN, V17, P178, DOI 10.1097/00002508-200106000-00011
   Burns DS, 2009, CANCER NURS, V32, pE8, DOI 10.1097/NCC.0b013e3181a4802c
   Chester SJ, 2018, PAIN, V159, P1790, DOI 10.1097/j.pain.0000000000001276
   Chokshi SK, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26424
   Czajkowski SM, 2015, HEALTH PSYCHOL, V34, P971, DOI 10.1037/hea0000161
   Darwin C., 1872, P374
   DeWalt DA, 2015, QUAL LIFE RES, V24, P2195, DOI 10.1007/s11136-015-0953-3
   Diorio C, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0529-3
   Dodd M, 2001, J ADV NURS, V33, P668, DOI 10.1046/j.1365-2648.2001.01697.x
   Dupuis LL, 2016, CANCER-AM CANCER SOC, V122, P1116, DOI 10.1002/cncr.29876
   Dupuis LL, 2013, PEDIATR BLOOD CANCER, V60, P1073, DOI 10.1002/pbc.24508
   Evans A, 2018, J PEDIATR ONCOL NURS, V35, P392, DOI 10.1177/1043454218782133
   Garra G, 2010, ACAD EMERG MED, V17, P50, DOI 10.1111/j.1553-2712.2009.00620.x
   Geyer R, 2011, PEDIATR PHYS THER, V23, P375, DOI 10.1097/PEP.0b013e318235628c
   Hall M, 2018, CHILDREN-BASEL, V5, DOI 10.3390/children5110154
   Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Hays RD, 2009, QUAL LIFE RES, V18, P873, DOI 10.1007/s11136-009-9496-9
   Hinds PS, 2019, PEDIATR BLOOD CANCER, V66, DOI 10.1002/pbc.27606
   Hinds PS, 2013, PEDIATR BLOOD CANCER, V60, P402, DOI 10.1002/pbc.24233
   Hockenberry MJ, 2015, ONCOL NURS FORUM, V42, P542, DOI 10.1188/15.ONF.542-549
   Jacobs SS, 2014, CHILDREN-BASEL, V1, P424, DOI 10.3390/children1030424
   Jibb LA, 2015, ONCOL NURS FORUM, V42, pE339, DOI 10.1188/15.ONF.E339-E357
   Jindal V, 2008, J PEDIAT HEMATOL ONC, V30, P431, DOI 10.1097/MPH.0b013e318165b2cc
   Kalaichandran A, 2018, PAED CHILD HEALT-CAN, V23, P12, DOI 10.1093/pch/pxx114
   Kemper KJ, 2008, PEDIATRICS, V122, P1374, DOI 10.1542/peds.2008-2173
   Knoerl R, 2022, J PAIN SYMPTOM MANAG, V63, pE357, DOI 10.1016/j.jpainsymman.2021.11.013
   Kohut SA, 2020, J CLIN PSYCHOL MED S, V27, P68, DOI 10.1007/s10880-019-09622-6
   Larson P., 1994, IMAGE, V26, P272, DOI [DOI 10.1111/J.1547-5069.1994.TB00333.X, 10.1111/j.1547-5069.1994.tb00333.x]
   Lewis JS, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-39
   Li RR, 2022, CANCER NURS, V45, P96, DOI 10.1097/NCC.0000000000000920
   Lüthi E, 2021, BMC COMPLEMENT MED, V21, DOI 10.1186/s12906-021-03271-9
   MacDonald C, 2019, CAN J DIABETES, V43, P377, DOI 10.1016/j.jcjd.2019.04.016
   Madden JR, 2010, J PEDIATR ONCOL NURS, V27, P133, DOI 10.1177/1043454209355452
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   McClafferty H, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-1961
   McGrath P, 1996, PAIN, V64, P435, DOI 10.1016/0304-3959(95)00171-9
   McGrath PatriciaA., 1990, Pain in Children: Nature, Assessment, and Treatment
   Misra SM, 2019, CLIN PEDIATR, V58, P738, DOI 10.1177/0009922819839232
   Momani TG, 2017, J PEDIATR ONCOL NURS, V34, P173, DOI 10.1177/1043454216688638
   Montgomery KE, 2024, J PEDIAT HEMAT ONC N, V41, P157, DOI 10.1177/27527530231214544
   Montgomery KE, 2020, CANCER NURS, V43, P281, DOI 10.1097/NCC.0000000000000721
   Montgomery KE, 2022, Cancer Care Research Online, V2, P020
   Moore I.M., 2004, Journal of Pediatric Oncology Nursing, V21, P128, DOI DOI 10.1177/1043454204264400
   Mora DC, 2022, INTEGR CANCER THER, V21, DOI 10.1177/15347354221105563
   Mora DC, 2022, BMC COMPLEMENT MED, V22, DOI 10.1186/s12906-022-03537-w
   Neu M, 2014, BIOL RES NURS, V16, P387, DOI 10.1177/1099800413516187
   Niedenthal PM, 2007, SCIENCE, V316, P1002, DOI 10.1126/science.1136930
   Niedenthal PM, 2009, J PERS SOC PSYCHOL, V96, P1120, DOI 10.1037/a0015574
   NIH, 2016, Why study complementary health approaches?
   Post-White J, 2009, J PEDIATR ONCOL NURS, V26, P7, DOI 10.1177/1043454208323914
   Pour PS, 2017, J ACUPUNCT MERIDIAN, V10, P187, DOI 10.1016/j.jams.2017.04.001
   Rae C, 2018, J PEDIAT HEMATOL ONC, V40, P580, DOI 10.1097/MPH.0000000000001235
   Ramesh G, 2018, CHILDREN-BASEL, V5, DOI 10.3390/children5120168
   Raybin JL, 2024, CANCER NURS, V47, P12, DOI 10.1097/NCC.0000000000001186
   Raybin JL, 2022, J PEDIAT HEMAT ONC N, V39, P60, DOI 10.1177/27527530211059432
   Raybin JL, 2022, J PEDIAT HEMAT ONC N, V39, P155, DOI 10.1177/27527530211055988
   Raybin Jennifer L., 2021, Pediatric Blood & Cancer, V68, pe29388, DOI 10.1002/pbc.29388
   Raybin JL, 2020, J PEDIATR ONCOL NURS, V37, P82, DOI 10.1177/1043454219878397
   Reeve BB, 2020, JNCI-J NATL CANCER I, V112, P1143, DOI 10.1093/jnci/djaa016
   Reeve BB, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26261
   Shamsi MohammadBagher, 2014, ISRN Orthop, V2014, P159465, DOI 10.1155/2014/159465
   Stein E, 2019, SUPPORT CARE CANCER, V27, P3769, DOI 10.1007/s00520-019-04673-9
   Sullivan Gail M, 2012, J Grad Med Educ, V4, P279, DOI 10.4300/JGME-D-12-00156.1
   Thissen D, 2016, QUAL LIFE RES, V25, P13, DOI 10.1007/s11136-015-1058-8
   Thrane S, 2013, J PEDIATR ONCOL NURS, V30, P320, DOI 10.1177/1043454213511538
   Thrane SE, 2017, AM J HOSP PALLIAT ME, V34, P373, DOI 10.1177/1049909116630973
   Tomlinson D, 2011, SUPPORT CARE CANCER, V19, P1857, DOI 10.1007/s00520-010-1029-0
   Tsze DS, 2015, ACAD EMERG MED, V22, P415, DOI 10.1111/acem.12620
   Uman LS, 2006, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD005179.pub3, 10.1002/14651858.CD005179]
   Varejao CD, 2019, J PEDIATR ONCOL NURS, V36, P44, DOI 10.1177/1043454218810140
   Victorson D, 2016, J ALTERN COMPLEM MED, V22, P778, DOI 10.1089/acm.2015.0121
   Walicka-Cuprys K, 2018, EUR SPINE J, V27, P497, DOI 10.1007/s00586-017-5409-8
   Wang JC, 2018, J PAIN SYMPTOM MANAG, V55, P359, DOI 10.1016/j.jpainsymman.2017.08.021
   Weaver MS, 2020, PALLIAT SUPPORT CARE, V18, P158, DOI 10.1017/S1478951519000555
   Weekly T, 2019, J PALLIAT CARE, V34, P164, DOI 10.1177/0825859718810727
   Wurz A, 2014, PEDIATR BLOOD CANCER, V61, P1828, DOI 10.1002/pbc.25096
   Zheng DJ, 2018, CANCER-AM CANCER SOC, V124, P571, DOI 10.1002/cncr.31085
   Zucchetti G, 2019, J PEDIATR ONCOL NURS, V36, P361, DOI 10.1177/1043454219845879
NR 84
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD MAY
PY 2025
VL 69
IS 5
BP 515
EP 526
DI 10.1016/j.jpainsymman.2025.02.013
EA APR 2025
PG 12
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
   Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; General & Internal Medicine;
   Neurosciences & Neurology
GA 1PA2W
UT WOS:001470247800001
PM 39971211
DA 2026-01-16
ER

PT J
AU Angelopoulou, E
   Anagnostouli, M
   Chrousos, GP
   Bougea, A
AF Angelopoulou, Efthalia
   Anagnostouli, Maria
   Chrousos, George P.
   Bougea, Anastasia
TI Massage therapy as a complementary treatment for Parkinson's disease: A
   Systematic Literature Review
SO COMPLEMENTARY THERAPIES IN MEDICINE
LA English
DT Review
DE Parkinson's disease (PD); Complementary and alternative medicine (CAM);
   Massage therapy; Non-motor symptoms; Systematic review
ID BREAST-CANCER PATIENTS; ALTERNATIVE MEDICINE; BRAIN-DEVELOPMENT;
   SYMPTOMS; PAIN; QUALITY; ACUPUNCTURE; OUTPATIENTS; SEROTONIN; DOPAMINE
AB Objective: There is no definite cure for Parkinson's disease (PD); therefore, the goals for symptomatic treatment are to improve quality of life and manage the motor and non-motor symptoms of the disease. Although massage is the one of the commonest used forms of complementary and alternative medicine (CAM), there is no systematically-oriented review focusing specifically on the efficacy of the different massage techniques on PD.Aim of this review was to evaluate the quality of evidence referring to massage therapy for PD.
   Design: A systematic search was conductedin the MEDLINE database to identify the efficacy of massage on PD between 01/01/1970 and 06/12/2019.
   Results: A total of 12 studies were analyzed in this systematic review. Massage therapy seems to induce relaxation in most cases, which is accompanied by biological measures involving urine stress hormones. Quality of life has been shown to be improved upon various therapeutic massage styles, involving classical whole-body therapeutic massage and reflexology. Non-motor symptoms, such as sleep disturbances, pain, fatigue, anxiety and depressive symptoms have been demonstrated to be improved upon different massage techniques, including classical deep therapeutic massage, Traditional Japanese (Anma) massage, Thai massage, neuromuscular therapy and Yin Tui Na massage. Regarding motor symptoms, classical therapeutic massage, Traditional Japanese (Anma) massage, Thai massage, and neuromuscular therapy seemed to improve motor symptoms, whereas Yin Tui Na technique combined with acupuncture was associated with worse motor scores.
   Conclusions: Despite the methodological concerns regarding the existing evidence, there is a wide range of safe massage techniques with beneficial effects on both motor and non-motor symptoms of PD. Longitudinal studies are needed to justify the introduction of massage therapy into clinical practice.
C1 [Angelopoulou, Efthalia; Anagnostouli, Maria; Bougea, Anastasia] Natl Kapodistrian Univ Athens, Aeginit Hosp, Fac Med, Dept Neurol 1, Athens, Greece.
   [Anagnostouli, Maria; Bougea, Anastasia] Natl Kapodistrian Univ Athens, Fac Med, Stress Management & Hlth Promot, Post Grad Course, Athens, Greece.
   [Chrousos, George P.] Natl & Kapodistrian Univ Athens, Aghia Sophia Childrens Hosp, Sch Med, Dept Pediat 1,Unit Dev & Behav Pediat, Athens, Greece.
C3 National & Kapodistrian University of Athens; National & Kapodistrian
   University of Athens; The Aghia Sophia Children's Hospital; National &
   Kapodistrian University of Athens
RP Bougea, A (corresponding author), Natl & Kapodistrian Univ Athens, Med Sch, Eginit Hosp, Dept Neurol 1,Memory & Movement Disorder Clin, Vassilisis Sophias Ave 72-74, Athens 11528, Greece.
EM annita139@yahoo.gr
RI BOUGEA, ANASTASIA/P-8197-2017; Angelopoulou, Efthalia/ABB-8167-2020;
   Chrousos, George/G-8702-2011; ANAGNOSTOULI, MARIA/HJP-5920-2023
OI BOUGEA, ANASTASIA/0000-0003-3006-8711; Angelopoulou,
   Efthalia/0000-0002-1426-3384; 
CR Airosa F, 2016, J HOLIST NURS, V34, P13, DOI 10.1177/0898010115579769
   Anderson Loretta, 2019, JBI Database System Rev Implement Rep, V17, P1668, DOI [10.11124/jbisrir-2017-003932, 10.11124/JBISRIR-2017-003932]
   Anselmi L, 2017, GASTROENTEROLOGY, V153, P1581, DOI 10.1053/j.gastro.2017.08.069
   Barone P, 2017, INT REV NEUROBIOL, V133, P499, DOI [10.1016/bs.im.2017.05.023, 10.1016/bs.irn.2017.05.023]
   Ben-Horin I, 2017, INTEGR CANCER THER, V16, P258, DOI 10.1177/1534735417690254
   Bereznick DE, 2002, CLIN BIOMECH, V17, P297, DOI 10.1016/S0021-9290(02)00014-3
   Bernhard FP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150552
   Cho KH, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00323
   Craig LH, 2006, MOVEMENT DISORD, V21, P2127, DOI 10.1002/mds.21132
   Donley S, 2019, PARKINSONISM RELAT D, V58, P46, DOI 10.1016/j.parkreldis.2018.08.003
   Donoyama N, 2014, COMPLEMENT THER CLIN, V20, P251, DOI 10.1016/j.ctcp.2014.07.010
   Donoyama N, 2012, J ALTERN COMPLEM MED, V18, P294, DOI 10.1089/acm.2011.0148
   Duval C, 2002, J MANIP PHYSIOL THER, V25, P455, DOI 10.1067/mmt.2002.126469
   Dyson-Hudson TA, 2001, ARCH PHYS MED REHAB, V82, P1038, DOI 10.1053/apmr.2001.24888
   Eng ML, 2006, J ALTERN COMPLEM MED, V12, P395, DOI 10.1089/acm.2006.12.395
   Ferry P, 2002, POSTGRAD MED J, V78, P612, DOI 10.1136/pmj.78.924.612
   Field T, 2005, INT J NEUROSCI, V115, P1397, DOI 10.1080/00207450590956459
   Field T, 2002, JCR-J CLIN RHEUMATOL, V8, P72, DOI 10.1097/00124743-200204000-00002
   Field T, 1998, ADOLESCENCE, V33, P555
   Field T, 2006, INFANT BEHAV DEV, V29, P574, DOI 10.1016/j.infbeh.2006.07.011
   Field T, 2016, COMPLEMENT THER CLIN, V24, P19, DOI 10.1016/j.ctcp.2016.04.005
   Field T, 2014, COMPLEMENT THER CLIN, V20, P224, DOI [10.1016/j.ctcp.2014.07.002, 10.1016/j.ctcp.2016.04.005]
   Finseth TA, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/874849
   Franklin NC, 2014, ARCH PHYS MED REHAB, V95, P1127, DOI 10.1016/j.apmr.2014.02.007
   George M, 2013, NURS CLIN N AM, V48, P53, DOI 10.1016/j.cnur.2012.11.002
   Green VL, 2010, EXP THER MED, V1, P97, DOI 10.3892/etm_00000018
   Guo TP, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000009697
   Guzzetta A, 2009, J NEUROSCI, V29, P6042, DOI 10.1523/JNEUROSCI.5548-08.2009
   Hart S, 2001, Eat Disord, V9, P289, DOI 10.1080/106402601753454868
   Hernandez-Reif M, 2004, J PSYCHOSOM RES, V57, P45, DOI 10.1016/S0022-3999(03)00500-2
   Hernandez -Reif M, 2002, J. Bodyw. Mov. Ther, V6, P177, DOI [DOI 10.1054/JBMT.2002.0282, 10.1054/jbmt.2002.0282]
   Ironson G, 1996, INT J NEUROSCI, V84, P205, DOI 10.3109/00207459608987266
   Jiang S, 2017, NEUROL SCI, V38, P1373, DOI 10.1007/s10072-017-2988-4
   Johns Christopher, 2010, Complement Ther Clin Pract, V16, P96, DOI 10.1016/j.ctcp.2009.10.003
   Juntakarn Chantip, 2017, Int J Ther Massage Bodywork, V10, P3, DOI 10.3822/ijtmb.v10i2.350
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P817, DOI 10.7326/0003-4819-136-11-200206040-00011
   Kim In-Hong, 2016, J Phys Ther Sci, V28, P2703, DOI 10.1589/jpts.28.2703
   Klein Penelope, 2017, Medicines (Basel), V4, DOI [10.3390/medicines4040069, 10.3390/medicines4040069]
   Kostic VS, 2016, MOV DISORD CLIN PRAC, V3, P323, DOI 10.1002/mdc3.12343
   Kumar S, 2013, INT J GEN MED, V6, P733, DOI 10.2147/IJGM.S50243
   Lidstone Sarah Christine, 2014, Handb Exp Pharmacol, V225, P139, DOI 10.1007/978-3-662-44519-8_8
   Liu D, 2000, NAT NEUROSCI, V3, P799, DOI 10.1038/77702
   McClurg D, 2016, AGE AGEING, V45, P299, DOI 10.1093/ageing/afw005
   MEARA RJ, 1993, ELECTROEN CLIN NEURO, V89, P261, DOI 10.1016/0168-5597(93)90105-X
   MEARA RJ, 1992, BRAIN, V115, P1167, DOI 10.1093/brain/115.4.1167
   Mercado NM., 2017, Austin Neurol Neurosci, V2
   Miyahara Yuka, 2018, J Tradit Complement Med, V8, P261, DOI [10.1016/j.jtcme.2018.01.004, 10.1016/j.jtcme.2018.01.004]
   Nelson NL, 2017, AM J PHYS MED REHAB, V96, P665, DOI 10.1097/PHM.0000000000000712
   Paterson Charlotte, 2005, Complement Ther Clin Pract, V11, P161, DOI 10.1016/j.ctcp.2004.12.008
   Quattrone A, 2018, MOVEMENT DISORD, V33, P1213, DOI 10.1002/mds.27438
   Ratey JJ, 2011, REV NEUROSCIENCE, V22, P171, DOI 10.1515/RNS.2011.017
   Rexilius Stephanie J, 2002, Oncol Nurs Forum, V29, pE35, DOI 10.1188/02.ONF.E35-E44
   Rizek P, 2016, CAN MED ASSOC J, V188, P1157, DOI 10.1503/cmaj.151179
   SCATTON B, 1983, BRAIN RES, V275, P321, DOI 10.1016/0006-8993(83)90993-9
   Sitte HH, 2017, EUR J NEUROSCI, V45, P1356, DOI 10.1111/ejn.13573
   Soares NM, 2019, J NEURAL TRANSM, V126, P219, DOI 10.1007/s00702-018-1947-4
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Stub T, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1770-8
   Suoh S, 2016, J BODYW MOV THER, V20, P364, DOI 10.1016/j.jbmt.2015.11.008
   TATTON WG, 1975, BRAIN RES, V100, P671, DOI 10.1016/0006-8993(75)90167-5
   Törnhage CJ, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-357
   Walton-Hadlock J, 1999, Am J Acupunct, V27, P31
   Wang QS, 2014, J NEUROSCI, V34, P12490, DOI 10.1523/JNEUROSCI.2238-14.2014
   Waters-Banker C, 2014, J APPL PHYSIOL, V116, P164, DOI 10.1152/japplphysiol.00573.2013
   Wen ZQ, 2012, NEURAL REGEN RES, V7, P1185, DOI 10.3969/j.issn.1673-5374.2012.15.010
   Wu JJ, 2014, COMPLEMENT THER MED, V22, P456, DOI 10.1016/j.ctim.2014.04.001
   Yu QJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-16790-8
NR 67
TC 24
Z9 25
U1 0
U2 30
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0965-2299
EI 1873-6963
J9 COMPLEMENT THER MED
JI Complement. Ther. Med.
PD MAR
PY 2020
VL 49
AR 102340
DI 10.1016/j.ctim.2020.102340
PG 8
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Integrative & Complementary Medicine
GA LG1NY
UT WOS:000527877700054
PM 32147033
DA 2026-01-16
ER

PT J
AU Xin, Y
   Dai, YY
   Zhang, XW
   Yang, HX
   Hou, AL
   Yang, K
   Li, ZY
   Li, B
   Liu, H
AF Xin, Yu
   Dai, Yan-Yan
   Zhang, Xiu-Wen
   Yang, Hao-Xin
   Hou, Ai-Lin
   Yang, Kai
   Li, Ze-Yu
   Li, Bo
   Liu, Hui
TI A brief discussion on evidence-based clinical research of traditional
   Chinese medicine
SO ANNALS OF PALLIATIVE MEDICINE
LA English
DT Article
DE Traditional Chinese medicine (TCM); evidence-based medicine (EBM);
   efficacy evaluation; clinical research
ID BREAST-CANCER; ACUPUNCTURE; WOMEN; PAIN
AB Background: The evaluation of clinical efficacy of traditional Chinese medicine (TCM) is the focus of the development of Chinese medicine, but at present there is no internationally recognized clinical efficacy evaluation system, which prevents TCM going abroad. Evidence-based medicine (EBM) research methods have achieved good results in the evaluation of TCM, but there are still some problems. How to use EBM methods in accordance with China's national conditions and develop evidence-based TCM that meets its own characteristics is the key to the current discussion.
   Methods: Search websites such as PubMed, China National Knowledge Infrastructure, Wanfang Data and VIP by computer, and search papers related to evidence-based clinical research of TCM.
   Results: A total of 15 high quality representative research papers published in internationally renowned journals were selected for example, including 4 randomized controlled trials (RCTs) related to Chinese medicine, 9 RCTs related to acupuncture, and 2 observational studies on the safety of TCM.
   Conclusions: EBM method is suitable for clinical research of TCM. There are differences between "disease" and "syndromes" in the use of TCM. Based on the further standardization of syndromes and classification of TCM, modern clinical research methods can be reasonably applied. However, the quality of clinical research related to TCM is not high, and there is a lack of research related to the safety of it, which should be paid attention to and improved in future research.
C1 [Xin, Yu; Li, Ze-Yu; Li, Bo] Capital Med Univ, Beijing Hosp Tradit Chinese Med, Beijing 100010, Peoples R China.
   [Xin, Yu; Dai, Yan-Yan; Zhang, Xiu-Wen; Yang, Hao-Xin; Hou, Ai-Lin; Yang, Kai] Beijing Univ Tradit Chinese Med, Dongzhimen Hosp, Beijing 100700, Peoples R China.
   [Li, Bo] Beijing Inst Tradit Chinese Med, Beijing 100010, Peoples R China.
   [Liu, Hui] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Informat, Beijing, Peoples R China.
C3 Capital Medical University; Beijing University of Chinese Medicine;
   Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College
RP Li, B (corresponding author), Capital Med Univ, Beijing Hosp Tradit Chinese Med, Beijing 100010, Peoples R China.; Xin, Y (corresponding author), Beijing Univ Tradit Chinese Med, Dongzhimen Hosp, Beijing 100700, Peoples R China.; Li, B (corresponding author), Beijing Inst Tradit Chinese Med, Beijing 100010, Peoples R China.; Liu, H (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Informat, Beijing, Peoples R China.
EM 2941172785@qq.com; libo@bjzhongyi.com; liuhui@pumc.edu.cn
RI Li, Bo/AAA-8968-2020; hou, ailin/GPX-6776-2022; Li, Zeyu/GXM-4336-2022
FU National Natural Science Foundation of China (NSFC) [81774146]; Chinese
   Academy of Engineering [2018-ZD-09-09]
FX This research was supported by the National Natural Science Foundation
   of China (NSFC) (No. 81774146) and Chinese Academy of Engineering (Grant
   No. 2018-ZD-09-09).
CR Bensoussan A, 1998, JAMA-J AM MED ASSOC, V280, P1585, DOI 10.1001/jama.280.18.1585
   Brinkhaus B, 2013, ANN INTERN MED, V158, P225, DOI 10.7326/0003-4819-158-4-201302190-00002
   Chen K, 2019, CHIN J INTEG TRAD WE, V39, P1159
   Enblom A, 2012, ANN ONCOL, V23, P1353, DOI 10.1093/annonc/mdr402
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hinman RS, 2014, JAMA-J AM MED ASSOC, V312, P1313, DOI 10.1001/jama.2014.12660
   Li B, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.01.62
   Li J, 2011, CHINA MED HERALD, V8, P113
   Liu H., 2011, GUIDING J TCM, V17, P15
   刘建平, 2007, [中医杂志, Journal of Traditional Chinese Medicine], V48, P26
   Liu J., 2006, EVIDENCE BASED CHINE, P5
   Liu ZS, 2017, JAMA-J AM MED ASSOC, V317, P2493, DOI 10.1001/jama.2017.7220
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Ren B., 2019, HLTH NEWSM 0709
   Song YL, 2019, CRIT CARE MED, V47, pE735, DOI 10.1097/CCM.0000000000003842
   Wang C, 2011, ANN INTERN MED, V155, P217, DOI 10.7326/0003-4819-155-4-201108160-00005
   Wang Jia-bo, 2016, Yaoxue Xuebao, V51, P1681, DOI 10.16438/j.0513-4870.2016-0812
   Wang X, 2018, CHINESE J EVIDENCE B, V10, P379
   Wu XK, 2017, JAMA-J AM MED ASSOC, V317, P2502, DOI 10.1001/jama.2017.7217
   Zhang Jun-Hua, 2018, Zhongguo Zhong Yao Za Zhi, V43, P1, DOI 10.19540/j.cnki.cjcmm.20171127.001
   [张俊华 Zhang Junhua], 2019, [中国循证医学杂志, Chinese Journal of Evidence-Based Medicine], V19, P515
   Zhang M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41118-z
   Zhao L, 2019, JAMA INTERN MED, V179, P1388, DOI 10.1001/jamainternmed.2019.2407
   Zhao L, 2017, JAMA INTERN MED, V177, P508, DOI 10.1001/jamainternmed.2016.9378
   Zheng R, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2018.09.26
NR 25
TC 7
Z9 7
U1 1
U2 29
PU AME PUBLISHING COMPANY
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2224-5820
EI 2224-5839
J9 ANN PALLIAT MED
JI Ann. Pallliat. Med.
PD DEC
PY 2021
VL 10
IS 12
BP 12937
EP 12944
DI 10.21037/apm-20-697
PG 8
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services
GA YZ0VV
UT WOS:000755202200092
PM 32819138
OA gold
DA 2026-01-16
ER

PT J
AU Jiang, YY
   Wu, L
   Wang, Y
   Tan, J
   Wang, L
   Cai, JQ
   Zhou, YH
   Sun, GW
   Song, ZH
   Gu, LB
AF Jiang, Yueyi
   Wu, Lei
   Wang, Yue
   Tan, Jing
   Wang, Li
   Cai, Jiaqin
   Zhou, Yihu
   Sun, Guowei
   Song, Zhenghuan
   Gu, Lianbing
TI Effects of Press Needling combined with general anesthesia on
   postoperative analgesia in thoracoscopic pulmonary resection for lung
   cancer: A randomized, single-blind, controlled trial
SO COMPLEMENTARY THERAPIES IN MEDICINE
LA English
DT Article
DE Analgesia; Lung surgery; Postoperative pulmonary complications; Press
   needle acupuncture; Video-assisted thoracoscopic surgery
ID ELECTRICAL ACUPOINT STIMULATION; ASSISTED THORACIC-SURGERY; ACUPUNCTURE;
   PAIN; COMPLICATIONS
AB Objectives: To investigate the effects of press needle therapy on postoperative analgesia and other relevant complications in patients undergoing thoracoscopic pulmonary resection.
   Design: randomized, single-blind, controlled trial
   Setting: Teaching hospitals affiliated with universities.
   Interventions: Eighty-six patients were randomized into: the Acu group (press-needle group) and the control group
   Main outcome measures: Pain levels 24, 48, and three months after surgery were measured using the numeric rating scale (NRS). Perioperative hemodynamics, total and effective pressing numbers of patient-controlled intravenous analgesia (PCIA), and incidence of postoperative pulmonary complications were recorded. Peripheral blood samples were collected to measure the levels of inflammatory mediators
   Results: Acu group had significantly lower NRS scores at 24 and 48 h after operation (NRS scores on movement at 24 h after surgery: Acu vs. Control, 3 (2,3) vs. 3 (3,5), Z = 3.393, P < 0.01 and NRS scores on movement at 48 h after surgery: 2 (1,3) vs. 3 (2,5), Z = 3.641, P < 0.01), lower number of PCIA attempts and effective rates (mean total pressing numbers: 4(2,8) vs. 6(3,19), Z = 1.994, P = 0.046 and mean effective pressing numbers: 3(2,8) vs. 6(3,16), Z = 2.116, P = 0.034). The Acu group had significantly reduced IL-1 (14.52 +/- 3.84 vs. 16.36 +/- 3.30, mean difference (MD): 1.85, 95% confidence interval (CI): 3.46, 0.23, P = 0.026), HIF-1 alpha (10.15 +/- 1.71 vs. 10.96 +/- 1.73, MD: 0.81, 95% CI: 1.59, 0.04, P = 0.040) and the incidence of pulmonary complications after surgery.
   Conclusion: Press needles are a non-invasive and feasible adjunctive intervention for postoperative analgesic management in patients undergoing thoracoscopic pulmonary resection.
C1 [Jiang, Yueyi; Wang, Yue; Zhou, Yihu; Gu, Lianbing] Nanjing Med Univ, Nanjing, Peoples R China.
   [Wu, Lei; Tan, Jing; Wang, Li; Song, Zhenghuan; Gu, Lianbing] Jiangsu Canc Hosp, Dept Anesthesiol, Nanjing, Peoples R China.
   [Cai, Jiaqin] Xuzhou Med Univ, Xuzhou, Peoples R China.
   [Sun, Guowei] Dalian Med Univ, Dalian, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Xuzhou Medical
   University; Dalian Medical University
RP Gu, LB (corresponding author), Nanjing Med Univ, Nanjing, Peoples R China.; Song, ZH; Gu, LB (corresponding author), Jiangsu Canc Hosp, Dept Anesthesiol, Nanjing, Peoples R China.
EM ongzhenghuan@njmu.edu.cn; 13951947684@163.com
RI Wu, Lei/PDY-3999-2025
FU Jiangsu Province Traditional Chinese Medicine Science and Technology
   Development Project [YB201986]
FX Funding This work was supported by Jiangsu Province Traditional
   Chinese Medicine Science and Technology Development Project (YB201986) .
CR Bendixen M, 2016, LANCET ONCOL, V17, P836, DOI 10.1016/S1470-2045(16)00173-X
   Calvo E, 2019, ARCH ORTHOP TRAUM SU, V139, P669, DOI 10.1007/s00402-018-3100-0
   Chen HY, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-362
   Chen JH, 2020, THORAC CANCER, V11, P928, DOI 10.1111/1759-7714.13343
   [陈永菊 Chen Yongju], 2019, [实用口腔医学杂志, Journal of Practical Stomatology], V35, P81
   Cheng D, 2007, INNOVATIONS, V2, P261, DOI 10.1097/IMI.0b013e3181662c6a
   Dai FQ, 2016, J THORAC DIS, V8, P2872, DOI 10.21037/jtd.2016.10.27
   De Conno E, 2009, ANESTHESIOLOGY, V110, P1316, DOI 10.1097/ALN.0b013e3181a10731
   de la Gala F, 2017, BRIT J ANAESTH, V119, P655, DOI 10.1093/bja/aex230
   Deng G, 2008, J THORAC CARDIOV SUR, V136, P1464, DOI 10.1016/j.jtcvs.2008.07.053
   Fan Min, 2022, China Med Pharm, V12, P113
   Feng JJ, 2020, Shanghai J Acupunct Moxibust, V39, P584
   Fiorelli A, 2012, EUR J CARDIO-THORAC, V41, P861, DOI 10.1093/ejcts/ezr108
   [傅国强 Fu Guoqiang], 2011, [针刺研究, Acupuncture Research], V36, P361
   Gao Y, 2017, Beijing J Tradit Chin Med, V36, P373
   Gavronsky S, 2012, PAIN MANAG NURS, V13, P150, DOI 10.1016/j.pmn.2009.08.001
   Han JS, 2011, PAIN, V152, pS41, DOI 10.1016/j.pain.2010.10.012
   Hieber S, 2009, EUR J ANAESTH, V26, P201, DOI 10.1097/EJA.0b013e3283212cbb
   Hsu HC, 2022, J NURS SCHOLARSHIP, V54, P411, DOI 10.1111/jnu.12751
   Huang S, 2017, J ANESTH, V31, P58, DOI 10.1007/s00540-015-2057-1
   Jin H, 2021, World Latest Med Inf, V21, P102
   Liang F, 2019, Guid J Tradit Chin Med Pharmacol, V25, P122
   Liou KT, 2021, SUPPORT CARE CANCER, V29, P427, DOI 10.1007/s00520-020-05504-y
   Liu Tongshuai, 2016, Zhongguo Zhen Jiu, V36, P1135, DOI 10.13703/j.0255-2930.2016.11.005
   MacPherson Hugh, 2010, J Evid Based Med, V3, P140, DOI 10.1111/j.1756-5391.2010.01086.x
   Park S, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0254093
   Paul-Clark MJ, 2009, AM J RESP CRIT CARE, V179, P299, DOI 10.1164/rccm.200707-1019OC
   Ren Q, 2011, Chin J Surg Integr Tradit West Med., V17, P250
   Ruengwongroj P, 2020, COMPLEMENT THER CLIN, V40, DOI 10.1016/j.ctcp.2020.101202
   Sun Y, 2008, BRIT J ANAESTH, V101, P151, DOI 10.1093/bja/aen146
   Tang JH, 2023, Tradit Chin Med Res, V36, P92, DOI DOI 10.3969/J.ISSN.1001-6910.2023.01.24
   Verhage RJJ, 2014, BRIT J ANAESTH, V112, P920, DOI 10.1093/bja/aet476
   Wang H, 2014, BRIT J ANAESTH, V112, P1075, DOI 10.1093/bja/aeu001
   Wetzel B, 2011, CLIN J PAIN, V27, P262, DOI 10.1097/AJP.0b013e3181fd516c
   White Adrian, 2004, Acupunct Med, V22, P122
   Xu Y, 2021, EVID-BASED COMPL ALT, V2021, DOI 10.1155/2021/5578104
   Yang L, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.920648
   Yao T, 2020, World Latest Med Inf, V20, P71
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
NR 39
TC 4
Z9 4
U1 3
U2 14
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0965-2299
EI 1873-6963
J9 COMPLEMENT THER MED
JI Complement. Ther. Med.
PD OCT
PY 2023
VL 77
AR 102980
DI 10.1016/j.ctim.2023.102980
EA AUG 2023
PG 8
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA S2KK1
UT WOS:001069506900001
PM 37640166
OA gold
DA 2026-01-16
ER

PT J
AU Dusek, JA
   Griffin, KH
   Finch, MD
   Rivard, RL
   Watson, D
AF Dusek, Jeffery A.
   Griffin, Kristen H.
   Finch, Michael D.
   Rivard, Rachael L.
   Watson, David
TI Cost Savings from Reducing Pain Through the Delivery of Integrative
   Medicine Program to Hospitalized Patients
SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
DE integrative medicine; outcomes research; pain; electronic health record;
   costs and cost analysis; inpatients; hospitalization
ID ACUTE POSTOPERATIVE PAIN; RANDOMIZED CONTROLLED-TRIALS; ALTERNATIVE
   MEDICINE; MASSAGE THERAPY; BACK-PAIN; COMPLEMENTARY; ACUPUNCTURE;
   METAANALYSIS; ECONOMICS; ONCOLOGY
AB Objectives: An important task facing hospitals is improving pain management without raising costs. Integrative medicine (IM), a promising nonpharmacologic pain management strategy, is yet to be examined for its cost implications in an inpatient setting. This institution has had an inpatient IM department for over a decade. The purpose was to examine the relationship between changes in patients' pain, as a result of receiving IM therapy, and total cost of care during an inpatient hospital admission. Design: In this retrospective analysis, data from an EPIC-based electronic health record (EHR) patient demographics, length of stay (LOS), and All Patient Refined Diagnosis Related Groups (APR-DRG) severity of illness measures were utilized. IM practitioners collected and entered patient-reported pain scores into the EHR. The authors regressed the demographic, change in pain, LOS, and APR-DRG variables with changes in pain on total cost for the hospital admission. To estimate cost savings to the hospital, they computed the average reduction in cost associated with reduction in pain by multiplying the coefficient for change in pain by average total cost. Setting/Location: A large, tertiary care hospital in Minneapolis, MN. Subjects: Adult inpatient admissions, 2730, during the study period where patients received IM for pain and met eligibility criteria. Intervention: IM services provided to inpatients. Outcome measures: Change in pain on an 11-point numeric rating scale before and after initial IM sessions; total costs for hospital admissions. Results: Both LOS and age were found to increase cost, as did being white, male, married, and having APR-DRG severity coded as extreme. For patients receiving IM therapies, pain was reduced by an average of 2.05 points and this pain reduction was associated with a cost savings of $898 per hospital admission. Conclusions: For patients receiving IM therapies, pain was significantly reduced and costs were lowered by about 4%.
C1 [Dusek, Jeffery A.; Griffin, Kristen H.; Rivard, Rachael L.] Allina Hlth, Penny George Inst Hlth & Healing, Integrat Hlth Res Ctr, Minneapolis, MN USA.
   [Finch, Michael D.; Watson, David] Childrens Minnesota, Childrens Minnesota Res Inst, Minneapolis, MN USA.
   [Finch, Michael D.; Watson, David] Kripalu Ctr Yoga & Hlth, 57 Interlaken Rd, Stockbridge, MA 01262 USA.
C3 Allina Health System; Children's Hospitals & Clinics of Minnesota
RP Dusek, JA (corresponding author), Kripalu Ctr Yoga & Hlth, 57 Interlaken Rd, Stockbridge, MA 01262 USA.
EM jeffd@kripalu.org
RI ; Finch, Mike/AAN-7772-2021; Rivard, Rachael/IQU-0437-2023
OI Dusek, Jeffery/0000-0001-9581-0564; Finch, Mike/0000-0001-7770-1102; 
FU National Center for Complementary and Integrative Health (NCCIH) of the
   National Institutes of Health [AT006518]
FX The authors thank Jill Johnson, PhD, and KC Nate for their edits and
   suggestions on a late draft of the article, and Mimi Lindell for her
   collaborative spirit in leading the IM inpatient team during the study
   period. This research was funded, in part, by a grant from the National
   Center for Complementary and Alternative Medicine (NCCAM) now the
   National Center for Complementary and Integrative Health (NCCIH) of the
   National Institutes of Health to JAD (AT006518). The views espoused in
   this article are solely attributable to the authors and not to NCCIH or
   NIH.
CR Andronis L, 2017, APPL HEALTH ECON HEA, V15, P173, DOI 10.1007/s40258-016-0268-8
   [Anonymous], 2012, Sentinel Event Alert, P1
   [Anonymous], 2012, ED Manag, V24, P112
   [Anonymous], 2003, ALL PAT REF DIAGN RE, P1
   [Anonymous], 2015, REV PAIN MAN STAND E
   Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E
   Baker DW, 2017, JAMA-J AM MED ASSOC, V317, P1117, DOI 10.1001/jama.2017.0935
   Boitor M, 2017, HEART LUNG, V46, P339, DOI 10.1016/j.hrtlng.2017.05.005
   Carey TS, 2015, J AM BOARD FAM MED, V28, P658, DOI 10.3122/jabfm.2015.05.140353
   Carr DB, 1999, LANCET, V353, P2051, DOI 10.1016/S0140-6736(99)03313-9
   Cassileth BR, 2004, J PAIN SYMPTOM MANAG, V28, P244, DOI 10.1016/j.jpainsymman.2003.12.016
   Clarke Tainya C, 2015, Natl Health Stat Report, P1
   Coulthard Paul, 2008, Int J Surg, V6, P57, DOI 10.1016/j.ijsu.2007.07.002
   Crawford C, 2016, PAIN MED, V17, P1353, DOI 10.1093/pm/pnw099
   Crespin DJ, 2015, PAIN MED, V16, P1195, DOI 10.1111/pme.12685
   Dadkhah K, 2011, TAYLOR SERIES ITS AP
   Dalton JA, 2000, J PAIN SYMPTOM MANAG, V19, P295, DOI 10.1016/S0885-3924(00)00105-6
   Dunwoody Colleen J, 2008, J Perianesth Nurs, V23, pS15, DOI 10.1016/j.jopan.2007.11.007
   Dusek Jeffery A, 2010, J Patient Saf, V6, P48, DOI 10.1097/PTS.0b013e3181d10ad5
   Dybvik L, 2017, PAIN RES MANAG, V2017, DOI 10.1155/2017/9431984
   Forward John Brent, 2015, Perm J, V19, P18, DOI [10.7812/tpp/14-236, 10.7812/TPP/14-236]
   Frakt AB, 2014, HEALTH SERV RES, V49, P1, DOI 10.1111/1475-6773.12105
   Frass M, 2012, OCHSNER J, V12, P45
   Furlan AD, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/953139
   Gaskin DJ, 2012, J PAIN, V13, P715, DOI 10.1016/j.jpain.2012.03.009
   Griffin KH, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012006
   Herman PM, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001046
   Herzig SJ, 2014, J HOSP MED, V9, P73, DOI 10.1002/jhm.2102
   Ishak KJ, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-439
   Johnson JR, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-486
   Johnson Jill R., 2014, Journal of the National Cancer Institute Monographs, P330, DOI 10.1093/jncimonographs/lgu030
   Joshi Girish P, 2005, Anesthesiol Clin North Am, V23, P21, DOI 10.1016/j.atc.2004.11.013
   Kanodia AK, 2010, J AM BOARD FAM MED, V23, P354, DOI 10.3122/jabfm.2010.03.080252
   Kim SY, 2012, ACUPUNCT MED, V30, P273, DOI 10.1136/acupmed-2012-010178
   Kinchen E, 2015, J HOLIST NURS, V33, P238, DOI 10.1177/0898010114563312
   Kligler B, 2011, AM J MANAG CARE, V17, P779
   Knutson L, 2013, J NURS ADMIN, V43, P101, DOI 10.1097/NNA.0b013e31827f2229
   Kong LJ, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/613279
   Lee A, 2007, CLIN J PAIN, V23, P726, DOI 10.1097/AJP.0b013e318148b95f
   Lee C, 2012, SYST REV, V1, DOI 10.1186/2046-4053-1-46
   Maxion-Bergemann S, 2006, FORSCH KOMPLEMENTMED, V13, P42, DOI 10.1159/000093313
   Mitchinson AR, 2007, ARCH SURG-CHICAGO, V142, P1158, DOI 10.1001/archsurg.142.12.1158
   Nate KC, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/394040
   Painovich J., 2012, EVID-BASED COMPL ALT, V2012
   Pavlin DJ, 2002, ANESTH ANALG, V95, P627, DOI 10.1097/00000539-200209000-00025
   Pelletier KR, 2010, EXPLORE-NY, V6, P86, DOI 10.1016/j.explore.2009.12.009
   The Joint Commission, 2017, JOINT COMMISSION PER, V37, P1
   Vaishya R, 2015, ACTA ORTHOP BELG, V81, P720
   Verhoef MJ, 2005, COMPLEMENT THER MED, V13, P206, DOI 10.1016/j.ctim.2005.05.001
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Westfall JM, 2007, JAMA-J AM MED ASSOC, V297, P403, DOI 10.1001/jama.297.4.403
   Whelan CT, 2004, ARCH INTERN MED, V164, P175, DOI 10.1001/archinte.164.2.175
   Wong RHL, 2006, ANN THORAC SURG, V81, P2031, DOI 10.1016/j.athoracsur.2005.12.064
   Woods B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172749
NR 54
TC 49
Z9 62
U1 0
U2 10
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1075-5535
EI 1557-7708
J9 J ALTERN COMPLEM MED
JI J. Altern. Complement Med.
PD JUN
PY 2018
VL 24
IS 6
BP 557
EP 563
DI 10.1089/acm.2017.0203
EA FEB 2018
PG 7
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA HK9XQ
UT WOS:000426036900001
PM 29474095
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Baker, BS
   Hoffman, CJ
AF Baker, Barbara S.
   Hoffman, Caroline J.
TI Emotional Freedom Techniques (EFT) to reduce the side effects associated
   with tamoxifen and aromatase inhibitor use in women with breast cancer:
   A service evaluation
SO EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Article
DE Breast cancer; Emotional Freedom Techniques; Adjuvant hormonal
   therapies; Side effects
ID QUALITY-OF-LIFE; ADJUVANT ENDOCRINE THERAPY; HORMONAL-THERAPY;
   MENOPAUSAL SYMPTOMS; DISCONTINUATION; ANASTROZOLE; FATIGUE; ACUPUNCTURE;
   RECURRENCE; ADHERENCE
AB Introdution: Adverse effects associated with tamoxifen and aromatase inhibitor use are the most common reason reported by women with breast cancer for discontinuing hormonal therapies. Poor compliance is associated with an increased risk of mortality and early recurrence. The primary aim of this study was to evaluate Emotional Freedom Techniques (EFT) for improving mood state, and secondarily, menopausal symptoms, fatigue, and pain experienced by women with breast cancer receiving hormonal therapies.
   Methods: Participants (n = 41) received a three-week course of EFT, consisting of one session of three hours per week, followed by use of the self-tool over the next nine weeks as required. Self-report questionnaires were used to assess mood, pain, fatigue, endocrine (menopausal) symptoms and hot flushes and night sweats, together with a hot flush diary, at baseline and at 6 and 12 weeks. Participants also completed 7-day home practice sheets for the first six weeks, a feedback form at six weeks and were invited to attend a follow-up focus group at eight weeks.
   Results: Statistically significant improvements in Total Mood Disturbance (p = 0.005; p = 0.008), and anxiety (p = 0.003; p = 0.028), depression(p = 0.006; p = 0.020) and fatigue (p = 0.008; p = 0.033) occurred at both 6 and 12 weeks, respectively, compared to baseline. In addition, mean fatigue interference and global scores, numbers of hot flushes and the hot flush problem rating score decreased at 6 and/or 12 weeks.
   Discussion/conclusions: These preliminary findings suggest that EFT may be an effective self-help tool for women with breast cancer experiencing side effects from hormonal therapies. (C) 2014 Elsevier GmbH. All rights reserved.
C1 [Baker, Barbara S.; Hoffman, Caroline J.] The Haven, London SW6 1TB, England.
RP Baker, BS (corresponding author), The Haven, Effie Rd, London SW6 1TB, England.
EM barbara.baker@thehaven.org.uk; caroline.hoffman@thehaven.org.uk
CR Ayers B, 2012, MENOPAUSE, V19, P749, DOI 10.1097/gme.0b013e31823fe835
   Ayres LR, 2014, INT J CLIN PHARM-NET, V36, P45, DOI 10.1007/s11096-013-9833-5
   Baker BS, 2013, EUR J INTEGR MED, V5, P153, DOI 10.1016/j.eujim.2012.10.002
   Barron TI, 2013, BRIT J CANCER, V109, P1513, DOI 10.1038/bjc.2013.518
   Bougea AM, 2013, EXPLORE-NY, V9, P91, DOI 10.1016/j.explore.2012.12.005
   Bowles EJA, 2012, J ONCOL PRACT, V8, pE149, DOI 10.1200/JOP.2012.000543
   Brattberg G., 2008, Integrative Medicine: A Clinician's Journal, V7, P30
   CASSILETH B R, 1985, Journal of Psychosocial Oncology, V3, P99
   Church D., 2013, Psychology, V4, P645, DOI [DOI 10.4236/PSYCH.2013.48092, 10.4236/psych.2013.48092]
   Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129
   Craig G., 2011, The EFT manual
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Cuzick J, 2010, LANCET ONCOL, V11, P1135, DOI 10.1016/S1470-2045(10)70257-6
   Davies C, 2011, LANCET, V378, P771, DOI 10.1016/S0140-6736(11)60993-8
   Davies C, 2013, LANCET, V381, P805, DOI 10.1016/S0140-6736(12)61963-1
   Desai K, 2013, SUPPORT CARE CANCER, V21, P43, DOI 10.1007/s00520-012-1490-z
   Fallowfield LJ, 1999, BREAST CANCER RES TR, V55, P189
   Feinstein D, 2012, REV GEN PSYCHOL, V16, P364, DOI 10.1037/a0028602
   Gallicchio L, 2012, CLIMACTERIC, V15, P339, DOI 10.3109/13697137.2011.620658
   Glaus A, 2006, ANN ONCOL, V17, P801, DOI 10.1093/annonc/mdl030
   Hershman DL, 2011, BREAST CANCER RES TR, V126, P529, DOI 10.1007/s10549-010-1132-4
   HUNTER MS, 1995, BRIT J CLIN PSYCHOL, V34, P589, DOI 10.1111/j.2044-8260.1995.tb01493.x
   Makubate B, 2013, BRIT J CANCER, V108, P1515, DOI 10.1038/bjc.2013.116
   Mann E, 2012, LANCET ONCOL, V13, P309, DOI 10.1016/S1470-2045(11)70364-3
   Mao JJ, 2013, PHARMACOEPIDEM DR S, V22, P256, DOI 10.1002/pds.3365
   McNair DM, 1971, EITS MANUAL PROFILE
   Mendoza TR, 1999, CANCER-AM CANCER SOC, V85, P1186, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Rostock M, 2011, GYNECOL ENDOCRINOL, V27, P844, DOI 10.3109/09513590.2010.538097
   Savard J, 2005, J CLIN ONCOL, V23, P6083, DOI 10.1200/JCO.2005.09.548
   Shi QL, 2013, J PAIN, V14, P290, DOI 10.1016/j.jpain.2012.11.010
   Sloan JA, 2001, J CLIN ONCOL, V19, P4280, DOI 10.1200/JCO.2001.19.23.4280
   Stewart A., 2013, Journal of Psychological Therapies in Primary Care, V2, P71
   Takei H, 2012, BREAST CANCER RES TR, V133, P227, DOI 10.1007/s10549-011-1943-y
NR 34
TC 15
Z9 19
U1 1
U2 30
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1876-3820
EI 1876-3839
J9 EUR J INTEGR MED
JI Eur. J. Integr. Med.
PD APR
PY 2015
VL 7
IS 2
BP 136
EP 142
DI 10.1016/j.eujim.2014.10.004
PG 7
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA CG5SA
UT WOS:000353353100007
DA 2026-01-16
ER

PT J
AU Lee, PLT
   Tam, KW
   Yeh, ML
   Wu, WW
AF Lee, Phoebe Lyssandra Tan
   Tam, Ka-Wai
   Yeh, Mei-Ling
   Wu, Wei-Wen
TI Acupoint stimulation, massage therapy and expressive writing for breast
   cancer: A systematic review and meta-analysis of randomized controlled
   trials
SO COMPLEMENTARY THERAPIES IN MEDICINE
LA English
DT Review
DE Meta-analysis; Systematic review; Breast cancer; Acupoint stimulation;
   Massage therapy; Expressive writing; Pain; Anxiety; Quality of life
ID QUALITY-OF-LIFE; SLEEP QUALITY; DOUBLE-BLIND; DUAL-CENTER; WOMEN;
   ACUPUNCTURE; FATIGUE; SURVIVORS; SYMPTOMS; DEPRESSION
AB Researches have accumulated using non-pharmacologic interventions including acupoint stimulation, massage therapy and expressive writing to manage breast cancer-related symptoms. Results from randomized controlled trials (RCTs) can get contradictory.
   Objective: A systematic review and meta-analysis were conducted to determine the effects on the quality of life, negative emotions and disease-related symptoms among women with breast cancer.
   Methods: Two independent researchers performed a structured search using data sources including MEDLINE, CINAHL, Cochrane Central Register of Controlled Trials, EMBASE, PubMed and PsychINFO from the beginning of time until the first week of January 2015. A total of 23 acupoint stimulation, massage therapy and expressive writing RCTs were included in the review.
   Results: The study showed that no single intervention could be put under the spotlight exhibiting an overall effective result on all measured outcomes; however, looking into each one in detail shows different results in specific outcomes. Among the three interventions, acupoint stimulation has a treatment effect for general pain (MD = -1.46, 95% CI = -2.38 to -0.53) and fatigue (MD = -2.22, 95% CI = -3.68 to -0.77), massage therapy has a treatment effect for anxiety (MD = -0.50, 95% CI = -0.77 to -0.24), and expressive writing has a treatment effect for quality of life (MD = 7.18, 95% Cl = 0.38 to 13.98). The measurement other outcomes showed either ineffective or equivocal results.
   Conclusion: Non-pharmacologic interventions including acupoint stimulation, massage therapy and expressive writing have an effect on a middle-age woman with breast cancer. However, because of limitations, the seemingly promising results should be interpreted with caution. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Lee, Phoebe Lyssandra Tan; Wu, Wei-Wen] Natl Taipei Univ Nursing & Hlth Sci, Sch Nursing, Coll Nursing, 365 Min Te Rd, Taipei 11219, Taiwan.
   [Tam, Ka-Wai] Taipei Med Univ, Sch Med, Dept Surg, Coll Med, Taipei, Taiwan.
   [Tam, Ka-Wai] Taipei Med Univ, Div Gen Surg, Dept Surg, Shuang Ho Hosp, 250 Wu Hsing St, Taipei 11031, Taiwan.
   [Yeh, Mei-Ling] Natl Taipei Univ Nursing & Hlth Sci, Grad Inst Integrat Tradit Chinese Med Western Nur, Coll Nursing, 365 Min Te Rd, Taipei 11219, Taiwan.
C3 National Taipei University of Nursing & Health Science (NTUNHS); Taipei
   Medical University; Taipei Medical University; Shuang Ho Hospital;
   National Taipei University of Nursing & Health Science (NTUNHS)
RP Yeh, ML (corresponding author), Natl Taipei Univ Nursing & Hlth Sci, Grad Inst Integrat Tradit Chinese Med Western Nur, Coll Nursing, 365 Min Te Rd, Taipei 11219, Taiwan.
EM phoebeelee@gmail.com; kelvintam@h.tmu.edu.tw; meiling@ntunhs.edu.tw;
   weiwen@ntunhs.edu.tw
OI Wu, Wei-Wen/0000-0002-6439-5369
CR Ahlberg K, 2004, J ADV NURS, V45, P205, DOI 10.1046/j.1365-2648.2003.02882.x
   [Anonymous], 2006, MASS THER INTR
   Bao T, 2014, CANCER-AM CANCER SOC, V120, P381, DOI 10.1002/cncr.28352
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Bardwell WA, 2008, PSYCHO-ONCOLOGY, V17, P9, DOI 10.1002/pon.1192
   Billhult A, 2007, J ALTERN COMPLEM MED, V13, P53, DOI 10.1089/acm.2006.6049
   Bokmand S, 2013, BREAST, V22, P320, DOI 10.1016/j.breast.2012.07.015
   Boon Heather S, 2007, BMC Womens Health, V7, P4, DOI 10.1186/1472-6874-7-4
   Bower JE, 2006, CANCER-AM CANCER SOC, V106, P751, DOI 10.1002/cncr.21671
   Calvert R., 2002, The history of massage: An illustrated survey from around the world
   Chen HY, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-362
   Chen SF, 2015, IRAN RED CRESCENT ME, V17, DOI 10.5812/ircmj.31277
   Craft MA, 2013, J ADV NURS, V69, P305, DOI 10.1111/j.1365-2648.2012.06008.x
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Curran SL, 2004, J BEHAV MED, V27, P425, DOI 10.1023/B:JOBM.0000047608.03692.0c
   de Moor Janet S, 2008, J Soc Integr Oncol, V6, P59
   de Souza BF, 2014, REV LAT-AM ENFERM, V22, P866, DOI 10.1590/0104-1169.3564.2491
   FELCE D, 1995, RES DEV DISABIL, V16, P51, DOI 10.1016/0891-4222(94)00028-8
   Forsythe LP, 2013, BREAST CANCER RES TR, V137, P617, DOI 10.1007/s10549-012-2335-7
   Gellaitry G, 2010, PSYCHO-ONCOLOGY, V19, P77, DOI 10.1002/pon.1532
   Goudas LC, 2005, CANCER INVEST, V23, P182, DOI 10.1081/CNV-200050482
   Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667
   Henry EA, 2010, ONCOL NURS FORUM, V37, P749, DOI 10.1188/10.ONF.749-757
   Hernandez-Reif M, 2005, INT J NEUROSCI, V115, P495, DOI 10.1080/00207450590523080
   Hernandez-Reif M, 2004, J PSYCHOSOM RES, V57, P45, DOI 10.1016/S0022-3999(03)00500-2
   Hou WH, 2010, J CLIN PSYCHIAT, V71, P894, DOI 10.4088/JCP.09r05009blu
   Jensen-Johansen MB, 2013, PSYCHO-ONCOLOGY, V22, P1492, DOI 10.1002/pon.3193
   Johnston MF, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-49
   Julian LJ, 2011, ARTHRIT CARE RES, V63, pS467, DOI 10.1002/acr.20561
   Kane HL, 2014, CA-CANCER J CLIN, V64, P377, DOI 10.3322/caac.21245
   Lepore StephenJ., 2002, WRITING CURE EXPRESS
   Li Zu-guang, 2010, Zhen Ci Yan Jiu, V35, P78
   Lim CC, 2011, INT J EVID-BASED HEA, V9, P215, DOI 10.1111/j.1744-1609.2011.00221.x
   Listing M, 2010, ARCH WOMEN MENT HLTH, V13, P165, DOI 10.1007/s00737-009-0143-9
   Listing M, 2009, PSYCHO-ONCOLOGY, V18, P1290, DOI 10.1002/pon.1508
   Liu LQ, 2009, PSYCHO-ONCOLOGY, V18, P187, DOI 10.1002/pon.1412
   Low CA, 2010, HEALTH PSYCHOL, V29, P460, DOI 10.1037/a0020153
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   McNair D.M., 1981, POMS manual, V2nd
   Mogk Carolin, 2006, Psychosoc Med, V3, pDoc06
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Mosher CE, 2012, PSYCHOL HEALTH, V27, P88, DOI 10.1080/08870446.2010.551212
   Moyer CA, 2004, PSYCHOL BULL, V130, P3, DOI 10.1037/0033-2909.130.1.3
   Newby TA, 2015, PSYCHO-ONCOLOGY, V24, P1686, DOI 10.1002/pon.3781
   Oh B, 2013, ACUPUNCT MED, V31, P264, DOI 10.1136/acupmed-2012-010309
   Otte JL, 2010, J PAIN SYMPTOM MANAG, V39, P535, DOI 10.1016/j.jpainsymman.2009.07.004
   PENNEBAKER JW, 1986, J ABNORM PSYCHOL, V95, P274, DOI 10.1037/0021-843X.95.3.274
   Sanford SD, 2013, SUPPORT CARE CANCER, V21, P959, DOI 10.1007/s00520-012-1612-7
   Satija A, 2014, INDIAN J MED RES, V139, P216
   Schulz KF, 2005, EQUINE VET J, V37, P394, DOI 10.2746/042516405774479979
   SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408
   Sharp DM, 2010, EUR J CANCER, V46, P312, DOI 10.1016/j.ejca.2009.10.006
   Smith C, 2013, ACUPUNCT MED, V31, P9, DOI 10.1136/acupmed-2012-010228
   Tao WW, 2016, J PAIN SYMPTOM MANAG, V51, P728, DOI 10.1016/j.jpainsymman.2015.11.027
   Theofilou P, 2013, EUR J PSYCHOL, V9, P150, DOI 10.5964/ejop.v9i1.337
   Travagin G, 2015, CLIN PSYCHOL REV, V36, P42, DOI 10.1016/j.cpr.2015.01.003
   van den Dolder PA, 2014, MANUAL THER, V19, P72, DOI 10.1016/j.math.2013.08.002
   Vogel BA, PATIENT ED COUNS
   Wang TF, 2008, AM J CHINESE MED, V36, P1, DOI 10.1142/S0192415X08005540
   Wilkinson S, 2008, J ADV NURS, V63, P430, DOI 10.1111/j.1365-2648.2008.04712.x
   Wu HC, 2012, SLEEP MED, V13, P906, DOI 10.1016/j.sleep.2012.04.008
   Wyatt G, 2012, ONCOL NURS FORUM, V39, P568, DOI 10.1188/12.ONF.568-577
   Zainal NZ, 2013, ASIAN PAC J CANCER P, V14, P2649, DOI 10.7314/APJCP.2013.14.4.2649
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 64
TC 28
Z9 37
U1 1
U2 53
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0965-2299
EI 1873-6963
J9 COMPLEMENT THER MED
JI Complement. Ther. Med.
PD AUG
PY 2016
VL 27
BP 87
EP 101
DI 10.1016/j.ctim.2016.06.003
PG 15
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Integrative & Complementary Medicine
GA DU7PZ
UT WOS:000382408400014
PM 27515882
DA 2026-01-16
ER

PT J
AU Venkatasalu, MR
   Murang, ZR
   Ramasamy, DTR
   Dhaliwal, JS
AF Venkatasalu, Munikumar Ramasamy
   Murang, Zaidah Rizidah
   Ramasamy, Divya Thirumalai Rajam
   Dhaliwal, Jagjit Singh
TI Oral health problems among palliative and terminally ill patients: an
   integrated systematic review
SO BMC ORAL HEALTH
LA English
DT Review
DE Oral conditions; Oral diseases; Palliative; Terminally-ill; Cancer;
   Integrated review
ID CANCER-TREATMENT; OLDER-ADULTS; CARE; MUCOSITIS; END; HOSPICE; PAIN
AB Background High incidence of treatable oral conditions has been reported among palliative patients. However, a large proportion of palliative patients lose their ability to communicate their sufferings. Therefore, it may lead to under-reporting of oral conditions among these patients. This review systematically synthesized the published evidence on the presence of oral conditions among palliative patients, the impact, management, and challenges in treating these conditions. Methods An integrative review was undertaken with defined search strategy from five databases and manual search through key journals and reference list. Studies which focused on oral conditions of palliative patients and published between years 2000 to 2017 were included. Results Xerostomia, oral candidiasis and dysphagia were the three most common oral conditions among palliative patients, followed by mucositis, orofacial pain, taste change and ulceration. We also found social and functional impact of having certain oral conditions among these patients. In terms of management, complementary therapies such as acupuncture has been used but not well explored. The lack of knowledge among healthcare providers also posed as a challenge in treating oral conditions among palliative patients. Conclusions This review is first in its kind to systematically synthesize the published evidence regarding the impact, management and challenges in managing oral conditions among palliative patients. Although there is still lack of study investigating palliative oral care among specific group of patients such as patients with dementia, geriatric or pediatric advanced cancer patients, this review has however provided baseline knowledge that may guide health care professionals in palliative settings.
C1 [Venkatasalu, Munikumar Ramasamy; Murang, Zaidah Rizidah; Ramasamy, Divya Thirumalai Rajam; Dhaliwal, Jagjit Singh] Univ Brunei Darussalam, Pengiran Anak Puteri Rashidah Saadatul Bolkiah In, Bandar Seri Begawan, Brunei.
C3 University Brunei Darussalam
RP Dhaliwal, JS (corresponding author), Univ Brunei Darussalam, Pengiran Anak Puteri Rashidah Saadatul Bolkiah In, Bandar Seri Begawan, Brunei.
EM jagjit.dhaliwal@ubd.edu.bn
OI Dhaliwal, Jagjit Singh/0000-0002-3357-388X
FU Universiti Brunei Darussalam [UBD/OAVCRI/CRGWG (014)/171001]
FX Universiti Brunei Darussalam; Grant information: UBD/OAVCRI/CRGWG
   (014)/171001.
CR Amódio J, 2014, CLINICS, V69, P706, DOI 10.6061/clinics/2014(10)10
   [Anonymous], 2017, Checklist for analytical cross sectional studies
   [Anonymous], ORAL COMPLICATIONS C
   Barker GJ, 2005, SUPPORT CARE CANCER, V13, P32, DOI 10.1007/s00520-004-0691-5
   Bogaardt H, 2015, DYSPHAGIA, V30, P145, DOI 10.1007/s00455-014-9590-1
   Chen X, 2015, J AM GERIATR SOC, V63, P375, DOI 10.1111/jgs.13240
   Chen X, 2013, J AM DENT ASSOC, V144, P1234, DOI 10.14219/jada.archive.2013.0051
   Chung J P, 2000, Spec Care Dentist, V20, P12, DOI 10.1111/j.1754-4505.2000.tb00004.x
   Davies AN, 2006, ORAL ONCOL, V42, P698, DOI 10.1016/j.oraloncology.2005.11.010
   Ezenwa MO, 2016, SUPPORT CARE CANCER, V24, P4769, DOI 10.1007/s00520-016-3328-6
   Fischer DJ, 2014, SUPPORT CARE CANCER, V22, P803, DOI 10.1007/s00520-013-2037-7
   Gligorov J, 2011, INT J RADIAT ONCOL, V80, P532, DOI 10.1016/j.ijrobp.2010.02.006
   Kvalheim SF, 2016, GERODONTOLOGY, V33, P522, DOI 10.1111/ger.12198
   Lagman R, 2017, AM J HOSP PALLIAT ME, V34, P645, DOI 10.1177/1049909116643927
   Lalla Rajesh V, 2008, Dent Clin North Am, V52, P61, DOI 10.1016/j.cden.2007.10.002
   Liberati Alessandro, 2009, PLoS Med, V6, pe1000100, DOI 10.1371/journal.pmed.1000100
   Ling IS, 2011, SUPPORT CARE CANCER, V19, P1343, DOI 10.1007/s00520-010-0955-1
   Matsuo K, 2016, SUPPORT CARE CANCER, V24, P157, DOI 10.1007/s00520-015-2759-9
   Meidell L, 2009, INT J PALLIAT NURS, V15, P12, DOI 10.12968/ijpn.2009.15.1.37947
   Mercadante S, 2015, SUPPORT CARE CANCER, V23, P3249, DOI 10.1007/s00520-015-2720-y
   Miller M, 2001, CANCER NURS, V24, P241, DOI 10.1097/00002820-200108000-00001
   Momo K, 2017, SUPPORT CARE CANCER, V25, P2997, DOI 10.1007/s00520-017-3817-2
   Mulk BS, 2014, J CLIN DIAGN RES, V8, pZE1, DOI 10.7860/JCDR/2014/8898.4427
   Nakajima N, 2017, AM J HOSP PALLIAT ME, V34, P430, DOI 10.1177/1049909116633063
   Ohno T, 2016, SUPPORT CARE CANCER, V24, P19, DOI 10.1007/s00520-015-2734-5
   Qutob AF, 2013, SUPPORT CARE CANCER, V21, P1113, DOI 10.1007/s00520-012-1633-2
   Rohr Y, 2010, INT J PALLIAT NURS, V16, P439, DOI 10.12968/ijpn.2010.16.9.78638
   Rydholm Marareta, 2002, Int J Palliat Nurs, V8, P318
   Saini R, 2009, INDIAN J PALLIAT CAR, V15, P26, DOI 10.4103/0973-1075.53508
   Tebidze N, 2017, Translational and Clinical Medicine - Georgian Medical Journal, P20, DOI [10.29088/tcm-gmj.2017.20, DOI 10.29088/TCM-GMJ.2017.20]
   Velten DB, 2017, BMC ORAL HEALTH, V17, DOI 10.1186/s12903-016-0331-8
   Whittemore R, 2005, J ADV NURS, V52, P546, DOI 10.1111/j.1365-2648.2005.03621.x
   Wilberg P, 2012, SUPPORT CARE CANCER, V20, P3115, DOI 10.1007/s00520-012-1441-8
NR 33
TC 45
Z9 62
U1 1
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1472-6831
J9 BMC ORAL HEALTH
JI BMC Oral Health
PD MAR 18
PY 2020
VL 20
IS 1
AR 79
DI 10.1186/s12903-020-01075-w
PG 11
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Dentistry, Oral Surgery & Medicine
GA KW9DT
UT WOS:000521484200002
PM 32188452
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Loy, MH
   Prisco, L
   Parikh, C
AF Loy, Michelle H.
   Prisco, Lauren
   Parikh, Chiti
TI Implementation of Virtual Integrative Oncology Shared Medical
   Appointment Series (VIOSMAS) Within Mixed Diagnosis Population
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE integrative oncology (IO); shared medical appointment (SMA); group
   medical visits (GMV); nutrition; culinary medicine; acupuncture; herbs;
   botanicals; vitamins; supplements; yoga; qi gong; mind-body;
   complementary integrative medicine; telehealth; virtual integrative
   oncology shared medical appointment series (VIOSMAS)
ID GROUP PRENATAL-CARE; SOCIAL NETWORKS; IMPROVING-ACCESS; GROUP VISITS;
   MORTALITY; MODEL; COMPLEMENTARY; BURNOUT; ADULTS; YOUNG
AB Background:Integrative oncology [IO] is sought-after by patients, endorsed by clinical guidelines, and valued within National Cancer Institute Centers. Shared Medical Appointments [SMA] leverage health education and social connection to deliver enhanced patient experience, population health, cost-reduction, and clinician well-being. Integrative Oncology Shared Medical Appointments increase access to integrative medicine but delivering these services via telehealth have not been evaluated.Objective:We created, and pilot tested a Virtual Integrative Oncology Shared Medical Appointment Series (VIOSMAS) to assess its feasibility, acceptability, and efficacy at an urban academic teaching hospital.Methods:The 7-session hour-long Living Well with and after Cancer series included didactics, multi-disciplinary experiential sessions, and group discussion. Topics included (1) Introduction, (2) Herbs/Botanicals/Fungi, (3) Mindful Movement, (4) Acupuncture, (5) Narratives and Nature, (6) Diet and Culinary Medicine, and (7) Vitamins/Supplements. Virtual visits via telehealth were offered to enhance patient participation during the pandemic. Outcome measures included recruitment, retention, pre/post-series patient survey and qualitative clinician feedback.Results:Between 9/2021 and 4/2023, 72 unique patients were recruited to 5 cohorts and had a total of 332 VIOSMAS visits. A total of 50 patients (69%) attended 4 or more of the 7-session series; 60 (83% were women); patients ranged in age from 28 to 93 years (median 66); 36 (50%) lived outside the city center; the most common cancer diagnoses were breast, lymphoma, and lung cancer. Patients were from diverse demographics. Pre-program, patients reported desiring assistance in addressing diverse symptoms including fatigue, insomnia, pain, gastrointestinal (GI) symptoms, anxiety, and depression. Post-series, patients reported that the VIOSMAS addressed their goals and symptoms; they also reported incorporating recommended lifestyle changes in diet, exercise, sleep, and stress management; they were satisfied with the number of sessions and telehealth format. The participating clinicians reported high levels of satisfaction with VIOSMAS. Revenue to the institution from VIOSMAS exceeded the revenue potential of equivalent time spent for individual visits while supporting extended physician-patient contact.Conclusion:VIOSMAS is feasible for patients and clinicians, addresses patients' symptoms and questions about lifestyle and complementary therapies, and generates more revenue than individual visits. Larger implementation trials with appropriate comparison groups are recommended.
C1 [Loy, Michelle H.; Prisco, Lauren; Parikh, Chiti] Cornell Univ, New York, NY USA.
   [Loy, Michelle H.; Parikh, Chiti] Weill Cornell Med New York Presbyterian Hosp, New York, NY USA.
   [Loy, Michelle H.] Cornell Univ, Dept Med, Div Integrat Med, 436 East 69th St, New York, NY 10065 USA.
   [Loy, Michelle H.] Cornell Univ, Weill Cornell Med, Dept Pediat, 436 East 69th St, New York, NY 10065 USA.
C3 Cornell University; Cornell University; Weill Cornell Medicine;
   NewYork-Presbyterian Hospital; Cornell University; Cornell University;
   Weill Cornell Medicine
RP Loy, MH (corresponding author), Cornell Univ, Dept Med, Div Integrat Med, 436 East 69th St, New York, NY 10065 USA.; Loy, MH (corresponding author), Cornell Univ, Weill Cornell Med, Dept Pediat, 436 East 69th St, New York, NY 10065 USA.
EM mhloy@med.cornell.edu
RI Loy, Michelle/HII-2996-2022
OI Loy, Michelle/0000-0002-9935-6888
CR Abbott RB, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep195
   Bari S, 2021, INTEGR CANCER THER, V20, DOI 10.1177/15347354211051622
   BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674
   Bodenheimer T, 2014, ANN FAM MED, V12, P573, DOI 10.1370/afm.1713
   Cao EL, 2021, J MED HUMANIT, V42, P627, DOI 10.1007/s10912-021-09701-6
   Carlsson SV, 2021, UROL PRACT, V8, P541, DOI [10.1097/UPJ.0000000000000247, 10.1097/upj.0000000000000247]
   Charlot M, 2019, J ALTERN COMPLEM MED, V25, P762, DOI 10.1089/acm.2019.0016
   Charon R, 2001, JAMA-J AM MED ASSOC, V286, P1897, DOI 10.1001/jama.286.15.1897
   Comander A, 2021, AM J LIFESTYLE MED, V15, P242, DOI 10.1177/1559827620986066
   Cornelio-Flores O, 2018, J ALTERN COMPLEM MED, V24, P125, DOI 10.1089/acm.2017.0132
   Culhane-Pera KA, 2005, J HEALTH CARE POOR U, V16, P315, DOI 10.1353/hpu.2005.0030
   Desai K, 2021, J ALTERN COMPLEM MED, V27, P1011, DOI 10.1089/acm.2021.0102
   Dragomanovich Hannah M, 2021, Glob Adv Health Med, V10, p21649561211044693, DOI [10.1177/21649561211044693, 10.1177/21649561211044693]
   Earnshaw VA, 2016, WOMEN HEALTH ISS, V26, P110, DOI 10.1016/j.whi.2015.09.011
   EGOLF B, 1992, AM J PUBLIC HEALTH, V82, P1089, DOI 10.2105/AJPH.82.8.1089
   Gareau S, 2016, MATERN CHILD HLTH J, V20, P1384, DOI 10.1007/s10995-016-1935-y
   Gonzalez A, 2022, PHILOS T R SOC B, V377, DOI 10.1098/rstb.2021.0059
   Gowda D, 2019, PERSPECT MED EDUC, V8, P52, DOI 10.1007/s40037-019-0497-2
   Haun JN, 2020, EXPLORE-NY, V16, P85, DOI 10.1016/j.explore.2019.08.001
   Heath C, 2022, FRONT NUTR, V9, DOI 10.3389/fnut.2022.795387
   Hinzey A, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0700-x
   Kakareka R, 2019, J ALTERN COMPLEM MED, V25, P709, DOI 10.1089/acm.2019.0091
   Kirsh SR, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2064-z
   Kjaer K, 2021, NEJM CATAL INNOV CAR, V2, DOI 10.1056/CAT.21.0275
   Kligler Benjamin, 2015, Glob Adv Health Med, V4, P33, DOI [10.7453/gahmj.2015.064, 10.7453/gahmj.2015.064]
   Kroenke CH, 2017, PSYCHO-ONCOLOGY, V26, P544, DOI 10.1002/pon.4059
   Kroenke CH, 2013, BREAST CANCER RES TR, V137, P261, DOI 10.1007/s10549-012-2253-8
   Latte-Naor S, 2019, J ONCOL PRACT, V15, P7, DOI 10.1200/JOP.18.00554
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Mahajan UV, 2022, NEUROSURG FOCUS, V52, DOI 10.3171/2022.4.FOCUS21764
   Mao JJ, 2007, FAM MED, V39, P16
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2022, CA-CANCER J CLIN, V72, P144, DOI 10.3322/caac.21706
   Mao JJ, 2011, J CANCER SURVIV, V5, P8, DOI 10.1007/s11764-010-0153-7
   Mascaro JS, 2022, INTEGR MED REP, V1, P66, DOI 10.1089/imr.2021.0004
   Mirsky JB, 2021, AM J HEALTH PROMOT, V35, P904, DOI 10.1177/08901171211012543
   Nahin Richard L, 2016, NCHS Data Brief, P1
   NCI N. NCI Telehealth Research Centers of Excellence (TRACE), 2023, About us
   Osborn R, 2016, HEALTH AFFAIR, V35, P2327, DOI 10.1377/hlthaff.2016.1088
   Panagioti M, 2017, JAMA INTERN MED, V177, P195, DOI 10.1001/jamainternmed.2016.7674
   Pantell M, 2013, AM J PUBLIC HEALTH, V103, P2056, DOI 10.2105/AJPH.2013.301261
   Patel KB, 2023, JAMA NETW OPEN, V6, DOI 10.1001/jamanetworkopen.2022.50211
   Ramdas K, 2020, LANCET DIGIT HEALTH, V2, pE288, DOI 10.1016/S2589-7500(20)30101-1
   Reed SC, 2015, J ONCOL PRACT, V11, P6, DOI 10.1200/JOP.2014.001411
   Remein CD, 2022, ADV MED EDUC PRACT, V13, P265, DOI 10.2147/AMEP.S350246
   Roth I, 2020, J ALTERN COMPLEM MED, V26, P261, DOI 10.1089/acm.2019.0425
   Rowley RA, 2016, MATERN CHILD HLTH J, V20, P1, DOI 10.1007/s10995-015-1802-2
   Shanafelt TD, 2009, ARCH INTERN MED, V169, P990, DOI 10.1001/archinternmed.2009.70
   Shanahan S, 2022, PERSPECT BIOL MED, V65, P143, DOI 10.1353/pbm.2022.0009
   Sidorsky T, 2010, ARCH DERMATOL, V146, P374, DOI 10.1001/archdermatol.2010.32
   SPIEGEL D, 1989, LANCET, V2, P888
   Thompson-Lastad Ariana, 2020, Glob Adv Health Med, V9, p2164956120973979, DOI [10.1177/2164956120973979, 10.1177/2164956120973979]
   Thompson-Lastad A, 2019, J ALTERN COMPLEM MED, V25, P733, DOI 10.1089/acm.2019.0073
   Thompson-Lastad A, 2019, HEALTH EQUITY, V3, P1, DOI 10.1089/heq.2018.0081
   Thompson-Lastad A, 2018, QUAL HEALTH RES, V28, P1065, DOI 10.1177/1049732318759528
   Wan W, 2018, DIABETES, V67, DOI 10.2337/db18-8-OR
   Witt Claudia M., 2017, Journal of the National Cancer Institute Monographs, P3, DOI [10.1093/jncimonographs/lgx012, 10.1093/jncimonographs/lgx012]
   Wolchok J., 2023, Cancer Lett, V49, P5
   Yaguda S, 2019, J ALTERN COMPLEM MED, V25, P675, DOI 10.1089/acm.2019.0071
   Yun Hyeongjun, 2017, Journal of the National Cancer Institute Monographs, P29, DOI [10.1093/jncimonographs/lgx004, 10.1093/jncimonographs/lgx004]
NR 60
TC 6
Z9 6
U1 2
U2 19
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PY 2024
VL 23
AR 15347354231223969
DI 10.1177/15347354231223969
PG 12
WC Oncology; Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Integrative & Complementary Medicine
GA FL0U3
UT WOS:001145832500001
PM 38243739
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Roth, I
   Highfield, L
   Cuccaro, P
   Wells, R
   Misra, S
   Engebretson, J
AF Roth, Isabel
   Highfield, Linda
   Cuccaro, Paula
   Wells, Rebecca
   Misra, Sanghamitra
   Engebretson, Joan
TI Employing Evidence in Evaluating Complementary Therapies: Findings from
   an Ethnography of Integrative Pain Management at a Large Urban Pediatric
   Hospital
SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
DE complementary therapies; integrative medicine; pain management;
   ethnography; qualitative methods; pediatric
ID ALTERNATIVE MEDICINE; UNITED-STATES; CHILDREN; ACUPUNCTURE; CAM;
   PRACTITIONERS; CHALLENGES; EXPERIENCE; KNOWLEDGE; CANCER
AB Background: Complementary and Integrative Medicine (CIM) shows positive clinical benefit with minimal side effects, yet, challenges to effective integration of CIM providers in biomedical health care settings remain. This study aimed to better understand the role evidence played in the process of integration of complementary therapies into a large urban pediatric hospital from the perspective of patients, caregivers, providers, and administrators through applied medical ethnography. Methods: An ethnography was conducted over the course of 6 months in a large urban pediatric hospital in the Southern United States. At the time, the hospital was piloting an integrative medicine (IM) pain consult service. Purposive sampling was used to select providers, patients, administrators, and caregivers to follow as they engaged with both the preexisting pain service and pilot IM pain services. Field observation and interviews were conducted with 34 participants. Thematic content analysis was used to analyze field notes, interview transcripts, and documents collected. Findings: Analysis of the data revealed five themes regarding the role of evidence in the process of integration: Anecdotal Evidence and Personal Experience Effecting CIM Use, Open to Trying Whatever Works, Resistance to the Unfamiliar, Patients and Parents Trusting Doctors as Experts, and Importance of Scientific Evidence to Biomedicine. All themes address the role of evidence in relationship to acceptance of complementary therapies and correspond with three thought processes: critical thinking, relying on others for evidence, and reactionary thinking. Conclusion: Both scientific and anecdotal evidence informed CIM use in this context. Biomedical environments seeking to integrate CIM into pain treatment regimens will need to engage all relevant stakeholders in building education, clinical training, and research programs that are critically informed about the context and evidence for CIM.
C1 [Roth, Isabel] Univ N Carolina, Sch Med, Dept Phys Med & Rehabil, Program Integrat Med, Wing D,Rm 186, Chapel Hill, NC 27514 USA.
   [Highfield, Linda; Wells, Rebecca] Univ Texas Hlth Sci Ctr Sch Publ Hlth UTHlth, Dept Management Policy & Community Hlth, Houston, TX USA.
   [Cuccaro, Paula] Univ Texas Hlth Sci Ctr Sch Publ Hlth UTHlth, Dept Hlth Promot & Behav Sci, Houston, TX USA.
   [Misra, Sanghamitra] Baylor Coll Med, Dept Acad Gen Pediat, Houston, TX 77030 USA.
   [Engebretson, Joan] Univ Texas Hlth Sci Ctr Cizik Sch Nursing UTHlth, Dept Family Hlth, Houston, TX USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine; Baylor College of
   Medicine
RP Roth, I (corresponding author), Univ N Carolina, Sch Med, Dept Phys Med & Rehabil, Program Integrat Med, Wing D,Rm 186, Chapel Hill, NC 27514 USA.
EM iroth@email.unc.edu
RI Highfield, Linda/HKN-4504-2023; Cuccaro, Paula/LYP-2956-2024
OI Highfield, Linda/0000-0001-6958-9333; Misra,
   Sanghamitra/0000-0001-5192-5095; Roth, Isabel/0000-0002-4502-3041; 
FU University of Texas Health Science Center at Houston School of Public
   Health (UTHealth); National Center for Complementary and Integrative
   Health [5T32AT00378-12]
FX This research was supported by a Dissertation Award from the University
   of Texas Health Science Center at Houston School of Public Health
   (UTHealth). I.R.'s contribution to this article was partially supported
   by a T32 Fellowship from the National Center for Complementary and
   Integrative Health (5T32AT00378-12).
CR Abrams DI, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-146
   Anheyer D, 2018, COMPLEMENT THER MED, V41, P186, DOI 10.1016/j.ctim.2018.09.025
   [Anonymous], 2002, Natl. Health Stat. Rep
   Black Lindsey I, 2015, Natl Health Stat Report, P1
   Bradt J, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006911, 10.1002/14651858.CD006911.pub4, 10.1002/14651858.CD006911.pub2]
   Brooks MR, 2016, PEDIATR ANESTH, V26, P794, DOI 10.1111/pan.12948
   Coulter I, 2008, HEALTH SOCIOL REV, V17, P368, DOI 10.5172/hesr.451.17.4.368
   Crabtree BF, 1992, DOING QUALITATIVE RE, V3, P3
   Dusek Jeffery A, 2010, J Patient Saf, V6, P48, DOI 10.1097/PTS.0b013e3181d10ad5
   Eckert M, 2018, CHILDREN-BASEL, V5, DOI 10.3390/children5090122
   Esparham A, 2018, CHILDREN-BASEL, V5, DOI 10.3390/children5080111
   Frank L., JAMA, V312, P1513
   Frenkel M, 2007, J ALTERN COMPLEM MED, V13, P387, DOI 10.1089/acm.2006.6293
   Friedrichsdorf Stefan J, 2015, Hosp Pediatr, V5, P18, DOI [10.1542/hpeds.2014-0084, 10.1542/hpeds.2014-0084]
   Gagnon EM, 2003, PSYCHO-ONCOLOGY, V12, P442, DOI 10.1002/pon.655
   Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117
   Gardiner P, 2017, CONTEMP CLIN TRIALS, V54, P25, DOI 10.1016/j.cct.2016.12.013
   Gilchrist Julie, 2012, Morbidity and Mortality Weekly Report, V61, P270
   Golianu B, 2014, CHILDREN-BASEL, V1, P134, DOI 10.3390/children1020134
   Gray B, 2014, J ALTERN COMPLEM MED, V20, P342, DOI 10.1089/acm.2013.0167
   Groenewald CB, 2017, ACAD PEDIATR, V17, P785, DOI 10.1016/j.acap.2017.02.008
   Hechler T, 2015, PEDIATRICS, V136, P115, DOI 10.1542/peds.2014-3319
   Highfield ES, 2005, J ALTERN COMPLEM MED, V11, P373, DOI 10.1089/acm.2005.11.373
   Hollenberg D, 2010, HEALTH SOCIOL REV, V19, P34, DOI 10.5172/hesr.2010.19.1.034
   Johnny S., 2013, CODING MANUAL QUALIT, V2nd
   Joseph-Williams N, 2014, PATIENT EDUC COUNS, V94, P291, DOI 10.1016/j.pec.2013.10.031
   Kemper KJ, 2008, PEDIATRICS, V122, P1374, DOI 10.1542/peds.2008-2173
   Kemper KJ, 2004, AMBUL PEDIATR, V4, P482, DOI 10.1367/A04-050R.1
   Knipper E, 2017, PEDIATR ANESTH, V27, P1070, DOI 10.1111/pan.13225
   Kuttner L, 2012, PEDIATR ANESTH, V22, P573, DOI 10.1111/j.1460-9592.2012.03860.x
   Mandel Susan E, 2014, Hosp Top, V92, P28, DOI 10.1080/00185868.2014.906830
   McClafferty H, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-1961
   Mittring N, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/316950
   NCCAM Clearinghouse, COMPL ALT INT HLTH W
   Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487
   Pioneer Support Services I, PION TRANSCR SERV AL
   Robinson N., EUR J INTEGR MED, V1, P43
   Roth I., 2017, ETHNOGRAPHY INTEGRAT
   Salkeld EJ, 2014, MED ANTHROPOL Q, V28, P44, DOI 10.1111/maq.12074
   Schensul J., 1999, Ethnographer's Toolkit 3. Essential Ethnographic Methods: Audiovisual Techniques, Focused Group Interviews
   Sharf BF, 2012, PATIENT EDUC COUNS, V89, P434, DOI 10.1016/j.pec.2012.03.006
   Shuval JT, 2012, QUAL HEALTH RES, V22, P1317, DOI 10.1177/1049732312450326
   Smithson J, 2010, J HEALTH SERV RES PO, V15, P54, DOI 10.1258/jhsrp.2009.009104
   Spradley J.P., 2016, The ethnographic interview
   Taylor SL, 2018, MED ACUPUNCT, V30, P252, DOI 10.1089/acu.2018.1286
   Thompson MS, 2013, QUANT METH EDUC BEHA, P163
   Thrane S, 2013, J PEDIATR ONCOL NURS, V30, P320, DOI 10.1177/1043454213511538
   Uman LS, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005179.pub3
   Vohra S, 2005, BMC HEALTH SERV RES, V5, DOI 10.1186/1472-6963-5-78
   Weeks John, 2015, Integr Med (Encinitas), V14, P14
   Weeks J, 2016, J ALTERN COMPLEM MED, V22, P947, DOI 10.1089/acm.2016.29016.jjw
   Witt CM, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/652546
   Wolcott H.F., 2008, Ethnography: A way of seeing, V2nd
   Yang CS, 2015, PEDIATR RES, V78, P112, DOI 10.1038/pr.2015.91
   Yinger OS, 2015, J MUSIC THER, V52, P1, DOI 10.1093/jmt/thv004
NR 55
TC 11
Z9 13
U1 1
U2 7
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1075-5535
EI 1557-7708
J9 J ALTERN COMPLEM MED
JI J. Altern. Complement Med.
PD MAR
PY 2019
VL 25
SU 1
BP S95
EP S105
DI 10.1089/acm.2018.0369
PG 11
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Integrative & Complementary Medicine
GA HP4RP
UT WOS:000461664000012
PM 30870018
OA Green Published, Bronze
DA 2026-01-16
ER

PT J
AU Mate, A
   Molnar, I
   Szoke, H
   Hegyi, G
AF Mate, Agnes
   Molnar, Istvan
   Szoke, Henrik
   Hegyi, Gabriella
TI Newer application of Oncothermia to non-malignant diseases such as
   Dupuytren's contracture of the hand and chronic lower back pain lasting
   more than 4 weeks
SO ACUPUNCTURE & ELECTRO-THERAPEUTICS RESEARCH
LA English
DT Article
DE Physiotherapy; Oncothermia; Dupuytren's contracture; Non-specific low
   back pain
ID CANCER
AB Oncothermia (OTM) is based on electromagnetic interactions with the living matter. Its nano-targeting approach establishes a new paradigm. OTM could be applied not only to treat malignancies but it is feasible to apply for other diseases too. OTH is well proven method from the laboratory level to the clinical applications, promoting the natural processes, re-establishing of the synchronization between the cells. This approach allows therapy of some nonmalignant diseases too. Our objective is to use OTM for the irregularities of tissue-growth and for pain syndromes as well. OTM uses precisely tuned radiofrequency (RF) current flowing through the treated part of the body. We made extensive study, proving in details the applicability of the OTM for Dupuytren's contracture and chronic low back pain, in conjunction with permanent acupuncture method, a modified process of traditional Chinese Medicine (TCM). The synergy of the ancient and the state-of-art medical knowledges is the basic method of the present research. Our results with application of OTM for chronic low back pain and Dupuytren's contracture shows definite improvements of the patients involved in the study. We measured the success with the Visual Analog Scale (VAS), with anecdotic quality of life (QoL), and the shortening of the of-work period due to the disease. We measured that VAS decreased significantly, the hand contracture became less rigid and less contracted. The QoL of patients improved and their complaints which blocked their regular activity has significantly reduced. OTM method was safe & no adverse effects were observed. Recognition of the distortions in the healthy tissue have some common principles and possibilities in TCM and OTM: both the methods recognize the loss of complexity of the living organization. Data of our recent study verified the relevant end-points of our present study: the safety, the quality of life (QoL), the prolonged painless status of the patient.
C1 [Mate, Agnes; Molnar, Istvan] Pecs Univ, Hlth Sci Fac, Pecs, Hungary.
   [Szoke, Henrik; Hegyi, Gabriella] Pecs Univ, Hlth Sci Dept, CAM Div, Pecs, Hungary.
C3 University of Pecs; University of Pecs
RP Hegyi, G (corresponding author), Petofi U 79, H-1196 Budapest, Hungary.
EM drhegyi@hu.inter.net
RI Szoke, Henrik/JXN-8803-2024; Dr. Hegyi, Gabriella/AAD-3441-2022
CR Andocs G, 2009, ELECTROMAGN BIOL MED, V28, P148, DOI 10.1080/15368370902724633
   Andocs G, 2009, STRAHLENTHER ONKOL, V185, P120, DOI 10.1007/s00066-009-1903-1
   Ballerini M, 2013, C PAPERS MED, V2013
   Beachy SH, 2011, INT J HYPERTHER, V27, P344, DOI 10.3109/02656736.2011.562873
   Hegyi G, 2013, C PAPERS MED, V2013
   Hegyi G, 2012, J ALTERN COMPLEM MED, V18, P1
   Hegyi G., 2013, 32 ANN C ICHS 2013 P
   Hegyi G., 2012, Open Journal of Biophysics, V02, P60, DOI DOI 10.4236/OJBIPHY.2012.23009
   Hegyi G, 2013, ACUPUNCTURE ELECTRO, V38, P161, DOI 10.3727/036012913X13831832269243
   Kanodia AK, 2010, J AM BOARD FAM MED, V23, P354, DOI 10.3122/jabfm.2010.03.080252
   Szasz A., 2013, ELECTROMAGNETIC EFFE
   Szasz A., 2013, Therm. Med, V29, P1, DOI DOI 10.3191/THERMALMED.29.1
   Szasz A., 2013, HYPERTHERMIA
   Szasz A, 2011, ONCOTHERMIA: PRINCIPLES AND PRACTICES, P1, DOI 10.1007/978-90-481-9498-8
   Szasz O., 2014, J Cancer Sci Ther, V6, P117
   Yang KL, 2016, ONCOTARGET, V7, P84082, DOI 10.18632/oncotarget.11444
   Zais O, 2013, C PAPERS MED, V2013
NR 17
TC 1
Z9 1
U1 0
U2 12
PU COGNIZANT COMMUNICATION CORP
PI PUTNAM VALLEY
PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA
SN 0360-1293
EI 2167-9010
J9 ACUPUNCTURE ELECTRO
JI Acupunct. Electro-Ther. Res.
PY 2017
VL 42
IS 2
BP 121
EP 133
DI 10.3727/036012917X15004036818267
PG 13
WC Integrative & Complementary Medicine; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine; Neurosciences & Neurology
GA FD9WH
UT WOS:000407872300004
DA 2026-01-16
ER

PT J
AU Dyer, NL
   Surdam, J
   Srinivasan, R
   Agarwal, A
   Dusek, JA
AF Dyer, Natalie L.
   Surdam, Jessica
   Srinivasan, Roshini
   Agarwal, Ankita
   Dusek, Jeffery A.
TI The Impact of Individualized Complementary and Integrative Health
   Interventions Provided in Clinical Settings on Quality of Life: A
   Systematic Review of Practice-Based Research
SO JOURNAL OF INTEGRATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Review
DE systematic review; complementary and integrative health; integrative
   medicine; practice-based research; quality of life; well-being; cancer;
   pain
ID PATIENT-REPORTED OUTCOMES; RANDOMIZED CONTROLLED-TRIALS; MEDICAL-CENTER;
   CANCER CARE; PAIN; ACUPUNCTURE; RECOMMENDATIONS; IMPLEMENTATION;
   VETERANS; SCIENCE
AB Background: The goal of this systematic review was to evaluate the impact of individualized complementary and integrative health (CIH) interventions on quality-of-life outcomes as collected in CIH outpatient clinics.Methods: A systematic review was conducted using PubMed, OVID, Cochrane, Web of Science, Scopus, and Embase through December 2020. Inclusion criteria were as follows: individualized CIH treatment, longitudinal effectiveness design, patient-reported outcomes, outpatient CIH clinic setting, participants aged >= 18 years, sample size of >= 25, and English full text. The study was listed in the PROSPERO database (CRD42020159193), and PRISMA guidelines were used. The variables extracted from articles focused on study details/demographics, CIH intervention characteristics, and outcome characteristics.Results: The literature search yielded 3316 records with 264 assessed for full-text review. Of these, 19 studies (including similar to 14,002 patients) were specific to quality of life (or well-being) as a main outcome. Most studies included were multidisciplinary studies (n = 12), followed by acupuncture (n = 4), chiropractic (n = 3), and massage or reflexology (n = 1). The short-form group of questionnaires (SF-12, SF-36, SF-8) were the most used quality-of-life/well-being questionnaire, comprising 37% of studies (n = 7), and the Patient Reported Outcomes Measurement Information System (PROMIS) measures comprised 21% (n = 4). Both questionnaires are normed to U.S. population, allowing for comparison. The average improvement across the comparable SF and PROMIS measures for Physical Health was 6% (range 2%-20%) and for Mental Health was 5% (range 1%-11%), demonstrating clinical significance. Improvements in the observational studies are comparable to improvements reported from randomized controlled trials.Conclusions: Results from this systematic review indicate that CIH therapies largely have positive effects on health-related quality of life and well-being for various patient populations seen in CIH clinical settings. Direct comparisons across studies were limited due to the variability in study design and incomplete reporting in some of the publications. Suggestions for improving the design and reporting for future practice-based research are provided.
C1 [Dyer, Natalie L.; Surdam, Jessica; Dusek, Jeffery A.] Univ Hosp Cleveland, Connor Whole Hlth, Cleveland, OH 44106 USA.
   [Srinivasan, Roshini] Duke Univ, Sch Med, Durham, NC USA.
   [Agarwal, Ankita] Case Western Reserve Univ, Dept Nutr, Cleveland, OH USA.
   [Dusek, Jeffery A.] Case Western Reserve Univ, Dept Family Med & Community Hlth, Cleveland, OH USA.
   [Dusek, Jeffery A.] Univ Hosp Cleveland, Connor Whole Hlth, 11000 Euclid Ave, Cleveland, OH 44106 USA.
C3 University Hospitals of Cleveland; Duke University; University System of
   Ohio; Case Western Reserve University; University System of Ohio; Case
   Western Reserve University; University Hospitals of Cleveland
RP Dusek, JA (corresponding author), Univ Hosp Cleveland, Connor Whole Hlth, 11000 Euclid Ave, Cleveland, OH 44106 USA.
EM jeffery.dusek@uhhospitals.org
OI Srinivasan, Roshini/0000-0003-1967-4630; Dusek,
   Jeffery/0000-0001-9581-0564; Dyer, Natalie/0000-0002-9592-194X
CR Abrams DI, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-146
   Ananth S., 2010, COMPLEMENTARY ALTERN
   Askew RL, 2016, J CLIN EPIDEMIOL, V73, P103, DOI 10.1016/j.jclinepi.2015.08.035
   Barnes PM., 2008, NATL HLTH STAT REPOR, DOI DOI 10.1037/E623942009-001
   Basch E, 2016, J CLIN ONCOL, V34, P557, DOI 10.1200/JCO.2015.63.0830
   Bauereiss N, 2018, PSYCHO-ONCOLOGY, V27, P2531, DOI 10.1002/pon.4829
   Beidelschies M, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.14017
   Brazier A, 2008, INTEGR CANCER THER, V7, P5, DOI 10.1177/1534735407313395
   Clark D, 2021, J ALTERN COMPLEM MED, V27, pS7, DOI 10.1089/acm.2020.0446
   Clarke TC, 2018, J ALTERN COMPLEM MED, V24, P139, DOI 10.1089/acm.2016.0182
   Clarke Tainya C, 2015, Natl Health Stat Report, P1
   Coens C, 2020, LANCET ONCOL, V21, pE83, DOI 10.1016/S1470-2045(19)30790-9
   Crocker RL, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/8595409
   den Hollander D, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000914
   Dusek JA, 2018, COMPLEMENT THER MED, V37, P43, DOI 10.1016/j.ctim.2018.01.012
   Dyer NL, 2022, PAIN MED, V23, P189, DOI 10.1093/pm/pnab151
   Elwy AR, 2020, MED CARE, V58, pS125, DOI 10.1097/MLR.0000000000001357
   Elwy AR, 2014, MED CARE, V52, pS70, DOI 10.1097/MLR.0000000000000228
   Fayers PM, 2015, QUALITY LIFE ASSESSM
   Feng R, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0382-1
   Ferguson CJ, 2009, PROF PSYCHOL-RES PR, V40, P532, DOI 10.1037/a0015808
   Frenkel M, 2010, INTEGR CANCER THER, V9, P276, DOI 10.1177/1534735410378663
   Furlan AD, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/953139
   Gedin F, 2019, J BODYW MOV THER, V23, P241, DOI 10.1016/j.jbmt.2018.02.012
   GREEN SB, 1991, MULTIVAR BEHAV RES, V26, P499, DOI 10.1207/s15327906mbr2603_7
   Greeson JM, 2008, J ALTERN COMPLEM MED, V14, P763, DOI 10.1089/acm.2008.0114
   Haraldstad K, 2019, QUAL LIFE RES, V28, P2641, DOI 10.1007/s11136-019-02214-9
   Harrington J E, 2012, Complement Ther Clin Pract, V18, P10, DOI 10.1016/j.ctcp.2011.05.002
   Harris Philip, 2010, Complement Ther Clin Pract, V16, P31, DOI 10.1016/j.ctcp.2009.06.005
   Haslam A, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.0363
   Hays RD, 2001, ANN MED, V33, P350, DOI 10.3109/07853890109002089
   Hays RD, 2019, SPINE, V44, P647, DOI 10.1097/BRS.0000000000002902
   Herman PM, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-132
   Hopton A, 2010, PAIN PRACT, V10, P94, DOI 10.1111/j.1533-2500.2009.00337.x
   Hu CQ, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/1720239
   Kotronoulas G, 2014, J CLIN ONCOL, V32, P1480, DOI 10.1200/JCO.2013.53.5948
   Kroenke K, 2019, J CLIN EPIDEMIOL, V115, P116, DOI 10.1016/j.jclinepi.2019.06.018
   KUYKEN W, 1995, SOC SCI MED, V41, P1403, DOI 10.1016/0277-9536(95)00112-k
   Lakens D, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00863
   Leather DA, 2020, ADV THER, V37, P977, DOI 10.1007/s12325-019-01192-1
   Lin WF, 2019, CANCER MANAG RES, V11, P6663, DOI 10.2147/CMAR.S195935
   Lopez G, 2017, J CANCER, V8, P395, DOI 10.7150/jca.17506
   MacPherson H, 2017, PAIN, V158, P784, DOI 10.1097/j.pain.0000000000000747
   Medvedev O.N., 2018, PEERJ, V6, pe4903, DOI [10.7717/peerj.4903, DOI 10.7717/PEERJ.4903]
   Miller KR, 2019, AM J HOSP PALLIAT ME, V36, P326, DOI 10.1177/1049909118804464
   Mulkins A, 2003, J ALTERN COMPLEM MED, V9, P585, DOI 10.1089/107555303322284893
   Myklebust M, 2008, J ALTERN COMPLEM MED, V14, P821, DOI 10.1089/acm.2008.0154
   National Center for Complementary and Integrative Health, 2020, WHY STUD COMPL HLTH
   Niemtzow RC, 2008, MED ACUPUNCT, V20, P255, DOI 10.1089/acu.2008.0594
   Secor ER Jr, 2004, J ALTERN COMPLEM MED, V10, P506, DOI 10.1089/1075553041323704
   Singer J, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-167
   Skevington SM, 2002, QUAL LIFE RES, V11, P135, DOI 10.1023/A:1015013312456
   Smith C, 2013, ACUPUNCT MED, V31, P9, DOI 10.1136/acupmed-2012-010228
   Taylor SL, 2021, J ALTERN COMPLEM MED, V27, pS1, DOI 10.1089/acm.2021.0080
   Thompson LMA, 2015, J ACUPUNCT MERIDIAN, V8, P127, DOI 10.1016/j.jams.2015.04.002
   Tick H, 2018, EXPLORE-NY, V14, P177, DOI 10.1016/j.explore.2018.02.001
   Tsu JHL, 2020, HONG KONG MED J, V26, P88, DOI 10.12809/hkmj205095
   Vodicka E, 2015, CONTEMP CLIN TRIALS, V43, P1, DOI 10.1016/j.cct.2015.04.004
   Wayne PM, 2018, J CANCER SURVIV, V12, P256, DOI 10.1007/s11764-017-0665-5
   Weiss J, 2013, J ALTERN COMPLEM MED, V19, P935, DOI 10.1089/acm.2012.0338
   Westfall JM, 2007, JAMA-J AM MED ASSOC, V297, P403, DOI 10.1001/jama.297.4.403
   World Health Organization, 2019, WHOQOL MEAS QUAL LIF
   Yan B, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/7479459
NR 63
TC 15
Z9 16
U1 0
U2 8
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2768-3605
EI 2768-3613
J9 J INTEGR COMPLEMENT
JI J. Integr. Complement. Med.
PD AUG
PY 2022
VL 28
IS 8
BP 618
EP 640
DI 10.1089/jicm.2021.0413
EA JUL 2022
PG 23
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA S6JB5
UT WOS:000826935600001
PM 35834609
OA Green Submitted
DA 2026-01-16
ER

PT J
AU Li, ZG
   Li, Y
   Li, XK
   Zhang, LD
   Zhao, NQ
   Du, HB
   Zhou, B
   Ye, YA
AF Li, Zhiguo
   Li, Ying
   Li, Xiaoke
   Zhang, Ludan
   Zhao, Nanqi
   Du, Hongbo
   Zhou, Bo
   Ye, Yong'an
TI Statins on hepatocellular carcinoma risk in hepatitis B or C patients
   protocol for a systematic review and meta-analysis
SO MEDICINE
LA English
DT Review
DE hepatitis; hepatocellular carcinoma; statins; systematic review
ID LOW-BACK-PAIN; LUMBAR DISC HERNIATION; INTERVERTEBRAL DISC; CLINICAL
   IMPORTANCE; FUNCTIONAL STATUS; ACUPOTOMY; OUTCOMES; ACUPUNCTURE;
   MEDICINE; SAFETY
AB Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. Chronic hepatitis B (HBV) and C virus (HCV) infection causes liver cancer. This protocol is to provide the methods used to assess the relationship between statins and HCC risk in hepatitis B or C patients.
   Methods: We will search comprehensively the PubMed (medline), Embase, Web of Science, Cochrane Library, and China National Knowledge Infrastructure, Wanfang Database from their inception to November 2017. We will include studies that evaluated and clearly defined exposure to statins, reported the HCC incidence in hepatitis B/C patients or HBV/HCV-related cirrhosis patients, provided effective comparison groups, and reported risk estimates, such as hazard ratios, relative risks, or odds ratios with corresponding 95% confidence intervals or sufficient data for their estimation. We will use Stata (version 15.0) to compute the data synthesis carefully when a meta-analysis is allowed.
   Results: This study will provide a high-quality synthesis of current evidence of statins on HCC risk in hepatitis B or C patients.
   Conclusion: The conclusion of our systematic review will provide evidence to judge whether statin is an effective intervention for hepatitis B or C patients.
C1 [Li, Zhiguo; Li, Ying; Li, Xiaoke; Zhang, Ludan; Du, Hongbo; Ye, Yong'an] BUCM, Dongzhimen Hosp, Dept Gastroenterol, Beijing 100700, Peoples R China.
   [Li, Zhiguo; Li, Ying; Zhang, Ludan; Zhao, Nanqi; Zhou, Bo] Beijing Univ Chinese Med, Beijing, Peoples R China.
   [Li, Xiaoke; Du, Hongbo; Ye, Yong'an] BUCM, Inst Liver Dis, Beijing, Peoples R China.
   [Zhao, Nanqi] BUCM, Ctr Evidence Based Chinese Med, Beijing, Peoples R China.
C3 Beijing University of Chinese Medicine; Beijing University of Chinese
   Medicine; Beijing University of Chinese Medicine
RP Ye, YA (corresponding author), BUCM, Dongzhimen Hosp, Dept Gastroenterol, Beijing 100700, Peoples R China.
EM Yeyongan@vip.163.com
FU China National Science and Technology major projects 12th 5-year plan
   [2012ZX10005004]
FX This work is supported by China National Science and Technology major
   projects 12th 5-year plan (No. 2012ZX10005004).
CR BEURSKENS AJ, 1995, SPINE, V20, P1017, DOI 10.1097/00007632-199505000-00008
   Beurskens AJHM, 1996, PAIN, V65, P71, DOI 10.1016/0304-3959(95)00149-2
   Chapman JR, 2011, SPINE, V36, pS54, DOI 10.1097/BRS.0b013e31822ef74d
   Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005
   Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9
   Guo CQ, 2014, J TRADIT CHIN MED, V34, P194, DOI 10.1016/S0254-6272(14)60078-9
   Hutchinson AJP, 2012, J ORTHOP SURG RES, V7, DOI 10.1186/1749-799X-7-36
   김소연, 2014, Journal of Acupuncture Research, V31, P183
   In-shik Park, 2007, Journal of Acupuncture Research, V24, P97
   JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6
   Jeon G-S., 2010, J Korean public health Nurs, V24, P182
   Jeong JK, 2017, ACUPUNCTURE, V34, P19, DOI [10.13045/acupunct.2017080, DOI 10.13045/ACUPUNCT.2017080]
   Kim E, 2017, INTEGR MED RES, V6, P310, DOI 10.1016/j.imr.2017.07.005
   Kim Hye Su, 2015, Journal of Acupuncture Research, V32, P185, DOI 10.13045/acupunct.2015050
   Kim HJ, 2016, J ACUPUNCT MERIDIAN, V9, P31, DOI 10.1016/j.jams.2015.09.001
   Kim JD, 2014, 2013 NATL HLTH INSUR, p[556, 612]
   Kim JY, 2013, INT CONF ADV COMMUN, P552
   Kim S, 2018, EVID-BASED COMPL ALT, V2018
   Lee GM, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/212098
   Lee S., 2011, VALIDITY RELIABILITY, P40
   Lee S, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1027-y
   Liang YD, 2017, J PAIN RES, V10, P951, DOI 10.2147/JPR.S132808
   Ogon M, 1996, PAIN, V64, P425, DOI 10.1016/0304-3959(95)00208-1
   Ostelo RWJG, 2005, BEST PRACT RES CL RH, V19, P593, DOI 10.1016/j.berh.2005.03.003
   ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004
   Seong SC, 2016, 2015 NATL HLTH INSUR, p[562, 618]
   Shin SH, 2015, SPINE, V40, pE859, DOI 10.1097/BRS.0000000000000990
   Son MS, 2014, 2014 NATL HLTH INSUR, p[554, 610]
   Stratford PW, 1999, J ORTHOP SPORT PHYS, V29, P232, DOI 10.2519/jospt.1999.29.4.232
   성상석, 2004, [Journal of Rheumatic Diseases, 대한류마티스학회지], V11, P254
   Tousignant M, 2005, DISABIL REHABIL, V27, P553, DOI 10.1080/09638280400018411
   Yang H, 2015, INT J CLIN EXP MED, V8, P1634
   Zhang B, 2017, BIOSCI TRENDS, V11, P406, DOI 10.5582/bst.2017.01199
NR 33
TC 7
Z9 7
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD AUG
PY 2018
VL 97
IS 34
AR e11950
DI 10.1097/MD.0000000000011950
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GW0XD
UT WOS:000446592300069
PM 30142817
OA Green Published, gold
DA 2026-01-16
ER

PT J
AU Ehret, CJ
   Almodallal, Y
   Le-Rademacher, JG
   Martin, NA
   Moynagh, MR
   Rajotia, A
   Jatoi, A
AF Ehret, Christopher J.
   Almodallal, Yahya
   Le-Rademacher, Jennifer G.
   Martin, Nichole A.
   Moynagh, Michael R.
   Rajotia, Arush
   Jatoi, Aminah
TI Hiccups in patients with cancer: a multi-site, single-institution study
   of etiology, severity, complications, interventions, and outcomes
SO BMC CANCER
LA English
DT Article
DE Hiccups; Morbidity; Complications; Palliation
ID DEXAMETHASONE; BACLOFEN; GABAPENTIN; THERAPY
AB Background To our knowledge, previous studies have not investigated hiccups in patients with cancer with detailed patient-level data with the goal of capturing a broad spectrum of hiccup symptomatology. Methods This multi-site, single institution study examined consecutive medical records to better understand hiccups in patients with cancer. Results A total of 320 patients are the focus of this report. The median age of patients when hiccups were first reported in the medical record was 63 years (range: 21, 97 years) with 284 (89%) men and 36 (11%) women. The most common diagnose was gastrointestinal cancer. Hiccups most frequently occurred daily, as seen in 194 patients (62%), and the most common duration was less than 1 week, as seen in 146 patients (47%). However, nine patients had had daily hiccups for greater than 6 weeks, and 5 had symptoms for years. Cited etiology was non-chemotherapy medications in 36 (11%) and cancer chemotherapy in 19 (6%). Complications occurred in approximately a third and included insomnia in 51 patients (16%); hospitalization or emergency department visit in 34 (11%); and musculoskeletal pain in 23 (7%). Baclofen was the single most prescribed agent for hiccup palliation, but 100 patients received more than one medication. Medical procedures, which included acupuncture, paracentesis, or phrenic nerve block, were performed in 5 patients. In 234 patients (73%), the medical record documented hiccup cessation. Conclusions Hiccups appear to be highly problematic in a small subset of patients with cancer with no well-defined palliative approaches.
C1 [Ehret, Christopher J.; Almodallal, Yahya; Martin, Nichole A.; Rajotia, Arush; Jatoi, Aminah] Mayo Clin, Dept Oncol, 200 First St SW, Rochester, MN 55905 USA.
   [Le-Rademacher, Jennifer G.] Mayo Clin, Div Clin Trials & Biostat, 200 First St SW, Rochester, MN 55905 USA.
   [Moynagh, Michael R.] Mayo Clin, Dept Radiol, 200 First St SW, Rochester, MN 55905 USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic
RP Jatoi, A (corresponding author), Mayo Clin, Dept Oncol, 200 First St SW, Rochester, MN 55905 USA.
EM jatoi.aminah@mayo.edu
RI Almodallal, Yahya/KFS-0360-2024
OI Almodallal, Yahya/0000-0002-8613-483X; Ehret,
   Christopher/0000-0001-5077-4563; Martin, Nichole/0000-0002-1051-9557
FU Mayo Clinic
FX This work was supported by Mayo Clinic internal funding.
CR [Anonymous], 2021, CHRON HICC
   [Anonymous], 2021, HICC CHRON
   BURCHARTH F, 1974, ACTA CHIR SCAND, V140, P340
   Ehret C, 2022, AM J HOSP PALLIAT ME, V39, P147, DOI 10.1177/10499091211006923
   GUELAUD C, 1995, EUR RESPIR J, V8, P235, DOI 10.1183/09031936.95.08020235
   Hendrix K, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0857-4
   Hosoya R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172057
   Jatoi A, 2022, BMJ SUPPORT PALLIAT, V12, P475, DOI 10.1136/bmjspcare-2022-003676
   Lee GW, 2013, ONCOLOGIST, V18, P1229, DOI 10.1634/theoncologist.2013-0224
   Liaw CC, 2005, J PAIN SYMPTOM MANAG, V30, P359, DOI 10.1016/j.jpainsymman.2005.08.008
   Mirijello A, 2013, INT J CLIN PRACT, V67, P918, DOI 10.1111/ijcp.12184
   Moretti R, 1999, EUR J NEUROL, V6, P617, DOI 10.1046/j.1468-1331.1999.650617.x
   Moretto EN, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008768.pub2
   Porzio G, 2010, CLIN NEUROPHARMACOL, V33, P179, DOI 10.1097/WNF.0b013e3181de8943
   RAMIREZ FC, 1992, AM J GASTROENTEROL, V87, P1789
   Steger M, 2015, ALIMENT PHARM THER, V42, P1037, DOI 10.1111/apt.13374
   Thompson DF, 2013, ANN PHARMACOTHER, V47, P897, DOI 10.1345/aph.1S018
   Vardy J, 2006, BRIT J CANCER, V94, P1011, DOI 10.1038/sj.bjc.6603048
   Walsh D, 2000, SUPPORT CARE CANCER, V8, P175, DOI 10.1007/s005200050281
   Wang T, 2014, INTERN MED J, V44, P1205, DOI 10.1111/imj.12542
   Zhang CE, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-295
   Zhang Ruifu, 2004, Yingyong Shengtai Xuebao, V15, P295
NR 22
TC 4
Z9 5
U1 1
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JUN 15
PY 2022
VL 22
IS 1
AR 659
DI 10.1186/s12885-022-09760-5
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 2D7SI
UT WOS:000811741400001
PM 35705907
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Stela, M
   Cichon, N
   Splawska, A
   Szyposzynska, M
   Bijak, M
AF Stela, Maksymilian
   Cichon, Natalia
   Splawska, Aleksandra
   Szyposzynska, Monika
   Bijak, Michal
TI Therapeutic Potential and Mechanisms of Bee Venom Therapy: A
   Comprehensive Review of Apitoxin Applications and Safety Enhancement
   Strategies
SO PHARMACEUTICALS
LA English
DT Review
DE bee venom therapy; melittin; apamin; anti-inflammatory therapy;
   anticancer therapy; natural compounds; allergy
ID NF-KAPPA-B; ACUPUNCTURE APIPUNCTURE; HONEYBEE VENOM; ACUPOINT
   STIMULATION; MEDIATOR GENERATION; PARKINSONS-DISEASE;
   ALZHEIMERS-DISEASE; HYMENOPTERA VENOM; CANCER CELLS; BONE-MARROW
AB Apitoxin therapy (BVT-bee venom therapy) is an emerging complementary treatment utilizing bee venom for various medical conditions. This review explores the potential and therapeutic mechanisms of bee venom, focusing on its chemical composition and the methods for its extraction and purification to enhance safety while maintaining bioactivity. Bee venom contains amphipathic peptides such as melittin and apamin, enzymes like phospholipase A2, and bioamines including histamine and catecholamines, contributing to its pleiotropic effects. The therapeutic applications of bee venom span anti-inflammatory, analgesic, antimicrobial, antiviral, neuroprotective, anti-arthritic, and anti-cancer activities. Clinical and laboratory studies have demonstrated its efficacy in treating chronic and autoimmune diseases, pain management, and improving quality of life. The immunogenic properties of bee venom necessitate ongoing research to mitigate allergic reactions, ensuring its safe and effective use in medical practice. This review summarizes the current state of research on bee venom therapy, highlighting its potential benefits and future research directions.
C1 [Stela, Maksymilian; Cichon, Natalia; Bijak, Michal] Univ Lodz, Fac Biol & Environm Protect, Biohazard Prevent Ctr, Pomorska 141-143, PL-90236 Lodz, Poland.
   [Splawska, Aleksandra; Szyposzynska, Monika] Mil Inst Chem & Radiometry, CBRN Reconnaissance & Decontaminat Dept, Antoniego Chrusciela Montera 105, PL-00910 Warsaw, Poland.
C3 University of Lodz; Military Institute of Chemistry & Radiometry
RP Cichon, N (corresponding author), Univ Lodz, Fac Biol & Environm Protect, Biohazard Prevent Ctr, Pomorska 141-143, PL-90236 Lodz, Poland.
EM maksymilian.stela@biol.uni.lodz.pl; natalia.cichon@biol.uni.lodz.pl;
   michal.bijak@biol.uni.lodz.pl
RI ; Szyposzyńska, Monika/JDW-6816-2023
OI Stela, Maksymilian/0000-0002-7471-4175; Szyposzyńska,
   Monika/0000-0001-5978-3386; Cichon, Natalia/0000-0002-0139-2451;
   Spławska, Aleksana/0000-0002-1308-3007; Bijak,
   Michal/0000-0002-7838-4097
CR Akbarzadeh-Khiavi M, 2022, EXPERT OPIN BIOL TH, V22, P895, DOI 10.1080/14712598.2022.2088277
   Alvarez-Fischer D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061700
   Alves E.M., 2011, Google Patents, Patent No. [WO2011041865, 2011041865]
   dos Santos-Pinto JRA, 2018, TOXICON, V148, P172, DOI 10.1016/j.toxicon.2018.04.029
   Baek YH, 2006, BRAIN RES, V1073, P305, DOI 10.1016/j.brainres.2005.12.086
   Barrajón-Catalán E, 2010, CANCER LETT, V290, P192, DOI 10.1016/j.canlet.2009.09.010
   Bava R, 2023, VET SCI, V10, DOI 10.3390/vetsci10020119
   Berchtold NC, 1998, NEUROBIOL AGING, V19, P173, DOI 10.1016/S0197-4580(98)00052-9
   Bessis N, 2006, JOINT BONE SPINE, V73, P169, DOI 10.1016/j.jbspin.2005.01.013
   Betten DP, 2006, PEDIATRICS, V117, P231, DOI 10.1542/peds.2005-1075
   Biló BM, 2005, ALLERGY, V60, P1339, DOI 10.1111/j.1398-9995.2005.00963.x
   Bloom GS, 2014, JAMA NEUROL, V71, P505, DOI 10.1001/jamaneurol.2013.5847
   Burzynska M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168371
   CHANG YH, 1979, AGENTS ACTIONS, V9, P205, DOI 10.1007/BF02024736
   Chen MH, 2005, J ETHNOPHARMACOL, V97, P7, DOI 10.1016/j.jep.2004.09.040
   Chen Yong-Qiang, 2004, Zhong Xi Yi Jie He Xue Bao, V2, P208
   Cho SY, 2013, COMPLEMENT THER MED, V21, P155, DOI 10.1016/j.ctim.2013.02.001
   Cho SY, 2012, PARKINSONISM RELAT D, V18, P948, DOI 10.1016/j.parkreldis.2012.04.030
   Choi S, 2019, TOXINS, V11, DOI 10.3390/toxins11070396
   Chung ES, 2012, BRAIN BEHAV IMMUN, V26, P1322, DOI 10.1016/j.bbi.2012.08.013
   Coulter-Parkhill A, 2021, CLIN MED INSIGHTS-EN, V14, DOI 10.1177/11795514211006071
   Darwish SF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079284
   Doo AR, 2010, NEUROL RES, V32, pS88, DOI 10.1179/016164109X12537002794282
   Duffy C, 2020, NPJ PRECIS ONCOL, V4, DOI 10.1038/s41698-020-00129-0
   El Bakary NM, 2020, INTEGR CANCER THER, V19, DOI 10.1177/1534735420944476
   Er-Rouassi H, 2023, BIOMOLECULES, V13, DOI 10.3390/biom13040680
   Fadeel B, 1999, BIOCHEM BIOPH RES CO, V266, P504, DOI 10.1006/bbrc.1999.1820
   Gajski G, 2024, TOXINS, V16, DOI 10.3390/toxins16030117
   Garaj-Vrhovac V, 2009, ARH HIG RADA TOKSIKO, V60, P27, DOI 10.2478/10004-1254-60-2009-1896
   GREEN JA, 1991, INFLAMMATION, V15, P355, DOI 10.1007/BF00917352
   Gu SM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0344-2
   HAIT WN, 1985, CANCER CHEMOTH PHARM, V14, P202, DOI 10.1007/BF00258116
   Hall S., 2011, wiat Nauki, V236, P40
   Han SM, 2013, J INTEGR MED-JIM, V11, P320, DOI 10.3736/jintegrmed2013043
   Han SM, 2007, J ETHNOPHARMACOL, V111, P176, DOI 10.1016/j.jep.2006.11.008
   HAVAS LJ, 1950, NATURE, V166, P567, DOI 10.1038/166567a0
   HOFFMAN DR, 1984, ANN ALLERGY, V52, P276
   Hong SJ, 2005, TOXICON, V46, P39, DOI 10.1016/j.toxicon.2005.03.015
   Hu HY, 2006, J PHARM SCI-US, V95, P192, DOI 10.1002/jps.20517
   Huang C, 2013, ACS NANO, V7, P5791, DOI 10.1021/nn400683s
   Huh JE, 2018, ALTERN THER HEALTH M, V24, P28
   Hyde C, 2013, AGE AGEING, V42, P14, DOI 10.1093/ageing/afs165
   Jang HS, 2005, J ETHNOPHARMACOL, V99, P157, DOI 10.1016/j.jep.2005.02.026
   Jang S, 2020, TOXINS, V12, DOI 10.3390/toxins12090558
   Jepson TA, 2022, BIOPHYS J, V121, P1417, DOI 10.1016/j.bpj.2022.03.019
   Jo M, 2012, TOXICOL APPL PHARM, V258, P72, DOI 10.1016/j.taap.2011.10.009
   Kang DW, 2021, J VET SCI, V22, DOI 10.4142/jvs.2021.22.e9
   Khalil A, 2021, MOLECULES, V26, DOI 10.3390/molecules26164941
   Khalil WKB, 2015, NEUROCHEM INT, V80, P79, DOI 10.1016/j.neuint.2014.11.008
   Khamis AAA, 2018, BIOMED PHARMACOTHER, V105, P1335, DOI 10.1016/j.biopha.2018.06.105
   KILLION JJ, 1986, BIOCHEM BIOPH RES CO, V139, P222, DOI 10.1016/S0006-291X(86)80102-4
   Kim HW, 2005, PHARMACOL RES, V51, P183, DOI 10.1016/j.phrs.2004.07.011
   Kim HW, 2003, J VET MED SCI, V65, P349, DOI 10.1292/jvms.65.349
   Kim H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114726
   Kim SJ, 2011, J ATHEROSCLER THROMB, V18, P1117, DOI 10.5551/jat.8474
   Kim SJ, 2010, AM J CHINESE MED, V38, P921, DOI 10.1142/S0192415X10008354
   Köhler J, 2014, J ALLERGY CLIN IMMUN, V133, P1383, DOI 10.1016/j.jaci.2013.10.060
   Kolaczek A, 2017, POSTEP DERM ALERGOL, V34, P159, DOI 10.5114/ada.2017.67082
   Kolecki P, 1999, ANN EMERG MED, V33, P114, DOI 10.1016/S0196-0644(99)70428-2
   Korosec P, 2015, CLIN EXP ALLERGY, V45, P1579, DOI 10.1111/cea.12582
   KORTESUO PT, 1992, EUR J CLIN CHEM CLIN, V30, P263
   Kurek-Górecka A, 2021, MOLECULES, V26, DOI 10.3390/molecules26010148
   Kwon YB, 2001, ACUPUNCTURE ELECTRO, V26, P59, DOI 10.3727/036012901816356054
   LAZO JS, 1986, CANCER RES, V46, P2236
   Lee G, 2016, MOLECULES, V21, DOI 10.3390/molecules21050616
   LEE GL, 1985, LIFE SCI, V36, P347, DOI 10.1016/0024-3205(85)90120-1
   Lee HS, 2021, APPL BIOCHEM BIOTECH, V193, P4068, DOI 10.1007/s12010-021-03653-2
   Lee JH, 2020, TOXINS, V12, DOI 10.3390/toxins12120737
   Lee JA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006140
   Lee KG, 2009, J ETHNOPHARMACOL, V123, P15, DOI 10.1016/j.jep.2009.02.044
   Lee WR, 2010, AM J CHINESE MED, V38, P1077, DOI 10.1142/S0192415X10008482
   Lee Y, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/2353280
   Li B, 2006, ONKOLOGIE, V29, P367, DOI 10.1159/000094711
   Li DX, 2020, TOXINS, V12, DOI 10.3390/toxins12120775
   Li DX, 2020, TOXINS, V12, DOI 10.3390/toxins12100620
   Liu SJ, 2008, HEPATOLOGY, V47, P1964, DOI 10.1002/hep.22240
   Liuzzo G, 2001, Rays, V26, P221
   Luo Q., 2013, Patent No. [WO/2013/135103, 2013135103]
   Lv QY, 2019, FRONT INTEGR NEUROSC, V13, DOI 10.3389/fnint.2019.00038
   Malek A, 2023, CANCERS, V15, DOI 10.3390/cancers15143714
   Mansour GH, 2021, BIOORG CHEM, V116, DOI 10.1016/j.bioorg.2021.105329
   Markovic-Housley Z, 2000, STRUCTURE, V8, P1025, DOI 10.1016/S0969-2126(00)00511-6
   Matysiak J, 2016, ANN AGR ENV MED, V23, P120, DOI 10.5604/12321966.1196866
   MCDONALD JA, 1979, J OCCUP ENVIRON MED, V21, P811
   Moon DO, 2008, TOXICON, V51, P112, DOI 10.1016/j.toxicon.2007.08.015
   Moon DO, 2007, INT IMMUNOPHARMACOL, V7, P1092, DOI 10.1016/j.intimp.2007.04.005
   Moreno M, 2015, TOXINS, V7, P1126, DOI 10.3390/toxins7041126
   Nam KW, 2003, ARCH PHARM RES, V26, P383, DOI 10.1007/BF02976695
   Nishikawa H, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/872152
   Nusair SA, 2024, EGYPTIAN J MED HUMAN, V25, DOI 10.1186/s43042-024-00524-3
   OERTEL WH, 1995, PATIENT EDUC COUNS, V26, P71, DOI 10.1016/0738-3991(95)00757-Q
   Ombredane AS, 2021, EXP DERMATOL, V30, P710, DOI 10.1111/exd.14289
   Pan H, 2011, WIRES NANOMED NANOBI, V3, P318, DOI 10.1002/wnan.126
   Park HJ, 2004, ARTHRITIS RHEUM-US, V50, P3504, DOI 10.1002/art.20626
   Park HJ, 2007, BIOCHEM PHARMACOL, V73, P237, DOI 10.1016/j.bcp.2006.09.023
   Park JH, 2012, APOPTOSIS, V17, P61, DOI 10.1007/s10495-011-0659-0
   Park JH, 2010, MOL CELLS, V29, P209, DOI 10.1007/s10059-010-0028-9
   Popplewell JF, 2007, BBA-BIOMEMBRANES, V1768, P13, DOI 10.1016/j.bbamem.2006.05.016
   Rady I, 2017, CANCER LETT, V402, P16, DOI 10.1016/j.canlet.2017.05.010
   REISMAN RE, 1988, ANN ALLERGY, V61, P383
   Reitinger S, 2008, PROTEIN EXPRES PURIF, V57, P226, DOI 10.1016/j.pep.2007.10.001
   Roh DH, 2004, J PAIN, V5, P297, DOI 10.1016/j.jpain.2004.05.003
   Romero-Curiel A, 2011, SYNAPSE, V65, P1062, DOI 10.1002/syn.20938
   Ruff F., 2023, Allergol. Select, V7, P154, DOI DOI 10.5414/ALX02430E
   Seo BK, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-16
   Shin JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069380
   Sobral F, 2016, FOOD CHEM TOXICOL, V94, P172, DOI 10.1016/j.fct.2016.06.008
   Sobw T., 2007, Postpy Psychiatr. Neurol, V16, P75
   Soman NR, 2008, NANO LETT, V8, P1131, DOI 10.1021/nl073290r
   Soman NR, 2009, J CLIN INVEST, V119, P2830, DOI 10.1172/JCI38842
   Son DJ, 2007, J TOXICOL ENV HEAL A, V70, P1350, DOI 10.1080/15287390701428689
   Song Chang-Cheng, 2007, Ai Zheng, V26, P1315
   Sung SH, 2021, TOXINS, V13, DOI 10.3390/toxins13090608
   Thor P., 2007, Podstawy Patofizjologii Czowieka, P439
   Turillazzi F, 2022, MOLECULES, V27, DOI 10.3390/molecules27248821
   ukasiewicz A., 2021, Aesthetic Cosmetol. Med, V10, P23, DOI [10.52336/acm.2021.10.1.04, DOI 10.52336/ACM.2021.10.1.04]
   Ullah A, 2023, SAUDI PHARM J, V31, P96, DOI 10.1016/j.jsps.2022.11.008
   Vazquez-Revuelta P, 2018, J INVEST ALLERG CLIN, V28, P45, DOI 10.18176/jiaci.0202
   Wang C, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100767
   Wehbe R, 2019, MOLECULES, V24, DOI 10.3390/molecules24162997
   Woo S, 2019, TOXINS, V11, DOI 10.3390/toxins11080477
   Yang EJ, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-69
   Yang X, 2014, TUMOR BIOL, V35, P10443, DOI 10.1007/s13277-014-2218-0
   Ye M, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0476-z
   ylicz Z., 2003, Adv. Palliat. Med, V2, P49
   Zhang Chen, 2007, Zhong Xi Yi Jie He Xue Bao, V5, P559, DOI 10.3736/jcim20070517
   Zhang SF, 2021, BIOCELL, V45, P167, DOI 10.32604/biocell.2021.013636
   Zhang ZH, 2009, ANGEW CHEM INT EDIT, V48, P9171, DOI 10.1002/anie.200903112
   Zhao XR, 2011, BIOTECHNOL APPL BIOC, V58, P405, DOI 10.1002/bab.57
NR 129
TC 11
Z9 13
U1 7
U2 24
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1424-8247
J9 PHARMACEUTICALS-BASE
JI Pharmaceuticals
PD SEP
PY 2024
VL 17
IS 9
AR 1211
DI 10.3390/ph17091211
PG 20
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA H4T2Z
UT WOS:001323375000001
PM 39338374
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Pachman, DR
   Watson, JC
   Loprinzi, CL
AF Pachman, Deirdre R.
   Watson, James C.
   Loprinzi, Charles L.
TI Therapeutic Strategies for Cancer Treatment Related Peripheral
   Neuropathies
SO CURRENT TREATMENT OPTIONS IN ONCOLOGY
LA English
DT Article
DE Chemotherapy-induced peripheral neuropathy
ID ACETYL-L-CARNITINE; QUALITY-OF-LIFE; DOUBLE-BLIND; TOPICAL
   AMITRIPTYLINE; ADJUVANT BREAST; PAIN SYNDROMES; NEUROSENSORY TOXICITY;
   INDUCED NEUROTOXICITY; SCRAMBLER THERAPY; OXALIPLATIN
AB Chemotherapy-induced peripheral neuropathy (CIPN) is a common toxicity associated with multiple chemotherapeutic agents. CIPN may have a detrimental impact on patients' quality of life and functional ability, as well as result in chemotherapy dose reductions. Although symptoms of CIPN can improve with treatment completion, symptoms may persist. Currently, the treatment options for CIPN are quite limited. Duloxetine, a serotonin-norepinephrine reuptake inhibitor, has the most evidence supporting its use in the treatment of CIPN. Other agents with potential benefit for the treatment of established CIPN include gabapentinoids, venlafaxine, tricyclic antidepressants, and a topical gel consisting of the combination of amitriptyline, ketamine, and baclofen; none of these, however, has been proven to be helpful and ongoing/future studies may well show that they are not beneficial. The use of these agents is often based on their efficacy in the treatment of non-CIPN neuropathic pain, but this does not necessarily mean that they will be helpful for CIPN-related symptoms. Other nonpharmacologic interventions including acupuncture and Scrambler therapy are supported by positive preliminary data; however, further larger, placebo-controlled trial data are needed to confirm or refute their effectiveness.
C1 [Pachman, Deirdre R.; Watson, James C.; Loprinzi, Charles L.] Mayo Clin Rochester, Rochester, MN 55905 USA.
C3 Mayo Clinic
RP Pachman, DR (corresponding author), Mayo Clin Rochester, 200 First St SW, Rochester, MN 55905 USA.
EM pachman.deirdre@mayo.edu
CR Barton DL, 2011, SUPPORT CARE CANCER, V19, P833, DOI 10.1007/s00520-010-0911-0
   Bianchi G, 2005, EUR J CANCER, V41, P1746, DOI 10.1016/j.ejca.2005.04.028
   Bley KR, 2004, EXPERT OPIN INV DRUG, V13, P1445, DOI 10.1517/13543784.13.11.1445
   Campbell TC, 2013, J CLIN ONCOL, V31
   Colvin LA, 2008, J CLIN ONCOL, V26, P4519, DOI 10.1200/JCO.2008.18.5017
   Coyne Patrick J, 2013, J Pain Palliat Care Pharmacother, V27, P359, DOI 10.3109/15360288.2013.847519
   Derry Sheena, 2013, Cochrane Database Syst Rev, pCD007393, DOI 10.1002/14651858.CD007393.pub3
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Durand JP, 2012, ANN ONCOL, V23, P200, DOI 10.1093/annonc/mdr045
   Durand JP, 2003, ANTI-CANCER DRUG, V14, P423, DOI 10.1097/00001813-200307000-00006
   Durand JP, 2005, ANTI-CANCER DRUG, V16, P587, DOI 10.1097/00001813-200506000-00015
   Durand JP, 2002, ANTI-CANCER DRUG, V13, P777, DOI 10.1097/00001813-200208000-00013
   Dworkin RH, 2010, MAYO CLIN PROC, V85, pS3, DOI 10.4065/mcp.2009.0649
   Evans JD, 2008, ANN PHARMACOTHER, V42, P1686, DOI 10.1345/aph.1L201
   Gedlicka C, 2002, J CLIN ONCOL, V20, P3359, DOI 10.1200/JCO.2002.99.502
   Gedlicka C, 2003, ANN ONCOL, V14, P339, DOI 10.1093/annonc/mdg051
   Gewandter JS, 2013, SUPPORT CARE CANCER, V21, P2059, DOI 10.1007/s00520-013-1766-y
   Gewandter JS, 2014, SUPPORT CARE CANCER, V22, P1807, DOI 10.1007/s00520-014-2158-7
   Guo Y, 2011, J CLIN ONCOLOGY S, V29, P9010
   Hammack JE, 2002, PAIN, V98, P195, DOI 10.1016/S0304-3959(02)00047-7
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Hershman DL, 2013, J CLIN ONCOL, V31, P2627, DOI 10.1200/JCO.2012.44.8738
   Hershman DL, 2011, BREAST CANCER RES TR, V125, P767, DOI 10.1007/s10549-010-1278-0
   Jiang Hequn, 2006, J Tradit Chin Med, V26, P8
   Kautio AL, 2008, J PAIN SYMPTOM MANAG, V35, P31, DOI 10.1016/j.jpainsymman.2007.02.043
   Kidwell KM, 2012, CANCER-AM CANCER SOC, V118, P5614, DOI 10.1002/cncr.27593
   Kluding PM, 2012, J DIABETES COMPLICAT, V26, P424, DOI 10.1016/j.jdiacomp.2012.05.007
   Kohrman M, 2012, J CLIN ONCOL, V30
   Liu YC, 2012, CANCER-AM CANCER SOC, V118, P1718, DOI 10.1002/cncr.26430
   Loprinzi CL, 2011, J CLIN ONCOL, V29, P1472, DOI 10.1200/JCO.2010.33.0308
   Lynch ME, 2005, ANESTHESIOLOGY, V103, P140, DOI 10.1097/00000542-200507000-00021
   Lynch ME, 2005, J PAIN, V6, P644, DOI 10.1016/j.jpain.2005.04.008
   Lynch ME, 2003, CLIN J PAIN, V19, P323, DOI 10.1097/00002508-200309000-00007
   Maestri A, 2005, TUMORI J, V91, P135, DOI 10.1177/030089160509100206
   Mariani G, 2000, P AM SOC CLIN ONCOL, V19
   Marineo G, 2012, J PAIN SYMPTOM MANAG, V43, P87, DOI 10.1016/j.jpainsymman.2011.03.015
   Mols F, 2013, J CLIN ONCOL, V31, P2699, DOI 10.1200/JCO.2013.49.1514
   Moore R Andrew, 2009, Cochrane Database Syst Rev, pCD007076, DOI 10.1002/14651858.CD007076.pub2
   Ozdoan M., 2004, TURKISH J CANC, V34, P110
   Pachman DR, 2014, J CLIN ONCOL, V32, P5
   Park SB, 2008, CURR MED CHEM, V15, P3081, DOI 10.2174/092986708786848569
   Pike Crystal T, 2012, Chemother Res Pract, V2012, P913848, DOI 10.1155/2012/913848
   Podratz JL, 2011, NEUROBIOL DIS, V41, P661, DOI 10.1016/j.nbd.2010.11.017
   Portenoy RK, 2011, LANCET, V377, P2236, DOI 10.1016/S0140-6736(11)60236-5
   Rao RD, 2007, CANCER-AM CANCER SOC, V110, P2110, DOI 10.1002/cncr.23008
   Reeves BN, 2012, CANCER-AM CANCER SOC, V118, P5171, DOI 10.1002/cncr.27489
   Rowbotham MC, 2003, NEW ENGL J MED, V348, P1223, DOI 10.1056/NEJMoa021420
   Saarto T, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005454.pub2
   Saif MW, 2010, ANTICANCER RES, V30, P2927
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Smith TJ, 2010, J PAIN SYMPTOM MANAG, V40, P883, DOI 10.1016/j.jpainsymman.2010.03.022
   Speck R, 2012, SUPPORT CARE CANCER, V20, P2433, DOI 10.1007/s00520-011-1365-8
   Storey Dawn J, 2010, J Pain Symptom Manage, V39, pe2, DOI 10.1016/j.jpainsymman.2010.02.004
   Storey DJ, 2010, J CLIN ONCOL S, V28
   Stubblefield MD, 2012, CANCER-AM CANCER SOC, V118, P2250, DOI 10.1002/cncr.27463
   Sucheston LE, 2011, BREAST CANCER RES TR, V130, P993, DOI 10.1007/s10549-011-1671-3
   Ta LE, 2006, NEUROTOXICOLOGY, V27, P992, DOI 10.1016/j.neuro.2006.04.010
   Tong YQ, 2010, J ACUPUNCT MERIDIAN, V3, P95, DOI 10.1016/S2005-2901(10)60018-0
   Tsavaris N, 2008, PAIN MED, V9, P1209, DOI 10.1111/j.1526-4637.2007.00325.x
   Weisbroad BL, 2014, J CLIN ONCOL S, V32
   WHITE CM, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003904.PUB2
   Windebank AJ, 2008, J PERIPHER NERV SYST, V13, P27, DOI 10.1111/j.1529-8027.2008.00156.x
   Wolf SL, 2012, SUPPORT CARE CANCER, V20, P625, DOI 10.1007/s00520-011-1141-9
   Won HH, 2012, CANCER-AM CANCER SOC, V118, P2828, DOI 10.1002/cncr.26614
   Wong Raimond, 2006, Acupunct Med, V24, P87
   Xu Wei-Ru, 2010, Zhongguo Zhen Jiu, V30, P457
   Yang YH, 2012, SUPPORT CARE CANCER, V20, P1491, DOI 10.1007/s00520-011-1237-2
   Ziegler D, 2004, DIABETIC MED, V21, P114, DOI 10.1111/j.1464-5491.2004.01109.x
NR 69
TC 24
Z9 29
U1 0
U2 35
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1527-2729
EI 1534-6277
J9 CURR TREAT OPTION ON
JI Curr. Treat. Options Oncol.
PD DEC
PY 2014
VL 15
IS 4
BP 567
EP 580
DI 10.1007/s11864-014-0303-7
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AS8ZG
UT WOS:000344532800005
PM 25119581
DA 2026-01-16
ER

PT J
AU Green, OJ
   Green, JP
   Carroll, PJ
AF Green, Olivia J.
   Green, Joseph P.
   Carroll, Patrick J.
TI The Perceived Credibility of Complementary and Alternative Medicine: A
   Survey of Undergraduate and Graduate Students
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL HYPNOSIS
LA English
DT Article
ID UNITED-STATES; THERAPEUTIC TOUCH; BACK-PAIN; CANCER; METAANALYSIS;
   HYPNOSIS; BENEFITS; PREVALENCE; THERAPIES; INTERNET
AB The popularity of complementary and alternative medicine (CAM) appears to be increasing, especially among college students. We surveyed 146 undergraduate and graduate students with the CAM Health Belief Questionnaire and obtained credibility and frequency ratings for a select group of CAM therapies: yoga, meditation, massage, chiropractic medicine, biofeedback, hypnosis, acupuncture, spirituality/religion, therapeutic touch, the use of herbs/vitamins, and aromatherapy/essential oils. Graduate students held more favorable views about integrating CAM into conventional medical practice. Female students reported using a wider variety of therapies than male students. Spirituality/religion and herbs/vitamins were the most popular CAM approaches. Students rated yoga, meditation, and massage as being highly credible practices. They rated hypnosis and therapeutic touch low in credibility. We discuss hypnosis as an example of a therapy that suffers from poor public perception despite having a relatively strong evidentiary base.
C1 [Green, Olivia J.] Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA.
   [Green, Joseph P.; Carroll, Patrick J.] Ohio State Univ, Dept Psychol, 4240 Campus Dr, Lima, OH 45804 USA.
C3 University System of Ohio; Ohio State University; University System of
   Ohio; Ohio State University
RP Green, JP (corresponding author), Ohio State Univ, Dept Psychol, 4240 Campus Dr, Lima, OH 45804 USA.
EM green.301@osu.edu
RI Carroll, Patrick/P-6946-2019
CR AJZEN I, 1974, HUM RELAT, V27, P1, DOI 10.1177/001872677402700101
   [Anonymous], 2018, Complementary, Alternative, or Integrative Health: What's In a Name?
   Arslan IO, 2012, HEALTHMED, V6, P2185
   Atsumi K, 2005, IEEE ENG MED BIOL, V24, P30, DOI 10.1109/MEMB.2005.1411345
   Bervoets DC, 2015, J PHYSIOTHER, V61, P106, DOI 10.1016/j.jphys.2015.05.018
   Bishop FL, 2011, PROSTATE CANCER P D, V14, P1, DOI 10.1038/pcan.2010.38
   Cassileth BR, 1999, CA-CANCER J CLIN, V49, P362, DOI 10.3322/canjclin.49.6.362
   Centers for Disease Control and Prevention, 2018, REP NAT CTR HLTH STA
   Chang HY, 2007, J ADV NURS, V58, P307, DOI 10.1111/j.1365-2648.2007.04291.x
   Chang HY, 2015, J CLIN NURS, V24, P1466, DOI 10.1111/jocn.12790
   CLARK PE, 1984, NURS RES, V33, P37
   Cole SW, 2015, PSYCHONEUROENDOCRINO, V62, P11, DOI 10.1016/j.psyneuen.2015.07.001
   College Board, 2019, AP PSYCH UPD 2019 20
   Coulter ID, 2018, SPINE J, V18, P866, DOI 10.1016/j.spinee.2018.01.013
   Cronk BC, 2002, BEHAV RES METH INS C, V34, P177, DOI 10.3758/BF03195440
   Dolnicar S, 2009, J TRAVEL RES, V47, P295, DOI 10.1177/0047287508326506
   EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406
   Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569
   Elkins G., 2016, HDB MED PSYCHOL HYPN, DOI DOI 10.1891/9780826124876
   Elkins G, 2007, INT J CLIN EXP HYP, V55, P275, DOI 10.1080/00207140701338621
   Ernst E, 2004, J MED ETHICS, V30, P156, DOI 10.1136/jme.2003.007021
   Ernst E, 1998, ARCH INTERN MED, V158, P2235, DOI 10.1001/archinte.158.20.2235
   Ernst E, 1998, CANCER-AM CANCER SOC, V83, P777, DOI 10.1002/(SICI)1097-0142(19980815)83:4<777::AID-CNCR22>3.0.CO;2-O
   Fredrickson BL, 2013, P NATL ACAD SCI USA, V110, P13684, DOI 10.1073/pnas.1305419110
   Gahche Jamie, 2011, NCHS Data Brief, P1
   Gosling SD, 2004, AM PSYCHOL, V59, P93, DOI 10.1037/0003-066X.59.2.93
   Green J.P., 2014, Psychology of Consciousness: Theory, Research, and Practice, V1, P199, DOI DOI 10.1037/CNS0000015
   Green J. P., 2019, COGN BEH THER, DOI [10.1002/9781119139676, DOI 10.1002/9781119139676]
   Green JP, 2017, INT J CLIN EXP HYP, V65, P308, DOI 10.1080/00207144.2017.1314740
   Hall HG, 2011, MIDWIFERY, V27, P817, DOI 10.1016/j.midw.2010.08.007
   Horneber M, 2012, INTEGR CANCER THER, V11, P187, DOI 10.1177/1534735411423920
   Hui KK, 2002, J ALTERN COMPLEM MED, V8, P507, DOI 10.1089/107555302760253711
   Iyioha I, 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1155/2011/389518
   Izzo AA, 2009, DRUGS, V69, P1777, DOI 10.2165/11317010-000000000-00000
   Jensen MP, 2017, NEUROSCI CONSCIOUS, V3, DOI 10.1093/nc/nix004
   Joyce Paul, 2016, J Complement Integr Med, V13, P333, DOI [10.1515/jcim-2014-0053, 10.1515/jcim-2014-0053]
   Kessler RC, 2001, ANN INTERN MED, V135, P262, DOI 10.7326/0003-4819-135-4-200108210-00011
   Keyes CLM, 2012, AM J PUBLIC HEALTH, V102, P2164, DOI 10.2105/AJPH.2012.300918
   Kristoffersen AE, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-463
   Lee J, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2362-7
   Lie Desiree, 2004, BMC Med Educ, V4, P2, DOI 10.1186/1472-6920-4-2
   Lynn S. J., 2019, WILEY ENCY HLTH PSYC
   Lynn S.J., 2010, Handbook of Clinical Hypnosis, V2nd, DOI DOI 10.2307/J.CTV1CHS5QJ.34
   Lynn SJ, 2019, INT J CLIN EXP HYP, V67, P475, DOI 10.1080/00207144.2019.1649541
   Martínez ME, 2012, JNCI-J NATL CANCER I, V104, P732, DOI 10.1093/jnci/djs195
   Martins N, 2010, SOUTH AFR BUS REV, V14, P77
   Merriam-Webster Incorporated, 2019, DICT MERR WEBST AM T
   Montgomery GH, 2000, INT J CLIN EXP HYP, V48, P138, DOI 10.1080/00207140008410045
   Musallam AB, 2011, COMPUT HUM BEHAV, V27, P1915, DOI 10.1016/j.chb.2011.04.016
   National Center for Complementary and Integrative Health, 2018, US COMPL ALT MED US
   Nowak ALV, 2008, AM J HEALTH EDUC, V39, P80, DOI 10.1080/19325037.2008.10599019
   Nowak ALV, 2015, J AM COLL HEALTH, V63, P362, DOI 10.1080/07448481.2015.1042878
   Ostwald M., 1962, LIB LIBERAL ARTS
   Peters RM, 1999, NURS SCI QUART, V12, P52, DOI 10.1177/08943189922106413
   Rosa L, 1998, JAMA-J AM MED ASSOC, V279, P1005, DOI 10.1001/jama.279.13.1005
   Schneider CraigD., 2003, BMC MED EDUC, V3, P1
   Sullivan MB, 2018, FRONT HUM NEUROSCI, V12, DOI 10.3389/fnhum.2018.00067
   Tabish Syed Amin, 2008, Int J Health Sci (Qassim), V2, pV
   Tefikow S, 2013, CLIN PSYCHOL REV, V33, P623, DOI 10.1016/j.cpr.2013.03.005
   Ventola C Lee, 2010, P T, V35, P461
   WebMD, 2019, WHAT EX ALT MED
   *WHO, 2011, TRAD MED DEF
   Yamashita H, 2002, COMPLEMENT THER MED, V10, P84, DOI 10.1054/ctim.2002.0519
   Zick SM, 2004, ALTERN THER HEALTH M, V10, P50
NR 64
TC 6
Z9 8
U1 0
U2 13
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0020-7144
EI 1744-5183
J9 INT J CLIN EXP HYP
JI Int. J. Clin. Exp. Hypn.
PD JUL 2
PY 2020
VL 68
IS 3
BP 327
EP 347
DI 10.1080/00207144.2020.1756695
EA MAY 2020
PG 21
WC Psychology, Clinical; Psychiatry
WE Social Science Citation Index (SSCI)
SC Psychology; Psychiatry
GA ND5EP
UT WOS:000532222300001
PM 32364462
DA 2026-01-16
ER

PT J
AU Srinivasan, R
   Rodgers-Melnick, SN
   Rivard, RL
   Kaiser, C
   Vincent, D
   Adan, F
   Dusek, JA
AF Srinivasan, Roshini
   Rodgers-Melnick, Samuel N.
   Rivard, Rachael L.
   Kaiser, Christine
   Vincent, David
   Adan, Francoise
   Dusek, Jeffery A.
TI Implementing paper-based patient-reported outcome collection within
   outpatient integrative health and medicine
SO PLOS ONE
LA English
DT Article
ID QUALITY-OF-LIFE; CANCER CLINICAL-TRIALS; PAIN; CARE; COMPLEMENTARY;
   INFORMATION; THERAPIES; SYMPTOMS; FUTURE; TIME
AB Objective To investigate the feasibility of pre- and post-encounter patient-reported outcome (PRO) measure collection within an outpatient integrative health and medicine (IHM) clinic and to characterize factors associated with successful completion.Methods We conducted a retrospective review of 27,464 outpatient IHM encounters including 9,520 chiropractic; 8,237 acupuncture; 5,847 massage; 2,345 IHM consultation; and 1,515 osteopathic manipulation treatment encounters at four clinics offering IHM over 18 months. Patients were asked to complete paper questionnaires rating pain, anxiety, and stress from 0-10 immediately pre- and post-encounter. Generalized linear mixed effect regression models were used to examine the relationship between demographic, clinical, and operational covariates and completing (1) pre-encounter and (2) paired (i.e., pre and post) PROs.Results Patients (N = 5587, mean age 49 years, 74% white, 77% female) generally presented for musculoskeletal conditions (81.7%), with a chief complaint of pain (55.1%). 21,852 (79.6%) encounters were among patients who completed pre-encounter PROs; 11,709/21,852 (53.6%) completed subsequent post-encounter PROs. Odds of PRO completion were more impacted by provider, operational, and clinical-level factors than patient factors. Covariates associated with increased odds of pre-encounter PRO completion included being female, having additional IHM encounters, and having a pain or anxiety complaint. Covariates associated with increased odds of paired PRO completion included being aged 31-40 vs. 51-60 years and having additional IHM encounters.Conclusion Implementing a paper-based PRO collection system in outpatient IHM is feasible; however, collecting post-encounter PROs was challenging. Future endeavors should leverage the electronic health record and patient portals to optimize PRO collection and engage patients and clinical providers.
C1 [Srinivasan, Roshini; Rodgers-Melnick, Samuel N.; Rivard, Rachael L.; Kaiser, Christine; Vincent, David; Adan, Francoise] Univ Hosp Cleveland, Connor Whole Hlth, Cleveland, OH 44106 USA.
   [Srinivasan, Roshini] Duke Univ, Sch Med, Durham, NC 27708 USA.
   [Rodgers-Melnick, Samuel N.] Case Western Reserve Univ, Sch Med, Dept Populat & Quantitat Hlth Sci, Cleveland, OH USA.
   [Rivard, Rachael L.] HealthPartners Inst, Ctr Evaluat & Survey Res, Minneapolis, MN USA.
   [Adan, Francoise] Case Western Reserve Univ, Sch Med, Dept Psychiat, Cleveland, OH USA.
   [Dusek, Jeffery A.] Univ Calif Irvine, Susan Samueli Integrat Hlth Inst, Irvine, CA USA.
   [Dusek, Jeffery A.] Univ Calif Irvine, Dept Med, Irvine, CA USA.
C3 University Hospitals of Cleveland; Duke University; University System of
   Ohio; Case Western Reserve University; University System of Ohio; Case
   Western Reserve University; University of California System; University
   of California Irvine; University of California System; University of
   California Irvine
RP Srinivasan, R (corresponding author), Univ Hosp Cleveland, Connor Whole Hlth, Cleveland, OH 44106 USA.; Srinivasan, R (corresponding author), Duke Univ, Sch Med, Durham, NC 27708 USA.
EM Rs499@duke.edu
RI Rodgers-Melnick, Samuel/ABK-4891-2022; Rivard, Rachael/IQU-0437-2023
OI Dusek, Jeffery/0000-0001-9581-0564; Srinivasan,
   Roshini/0000-0003-1967-4630; 
FX We extend our sincere gratitude to all the UHCWH patients who received
   the integrative health and medicine modalities analyzed in this study.
   We would also like to thank the following collaborators on this study:
   The Information Technology Senior Developers Carl Langdon and Ryan
   Jaskolka; study coordinators Tracy Segall, MSHS and Jessica Surdam, MPH,
   CCRC; Operations Manager Vanessa Lapohn, MPH; the patient service
   representatives; and all participating integrative health and medicine
   practitioners. We especially appreciate the generous philanthropic
   support of Chris and Sarah Connor.
CR Abrams DI, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-146
   Alghadir AH, 2018, J PAIN RES, V11, P851, DOI 10.2147/JPR.S158847
   Amorim D, 2018, COMPLEMENT THER CLIN, V31, P31, DOI 10.1016/j.ctcp.2018.01.008
   [Anonymous], 2022, QuickFacts Cuyahoga County
   Au HJ, 2010, EXPERT REV PHARM OUT, V10, P119, DOI [10.1586/erp.10.15, 10.1586/ERP.10.15]
   Basch Ethan, 2018, Am Soc Clin Oncol Educ Book, V38, P122, DOI [10.1200/edbk_200383, 10.1200/EDBK_200383]
   Bishop FL, 2010, EVID-BASED COMPL ALT, V7, P11, DOI 10.1093/ecam/nen023
   Black N, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f167
   Bokhour BG, 2020, MED CARE, V58, P295, DOI 10.1097/MLR.0000000000001316
   Brown ML, 2019, PEDIATR ANN, V48, pE226, DOI 10.3928/19382359-20190515-05
   Cella D, 2014, QUAL LIFE RES, V23, P2651, DOI 10.1007/s11136-014-0732-6
   Cella D, 2010, J CLIN EPIDEMIOL, V63, P1179, DOI 10.1016/j.jclinepi.2010.04.011
   Clarke Tainya C, 2015, Natl Health Stat Report, P1
   Coons SJ, 2015, PATIENT, V8, P301, DOI 10.1007/s40271-014-0090-z
   Corp N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200879
   Cramer H, 2018, DEPRESS ANXIETY, V35, P830, DOI 10.1002/da.22762
   Crocker RL, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/8595409
   Dale O, 2007, J CLIN EPIDEMIOL, V60, P8, DOI 10.1016/j.jclinepi.2006.04.005
   David A, 2021, CURR ONCOL REP, V23, DOI 10.1007/s11912-021-01135-6
   Dusek JA, 2018, COMPLEMENT THER MED, V37, P43, DOI 10.1016/j.ctim.2018.01.012
   Dusek JA, 2022, COMPLEMENT THER MED, V71, DOI 10.1016/j.ctim.2022.102904
   Dusek JA, 2018, J ALTERN COMPLEM MED, V24, P557, DOI 10.1089/acm.2017.0203
   Dyer NL, 2022, J INTEGR COMPLEMENT, V28, P618, DOI 10.1089/jicm.2021.0413
   Dyer NL, 2022, PAIN MED, V23, P189, DOI 10.1093/pm/pnab151
   Eton DT, 2014, PATIENT-RELAT OUTCOM, V5, P7, DOI 10.2147/PROM.S55069
   Field J, 2019, PATIENT-RELAT OUTCOM, V10, P233, DOI 10.2147/PROM.S156291
   Foster A, 2018, J PATIENT-REP OUTCOM, V2, DOI 10.1186/s41687-018-0072-3
   Ganser AL., 2016, Data quality and power in clinical trials: a comparison of ePRO and paper in a randomized trial
   Gelkopf M, 2022, INT J QUAL HEALTH C, V34, P13, DOI 10.1093/intqhc/mzz133
   Glass DC, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2350-9
   Glenwright BG, 2023, J PATIENT-REP OUTCOM, V7, DOI 10.1186/s41687-023-00554-2
   Greenwood MC, 2006, RHEUMATOLOGY, V45, P66, DOI 10.1093/rheumatology/kei100
   Hahn EA, 2007, MAYO CLIN PROC, V82, P1244, DOI 10.4065/82.10.1244
   Health NCfCaI, 2021, Complementary, alternative, or integrative health: what's in a name?
   Hui DV, 2023, J PAIN SYMPTOM MANAG, V66, pe197, DOI 10.1016/j.jpainsymman.2023.04.012
   Hyland CJ, 2022, J PATIENT-REP OUTCOM, V6, DOI 10.1186/s41687-022-00428-z
   Johnson JR, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-486
   Johnson Jill R., 2014, Journal of the National Cancer Institute Monographs, P330, DOI 10.1093/jncimonographs/lgu030
   Karamanidou C, 2020, JCO CLIN CANCER INFO, V4, P647, DOI 10.1200/CCI.20.00015
   Karvounides D, 2016, Pediatric Dimensions, V1, DOI [10.15761/pd.1000124, 10.15761/pd.1000124, 10.15761/PD.1000124]
   Kligler B, 2016, AM FAM PHYSICIAN, V94, P369
   Klinger EV, 2015, J GEN INTERN MED, V30, P719, DOI 10.1007/s11606-014-3102-8
   Kluetz PG, 2016, CLIN CANCER RES, V22, P1553, DOI 10.1158/1078-0432.CCR-15-2035
   Long C, 2022, QUAL LIFE RES, V31, P1711, DOI 10.1007/s11136-021-02999-8
   McAllister M, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-157
   Meirte Jill, 2020, JMIR Perioper Med, V3, pe15588, DOI [10.2196/15588, 10.2196/15588]
   Meister TL, 2022, J INFECT DIS, V226, P1608, DOI 10.1093/infdis/jiac170
   Mercieca-Bebber R, 2018, PATIENT-RELAT OUTCOM, V9, P353, DOI 10.2147/PROM.S156279
   Miri S, 2023, INT WOUND J, V20, P2440, DOI 10.1111/iwj.14089
   Muehlhausen W, 2015, HEALTH QUAL LIFE OUT, V13, DOI 10.1186/s12955-015-0362-x
   Murthy V, 2015, SPINE J, V15, P1870, DOI 10.1016/j.spinee.2015.04.049
   Nguyen Mai P, 2022, OTA Int, V5, pe212, DOI [10.1097/oi9.0000000000000212, 10.1097/OI9.0000000000000212]
   Prokopowicz A, 2022, GINEKOL POL, V93, P686, DOI 10.5603/GP.a2021.0197
   Rice RE, 2006, INT J MED INFORM, V75, P8, DOI 10.1016/j.ijmedinf.2005.07.032
   Robles B, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/fpubh.2017.00056
   Rodgers-Melnick SN, 2023, JMIR HUM FACTORS, V10, DOI 10.2196/46528
   Rodgers-Melnick SN, 2024, J INTEGR COMPLEMENT, V30, P57, DOI 10.1089/jicm.2022.0701
   Rodgers-Melnick SN, 2023, PAIN REP, V8, DOI 10.1097/PR9.0000000000001074
   Rodgers-Melnick SN, 2023, PEDIATR BLOOD CANCER, V70, DOI 10.1002/pbc.30243
   Rodgers-Melnick SN, 2022, INTEGR CANCER THER, V21, DOI 10.1177/15347354221142538
   Rose M, 2014, DIALOGUES CLIN NEURO, V16, P197
   Rubinstein SM, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.l689
   Ruseckaite R, 2023, HEALTH QUAL LIFE OUT, V21, DOI 10.1186/s12955-023-02155-5
   Saper Robert, 2016, Glob Adv Health Med, V5, P5, DOI [10.7453/gahmj.2015.133, 10.7453/gahmj.2015.133]
   Schamber EM, 2013, J ARTHROPLASTY, V28, P1449, DOI 10.1016/j.arth.2013.06.025
   Shi YM, 2023, J INTEGR COMPLEMENT, V29, P674, DOI 10.1089/jicm.2022.0709
   Silveira A, 2022, HEALTH QUAL LIFE OUT, V20, DOI 10.1186/s12955-022-01987-x
   Sisodia RC, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.2764
   Squitieri L, 2017, VALUE HEALTH, V20, P834, DOI 10.1016/j.jval.2017.02.003
   Stehlik J, 2017, J CARD FAIL, V23, P813, DOI 10.1016/j.cardfail.2017.09.009
   Trager RJ, 2023, BMJ OPEN, V13, DOI 10.1136/bmjopen-2023-073258
   Trager RJ, 2022, MED ACUPUNCT, V34, P177, DOI 10.1089/acu.2021.0086
   Trager RJ, 2022, BMJ OPEN, V12, DOI 10.1136/bmjopen-2021-058769
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Weldring T, 2013, HEALTH SERV INSIGHTS, V6, P61, DOI 10.4137/HSI.S11093
   Wickham H., 2022, stringr: Simple, Consistent Wrappers for Common String Operations
NR 76
TC 2
Z9 2
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 29
PY 2024
VL 19
IS 5
AR e0303985
DI 10.1371/journal.pone.0303985
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA SU6I0
UT WOS:001236995300010
PM 38809886
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Park, JW
   Jeon, JH
   Yoon, J
   Jung, TY
   Kwon, KR
   Cho, CK
   Lee, YW
   Sagar, S
   Wong, R
   Yoo, HS
AF Park, Jae-Woo
   Jeon, Ju-Hyun
   Yoon, Jeungwon
   Jung, Tae-Young
   Kwon, Ki-Rok
   Cho, Chong-Kwan
   Lee, Yeon-Weol
   Sagar, Stephen
   Wong, Raimond
   Yoo, Hwa-Seung
TI Effects of Sweet Bee Venom Pharmacopuncture Treatment for
   Chemotherapy-Induced Peripheral Neuropathy: A Case Series
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE sweet bee venom pharmacopuncture; chemotherapy-induced peripheral
   neuropathy; VAS; melittin; Korean medicine; safety
ID CANCER; INFLAMMATION; ACUPUNCTURE; APIPUNCTURE; THERAPY; PAIN
AB Objective. This is a case series reporting safety and degree of response to 1 dose level of sweet bee venom pharmacopuncture (SBVP) or melittin as a symptom-control therapy for chemotherapy-induced peripheral neuropathy (CIPN). Setting. All treatments were conducted at the East West Cancer Center (EWCC), Dunsan Oriental Hospital, Daejeon University, Republic of Korea, an institution that uses complementary therapies for cancer patients. Methods. Five consecutive patients with CIPN were referred to the EWCC from March 20, 2010, to April 10, 2010. Patients with World Health Organization Chemotherapy-Induced Peripheral Neuropathy (WHO CIPN) grade 2 or more were treated with SBVP for 3 treatment sessions over a 1-week period. Measures of efficacy and safety. Validated Visual Analog System (VAS) pain scale, WHO CIPN grade, and Functional Assessment of Cancer Therapy-General (FACT-G) were compared before and after the 1-week course of treatment. To ensure the safety of SBVP, pretreatment skin response tests were given to patients to avoid any potential anaphylactic adverse effects. All patients were closely examined for any allergenic responses following each treatment session. Results. One patient discontinued treatment after the first session, and 4 patients completed all treatment sessions. Using each patient as their own comparator, marked improvements of VAS, WHO CIPN grade, and physical section scores of FACT-G were seen in 3 patients. Most important, there were no related adverse side effects found. Conclusion. This safety results of the SBVP therapy merits further investigations in a larger size trial for it to develop into a potential intervention for managing CIPN symptoms. This study will be extended to a dose-response evaluation to further establish safety and response, prior to a randomized trial.
C1 [Park, Jae-Woo; Jeon, Ju-Hyun; Yoon, Jeungwon; Jung, Tae-Young; Cho, Chong-Kwan; Lee, Yeon-Weol; Yoo, Hwa-Seung] Daejeon Univ, Taejon, South Korea.
   [Kwon, Ki-Rok] Korean Pharmacopuncture Inst, Seoul, South Korea.
   [Sagar, Stephen; Wong, Raimond] McMaster Univ, Hamilton, ON, Canada.
C3 Daejeon University; McMaster University
RP Yoo, HS (corresponding author), Daejeon Univ, EW Canc Ctr, Dunsan Oriental Hosp, 1136 Dunsan Dong, Taejon, South Korea.
EM altyhs@dju.kr
RI Park, Jae-Woo/AAH-9097-2020
OI Sagar, Stephen/0009-0002-9013-1989
CR CARLSSON AM, 1983, PAIN, V16, P87, DOI 10.1016/0304-3959(83)90088-X
   Cavaletti G, 2002, EUR J CANCER, V38, P1832, DOI 10.1016/S0959-8049(02)00229-0
   Cella D., 1997, MANUAL FUNCTIONAL AS
   CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570
   CHAUDHRY V, 1994, ANN NEUROL, V35, P304, DOI 10.1002/ana.410350310
   Chaudhry V, 2003, NEUROLOGY, V60, P337, DOI 10.1212/01.WNL.0000043691.53710.53
   Choi YC, 2006, J PHARMACOPUNCT, V9, P105
   DOH WS, 1995, J KOR ACUP MOX SOC, V12, P211
   Hammack JE, 2002, PAIN, V98, P195, DOI 10.1016/S0304-3959(02)00047-7
   Hausheer FH, 2006, SEMIN ONCOL, V33, P15, DOI 10.1053/j.seminoncol.2005.12.010
   Kang KS, 2009, J PHARMACOPUNCT, V12, P33, DOI 10.3831/KPI.2009.12.4.033
   Kim YJ, 2009, J PHARMACOPUNCT, V12, P5, DOI 10.3831/KPI.2009.12.4.005
   Kim YS, 2005, EVID-BASED COMPL ALT, V2, P325, DOI 10.1093/ecam/neh102
   Korean Pharmacopuncture Institute Academic Committee, 2008, PHARM, P167
   Koyama N, 2007, PAIN RES, V22, P35, DOI 10.11154/pain.22.35
   KWON GR, 1998, P C KOR MED, P130
   Kwon KR, 2008, PHARMACOPUNCTUROLOGY
   Lee JD, 2005, EVID-BASED COMPL ALT, V2, P79, DOI 10.1093/ecam/neh070
   Lee JH, 2001, J VET MED SCI, V63, P251, DOI 10.1292/jvms.63.251
   Lee JS, 2006, J PHARMACOPUNCT, V9, P61
   MacPherson H, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000261
   MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
   Moon DO, 2007, INT IMMUNOPHARMACOL, V7, P1092, DOI 10.1016/j.intimp.2007.04.005
   Münstedt K, 2005, AM BEE J, V145, P665
   Ocean AJ, 2004, SUPPORT CARE CANCER, V12, P619, DOI 10.1007/s00520-004-0657-7
   Park HJ, 2004, ARTHRITIS RHEUM-US, V50, P3504, DOI 10.1002/art.20626
   Roh DH, 2004, J PAIN, V5, P297, DOI 10.1016/j.jpain.2004.05.003
   Rok KK, 2006, J PHARMACOPUNCT, V9, P79
   Verstappen CCP, 2003, DRUGS, V63, P1549, DOI 10.2165/00003495-200363150-00003
   WANG OH, 2001, J KOR ACU MOX SOC, V18, P35
   Wong Raimond, 2006, Acupunct Med, V24, P87
   Yoo HS, 2008, J PHARMACOPUNCT, V11, P21, DOI 10.3831/KPI.2008.11.1.021
NR 32
TC 40
Z9 43
U1 0
U2 18
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD JUN
PY 2012
VL 11
IS 2
BP 166
EP 171
DI 10.1177/1534735411413265
PG 6
WC Oncology; Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Integrative & Complementary Medicine
GA 953QF
UT WOS:000304885400009
PM 21715371
OA gold
DA 2026-01-16
ER

PT J
AU Miron, O
   Wolff-Sagy, Y
   Levin, M
   Lubich, E
   Lewinski, J
   Shpunt, M
   Ahmad, WA
   Borochov, I
   Netzer, D
   Lavie, G
AF Miron, Oren
   Wolff-Sagy, Yael
   Levin, Mark
   Lubich, Esti
   Lewinski, Jordan
   Shpunt, Maya
   Ahmad, Wiessam Abu
   Borochov, Ilya
   Netzer, Doron
   Lavie, Gil
TI Fentanyl Initiation Rate Following the Requirement for Specialist
   Approval
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
ID SAFETY
AB BackgroundHealthcare organizations attempt to address unwarranted fentanyl use, which often leads to increased risk of addiction and overdose.ObjectiveTo assess the impact of a requirement for a specialist's approval on fentanyl initiation for non-oncological pain.DesignA retrospective cohort study based on observational data.ParticipantsAll 4.4 million non-oncological members of Clalit Health Services were included, from July 20, 2021, to July 19, 2023.Main MeasuresThe rate of fentanyl initiation was assessed before and after the implementation of the requirement for specialist's approval, which was introduced on July 2022, and expanded 6 months later for continued use. A sub-group analysis by age group was performed, and patient characteristics and indications were assessed. We also compared total opioid dispensation in the 6th and 12th months after the implementation with the predicted rate based on pre-implementation rates.Key ResultsFentanyl initiation rate in the year before the requirement was 711 per million capita, which decreased following the requirement by - 81% (95% CI: - 77%; - 85%). The decrease attenuated with age. The prevalence of diagnosis with substance abuse disorders at the time of fentanyl initiation decreased from 6 to 3%. In the 6th and 12th months after the requirement was implemented, the morphine milligram equivalent (MME) from dispensation of total opioids was lower than predicted based on pre-implementation rates by 7% and 26%, respectively.ConclusionsRequiring specialist approval for fentanyl initiation for non-oncological chronic pain was associated with a decrease in fentanyl prescription initiations, especially among non-elderly patients. A decrease also occurred gradually in total opioid dispensations, further decreasing following the extension of the requirement to continuous fentanyl. The requirement for specialist approval upon fentanyl initiation and continuous fentanyl may present an effective tool for limiting the use of fentanyl and total opioids in healthcare systems.
C1 [Miron, Oren; Wolff-Sagy, Yael; Ahmad, Wiessam Abu; Lavie, Gil] Clalit Hlth Serv, Branch Planning & Strategy, Tel Aviv, Israel.
   [Miron, Oren] Bengurion Univ Negev, Dept Hlth Policy & Management, Beer Sheva, Israel.
   [Levin, Mark; Lubich, Esti; Lewinski, Jordan; Shpunt, Maya; Borochov, Ilya; Netzer, Doron] Clalit Hlth Serv, Community Med Serv Div, Tel Aviv, Israel.
   [Ahmad, Wiessam Abu] Hebrew Univ Jerusalem Hadassah Hosp & Med Sch, Braun Sch Publ Hlth, Jerusalem, Israel.
   [Netzer, Doron] Ariel Univ, Adelson Sch Med, Ariel, Israel.
   [Lavie, Gil] Technion Israel Inst Technol, Ruth & Bruce Rappaport Fac Med, Haifa, Israel.
C3 Clalit Health Services; Ben-Gurion University of the Negev; Clalit
   Health Services; Hebrew University of Jerusalem; Hadassah University
   Medical Center; Hadassah University Hospital; Ariel University; Technion
   Israel Institute of Technology; Rappaport Faculty of Medicine
RP Miron, O (corresponding author), Clalit Hlth Serv, Branch Planning & Strategy, Tel Aviv, Israel.
EM Orenmir@post.bgu.ac.il
RI Wolff Sagy, Yael/NXC-0158-2025
OI Wolff Sagy, Yael/0000-0002-2007-343X
CR Abouk R, 2021, ECON HUM BIOL, V42, DOI 10.1016/j.ehb.2021.101000
   Aggarwal P, 2021, J AM ACAD DERMATOL, V85, P388, DOI 10.1016/j.jaad.2021.03.109
   Ahmad F.B., 2024, Provisional drug overdose death counts, DOI DOI 10.5281/ZENODO.13352530
   Allen LD, 2024, JAMA-HEALTH FORUM, V5, DOI 10.1001/jamahealthforum.2023.4731
   [Anonymous], 2022, I24 NEWS        0105
   Dressler RL, 2023, ISR J HEALTH POLICY, V12, DOI 10.1186/s13584-023-00581-w
   Evans WN, 2019, REV ECON STAT, V101, P1, DOI 10.1162/rest_a_00755
   Fox LM, 2018, ADDICTION, V113, P59, DOI 10.1111/add.13925
   Friesen KJ, 2016, CAN MED ASSOC J, V188, P648, DOI 10.1503/cmaj.150961
   Israel Central Bureau of Statistics, 2021, CHARACTERIZATION CLA
   Jeffery MM, 2020, MED CARE, V58, P4, DOI 10.1097/MLR.0000000000001221
   Jeffery MM, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.2875
   McEvoy Theresa, 2014, Hosp Pharm, V49, P942, DOI 10.1310/hpj4910-942
   McGinty EE, 2022, ANN INTERN MED, V175, P617, DOI 10.7326/M21-4363
   Ministry of Health, 2016, GUIDELINES NARCOTICS
   Miron O, 2020, REGION ANESTH PAIN M
   Miron O, 2021, MEDRXIV
   OECD, ADDRESSING PROBLEMAT
NR 18
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD SEP
PY 2025
VL 40
IS 13
BP 3097
EP 3103
DI 10.1007/s11606-024-09160-4
EA NOV 2024
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; General & Internal Medicine
GA 8IU9V
UT WOS:001347891300007
PM 39495456
OA Green Accepted, Bronze
DA 2026-01-16
ER

PT J
AU Bari, S
   Chineke, I
   Darwin, A
   Umar, A
   Jim, H
   Muzaffar, J
   Kucuk, O
AF Bari, Shahla
   Chineke, Iloabueke
   Darwin, Alicia
   Umar, Anam
   Jim, Heather
   Muzaffar, Jameel
   Kucuk, Omer
TI Awareness, Use and Outlook of Complementary and Alternative Medicine
   (CAM) Options in an Underserved, Uninsured Minority Cancer Patient
   Population
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE complementary medicine; alternative medicine; integrative medicine;
   health disparity; CAM
ID DISCLOSURE; COMMUNICATION; THERAPIES
AB Integrative oncology aims to coordinate the delivery of conventional medicine and evidence-supported complementary and alternative medicine (CAM) to patients receiving cancer care. This field developed out of an increased interest in CAM usage among cancer patients. However, CAM use among medically underserved cancer patients remains to be well characterized. We evaluated CAM awareness as well as prevalence and characteristics of CAM use in 170 consecutive, medically underserved cancer patients presenting to a large, academic, inner-city cancer clinic, using a survey tool. Fifty-three participants declined participation and 17 survey results were incomplete. Therefore, 100 survey results were included in the final analysis. There were 65 males and 35 females in the survey with a mean age of 64.2 years. About 98% of the respondents were African American while 2% identified themselves as Hispanic. About 45% of patients had metastatic cancer, 24% had early-stage disease while 31% of patients were not aware of the stage of their cancer. About 55% patients had elementary school or lower level of education while only 16% had a college degree or higher. About 92% of respondents were unemployed. Some knowledge of CAM was reported by 22% of patients, while CAM use was reported in only 16% of patients. Female sex and college degree were significantly associated with CAM use. The most commonly used CAM modality was meditation (56%), followed by herbal remedies (31%), yoga (31%), and acupuncture (12%). Among CAM users, a majority used multiple CAM therapies. All users reported benefit from CAM use. Emotional wellbeing was the most common benefit followed by improvement in treatment related adverse effects, chemotherapy related symptoms, pain, and sleep. Even though the majority of our surveyed patients never used CAM, 90% of non-users were interested in gaining more information about the various CAM options and exploring its use and potential benefits. The majority (70%) wanted their primary oncologist to provide information about CAM options and discuss its safety and potential complementary benefit in management of their cancer and associated symptoms.
C1 [Bari, Shahla; Jim, Heather; Muzaffar, Jameel] H Lee Moffitt Canc Ctr & Res Inst, 12902 USF Magnolia Dr, Tampa, FL 33612 USA.
   [Bari, Shahla; Chineke, Iloabueke; Umar, Anam] Morehouse Sch Med, Atlanta, GA 30310 USA.
   [Darwin, Alicia] Univ S Florida, Tampa, FL 33620 USA.
   [Kucuk, Omer] Emory Univ, Atlanta, GA 30322 USA.
C3 State University System of Florida; University of South Florida; H Lee
   Moffitt Cancer Center & Research Institute; Morehouse School of
   Medicine; State University System of Florida; University of South
   Florida; Emory University
RP Bari, S (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, 12902 USF Magnolia Dr, Tampa, FL 33612 USA.
EM Shahla.bari@moffitt.org
RI Jim, Heather/T-2957-2019; Muzaffar, Jameel/OOM-8994-2025
OI bari, shahla/0000-0002-8459-8518; Darwin, Alicia/0000-0002-7776-3263
CR [Anonymous], 2010, QUICKFACTS
   Barry CA, 2006, SOC SCI MED, V62, P2646, DOI 10.1016/j.socscimed.2005.11.025
   Black DS, 2016, J ALTERN COMPLEM MED, V22, P473, DOI 10.1089/acm.2015.0332
   Cassileth BR, 2005, J CLIN ONCOL, V23, P2590, DOI 10.1200/JCO.2005.11.922
   Chao MT, 2008, ETHNIC DIS, V18, P65
   Collins Sara R, 2015, Issue Brief (Commonw Fund), V2, P1
   Davis EL, 2012, ONCOLOGIST, V17, P1475, DOI 10.1634/theoncologist.2012-0223
   Grotmol KS, 2017, J PAIN SYMPTOM MANAG, V54, P889, DOI 10.1016/j.jpainsymman.2017.04.010
   Horneber M, 2012, INTEGR CANCER THER, V11, P187, DOI 10.1177/1534735411423920
   Jones D, 2018, INTEGR CANCER THER, V17, P371, DOI 10.1177/1534735417735892
   Luo QL, 2017, INTEGR CANCER THER, V16, P104, DOI 10.1177/1534735416643384
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Markman M, 2002, J CLIN ONCOL, V20, p39S, DOI 10.1200/JCO.2002.07.036
   National Center for Complementary and Alternative Medicine, COMPLEMENTARY ALTERN
   Paltiel O, 2001, J CLIN ONCOL, V19, P2439, DOI 10.1200/JCO.2001.19.9.2439
   Robinson A, 2004, COMPLEMENT THER MED, V12, P90, DOI 10.1016/j.ctim.2004.09.006
   Robotin MC, 2006, MED J AUSTRALIA, V185, P377, DOI 10.5694/j.1326-5377.2006.tb00614.x
   Sohl SJ, 2015, CANCER-AM CANCER SOC, V121, P900, DOI 10.1002/cncr.29138
   Wanchai A, 2010, CLIN J ONCOL NURS, V14, P431, DOI 10.1188/10.CJON.E45-E55
   Witt Claudia M., 2017, Journal of the National Cancer Institute Monographs, P3, DOI [10.1093/jncimonographs/lgx012, 10.1093/jncimonographs/lgx012]
   Yun Hyeongjun, 2017, Journal of the National Cancer Institute Monographs, P29, DOI [10.1093/jncimonographs/lgx004, 10.1093/jncimonographs/lgx004]
NR 21
TC 15
Z9 16
U1 2
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD DEC
PY 2021
VL 20
AR 15347354211051622
DI 10.1177/15347354211051622
PG 6
WC Oncology; Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Integrative & Complementary Medicine
GA XV2BL
UT WOS:000734753900003
PM 34923869
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Mezzanotte, JN
   Grimm, M
   Shinde, N
   Nolan, T
   Worthen-Chaudhari, L
   Williams, NO
   Lustberg, MB
AF Mezzanotte, Jessica N.
   Grimm, Michael
   Shinde, Namrata, V
   Nolan, Timiya
   Worthen-Chaudhari, Lise
   Williams, Nicole O.
   Lustberg, Maryam B.
TI Updates in the Treatment of Chemotherapy-Induced Peripheral Neuropathy
SO CURRENT TREATMENT OPTIONS IN ONCOLOGY
LA English
DT Review
DE Chemotherapy-induced peripheral neuropathy; Duloxetine; Acupuncture;
   Exercise therapy
ID PLACEBO-CONTROLLED TRIAL; CANCER-PATIENTS; DOUBLE-BLIND; TOPICAL
   AMITRIPTYLINE; SCRAMBLER THERAPY; PAIN; PREVENTION; PACLITAXEL;
   MANAGEMENT; OXALIPLATIN
AB Opinion statement Chemotherapy-induced peripheral neuropathy (CIPN) is a common toxicity associated with treatment with platinum-based agents, taxanes, vinca alkaloids, and other specific agents. The long-term consequences of this condition can result in decreased patient quality of life and can lead to reduced dose intensity, which can negatively impact disease outcomes. There are currently no evidence-based preventative strategies for CIPN and only limited options for treatment. However, there are several strategies that can be utilized to improve patient experience and outcomes as more data are gathered in the prevention and treatment setting. Before treatment, patient education on the potential side effects of chemotherapy is key, and although trials have been limited, recommending exercise and a healthy lifestyle before and while undergoing chemotherapy may provide some overall benefit. In patients who develop painful CIPN, our approach is to offer duloxetine and titrate up to 60 mg daily. Chemotherapy doses may also need to be reduced if intolerable symptoms develop during treatment. Some patients may also try acupuncture and physical therapy to help address their symptoms, although this can be limited by cost, time commitment, and patient motivation. Additionally, data on these modalities are currently limited, as studies are ongoing. Overall, approaching each patient on an individual level and tailoring treatment options for them based on overall physical condition, their disease burden, goals of care and co-morbid health conditions, and willingness to trial different approaches is necessary when addressing CIPN.
C1 [Mezzanotte, Jessica N.] Ohio State Univ, Wexner Med Ctr, Dept Internal Med, 395 W 12th Ave,Room 3348, Columbus, OH 43210 USA.
   [Grimm, Michael] Ohio State Univ, Comprehens Canc Ctr, 460 W 10th Ave, Columbus, OH 43210 USA.
   [Shinde, Namrata, V] Ohio State Univ, Wexner Med Ctr, Dept Radiol, 395 W 12th Ave, Columbus, OH 43210 USA.
   [Nolan, Timiya] Ohio State Univ, Coll Nursing, 1585 Neil Ave, Columbus, OH 43210 USA.
   [Worthen-Chaudhari, Lise] Ohio State Univ, Wexner Med Ctr, Dept Phys Med & Rehabil, 480 Med Ctr Dr,Dodd Hall,Suite 1060, Columbus, OH 43210 USA.
   [Williams, Nicole O.] Ohio State Univ, Wexner Med Ctr, Dept Med Oncol, 1800 Cannon Dr,1310K Lincoln Tower, Columbus, OH 43210 USA.
   [Lustberg, Maryam B.] Smilow Canc Hosp, Yale Canc Ctr, 35 Pk St, New Haven, CT 06519 USA.
C3 University System of Ohio; Ohio State University; University System of
   Ohio; Ohio State University; James Cancer Hospital & Solove Research
   Institute; University System of Ohio; Ohio State University; University
   System of Ohio; Ohio State University; University System of Ohio; Ohio
   State University; University System of Ohio; Ohio State University; Yale
   University; Yale New Haven Hospital
RP Lustberg, MB (corresponding author), Smilow Canc Hosp, Yale Canc Ctr, 35 Pk St, New Haven, CT 06519 USA.
EM Maryam.lustberg@yale.edu
RI ; Worthen-Chaudhari, Lise/B-5618-2012
OI Nolan, Timiya/0000-0002-6700-3105; Worthen-Chaudhari,
   Lise/0000-0003-1826-0380; Mezzanotte Sharpe, Jessica/0000-0003-2041-5978
FU National Cancer Institute [R01CA238946] Funding Source: NIH RePORTER;
   National Institute on Aging [R21AG068831] Funding Source: NIH RePORTER;
   NCI NIH HHS [R01 CA238946] Funding Source: Medline; NIA NIH HHS [R21
   AG068831] Funding Source: Medline
CR Alkislar I, 2021, BIOL PSYCHIAT-COGN N, V6, P479, DOI 10.1016/j.bpsc.2020.11.015
   Ambrosone CB, 2020, J CLIN ONCOL, V38, P804, DOI 10.1200/JCO.19.01203
   Aziz MT, 2014, ANN PHARMACOTHER, V48, P626, DOI 10.1177/1060028014525033
   Bao T, 2020, JNCI CANCER SPECT, V4, DOI 10.1093/jncics/pkaa048
   Barton DL, 2011, SUPPORT CARE CANCER, V19, P833, DOI 10.1007/s00520-010-0911-0
   Ben-Horin I, 2017, INTEGR CANCER THER, V16, P258, DOI 10.1177/1534735417690254
   Besson M, 2015, PAIN, V156, P397, DOI 10.1097/01.j.pain.0000460331.33385.e8
   Bland KA, 2019, CLIN BREAST CANCER, V19, P411, DOI 10.1016/j.clbc.2019.05.013
   Bonhof CS, 2018, GYNECOL ONCOL, V149, P455, DOI 10.1016/j.ygyno.2018.03.052
   Brown TJ, 2019, JAMA ONCOL, V5, P750, DOI 10.1001/jamaoncol.2018.6771
   Caillaud M, 2021, CANCERS, V13, DOI 10.3390/cancers13010069
   Chen SC, 2020, EUR J ONCOL NURS, V49, DOI 10.1016/j.ejon.2020.101834
   Clark PG, 2012, J EVID-BASED INTEGR, V17, P161, DOI 10.1177/2156587212450175
   Courneya KS, 2014, CANCER EPIDEM BIOMAR, V23, P857, DOI 10.1158/1055-9965.EPI-13-1163
   Coyne Patrick J, 2013, J Pain Palliat Care Pharmacother, V27, P359, DOI 10.3109/15360288.2013.847519
   Desideri I, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-0907-4
   Dhawan S, 2020, CANCER NURS, V43, P269, DOI 10.1097/NCC.0000000000000693
   Dorsey SG, 2019, JNCI-J NATL CANCER I, V111, P531, DOI 10.1093/jnci/djz011
   Duregon F, 2018, CRIT REV ONCOL HEMAT, V121, P90, DOI 10.1016/j.critrevonc.2017.11.002
   Fallon MT, 2015, SUPPORT CARE CANCER, V23, P2769, DOI 10.1007/s00520-015-2642-8
   Farshchian N, 2018, CANCER CHEMOTH PHARM, V82, P787, DOI 10.1007/s00280-018-3664-y
   Fradkin M, 2019, CURR MED CHEM, V26, P4698, DOI 10.2174/0929867326666190107163756
   Fujita S, 2019, J NEUROCHEM, V148, P373, DOI 10.1111/jnc.14607
   Galantino ML, 2019, INTEGR CANCER THER, V18, DOI 10.1177/1534735419850627
   Gamelin E, 2002, SEMIN ONCOL, V29, P21, DOI 10.1053/sonc.2002.35525
   Gerdts J, 2015, SCIENCE, V348, P453, DOI 10.1126/science.1258366
   Gewandter JS, 2013, SUPPORT CARE CANCER, V21, P2059, DOI 10.1007/s00520-013-1766-y
   Gewandter JS, 2018, NEUROLOGY, V91, P403, DOI 10.1212/WNL.0000000000006083
   Gewandter JS, 2014, SUPPORT CARE CANCER, V22, P1807, DOI 10.1007/s00520-014-2158-7
   Glimelius B, 2018, ACTA ONCOL, V57, P393, DOI 10.1080/0284186X.2017.1398836
   Hammack JE, 2002, PAIN, V98, P195, DOI 10.1016/S0304-3959(02)00047-7
   Hammond EA, 2020, NEUROREHAB NEURAL RE, V34, P235, DOI 10.1177/1545968319899918
   Hanai A, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx178
   Hartrick CT, 2012, EXPERT OPIN INV DRUG, V21, P1827, DOI 10.1517/13543784.2012.731393
   Hershman DL, 2013, J CLIN ONCOL, V31, P2627, DOI 10.1200/JCO.2012.44.8738
   Hoschneider DP, 2007, BRAIN RES, V1184, P96, DOI 10.1016/j.brainres.2007.09.081
   Hu SY, 2019, CLIN CANCER RES, V25, P6295, DOI 10.1158/1078-0432.CCR-18-2152
   Jordan B, 2020, ANN ONCOL, V31, P1306, DOI 10.1016/j.annonc.2020.07.003
   Kanbayashi Y, 2020, BREAST, V49, P219, DOI 10.1016/j.breast.2019.12.011
   Kanzawa-Lee GA, 2020, CANCER NURS, V43, pE172, DOI 10.1097/NCC.0000000000000801
   Kautio AL, 2008, J PAIN SYMPTOM MANAG, V35, P31, DOI 10.1016/j.jpainsymman.2007.02.043
   Kelley MR, 2016, J PHARMACOL EXP THER, V359, P300, DOI 10.1124/jpet.116.235283
   Kelley MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106485
   Kerr GW, 2001, EMERG MED J, V18, P236, DOI 10.1136/emj.18.4.236
   Kleckner IR, 2018, SUPPORT CARE CANCER, V26, P1019, DOI 10.1007/s00520-017-4013-0
   Kneis S, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5522-7
   Kroigård T, 2014, EUR J NEUROL, V21, P623, DOI 10.1111/ene.12353
   Kyte SL, 2018, J PHARMACOL EXP THER, V364, P110, DOI 10.1124/jpet.117.243972
   Leonard GD, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-116
   Li Y, 2018, J NEUROSCI, V38, P1124, DOI 10.1523/JNEUROSCI.0899-17.2017
   Loprinzi C, 2020, SUPPORT CARE CANCER, V28, P1183, DOI 10.1007/s00520-019-04881-3
   Loprinzi CL, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01399
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Maihöfner C, 2021, SUPPORT CARE CANCER, V29, P4223, DOI 10.1007/s00520-021-06042-x
   Masocha W, 2018, PAIN RES MANAG, V2018, DOI 10.1155/2018/5234943
   McCrary JM, 2019, SUPPORT CARE CANCER, V27, P3849, DOI 10.1007/s00520-019-04680-w
   Mercadante S, 2015, EXPERT REV NEUROTHER, V15, P1249, DOI 10.1586/14737175.2015.1101347
   Mishra S, 2012, AM J HOSP PALLIAT ME, V29, P177, DOI 10.1177/1049909111412539
   Mongiovi JM, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-1077-9
   Mustafa G, 2013, PAIN, V154, P2547, DOI 10.1016/j.pain.2013.07.041
   Nyrop KA, 2019, CANCER-AM CANCER SOC, V125, P2945, DOI 10.1002/cncr.32175
   Pachman DR, 2015, SUPPORT CARE CANCER, V23, P943, DOI 10.1007/s00520-014-2424-8
   Paice JA, 2019, J NATL COMPR CANC NE, V17, P595, DOI 10.6004/jnccn.2019.5010
   Paice JA, 2019, CURR TREAT OPTION ON, V20, DOI 10.1007/s11864-019-0647-0
   Paice JA, 2017, J PAIN, V18, P233, DOI 10.1016/j.jpain.2016.10.020
   Pease-Raissi SE, 2017, NEURON, V96, P373, DOI 10.1016/j.neuron.2017.09.034
   Piccolo J, 2014, AM J HEALTH-SYST PH, V71, P19, DOI 10.2146/ajhp130126
   Prinsloo S, 2018, J PAIN SYMPTOM MANAG, V55, P1276, DOI 10.1016/j.jpainsymman.2018.01.010
   Prinsloo S, 2017, CANCER-AM CANCER SOC, V123, P1989, DOI 10.1002/cncr.30649
   Privitera R, 2021, CURR OPIN SUPPORT PA, V15, P125, DOI 10.1097/SPC.0000000000000545
   Rao RD, 2008, CANCER, V112, P2802, DOI 10.1002/cncr.23482
   Rao RD, 2007, CANCER-AM CANCER SOC, V110, P2110, DOI 10.1002/cncr.23008
   Rosenbaek F, 2020, SUPPORT CARE CANCER, V28, P3763, DOI 10.1007/s00520-019-05196-z
   Saif MW, 2008, CANCER CHEMOTH PHARM, V61, P349, DOI 10.1007/s00280-007-0584-7
   Schneider BP, 2015, ADV EXP MED BIOL, V862, P77, DOI 10.1007/978-3-319-16366-6_6
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Schwenk M, 2016, GERONTOLOGY, V62, P553, DOI 10.1159/000442253
   Shah A, 2018, J NEUROL NEUROSUR PS, V89, P636, DOI 10.1136/jnnp-2017-317215
   Shi ZX, 2020, BREAST CANCER RES TR, V179, P229, DOI 10.1007/s10549-019-05457-9
   Shigematsu H, 2020, SUPPORT CARE CANCER, V28, P5005, DOI 10.1007/s00520-020-05345-9
   Shinde SS, 2016, SUPPORT CARE CANCER, V24, P547, DOI 10.1007/s00520-015-2807-5
   Siddiqui, 2021, CANCERS, V13
   Smith EML, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12421
   Smith EML, 2018, CANCER CONTROL, V25, DOI 10.1177/1073274818756608
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Smith TJ, 2020, J PALLIAT CARE, V35, P53, DOI 10.1177/0825859719827589
   Speck R, 2012, SUPPORT CARE CANCER, V20, P2433, DOI 10.1007/s00520-011-1365-8
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Storey Dawn J, 2010, J Pain Symptom Manage, V39, pe2, DOI 10.1016/j.jpainsymman.2010.02.004
   Streckmann F, 2019, SUPPORT CARE CANCER, V27, P2471, DOI 10.1007/s00520-018-4531-4
   Szepanowski F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0612-9
   Tan AC, 2019, SUPPORT CARE CANCER, V27, P4771, DOI 10.1007/s00520-019-04781-6
   Ulker E, 2020, ONCOLOGIST, V25, P189, DOI 10.1634/theoncologist.2019-0540
   Waissengrin B, 2021, THER ADV MED ONCOL, V13, DOI 10.1177/1758835921990203
   Ward SJ, 2014, BRIT J PHARMACOL, V171, P636, DOI 10.1111/bph.12439
   Wesselink E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10040398
   Wong Raimond, 2006, Acupunct Med, V24, P87
   Zajaczkowska R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061451
   Zhu J, 2016, SCI REP-UK, V6, DOI 10.1038/srep28861
   Zhu YY, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-19
   Zimmer P, 2018, SUPPORT CARE CANCER, V26, P615, DOI 10.1007/s00520-017-3875-5
   Zirpoli GR, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx098
NR 102
TC 50
Z9 57
U1 3
U2 25
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1527-2729
EI 1534-6277
J9 CURR TREAT OPTION ON
JI Curr. Treat. Options Oncol.
PD JAN
PY 2022
VL 23
IS 1
BP 29
EP 42
DI 10.1007/s11864-021-00926-0
EA FEB 2022
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ZL0UR
UT WOS:000759028700004
PM 35167004
OA Green Submitted
DA 2026-01-16
ER

PT J
AU Ko, MM
   Jang, S
   Lee, JA
   Kang, BK
   Jung, J
AF Ko, Mi Mi
   Jang, Soobin
   Lee, Ju Ah
   Kang, Byung Kab
   Jung, Jeeyoun
TI Blood Stasis Therapy for Traumatic Injury: A Prospective, Single-Arm,
   Pre-Post Pilot Study
SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
DE blood stasis; diagnosis; Traditional Korean Medicine; traumatic injury;
   pain; perfusion index
ID PERFUSION INDEX; STIMULATION
AB Objectives: Blood stasis is an important pathophysiologic concept in Traditional East Asian Medicine. It has been considered to be a pathogenic factor in chronic and incurable conditions such as pain, infertility, cancer, coronary heart disease, and others. The aim of this study was to investigate the effects of pain reduction by blood stasis treatment for blood stasis syndromes with traumatic injury. Methods: A single-center prospective pretest-post-test pilot study included 73 patients with a trauma that occurred within the past 2 weeks who were admitted into Jaseng Hospital of Korean Medicine from August 2015 through December 2015. Of the 50 patients analyzed in this study, 42 were women (mean age, 33.52). Triple Energizer-reinforcing Saam acupuncture set, herbal medicine (Dangkwisoo-san), and wet cupping on tender point, which are Korean medical therapies generally executed to treat post-traumatic pain, were performed. The patients had to receive at least six sessions of treatment during the 2 weeks, with subsequent treatment being performed within 31 days after the previous treatment. Numeric rating scale (NRS) score and general pain severity indicator was measured as a primary outcome measure. The blood stasis questionnaire, oximetry, and patient's satisfaction were also measured. Results: The mean size of subcutaneous bleeding (width and length) and NRS score as a general pain indicator significantly decreased over the visits (all p<0.01, visit 1 vs. visit 6). Among the blood stasis symptoms in the questionnaire, 11 blood stasis indicators significantly decreased (all p<0.05). The patients showed significant improvement in the minimum and maximum value of peripheral perfusion index after the treatment (p=0.011 and p=0.15, respectively). Conclusions: This study reveals that blood stasis treatment may help improve the pain of patients with traumatic injury by enhancing the peripheral blood flow. The significant results observed in this study support some evidence of the theories of diagnosing blood stasis pattern and treatments of that pattern in Korean Medicine.
C1 [Ko, Mi Mi; Jang, Soobin; Kang, Byung Kab; Jung, Jeeyoun] Korea Inst Oriental Med, Clin Med Div, Daejeon 305811, South Korea.
   [Lee, Ju Ah] Gachon Univ, Coll Korean Med, Dept Korean Internal Med, Seongnam, South Korea.
C3 Korea Institute of Oriental Medicine (KIOM); Gachon University
RP Jung, J (corresponding author), Korea Inst Oriental Med, Clin Med Div, Daejeon 305811, South Korea.
EM jjy0918@kiom.re.kr
RI Jung, Jeeyoun/G-8438-2018; KO, MIMI/D-5341-2011; Jang,
   Soobin/ODN-1434-2025
OI Jang, Soobin/0000-0003-0943-9290
FU Korea Institute of Oriental Medicine [K18191, K18192]
FX This research was supported by a Grant from the Korea Institute of
   Oriental Medicine (K18191 and K18192). The authors thank the Gangnam and
   Daejeon branches of Jaseng Oriental Medicinal Hospital for this study.
CR [Anonymous], 2018, RAD 7 PULS COOX
   [Anonymous], 2019, W PAC REG PARTN FOR
   김유진, 2008, [Journal of Korean Medicine Rehabilitation, 한방재활의학과학회지], V18, P119
   Choi TY, 2016, EUR J INTEGR MED, V8, P158, DOI 10.1016/j.eujim.2015.09.137
   De Felice C, 2002, EUR J PEDIATR, V161, P561, DOI 10.1007/s00431-002-1042-5
   신경민, 2010, Journal of Acupuncture Research, V27, P83
   Fang LY, 1991, ZHONG XI YI JIE HE Z, V11, p[411, 389]
   Gunter RN, 2007, BLOOD STASISCHINAS C
   Hagar H, 2004, Anesthesiology, V101, pA514
   HALES JRS, 1989, CLIN EXP PHARMACOL P, V16, P403, DOI 10.1111/j.1440-1681.1989.tb01578.x
   Hasanin A, 2017, J CLIN MONIT COMPUT, V31, P961, DOI 10.1007/s10877-016-9936-3
   Hsiu H, 2011, MICROVASC RES, V81, P289, DOI 10.1016/j.mvr.2011.03.001
   Jeong Suhyeon, 2015, [Journal of Korean Medicine Rehabilitation, 한방재활의학과학회지], V25, P87, DOI 10.18325/jkmr.2015.25.1.087
   Jin XY, 2008, J ETHNOPHARMACOL, V117, P473, DOI 10.1016/j.jep.2008.02.033
   Jung J, 2018, CHIN J INTEGR MED, V24, P254, DOI 10.1007/s11655-017-2788-y
   Jung J, 2018, CHIN J INTEGR MED, V24, P752, DOI 10.1007/s11655-017-2813-1
   Kang BK, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/8049481
   Kim Ji Hyun, 2011, Evid Based Complement Alternat Med, V2011, P718302, DOI 10.1155/2011/718302
   Knapp TR, 2016, CLIN NURS RES, V25, P467, DOI 10.1177/1054773816666280
   Korea Center for Disease Control and Prevention, 2015, CHRON DIS STAT ISS 2
   Lee JA, 2014, EUR J INTEGR MED, V7, P417
   Lee SMK, 2014, NUTR HEALTH SER, P423, DOI 10.1007/978-1-4939-0548-5_29
   Liao JQ, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005533
   Liu H, 1993, Zhongguo Zhong Xi Yi Jie He Za Zhi, V13, P714
   M.D. Sung Uk Cho，, 2011, [Journal of The Korean Society of Emergency Medicine, 대한응급의학회지], V22, P59
   Moon S.-K., 2005, The Journal of Korean Medicine, V26, P115
   Nishimura T, 2014, J PAIN RES, V7, P91, DOI 10.2147/JPR.S57140
   Park B, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/316872
   Park B, 2014, AM J TRANSL RES, V6, P857
   김도형, 2014, [The Journal of Korean Oriental Internal Medicine, 대한한방내과학회지], V35, P24
   Ryu SH, 2001, KOREAN J ORIENTAL IN, V22, P199
   Shi N, 2008, CHIN J INTEGR MED, V14, P303, DOI 10.1007/s11655-008-0303-1
   Terasawa K, 1983, JPN J ORIENT MED, V34, P1, DOI DOI 10.3937/KAMPOMED.34.1
   Xu QY, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/490292
   Yang DH, 2006, J Korea Inst Orient Med Diag, V10, P141
   Yu G, 2014, CHIN J INTEGR MED, V20, P300, DOI 10.1007/s11655-013-1332-3
   Zhang J Z, 1993, Zhongguo Zhong Xi Yi Jie He Za Zhi, V13, P397
NR 37
TC 7
Z9 8
U1 0
U2 11
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1075-5535
EI 1557-7708
J9 J ALTERN COMPLEM MED
JI J. Altern. Complement Med.
PD MAR
PY 2019
VL 25
IS 3
BP 359
EP 365
DI 10.1089/acm.2018.0134
PG 7
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA HR6SW
UT WOS:000463284500011
PM 30156424
DA 2026-01-16
ER

PT J
AU Kasozi, KI
   Niedbala, G
   Alqarni, M
   Zirintunda, G
   Ssempijja, F
   Musinguzi, SP
   Usman, IM
   Matama, K
   Hetta, HF
   Mbiydzenyuy, NE
   Batiha, GE
   Beshbishy, AM
   Welburn, SC
AF Kasozi, Keneth Iceland
   Niedbala, Gniewko
   Alqarni, Mohammed
   Zirintunda, Gerald
   Ssempijja, Fred
   Musinguzi, Simon Peter
   Usman, Ibe Michael
   Matama, Kevin
   Hetta, Helal F.
   Mbiydzenyuy, Ngala Elvis
   Batiha, Gaber El-Saber
   Beshbishy, Amany Magdy
   Welburn, Susan Christina
TI Bee Venom-A Potential Complementary Medicine Candidate for SARS-CoV-2
   Infections
SO FRONTIERS IN PUBLIC HEALTH
LA English
DT Review
DE bee venom; complementary medicine and alternative medicine; SARS-CoV-2
   (2019-nCoV); pharmokinetics of bee poison; COVID-19 and complementary
   medicine; bee venom in clinical trials
ID PHOSPHOLIPASE A(2); IN-VITRO; MELITTIN; CELLS; COVID-19; PAIN;
   IMMUNOTHERAPY; ACUPUNCTURE; MODEL; EPIDEMIOLOGY
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by severe cytokine storm syndrome following inflammation. SARS-CoV-2 directly interacts with angiotensin-converting enzyme 2 (ACE-2) receptors in the human body. Complementary therapies that impact on expression of IgE and IgG antibodies, including administration of bee venom (BV), have efficacy in the management of arthritis, and Parkinson's disease. A recent epidemiological study in China showed that local beekeepers have a level of immunity against SARS-CoV-2 with and without previous exposure to virus. BV anti-inflammatory properties are associated with melittin and phospholipase A2 (PLA2), both of which show activity against enveloped and non-enveloped viruses, including H1N1 and HIV, with activity mediated through antagonist activity against interleukin-6 (IL-6), IL-8, interferon-gamma (IFN-gamma), and tumor necrosis factor-alpha (TNF-alpha). Melittin is associated with the underexpression of proinflammatory cytokines, including nuclear factor-kappa B (NF-kappa B), extracellular signal-regulated kinases (ERK1/2), and protein kinase Akt. BV therapy also involves group III secretory phospholipase A(2) in the management of respiratory and neurological diseases. BV activation of the cellular and humoral immune systems should be explored for the application of complementary medicine for the management of SARS-CoV-2 infections. BV "vaccination" is used to immunize against cytomegalovirus and can suppress metastases through the PLA2 and phosphatidylinositol-(3,4)-bisphosphate pathways. That BV shows efficacy for HIV and H1NI offers opportunity as a candidate for complementary therapy for protection against SARS-CoV-2.
C1 [Kasozi, Keneth Iceland; Welburn, Susan Christina] Univ Edinburgh, Coll Med & Vet Med, Infect Med, Deanery Biomed Sci, Edinburgh, Midlothian, Scotland.
   [Kasozi, Keneth Iceland; Musinguzi, Simon Peter] Kabale Univ, Sch Med, Kabale, Uganda.
   [Niedbala, Gniewko] Poznan Univ Life Sci, Fac Environm Engn & Mech Engn, Dept Biosyst Engn, Poznan, Poland.
   [Alqarni, Mohammed] Taif Univ, Coll Pharm, Dept Pharmaceut Chem, At Taif, Saudi Arabia.
   [Zirintunda, Gerald] Busitema Univ, Fac Agr & Anim Sci, Arapai Campus, Soroti, Uganda.
   [Ssempijja, Fred; Usman, Ibe Michael] Kampala Int Univ, Fac Biomed Sci, Western Campus, Bushenyi, Uganda.
   [Matama, Kevin] Kampala Int Univ, Sch Pharm, Dept Clin Pharm & Pharm Practice, Western Campus, Bushenyi, Uganda.
   [Hetta, Helal F.] Assiut Univ, Fac Med, Dept Med Microbiol & Immunol, Assiut, Egypt.
   [Mbiydzenyuy, Ngala Elvis] Copperbelt Univ, Michael Chilufya Sata Sch Med, Dept Basic Med Sci, Ndola, Zambia.
   [Batiha, Gaber El-Saber] Damanhour Univ, Fac Vet Med, Dept Pharmacol & Therapeut, Damanhour, Egypt.
   [Beshbishy, Amany Magdy] Obihiro Univ Agr & Vet Med, Natl Res Ctr Protozoan Dis, Obihiro, Hokkaido, Japan.
   [Welburn, Susan Christina] Zhejiang Univ, Sch Med, Univ Edinburgh Inst, Haining, Peoples R China.
C3 University of Edinburgh; Kabale University; Poznan University of Life
   Sciences; Taif University; Busitema University; Egyptian Knowledge Bank
   (EKB); Assiut University; Copperbelt University; Egyptian Knowledge Bank
   (EKB); Damanhour University; Obihiro University of Agriculture &
   Veterinary Medicine; Zhejiang University
RP Kasozi, KI; Welburn, SC (corresponding author), Univ Edinburgh, Coll Med & Vet Med, Infect Med, Deanery Biomed Sci, Edinburgh, Midlothian, Scotland.; Kasozi, KI (corresponding author), Kabale Univ, Sch Med, Kabale, Uganda.; Niedbala, G (corresponding author), Poznan Univ Life Sci, Fac Environm Engn & Mech Engn, Dept Biosyst Engn, Poznan, Poland.; Batiha, GE (corresponding author), Damanhour Univ, Fac Vet Med, Dept Pharmacol & Therapeut, Damanhour, Egypt.; Welburn, SC (corresponding author), Zhejiang Univ, Sch Med, Univ Edinburgh Inst, Haining, Peoples R China.
EM kicelandy@gmail.com; gniewko@up.poznan.pl; gaberbatiha@gmail.com;
   sue.welburn@ed.ac.uk
RI Niedbała, Gniewko/ABG-0367-2022; Usman, Ibe Michael/AAZ-1414-2020;
   Ssempijja, Fred/W-2653-2018; Hetta, Helal/U-6794-2019; Musinguzi, Simon
   Peter/AAF-4360-2020; ALQARNI, MOHAMMED/GQI-3737-2022; Kasozi, Keneth
   Iceland/W-1956-2018
OI Niedbała, Gniewko/0000-0003-3721-6473; Usman, Ibe
   Michael/0000-0001-6624-1286; Ssempijja, Fred/0000-0003-1849-7185; Elvis
   Mbiydzenyuy, Ngala/0000-0003-2627-9639; Musinguzi, Simon
   Peter/0000-0003-0050-1043; ALQARNI, MOHAMMED/0000-0002-9028-2288;
   Kasozi, Keneth Iceland/0000-0002-5763-7964
FU Zhejiang University Education Foundation Emergency Research Fund; Global
   Challenges Research Fund; University of Edinburgh
FX This work was supported by Zhejiang University Education Foundation
   Emergency Research Fund (SCW); Global Challenges Research Fund and the
   University of Edinburgh.
CR Abd El-Wahed AA, 2018, STUD NAT PROD CHEM, V60, P459, DOI 10.1016/B978-0-444-64181-6.00013-9
   Abusabbah M, 2016, J ENTOMOL ZOOL STUD, V4, P23
   Al-Samie M.A.M.A., 2012, INT J ADV RES TECHNO, V1, P1
   Almunia C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067645
   Alvarez-Fischer D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061700
   An HJ, 2014, INT J MOL MED, V34, P1341, DOI 10.3892/ijmm.2014.1933
   An WW, 2004, ACTA PHARMACOL SIN, V25, P1502
   [Anonymous], 2019, FRONT IMMUNOL
   [Anonymous], 2020, AAPS J
   Antonicelli L, 2002, CURR OPIN ALLERGY CL, V2, P341, DOI 10.1097/00130832-200208000-00008
   Babon A, 2005, FEBS LETT, V579, P1658, DOI 10.1016/j.febslet.2005.02.019
   BACHMAYER H, 1972, J INSECT PHYSIOL, V18, P1515, DOI 10.1016/0022-1910(72)90230-2
   Baek YH, 2006, BRAIN RES, V1073, P305, DOI 10.1016/j.brainres.2005.12.086
   Balozet L, 1971, CONTRIBUTORS THIS VO, V3, P1
   Beck BF, 1981, BEE VENOM THERAPY, P238
   Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513
   Bhalotia S., 2016, Journal of Basic and Applied Engineering Research, V3, P96
   Bilò MB, 2009, CLIN EXP ALLERGY, V39, P1467, DOI 10.1111/j.1365-2222.2009.03324.x
   Block J., 2020, HIGH RISK COVID 19 P, P2020040013, DOI [DOI 10.20944/PREPRINTS202004.0013.V1, 10.20944/preprints202004.0013.v1]
   Boens S, 2013, METHODS MOL BIOL, V1053, P271, DOI 10.1007/978-1-62703-562-0_16
   Bostanci N, 2012, FEMS MICROBIOL LETT, V333, P1, DOI 10.1111/j.1574-6968.2012.02579.x
   Bramwell VW, 2004, J DRUG TARGET, V11, P525, DOI 10.1080/10611860410001670080
   Brás NF, 2018, J PHYS CHEM B, V122, P3889, DOI 10.1021/acs.jpcb.8b01321
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Caramalho I, 2015, ALLERGY, V70, P1340, DOI 10.1111/all.12691
   Casewell NR, 2013, TRENDS ECOL EVOL, V28, P219, DOI 10.1016/j.tree.2012.10.020
   Chen J, 2016, NEUROSCI BULL, V32, P265, DOI 10.1007/s12264-016-0024-y
   Cherniack EP, 2018, TOXICON, V154, P74, DOI 10.1016/j.toxicon.2018.09.013
   Chirumbolo S, 2011, ALLERGY ASTHMA IMMUN, V3, P58, DOI 10.4168/aair.2011.3.1.58
   Cho HJ, 2010, J ETHNOPHARMACOL, V127, P662, DOI 10.1016/j.jep.2009.12.007
   Choi J, 2017, TOXINS, V9, DOI 10.3390/toxins9110351
   Clerkin KJ, 2020, CIRCULATION, V141, P1648, DOI 10.1161/CIRCULATIONAHA.120.046941
   CONNOLLY TM, 1986, CELL, V46, P951, DOI 10.1016/0092-8674(86)90077-2
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Dams D, 2019, ADV EXP MED BIOL, V1148, P233, DOI 10.1007/978-981-13-7709-9_11
   Dawood AA, 2020, NEW MICROB NEW INFEC, V35, DOI 10.1016/j.nmni.2020.100673
   de Haan CAM, 1998, J VIROL, V72, P6838, DOI 10.1128/JVI.72.8.6838-6850.1998
   Lima P. R. de, 2003, J. Venom. Anim. Toxins incl. Trop. Dis, V9, P149, DOI 10.1590/S1678-91992003000200002
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Duan K, 2020, P NATL ACAD SCI USA, V117, P9490, DOI 10.1073/pnas.2004168117
   Dunbar JP, 2019, CLIN TOXICOL, V57, P677, DOI 10.1080/15563650.2019.1578367
   Erzen R, 2012, ALLERGY, V67, P822, DOI 10.1111/j.1398-9995.2012.02817.x
   Fenard D, 1999, J CLIN INVEST, V104, P611, DOI 10.1172/JCI6915
   Garraud O, 2017, BMC IMMUNOL, V18, DOI 10.1186/s12865-017-0207-y
   Ghosh R, 2020, MAYO CLIN PROC, V95, P1797, DOI 10.1016/j.mayocp.2020.05.027
   GOLDEN DBK, 1989, ALLERGY PROC, V10, P103, DOI 10.2500/108854189778960964
   Gu H, 2020, TOXINS, V12, DOI 10.3390/toxins12030195
   Gu H, 2018, MOL MED REP, V18, P3711, DOI 10.3892/mmr.2018.9398
   Gupta T, 2020, INT IMMUNOPHARMACOL, V86, DOI 10.1016/j.intimp.2020.106717
   Gurunathan S, 2013, INT J NANOMED, V8, P4399, DOI 10.2147/IJN.S51881
   Hauser R. A., 2001, Alternative and Complementary Therapies, V7, P37, DOI [https://doi.org/10.1089/107628001300000714, DOI 10.1089/107628001300000714, 10.1089/107628001300000714]
   HERMANN K, 1993, CLIN EXP ALLERGY, V23, P762, DOI 10.1111/j.1365-2222.1993.tb00364.x
   HOLTSBERG FW, 1995, BIOCHEM J, V309, P141, DOI 10.1042/bj3090141
   Hong JJ, 2019, MOLECULES, V24, DOI 10.3390/molecules24091775
   Hossen MS, 2017, J CHEM-NY, V2017, DOI 10.1155/2017/4035626
   Issa MF, 2019, MEAS SCI REV, V19, P101, DOI 10.2478/msr-2019-0016
   Jakob T, 2020, CURR ALLERGY ASTHM R, V20, DOI 10.1007/s11882-020-00943-3
   Ji YP, 2020, LANCET GLOB HEALTH, V8, pE480, DOI 10.1016/S2214-109X(20)30068-1
   Jilek S, 2001, J IMMUNOL, V166, P3612, DOI 10.4049/jimmunol.166.5.3612
   Jilo NAK, 2016, Advances in life science and technology, V44, P18
   Johansen P, 2005, CLIN EXP ALLERGY, V35, P1591, DOI 10.1111/j.1365-2222.2005.02384.x
   Jung GB, 2018, BIOMED OPT EXPRESS, V9, P5703, DOI 10.1364/BOE.9.005703
   JUTEL M, 1995, J IMMUNOL, V154, P4187
   Kang CK, 2020, KOREAN J INTERN MED, V35, P782, DOI 10.3904/kjim.2020.157
   Karamitros CS, 2014, J BIOL CHEM, V289, P12962, DOI 10.1074/jbc.M113.545038
   Kim C.M. H., 2013, Biotherapy - History, Principles and Practice, P77, DOI DOI 10.1007/978-94-007-6585-6_4
   Kim H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114726
   King TP, 2003, INT ARCH ALLERGY IMM, V131, P25, DOI 10.1159/000070431
   Klimek L, 2020, ALLERGY, V75, P1546, DOI 10.1111/all.14336
   Klok FA, 2020, THROMB RES, V191, P145, DOI [10.1016/j.thromres.2020.04.013, 10.1016/j.thromres.2020.04.041]
   Komi DEA, 2018, CLIN REV ALLERG IMMU, V54, P386, DOI 10.1007/s12016-017-8597-4
   LaFerla FM, 2007, NAT REV NEUROSCI, V8, P499, DOI 10.1038/nrn2168
   Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0
   Leandro LF, 2015, AN ACAD BRAS CIENC, V87, P147, DOI 10.1590/0001-3765201520130511
   Lee G, 2016, TOXINS, V8, DOI 10.3390/toxins8020048
   Li GP, 2020, J AUTOIMMUN, V112, DOI 10.1016/j.jaut.2020.102463
   Liu SJ, 2008, HEPATOLOGY, V47, P1964, DOI 10.1002/hep.22240
   Marichal T, 2013, IMMUNITY, V39, P963, DOI 10.1016/j.immuni.2013.10.005
   de Toledo LFM, 2018, REV SOC BRAS MED TRO, V51, P560, DOI 10.1590/0037-8682-0341-2017
   Mason RJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00607-2020
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Memariani H, 2020, EUR J CLIN MICROBIOL, V39, P5, DOI 10.1007/s10096-019-03674-0
   Mingomataj EÇ, 2012, J INVEST ALLERG CLIN, V22, P237
   Mizumoto K, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.10.2000180
   Moreno M, 2015, TOXINS, V7, P1126, DOI 10.3390/toxins7041126
   Mousavizadeh L, 2021, J MICROBIOL IMMUNOL, V54, P159, DOI 10.1016/j.jmii.2020.03.022
   Mozzini C, 2020, THROMB RES, V191, P26, DOI 10.1016/j.thromres.2020.04.031
   MULLER U, 1979, ALLERGY, V34, P369, DOI 10.1111/j.1398-9995.1979.tb02006.x
   Murakami M, 2017, CRIT REV IMMUNOL, V37, P121, DOI 10.1615/CritRevImmunol.v37.i2-6.20
   Okba NMA, 2017, CURR OPIN VIROL, V23, P49, DOI 10.1016/j.coviro.2017.03.007
   Organization WH, 2020, Coronavirus Disease 2019 (COVID-19): Situation Report, 209
   Oudit GY, 2003, TRENDS CARDIOVAS MED, V13, P93, DOI 10.1016/S1050-1738(02)00233-5
   OWEN MD, 1995, TOXICON, V33, P1181, DOI 10.1016/0041-0101(95)00054-P
   Palm NW, 2013, IMMUNITY, V39, P976, DOI 10.1016/j.immuni.2013.10.006
   Palm NW, 2012, NATURE, V484, P465, DOI 10.1038/nature11047
   Park S, 2015, IMMUN INFLAMM DIS, V3, P386, DOI 10.1002/iid3.76
   Pereira-Santos MC, 2008, CLIN EXP ALLERGY, V38, P291, DOI 10.1111/j.1365-2222.2007.02887.x
   Péterfi O, 2019, MOLECULES, V24, DOI 10.3390/molecules24152778
   Putz T, 2006, CANCER IMMUNOL IMMUN, V55, P1374, DOI 10.1007/s00262-006-0143-9
   Quaresima V, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012488
   Rady I, 2017, CANCER LETT, V402, P16, DOI 10.1016/j.canlet.2017.05.010
   Rajendiran C, 2012, J Assoc Physicians India, V60, P122
   Rawizza HE, 2019, J ANTIMICROB CHEMOTH, V74, P2707, DOI 10.1093/jac/dkz219
   Reber LL, 2017, J ALLERGY CLIN IMMUN, V140, P335, DOI 10.1016/j.jaci.2017.06.003
   Rizk JG, 2020, DRUGS, V80, P1267, DOI 10.1007/s40265-020-01367-z
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Roy A, 2021, INT J PEPT RES THER, V27, P129, DOI 10.1007/s10989-020-10073-z
   Saeed W. S. E., 2017, Journal of Vaccines and Vaccination, V8, P372, DOI [10.4172/2157-7560.1000372, 10.4172/2157-7560.1000372]
   SCHUMACHER MJ, 1994, J ALLERGY CLIN IMMUN, V93, P831, DOI 10.1016/0091-6749(94)90373-5
   Seif F, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0177-y
   Semuel Mokosuli Yermia, 2017, Journal of Entomology and Zoology Studies, V5, P112
   Seo BK, 2017, TOXINS, V9, DOI 10.3390/toxins9110361
   Shen L, 2020, J PHARMACOPUNCT, V23, P44, DOI 10.3831/KPI.2020.23.008
   SHKENDEROV S, 1982, TOXICON, V20, P317, DOI 10.1016/0041-0101(82)90234-3
   Soliman C, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224028
   Soman NR, 2009, J CLIN INVEST, V119, P2830, DOI 10.1172/JCI38842
   Son DJ, 2007, PHARMACOL THERAPEUT, V115, P246, DOI 10.1016/j.pharmthera.2007.04.004
   Son DJ, 2007, J TOXICOL ENV HEAL A, V70, P1350, DOI 10.1080/15287390701428689
   South AM, 2020, AM J PHYSIOL-HEART C, V318, pH1084, DOI 10.1152/ajpheart.00217.2020
   Stahelin R.V., 2016, Biochem. Lipids, VSixth, P237, DOI DOI 10.1016/B978-0-444-63438-2.00008-0
   Stoevesandt J, 2020, ALLERGY, V75, P535, DOI 10.1111/all.13945
   Stone KD, 2010, J ALLERGY CLIN IMMUN, V125, pS73, DOI 10.1016/j.jaci.2009.11.017
   Sun YR, 2018, SAUDI J BIOL SCI, V25, P213, DOI 10.1016/j.sjbs.2017.10.010
   Szulc P., 2013, BIOCHEMICAL MARKERS, P1573, DOI [10.1016/B978-0-12-415853-5.00067-4, DOI 10.1016/B978-0-12-415853-5.00067-4]
   Taketomi Y, 2013, NAT IMMUNOL, V14, P554, DOI 10.1038/ni.2586
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Uddin M, 2016, J MICROBIOL, V54, P853
   Vetter RS, 1998, INT J DERMATOL, V37, P481, DOI 10.1046/j.1365-4362.1998.00455.x
   Vijay R, 2015, J EXP MED, V212, P1851, DOI 10.1084/jem.20150632
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wehbe R, 2019, MOLECULES, V24, DOI 10.3390/molecules24162997
   White J, 2010, GENDERED SCREEN: CANADIAN WOMEN FILMMAKERS, P233
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Yang W, 2020, TOXICON, V181, P69, DOI 10.1016/j.toxicon.2020.04.105
   Youngren-Ortiz SR, 2016, THESIS
   Zahirovic A, 2020, CLIN REV ALLERG IMMU, V58, P326, DOI 10.1007/s12016-019-08752-x
   Zhang S, 2018, TOXICON, V148, P64, DOI 10.1016/j.toxicon.2018.04.012
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zheng YY, 2020, NAT REV CARDIOL, V17, P259, DOI 10.1038/s41569-020-0360-5
NR 141
TC 39
Z9 45
U1 2
U2 28
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-2565
J9 FRONT PUBLIC HEALTH
JI Front. Public Health
PD DEC 10
PY 2020
VL 8
AR 594458
DI 10.3389/fpubh.2020.594458
PG 14
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health
GA PI7OX
UT WOS:000601276900001
PM 33363088
OA Green Submitted, Green Published, gold
DA 2026-01-16
ER

PT J
AU Omura, Y
AF Omura, Yoshiaki
TI High Frequency Vibration of Worst Ear Lobule induced short period of
   Rapid Inhibition of any Cancer Activity including Advanced Terminal
   Cancers, Most Malignant Brain Tumor "Glioblastoma" as well as Cancer of
   Lung, Breast & Gastrointestinal Cancers particularly Pancreatic Cancer
SO ACUPUNCTURE & ELECTRO-THERAPEUTICS RESEARCH
LA English
DT Article
DE Bi-Digital O-Ring Test (BDORT); Ear lobules; Abnormally reduced
   Acetylcholine of brain; Optimal dose or overdose of medicine; drinks or
   food; Beneficial effect of optimal dose of Vitamin D-3 tablets &amp;
   Methylcobalamin; New Immune System on middle fingers; DNA mutations and
   cancer
ID ADENOASSOCIATED VIRUS; TELOMERE LENGTH; VECTORS; GLUCOSE; PROMOTE; RING
AB While a visiting Professor at the University of Paris, VI (formerly Sorvonne) more than 40 years ago, the Author became very good friends with Dr. Paul Nogier who periodically gave seminars and workshops in Paris. After the author diagnosed his cervical problem & offered him simple help, Dr. Nogier asked the Author to present lectures and demonstrations on the effects of ear stimulation, namely the effects of acupuncture & electrical stimulation of the ear lobules. It is only now, in 2019 that we have discovered 2 - 5 minute high frequency stimulation of the car lobule inhibits cancer activity for 1- 4 hours post stimulation. Although the procedure is extremely simple. First take optimal dose of Vitamin D-3, which has the most essential 10 unique beneficial factors required for every human cell activity. Next, apply high frequency stimulation to car lobule while the worst ear lobule is held by all fingers with vibrator directly touching the surface of the worst ear lobule, preferably after patient repeatedly takes optimal dose of Vitamin D-3. When the worst ear lobule is held between thumb & index fingers and applying mechanical stimulation of 250 similar to 500 mechanical vibration/second for 2 similar to 5 minutes using an electrical vibrator, there is rapid disappearance of cancer activity in both the brain and rest of the body for short time duration 1 similar to 4 hours. The effect often increases by additional pressure by holding fingers. As of May 2019, the Author found that many people from various regions of the world developed early stages of multiple cancers. For evaluation of this study, U.S. patented Bi-Digital O-Ring Test (BDORT) was used which was developed by the Author while doing his Graduate experimental physics research at Colombia University. BDORT was found to be most essential for determining the beneficial effects as well as harmful effects of any substance or treatment. Using BDORT, Author was the first to recognize severe increasing mid-backache was an early sign of pancreatic cancer of President of New York State Board of Medicine after top pain specialists failed to detect the cause after 3 years of effort, while the BDORT showed early stages of cancer whereas conventional X-Ray of the pancreas did not show any cancer image until 2 months after Author detected with BDORT. For example, the optimal dose of the banana is usually about 2.0 - 2.5 millimeters cross section of the banana. A whole banana is more than 50 similar to 100 times the optimal dose. Any substance eaten in more than 25 times of its optimal dose becomes highly toxic and creates DNA mutations which can cause multiple malignancies in the presence of strong electro-magnetic field. With standard medication given by doctor, patients often become sick and they are unable to reduce body weight, unless medication is reduced or completely stopped. When the amount of zinc is very high, DNA often becomes unstable and multiple cancers can grow rapidly in the presence of strong electromagnetic field. Large amount of Vitamin C from regular orange or orange juice inhibit the most important Vitamin D3 effects. At least 3 kinds of low Vitamin C oranges will not inhibit Vitamin D3. Since B12 particularly methyl cobalamin which is a red small tablet is known to improve brain circulation very significantly we examined its effect within 20 seconds of oral intake we found the following very significant changes. Acetylcholine in both sides of the brain often increases over 4,500 ng.
   Longevity gene Sirtuin 1 level increases significantly for short time of few hours.
   Thymosin alpha 1 and Thymosin beta 4 both increase to over 1500 ng from 20 ng or less.
C1 [Omura, Yoshiaki] New York Med Coll, Family & Community Med, New York, NY USA.
   [Omura, Yoshiaki] Int Assoc Bidigital O Ring Test Med Soc, Yokohama, Kanagawa, Japan.
   [Omura, Yoshiaki] Int Coll Acupuncture & Electrotherapeut, New York, NY USA.
   [Omura, Yoshiaki] Heart Dis Res Fdn, Med Res, Brooklyn, NY USA.
C3 New York Medical College
RP Omura, Y (corresponding author), 800 Riverside Dr Suite 8-1, New York, NY 10032 USA.
EM icaet@yahoo.com
CR de Jesus BB, 2012, EMBO MOL MED, V4, P691, DOI 10.1002/emmm.201200245
   Büning H, 2008, J GENE MED, V10, P717, DOI 10.1002/jgm.1205
   Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003
   Flores I, 2005, SCIENCE, V309, P1253, DOI 10.1126/science.1115025
   Francis PT, 2005, CNS SPECTRUMS, V10, P6, DOI 10.1017/S1092852900014164
   Gao GP, 2002, P NATL ACAD SCI USA, V99, P11854, DOI 10.1073/pnas.182412299
   González-Suárez E, 2002, MOL CELL BIOL, V22, P7291, DOI 10.1128/MCB.22.20.7291-7301.2002
   Grossberg S, 2017, FRONT NEURAL CIRCUIT, V11, DOI 10.3389/fncir.2017.00082
   Guarente L, 2006, NATURE, V444, P868, DOI 10.1038/nature05486
   Harley CB, 2011, REJUV RES, V14, P45, DOI 10.1089/rej.2010.1085
   Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9
   Hikosaka O, 2002, CURR OPIN NEUROBIOL, V12, P217, DOI 10.1016/S0959-4388(02)00307-0
   Jaskelioff M, 2011, NATURE, V469, P102, DOI 10.1038/nature09603
   Kuhlow D, 2010, AGING-US, V2, P650, DOI 10.18632/aging.100200
   Mas A, 2006, DIABETES, V55, P1546, DOI 10.2337/db05-1615
   Matsushita T, 1998, GENE THER, V5, P938, DOI 10.1038/sj.gt.3300680
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   OMURA Y, 1990, ACUPUNCTURE ELECTRO, V15, P217, DOI 10.3727/036012990816358135
   Omura Y, 1993, US Patent, Patent No. [5,188,107, 5188107]
   Omura Y, 2019, 9 INT C CARD DIS THE
   Omura Y, 2015, ACUPUNCTURE ELECTRO, V40, P297, DOI 10.3727/036012916X14533115160606
   Omura Y, 2010, ACUPUNCTURE ELECTRO, V35, P45, DOI 10.3727/036012910803860977
   Ornish D, 2008, LANCET ONCOL, V9, P1048, DOI 10.1016/S1470-2045(08)70234-1
   Sahin E, 2011, NATURE, V470, P359, DOI 10.1038/nature09787
   Schoeftner S, 2009, P NATL ACAD SCI USA, V106, P19387, DOI 10.1073/pnas.0909265106
   Tafuro S, 2009, CARDIOVASC RES, V83, P663, DOI 10.1093/cvr/cvp152
NR 26
TC 1
Z9 1
U1 0
U2 10
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0360-1293
EI 2167-9010
J9 ACUPUNCTURE ELECTRO
JI Acupunct. Electro-Ther. Res.
PY 2020
VL 44
IS 3-4
BP 241
EP 249
DI 10.3727/036012920X15779969212982
PG 9
WC Integrative & Complementary Medicine; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine; Neurosciences & Neurology
GA KM0ZL
UT WOS:000513846500006
DA 2026-01-16
ER

PT J
AU Ben-Arye, E
   Lopez, AM
   Daoud, N
   Zoller, L
   Walker, E
   Davidescu, M
   Shulman, K
   Gressel, O
   Stein, N
   Brosh, S
   Schiff, E
   Samuels, N
AF Ben-Arye, Eran
   Lopez, Ana Maria
   Daoud, Nihaya
   Zoller, Lilach
   Walker, Eleanor
   Davidescu, Michal
   Shulman, Katerina
   Gressel, Orit
   Stein, Nili
   Brosh, Shani
   Schiff, Elad
   Samuels, Noah
TI Identifying Factors Associated With Disparities in Access to Integrative
   Oncology Program
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE Integrative oncology; disparities; integrative medicine; chemotherapy;
   acupuncture; cross-cultural; diversity; equity and inclusion
ID BREAST-CANCER; ARAB PATIENTS; COMPLEMENTARY; PERSPECTIVES; THERAPIES;
   SERVICE; WOMEN; CARE; PAIN
AB Context and Objectives. Cancer centers are increasingly providing complementary medicine as part of an emerging discipline termed ' integrative oncology ' (IO). The present study explored factors associated with disparities in referral and adherence to a freely-provided IO program. Methods. The databases of three oncology centers in northern Israel were searched retrospectively for chemotherapy-treated oncology patients eligible for referral by their oncology healthcare professionals to an integrative physician (IP) consultation. Demographic and cancer-related variables associated with the referral, and attendance by patients at the consultation were identi fi ed, as was adherence to the 6-week IO treatment program (high adherence, attending >= 4 IO treatment sessions; low adherence, 0 - 3 sessions). Results. Of 4988 eligible patients, 1694 (34%) were referred to the IP consultation, with 1331 (78.6%) attending the consultation of which 766 (57.6%) were adherent to IO treatments. Multivariate analysis revealed lower referral rates among patients speaking primarily Arabic and Russian vs. Hebrew (OR = 3.0, 95% CI = 2.0 - 4.6, P < 0.0001); males vs. females (OR = 1.94, CI = 1.3 - 2.9, P = 0.001); those not reporting emotional distress (OR = 1.5, CI = 1.02 - 2.16, P = 0.037); and older age (OR = 1.04, CI = 1.03 - 1.06, P < 0.0001). Arabic and Russian-speaking patients were less likely to adhere to IO treatments (OR = 0.52, 95% CI = 0.32 - 0.83, P = 0.006). Conclusion. Patients ' ethno-national origin and immigration status (primary language, Arabic and Russian), male gender and older age were associated with lower rates of referral to and attendance of the IP consultation, with reduced adherence to weekly IO treatments. These fi ndings require further study to identify barriers toward diversity, equity and inclusion in IO care, increasing awareness among healthcare professionals regarding the bene fi ts of these services for improving patient wellbeing. J Pain Symptom Manage 2024;68:10 - 21. (c) 2024 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
C1 [Ben-Arye, Eran; Davidescu, Michal] Lin Zebulun Carmel Med Ctr, Integrat Oncol Program, Oncol Serv, Clalit Hlth Serv, Haifa, Israel.
   [Ben-Arye, Eran; Shulman, Katerina; Schiff, Elad] Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel.
   [Lopez, Ana Maria] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA USA.
   [Lopez, Ana Maria] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA USA.
   [Daoud, Nihaya] Ben Gurion Univ Negev, Fac Hlth Sci, Sch Publ Hlth, Beer Sheva, Israel.
   [Zoller, Lilach] Clalit Hlth Serv, Haifa & Western Galilee Dist, Haifa, Israel.
   [Walker, Eleanor] Henry Ford Hosp, Detroit, MI USA.
   [Shulman, Katerina] Lin & Zebulun Med Ctr, Oncol Serv, Clalit Hlth Serv, Haifa, Israel.
   [Stein, Nili] Carmel Hosp, Dept Community Med & Epidemiol, Haifa, Israel.
   [Brosh, Shani] Carmel Hosp, Haifa, Israel.
   [Schiff, Elad] Bnai Zion Hosp, Dept Internal Med & Integrat Med Serv, Haifa, Israel.
   [Samuels, Noah] Hebrew Univ Jerusalem, Fac Med, Ctr Integrat Complementary Med, Shaarei Zedek Med Ctr, Jerusalem, Israel.
C3 Clalit Health Services; Technion Israel Institute of Technology;
   Rappaport Faculty of Medicine; Thomas Jefferson University; Thomas
   Jefferson University; Ben-Gurion University of the Negev; Clalit Health
   Services; Henry Ford Health System; Henry Ford Hospital; Clalit Health
   Services; Clalit Health Services; Carmel Medical Center; Clalit Health
   Services; Carmel Medical Center; Bnai Zion Medical Center; Hebrew
   University of Jerusalem; Shaare Zedek Medical Center
RP Ben-Arye, E (corresponding author), Lin Med Ctr, Oncol Serv, 35 Rothschild St, IL-35152 Haifa, Israel.
EM eranben@netvision.net.il
RI ; Daoud, Nihaya/AAE-6602-2020
OI Lopez, Ana Maria/0000-0002-2759-5353; Gressel, Orit/0000-0002-0184-0453;
   
CR Andreae MH, 2017, PAIN MED, V18, P265, DOI 10.1093/pm/pnw161
   Annesi CA, 2022, ANN THORAC SURG, V113, P1291, DOI 10.1016/j.athoracsur.2021.04.096
   [Anonymous], WHO global report on traditional and complementary medicine 2019
   Ben-Arye E, 2014, ANN ONCOL, V25, P476, DOI 10.1093/annonc/mdt554
   Ben-Arye E, 2024, BMJ SUPPORT PALLIAT, V14, P178, DOI 10.1136/spcare-2022-004117
   Ben-Arye E, 2015, J PAIN SYMPTOM MANAG, V49, P871, DOI 10.1016/j.jpainsymman.2014.09.014
   Ben-Arye Eran, 2015, Harefuah, V154, P26
   Ben-Arye E, 2012, PATIENT EDUC COUNS, V89, P423, DOI 10.1016/j.pec.2012.02.011
   Ben-Arye E, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/401867
   BenArye E., 2021, Oxford textbook of palliative medicine, V6th, P849
   Bonilla J, 2021, BMC WOMENS HEALTH, V21, DOI 10.1186/s12905-021-01200-z
   Boulware LE, 2022, NEW ENGL J MED, V386, P201, DOI 10.1056/NEJMp2112233
   Bright-Gbebry M, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-30
   Deng G, 2005, CA-CANCER J CLIN, V55, P109, DOI 10.3322/canjclin.55.2.109
   Fouladbakhsh Judith M, 2010, Oncol Nurs Forum, V37, pE7, DOI 10.1188/10.ONF.E7-E15
   Frenkel M, 2010, INTEGR CANCER THER, V9, P276, DOI 10.1177/1534735410378663
   Grubbs V, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMpv2022639
   Haddad Haj-Yahya N, Yearbook of the Arab society in Israel 202.
   Hietala M, 2011, ACTA ONCOL, V50, P134, DOI 10.3109/0284186X.2010.484812
   Judson PL, 2017, INTEGR CANCER THER, V16, P96, DOI 10.1177/1534735416660384
   Keinan-Boker L, 2013, EUR J CANCER PREV, V22, P112, DOI 10.1097/CEJ.0b013e3283581d3c
   Lee MM, 2000, JNCI-J NATL CANCER I, V92, P42, DOI 10.1093/jnci/92.1.42
   Oyer RA, 2022, J CLIN ONCOL, V40, P2163, DOI 10.1200/JCO.22.00754
   Polite BN, 2017, J CLIN ONCOL, V35, P3075, DOI [10.1200/JCO.2017.73.6546, 10.3322/caac.21404, 10.1200/jco.2017.73.6546]
   Popper-Giveon A, 2012, PATIENT EDUC COUNS, V89, P381, DOI 10.1016/j.pec.2012.03.016
   Raz OG, 2020, J ALTERN COMPLEM MED, V26, P721, DOI 10.1089/acm.2019.0437
   Samuels N, 2023, J CANCER RES CLIN, V149, P10143, DOI 10.1007/s00432-023-04912-x
   Shalom-Sharabi I, 2018, INTEGR CANCER THER, V17, P697, DOI 10.1177/1534735418764839
   Society for Integrative Oncology, 2024, Health equity mission statement and land acknowledgment statement
   Witt Claudia M., 2017, Journal of the National Cancer Institute Monographs, P3, DOI [10.1093/jncimonographs/lgx012, 10.1093/jncimonographs/lgx012]
NR 30
TC 9
Z9 9
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD JUL
PY 2024
VL 68
IS 1
BP 10
EP 21
DI 10.1016/j.jpainsymman.2024.03.018
EA JUN 2024
PG 12
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
   Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; General & Internal Medicine;
   Neurosciences & Neurology
GA WC9N7
UT WOS:001252789600001
PM 38552747
OA hybrid
DA 2026-01-16
ER

PT J
AU Yamasaki, SC
   Mendes, MT
   Alponti, RF
   Silveira, PF
AF Yamasaki, Simone C.
   Mendes, Mariana T.
   Alponti, Rafaela F.
   Silveira, Paulo F.
TI Efficacy of parenteral administration of bee venom in experimental
   arthritis in the rat: A comparison with methotrexate
SO TOXICON
LA English
DT Article
DE Aminopeptidase; Bee venom; Animal venom; Disease-modifying
   anti-rheumatic drug; Experimental arthritis; Complementary and
   alternative medicine
ID DIPEPTIDYL-PEPTIDASE-IV; COLLAGEN-INDUCED ARTHRITIS; RENIN-ANGIOTENSIN
   SYSTEM; BLOOD MONONUCLEAR-CELLS; RHEUMATOID-ARTHRITIS; AMINOPEPTIDASE
   ACTIVITIES; ACUPUNCTURE APIPUNCTURE; NEUTRAL AMINOPEPTIDASE; ACUPOINT
   STIMULATION; RECENT INSIGHTS
AB The use of bee venom (BV) to treat inflammation and pain in arthritis has become increasingly common. This study aimed to compare the effects of BV and methotrexate (MTX), the most used disease-modifying anti-rheumatic drug, in arthritic rats. Edema, erythema, cyanosis, hyperalgesia, reduction of the body mass gain, high circulating tumor necrosis factor alpha (TNF-alpha.) and anti-type II collagen antibodies (AACII), and altered activity of basic (APB) and neutral (APN) aminopeptidases and dipeptidyl peptidase IV (DPPIV) are present in arthritic rats. MTX and/or BV do not affect AACII in healthy or arthritic individuals, but restores TNF-alpha to normal levels in arthritic rats. BV restores body mass gain to normal levels and MTX ameliorates body mass gain. BV contains DPPIV. BV restores APN in synovial fluid (SF) and in soluble fraction (S) from synovial tissue (ST), and DPPIV in solubilized membrane-bound fraction (M) from peripheral blood mononuclear cells (PBMCs). MTX restores APN of SF, as well as ameliorates APB of S-PBMCs, APN of S-ST and DPPIV of M-PBMCs. The combination therapy does not overcome the effects of BV or MTX alone on the peptidase activities. Edema is ameliorated by MTX or BV alone. MTX, but not BV, is effective in reducing hyperalgesia. Data show that anti-arthritic effects of BV at nonacupoints are not negligible when compared with MTX. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Yamasaki, Simone C.; Mendes, Mariana T.; Alponti, Rafaela F.; Silveira, Paulo F.] Inst Butantan, Unit Translat Endocrine Physiol & Pharmacol, Pharmacol Lab, BR-05503900 Sao Paulo, SP, Brazil.
   [Yamasaki, Simone C.] Inst Butantan, Interdept Biotechnol Program, BR-05508900 Sao Paulo, Brazil.
   [Yamasaki, Simone C.] Univ Sao Paulo, BR-05508900 Sao Paulo, Brazil.
C3 Instituto Butantan; Instituto Butantan; Universidade de Sao Paulo
RP Silveira, PF (corresponding author), Inst Butantan, Unit Translat Endocrine Physiol & Pharmacol, Pharmacol Lab, Av Vital Brasil 1500, BR-05503900 Sao Paulo, SP, Brazil.
EM paulo.silveira@butantan.gov.br
RI ; Vename, Rafaela/P-6346-2015; Silveira, Paulo/E-1829-2013; Vendrame,
   Rafaela/P-6346-2015; Yamasaki, Simone/J-2644-2012
OI Mendes, Mariana Trivilin/0000-0001-6481-0764; Vename,
   Rafaela/0000-0001-6415-6192; 
FU FAPESP (Sao Paulo Research Foundation, Brazil) [2007/08311-4]; CNPq
   (National Council for Scientific and Technological Development, Brazil)
   [PQ-302533/2011-7]; FAPESP; Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [07/08311-4] Funding Source: FAPESP
FX This work was supported by a Research Grant 2007/08311-4 from FAPESP
   (Sao Paulo Research Foundation, Brazil). P.F.S. was recipient of a CNPq
   (National Council for Scientific and Technological Development, Brazil)
   productivity grant (PQ-302533/2011-7). R.F.A. and M.T.M were recipientes
   of FAPESP fellowships. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript. We thank all the staff at the Unit of Translational
   Endocrine Pharmacology and Physiology at Laboratory of Pharmacology for
   technical support, and at Laboratory of Pain Physiology for kindly
   arranging the space and equipment for the assessment of hyperalgesia. We
   also thank the agency GLMS Scientific Language Services for having
   revised manuscript.
CR Abolmaali SS, 2013, CANCER CHEMOTH PHARM, V71, P1115, DOI 10.1007/s00280-012-2062-0
   Al-Abd AM, 2010, EUR J PHARMACOL, V644, P245, DOI 10.1016/j.ejphar.2010.07.006
   Alponti RF, 2010, OBESITY, V18, P1312, DOI 10.1038/oby.2009.378
   Ansorge S, 2009, CLIN CHEM LAB MED, V47, P253, DOI 10.1515/CCLM.2009.063
   Baek YH, 2006, BRAIN RES, V1073, P305, DOI 10.1016/j.brainres.2005.12.086
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Chen HS, 2006, EXP NEUROL, V200, P386, DOI 10.1016/j.expneurol.2006.02.118
   Cutolo M, 2001, ANN RHEUM DIS, V60, P729, DOI 10.1136/ard.60.8.729
   De Meester I, 2003, ADV EXP MED BIOL, V524, P3
   Doan T, 2005, J CLIN PHARMACOL, V45, P751, DOI 10.1177/0091270005277938
   Rached ICFS, 2010, J ETHNOPHARMACOL, V130, P175, DOI 10.1016/j.jep.2010.04.015
   Gasparello-Clemente E, 2003, PEPTIDES, V24, P1367, DOI 10.1016/j.peptides.2003.08.006
   Goldbergova MP, 2012, MOL IMMUNOL, V52, P273, DOI 10.1016/j.molimm.2012.06.006
   Guerrero ATG, 2006, PHARMACOL BIOCHEM BE, V84, P244, DOI 10.1016/j.pbb.2006.05.008
   Haringman JJ, 2006, ANN RHEUM DIS, V65, P294, DOI 10.1136/ard.2005.037176
   Hartog A, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471-2474-10-59
   Hashimoto T, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3470
   Hattori A, 2004, BIOL PHARM BULL, V27, P777, DOI 10.1248/bpb.27.777
   Hietala MA, 2004, EUR J IMMUNOL, V34, P1208, DOI 10.1002/eji.200424895
   IwakiEgawa S, 1997, CELL IMMUNOL, V178, P180, DOI 10.1006/cimm.1997.1123
   Kang SS, 2002, AM J CHINESE MED, V30, P73, DOI 10.1142/S0192415X02000089
   Kwon YB, 2001, ACUPUNCTURE ELECTRO, V26, P59, DOI 10.3727/036012901816356054
   Lee JD, 2005, EVID-BASED COMPL ALT, V2, P79, DOI 10.1093/ecam/neh070
   Lee VSY, 2007, INSECT MOL BIOL, V16, P231, DOI 10.1111/j.1365-2583.2006.00718.x
   Li Y., 2011, RHEUMATOL INT, V32, P2415
   Liu Xi-De, 2008, Zhen Ci Yan Jiu, V33, P197
   Mantle D, 1999, CLIN CHIM ACTA, V284, P45, DOI 10.1016/S0009-8981(99)00055-8
   Martínez-Martos JM, 2011, BREAST, V20, P444, DOI 10.1016/j.breast.2011.04.008
   Mendes M.T., 2013, Open J. Rheumatol. Autoimmun. Dis, V3, P255, DOI [10.4236/ojra.2013.34040, DOI 10.4236/OJRA.2013.34040]
   Mendes MT, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/730421
   Mendes MT, 2011, REGUL PEPTIDES, V167, P215, DOI 10.1016/j.regpep.2011.02.012
   Meugnier E, 2011, PHYSIOL GENOMICS, V43, P365, DOI 10.1152/physiolgenomics.00127.2010
   Mirshafiey A, 2006, IMMUNOPHARM IMMUNOT, V28, P397, DOI 10.1080/08923970600927447
   Nandakumar KS, 2010, CELL TISSUE RES, V339, P213, DOI 10.1007/s00441-009-0816-8
   Olivo R.A., 2008, CLIN DEV IMMUNOL, V2008
   Olivo RA, 2005, BIOCHEM PHARMACOL, V69, P1441, DOI 10.1016/j.bcp.2005.03.002
   Ospelt C, 2010, ARTHRITIS RHEUM-US, V62, P1224, DOI 10.1002/art.27395
   Park HJ, 2004, ARTHRITIS RHEUM-US, V50, P3504, DOI 10.1002/art.20626
   Peiren N, 2005, BBA-PROTEINS PROTEOM, V1752, P1, DOI 10.1016/j.bbapap.2005.07.017
   Penning TD, 2002, J MED CHEM, V45, P3482, DOI 10.1021/jm0200916
   Reinhold D, 2007, ANN NY ACAD SCI, V1110, P402, DOI 10.1196/annals.1423.042
   Roh DH, 2004, J PAIN, V5, P297, DOI 10.1016/j.jpain.2004.05.003
   Roubenoff R, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2658
   Ruiz-Ortega M, 2007, TRENDS CARDIOVAS MED, V17, P19, DOI 10.1016/j.tcm.2006.10.003
   Sakuta T, 2010, ARTHRITIS RHEUM-US, V62, P1319, DOI 10.1002/art.27384
   Sedo A, 2005, ARTHRITIS RES THER, V7, P253, DOI 10.1186/ar1852
   Simjee SU, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2290
   Snelgrove RJ, 2010, SCIENCE, V330, P90, DOI 10.1126/science.1190594
   Song XQ, 2010, BIOMED PHARMACOTHER, V64, P463, DOI 10.1016/j.biopha.2010.01.007
   Sromova L, 2010, CLIN CHIM ACTA, V411, P1046, DOI 10.1016/j.cca.2010.03.034
   Stojanovich L, 2010, AUTOIMMUN REV, V9, pA271, DOI 10.1016/j.autrev.2009.11.014
   Thanawala V, 2008, CURR DRUG TARGETS, V9, P887, DOI 10.2174/138945008785909356
   Upchurch KS, 2012, RHEUMATOLOGY, V51, P28, DOI 10.1093/rheumatology/kes278
   Wessels JAM, 2008, RHEUMATOLOGY, V47, P249, DOI 10.1093/rheumatology/kem279
   Williams YN, 2003, CLIN EXP IMMUNOL, V131, P68, DOI 10.1046/j.1365-2249.2003.02020.x
   Wood PB, 2009, CURR PAIN HEADACHE R, V13, P434, DOI 10.1007/s11916-009-0071-4
   Xian CJ, 2007, BONE, V41, P842, DOI 10.1016/j.bone.2007.07.021
   Yamasaki SC, 2012, REGUL PEPTIDES, V173, P47, DOI 10.1016/j.regpep.2011.09.004
   Zambotti-Villela L, 2008, J ENDOCRINOL INVEST, V31, P492, DOI 10.1007/BF03346396
NR 59
TC 10
Z9 11
U1 1
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAY
PY 2015
VL 98
BP 75
EP 88
DI 10.1016/j.toxicon.2015.02.016
PG 14
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA CG6PV
UT WOS:000353425100009
PM 25727381
DA 2026-01-16
ER

PT J
AU Sovak, G
   Budgell, B
AF Sovak, Guy
   Budgell, Brian
TI TENS-like Stimulation Downregulates Inflammatory Cytokines in a PC-12
   Cell Line
SO JOURNAL OF MANIPULATIVE AND PHYSIOLOGICAL THERAPEUTICS
LA English
DT Article
DE Transcutaneous Electrical Nerve Stimulation; Cytokines
ID ELECTRICAL NERVE-STIMULATION; NF-KAPPA-B; LOW-BACK-PAIN; SIGNALING
   PATHWAYS; SPINAL STENOSIS; ACUPUNCTURE; ACTIVATION; SURVIVAL
AB Objectives: The purpose of this study was to evaluate the effects of transcutaneous electrical nerve stimulation (TENS)-like stimulation on the expression of the proinflammatory cytokines tumor necrosis factor a (TNF-alpha), interleukin 1 beta (IL-1 beta), and IL-6 in PC-12 cells, which are commonly used as neuronal cell models.
   Methods: Nerve growth factor-differentiated PC-12 cells were exposed to electrical stimulation for 15 minutes at 1 mA, 200 mu s, and 100 Hz. Cell lysate from stimulated and control cells was assayed for TNF-alpha, IL-1 beta, and IL-6. In 6 trials, cells were preincubated with the L-type ion channel blocker nicardipine. Cultured cells were also incubated with Alexa Fluor 488 and visualized by fluorescence microscopy to determine the nuclear vs cytoplasmic distribution of the p65 sub-unit of NF-kappa B
   Results: Compared with control (unstimulated) cells, the stimulated cells had a downregulation of the assayed cytokines. However, preincubation with the L-type ion channel blocker nicardipine blocked this effect of stimulation. Additionally, it was noted that TENS-like stimulation promoted a relative sequestration of the p65 subunit of NF-kappa B in the cytoplasm vs the nucleus.
   Conclusions: It appears that in this cell line and with these stimulation parameters, TENS-like stimulation attenuated the expression of the assayed proinflammatory cytokines, in part by promoting the relative sequestration of the p65 subunit of NF-kappa B in the cytoplasm, and that voltage-dependent calcium channels have a role in the cascade of events initiated by the TENS-like stimulation.
C1 [Sovak, Guy; Budgell, Brian] Canadian Mem Chiropract Coll, 6100 Leslie St, Toronto, ON M2H 3J1, Canada.
RP Sovak, G (corresponding author), Canadian Mem Chiropract Coll, 6100 Leslie St, Toronto, ON M2H 3J1, Canada.
EM gsovak@cmcc.ca
RI ; Budgell, Brian Stephen/N-4541-2014
OI Sovak, Guy/0000-0002-7555-6914; Budgell, Brian
   Stephen/0000-0001-6095-0794
FU Canadian Memorial Chiropractic College
FX This work was supported by internal research funds from Canadian
   Memorial Chiropractic College. No external funding was received in
   support of this work. The investigators thank Amber Corless for
   technical assistance in the laboratory with cell culture, dotblot
   analysis, and immunofluoroscopy. No conflicts of interest were reported
   for this study.
CR Ammendolia C, 2015, SELF MANAGEMENT IMPR
   [Anonymous], COCHRANE DATABASE SY
   [Anonymous], COCHRANE DATABASE SY
   Buchmuller A, 2012, EUR J PAIN, V16, P656, DOI 10.1002/j.1532-2149.2011.00061.x
   Budgell BS, 2014, SPINAL CORD, V52, P744, DOI 10.1038/sc.2014.120
   Bui NT, 2001, J CELL BIOL, V152, P753, DOI 10.1083/jcb.152.4.753
   Cha MH, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/792765
   Chen YW, 2015, PHYS THER, V95, P76, DOI 10.2522/ptj.20130306
   DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0
   Fang JF, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-134
   Grant DJ, 1999, PAIN, V82, P9, DOI 10.1016/S0304-3959(99)00027-5
   GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424
   Kalra A, 2001, J PHARMACOL EXP THER, V298, P257
   Kaltschmidt B, 2005, BBA-MOL CELL RES, V1745, P287, DOI 10.1016/j.bbamcr.2005.05.009
   Keskin EA, 2012, GYNECOL OBSTET INVES, V74, P76, DOI 10.1159/000337720
   Khadilkar A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003008.pub3
   Kroeling P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004251.pub5
   Lilienbaum A, 2003, MOL CELL BIOL, V23, P2680, DOI 10.1128/MCB.23.8.2680-2698.2003
   Magis Delphine, 2013, J Headache Pain, V14, P95, DOI 10.1186/1129-2377-14-95
   Matsuo H, 2014, PAIN, V155, P1888, DOI 10.1016/j.pain.2014.06.022
   Ohtori S, 2012, SPINE, V37, P439, DOI 10.1097/BRS.0b013e318238af83
   Ohtori S, 2011, EUR SPINE J, V20, P942, DOI 10.1007/s00586-010-1595-3
   Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083
   Sekiguchi M, 2004, SPINE, V29, P1105, DOI 10.1097/00007632-200405150-00011
   Wooten MW, 2000, MOL CELL BIOL, V20, P4494, DOI 10.1128/MCB.20.13.4494-4504.2000
   Yates CC, 2013, MED ACUPUNCT, V25, P285, DOI 10.1089/acu.2012.0952
NR 26
TC 3
Z9 3
U1 0
U2 5
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-4754
J9 J MANIP PHYSIOL THER
JI J. Manip. Physiol. Ther.
PD JUL-AUG
PY 2017
VL 40
IS 6
BP 381
EP 386
DI 10.1016/j.jmpt.2017.03.008
PG 6
WC Health Care Sciences & Services; Integrative & Complementary Medicine;
   Rehabilitation
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; Integrative & Complementary Medicine;
   Rehabilitation
GA FM2JH
UT WOS:000414810500002
PM 28822472
DA 2026-01-16
ER

PT J
AU Dobos, G
   Tao, I
AF Dobos, Gustav
   Tao, Iven
TI The Model of Western Integrative Medicine: The Role of Chinese Medicine
SO CHINESE JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Article
DE integrative medicine; complementary and alternative medicine;
   traditional Chinese medicine; integrative oncology; evidence-based
   medicine; Chinese herbal medicine; acupuncture
ID RHEUMATOID-ARTHRITIS; CONTROLLED-TRIALS; VEGETARIAN DIET; RESEARCH
   DESIGN; LEECH THERAPY; TAI CHI; ACUPUNCTURE; CANCER; OSTEOARTHRITIS;
   METAANALYSIS
AB The basic concept of integrative medicine (IM) is that by combining mainstream (biomedicine) with complementary and alternative medicine (CAM), synergistic therapeutic effects can be attained. When the methods of mind/body medicine (MBM) are added to this combination, as in Western countries, a new concept emerges that drastically changes the approach toward illness.
   It is interesting to note that the joining of traditional Chinese medicine and Western medicine in the early days of the Peoples' Republic of China preceded the Western model of IM by almost 50 years. Several elements that make up the key components of IM as practiced today in the West were already present in the Chinese version of IM, and Chinese medicine has played and continues to play an important role in advancing IM. However, one of the major differences between the Chinese and the Western models of IM today, besides MBM and some other treatment options, is that Western integrative medicine (WIM) strictly requires its CAM methods to be supported by scientific evidence.
   The therapeutic methods of IM and their applications are many and varied. However, they are most frequently employed to treat chronic medical conditions, e.g., bronchial asthma, rheumatic disease, chronic inflammatory bowel disorder and chronic pain. Other fields in which IM may be applied are internal medicine (inflammatory bowel diseases and cardiovascular diseases), musculoskeletal disorders, oncology (chemotherapy-induced side effects), obstetrics and gynecology (dysmenorrhea, endometriosis, infertility and menopausal complaints), pediatrics, geriatrics, neurology (migraine and chronic headache), and psychiatry (anxiety and depression).
   The concept of WIM is discussed here in detail by reviewing its scope and implications for the practice of medicine and focusing on the role of Chinese medicine in WIM.
C1 [Dobos, Gustav; Tao, Iven] Univ Duisburg Essen, Dept Complementary & Integrat Med, Kliniken Essen Mitte, Knappschafts Krankenhaus, D-45276 Essen, Germany.
C3 Kliniken Essen-Mitte; University of Duisburg Essen
RP Dobos, G (corresponding author), Univ Duisburg Essen, Dept Complementary & Integrat Med, Kliniken Essen Mitte, Knappschafts Krankenhaus, Deimelsberg 34A, D-45276 Essen, Germany.
EM gustav.dobos@uni-duisburg-essen.de
CR Allensbach Poll (Umfrage), 2005, INT MED TRAD CHIN ME
   [Anonymous], 2004, **DROPPED REF**
   [Anonymous], COCHRANE DATABASE SY, DOI DOI 10.1002/14651858.CD001929.PUB2
   [Anonymous], 2005, COCHRANE DB SYST REV
   Antonovsky A., 1987, Unraveling the mystery of health
   Astin JA, 2003, J AM BOARD FAM PRACT, V16, P131, DOI 10.3122/jabfm.16.2.131
   Benson H., 2000, RELAXATION RESPONSE
   Benson H., 1993, The wellness book: The comprehensive guide to maintaining health and treating stressrelated illness
   Berman BM, 2010, NEW ENGL J MED, V363, P454, DOI 10.1056/NEJMct0806114
   Brinkhaus B, 2006, ARCH INTERN MED, V166, P450
   Cheong YC, 2008, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006920.pub2, 10.1002/14651858.CD009526.pub2]
   Cramp F, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006145.pub2
   Cutolo M, 2006, NEUROIMMUNOMODULAT, V13, P277, DOI 10.1159/000104855
   Diener HC, 2006, LANCET NEUROL, V5, P310, DOI 10.1016/S1474-4422(06)70382-9
   Dieterle S, 2009, FERTIL STERIL, V92, P1340, DOI 10.1016/j.fertnstert.2009.02.041
   Dobos G, 2006, Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, V49, P723, DOI 10.1007/s00103-006-0001-0
   Dobos G, 2006, TREATING CHRONIC DIS
   Dobos G, 2010, ESS CONS C 2009 FUT
   Dobos G, 2009, EUR J INTEGR MED, V1, P109, DOI 10.1016/j.eujim.2009.08.001
   Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569
   Ernst E, 1997, AM J CHINESE MED, V25, P3, DOI 10.1142/S0192415X97000032
   Gatenby RA, 2009, CANCER RES, V69, P4894, DOI 10.1158/0008-5472.CAN-08-3658
   Gillespie LD, 2009, COCHRANE DB SYST REV, V2
   Goldberg RJ, 2007, PAIN, V129, P210, DOI 10.1016/j.pain.2007.01.020
   HOFFMAN JW, 1982, SCIENCE, V215, P190, DOI 10.1126/science.7031901
   Kabat-Zin Jon., 1990, FULL CATASTROPHE LIV
   Kabat-Zinn J., 1987, Clinical Journal of Pain, V2, P159, DOI [10.1097/00002508-198602030-00004, DOI 10.1097/00002508-198602030-00004]
   KJELDSENKRAGH J, 1991, LANCET, V338, P899, DOI 10.1016/0140-6736(91)91770-U
   Klose P, 2009, EUR J INTEGR MED, V1, P247
   Koller M, 2006, MMW Fortschr Med, V148, P51
   Kuhn ThomasS., 1964, The Structure of Scientific Revolutions
   Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200
   Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795
   Lu AP, 2008, CHIN J INTEGR MED, V14, P234, DOI 10.1007/s11655-008-240-z
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   Matthiessen PF, 2008, FORSCH KOMPLEMENTMED, V15, P248, DOI 10.1159/000154039
   McCulloch M, 2006, J CLIN ONCOL, V24, P419, DOI 10.1200/JCO.2005.03.6392
   McIntosh H, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000527
   Melchart D, 2006, HEADACHE, V46, P632, DOI 10.1111/j.1526-4610.2006.00365.x
   Melchart D, 2007, NATUROPATHIC TREATME
   Melchart D, 2008, FORSCH KOMPLEMENTMED, V15, P308, DOI 10.1159/000166749
   Michalsen A, 2003, ANN INTERN MED, V139, P724, DOI 10.7326/0003-4819-139-9-200311040-00006
   Michalsen A, 2008, PAIN, V137, P452, DOI 10.1016/j.pain.2008.03.012
   Michalsen A, 2009, J PAIN, V10, P601, DOI 10.1016/j.jpain.2008.12.013
   MOBUS S, 2006, CHRONISCHE ERKRANKUN
   Müller H, 2001, SCAND J RHEUMATOL, V30, P1, DOI 10.1080/030097401750065256
   Pradhan EK, 2007, ARTHRIT RHEUM-ARTHR, V57, P1134, DOI 10.1002/art.23010
   Rakel D, 2007, INTEGRATIVE MED, P5
   REILLY RP, 1989, AM J PHYS MED REHAB, V68, P196, DOI 10.1097/00002060-198908000-00009
   Sackett DL, 1997, BRIT MED J, V315, P1636, DOI 10.1136/bmj.315.7123.1636
   Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71
   Scharf HP, 2006, ANN INTERN MED, V145, P12, DOI 10.7326/0003-4819-145-1-200607040-00005
   Schwickert M, 2006, FORSCH KOMP KLAS NAT, V13, P184, DOI 10.1159/000093449
   Shang AJ, 2007, INT J EPIDEMIOL, V36, P1086, DOI 10.1093/ije/dym119
   Sobel DS, 2000, JAMA-J AM MED ASSOC, V284, P1705, DOI 10.1001/jama.284.13.1705
   Song Juan-juan, 2006, Chin J Integr Med, V12, P312, DOI 10.1007/s11655-001-0312-9
   Tang JL, 1999, BMJ-BRIT MED J, V319, P160, DOI 10.1136/bmj.319.7203.160
   Taylor K, 2000, THESIS U CAMBRIDGE
   Thomas R, 2008, CHIN J INTEGR MED, V14, P194, DOI 10.1007/s11655-008-0194-1
   Vickers A, 1998, CONTROL CLIN TRIALS, V19, P159, DOI 10.1016/S0197-2456(97)00150-5
   Wang CC, 2010, NEW ENGL J MED, V363, P743, DOI 10.1056/NEJMoa0912611
   Wang CZ, 2007, CANCER CHEMOTH PHARM, V60, P69, DOI 10.1007/s00280-006-0350-2
   Wang QA, 1998, JAMA-J AM MED ASSOC, V280, P283, DOI 10.1001/jama.280.3.283
   Wesa K, 2008, HEMATOL ONCOL CLIN N, V22, P343, DOI 10.1016/j.hoc.2008.02.002
   WILLICH S, 2009, NATURA MED, V1, P22
   Witt C, 2005, LANCET, V366, P136, DOI 10.1016/S0140-6736(05)66871-7
   Xu H, 2008, J ALTERN COMPLEM MED, V14, P3, DOI 10.1089/acm.2006.6329
   Zhang ZT, 1990, SELECTED MED HLTH RE
   Zhao YT, 2009, ANN MED, V41, P301, DOI 10.1080/07853890802698834
   Zuger A, 2004, NEW ENGL J MED, V350, P69, DOI 10.1056/NEJMsr031703
NR 70
TC 65
Z9 86
U1 1
U2 114
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1672-0415
EI 1993-0402
J9 CHIN J INTEGR MED
JI Chin. J. Integr. Med.
PD JAN
PY 2011
VL 17
IS 1
BP 11
EP 20
DI 10.1007/s11655-011-0601-x
PG 10
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA 705ID
UT WOS:000286121200003
PM 21258891
DA 2026-01-16
ER

PT J
AU Kiss, G
   Póth-Szebenyi, B
   Rózsa, T
   Könyves, L
   Gábor, G
AF Kiss, Gerda
   Poth-Szebenyi, Bettina
   Rozsa, Tamas
   Konyves, Laszlo
   Gabor, Gyorgy
TI Usage of low-level laser therapy in human and veterinary practice
SO MAGYAR ALLATORVOSOK LAPJA
LA Hungarian
DT Article
ID KNEE OSTEOARTHRITIS; PHOTOBIOMODULATION; PAIN; MUSCULOSKELETAL;
   IRRADIATION; EFFICACY; RATS; RED; REHABILITATION; ACUPUNCTURE
AB The medicative affect of light has been known for several millennia. One of the latest findings in light terapies is Low-Level Laser Therapy (LLLT) which has become increasingly widespread in the recent years and its application is extremely broad from wound treatment and dentistry to physiotherapy and infertility management both in human and veterinary medicine. Its main effect is related to its ability to modulate cellular metabolism (enhancing ATP production, increasing intracellular Ca2+ concentration, enzymatic modulation) and its usage is fairly easy. As a consequence, experiments have been and are being carried out on almost all organ systems of the human and animal body in order to achieve better results with the most precise settings (wavelenght, power, time, frequence) and exact protocols. However, the current literature data is rather controversial about the efficacy of LLLT. Experiments on different species and disorders with different parameters and controls can be found which makes the data incomparable. More well established and detailed studies are needed to carry out and publish to make LLLT an affirmed complementary or, in the future, a primary therapeutic method. Although there are already a few summary studies on the subject, a high number of relevant publications appear every day, which shows the importance and topicality of LLLT. Our aim is shortly reviewing the experimental results published in the last 60 years since the finding of therapeutic laser sources in human and veterinary medicine around the world and to give an outlook on possible future applications, because low-level lasers are potential tools for the treatment of many severe diseases like tumors, or degenerative disorders like Alzheimer's- or Parkinson's disease.
C1 [Kiss, Gerda] Kharisz Vet Kft, Rakoczi U 152, Budapest, Hungary.
   [Poth-Szebenyi, Bettina] MATE, Kaposvari Campus, Kaposvari, Hungary.
   [Rozsa, Tamas] Safe Laser Trade Kft, Budapest, Hungary.
   [Konyves, Laszlo] Allatorvostudomanyi Egyet, Allathigieniai Allornany Egeszsegtani Tanszek & M, Budapest, Hungary.
   [Gabor, Gyorgy] Androvet Kft, Budapest, Hungary.
C3 Hungarian University of Agriculture & Life Sciences; University of
   Veterinary Medicine Budapest
RP Kiss, G (corresponding author), Kharisz Vet Kft, Rakoczi U 152, Budapest, Hungary.
EM khariszvet@gmail.com
CR Ad N, 2001, INT J CARDIOL, V80, P109, DOI 10.1016/S0167-5273(01)00503-4
   Ahmad MA, 2022, PHYSIOTHERAPY, V114, P85, DOI 10.1016/j.physio.2021.03.011
   Ahmed W, 2021, J EQUINE VET SCI, V98, DOI 10.1016/j.jevs.2020.103363
   Akbar A, 2023, J PHOTOCH PHOTOBIO B, V248, DOI 10.1016/j.jphotobiol.2023.112796
   AlGhamdi KM, 2012, LASER MED SCI, V27, P237, DOI 10.1007/s10103-011-0885-2
   Alves ED, 2019, J PHOTOCH PHOTOBIO B, V194, P6, DOI 10.1016/j.jphotobiol.2019.03.006
   Astuti SD, 2023, HELIYON, V9, DOI 10.1016/j.heliyon.2023.e23253
   Barolet D, 2008, SEMIN CUTAN MED SURG, V27, P227, DOI 10.1016/j.sder.2008.08.003
   BECKERMAN H, 1992, PHYS THER, V72, P483, DOI 10.1093/ptj/72.7.483
   Catalán J, 2020, THERIOGENOLOGY, V149, P88, DOI 10.1016/j.theriogenology.2020.03.024
   Cheung WKW, 2020, PHYSIOTHERAPY, V106, P24, DOI 10.1016/j.physio.2019.06.005
   Cho HJ, 2004, IN VIVO, V18, P585
   Corral-Baqués MI, 2009, LASER MED SCI, V24, P703, DOI 10.1007/s10103-008-0606-7
   de Almeida TG, 2019, LASER MED SCI, V34, P1001, DOI 10.1007/s10103-018-2690-7
   de Brito AA, 2020, J PHOTOCH PHOTOBIO B, V203, DOI 10.1016/j.jphotobiol.2019.111731
   de Moraes MB, 2020, J ORAL MAXIL SURG, V78, DOI 10.1016/j.joms.2020.05.018
   Draper WE, 2012, J SMALL ANIM PRACT, V53, P465, DOI 10.1111/j.1748-5827.2012.01242.x
   Dyson M., 1985, International congress Laser Medic Surgery, V1, P215
   El Faham DA, 2018, LASER MED SCI, V33, P1105, DOI 10.1007/s10103-018-2476-y
   Enwemeka CS, 2020, J PHOTOCH PHOTOBIO B, V207, DOI 10.1016/j.jphotobiol.2020.111891
   Farivar S, 2014, J LASERS MED SCI, V5, P58
   Fernandes GHC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121487
   Figurová M, 2016, PHOTOMED LASER SURG, V34, P53, DOI 10.1089/pho.2015.4013
   FITZPATRICK TB, 1959, J INVEST DERMATOL, V32, P229, DOI 10.1038/jid.1959.40
   Flemming K A, 1999, J Wound Care, V8, P111
   Fraga RS, 2020, J ORAL MAXIL SURG, V78, DOI 10.1016/j.joms.2020.08.002
   Gagnon D, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0689-5
   GAM AN, 1993, PAIN, V52, P63, DOI 10.1016/0304-3959(93)90114-5
   Ghamsari SM, 1996, BRIT VET J, V152, P583, DOI 10.1016/S0007-1935(96)80010-8
   Godine RL, 2014, PHOTOMED LASER SURG, V32, P1, DOI 10.1089/pho.2013.9867
   Grinsted A, 2019, EC GYNAECOL, V8, P875
   HALL J, 1994, BRIT J RHEUMATOL, V33, P142
   Hamblin MR, 2016, J BIOPHOTONICS, V9, P1122, DOI 10.1002/jbio.201670113
   Hamblin MR., 2006, PROC SPIE, DOI DOI 10.1117/12.646294
   Harrison KL, 2008, FERTIL STERIL, V90, pS321, DOI DOI 10.1016/J.FERTNSTERT.2008.07.1670
   Harrison TM, 2023, FOWLERS ZOO WILD ANI, V10, P319, DOI [10.1016/B978-0-323-82852-9.00048-4, DOI 10.1016/B978-0-323-82852-9.00048-4]
   Hasani A, 2020, LIFE SCI, V254, DOI 10.1016/j.lfs.2020.117767
   Haussler KK, 2020, J EQUINE VET SCI, V86, DOI 10.1016/j.jevs.2019.102891
   Jacobsen FM, 1997, PAIN, V73, P110
   John SS, 2020, J CRANIO MAXILL SURG, V48, P251, DOI 10.1016/j.jcms.2020.01.012
   KARU T, 1989, HEALTH PHYS, V56, P691, DOI 10.1097/00004032-198905000-00015
   Karu TI, 2008, PHOTOCHEM PHOTOBIOL, V84, P1091, DOI 10.1111/j.1751-1097.2008.00394.x
   Kelkar M, 2023, J CRANIO MAXILL SURG, V51, P316, DOI 10.1016/j.jcms.2023.05.003
   Kheiri A, 2020, ARCH ORAL BIOL, V117, DOI 10.1016/j.archoralbio.2020.104782
   KLEINKORT JA, 1984, AM J ACUPUNCTURE, V12, P51
   Kurach LM, 2015, VET SURG, V44, P988, DOI 10.1111/vsu.12407
   Laakso L, 1993, Aust J Physiother, V39, P95, DOI 10.1016/S0004-9514(14)60473-6
   Lapchak PA, 2007, NEUROSCIENCE, V148, P907, DOI 10.1016/j.neuroscience.2007.07.002
   Lorenzini L, 2010, RES VET SCI, V88, P159, DOI 10.1016/j.rvsc.2009.06.001
   Luna SPL, 2020, J EQUINE VET SCI, V85, DOI 10.1016/j.jevs.2019.102846
   Medeiros DM, 2020, PHYS THER SPORT, V42, P124, DOI 10.1016/j.ptsp.2020.01.006
   Meng CB, 2013, J NEUROSCI, V33, P13505, DOI 10.1523/JNEUROSCI.0918-13.2013
   Mester A, 2017, PHOTOMED LASER SURG, V35, P393, DOI 10.1089/pho.2017.4332
   MESTER E, 1985, LASER SURG MED, V5, P31, DOI 10.1002/lsm.1900050105
   MESTER E, 1971, AM J SURG, V122, P532, DOI 10.1016/0002-9610(71)90482-X
   Millis DL, 2023, ANIMALS-BASEL, V13, DOI 10.3390/ani13040667
   Milojevic Momir, 2003, Med Pregl, V56, P413, DOI 10.2298/MPNS0310413M
   Mirulla AI, 2023, HELIYON, V9, DOI 10.1016/j.heliyon.2023.e22379
   MULCAHY D, 1995, INJURY, V26, P315, DOI 10.1016/0020-1383(95)00048-E
   Naseri P, 2017, LASER MED SCI, V32, P1971, DOI 10.1007/s10103-017-2296-5
   Ohshiro T, 1991, J Clin Laser Med Surg, V9, P267
   Ohshiro T, 2005, LASER THER, V14, P121
   Ohshiro Toshio, 2012, Laser Ther, V21, P97, DOI 10.5978/islsm.12-OR-05
   Ohshiro Toshio, 2012, Laser Ther, V21, P275, DOI 10.5978/islsm.12-OR-16
   Olivieri L, 2015, VET DERMATOL, V26, P35, DOI 10.1111/vde.12170
   Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198
   Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8
   Oubiña G, 2019, PROG BIOPHYS MOL BIO, V145, P10, DOI 10.1016/j.pbiomolbio.2018.11.010
   Garcia GP, 2021, NEUROTRAUMA REP, V2, P548, DOI 10.1089/neur.2021.0005
   Petersen SL, 1999, EQUINE VET J, V31, P228, DOI 10.1111/j.2042-3306.1999.tb03177.x
   Pinheiro A L, 1997, J Clin Laser Med Surg, V15, P181
   Pryor B, 2015, VET CLIN N AM-SMALL, V45, P45, DOI 10.1016/j.cvsm.2014.09.003
   Quiney L, 2020, J EQUINE VET SCI, V86, DOI 10.1016/j.jevs.2019.102878
   Raja IS, 2024, BIOMATERIALS, V309, DOI 10.1016/j.biomaterials.2024.122623
   Reusing M. S. de Oliveira, 2021, Revue Veterinaire Clinique, V56, P177, DOI [10.1016/j.anicom.2021.08.001, 10.1016/j.anicom.2021.08.001]
   Alves MBR, 2016, LASER MED SCI, V31, P695, DOI 10.1007/s10103-016-1911-1
   Roelandts R, 2002, J AM ACAD DERMATOL, V46, P926, DOI 10.1067/mjd.2002.121354
   Ryan T, 2007, IRISH VET J, V60, P295, DOI 10.1186/2046-0481-60-5-295
   Safian F, 2020, PHOTOBIOMOD PHOTOMED, V38, P222, DOI 10.1089/photob.2019.4773
   Saylan A, 2023, REV INT ANDROL, V21, DOI 10.1016/j.androl.2022.04.001
   Schiffer F, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-46
   Shaver SL, 2009, J AVIAN MED SURG, V23, P209, DOI 10.1647/2008-038.1
   Siqueira AFP, 2016, LASER MED SCI, V31, P1245, DOI 10.1007/s10103-016-1966-z
   SKOBELKIN O K, 1991, Laser Therapy, V3, P169
   de Lima VHS, 2020, ORAL ONCOL, V102, DOI 10.1016/j.oraloncology.2019.104524
   Tadakuma Takushi, 1993, Keio Journal of Medicine, V42, P180
   Tan Gang, 2022, Photodiagnosis Photodyn Ther, V40, P103093, DOI [10.1016/j.pdpdt.2022.103093, 10.1016/j.pdpdt.2022.103093]
   Tanideh N, 2024, KNEE, V47, P208, DOI 10.1016/j.knee.2024.02.004
   Taylor DN, 2020, J CHIROPR MED, V19, P119, DOI 10.1016/j.jcm.2020.06.002
   Thiel H, 1986, J CAN CHIROPR ASS, V30, P133
   Tong SM, 2025, J PHOTOCH PHOTOBIO A, V459, DOI 10.1016/j.jphotochem.2024.116085
   Tsai HW, 2020, GYNECOL ENDOCRINOL, V36, P734, DOI 10.1080/09513590.2020.1712694
   Walsh LJ, 1997, AUST DENT J, V42, P302, DOI 10.1111/j.1834-7819.1997.tb00134.x
   Walsh LJ, 1997, AUST DENT J, V42, P247, DOI 10.1111/j.1834-7819.1997.tb00129.x
   Wang HB, 2023, HELIYON, V9, DOI 10.1016/j.heliyon.2023.e13821
   Whittaker P, 2004, LASER MED SCI, V19, P69, DOI 10.1007/s10103-004-0296-8
   Wilden L, 1998, J CLIN LASER MED SUR, V16, P159, DOI 10.1089/clm.1998.16.159
   Yuca Y, 2020, J CRANIO MAXILL SURG, V48, P308, DOI 10.1016/j.jcms.2020.01.017
   Yurtsever MÇ, 2020, J PHOTOCH PHOTOBIO B, V204, DOI 10.1016/j.jphotobiol.2019.111742
   Zielinska P, 2023, J EQUINE VET SCI, V120, DOI 10.1016/j.jevs.2022.104188
   Zipper R, 2022, J COMP EFFECT RES, V11, P843, DOI 10.2217/cer-2021-0281
NR 101
TC 0
Z9 0
U1 3
U2 3
PU MEZOGAZDA KIADO KFT
PI BUDAPEST
PA PO BOX 16, 1631 BUDAPEST, HUNGARY
SN 0025-004X
J9 MAGY ALLATORVOSOK
JI Magy. Allatorv. Lapja
PD JUL
PY 2025
VL 147
IS 7
BP 407
EP 427
DI 10.56385/magyallorv.2025.7.407-427
PG 21
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Veterinary Sciences
GA 6AD7N
UT WOS:001548491800004
DA 2026-01-16
ER

PT J
AU Mott, T
   Jones, G
   Roman, K
AF Mott, Timothy
   Jones, Gregory
   Roman, Kimberly
TI Costochondritis: Rapid Evidence Review
SO AMERICAN FAMILY PHYSICIAN
LA English
DT Review
ID NONCARDIAC CHEST-PAIN; PRIMARY-CARE; CLINICAL-PREDICTION; DIAGNOSIS;
   PATIENT; VALIDATION; MANAGEMENT; EMERGENCY; WALL; OUTPATIENTS
AB Costochondritis is a common cause of chest pain. It most commonly occurs in adults between 40 and 50 years of age, with a slight predominance in women. Although musculoskeletal and other chest wall conditions are the most common etiology for chest pain presenting to primary care, an initial differential diagnosis should include cardiovascular, psychogenic, pulmonary, gastrointestinal, and miscellaneous or unknown sources (more to less common, respectively). Additionally, physicians should remain vigilant throughout the work-up because a notable portion of patients with chest wall tenderness to palpation may also have acute myocardial infarction. After a musculoskeletal or chest wall source is determined, differential diagnosis includes costochondritis, muscle trauma (including postoperative) or overuse, arthritis, fibromyalgia, neoplasm, infection, herpes zoster, Tietze syndrome, painful xyphoid syndrome, and slipping rib syndrome. The diagnosis of costochondritis is largely based on history and a physical examination that demonstrates reproduction of pain through palpation of the parasternal region of the chest wall, performance of a crowing rooster maneuver, and/or a crossed-chest adduction maneuver. Although high-quality evidence is lacking, treatment options include local application of heat, oral or topical nonsteroidal anti-inflammatory drugs, lidocaine patches, capsaicin cream, physical therapy, and acupuncture. Most patients will have complete resolution of symptoms in a few weeks' time with conservative therapy. Recalcitrant cases may respond to corticosteroid injections. Copyright (C) 2021 American Academy of Family Physicians.
C1 [Mott, Timothy; Jones, Gregory; Roman, Kimberly] South Baldwin Reg Med Ctr, Family Med Residency Program, Foley, AL 36535 USA.
RP Mott, T (corresponding author), South Baldwin Reg Med Ctr, 1613 N McKenzie St, Foley, AL 36535 USA.
EM timothy_mott@chs.net
RI Mott, Timothy/IAN-0762-2023
OI Mott, Timothy/0000-0003-1560-3501
CR [Anonymous], 2008, SWISS MED WKLY, V138, P340
   Ayloo A, 2013, PRIMARY CARE, V40, P863, DOI 10.1016/j.pop.2013.08.007
   Bhuiya Farida A, 2010, NCHS Data Brief, P1
   Bösner S, 2010, CAN MED ASSOC J, V182, P1295, DOI 10.1503/cmaj.100212
   Boran M, 2017, World Journal of Pharmaceutical Research, P76, DOI 10.20959/wjpr20178-9026
   Bosner S, FAM PRACT, P363
   CHICARILLI ZN, 1986, PLAST RECONSTR SURG, V77, P50, DOI 10.1097/00006534-198601000-00009
   Cilia C, 2010, INTERN EMERG MED, V5, P427, DOI 10.1007/s11739-010-0401-x
   Dale AP, 2019, BRIT J GEN PRACT, V69, pE444, DOI 10.3399/bjgp19X704297
   DIEHR P, 1984, J CHRON DIS, V37, P215, DOI 10.1016/0021-9681(84)90149-8
   DISLA E, 1994, ARCH INTERN MED, V154, P2466, DOI 10.1001/archinte.154.21.2466
   Do AMP, 2009, AM FAM PHYSICIAN, V80, P617
   DynaMed, HERPES ZOSTER
   DynaMed, FIBR SUBSCR REQ FIBR SUBSCR REQ
   Ebell MH, 2011, AM FAM PHYSICIAN, V83, P603
   EPSTEIN SE, 1979, JAMA-J AM MED ASSOC, V241, P2793, DOI 10.1001/jama.241.26.2793
   Gregory PL, 2002, SPORTS MED, V32, P235, DOI 10.2165/00007256-200232040-00003
   Haasenritter J, 2015, CROAT MED J, V56, P422, DOI 10.3325/cmj.2015.56.422
   Harskamp RE, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-027081
   Hoorweg BBN, 2017, HEART, V103, P1727, DOI 10.1136/heartjnl-2016-310905
   How Jennifer, 2005, Eur J Intern Med, V16, P432, DOI 10.1016/j.ejim.2005.07.002
   Hsiao Chun-Ju, 2010, Natl Health Stat Report, P1
   Imazio M, 2011, ANN INTERN MED, V155, P409, DOI 10.7326/0003-4819-155-7-201110040-00359
   Kamel M, 1997, BRIT J RHEUMATOL, V36, P547
   KLINKMAN MS, 1994, J FAM PRACTICE, V38, P345
   Li B, 1998, J Tradit Chin Med, V18, P195
   Löwe B, 2003, J PSYCHOSOM RES, V55, P515, DOI 10.1016/S0022-3999(03)00072-2
   Maisch B, 2004, EUR HEART J, V25, P587, DOI 10.1016/j.ehj.2004.02.002
   McConaghy JR, 2013, AM FAM PHYSICIAN, V87, P177
   Metlay JP, 1997, JAMA-J AM MED ASSOC, V278, P1440, DOI 10.1001/jama.278.17.1440
   Panju AA, 1998, JAMA-J AM MED ASSOC, V280, P1256, DOI 10.1001/jama.280.14.1256
   PANTELL RH, 1983, PEDIATRICS, V71, P881
   Ronga A, 2012, BMC FAM PRACT, V13, DOI 10.1186/1471-2296-13-74
   Rovetta G, 2009, G Ital Med Lav Ergon, V31, P169
   Saltzman DA, 2001, PAEDIATR ANAESTH, V11, P740, DOI 10.1046/j.1460-9592.2001.00754.x
   Smythe HA, 1985, MUSCULOSKELETAL CHES
   Spalding L, 2003, J ROY SOC MED, V96, P122, DOI 10.1258/jrsm.96.3.122
   Tamariz LJ, 2004, AM J MED, V117, P676, DOI 10.1016/j.amjmed.2004.04.021
   Tietze A., 1921, Berliner Klinische Wochenschrift, V30, P829
   Van den Berg P, 2018, EUR HEART J-ACUTE CA, V7, P111, DOI 10.1177/2048872617710788
   Verdon F, CHEST
   Verdon F, 2007, BMC FAM PRACT, V8, DOI 10.1186/1471-2296-8-51
   von Kodolitsch Y, 2000, ARCH INTERN MED, V160, P2977, DOI 10.1001/archinte.160.19.2977
   Wang CS, 2005, JAMA-J AM MED ASSOC, V294, P1944, DOI 10.1001/jama.294.15.1944
   Wang WH, 2005, ARCH INTERN MED, V165, P1222, DOI 10.1001/archinte.165.11.1222
   Wells PS, 2001, ANN INTERN MED, V135, P98, DOI 10.7326/0003-4819-135-2-200107170-00010
   Wertli MM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211615
   WISE CM, 1992, ARCH PHYS MED REHAB, V73, P147
   WOLF E, 1976, ARCH INTERN MED, V136, P189, DOI 10.1001/archinte.136.2.189
   ZAPATERO J, 1988, BRIT J DIS CHEST, V82, P341, DOI 10.1016/0007-0971(88)90086-1
   Zimmerman J, 2004, SCAND J GASTROENTERO, V39, P212, DOI 10.1080/00365520310005333
NR 51
TC 1
Z9 1
U1 1
U2 4
PU AMER ACAD FAMILY PHYSICIANS
PI KANSAS CITY
PA 8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA
SN 0002-838X
EI 1532-0650
J9 AM FAM PHYSICIAN
JI Am. Fam. Physician
PD JUL 1
PY 2021
VL 104
IS 1
BP 73
EP 78
PG 6
WC Primary Health Care; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA TQ3GI
UT WOS:000678171700022
PM 34264599
DA 2026-01-16
ER

PT J
AU Lam, CS
   Zhou, K
   Loong, HHF
   Chung, VCH
   Ngan, CK
   Cheung, YT
AF Lam, Chun Sing
   Zhou, Keary
   Loong, Herbert Ho-Fung
   Chung, Vincent Chi-Ho
   Ngan, Chun-Kit
   Cheung, Yin Ting
TI The Use of Traditional, Complementary, and Integrative Medicine in
   Cancer: Data-Mining Study of 1 Million Web-Based Posts From Health
   Forums and Social Media Platforms
SO JOURNAL OF MEDICAL INTERNET RESEARCH
LA English
DT Article
DE traditional; complementary; integrative; social media; cancer; forums,
   digital health; traditional, complementary, and integrative medicine;
   TCIM; perceptions; machine learning; cancer care
ID QUALITY-OF-LIFE; ALTERNATIVE MEDICINE; CANNABIS USE; THERAPIES;
   COMMUNICATION; MANAGEMENT; SOCIETY
AB Background: Patients with cancer are increasingly using forums and social media platforms to access health information and share their experiences, particularly in the use of traditional, complementary, and integrative medicine (TCIM). Despite the popularity of TCIM among patients with cancer, few related studies have used data from these web-based sources to explore the use of TCIM among patients with cancer.
   Objective: This study leveraged multiple forums and social media platforms to explore patients' use, interest, and perception of TCIM for cancer care.
   Methods: Posts (in English) related to TCIM were collected from Facebook, Twitter, Reddit, and 16 health forums from inception until February 2022. Both manual assessments and natural language processing were performed. Descriptive analyses were performed to explore the most commonly discussed TCIM modalities for each symptom and cancer type. Sentiment analyses were performed to measure the polarity of each post or comment, and themes were identified from posts with positive and negative sentiments. TCIM modalities that are emerging or recommended in the guidelines were identified a priori. Exploratory topic-modeling analyses with latent Dirichlet allocation were conducted to investigate the patients' perceptions of these modalities.
   Results: Among the 1,620,755 posts available, cancer-related symptoms, such as pain (10/10, 100% cancer types), anxiety and depression (9/10, 90%), and poor sleep (9/10, 90%), were commonly discussed. Cannabis was among the most frequently discussed TCIM modalities for pain in 7 (70%) out of 10 cancer types, as well as nausea and vomiting, loss of appetite, anxiety and depression, and poor sleep. A total of 7 positive and 7 negative themes were also identified. The positive themes included TCIM, making symptoms manageable, and reducing the need for medication and their side effects. The belief that TCIM and conventional treatments were not mutually exclusive and intolerance to conventional treatment may facilitate TCIM use. Conversely, TCIM was viewed as leading to patients' refusal of conventional treatment or delays in diagnosis and treatment. Doctors' ignorance regarding TCIM and the lack of information provided about TCIM may be barriers to its use. Exploratory analyses showed that TCIM recommendations were well discussed among patients; however, these modalities were also used for many other indications. Other notable topics included concerns about the legalization of cannabis, acupressure techniques, and positive experiences of meditation.
   Conclusions: Using machine learning techniques, social media and health forums provide a valuable resource for patient-generated data regarding the pattern of use and patients' perceptions of TCIM. Such information will help clarify patients' needs and concerns and provide directions for research on integrating TCIM into cancer care. Our results also suggest that effective communication about TCIM should be achieved and that doctors should be more open-minded to actively discuss TCIM use with their patients.
C1 [Lam, Chun Sing; Zhou, Keary; Cheung, Yin Ting] Chinese Univ Hong Kong, Sch Pharm, Fac Med, Hong Kong, Peoples R China.
   [Loong, Herbert Ho-Fung] Chinese Univ Hong Kong, Fac Med, Dept Clin Oncol, Hong Kong, Peoples R China.
   [Chung, Vincent Chi-Ho] Chinese Univ Hong Kong, Sch Chinese Med, Fac Med, Hong Kong, Peoples R China.
   [Chung, Vincent Chi-Ho] Chinese Univ Hong Kong, Jockey Club Sch Publ Hlth & Primary Care, Fac Med, Hong Kong, Peoples R China.
   [Ngan, Chun-Kit] Worcester Polytech Inst, Data Sci Program, Worcester, MA USA.
   [Cheung, Yin Ting] Chinese Univ Hong Kong, Sch Pharm, Fac Med, Shatin, 8th Floor,Lo Kwee Seong Integrated Biomed Sci Bldg, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong;
   Chinese University of Hong Kong; Chinese University of Hong Kong;
   Worcester Polytechnic Institute; Chinese University of Hong Kong
RP Cheung, YT (corresponding author), Chinese Univ Hong Kong, Sch Pharm, Fac Med, Shatin, 8th Floor,Lo Kwee Seong Integrated Biomed Sci Bldg, Hong Kong, Peoples R China.
EM yinting.cheung@cuhk.edu.hk
RI Chung, Vincent/K-2447-2013; Cheung, Yin Ting/AAT-4384-2021; Loong,
   Herbert/J-5413-2017; Lam, Chun Sing/AFR-1212-2022
OI Loong, Herbert/0000-0002-6607-1106; Ngan, Chun-Kit/0000-0003-2151-0459;
   Zhou, Keary/0000-0001-5054-4290; Lam, Chun Sing/0000-0002-6478-6706
CR [Anonymous], 2022, SEARCH ENG MARK SHAR
   [Anonymous], 2017, TRADITIONAL COMPLEME
   [Anonymous], 2021, Meditation: In Depth
   [Anonymous], 2013, WHO TRADITIONAL MED, V1st
   [Anonymous], 2022, GLOB CANN REP
   Attai DJ, 2016, FUTURE ONCOL, V12, P1549, DOI 10.2217/fon-2016-0065
   Babcock ZR, 2020, J CANCER SURVIV, V14, P89, DOI 10.1007/s11764-019-00837-y
   Balaji TK, 2021, COMPUT SCI REV, V40, DOI 10.1016/j.cosrev.2021.100395
   Barde BV, 2017, 2017 INTERNATIONAL CONFERENCE ON INTELLIGENT COMPUTING AND CONTROL SYSTEMS (ICICCS), P745, DOI 10.1109/ICCONS.2017.8250563
   Bauer Mark S, 2015, BMC Psychol, V3, P32, DOI [10.1186/s40359-015-0089-9, 10.1186/s40359-015-0089-9]
   Ben-Arye E, 2021, SUPPORT CARE CANCER, V29, P6155, DOI 10.1007/s00520-021-06205-w
   Beusterien K, 2013, ECANCERMEDICALSCIENC, V7, DOI 10.3332/ecancer.2013.361
   Bird S., 2009, Natural Language Processing with Python
   Blei DM, 2003, J MACH LEARN RES, V3, P993, DOI 10.1162/jmlr.2003.3.4-5.993
   Buckner CA, 2018, CURR ONCOL, V25, pE275, DOI 10.3747/co.25.3884
   Buis LR, 2011, CIN-COMPUT INFORM NU, V29, P461, DOI 10.1097/NCN.0b013e318214093b
   Reddy YCAP, 2018, International Journal of Engineering & Technology, V7, P81, DOI [10.14419/ijet.v7i1.8.9977, 10.14419/ijet.v7i1.8.9977, DOI 10.14419/IJET.V7I1.8.9977]
   Chung VCH, 2011, EUR J INTEGR MED, V3, pE283, DOI 10.1016/j.eujim.2011.09.008
   Chung VCH, 2009, HEALTH POLICY, V90, P66, DOI 10.1016/j.healthpol.2008.09.005
   Cleeland Charles S, 2007, J Natl Cancer Inst Monogr, P16
   Davis EL, 2012, ONCOLOGIST, V17, P1475, DOI 10.1634/theoncologist.2012-0223
   Degenhardt L, 2008, PLOS MED, V5, P1053, DOI 10.1371/journal.pmed.0050141
   Deng G, 2013, NAT REV CLIN ONCOL, V10, P656, DOI 10.1038/nrclinonc.2013.125
   Deng GE, 2013, CHEST, V143, pE420, DOI 10.1378/chest.12-2364
   Deshields T, 2014, SUPPORT CARE CANCER, V22, P1089, DOI 10.1007/s00520-013-2049-3
   Dhaoui C, 2017, J CONSUM MARK, V34, P480, DOI 10.1108/JCM-03-2017-2141
   Dinov IvoD., 2018, Data science and predictive analytics: Biomedical and health applications using R, DOI DOI 10.1007/978-3-319-72347-1
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Hasan A, 2017, LECT NOTES COMPUT SC, V10584, P125, DOI 10.1007/978-3-319-68765-0_11
   Honnibal Matthew., 2020, Industrial-Strength Natural Language Processing in Python
   Jagarlamudi Jagadeesh., 2012, EACL, P204
   Johnson SB, 2018, JAMA ONCOL, V4, P1375, DOI 10.1001/jamaoncol.2018.2487
   Junger Jakob., 2019, Facepager. An application for automated data retrieval on the web
   Keene MR, 2019, COMPLEMENT THER CLIN, V35, P33, DOI 10.1016/j.ctcp.2019.01.004
   Lee RT, 2008, INTEGR CANCER THER, V7, P70, DOI 10.1177/1534735408319059
   Lognos B, 2019, JMIR CANCER, V5, DOI 10.2196/12536
   Loria S., 2020, TextBlob: Simplified Text Processing
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2022, CA-CANCER J CLIN, V72, P144, DOI 10.3322/caac.21706
   Martell K, 2018, CURR ONCOL, V25, P219, DOI 10.3747/co.25.3983
   Mazzocut M, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.5521
   Murphy CC, 2018, CANCER-AM CANCER SOC, V124, P2850, DOI 10.1002/cncr.31389
   Narayanan S, 2021, INTEGR CANCER THER, V20, DOI 10.1177/1534735421999101
   Pergam SA, 2017, CANCER-AM CANCER SOC, V123, P4488, DOI 10.1002/cncr.30879
   Portier Kenneth, 2013, Journal of the National Cancer Institute Monographs, P195, DOI 10.1093/jncimonographs/lgt025
   Robbins R, 2020, BJU INT, V125, P634, DOI 10.1111/bju.14986
   Roberts CS, 2005, J PSYCHOSOC ONCOL, V23, P35, DOI 10.1300/J077v23n04_03
   Schultz Pamela N, 2003, Clin J Oncol Nurs, V7, P663
   Shneerson C, 2013, COMPLEMENT THER MED, V21, P417, DOI 10.1016/j.ctim.2013.05.003
   Sofaer S, 2005, ANNU REV PUBL HEALTH, V26, P513, DOI 10.1146/annurev.publhealth.25.050503.153958
   Stein KD, 2008, CANCER-AM CANCER SOC, V112, P2577, DOI 10.1002/cncr.23448
   SUTHERLAND LR, 1994, J CLIN GASTROENTEROL, V19, P194, DOI 10.1097/00004836-199410000-00004
   van der Weijden T, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-10
   Verhoef MJ, 2009, CHRONIC DIS CAN, V29, P80
   Vyas MB, 2018, NURS OUTLOOK, V66, P56, DOI 10.1016/j.outlook.2017.08.012
   Wagner J, 2021, MOST POPULAR SOCIAL
   Wang JZ, 2020, J MED INTERNET RES, V22, DOI 10.2196/22152
   Weeks Laura, 2014, Open Med, V8, pe54
   Wilkie G, 2016, JAMA ONCOL, V2, P670, DOI 10.1001/jamaoncol.2016.0155
   Witt CM, 2022, J CANCER EDUC, V37, P499, DOI 10.1007/s13187-020-01829-8
   Wode K, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2452-5
   Worster B, 2022, JCO ONCOL PRACT, V18, P743, DOI 10.1200/OP.22.00080
   Zick SM, 2018, J ALTERN COMPLEM MED, V24, P1018, DOI 10.1089/acm.2018.0184
   Zörgo S, 2018, INTEGR CANCER THER, V17, P1270, DOI 10.1177/1534735418801533
NR 64
TC 10
Z9 12
U1 0
U2 12
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY East, Unit 1100, TORONTO, ON M5A 0P6, CANADA
SN 1438-8871
J9 J MED INTERNET RES
JI J. Med. Internet Res.
PD APR 21
PY 2023
VL 25
AR e45408
DI 10.2196/45408
PG 13
WC Health Care Sciences & Services; Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; Medical Informatics
GA I9OU6
UT WOS:001006009400001
PM 37083752
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Ben-Arye, E
   Greenberg, D
   Samuels, N
   Lopez, AM
   Simon-Tuval, T
AF Ben-Arye, Eran
   Greenberg, Dan
   Samuels, Noah
   Lopez, Ana Maria
   Simon-Tuval, Tzahit
TI Adherence to Integrative Care, Oncology Healthcare Utilization, Opioid
   Use and Hospitalization
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE integrative oncology; pain; palliative care; cancer; patients;
   adherence; healthcare utilization
ID COMPLEMENTARY MEDICINE; CANCER; ACUPUNCTURE; PROGRAM; MANAGEMENT;
   IMPACT; BREAST
AB Research on the relationship between integrative oncology (IO) programs and dispensing of chemotherapy agents and supportive care drugs, and hospitalization rates is limited. The present study examined these outcomes in chemotherapy-treated patients with cancer, comparing patients highly adherent to integrative care (high-AIC) to those with low adherence (low-AIC). Data from patients with cancer treated with taxane and/or platinum-based agents participating in an ongoing prospective, controlled pragmatic trial were examined retrospectively. Patients were referred to an IO consultation and weekly treatments at 3 medical centers in Northern Israel, with high-AIC defined as attending >= 4 sessions at 6 weeks; low-AIC, 0-3 sessions. Cancer-related parameters; dispensing of medication (chemotherapy agents, analgesics, anxiolytics and opioids); rates of hospitalizations and emergency room visits were analyzed using generalized linear regression models. Of 615 patients attending the IO consultation, 367 (59.7%) were high-AIC, with both groups having mostly similar baseline characteristics. Dispensing rates for taxanes (P = .336), platinum agents (P = .403), non-opioid analgesics (P = .201), and anxiolytics (P = .350), and number of emergency room visits were similar in both groups at 12 weeks. However, high-AIC patients had fewer dispensed opioid prescriptions (RR = 0.50, 95% CI = 0.30-0.85, P = .010); lower rates of hospitalization (OR = 0.59, 95% CI = 0.39-0.88, P = .010); and fewer hospitalization days (RR = 0.53, 95% CI = 0.31-0.90, P = .019). In conclusion, dispensing of chemotherapy drugs was similar between groups, though high-AIC patients used less opioids and had fewer hospitalizations at 12 weeks. Further research is needed with randomized and prospective studies exploring the relationship between adherence to IO care; adherence to chemotherapy; quality of life; opioid use; and hospitalization.
C1 [Ben-Arye, Eran] Clalit Hlth Serv, Oncol Serv, Integrat Oncol Program, Lin Med Ctr, Haifa, Israel.
   [Ben-Arye, Eran] Clalit Hlth Serv, Oncol Serv, Carmel Med Ctr, Haifa, Israel.
   [Ben-Arye, Eran] Clalit Hlth Serv, Oncol Serv, Zebulun Med Ctr, Haifa, Israel.
   [Ben-Arye, Eran] Technion Israel Inst Technol, Ruth & Bruch Rappaport Fac Med, Haifa, Israel.
   [Greenberg, Dan; Simon-Tuval, Tzahit] Ben Gurion Univ Negev, Guilford Glazer Fac Business & Management, Dept Hlth Policy & Management, Beer Sheva, Israel.
   [Greenberg, Dan; Simon-Tuval, Tzahit] Bengur Univ Negev, Fac Hlth Sci, Beer Sheva, Israel.
   [Samuels, Noah] Hebrew Univ Jerusalem, Fac Med, Ctr Integrat Complementary Med, Shaare Zedek Med Ctr, Jerusalem, Israel.
   [Lopez, Ana Maria] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA USA.
   [Lopez, Ana Maria] Thomas Jefferson Univ, Sydney Kimmel comprehens Canc Ctr, Philadelphia, PA USA.
C3 Clalit Health Services; Clalit Health Services; Carmel Medical Center;
   Clalit Health Services; Technion Israel Institute of Technology;
   Ben-Gurion University of the Negev; Ben-Gurion University of the Negev;
   Hebrew University of Jerusalem; Shaare Zedek Medical Center; Thomas
   Jefferson University; Thomas Jefferson University
RP Ben-Arye, E (corresponding author), Lin Med Ctr, Integrat Oncol Program, Oncol Serv, 35 Rothschild St, IL-35152 Haifa, Israel.
EM eranben@technion.ac.il
RI Tuval, Tzahit/E-6328-2011
CR Ben-Arye E, 2024, J PAIN SYMPTOM MANAG, V68, P10, DOI 10.1016/j.jpainsymman.2024.03.018
   Ben-Arye E, 2024, J PAIN SYMPTOM MANAG, V67, P69, DOI 10.1016/j.jpainsymman.2023.09.022
   Ben-Arye E, 2023, J CANCER RES CLIN, V149, P8177, DOI 10.1007/s00432-023-04758-3
   Ben-Arye E, 2024, BMJ SUPPORT PALLIAT, V14, P178, DOI 10.1136/spcare-2022-004117
   Ben-Arye E, 2022, SUPPORT CARE CANCER, V30, P4345, DOI 10.1007/s00520-022-06865-2
   Ben-Arye E, 2022, PSYCHO-ONCOLOGY, V31, P207, DOI 10.1002/pon.5794
   Ben-Arye E, 2021, J CANCER RES CLIN, V147, P2361, DOI 10.1007/s00432-020-03506-1
   Ben-Arye E, 2018, SUPPORT CARE CANCER, V26, P4039, DOI 10.1007/s00520-018-4271-5
   Ben-Arye E, 2015, CLIN NUTR, V34, P1215, DOI 10.1016/j.clnu.2014.12.011
   Ben-Arye E, 2012, PATIENT EDUC COUNS, V89, P423, DOI 10.1016/j.pec.2012.02.011
   Bower JE, 2024, J CLIN ONCOL, V42, DOI 10.1200/JCO.24.00541
   Cao LX, 2020, WORLD J GASTROENTERO, V26, DOI 10.3748/wjg.v26.i23.3271
   Carlson LE, 2023, J CLIN ONCOL, V41, P4562, DOI 10.1200/JCO.23.00857
   Central Bureau of Statistics of Israel, 2017, Characterization and classification of statistical areas within municipalities and local councils by the socio-economic level of the population
   Estores IM, 2018, EXPLORE-NY, V14, P212, DOI 10.1016/j.explore.2018.02.002
   Herman PM, 2018, J ALTERN COMPLEM MED, V24, P1025, DOI 10.1089/acm.2018.0155
   Kerner H, 2020, BMJ SUPPORT PALLIAT, V10, DOI 10.1136/bmjspcare-2017-001351
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2022, CA-CANCER J CLIN, V72, P144, DOI 10.3322/caac.21706
   Minchom A, 2016, EUR J CANCER, V61, P102, DOI 10.1016/j.ejca.2016.03.078
   Molassiotis A, 2021, ACUPUNCT MED, V39, P41, DOI 10.1177/0964528420920285
   Ng DQ, 2024, BMC MED, V22, DOI 10.1186/s12916-024-03626-2
   Oberoi DV, 2021, J ALTERN COMPLEM MED, V27, P390, DOI 10.1089/acm.2020.0386
   Segev Y, 2021, SUPPORT CARE CANCER, V29, P4055, DOI 10.1007/s00520-020-05961-5
   Shalom-Sharabi I, 2018, INTEGR CANCER THER, V17, P697, DOI 10.1177/1534735418764839
   Shalom-Sharabi I, 2017, J CANCER RES CLIN, V143, P2535, DOI 10.1007/s00432-017-2509-0
   Shalom-Sharabi I, 2017, SUPPORT CARE CANCER, V25, P3181, DOI 10.1007/s00520-017-3726-4
   Shalom-Sharabi I, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-1016-0
   Shalom-Sharabi I, 2017, J CANCER RES CLIN, V143, P1243, DOI 10.1007/s00432-017-2368-8
   Sim Chin-Keng, 2002, Acupunct Med, V20, P56
   Thronicke A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236426
   Tillery R, 2018, EUR J ONCOL NURS, V36, P1, DOI 10.1016/j.ejon.2018.06.004
   Wang PR, 2023, PHOTODIAGN PHOTODYN, V42, DOI 10.1016/j.pdpdt.2023.103611
   World Health Organization, 2025, Anatomical Therapeutic Chemical (ATC) Classification
NR 34
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PY 2025
VL 24
AR 15347354251387955
DI 10.1177/15347354251387955
PG 9
WC Oncology; Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Integrative & Complementary Medicine
GA 9CB2Y
UT WOS:001602773600001
PM 41147326
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Gao, L
   Chen, SY
   Gao, TL
   Yang, LY
   Tai, XT
AF Gao, Lin
   Chen, Suyu
   Gao, Tianlei
   Yang, Liuying
   Tai, Xiantao
TI A bibliometric analysis of the development trend of Tuina research:
   Based on the Web of Science (WOS) platform
SO MEDICINE
LA English
DT Article
DE bibliometric analysis; Chinese massage; research review; Tuina
ID LOW-BACK-PAIN; THERAPEUTIC-EFFICACY; CANCER-PATIENTS; NECK PAIN; TAI
   CHI; MANIPULATION; MASSAGE; ACUPUNCTURE; MEDICINE; COMPLEMENTARY
AB Background:Tuina has been proven to significantly relieve symptoms, demonstrating its clinical value. With the growth of related research, a comprehensive review is urgently needed to promote its development. This study aims to clarify the collaboration and current research status in the field of Tuina research using bibliometric analysis, and to discuss future directions.Methods:On February 4, 2023, the Web of Science Core Collection (WoSCC) database was searched using the keywords "tuina," "tui-na," "tui na," and "Chinese massage" to collect literature related to Tuina from its inception until December 31, 2022. The collected literature included all types of research articles and reviews. VOSviewer, CiteSpace, Pajek, and Scimago Graphica were utilized to perform a visual analysis of annual publication volume, as well as publication volume and collaboration networks of different countries, institutions, and authors, along with journal publication volume and keyword network analysis.Results:A total of 761 publications were included in the analysis, with the total number of papers showed an increasing trend over time. The countries and institutions with the most publications were China and Shanghai University of Traditional Chinese Medicine, respectively. The authors who contributed the most were Min Fang, Qingguang Zhu, Zhiwei Wu, Lingjun Kong and Yufeng Wang. The most widely published journal in the field was the Journal of Acupuncture and Tuina Science. The clinical efficacy evaluation of Tuina therapy for musculoskeletal and spinal diseases, apoplexy sequelae, chronic diseases, and pediatric diseases were research hotspots and developing trends in this field.Conclusion:The research on Tuina has been increasing year by year. Currently, the focus of Tuina research lies in clinical studies, including the treatment of skeletal muscle and spinal diseases, stroke sequelae, chronic diseases, and pediatric illnesses, with pediatric Tuina emerging as a hot topic of research. Basic research in this field is relatively scarce, and the mechanisms of action of this therapy have not yet been fully elucidated. Future efforts in this area should aim to strengthen basic research and promote cooperation among international institutions.
C1 [Gao, Lin; Chen, Suyu] Yunnan Univ Chinese Med, Clin Med Coll 1, Kunming, Peoples R China.
   [Gao, Tianlei; Yang, Liuying; Tai, Xiantao] Yunnan Univ Chinese Med, Clin Med Coll 2, Kunming, Peoples R China.
C3 Yunnan University of Chinese Medicine; Yunnan University of Chinese
   Medicine
RP Tai, XT (corresponding author), Yunnan Univ Chinese Med, Affiliated Hosp 2, Sch Clin Med 2, Kunming 650500, Peoples R China.
EM 1587920143@qq.com; 515064283@qq.com; 1587920143@qq.com;
   m18468028906@163.com; taixiantao@163.com
FU Yunnan Province Innovation Team for the Prevention and Treatment of
   Brain Diseases with Acupuncture and Tuina [202405AS350007]; Yunnan
   Provincial Department of Education Scientific Research Fund Project
   [2022Y367]
FX This study was supported by grants from the Yunnan Province Innovation
   Team for the Prevention and Treatment of Brain Diseases with Acupuncture
   and Tuina (no. 202405AS350007) and the Yunnan Provincial Department of
   Education Scientific Research Fund Project (no. 2022Y367).
CR Carmady B, 2011, CHIN MED-UK, V6, DOI 10.1186/1749-8546-6-22
   Chen B, 2019, IRAN J BIOTECHNOL, V17, P80, DOI 10.21859/ijb.1863
   Chen LL, 2022, MEDICINE, V101, DOI 10.1097/MD.0000000000028833
   Chen LF, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000021664
   Chen SC, 2022, PHYTOMEDICINE, V102, DOI 10.1016/j.phymed.2022.154191
   Chen WJ, 2020, J TRADIT CHIN MED, V40, P1026, DOI 10.19852/j.cnki.jtcm.2020.06.014
   Cheng ZJ, 2021, TRIALS, V22, DOI 10.1186/s13063-021-05557-2
   Fan ZY, 2021, COMPLEMENT THER CLIN, V43, DOI 10.1016/j.ctcp.2020.101293
   Fan ZY, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011979
   Fang L, 2018, CHIN J INTEGR MED, V24, P531, DOI 10.1007/s11655-016-2275-x
   Fang L, 2015, J TRADIT CHIN MED, V35, P558
   Feng X, 2022, TRIALS, V23, DOI 10.1186/s13063-022-06030-4
   Field T, 2005, INT J NEUROSCI, V115, P1397, DOI 10.1080/00207450590956459
   FLAWS B, 1993, AM J ACUPUNCTURE, V21, P267
   Fu SF, 2022, FRONT PEDIATR, V10, DOI 10.3389/fped.2022.1043322
   Gong ZC, 2023, J PAIN RES, V16, P2063, DOI 10.2147/JPR.S410603
   Guan HY, 2022, MEDICINE, V101, DOI 10.1097/MD.0000000000030699
   Guo GX, 2022, TRIALS, V23, DOI 10.1186/s13063-022-06633-x
   Guo M, 2023, MEDICINE, V102, DOI 10.1097/MD.0000000000035980
   Guo TP, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000009697
   Huang F, 2022, COMPLEMENT THER CLIN, V49, DOI 10.1016/j.ctcp.2022.101627
   Huang F, 2020, COMPLEMENT THER CLIN, V39, DOI 10.1016/j.ctcp.2020.101115
   Ji YY, 2022, MEDICINE, V101, DOI 10.1097/MD.0000000000028780
   Jia Y, 2017, OPEN LIFE SCI, V12, P285, DOI 10.1515/biol-2017-0033
   Jiang SC, 2016, EXP THER MED, V11, P1367, DOI 10.3892/etm.2016.3055
   Jiang Z, 2021, INT J ORAL SCI, V13, DOI 10.1038/s41368-021-00117-5
   Kim E, 2022, MEDICINE, V101, DOI 10.1097/MD.0000000000032086
   Kong LJ, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/578305
   Li HN, 2017, J TRADIT CHIN MED, V37, P819
   Li T, 2021, EVID-BASED COMPL ALT, V2021, DOI 10.1155/2021/8862399
   Li X, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000023016
   Li Y, 2021, INDIAN J PHARM SCI, V83, P205, DOI 10.36468/pharmaceutical-sciences.spl.395
   Li Z., 2024, Heliyon, V10, pe38675, DOI [DOI 10.1016/J.HELIYON.2024.E38675, 10.1016/j.heliyon.2024.e38675]
   Liang SB, 2020, COMPLEMENT THER MED, V51, DOI 10.1016/j.ctim.2020.102411
   Lin JH, 2013, MANUAL THER, V18, P308, DOI 10.1016/j.math.2012.11.005
   Liu MQ, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000023738
   Lu TY, 2021, HEALTH QUAL LIFE OUT, V19, DOI 10.1186/s12955-020-01636-1
   Mao H, 2022, COMPLEMENT THER MED, V71, DOI 10.1016/j.ctim.2022.102882
   Meng M, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000026013
   Morandi G, 2023, ALTERN THER HEALTH M, V29, P258
   Niu JF, 2019, COMPLEMENT THER MED, V42, P322, DOI 10.1016/j.ctim.2018.10.017
   Öztekin DS, 2007, TOHOKU J EXP MED, V211, P49, DOI 10.1620/tjem.211.49
   Ploner M, 2011, CEREB CORTEX, V21, P719, DOI 10.1093/cercor/bhq146
   Ren J, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000027700
   Song PF, 2018, J TRADIT CHIN MED, V38, P834
   Tan MGE, 2013, ANN ACAD MED SINGAP, V42, P133
   Tang SJ, 2016, COMPLEMENT THER MED, V25, P45, DOI 10.1016/j.ctim.2016.01.001
   Tao JM, 2022, FRONT PSYCHIATRY, V13, DOI 10.3389/fpsyt.2022.923721
   Tao JM, 2021, TRIALS, V22, DOI 10.1186/s13063-021-05469-1
   Tao WW, 2015, ONCOTARGET, V6, P39725, DOI 10.18632/oncotarget.5388
   Wang FY, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000026222
   Wang HR, 2022, FRONT NEUROSCI-SWITZ, V16, DOI 10.3389/fnins.2022.1007432
   Wang JK, 2024, COMPLEMENT THER MED, V86, DOI 10.1016/j.ctim.2024.103092
   Wang MY, 2008, J CLIN NURS, V17, P2531, DOI 10.1111/j.1365-2702.2008.02446.x
   Wen Y, 2022, FRONT NEUROSCI-SWITZ, V16, DOI 10.3389/fnins.2022.974792
   WOLFE HL, 1995, AM J ACUPUNCTURE, V23, P219
   Wu HY, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.787228
   Wu ZW, 2019, TRIALS, V20, DOI 10.1186/s13063-018-3096-3
   Xu H, 2023, PAIN MED, V24, P244, DOI 10.1093/pm/pnac127
   Yang YC, 2022, NEUROPSYCH DIS TREAT, V18, P187, DOI 10.2147/NDT.S339762
   Zhang PY, 2020, NEURAL PLAST, V2020, DOI 10.1155/2020/8828826
   Zhang QS, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-038705
   Zhang QS, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000020368
   Zhang SP, 2020, TRIALS, V21, DOI 10.1186/s13063-020-4198-2
   Zhang XH, 2022, TRIALS, V23, DOI 10.1186/s13063-022-06678-y
   Zhang XH, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010574
   Zhao S., 2024, Asian J Surg
   Zhou BW, 2021, J ACUPUNCT TUINA SCI, V19, P104, DOI 10.1007/s11726-021-1232-1
   Zhou RJ, 2022, FRONT NEUROL, V13, DOI 10.3389/fneur.2022.1006830
   Zhou X, 2022, FRONT NEUROL, V13, DOI 10.3389/fneur.2022.952346
   Zhou X, 2022, MEDICINE, V101, DOI 10.1097/MD.0000000000028883
   ZHU BY, 2022, J ACUPUNCT TUINA SCI, V20, P187, DOI 10.1007/s11726-022-1311-y
   Zhu DC, 2022, J PAIN RES, V15, P3043, DOI 10.2147/JPR.S384757
   Zhu QG, 2016, J TRADIT CHIN MED, V36, P314
   Zhu QG, 2015, J TRADIT CHIN MED, V35, P411, DOI 10.1016/S0254-6272(15)30117-5
NR 75
TC 0
Z9 0
U1 6
U2 33
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JAN 17
PY 2025
VL 104
IS 3
AR e41070
DI 10.1097/MD.0000000000041070
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA S8Z9W
UT WOS:001401048300048
PM 39833056
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Roostaei, G
   Rad, NK
   Fakhri, BMS
   Nikfar, S
   Abdollahi, M
AF Roostaei, Ghazal
   Rad, Niloofar Khoshnam
   Fakhri, B. Maryam S.
   Nikfar, Shekoufeh
   Abdollahi, Mohammad
TI Emerging therapies for opioid-induced constipation: what can we expect?
SO EXPERT OPINION ON PHARMACOTHERAPY
LA English
DT Article
DE Opioid-induced constipation; PAMORAs; OIC; emerging therapies;
   peripherally acting mu-opioid receptor antagonists; expert opinion;
   expert review
ID CHRONIC NONCANCER PAIN; RANDOMIZED PHASE-III; LONG-TERM SAFETY;
   EFFICACY; NALDEMEDINE; METHYLNALTREXONE; NALOXEGOL; METAANALYSIS;
   MANAGEMENT; EXTENSION
AB Introduction: The rise in opioid use for managing chronic and oncologic pain has led to a significant increase in opioid-induced constipation (OIC) that impacts patient quality of life and pain management.
   Areas covered: In this study, emerging therapies for OIC were criticized for refining advancements and novel treatment options. Key topics included the efficacy of peripherally acting mu-opioid receptor antagonists (PAMORAs) such as methylnaltrexone, naloxegol, and naldemedine, which specifically target opioid-induced gut dysfunction. Other treatment options, including intestinal secretagogues like lubiprostone and linaclotide, selective 5-HT receptor agonists such as prucalopride, and emerging adjunctive therapies like transcutaneous electrical nerve stimulation (TENS) and electroacupuncture were mentioned. Current guidelines from the American Gastroenterological Association (AGA) and the European consensus were criticized.
   Expert opinion: Experts stress the importance of a stepwise approach to managing OIC, considering patient-specific factors and the efficacy of various treatments. While PAMORAs have demonstrated effectiveness in improving bowel function, their high cost and lack of extensive head-to-head comparisons with traditional laxatives are significant concerns. Emerging therapies and adjunctive treatments offer promising results but require further validation through rigorous studies. Future research should focus on long-term outcomes, cost-effectiveness, and comparative effectiveness to better address the complex needs of patients with OIC and refine treatment protocols.
C1 [Roostaei, Ghazal; Fakhri, B. Maryam S.] Univ Tehran Med Sci, Dept Internal Med, Tehran, Iran.
   [Roostaei, Ghazal; Rad, Niloofar Khoshnam] Univ Tehran Med Sci, Imam Khomeini Hosp Complex, Thorac Res Ctr, Tehran, Iran.
   [Rad, Niloofar Khoshnam; Nikfar, Shekoufeh; Abdollahi, Mohammad] Univ Tehran Med Sci, Fac Pharm, Tehran, Iran.
   [Rad, Niloofar Khoshnam; Nikfar, Shekoufeh; Abdollahi, Mohammad] Univ Tehran Med Sci, Pharmaceut Sci Res Ctr PSRC, Tehran, Iran.
   [Nikfar, Shekoufeh] Univ Tehran Med Sci, Endocrinol & Metab Res Inst, Personalized Med Res Ctr, Tehran, Iran.
C3 Tehran University of Medical Sciences; Tehran University of Medical
   Sciences; Tehran University of Medical Sciences; Tehran University of
   Medical Sciences; Tehran University of Medical Sciences
RP Abdollahi, M (corresponding author), Tehran Univ Med Sci Toxicol & Pharmacol, Fac Pharm, Tehran 1417614411, Iran.; Abdollahi, M (corresponding author), Tehran Univ Med Sci Toxicol & Pharmacol, Pharmaceut Sci Res Ctr PSRC, Tehran 1417614411, Iran.
EM Mohammad@TUMS.Ac.Ir
RI Abdollahi, Mohammad/B-9232-2008; Khoshnam, Niloofar/JDN-1722-2023
CR Alvaro D, 2022, PAIN THER, V11, P477, DOI 10.1007/s40122-022-00354-4
   Zambrano CB, 2020, ANN ONCOL, V31, pS1066, DOI 10.1016/j.annonc.2020.08.1515
   Bosetti C, 2019, EUR J PAIN, V23, P697, DOI 10.1002/ejp.1337
   BouSaba J, 2022, THER ADV GASTROENTER, V15, DOI 10.1177/17562848221078638
   Braun UK, 2024, PHARMACY-BASEL, V12, DOI 10.3390/pharmacy12020048
   Brenner DM, 2020, PAIN, V161, P1027, DOI 10.1097/j.pain.0000000000001754
   Camilleri M, 2014, NEUROGASTROENT MOTIL, V26, P1386, DOI 10.1111/nmo.12417
   Camilleri M, 2021, J PAIN RES, V14, P2179, DOI 10.2147/JPR.S282738
   Candy B, 2022, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006332.pub4
   Chang L, 2023, GASTROENTEROLOGY, V164, P1086, DOI 10.1053/j.gastro.2023.03.214
   Chey WD, 2014, NEW ENGL J MED, V370, P2387, DOI 10.1056/NEJMoa1310246
   Clark K, 2012, AM J HOSP PALLIAT ME, V29, P122, DOI 10.1177/1049909111409389
   Dols MC, 2023, BMJ SUPPORT PALLIAT, V13, pE318, DOI 10.1136/bmjspcare-2020-002816
   Dols MC, 2021, BMJ SUPPORT PALLIAT, V11, P25, DOI 10.1136/bmjspcare-2020-002249
   Crockett SD, 2019, GASTROENTEROLOGY, V156, P218, DOI 10.1053/j.gastro.2018.07.016
   Davies A, 2022, CANCERS, V14, DOI 10.3390/cancers14051128
   Davies A, 2020, SUPPORT CARE CANCER, V28, P23, DOI 10.1007/s00520-019-05016-4
   De Giorgio R, 2021, ADV THER, V38, P3589, DOI 10.1007/s12325-021-01766-y
   De Schryver AM, 2005, SCAND J GASTROENTERO, V40, P422, DOI 10.1080/00365520510011641
   Dorn Spencer, 2014, Am J Gastroenterol Suppl, V2, P31, DOI 10.1038/ajgsup.2014.7
   Dzierzanowski T, 2022, ARCH MED SCI, V18, P1271, DOI 10.5114/aoms.2019.85943
   Essmat N, 2023, MOLECULES, V28, DOI 10.3390/molecules28237766
   Falletto E, 2023, TECH COLOPROCTOL, V27, P481, DOI 10.1007/s10151-023-02800-7
   Farmer AD, 2019, UNITED EUR GASTROENT, V7, P7, DOI 10.1177/2050640618818305
   Freedman MD, 1997, J CLIN PHARMACOL, V37, P904, DOI 10.1002/j.1552-4604.1997.tb04264.x
   Gharibo C, 2023, CUREUS J MED SCIENCE, V15, DOI 10.7759/cureus.44583
   Gillett EL, 2023, CLIN PEDIATR, V62, P721, DOI 10.1177/00099228221142129
   Greener Mark, 2024, Br J Community Nurs, V29, P348, DOI [10.12968/bjcn.2024.0069, 10.12968/bjcn.2024.0069]
   Guerriero F, 2016, DRUG DES DEV THER, V10, P1515, DOI 10.2147/DDDT.S106025
   Hale M, 2017, LANCET GASTROENTEROL, V2, P555, DOI 10.1016/S2468-1253(17)30105-X
   Horrigan J, 2023, J CLIN GASTROENTEROL, V57, P39, DOI 10.1097/MCG.0000000000001801
   Imran A, 2020, EXPERT REV GASTROENT, V14, P39, DOI 10.1080/17474124.2020.1708718
   Jesuyajolu DA, 2024, J PAIN SYMPTOM MANAG, V67, pe285, DOI 10.1016/j.jpainsymman.2023.12.010
   Juul T, 2017, TECH COLOPROCTOL, V21, P363, DOI 10.1007/s10151-017-1635-7
   Katakami N, 2018, ANN ONCOL, V29, P1461, DOI 10.1093/annonc/mdy118
   Kistemaker KRJ, 2024, CANCER TREAT REV, V125, DOI 10.1016/j.ctrv.2024.102704
   Liao SLS, 2021, DRUG AGING, V38, P503, DOI 10.1007/s40266-021-00850-w
   Liu N, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22157931
   Lu YY, 2024, MOL NUTR FOOD RES, V68, DOI [10.1002/mnfr.202470006, DOI 10.1002/mnfr.202470006]
   Markland AD, 2013, AM J GASTROENTEROL, V108, P796, DOI 10.1038/ajg.2013.73
   Martin EH, 2023, SEMIN ONCOL, V50, P149, DOI 10.1053/j.seminoncol.2023.07.001
   McLeskey C, 2023, PAIN MANAG NURS, V24, P237
   Mehta N, 2023, J PAIN RES, V16, P3529, DOI 10.2147/JPR.S416307
   Mehta N, 2016, POSTGRAD MED, V128, P282, DOI 10.1080/00325481.2016.1149017
   Mousavi T, 2023, EXPERT OPIN PHARMACO, V24, P359, DOI 10.1080/14656566.2022.2161883
   Müller-Lissner S, 2017, PAIN MED, V18, P1837, DOI 10.1093/pm/pnw255
   Naya N, 2023, CUREUS J MED SCIENCE, V15, DOI 10.7759/cureus.46090
   Nee J, 2018, CLIN GASTROENTEROL H, V16, P1569, DOI 10.1016/j.cgh.2018.01.021
   Nero R, 2023, AM J HEALTH-SYST PH, V80, pS70, DOI 10.1093/ajhp/zxac356
   Nishiba Hiromi, 2023, Ann Palliat Med, V12, P697, DOI [10.21037/apm-22-1130, 10.21037/apm-22-1130]
   Nishiyama S, 2024, PLOS ONE, V19, DOI 10.1371/journal.pone.0295952
   Okdahl T, 2023, EXPERT REV GASTROENT, V17, P975, DOI 10.1080/17474124.2023.2267441
   Ozaki A, 2022, CANCERS, V14, DOI 10.3390/cancers14092112
   Patel PB, 2020, INTENS CARE MED, V46, P747, DOI 10.1007/s00134-019-05913-6
   REKATSINA M, CUREUS J MED SCIENCE, V13, DOI DOI 10.7759/CUREUS.16201
   Rizwan MZ, 2023, CUREUS J MED SCIENCE, V15, DOI 10.7759/cureus.41422
   Saito Y, 2019, J PAIN RES, V12, P127, DOI 10.2147/JPR.S175900
   Sayuk GS, 2023, J CLIN MED, V12, DOI 10.3390/jcm12196148
   Serra J, 2024, REV ESP ENFERM DIG, V116, P546, DOI 10.17235/reed.2024.10242/2024
   Sloots CEJ, 2010, DIGEST DIS SCI, V55, P2912, DOI 10.1007/s10620-010-1229-y
   Squeo F, 2024, J NEUROGASTROENTEROL, V30, P131, DOI 10.5056/jnm23144
   Sugimoto M, 2020, J CLIN BIOCHEM NUTR, V66, P184, DOI 10.3164/jcbn.19-118
   Tobben D, 2024, CRIT CARE MED, V52, DOI 10.1097/01.ccm.0000999832.24501.d0
   Tobben D, 2024, ANN PHARMACOTHER, V58, P678, DOI 10.1177/10600280231205023
   Vadivelu N, 2018, CURR PAIN HEADACHE R, V22, DOI 10.1007/s11916-018-0670-z
   Vijayvargiya P, 2020, ALIMENT PHARM THER, V52, P37, DOI 10.1111/apt.15791
   Wang WM, 2023, JAMA NETW OPEN, V6, DOI 10.1001/jamanetworkopen.2023.0310
   Webster L, 2014, ALIMENT PHARM THER, V40, P771, DOI 10.1111/apt.12899
   Webster LR, 2018, PAIN MED, V19, P1195, DOI 10.1093/pm/pnx212
   Webster LR, 2018, PAIN, V159, P987, DOI 10.1097/j.pain.0000000000001174
   Webster LR, 2017, PAIN MED, V18, P1496, DOI 10.1093/pm/pnx148
   Wobbe B, 2023, BMJ SUPPORT PALLIAT, V13, pe578, DOI 10.1136/spcare-2022-003896
   Yagi Y, 2018, J CLIN ONCOL, V36, P1049, DOI 10.1200/JCO.2017.76.9349
   Ying Jianyue, 2023, Evid Based Complement Alternat Med, V2023, P5383821, DOI [10.1155/2023/5383821, 10.1155/2023/5383821]
   Żurek U, 2023, Journal of Education Health and Sport, V22, P147, DOI [10.12775/jehs.2023.22.01.012, 10.12775/JEHS.2023.22.01.012, DOI 10.12775/JEHS.2023.22.01.012]
NR 75
TC 0
Z9 0
U1 2
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1465-6566
EI 1744-7666
J9 EXPERT OPIN PHARMACO
JI Expert Opin. Pharmacother.
PD SEP 1
PY 2024
VL 25
IS 13
BP 1729
EP 1738
AR 2407013
DI 10.1080/14656566.2024.2407013
EA SEP 2024
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA I4O8V
UT WOS:001319840400001
PM 39308446
DA 2026-01-16
ER

PT J
AU Khalil, A
   Elesawy, BH
   Ali, TM
   Ahmed, OM
AF Khalil, Abdelwahab
   Elesawy, Basem H.
   Ali, Tarek M.
   Ahmed, Osama M.
TI Bee Venom: From Venom to Drug
SO MOLECULES
LA English
DT Review
DE bee venom; inflammatory and chronic diseases; nanoparticles; bee venom
   products
ID APIS-MELLIFERA VENOM; IN-VITRO; CANCER CELLS; MELITTIN; PEPTIDE;
   ANTIOXIDANT; ARTHRITIS; PAIN; ACUPUNCTURE; ACTIVATION
AB Insects of the order Hymenoptera have a defensive substance that contains many biologically active compounds. Specifically, venom from honeybees (Apis mellifera) contains many enzymes and peptides that are effective against various diseases. Different research papers stated the possibility of using bee venom (a direct bee sting or in an injectable form) in treating several complications; either in vivo or in vitro. Other reports used the active fractions of bee venom clinically or at labratory scale. Many reports and publications have stated that bee venom and its constituents have multiple biological activities including anti-microbial, anti-protozoan, anti-cancer, anti-inflammatory, and anti-arthritic properties. The present review aims to refer to the use of bee venom itself or its fractions in treating several diseases and counteracting drug toxicities as an alternative protocol of therapy. The updated molecular mechanisms of actions of bee venom and its components are discussed in light of the previous updated publications. The review also summarizes the potential of venom loaded on nanoparticles as a drug delivery vehicle and its molecular mechanisms. Finally, the products of bee venom available in markets are also demonstrated.
C1 [Khalil, Abdelwahab] Beni Suef Univ, Div Entomol, Dept Zool, Fac Sci, Bani Suwayf 62521, Egypt.
   [Elesawy, Basem H.] Taif Univ, Dept Clin Lab Sci, Coll Appl Med Sci, POB 11099, At Taif 21944, Saudi Arabia.
   [Elesawy, Basem H.] Mansoura Univ, Dept Pathol, Fac Med, Mansoura 35516, Egypt.
   [Ali, Tarek M.] Taif Univ, Dept Physiol, Coll Med, POB 11099, At Taif 21944, Saudi Arabia.
   [Ali, Tarek M.] Beni Suef Univ, Dept Physiol, Fac Med, Bani Suwayf 62521, Egypt.
   [Ahmed, Osama M.] Beni Suef Univ, Div Physiol, Dept Zool, Fac Sci, Bani Suwayf, Egypt.
C3 Egyptian Knowledge Bank (EKB); Beni Suef University; Taif University;
   Egyptian Knowledge Bank (EKB); Mansoura University; Taif University;
   Egyptian Knowledge Bank (EKB); Beni Suef University; Egyptian Knowledge
   Bank (EKB); Beni Suef University
RP Ahmed, OM (corresponding author), Beni Suef Univ, Div Physiol, Dept Zool, Fac Sci, Bani Suwayf, Egypt.
EM akhalil1980@gmail.com; basemelesawy2@gmail.com; tarek70ali@gmail.com;
   osamamoha@yahoo.com
RI ; Elesawy, Basem/AGY-2195-2022; Ahmed, Osama/P-8126-2018; Ali,
   Tarek/E-7358-2019
OI Khalil, Abdelwahab/0000-0001-6529-5645; Ahmed,
   Osama/0000-0003-3781-9709; Ali, Tarek/0000-0002-2998-247X
CR Abd El-Rahim A, 2018, Journal of The Arab Society for Medical Research, V13, P89, DOI [10.4103/jasmr.jasmr_24_18, 10.4103/jasmr.jasmr_24_18, DOI 10.4103/JASMR.JASMR_24_18, DOI 10.4103/JASMR.JASMR2418]
   Ahmed O, 2018, ARCH RHEUMATOL, V33, P198, DOI 10.5606/ArchRheumatol.2018.6519
   Ahmed OM, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10091317
   Akre R.D., 2009, ANTS WASPS BEES TXB, V2nd, P383
   Alalawy AI, 2020, INT J POLYM SCI, V2020, DOI 10.1155/2020/2785304
   Ali M.A., 2012, Int. J. Adv. Res. Technol, V1, P69
   Asafova N., 2001, PHYSL ACTIVE BEE PRO, P360
   Aufschnaiter A, 2020, TOXINS, V12, DOI 10.3390/toxins12020066
   Bachis A, 2010, EUR J NEUROSCI, V32, P570, DOI 10.1111/j.1460-9568.2010.07325.x
   Badawi JK, 2021, TOXINS, V13, DOI 10.3390/toxins13050337
   Bhalotia S., 2016, Journal of Basic and Applied Engineering Research, V3, P96
   Bilò BM, 2011, IMMUNOTHERAPY-UK, V3, P229, DOI 10.2217/IMT.10.88
   Bogdanov S., 2016, Bee Product Science, V25, P1
   Carpena M, 2020, NUTRIENTS, V12, DOI 10.3390/nu12113360
   Casewell NR, 2013, TRENDS ECOL EVOL, V28, P219, DOI 10.1016/j.tree.2012.10.020
   Chen J, 2016, NEUROSCI BULL, V32, P265, DOI 10.1007/s12264-016-0024-y
   Chen J, 2010, PROG NEUROBIOL, V92, P151, DOI 10.1016/j.pneurobio.2010.06.006
   Cheon S., 2015, INTEGR MED RES, V4, P55, DOI [10.1016/j.imr.2015.04.045, DOI 10.1016/J.IMR.2015.04.045]
   Cherniack EP, 2018, TOXICON, V154, P74, DOI 10.1016/j.toxicon.2018.09.013
   Cho SY, 2012, PARKINSONISM RELAT D, V18, P948, DOI 10.1016/j.parkreldis.2012.04.030
   Chung KS, 2015, EXP BIOL MED, V240, P1656, DOI 10.1177/1535370215590823
   Cornara L, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00412
   Danneels EL, 2015, TOXINS, V7, P4468, DOI 10.3390/toxins7114468
   Duffy C., 2020, NPJ PRECIS ONCOL, V4, P24, DOI DOI 10.1038/s41698-020-00129-0
   El-Banby M.A., 1994, HONEYBEES KORAN MED, P268
   El-Hanoun A, 2020, PHYSIOL BEHAV, V223, DOI 10.1016/j.physbeh.2020.112987
   Gajski G, 2016, TOXICON, V110, P56, DOI 10.1016/j.toxicon.2015.12.005
   Gajski G, 2013, ENVIRON TOXICOL PHAR, V36, P697, DOI 10.1016/j.etap.2013.06.009
   Gülmez Y, 2017, MARMARA PHARM J, V21, P251, DOI 10.12991/marupj.300329
   Habermehl G., 1981, VENOMOUS ANIMALS THE
   Han SM, 2013, PHARMACOGN MAG, V9, P220, DOI 10.4103/0973-1296.113271
   Hassan SA, 2021, J PHARM RES INT, V33, P200, DOI 10.9734/JPRI/2021/v33i29A31579
   Hauser R. A., 2001, Alternative and Complementary Therapies, V7, P37, DOI [https://doi.org/10.1089/107628001300000714, DOI 10.1089/107628001300000714, 10.1089/107628001300000714]
   Hong JJ, 2019, MOLECULES, V24, DOI 10.3390/molecules24091775
   Im E.J., 2016, EVID-BASED COMPL ALT, V2016, P3704764, DOI [10.1155/2016/3704764, DOI 10.1155/2016/3704764]
   Jung GB, 2018, BIOMED OPT EXPRESS, V9, P5703, DOI 10.1364/BOE.9.005703
   Kang SY, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/809062
   Kang SY, 2012, J PAIN, V13, P155, DOI 10.1016/j.jpain.2011.10.012
   Karimi A., 2011, The Journal of American Science, V7, P295
   Kim C.M. H., 2013, Biotherapy - History, Principles and Practice, P77, DOI DOI 10.1007/978-94-007-6585-6_4
   Kim Hyun-Woo, 2004, J Vet Sci, V5, P309
   Kim H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114726
   Kim KH, 2013, INT J CLIN EXP PATHO, V6, P2896
   Kingsland J., 2020, HONEYBEE VENOM KILLS
   Klocek G, 2009, BIOCHEMISTRY-US, V48, P2586, DOI 10.1021/bi802127h
   Kolayli S., 2020, Stud Nat Prod Chem, V66, P175, DOI DOI 10.1016/B978-0-12-817907-9.00007-6
   Krell R., 1996, Value-Added Products from Beekeeping
   Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263
   Krylov V., 2007, Theory and agents of apitherapy
   Krylov V., 1995, PCELNI YAD BEE VENOM, P221
   Kwon YB, 2001, PAIN, V90, P271, DOI 10.1016/S0304-3959(00)00412-7
   Leandro LF, 2015, AN ACAD BRAS CIENC, V87, P147, DOI 10.1590/0001-3765201520130511
   Lee CW, 1996, DERMATOLOGY, V193, P355, DOI 10.1159/000246293
   Lee G, 2016, MOLECULES, V21, DOI 10.3390/molecules21050616
   Lee J, 2018, VET IMMUNOL IMMUNOP, V200, P40, DOI 10.1016/j.vetimm.2018.04.006
   Lee WR, 2014, J INVEST DERMATOL, V134, P1922, DOI 10.1038/jid.2014.75
   Lee YJ, 2020, INFLAMMOPHARMACOLOGY, V28, P253, DOI 10.1007/s10787-019-00646-w
   Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620
   Lim BS, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/369324
   Lin TY, 2020, TOXINS, V12, DOI 10.3390/toxins12100618
   Liu SJ, 2008, HEPATOLOGY, V47, P1964, DOI 10.1002/hep.22240
   Liu X, 2003, J CONTROL RELEASE, V93, P293, DOI 10.1016/j.jconrel.2003.08.019
   Liu X, 2002, J PHARM PHARMACOL, V54, P1083, DOI 10.1211/002235702320266235
   Ludyanskii E. A., 1994, Apiterapia.
   Meier J., 1995, HDB CLIN TOXICOLOGY
   Minton S.A., 1974, Venom diseases
   Mohamed WA, 2019, TOXICOLOGY, V419, P11, DOI 10.1016/j.tox.2019.03.003
   Moreau SJM, 2015, TOXINS, V7, P2385, DOI 10.3390/toxins7072385
   Moreau SJM, 2009, ADV PARASIT, V70, P217, DOI 10.1016/S0065-308X(09)70008-9
   Moreno M, 2015, TOXINS, V7, P1126, DOI 10.3390/toxins7041126
   Mousavi SM, 2012, J ARTHROPOD-BORNE DI, V6, P136
   Mraz C., 1995, HLTH HONEYBEE
   NIH, 1995, AP ALT MED EXP MED H, P172
   Orsolic N, 2012, CANCER METAST REV, V31, P173, DOI 10.1007/s10555-011-9339-3
   Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239
   Park JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126971
   Park JH, 2010, ARCH PHARM RES, V33, P215, DOI 10.1007/s12272-010-0205-6
   Park MH, 2011, PROSTATE, V71, P801, DOI 10.1002/pros.21296
   Park MH, 2015, MOLECULES, V20, P15072, DOI 10.3390/molecules200815072
   Pawelek J., URBAN BEE GARDENS AR
   Pucca MB, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00611
   Pucca MB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02090
   Qiao MX, 2007, INT J PHARMACEUT, V345, P116, DOI 10.1016/j.ijpharm.2007.05.056
   Raghuraman H, 2007, BIOSCIENCE REP, V27, P189, DOI 10.1007/s10540-006-9030-z
   REISMAN RE, 1988, ANN ALLERGY, V61, P383
   Rho Young Hee, 2009, Korean Journal of Internal Medicine, V24, P283, DOI 10.3904/kjim.2009.24.3.283
   Rose A., 1994, Bees in Balance
   Saidemberg DM, 2011, PEPTIDES, V32, P1924, DOI 10.1016/j.peptides.2011.08.001
   Sharma H. C., 1983, Proceedings of the Second International Conference on Apiculture in Tropical Climates, New Delhi, February 29-March 4, 1980., P694
   Shkenderov S., 1983, PCELNI PRODUKTI BEE, P1
   Sig AK, 2019, Turkish Journal of Clinics and Laboratory, V10, P414, DOI 10.18663/tjcl.451586
   Singh D., 2020, Commercial Beekeeping (Production, Processing and Value Addition of Beehive Products for Income and Employment Generation), P257
   Sobral F, 2016, FOOD CHEM TOXICOL, V94, P172, DOI 10.1016/j.fct.2016.06.008
   Somwongin S, 2018, TOXICON, V145, P32, DOI 10.1016/j.toxicon.2018.02.049
   Son DJ, 2007, PHARMACOL THERAPEUT, V115, P246, DOI 10.1016/j.pharmthera.2007.04.004
   Strait J.E., 2013, Nanoparticles loaded with bee venom kill HIV
   Sturm GJ, 2018, ALLERGY, V73, P744, DOI 10.1111/all.13262
   Szabat P, 2019, J Educ Health Sport, V9, P384, DOI [DOI 10.5281/ZENODO.3376968, 10.5281/zenodo.3376968]
   TOSTESON MT, 1985, J MEMBRANE BIOL, V87, P35, DOI 10.1007/BF01870697
   Uddin M, 2016, J MICROBIOL, V54, P853
   Urtubey N., 2005, Apitoxin: from bee venom to apitoxin for medical use
   Wehbe R, 2019, MOLECULES, V24, DOI 10.3390/molecules24162997
   Wesselius T, 2005, NEUROLOGY, V65, P1764, DOI 10.1212/01.wnl.0000184442.02551.4b
   Yang L, 2001, BIOPHYS J, V81, P1475, DOI 10.1016/S0006-3495(01)75802-X
   Zhang S, 2018, TOXICON, V148, P64, DOI 10.1016/j.toxicon.2018.04.012
   Zheng J, 2015, ONCOTARGET, V6, P44437, DOI 10.18632/oncotarget.6295
NR 106
TC 83
Z9 91
U1 3
U2 123
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD AUG
PY 2021
VL 26
IS 16
AR 4941
DI 10.3390/molecules26164941
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA UI0CI
UT WOS:000690286400001
PM 34443529
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Wu, XY
   Lam, CS
   Chu, YS
   Deng, WS
   Chan, CWH
   Au, KY
   Man, SS
   Li, CK
   Zhong, CW
   Ho, L
   Cheung, YT
AF Wu, Xingyue
   Lam, Chun Sing
   Chu, Yau Shing
   Deng, Weishang
   Chan, Carmen Wing Han
   Au, Kwok Yin
   Man, Sze Shun
   Li, Chi Kong
   Zhong, Chenwen
   Ho, Leonard
   Cheung, Yin Ting
TI Efficacy of Traditional, Complementary, and Integrative Medicine in Pain
   and Psychological Distress Management for Pediatric Palliative Patients:
   A Systematic Review and Meta-Analysis of Randomized Controlled Trials
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE Traditional; complementary; and integrative medicine; Pediatric
   palliative care; Pain; Psychological distress; Meta-Analyses; Systematic
   review
ID QUALITY-OF-LIFE; MUSIC-THERAPY; CONSORT EXTENSION; CHILDREN; MASSAGE;
   ANXIETY; HYPNOSIS; CANCER; CARE
AB Context. Traditional, complementary, and integrative medicine (TCIM) is being increasingly used to manage symptoms in patients with palliative needs. However, there is a lack of evidence to guide its use in the pediatric palliative care (PPC) setting. Objectives. This study aimed to synthesize and evaluate the current evidence on the effectiveness of TCIM in reducing pain and psychological distress in PPC. Methods. Four English electronic databases were searched for randomized controlled trials (RCTs) published between January 2000 and August 2023. The standardized mean difference (SMD) was used to report the pooled magnitude of the treatment effect. The Grading of Recommendations Assessment, Development, and Evaluation system was used to assess the quality of the evidence for each treatment outcome. Results. Thirty RCTs were included. The interventions were massage (n = 9), music therapy (n = 6), hypnosis (n = 3), acupuncture, aromatherapy, and other TCIM modalities. Compared with the control interventions, music therapy significantly decreased pain (SMD:-1.07; 95% CI:-1.64 to-0.50; P< 0.05; I-2 = 72%) and relieved anxiety (SMD:-0.75; 95% CI:-1.35 to-0.15; P< 0.05; I-2 = 74%); massage significantly decreased pain (SMD:-0.74; 95% CI:-1.46 to-0.02; P< 0.05; I-2 = 83%) and relieved anxiety (SMD:-0.61; 95% CI:-1.21 to-0.01; P< 0.05; I2 = 71%). Hypnosis had significant effects on procedure-related anxiety, pain, and behavioral distress management (P< 0.05). The quality of evidence was rated as "moderate" for the efficacy of music therapy in alleviating pain and anxiety and "low" for the efficacy of all of the other interventions. Conclusions. Existing evidence supports the therapeutic benefits of music therapy, massage, and hypnosis on relieving pain and anxiety symptoms in the PPC setting, though the evidence is of low-to-moderate quality. (c) 2025 The Authors. Published by Elsevier Inc. on behalf of American Academy of Hospice and Palliative Medicine.
C1 [Wu, Xingyue; Lam, Chun Sing; Chu, Yau Shing; Deng, Weishang; Cheung, Yin Ting] Chinese Univ Hong Kong, Fac Med, Sch Pharm, Shatin, Lo Kwee Seong Integrated Biomed Sci Bldg Area 39, Hong Kong, Peoples R China.
   [Chan, Carmen Wing Han] Chinese Univ Hong Kong, Fac Med, Nethersole Sch Nursing, Hong Kong, Peoples R China.
   [Au, Kwok Yin] Chinese Univ Hong Kong, Integrat Med Ctr, Shatin, Hong Kong, Peoples R China.
   [Man, Sze Shun] Hong Kong Childrens Hosp, Hong Kong, Peoples R China.
   [Li, Chi Kong] Chinese Univ Hong Kong, Fac Med, Dept Paediat, Shatin, Hong Kong, Peoples R China.
   [Zhong, Chenwen; Ho, Leonard] Chinese Univ Hong Kong, Fac Med, JC Sch Publ Hlth & Primary Care, Shatin, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong;
   Chinese University of Hong Kong; Chinese University of Hong Kong;
   Chinese University of Hong Kong
RP Cheung, YT (corresponding author), Chinese Univ Hong Kong, Fac Med, Sch Pharm, Shatin, Lo Kwee Seong Integrated Biomed Sci Bldg Area 39, Hong Kong, Peoples R China.
EM yinting.cheung@cuhk.edu.hk
RI Cheung, Yin Ting/AAT-4384-2021; Ho, Leonard/HOF-2530-2023; Deng,
   Weishang/NTQ-3563-2025; Lam, Chun Sing/AFR-1212-2022
OI Ho, Leonard/0000-0001-8353-9631; Deng, Weishang/0000-0003-1131-6417;
   Lam, Chun Sing/0000-0002-6478-6706
FU Hong Kong Health Bureau Chinese Medicine Development Fund [23B2/072]
FX We would like to express our gratitude to Dr. Vincent Chi Ho Chung and
   Dr. Katy Ho Kee Koon from Hong Kong Health Bureau for their valuable
   insights and contributions to this review. This work was supported by
   Hong Kong Health Bureau Chinese Medicine Development Fund (23B2/072) .
   All authors declare no competing interests
CR Akard TF, 2021, J PALLIAT MED, V24, P680, DOI 10.1089/jpm.2020.0139
   [Anonymous], 2023, Traditional, Complementary and Integrative Medicine
   Barker MM, 2019, JAMA PEDIATR, V173, P835, DOI 10.1001/jamapediatrics.2019.1712
   Beecham E, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010750.pub2
   Ben-Pazi H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175028
   Boon MH, 2021, J CLIN EPIDEMIOL, V135, P42, DOI 10.1016/j.jclinepi.2021.01.001
   Boutron I, 2017, ANN INTERN MED, V167, P40, DOI 10.7326/M17-0046
   Carlson LE, 2023, J CLIN ONCOL, V41, P4562, DOI 10.1200/JCO.23.00857
   Chen ZQ, 2023, FRONT NEUROSCI-SWITZ, V17, DOI 10.3389/fnins.2023.1097477
   Chong LA, 2018, J PALLIAT MED, V21, P1242, DOI 10.1089/jpm.2017.0626
   Connor SR, 2017, J PAIN SYMPTOM MANAG, V53, P171, DOI 10.1016/j.jpainsymman.2016.08.020
   Batalha LMD, 2013, J PEDIAT-BRAZIL, V89, P595, DOI 10.1016/j.jped.2013.03.022
   Duymaz T, 2020, ANN CLIN ANAL MED, V11, P115, DOI 10.4328/ACAM.6171
   Faraone Stephen V, 2008, P T, V33, P700
   Ferro F, 2021, EUR J PEDIATR, V180, P2389, DOI 10.1007/s00431-021-04164-2
   Field T., 2001, Journal of Bodywork and Movement Therapies, V5, P271, DOI [10.1054/jbmt.2001.0228, DOI 10.1054/JBMT.2001.0228]
   Flyckt N, 2022, J PEDIATR REHAB MED, V15, P49, DOI 10.3233/PRM-210046
   Freedenberg VA, 2017, PEDIATR CARDIOL, V38, P1415, DOI 10.1007/s00246-017-1679-5
   Gurcan M, 2021, EUR J CANCER CARE, V30, DOI 10.1111/ecc.13491
   Harrison TM, 2020, NURS RES, V69, pS36, DOI 10.1097/NNR.0000000000000459
   Hatem Thamine P, 2006, J Pediatr (Rio J), V82, P186, DOI 10.2223/JPED.1473
   Haun Jolie N, 2009, Int J Ther Massage Bodywork, V2, P7
   Higgins J, 2024, COCHRANE HDB SYSTEMA
   Higgins J.P. T., 2019, Revised Cochrane risk-of-bias tool for randomized trials (RoB 2)
   Huang YL, 2021, J PERIANESTH NURS, V36, P243, DOI 10.1016/j.jopan.2020.08.004
   Mano KEJ, 2019, CLIN J PAIN, V35, P989, DOI 10.1097/AJP.0000000000000763
   Kammin V, 2024, PALLIATIVE MED, V38, P364, DOI 10.1177/02692163241230664
   Kodish I, 2011, PEDIATR CLIN N AM, V58, P55, DOI 10.1016/j.pcl.2010.10.002
   Koller D, 2012, J PEDIATR NURS, V27, P652, DOI 10.1016/j.pedn.2011.08.001
   Lam CS, 2022, BMJ PAEDIATR OPEN, V6, DOI 10.1136/bmjpo-2022-001701
   Landier W, 2010, J PEDIATR NURS, V25, P566, DOI 10.1016/j.pedn.2010.01.009
   Lemanek KL, 2009, J PEDIATR PSYCHOL, V34, P1091, DOI 10.1093/jpepsy/jsp015
   Li J, 2019, COMPLEMENT THER MED, V46, P180, DOI 10.1016/j.ctim.2019.08.014
   Liberati A, 2009, ANN INTERN MED, V151, pW65, DOI [10.7326/0003-4819-151-4-200908180-00136, 10.1371/journal.pmed.1000100, 10.1136/bmj.b2700]
   Liossi C, 2003, INT J CLIN EXP HYP, V51, P4, DOI 10.1076/iceh.51.1.4.14064
   Liossi C, 2006, HEALTH PSYCHOL, V25, P307, DOI 10.1037/0278-6133.25.3.307
   Liossi C, 2009, PAIN, V142, P255, DOI 10.1016/j.pain.2009.01.017
   Loizzo Alberto, 2009, Open Biochem J, V3, P18, DOI 10.2174/1874091X00903010018
   Lüthi E, 2021, BMC COMPLEMENT MED, V21, DOI 10.1186/s12906-021-03271-9
   Madden JR, 2010, J PEDIATR ONCOL NURS, V27, P133, DOI 10.1177/1043454209355452
   Mak C, 2018, DEV MED CHILD NEUROL, V60, P922, DOI 10.1111/dmcn.13923
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2022, CA-CANCER J CLIN, V72, P144, DOI 10.3322/caac.21706
   Marcus KL, 2022, J PAIN SYMPTOM MANAG, V63, P88, DOI 10.1016/j.jpainsymman.2021.07.010
   Marofi Maryam, 2015, Iran J Nurs Midwifery Res, V20, P247
   Mehling WE, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/450150
   Namisango E, 2019, PATIENT, V12, P15, DOI 10.1007/s40271-018-0333-5
   National Hospice and Palliative Care Organization, 2022, Standards of practice for pediatric palliative care
   Nilsson Stefan, 2011, Complement Ther Clin Pract, V17, P127, DOI 10.1016/j.ctcp.2010.11.003
   Nunns M, 2018, PSYCHO-ONCOLOGY, V27, P1889, DOI 10.1002/pon.4749
   Oh A, 2023, SEMIN PEDIATR NEUROL, V48, DOI 10.1016/j.spen.2023.101085
   Ostojic K, 2022, DEV MED CHILD NEUROL, V64, P1507, DOI 10.1111/dmcn.15303
   Pai M, 2015, RARE DIS, V3, DOI 10.1080/21675511.2015.1058463
   Park YL, 2019, HEALTH SYST REFORM, V5, P24, DOI 10.1080/23288604.2018.1539058
   Phipps S, 2012, PEDIATRICS, V129, pE762, DOI 10.1542/peds.2011-1816
   Phipps S, 2010, CANCER-AM CANCER SOC, V116, P3924, DOI 10.1002/cncr.25415
   Post-White J, 2009, J PEDIATR ONCOL NURS, V26, P16, DOI 10.1177/1043454208323295
   Rajendran Tara, 2021, Harnessing the therapeutic potential of music
   Robb SL, 2017, J PEDIATR PSYCHOL, V42, P208, DOI 10.1093/jpepsy/jsw050
   Rodríguez-Rodríguez RC, 2022, GLOBAL HEALTH ACTION, V15, DOI 10.1080/16549716.2022.2116774
   Ryan R., 2016, How to GRADE the Quality of the Evidence
   Santa IND, 2021, COMPLEMENT THER MED, V59, DOI 10.1016/j.ctim.2021.102725
   Staveski SL, 2018, PEDIATR CRIT CARE ME, V19, P725, DOI 10.1097/PCC.0000000000001615
   Stegemann Thomas, 2019, Medicines (Basel), V6, DOI [10.3390/medicines6010025, 10.3390/medicines6010025]
   Thanh NN, 2010, J PEDIATR ONCOL NURS, V27, P146, DOI 10.1177/1043454209355983
   Ting BR, 2022, J CLIN MED, V11, DOI 10.3390/jcm11040991
   Ting JM, 2025, PEDIATR CARDIOL, V46, P1142, DOI 10.1007/s00246-024-03535-4
   Tomlinson D, 2011, SUPPORT CARE CANCER, V19, P1857, DOI 10.1007/s00520-010-1029-0
   Uggla L, 2018, ACTA PAEDIATR, V107, P1986, DOI 10.1111/apa.14515
   van der Heijden MJE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133608
   Wan X, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-135
   Wiffen PJ, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012564.pub2
   Yu HB, 2009, INT J NURS STUD, V46, P1423, DOI 10.1016/j.ijnurstu.2009.05.007
   Zhao FY, 2022, WORLD J ACUPUNCT-MOX, V32, P1, DOI 10.1016/j.wjam.2021.07.005
   Zhu YW, 2022, NEUROSCI BIOBEHAV R, V143, DOI 10.1016/j.neubiorev.2022.104954
NR 75
TC 1
Z9 1
U1 3
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD MAY
PY 2025
VL 69
IS 5
BP e337
EP e358
DI 10.1016/j.jpainsymman.2025.01.002
EA APR 2025
PG 22
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
   Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; General & Internal Medicine;
   Neurosciences & Neurology
GA 1OV2R
UT WOS:001470117300001
PM 39800142
OA hybrid
DA 2026-01-16
ER

PT J
AU Wang, CZ
   He, H
   Wang, XY
   Yuan, CS
AF Wang, Chong-Zhi
   He, Hui
   Wang, Xiaoyu
   Yuan, Chun-Su
TI Trends in Scientific Publications of Chinese Medicine
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Traditional Chinese Medicine; TCM; Complementary and Alternative
   Medicine; CAM; American Journal of Chinese Medicine; AJCM; Publication
   Trends; Journal Impact Factor; Herbal Medicine; Inflammation; Cancer
   Research
ID ANOECTOCHILUS-FORMOSANUS; GANODERMA-LUCIDUM; ACTIVE COMPONENTS; TAI CHI;
   ACUPUNCTURE; ANTIOXIDANT; GINSENG; PAIN; OSTEOARTHRITIS; COMPLEMENTARY
AB Traditional Chinese medicine (TCM) is an important component of complementary and alternative medicine (CAM). The fast economic growth of mainland China in the past two decades has promoted the use of TCM beyond Chinese-speaking countries. Chinese researchers have published more TCM research studies in CAM-related professional journals, including the American Journal of Chinese Medicine (AJCM), the highest impact journal in Chinese medicine. The consistent increase of the impact factor of the AJCM suggests a growth in TCM popularity. This study analyzed articles published in the AJCM between 2004 and 2011. Our data show that while enthusiasm towards cardiovascular, nervous system and inflammation related research remained high, more herbal investigations and cancer studies were published. Furthermore, a reduction in TCM formulation studies was replaced by increasing botanical single constituent research. Examples of frequently cited studies, including those before 2004, are presented. These data are not only important to the scientific community for recognition of trends in TCM research, but also for providing information to TCM researchers who are targeting potentially highly cited studies.
C1 [Wang, Chong-Zhi] Univ Chicago, Pritzker Sch Med, Tang Ctr Herbal Med Res, Chicago, IL 60637 USA.
   [Wang, Chong-Zhi] Univ Chicago, Pritzker Sch Med, Dept Anesthesia & Crit Care, Chicago, IL 60637 USA.
C3 University of Chicago; University of Chicago
RP Wang, CZ (corresponding author), Univ Chicago, Pritzker Sch Med, Tang Ctr Herbal Med Res, 5841 S Maryland Ave,MC 4028, Chicago, IL 60637 USA.
EM CWang@dacc.uchicago.edu
RI Wang, Chong-Zhi/B-8337-2014
FU NIH/NCCAM [P01 AT004418, K01 AT005362]
FX This study is supported in part by the NIH/NCCAM grants P01 AT004418 and
   K01 AT005362.
CR Bian Zhao-Xiang, 2006, Zhong Xi Yi Jie He Xue Bao, V4, P120
   Carpenter RJ, 2010, AM J CHINESE MED, V38, P839, DOI 10.1142/S0192415X10008287
   Chan E, 2010, AM J CHINESE MED, V38, P815, DOI 10.1142/S0192415X10008263
   Chang HC, 2002, AM J CHINESE MED, V30, P307, DOI 10.1142/S0192415X02000223
   Chen MJ, 2010, AM J CHINESE MED, V38, P1131, DOI 10.1142/S0192415X10008524
   Cheung F, 2011, NATURE, V480, pS94, DOI 10.1038/480S94a
   COAN RM, 1980, AM J CHINESE MED, V8, P181, DOI 10.1142/S0192415X80000141
   Dagenais Simon, 2006, Zhong Xi Yi Jie He Xue Bao, V4, P455, DOI 10.3736/jcim20060504
   Ernst E, 2011, AM J CHINESE MED, V39, P423, DOI 10.1142/S0192415X11008920
   Hsieh CH, 2010, AM J CHINESE MED, V38, P675, DOI 10.1142/S0192415X10008147
   Hsu WH, 2010, AM J CHINESE MED, V38, P661, DOI 10.1142/S0192415X10008135
   Huang ST, 2005, AM J CHINESE MED, V33, P157, DOI 10.1142/S0192415X0500276X
   ISI Web of Knowledge, 2012, J CITATION REPORTS Q
   Jang HI, 2010, AM J CHINESE MED, V38, P949, DOI 10.1142/S0192415X10008378
   Kim SJ, 2011, AM J CHINESE MED, V39, P587, DOI 10.1142/S0192415X11009056
   Kuo YC, 1996, AM J CHINESE MED, V24, P111, DOI 10.1142/S0192415X96000165
   Kwon YB, 2001, AM J CHINESE MED, V29, P187, DOI 10.1142/S0192415X01000228
   Lee HZ, 2011, AM J CHINESE MED, V39, P201, DOI 10.1142/S0192415X11008750
   LEI XL, 1986, AM J CHINESE MED, V14, P145, DOI 10.1142/S0192415X86000235
   Li J, 2010, AM J CHINESE MED, V38, P569, DOI 10.1142/S0192415X10008068
   Li L, 2010, AM J CHINESE MED, V38, P449, DOI 10.1142/S0192415X1000797X
   Li SP, 2011, J PHARMACEUT BIOMED, V55, P802, DOI 10.1016/j.jpba.2010.12.011
   Liao HF, 2010, AM J CHINESE MED, V38, P173, DOI 10.1142/S0192415X10007749
   Lin CC, 1996, AM J CHINESE MED, V24, P31, DOI 10.1142/S0192415X96000050
   Lin CC, 2000, AM J CHINESE MED, V28, P87, DOI 10.1142/S0192415X00000118
   Lin JG, 2008, AM J CHINESE MED, V36, P635, DOI 10.1142/S0192415X08006107
   Lin JG, 2012, AM J CHINESE MED, V40, P219, DOI 10.1142/S0192415X12500176
   Lin JG, 1999, AM J CHINESE MED, V27, P265, DOI 10.1142/S0192415X99000306
   LIN JM, 1993, AM J CHINESE MED, V21, P59, DOI 10.1142/S0192415X9300008X
   Maciaszek J, 2010, AM J CHINESE MED, V38, P219, DOI 10.1142/S0192415X10007798
   MARGOLIN A, 1993, AM J CHINESE MED, V21, P103, DOI 10.1142/S0192415X93000133
   Su SL, 2010, AM J CHINESE MED, V38, P777, DOI 10.1142/S0192415X10008238
   Sun MY, 2010, AM J CHINESE MED, V38, P849, DOI 10.1142/S0192415X10008299
   Tang NY, 2010, AM J CHINESE MED, V38, P51, DOI 10.1142/S0192415X10007786
   THOMAS M, 1991, AM J CHINESE MED, V19, P95, DOI 10.1142/S0192415X91000156
   Tian JH, 2010, AM J CHINESE MED, V38, P15, DOI 10.1142/S0192415X10007646
   Vincent A, 2010, AM J CHINESE MED, V38, P695, DOI 10.1142/S0192415X10008160
   Wang CZ, 2007, AM J CHINESE MED, V35, P543, DOI 10.1142/S0192415X07005053
   Wang CZ, 2012, AM J CHINESE MED, V40, P657, DOI 10.1142/S0192415X12500498
   Wang CZ, 2011, AM J CHINESE MED, V39, P1161, DOI 10.1142/S0192415X11009470
   Wang J, 2011, AM J CHINESE MED, V39, P651, DOI 10.1142/S0192415X11009093
   Wetzel MS, 2003, ANN INTERN MED, V138, P191, DOI 10.7326/0003-4819-138-3-200302040-00011
   Wong CK, 2005, AM J CHINESE MED, V33, P381, DOI 10.1142/S0192415X05002990
   Wright PA, 2011, AM J CHINESE MED, V39, P461, DOI 10.1142/S0192415X11008968
   Wu JA, 2001, AM J CHINESE MED, V29, P69, DOI 10.1142/S0192415X01000083
   Wu SJ, 2010, AM J CHINESE MED, V38, P99, DOI 10.1142/S0192415X10007695
   WU WL, 1991, AM J CHINESE MED, V19, P207, DOI 10.1142/S0192415X91000284
   Xie JT, 2005, AM J CHINESE MED, V33, P397, DOI 10.1142/S0192415X05003004
   Xu M, 2010, AM J CHINESE MED, V38, P401, DOI 10.1142/S0192415X10007932
   Xu ZT, 2011, AM J CHINESE MED, V39, P15, DOI 10.1142/S0192415X11008610
   Xutian S, 2012, AM J CHINESE MED, V40, P231, DOI 10.1142/S0192415X12500188
   Xutian S, 2009, AM J CHINESE MED, V37, P411, DOI 10.1142/S0192415X09006941
   Yin YY, 2010, AM J CHINESE MED, V38, P517, DOI 10.1142/S0192415X10008020
   Zakaria ZA, 2011, AM J CHINESE MED, V39, P183, DOI 10.1142/S0192415X11008749
   Zeng XX, 2011, AM J CHINESE MED, V39, P1061, DOI 10.1142/S0192415X11009408
   Zhen Z, 2011, AM J CHINESE MED, V39, P53, DOI 10.1142/S0192415X11008646
   ZHOU W, 1990, AM J CHINESE MED, V18, P19, DOI 10.1142/S0192415X90000046
NR 58
TC 20
Z9 23
U1 4
U2 74
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192-415X
EI 1793-6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PY 2012
VL 40
IS 6
BP 1099
EP 1108
DI 10.1142/S0192415X12500814
PG 10
WC Integrative & Complementary Medicine; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine; General & Internal Medicine
GA 052PN
UT WOS:000312210400001
PM 23227784
DA 2026-01-16
ER

PT J
AU Sung, SH
   Kim, JW
   Han, JE
   Shin, BC
   Park, JK
   Lee, G
AF Sung, Soo-Hyun
   Kim, Ji-Won
   Han, Ji-Eun
   Shin, Byung-Cheul
   Park, Jang-Kyung
   Lee, Gihyun
TI Animal Venom for Medical Usage in Pharmacopuncture in Korean Medicine:
   Current Status and Clinical Implication
SO TOXINS
LA English
DT Review
DE animal venom; bee venom; snake venom; toad venom; pharmacopuncture
ID BEE STING THERAPY; SNAKE-VENOM; ADHESIVE CAPSULITIS; SHOULDER PAIN;
   ACUPUNCTURE; EFFICACY; PHYSIOTHERAPY; HEMOCOAGULASE; COAGULATION;
   TOXICITY
AB Animal venoms, widespread throughout the world, are complex mixtures, the composition of which depends on the venom-producing species. The objective of this study was to contribute to the development of animal venom-based medicines by investigating the use of animal venom pharmacopuncture in Korean medicine (KM) institutions. We surveyed 256 public health centers from 1 through 31 October 2019 as guided by the Ministry of Health and Welfare (MoHW). A questionnaire developed by an expert group was distributed and collected for statistical analysis. The survey identified three types of animal venom-based pharmacopuncture: bee, snake, and toad venoms. The medications are based on a single animal venom ingredient and produced in 11 external herbal dispensaries (EHDs). Each animal venom is processed, refined, and freeze-dried in a cleanroom to produce a powder formulation that is later measured, diluted, filtered, filled, sealed, sterilized, and packaged as pharmacopuncture injections used in KM institutions. Bee venom therapy is effective in treating musculoskeletal pain, snake venom therapy is effective in controlling bleeding during surgery, and toad venom therapy is effective in cancer treatment. The study suggests that bee, snake, and toad venoms could be used in medical institutions and have the potential for drug development.
C1 [Sung, Soo-Hyun; Kim, Ji-Won; Han, Ji-Eun] Natl Dev Inst Korean Med, Dept Policy Dev, Seoul 04554, South Korea.
   [Shin, Byung-Cheul; Park, Jang-Kyung] Pusan Natl Univ, Sch Korean Med, Div Clin Med, Yangsan 50612, South Korea.
   [Lee, Gihyun] Dongshin Univ, Coll Korean Med, Naju 58245, South Korea.
C3 Pusan National University; Dongshin University
RP Lee, G (corresponding author), Dongshin Univ, Coll Korean Med, Naju 58245, South Korea.
EM koyote10010@nikom.or.kr; cactus@nikom.or.kr; jieun2342@nikom.or.kr;
   drshinbc@pusan.ac.kr; vivat314@pusan.ac.kr; glee@khu.ac.kr
RI ; Soo-Hyun, Sung/ADL-0758-2022
OI Lee, Gihyun/0000-0001-6250-8852; Park, Jang Kyung/0000-0002-4323-278X;
   Soo-Hyun, Sung/0000-0001-7606-0147
FU Project of National Development Institute of Korean Medicine,
   Accreditation of External Herbal Dispensaries of Traditional Korean
   Medicine Clinics - Korean Ministry of Health and Welfare
FX This research was supported by a grant from the Project of National
   Development Institute of Korean Medicine, Accreditation of External
   Herbal Dispensaries of Traditional Korean Medicine Clinics, funded by
   the Korean Ministry of Health and Welfare.
CR Abd El-Aziz TM, 2019, TOXINS, V11, DOI 10.3390/toxins11100564
   Alqutub AN, 2011, WORLD J HEPATOL, V3, P268, DOI 10.4254/wjh.v3.i10.268
   Amin MR, 2008, J VENOM ANIM TOXINS, V14, P660, DOI 10.1590/S1678-91992008000400009
   [Anonymous], 2003, J Orient Rehab Med
   [Anonymous], 2017, STUDY METHODS PROVE
   Banfi FF, 2016, KOREAN J PARASITOL, V54, P415, DOI 10.3347/kjp.2016.54.4.415
   Boussios S, 2012, ANN GASTROENTEROL, V25, P106
   Byeong-Jun A, 2006, J PHARMACOPUNCT, V9, P167
   Camargo ACM, 2012, TOXICON, V59, P516, DOI 10.1016/j.toxicon.2011.07.013
   Castro HC, 2004, CELL MOL LIFE SCI, V61, P843, DOI 10.1007/s00018-003-3325-z
   Chan YS, 2016, APPL MICROBIOL BIOT, V100, P6165, DOI 10.1007/s00253-016-7610-9
   Chen Na, 2018, Biophys Rep, V4, P233, DOI [10.1007/s41048-018-0067-x, 10.1007/s41048-018-0067-x]
   Chen Shi-Yun, 2018, Zhen Ci Yan Jiu, V43, P251, DOI 10.13702/j.1000-0607.170506
   Chen Zhe, 2003, Zhong Xi Yi Jie He Xue Bao, V1, P184
   Chippaux JP, 2015, J VENOM ANIM TOXINS, V21, DOI 10.1186/s40409-015-0011-1
   Cho S.W., 2005, J. Korean Med. Rehabil, V15, P77
   Cho SY, 2018, J ALTERN COMPLEM MED, V24, P25, DOI 10.1089/acm.2016.0250
   Cho SY, 2013, COMPLEMENT THER MED, V21, P155, DOI 10.1016/j.ctim.2013.02.001
   Cho SY, 2012, PARKINSONISM RELAT D, V18, P948, DOI 10.1016/j.parkreldis.2012.04.030
   Conrad VJ, 2019, J ALTERN COMPLEM MED, V25, P845, DOI 10.1089/acm.2019.0121
   de Souza JM, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00145
   Eom JY, 2006, J PHARMACOPUNCT, V9, P139
   GALE AN, 1982, BRIT MED J, V284, P20, DOI 10.1136/bmj.284.6308.20
   GAMBA G, 1979, BLUT, V39, P89, DOI 10.1007/BF01008084
   Gowda R M, 2003, Heart, V89, pe14, DOI 10.1136/heart.89.4.e14
   Gwaltney-Brant S.M, 2017, ZOOTOXINS REPROD DEV, V2nd
   Hakim MA, 2015, TOXINS, V7, P4832, DOI 10.3390/toxins7114832
   Hartmann A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158235
   Hayes WK, 2020, METHODS MOL BIOL, V2068, P53, DOI 10.1007/978-1-4939-9845-6_3
   Hoon Kim Ji, 2017, [Journal of Korean Medicine, 대한한의학회지], V38, P81, DOI [10.13048/jkm.17008, 10.13048/jkm.17008]
   안웅찬, 2016, [The Journal of Herbal Formula Science, 대한한의학 방제학회지], V24, P1, DOI [10.14374/hfs.2016.24.1.1, 10.14374/HFS.2016.24.1.1]
   HUANG DX, 1992, ACTA CARDIOL, V47, P445
   Huh JE, 2010, CANCER LETT, V292, P98, DOI 10.1016/j.canlet.2009.11.013
   Jang S, 2020, TOXINS, V12, DOI 10.3390/toxins12090558
   Jung JW, 2012, ALLERGY ASTHMA IMMUN, V4, P107, DOI 10.4168/aair.2012.4.2.107
   Kim D.H., 2015, POLICY IMPROVEMENT P
   Kim JS, 2001, CEREBROVASC DIS, V11, P251, DOI 10.1159/000047647
   Kim SK, 2014, J PHYS THER SCI, V26, P1419, DOI 10.1589/jpts.26.1419
   Koh PS, 2013, J SHOULDER ELB SURG, V22, P1053, DOI 10.1016/j.jse.2012.10.045
   Korean Pharmacopuncture Institute, 2011, Pharmacopuncturology
   Kwon YB, 2001, AM J CHINESE MED, V29, P187, DOI 10.1142/S0192415X01000228
   Kwon-Eui H, 2010, J PHARMACOPUNCT, V13, P91, DOI 10.3831/KPI.2010.13.3.091
   이대용, 2006, Journal of Acupuncture Research, V23, P69
   Lee G, 2016, TOXINS, V8, DOI 10.3390/toxins8020048
   유상민, 2006, Journal of Acupuncture Research, V23, P39
   Lee KG, 2009, J ETHNOPHARMACOL, V123, P15, DOI 10.1016/j.jep.2009.02.044
   Lee MS, 2008, J PAIN, V9, P289, DOI 10.1016/j.jpain.2007.11.012
   Lee SH., 2003, Journal of Acupuncture Research, V20, P80
   Lim BS, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/369324
   Lim SM, 2015, J INTEGR MED-JIM, V13, P241, DOI 10.1016/S2095-4964(15)60178-9
   Liu M, 1998, J Stroke Cerebrovasc Dis, V7, P63, DOI 10.1016/S1052-3057(98)80023-2
   Mehta S R, 2002, Med J Armed Forces India, V58, P247, DOI 10.1016/S0377-1237(02)80140-X
   Meng Z, 2012, BRIT J CANCER, V107, P411, DOI 10.1038/bjc.2012.283
   Ministry of Health and Welfare National Development Institute of Korean Medicine Gallup Korea, 2017 YEARS NATL SURV
   Mohamed E.A., 2016, INT J PHARMTECH RES, V9, P66
   Nitecka-Buchta A, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/296053
   Park J.A., 2011, THE J, V2, P37
   고창남, 2007, [Journal of Korean Medicine, 대한한의학회지], V28, P11
   Park J, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/4683121
   Park YC, 2014, J ALTERN COMPLEM MED, V20, P919, DOI 10.1089/acm.2014.0220
   Qiu MG, 2017, INJURY, V48, P914, DOI 10.1016/j.injury.2016.11.028
   Reisman RE, 2005, CURR OPIN ALLERGY CL, V5, P355, DOI 10.1097/01.all.0000173782.35283.b6
   Ren X.H., 2004, J CLIN ACUPUNCT MOXI, V20, P54
   Schmeda-Hirschmann G, 2014, J ETHNOPHARMACOL, V155, P1076, DOI 10.1016/j.jep.2014.06.025
   Seo BK, 2017, TOXINS, V9, DOI 10.3390/toxins9110361
   서진우, 2006, Journal of Acupuncture Research, V23, P95
   Shen L, 2020, J PHARMACOPUNCT, V23, P44, DOI 10.3831/KPI.2020.23.008
   Shetty V, 2015, J CRANIO MAXILL SURG, V43, P2000, DOI 10.1016/j.jcms.2015.08.032
   Shin BC, 2012, EUR J INTEGR MED, V4, pE271, DOI 10.1016/j.eujim.2012.02.005
   Song HS, 2005, J PHARMACOPUNCT, V8, P11
   배의종, 2009, [Korean Journal of Dermatology, 대한피부과학회지], V47, P350
   Sung SH, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906-020-03094-0
   Sung SH, 2019, J PHARMACOPUNCT, V22, P75, DOI 10.3831/KPI.2019.22.009
   TAE KIM KYUNG, 2005, Journal of Acupuncture Research, V22, P113
   TAE KIM KYUNG, 2005, Journal of Acupuncture Research, V22, P189
   Utkin Yuri N, 2015, World J Biol Chem, V6, P28, DOI 10.4331/wjbc.v6.i2.28
   Vetter RS, 1999, WESTERN J MED, V170, P223
   Wang TT, 2018, PAK J PHARM SCI, V31, P1609
   WARPINSKI JR, 1990, J WILDERNESS MED, V1, P249, DOI 10.1580/0953-9859-1.4.249
   Wesselius T, 2005, NEUROLOGY, V65, P1764, DOI 10.1212/01.wnl.0000184442.02551.4b
   Wu JR, 2020, J TRADIT CHIN MED, V40, P749, DOI 10.19852/j.cnki.jtcm.2020.05.004
   Xu Jing, 2019, Zhongguo Zhong Yao Za Zhi, V44, P2627, DOI 10.19540/j.cnki.cjcmm.20190304.003
   Yasin M. M., 2018, Journal of Applied Pharmaceutical Science, V8, P159, DOI 10.7324/japs.2018.8124
   Yun Jung Min, 2018, [Society of Preventive Korean Medicine, 대한예방한의학회지], V22, P55, DOI [10.25153/spkom.2018.22.2.006, 10.25153/spkom.2018.22.2.006]
   Zhang D, 2020, J TRADIT CHIN MED, V40, P167
   Zhang J.W., 1995, SHANGHAI J ACUPUNCT, V3, P126
   Zhang S Y, 1994, Zhonghua Nei Ke Za Zhi, V33, P244
   Zheng YR, 2022, PLANTA MED, V88, P43, DOI 10.1055/a-1248-2626
NR 88
TC 23
Z9 26
U1 0
U2 26
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
EI 2072-6651
J9 TOXINS
JI Toxins
PD FEB
PY 2021
VL 13
IS 2
AR 105
DI 10.3390/toxins13020105
PG 14
WC Food Science & Technology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Toxicology
GA QO6VW
UT WOS:000623280300001
PM 33535603
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Sarradon-Eck, A
   Bouhnik, AD
   Rey, D
   Bendiane, MK
   Huiart, L
   Peretti-Watel, P
AF Sarradon-Eck, Aline
   Bouhnik, Anne-Deborah
   Rey, Dominique
   Bendiane, Marc-Karim
   Huiart, Laetitia
   Peretti-Watel, Patrick
TI Use of non-conventional medicine two years after cancer diagnosis in
   France: evidence from the VICAN survey
SO JOURNAL OF CANCER SURVIVORSHIP
LA English
DT Article
DE Complementary and alternative medicine; Integrative medicine; Cancer
   survivors; Cohort study; Coping; France
ID QUALITY-OF-LIFE; ALTERNATIVE MEDICINE; BREAST-CANCER;
   COMPLEMENTARY/ALTERNATIVE MEDICINE; UNITED-STATES; HEALTH-CARE; THERAPY
   USE; LONG-TERM; WOMEN; PREVALENCE
AB The purpose of this study was to assess the use of non-conventional medicine (NCM) in a representative sample of French patients 2 years after cancer diagnosis.
   The study was based on data obtained in the VICAN survey (2012) on a representative sample of 4349 patients 2 years after cancer diagnosis. Self-reported data were collected at telephone interviews with patients. The questionnaire addressed the various types of non-conventional treatments used at the time of the survey.
   Among the participants, 16.4% reported that they used NCM, and 45.3% of this group had not used NCM before cancer diagnosis (new NCM users). Commonly, NCMs used were homeopathy (64.0%), acupuncture (22.1%), osteopathy (15.1%), herbal medicine (8.1%), diets (7.3%) and energy therapies (5.8%). NCM use was found to be significantly associated with younger age, female gender and a higher education level. Previous NCM use was significantly associated with having a managerial occupation and an expected 5-year survival rate ae<yen>80% at diagnosis; recent NCM use was associated with cancer progression since diagnosis, impaired quality of life and higher pain reports.
   This is the first study on NCM use 2 years after cancer diagnosis in France. In nearly half of the NCM users, cancer diagnosis was one of the main factors which incited patients to use NCM. Apart from the NCM users' socioeconomic profile, the present results show that impaired health was a decisive factor: opting for unconventional approaches was therefore a pragmatic response to needs which conventional medicine fails to meet during the course of the disease.
   Better information of patients and caregivers is needed to allow access to these therapies to a larger population of survivors.
C1 [Sarradon-Eck, Aline; Bouhnik, Anne-Deborah; Rey, Dominique; Bendiane, Marc-Karim; Huiart, Laetitia; Peretti-Watel, Patrick] Aix Marseille Univ, INSERM, IRD, SESSTIM,Econ & Social Sci Appl Hlth & Anal Med In, Marseille, France.
   [Sarradon-Eck, Aline] SESSTIM, Inst Paoli Calmettes, Marseille, France.
   [Rey, Dominique; Bendiane, Marc-Karim; Peretti-Watel, Patrick] ORS PACA, Southeastern Hlth Reg Observ, Marseille, France.
   [Huiart, Laetitia] CHU Reunion, Unite Soutien Methodol, St Denis, Reunion, France.
   [Huiart, Laetitia] CHU Reunion, INSERM, CIC 1410, St Pierre, Reunion, France.
C3 Aix-Marseille Universite; Institut de Recherche pour le Developpement
   (IRD); Institut National de la Sante et de la Recherche Medicale
   (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Aix-Marseille
   Universite; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Aix-Marseille Universite; CHU Reunion; Institut National de la
   Sante et de la Recherche Medicale (Inserm); CHU Reunion
RP Sarradon-Eck, A (corresponding author), Aix Marseille Univ, INSERM, IRD, SESSTIM,Econ & Social Sci Appl Hlth & Anal Med In, Marseille, France.; Sarradon-Eck, A (corresponding author), SESSTIM, Inst Paoli Calmettes, Marseille, France.
EM aline.sarradon@inserm.fr
RI Bendiane, Marc-Karim/F-5414-2010; Bouhnik, Anne-Deborah/M-2829-2019;
   Huiart, Laetitia/LXA-7410-2024; Peretti-Watel, Patrick/P-4535-2017
OI Bendiane, Marc-Karim/0000-0003-4329-8807; SARRADON-ECK,
   Aline/0000-0002-6697-8058; Bouhnik, Anne-Deborah/0000-0002-5418-4592; 
FU National Institute of Cancer (INCa) [05-2011]
FX This study was funded by the National Institute of Cancer (INCa),
   "Contrat de recherche et developpement no. 05-2011." The authors thank
   Dr. Jessica Blanc for revising the English manuscript.
CR Adler SR, 1999, MED ANTHROPOL Q, V13, P214, DOI 10.1525/maq.1999.13.2.214
   [Anonymous], 2015, TRENDS USE COMPLEMEN
   Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548
   Baider L, 2003, CRIT REV ONCOL HEMAT, V46, P5, DOI 10.1016/S1040-8428(02)00134-8
   Balneaves LG, 2007, SUPPORT CARE CANCER, V15, P973, DOI 10.1007/s00520-007-0282-3
   Bartmann JA, 1996, J APPL GERONTOL, V15, P376, DOI 10.1177/073346489601500307
   Baum M, 2006, EUR J CANCER, V42, P1711, DOI 10.1016/j.ejca.2006.02.019
   Bauml J, 2014, SUPPORT CARE CANCER, V22, P2465, DOI 10.1007/s00520-014-2220-5
   Bauml JM, 2015, CANCER-AM CANCER SOC, V121, P2431, DOI 10.1002/cncr.29173
   Begot, 2010, MED PARALLELES CANC
   Boon H, 2000, J CLIN ONCOL, V18, P2515, DOI 10.1200/JCO.2000.18.13.2515
   Bouhassira D, 2005, PAIN, V114, P29, DOI 10.1016/j.pain.2004.12.010
   Bouhnik AD, 2006, JAIDS-J ACQ IMM DEF, V42, P597, DOI 10.1097/01.qai.0000221674.76327.d7
   Bouhnik AD, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-005971
   Burdine JN, 2000, HEALTH SERV RES, V35, P885
   Burstein HJ, 1999, NEW ENGL J MED, V340, P1733, DOI 10.1056/NEJM199906033402206
   Bury M, 1982, Sociol Health Illn, V4, P167, DOI 10.1111/1467-9566.ep11339939
   Carlsson M, 2001, CANCER NURS, V24, P395, DOI 10.1097/00002820-200110000-00012
   CASSILETH BR, 1986, CANCER INVEST, V4, P591, DOI 10.3109/07357908609039837
   Chan JM, 2005, UROLOGY, V66, P1223, DOI 10.1016/j.urology.2005.06.003
   Chrystal K, 2003, NZ MED J, V116, P1168
   Cohen P, 2016, CANC PLURALISME THER
   Crocetti E, 1998, EUR J CANCER, V34, P324, DOI 10.1016/S0959-8049(97)10043-0
   Deng GE, 2013, CHEST, V143, pE420, DOI 10.1378/chest.12-2364
   Edwards GV, 2014, ASIA-PAC J CLIN ONCO, V10, P346, DOI 10.1111/ajco.12203
   EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406
   Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569
   Elziere P, 1986, SCI SOC SANTE, V4, P39, DOI [10.3406/sosan.1986.1033, DOI 10.3406/SOSAN.1986.1033]
   Ernst E, 2000, B WORLD HEALTH ORGAN, V78, P252
   Ganz PA, 2002, JNCI-J NATL CANCER I, V94, P39
   Gözüm S, 2003, CANCER NURS, V26, P230
   Groenvold M, 1997, J CLIN EPIDEMIOL, V50, P441, DOI 10.1016/S0895-4356(96)00428-3
   HACK TF, 1994, SOC SCI MED, V39, P279, DOI 10.1016/0277-9536(94)90336-0
   HOLLAND JC, 1982, CA-CANCER J CLIN, V32, P10, DOI 10.3322/canjclin.32.1.10
   Horneber M, 2012, INTEGR CANCER THER, V11, P187, DOI 10.1177/1534735411423920
   Horner MJ, 2009, SEER CANC STAT REV, V1975-2006
   Huiart L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081677
   Hunter D, 2014, SUPPORT CARE CANCER, V22, P1571, DOI 10.1007/s00520-014-2120-8
   Hyodo I, 2005, J CLIN ONCOL, V23, P2645, DOI 10.1200/JCO.2005.04.126
   Kelner M, 1997, SOC SCI MED, V45, P203, DOI 10.1016/S0277-9536(96)00334-6
   Kersnik J, 2000, SCHWEIZ MED WSCHR, V130, P390
   Kessler RC, 2001, ANN INTERN MED, V135, P262, DOI 10.7326/0003-4819-135-4-200108210-00011
   Kim SG, 2007, J CLIN ONCOL, V25, P5267, DOI 10.1200/JCO.2007.11.9651
   Lanoe JL., 2005, ETUDES RESULTATS, V436, P1
   Laplantine F., 1987, Les medecines paralleles
   Le Corroller-Soriano AG, 2011, EUR J CANCER CARE, V20, P132, DOI 10.1111/j.1365-2354.2009.01160.x
   Lee MM, 2000, JNCI-J NATL CANCER I, V92, P42, DOI 10.1093/jnci/92.1.42
   Maskarinec G, 2001, CANCER PRACT, V9, P183, DOI 10.1046/j.1523-5394.2001.94006.x
   McGregor KJ, 1996, SOC SCI MED, V43, P1317, DOI 10.1016/0277-9536(95)00405-X
   Molassiotis A, 2005, ANN ONCOL, V16, P655, DOI 10.1093/annonc/mdi110
   Montbriand MJ, 1998, CANCER NURS, V21, P36, DOI 10.1097/00002820-199802000-00005
   Morris KT, 2000, AM J SURG, V179, P407, DOI 10.1016/S0002-9610(00)00358-5
   *NAT CTR COMPL ALT, 2000, EXP HOR HEALTHC 5 YE
   Navo MA, 2004, J CLIN ONCOL, V22, P671, DOI 10.1200/JCO.2004.04.162
   Pedersen CG, 2009, EUR J CANCER, V45, P3172, DOI 10.1016/j.ejca.2009.09.005
   Portenoy R, 2006, CURR MED RES OPIN, V22, P1555, DOI 10.1185/030079906X115702
   Préau M, 2007, AIDS, V21, pS19, DOI 10.1097/01.aids.0000255081.24105.d7
   Richardson MA, 2000, J CLIN ONCOL, V18, P2505, DOI 10.1200/JCO.2000.18.13.2505
   Risberg T, 1998, J CLIN ONCOL, V16, P6, DOI 10.1200/JCO.1998.16.1.6
   Simon L, 2007, B CANCER, V94, P483
   Smith PJ, 2014, ASIA-PAC J CLIN ONCO, V10, P1, DOI 10.1111/ajco.12115
   Söllner W, 2000, CANCER-AM CANCER SOC, V89, P873, DOI 10.1002/1097-0142(20000815)89:4<873::AID-CNCR21>3.0.CO;2-K
   Thomas-Schoemann A, 2011, B CANCER, V98, P645, DOI 10.1684/bdc.2011.1375
   Träger-Maury S, 2007, B CANCER, V94, P1017
   Truant T, 1999, PATIENT EDUC COUNS, V38, P131, DOI 10.1016/S0738-3991(99)00060-9
   Tuppin P, 2010, REV EPIDEMIOL SANTE, V58, P286, DOI 10.1016/j.respe.2010.04.005
   Vincent C, 1996, BRIT J CLIN PSYCHOL, V35, P37, DOI 10.1111/j.2044-8260.1996.tb01160.x
   YATES PM, 1993, SOCIOL HEALTH ILL, V15, P199, DOI 10.1111/1467-9566.ep11346886
   Zaloznik A J, 1994, Cancer Pract, V2, P19
NR 69
TC 13
Z9 13
U1 0
U2 20
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1932-2259
EI 1932-2267
J9 J CANCER SURVIV
JI J. Cancer Surviv.-Res. Pract.
PD AUG
PY 2017
VL 11
IS 4
BP 421
EP 430
DI 10.1007/s11764-017-0599-y
PG 10
WC Oncology; Social Sciences, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Oncology; Biomedical Social Sciences
GA FA0EM
UT WOS:000405104100001
PM 28150122
DA 2026-01-16
ER

PT J
AU Jacobson, KA
   Reitman, ML
AF Jacobson, Kenneth A.
   Reitman, Marc L.
TI Adenosine-Related Mechanisms in Non-Adenosine Receptor Drugs
SO CELLS
LA English
DT Review
DE adenosine receptor; nucleoside transport; CNS; inflammation;
   cardiovascular system; pain
ID EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; INCREASES EXTRACELLULAR ADENOSINE;
   A(1) RECEPTORS; A(2A) RECEPTOR; REPERFUSION INJURY; AICA RIBOSIDE;
   IN-VIVO; INHIBITION; INVOLVEMENT; MICE
AB Many ligands directly target adenosine receptors (ARs). Here we review the effects of noncanonical AR drugs on adenosinergic signaling. Non-AR mechanisms include raising adenosine levels by inhibiting adenosine transport (e.g., ticagrelor, ethanol, and cannabidiol), affecting intracellular metabolic pathways (e.g., methotrexate, nicotinamide riboside, salicylate, and 5-aminoimidazole-4-carboxamide riboside), or undetermined means (e.g., acupuncture). However, other compounds bind ARs in addition to their canonical 'on-target' activity (e.g., mefloquine). The strength of experimental support for an adenosine-related role in a drug's effects varies widely. AR knockout mice are the 'gold standard' method for investigating an AR role, but few drugs have been tested on these mice. Given the interest in AR modulation for treatment of cancer, CNS, immune, metabolic, cardiovascular, and musculoskeletal conditions, it is informative to consider AR and non-AR adenosinergic effects of approved drugs and conventional treatments.
C1 [Jacobson, Kenneth A.] NIDDK, Mol Recognit Sect, Bioorgan Chem Lab, Bethesda, MD 20892 USA.
   [Reitman, Marc L.] NIDDK, Diabet Endocrinol & Obes Branch, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of
   Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of
   Health (NIH) - USA; NIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK)
RP Jacobson, KA (corresponding author), NIDDK, Mol Recognit Sect, Bioorgan Chem Lab, Bethesda, MD 20892 USA.
EM kennethj@niddk.nih.gov; marc.reitman@nih.gov
RI Reitman, Marc/B-4448-2013; Jacoon, Kenneth/A-1530-2009
OI Reitman, Marc/0000-0002-0426-9475; Jacoon, Kenneth/0000-0001-8104-1493
FU NIH (NIDDK) [ZIADK031117, ZIADK075063]; National Institute of Diabetes
   and Digestive and Kidney Diseases [ZIADK075063, ZIADK075062,
   ZIADK031117] Funding Source: NIH RePORTER
FX Support from the NIH Intramural Research Grants ZIADK031117 and
   ZIADK075063 (NIDDK) is acknowledged.
CR Allard B, 2016, CURR OPIN PHARMACOL, V29, P7, DOI 10.1016/j.coph.2016.04.001
   Alnouri MW, 2015, PURINERG SIGNAL, V11, P389, DOI 10.1007/s11302-015-9460-9
   Ameyaw Elvis Ofori, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P557, DOI [10.1515/jbcpp-2015-0108, 10.1515/jbcpp-2015-0108]
   Amouzadeh HR, 2019, TRANSL ONCOL, V12, P1296, DOI 10.1016/j.tranon.2019.05.018
   Antonioli H.GL., 2018, The Adenosine Receptors, V34, P499, DOI 10.1007/978-3-319- 90808-3_20
   Antonioli L, 2007, J PHARMACOL EXP THER, V322, P435, DOI 10.1124/jpet.107.122762
   Arruda MA, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00908
   Azimzadeh K, 2017, PHARMACEUT BIOMED RE, V3, P17, DOI 10.29252/pbr.3.3.17
   Bai YS, 2011, CLIN EXP PHARMACOL P, V38, P658, DOI 10.1111/j.1440-1681.2011.05550.x
   Barczyk K, 2010, BLOOD, V116, P446, DOI 10.1182/blood-2009-10-247106
   Baxter GF, 2002, CARDIOVASC RES, V55, P483, DOI 10.1016/S0008-6363(02)00280-8
   BLARDI P, 1993, EUR J CLIN PHARMACOL, V44, P505, DOI 10.1007/BF00315554
   Boison D, 2013, PHARMACOL REV, V65, P906, DOI 10.1124/pr.112.006361
   Borroto-Escuela DO, 2019, J NEURAL TRANSM, V126, P455, DOI 10.1007/s00702-019-01969-2
   Borroto-Escuela DO, 2018, MOL NEUROBIOL, V55, P7038, DOI 10.1007/s12035-018-0887-1
   Boss M, 2016, SCI REP-UK, V6, DOI 10.1038/srep32111
   Boswell-Casteel RC, 2017, NUCLEOS NUCLEOT NUCL, V36, P7, DOI 10.1080/15257770.2016.1210805
   Braganhol E, 2007, BBA-GEN SUBJECTS, V1770, P1352, DOI 10.1016/j.bbagen.2007.06.003
   Burnstock G, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00661
   Burstein S, 2015, BIOORGAN MED CHEM, V23, P1377, DOI 10.1016/j.bmc.2015.01.059
   Calker D, 2005, NEUROCHEM RES, V30, P1205, DOI 10.1007/s11064-005-8792-1
   Camici M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030784
   Carlin JL, 2017, NEUROPHARMACOLOGY, V114, P101, DOI 10.1016/j.neuropharm.2016.11.026
   Carreira MC, 2006, J ENDOCRINOL, V191, P147, DOI 10.1677/joe.1.06714
   Carrier EJ, 2006, P NATL ACAD SCI USA, V103, P7895, DOI 10.1073/pnas.0511232103
   Castillo A, 2010, NEUROBIOL DIS, V37, P434, DOI 10.1016/j.nbd.2009.10.023
   Cattaneo M, 2012, THROMB HAEMOSTASIS, V108, P1031, DOI 10.1160/TH12-08-0547
   Choi DS, 2004, NAT NEUROSCI, V7, P855, DOI 10.1038/nn1288
   Cronstein BN, 1999, P NATL ACAD SCI USA, V96, P6377, DOI 10.1073/pnas.96.11.6377
   Cunha MP, 2015, PURINERG SIGNAL, V11, P215, DOI 10.1007/s11302-015-9446-7
   Drury AN, 1929, J PHYSIOL-LONDON, V68, P213, DOI 10.1113/jphysiol.1929.sp002608
   Fang T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12689-6
   Ferré S, 2018, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00722
   Fiebich BL, 1996, GLIA, V18, P152, DOI 10.1002/(SICI)1098-1136(199610)18:2<152::AID-GLIA7>3.0.CO;2-2
   Fong M, 2010, CIRC J, V74, P181, DOI 10.1253/circj.CJ-09-0372
   Fraser CM, 1997, EUR NEUROPSYCHOPHARM, V7, P267, DOI 10.1016/S0924-977X(97)00032-1
   Fredholm BB, 2007, CELL DEATH DIFFER, V14, P1315, DOI 10.1038/sj.cdd.4402132
   FRIES JF, 1993, ARCH INTERN MED, V153, P2465, DOI 10.1001/archinte.153.21.2465
   Futatsuki T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21252-w
   Gadalla AE, 2004, J NEUROCHEM, V88, P1272, DOI 10.1046/j.1471-4159.2003.02253.x
   Gadangi P, 1996, J IMMUNOL, V156, P1937
   Gandhi AV, 2015, NEURON, V85, P1193, DOI 10.1016/j.neuron.2015.02.016
   Gao Z. G., 2018, THE RECEPTERS, V34, P59, DOI [10.1007/978-3-319-90808-3_4, DOI 10.1007/978-3-319-90808-3_4]
   Gillespie RJ, 2008, BIOORG MED CHEM LETT, V18, P2916, DOI 10.1016/j.bmcl.2008.03.075
   Ginés S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097
   Goldfine AB, 2013, ANN INTERN MED, V159, P1, DOI 10.7326/0003-4819-159-1-201307020-00003
   Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562
   GRUBER HE, 1989, CIRCULATION, V80, P1400, DOI 10.1161/01.CIR.80.5.1400
   Guieu R, 1998, KIDNEY INT, V53, P200, DOI 10.1046/j.1523-1755.1998.00727.x
   Guo ZF, 2019, NAT CHEM, V11, P254, DOI 10.1038/s41557-018-0187-4
   Haskó G, 2008, NAT REV DRUG DISCOV, V7, P759, DOI 10.1038/nrd2638
   HAWKINS M, 1988, PHARMACOL BIOCHEM BE, V30, P303, DOI 10.1016/0091-3057(88)90459-5
   Hines DJ, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2012.136
   Hoffmann K, 2013, EUR J PHARMACOL, V700, P152, DOI 10.1016/j.ejphar.2012.12.003
   Hu X, 2016, CELL REP, V16, P106, DOI 10.1016/j.celrep.2016.05.080
   Hughes V, 2018, BRIT J PHARMACOL, V175, P1471, DOI 10.1111/bph.14152
   Hur KY, 2015, J DIABETES INVEST, V6, P600, DOI 10.1111/jdi.12328
   HUTCHISON AJ, 1989, J PHARMACOL EXP THER, V251, P47
   Jacobson KA, 2002, ADV EXP MED BIOL, V505, P163
   Jacobson KA, 2020, PAIN, V161, P1425, DOI 10.1097/j.pain.0000000000001857
   Kalkan S, 2018, INT J PHARMACOL, V14, P116, DOI 10.3923/ijp.2018.116.120
   KAPLAN GB, 1992, J PHARM PHARMACOL, V44, P700, DOI 10.1111/j.2042-7158.1992.tb05502.x
   Kemeny-Beke A, 2007, PHARMACOL RES, V56, P124, DOI 10.1016/j.phrs.2007.04.017
   Kim HH, 2008, ARTERIOSCL THROM VAS, V28, pS39, DOI 10.1161/ATVBAHA.107.160226
   Kim Y, 2019, KOREAN J ANESTHESIOL, V72, P60, DOI 10.4097/kja.d.18.00022
   Knowles HJ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060624
   Kowaluk EA, 2000, J PHARMACOL EXP THER, V295, P1165
   Lanaspa MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048801
   Le DE, 2020, AM J PHYSIOL-HEART C, V318, pH189, DOI 10.1152/ajpheart.00217.2019
   Li RWS, 2012, J CARDIOVASC PHARM, V59, P10, DOI 10.1097/FJC.0b013e31820eb788
   Liao HY, 2017, SCI REP-UK, V7, DOI 10.1038/srep42531
   Liou GI, 2008, INVEST OPHTH VIS SCI, V49, P5526, DOI 10.1167/iovs.08-2196
   Liu J, 2013, EUR J PHARMACOL, V698, P213, DOI 10.1016/j.ejphar.2012.10.042
   Liu YG, 2001, CARDIOVASC DRUG REV, V19, P369, DOI 10.1111/j.1527-3466.2001.tb00076.x
   Lobato KR, 2008, PROG NEURO-PSYCHOPH, V32, P994, DOI 10.1016/j.pnpbp.2008.01.012
   Mackey JR, 1998, DRUG RESIST UPDATE, V1, P310, DOI 10.1016/S1368-7646(98)80047-2
   Martens CR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03421-7
   Martins DF, 2015, J PERIPHER NERV SYST, V20, P403, DOI 10.1111/jns.12149
   Martins DF, 2015, J NEUROSCI RES, V93, P157, DOI 10.1002/jnr.23461
   Masino SA, 2011, J CLIN INVEST, V121, P2679, DOI 10.1172/JCI57813
   Mazar J, 2005, ANESTHESIOLOGY, V102, P1174, DOI 10.1097/00000542-200506000-00017
   Mediero A, 2013, TRENDS ENDOCRIN MET, V24, P290, DOI 10.1016/j.tem.2013.02.001
   Meijer P, 2009, ARTERIOSCL THROM VAS, V29, P963, DOI 10.1161/ATVBAHA.108.179622
   Mittal SPK, 2016, BBA-GEN SUBJECTS, V1860, P2377, DOI 10.1016/j.bbagen.2016.07.005
   MOSER GH, 1989, AM J PHYSIOL, V256, pC799, DOI 10.1152/ajpcell.1989.256.4.C799
   Müller CE, 2011, BBA-BIOMEMBRANES, V1808, P1290, DOI 10.1016/j.bbamem.2010.12.017
   Naassila M, 2002, J NEUROSCI, V22, P10487
   NAGY LE, 1990, J BIOL CHEM, V265, P1946
   NEWBY AC, 1984, TRENDS BIOCHEM SCI, V9, P42, DOI 10.1016/0968-0004(84)90176-2
   Nylander S, 2013, J THROMB HAEMOST, V11, P1867, DOI 10.1111/jth.12360
   Okumura T, 2016, J NEUROL SCI, V362, P106, DOI 10.1016/j.jns.2016.01.031
   Ouyang JY, 2011, J BIOL CHEM, V286, P1, DOI 10.1074/jbc.M110.121806
   Paiva M, 2009, J CARDIOVASC PHARM, V53, P373, DOI 10.1097/FJC.0b013e31819fd4e7
   Parsons W.J., 1998, MOL PHARM, V33, P441
   PHILLIS JW, 1982, COMP BIOCHEM PHYS C, V72, P179, DOI 10.1016/0306-4492(82)90082-X
   Posadzki PP, 2018, BMC MED, V16, DOI 10.1186/s12916-017-1000-8
   Rena G, 2017, DIABETOLOGIA, V60, P1577, DOI 10.1007/s00125-017-4342-z
   Ribeiro A, 2012, EUR J PHARMACOL, V678, P78, DOI 10.1016/j.ejphar.2011.12.043
   Ribeiro LR, 2017, TOXICOL APPL PHARM, V317, P41, DOI 10.1016/j.taap.2016.12.021
   Rodriguez D, 2016, ACS CHEM BIOL, V11, P2763, DOI 10.1021/acschembio.6b00357
   Ruby Christina L, 2010, Curr Drug Abuse Rev, V3, P163
   Salloum FN, 2007, J MOL CELL CARDIOL, V43, P545, DOI 10.1016/j.yjmcc.2007.08.014
   Sandner-Kiesling A, 2001, ANESTHESIOLOGY, V95, P1455, DOI 10.1097/00000542-200112000-00026
   Schmidt K, 2010, EUR HEART J, V31, P1655, DOI 10.1093/eurheartj/ehp555
   Serchov T, 2015, NEURON, V87, P549, DOI 10.1016/j.neuron.2015.07.010
   Siddiqi SM, 1996, NUCLEOS NUCLEOT, V15, P693, DOI 10.1080/07328319608002416
   Silva RL, 2019, TOXICOL APPL PHARM, V368, P63, DOI 10.1016/j.taap.2019.02.011
   Singh L, 2018, KOREAN J PHYSIOL PHA, V22, P225, DOI 10.4196/kjpp.2018.22.3.225
   Smith RG, 2005, ENDOCR REV, V26, P346, DOI 10.1210/er.2004-0019
   Stolz ED, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/5890590
   STONE TW, 1979, NATURE, V281, P227, DOI 10.1038/281227a0
   STRIESSNIG J, 1985, EUR J BIOCHEM, V150, P67, DOI 10.1111/j.1432-1033.1985.tb08989.x
   Surendra H, 2013, J MOL CELL CARDIOL, V60, P142, DOI 10.1016/j.yjmcc.2013.04.010
   SWEENEY MI, 1987, EUR J PHARMACOL, V141, P169, DOI 10.1016/0014-2999(87)90428-6
   Terasaka T, 2004, J AM CHEM SOC, V126, P34, DOI 10.1021/ja038606l
   Tian HH, 2007, BULL HOSP JT DIS, V65, P168
   Tosh DK, 2019, J MED CHEM, V62, P1502, DOI 10.1021/acs.jmedchem.8b01662
   Uzbay TI, 2007, NEUROPSYCHOPHARMACOL, V32, P412, DOI 10.1038/sj.npp.1301143
   van den Berg TNA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111248
   Varani K, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/2740963
   Vecchio EA, 2018, BRIT J PHARMACOL, V175, P4036, DOI 10.1111/bph.14337
   Vincenzi F., 2018, ORTHOPAED P, V100, P35, DOI [10.1302/1358-992X.2018.15.035, DOI 10.1302/1358-992X.2018.15.035]
   Wan T.C., 2004, 4 INT S NUCLEOSIDES
   Wan TC, 2019, BIOCHEM PHARMACOL, V163, P21, DOI 10.1016/j.bcp.2019.01.022
   Wang ML, 2015, SCI REP-UK, V5, DOI 10.1038/srep16107
   Wessels JAM, 2006, ARTHRITIS RHEUM, V54, P2830, DOI 10.1002/art.22032
   WILLIAMS M, 1981, CAN J PHYSIOL PHARM, V59, P897, DOI 10.1139/y81-136
   Xiao CY, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000161
   Zakaria ZA, 2018, PAIN RES MANAG, V2018, DOI 10.1155/2018/9536406
NR 129
TC 22
Z9 23
U1 2
U2 12
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD APR
PY 2020
VL 9
IS 4
AR 956
DI 10.3390/cells9040956
PG 20
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA LR2XW
UT WOS:000535559500167
PM 32295065
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Pan, WT
   Ji, MH
   Ma, DQ
   Yang, JJ
AF Pan, Wei-Tong
   Ji, Mu-huo
   Ma, Daqing
   Yang, Jian-Jun
TI Effect of perioperative autonomic nervous system imbalance on surgical
   outcomes: a systematic review
SO BRITISH JOURNAL OF ANAESTHESIA
LA English
DT Article
DE autonomic nervous system; perioperative autonomic imbalance;
   parasympathetic tone; perioperative
ID HEART-RATE-VARIABILITY; BETA-BLOCKERS; SURGERY; DEXMEDETOMIDINE;
   HYPERTENSION; INFLAMMATION; INNERVATION; MECHANISMS; RESPONSES; IMMUNITY
AB The autonomic nervous system (ANS) is essential for maintaining physiological homeostasis. Autonomic nervous system imbalance, characterised by sympathetic hyperactivation and low parasympathetic tone, can occur during the perioperative period. These changes drive systemic stress responses, cardiovascular instability, impaired tissue repair, and immunosuppression, which in turn increase infection risk, neurocognitive decline, and multiorgan dysfunction. Surgical trauma, anaesthesia, pain, hypothermia, and psychological stressors all contribute to this dysregulation, and consequently low parasympathetic tone results in the cholinergic anti-inflammatory pathway being less effective. High sympathetic nervous system activity promotes catecholamine surges and pro-inflammatory cytokine release. Pharmacological interventions, including dexmedetomidine and beta-blockers, together with nonpharmacological strategies, such as electroacupuncture and temperature management, are measures that have potential to restore ANS balance. This systematic review covers ANS-mediated organ regulation, pathophysiological consequences of perioperative dysautonomia, and evidence-based therapeutic strategies. By integrating findings from multiple basic and clinical studies, the pivotal roles of ANS modulation in mitigating postoperative complications, including neurocognitive disorders, immunosuppression, and cancer recurrence, are discussed. Maintaining balance of the sympathetic and parasympathetic nervous systems is an important prospect in perioperative medicine that could benefit surgical patients' short- or long
C1 [Pan, Wei-Tong; Yang, Jian-Jun] Zhengzhou Univ, Affiliated Hosp 1, Dept Anesthesiol Pain & Perioperat Med, Zhengzhou, Henan, Peoples R China.
   [Pan, Wei-Tong; Yang, Jian-Jun] Zhengzhou Univ Acad Med Sci, Neurosci Res Inst, Zhengzhou, Henan, Peoples R China.
   [Ji, Mu-huo] Nanjing Med Univ, Affiliated Hosp 2, Dept Anesthesiol, Nanjing, Jiangsu, Peoples R China.
   [Ma, Daqing] Zhejiang Univ, Childrens Hosp, Natl Clin Res Ctr Child Hlth, Perioperat & Syst Med Lab,Sch Med, Hangzhou, Peoples R China.
   [Ma, Daqing] Zhejiang Univ, Childrens Hosp, Natl Clin Res Ctr Child Hlth, Dept Anesthesiol,Sch Med, Hangzhou, Peoples R China.
   [Ma, Daqing] Ningbo Univ, Affiliated Hosp 1, Dept Anesthesiol, Ningbo, Zhejiang, Peoples R China.
   [Ma, Daqing] Imperial Coll London, Chelsea & Westminster Hosp, Dept Surg & Canc, Fac Med,Div Anaesthet Pain Med & Intens Care, London, England.
C3 Zhengzhou University; Nanjing Medical University; Zhejiang University;
   Zhejiang University; Ningbo University; Imperial College London
RP Yang, JJ (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Anesthesiol Pain & Perioperat Med, Zhengzhou, Henan, Peoples R China.; Yang, JJ (corresponding author), Zhengzhou Univ Acad Med Sci, Neurosci Res Inst, Zhengzhou, Henan, Peoples R China.; Ma, DQ (corresponding author), Zhejiang Univ, Childrens Hosp, Natl Clin Res Ctr Child Hlth, Perioperat & Syst Med Lab,Sch Med, Hangzhou, Peoples R China.; Ma, DQ (corresponding author), Zhejiang Univ, Childrens Hosp, Natl Clin Res Ctr Child Hlth, Dept Anesthesiol,Sch Med, Hangzhou, Peoples R China.; Ma, DQ (corresponding author), Ningbo Univ, Affiliated Hosp 1, Dept Anesthesiol, Ningbo, Zhejiang, Peoples R China.; Ma, DQ (corresponding author), Imperial Coll London, Chelsea & Westminster Hosp, Dept Surg & Canc, Fac Med,Div Anaesthet Pain Med & Intens Care, London, England.
EM d.ma@imperial.ac.uk; yjyangjj@126.com
OI Ma, Daqing/0000-0003-1235-0537
FU National Natural Science Foundation of China [U23A20421]; European
   Society of Anesthesiology and Intensive Care; Ningbo Top Medial and
   Health Research Program [2024010317]; British Journal of Anaesthesia
FX National Natural Science Foundation of China (U23A20421 to JJY) ;
   British Journal of Anaesthesia; European Society of Anesthesiology and
   Intensive Care; and Ningbo Top Medial and Health Research Program
   (2024010317 to DM) .
CR Ackermann W, 2018, FRONT SURG, V5, DOI 10.3389/fsurg.2018.00064
   Adachi A, 2024, PEDIATR SURG INT, V40, DOI 10.1007/s00383-024-05802-0
   Alam A, 2018, EBIOMEDICINE, V37, P547, DOI 10.1016/j.ebiom.2018.10.021
   Alazawi W, 2016, ANN SURG, V264, P73, DOI 10.1097/SLA.0000000000001691
   Angka L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081787
   Bain CR, 2023, ANAESTHESIA, V78, P356, DOI 10.1111/anae.15896
   Bari DS, 2020, J BIOL PHYS, V46, P177, DOI 10.1007/s10867-020-09547-4
   Bayoumy K, 2021, NAT REV CARDIOL, V18, P581, DOI 10.1038/s41569-021-00522-7
   Bazoukis G, 2023, J AM HEART ASSOC, V12, DOI 10.1161/JAHA.123.030539
   Buse S, 2017, RESUSCITATION, V118, P35, DOI 10.1016/j.resuscitation.2017.07.003
   Caravaca AS, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2023285119
   Carrara M, 2021, ANN INTENSIVE CARE, V11, DOI 10.1186/s13613-021-00869-7
   Cero C, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.139160
   Chang E, 2024, Med
   Chang WC, 2016, INT J GYNECOL CANCER, V26, P156, DOI 10.1097/IGC.0000000000000578
   Chen BK, 2023, J ORTHOP SURG RES, V18, DOI 10.1186/s13018-023-03516-y
   Chen C, 2025, BASIC CLIN PHARMACOL, V136, DOI [10.1111/bcpt.70032, 10.1111/bcpt.70032]
   Chen HY, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0257816
   Chen ML, 2022, J ANESTH, V36, P5, DOI 10.1007/s00540-021-02982-0
   Chen Q, 2016, ONCOTARGET, V7, P55990, DOI 10.18632/oncotarget.10809
   Chen XT, 2024, CLIN INTERV AGING, V19, P981, DOI 10.2147/CIA.S455987
   Cheng C, 2022, J NEUROINFLAMM, V19, DOI 10.1186/s12974-022-02656-y
   Cheng H, 2017, SURG INFECT, V18, P722, DOI 10.1089/sur.2017.089
   Claassen JAHR, 2021, PHYSIOL REV, V101, P1487, DOI 10.1152/physrev.00022.2020
   Dellacqua LO, 2024, J APPL PHYSIOL, V136, P189, DOI 10.1152/japplphysiol.00433.2023
   Deng M, 2024, ANESTHES PERIOP SCI, V2, DOI [10.1007/s44254-024-00078-y, 10.1007/s44254-024-00078-y]
   Devereaux PJ, 2008, LANCET, V371, P1839, DOI 10.1016/S0140-6736(08)60601-7
   Devereaux PJ, 2015, NEW ENGL J MED, V373, P2258, DOI 10.1056/NEJMra1502824
   Dick TE, 2014, PROG BRAIN RES, V209, P191, DOI 10.1016/B978-0-444-63274-6.00010-2
   Dingová D, 2025, AM J PHYSIOL-HEART C, V328, pH526, DOI 10.1152/ajpheart.00672.2024
   Dobrev D, 2019, NAT REV CARDIOL, V16, P417, DOI 10.1038/s41569-019-0166-5
   Duan HW, 2025, ADV SCI, V12, DOI 10.1002/advs.202411433
   Erdem S, 2021, INT OPHTHALMOL, V41, P2555, DOI 10.1007/s10792-021-01814-0
   Evered L, 2022, ANAESTHESIA, V77, P34, DOI 10.1111/anae.15613
   Faber CL, 2020, DIABETOLOGIA, V63, P2086, DOI 10.1007/s00125-020-05204-6
   Fonseca RC, 2019, BRAIN BEHAV IMMUN, V81, P444, DOI 10.1016/j.bbi.2019.06.041
   Frost S, 2024, J APPL PHYSIOL, V137, P364, DOI 10.1152/japplphysiol.00128.2024
   Fukuda K, 2015, CIRC RES, V116, P2005, DOI 10.1161/CIRCRESAHA.116.304679
   Gabanyi I, 2016, CELL, V164, P378, DOI 10.1016/j.cell.2015.12.023
   Gao W, 2021, SURGERY, V170, P1618, DOI 10.1016/j.surg.2021.08.007
   Germán-Salló Z, 2016, PROC TECH, V22, P645, DOI 10.1016/j.protcy.2016.01.134
   Gordan R, 2015, WORLD J CARDIOL, V7, P204, DOI 10.4330/wjc.v7.i4.204
   Grassi G, 2019, J HYPERTENS, V37, P1746, DOI 10.1097/HJH.0000000000002093
   Gu JT, 2011, CRIT CARE, V15, DOI 10.1186/cc10283
   Gullett N, 2023, INT J PSYCHOPHYSIOL, V192, P35, DOI 10.1016/j.ijpsycho.2023.08.001
   Gumbert SD, 2020, ANESTHESIOLOGY, V132, P180, DOI 10.1097/ALN.0000000000002968
   Guo QH, 2023, J CLIN HYPERTENS, V25, P227, DOI 10.1111/jch.14616
   Han TK, 2019, BRAIN RES, V1707, P154, DOI 10.1016/j.brainres.2018.11.035
   Han ZX, 2023, MED SCI MONITOR, V29, DOI 10.12659/MSM.941262
   Hayakawa Y, 2017, CANCER CELL, V31, P21, DOI 10.1016/j.ccell.2016.11.005
   He HL, 2024, WORLD J MENS HEALTH, V42, P1, DOI 10.5534/wjmh.220248
   Hiller JG, 2018, NAT REV CLIN ONCOL, V15, P205, DOI 10.1038/nrclinonc.2017.194
   Hu J, 2022, BMC ANESTHESIOL, V22, DOI 10.1186/s12871-022-01589-6
   Huang L, 2020, CELL MOL IMMUNOL, V17, P1092, DOI 10.1038/s41423-020-00522-6
   Huffman WJ, 2019, BRAIN STIMUL, V12, P19, DOI 10.1016/j.brs.2018.10.005
   Hunt T, 2025, BRIT J ANAESTH, V134, P1671, DOI 10.1016/j.bja.2025.02.031
   Johner N, 2024, EUR J CLIN INVEST, V54, DOI 10.1111/eci.14309
   Kao LC, 2016, PSYCHIAT INVEST, V13, P397
   Kay MW, 2022, PHYSIOLOGY, V37, P39, DOI 10.1152/physiol.00023.2021
   Khan AA, 2019, EUR J CLIN INVEST, V49, DOI 10.1111/eci.13174
   Kim EH, 2016, J CLIN ANESTH, V35, P332, DOI 10.1016/j.jclinane.2016.09.012
   Koenig J, 2016, CLIN J PAIN, V32, P218, DOI 10.1097/AJP.0000000000000242
   Kolmus K, 2015, BRAIN BEHAV IMMUN, V45, P297, DOI 10.1016/j.bbi.2014.10.007
   Kong YS, 2021, IEEE T BIO-MED ENG, V68, P3122, DOI 10.1109/TBME.2021.3065218
   Koziol-White C, 2020, AM J PHYSIOL-LUNG C, V318, pL345, DOI 10.1152/ajplung.00393.2019
   Kulkarni K, 2016, IEEE ENG MED BIO, P149, DOI 10.1109/EMBC.2016.7590662
   Kumari R, 2024, CELL REP, V43, DOI 10.1016/j.celrep.2024.113674
   Lee LY, 2014, COMPR PHYSIOL, V4, P287, DOI 10.1002/cphy.c130020
   Li S, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00431-1
   Li XC, 2023, ISCIENCE, V26, DOI 10.1016/j.isci.2023.108128
   Li XL, 2023, AM J HEALTH BEHAV, V47, P65, DOI 10.5993/AJHB.47.1.8
   Lindgren M, 2021, DIABETES RES CLIN PR, V176, DOI 10.1016/j.diabres.2021.108833
   Longbottom ER, 2016, ANN SURG, V264, P370, DOI 10.1097/SLA.0000000000001484
   Ma JB, 2020, ANESTH ANALG, V130, P1054, DOI 10.1213/ANE.0000000000003820
   Mahfoud F, 2024, CURR MED RES OPIN, V40, P25, DOI 10.1080/03007995.2024.2318003
   Margraf A, 2020, ANESTH ANALG, V131, P1693, DOI 10.1213/ANE.0000000000005175
   Martelli D, 2014, AUTON NEUROSCI-BASIC, V182, P65, DOI 10.1016/j.autneu.2013.12.007
   Nakamura Y, 2023, COMMUN BIOL, V6, DOI 10.1038/s42003-023-05051-2
   Nazari MA, 2023, LANCET DIABETES ENDO, V11, P942, DOI 10.1016/S2213-8587(23)00256-5
   Nilsson MB, 2020, J NEUROIMMUNE PHARM, V15, P27, DOI 10.1007/s11481-019-09891-w
   O'Neill E, 2020, BRIT J PHARMACOL, V177, P282, DOI 10.1111/bph.14862
   Oliver E, 2019, REV ESP CARDIOL, V72, P853, DOI 10.1016/j.rec.2019.04.006
   Ommen SR, 2024, CIRCULATION, V149, pe1239, DOI 10.1161/CIR.0000000000001250
   Patel ABU, 2022, BRIT J ANAESTH, V128, P135, DOI 10.1016/j.bja.2021.08.037
   Petersen MC, 2017, NAT REV ENDOCRINOL, V13, P572, DOI 10.1038/nrendo.2017.80
   Pinto ML, 2017, BIOMATERIALS, V124, P211, DOI 10.1016/j.biomaterials.2017.02.004
   Poveda-Jaramillo R, 2018, J CARDIOTHOR VASC AN, V32, P1415, DOI 10.1053/j.jvca.2017.11.039
   Prete A, 2018, CLIN ENDOCRINOL, V89, P554, DOI 10.1111/cen.13820
   Price LC, 2021, BRIT J ANAESTH, V126, P774, DOI 10.1016/j.bja.2021.01.005
   Qin ZJ, 2019, BMC ANESTHESIOL, V19, DOI 10.1186/s12871-019-0859-7
   Rahimzadeh P, 2014, HEPAT MON, V14, DOI 10.5812/hepatmon.19881
   Ribeiro IMR, 2018, AM J PHYSIOL-GASTR L, V315, pG538, DOI 10.1152/ajpgi.00290.2017
   Renz BW, 2018, CANCER DISCOV, V8, P1458, DOI 10.1158/2159-8290.CD-18-0046
   Salvador AF, 2021, NAT REV IMMUNOL, V21, P526, DOI 10.1038/s41577-021-00508-z
   Sander M, 2020, KOREAN J ANESTHESIOL, V73, P103, DOI 10.4097/kja.20022
   Scridon A, 2022, FRONT PHYSIOL, V13, DOI 10.3389/fphys.2022.1058427
   Sharma AE, 2025, CANCERS, V17, DOI 10.3390/cancers17081357
   Simegn GD, 2021, ANN MED SURG, V72, DOI 10.1016/j.amsu.2021.103059
   Singh A, 2023, CUREUS J MED SCIENCE, V15, DOI 10.7759/cureus.43894
   Stern T, 2015, JAMA-J AM MED ASSOC, V313, P2486, DOI 10.1001/jama.2015.3086
   Su X, 2016, LANCET, V388, P1893, DOI 10.1016/S0140-6736(16)30580-3
   Sun QZ, 2024, BIOMED PHARMACOTHER, V174, DOI 10.1016/j.biopha.2024.116462
   Tang L, 2024, EXP GERONTOL, V194, DOI 10.1016/j.exger.2024.112507
   Tatsumi S, 2025, PHYSIOL BEHAV, V288, DOI 10.1016/j.physbeh.2024.114721
   Travica N, 2022, NEUROBIOL LEARN MEM, V193, DOI 10.1016/j.nlm.2022.107656
   Turan A, 2020, LANCET, V396, P177, DOI 10.1016/S0140-6736(20)30631-0
   Udit S, 2022, NAT REV NEUROSCI, V23, P157, DOI 10.1038/s41583-021-00555-4
   van Herk L, 2024, NEUROBIOL STRESS, V31, DOI 10.1016/j.ynstr.2024.100659
   Wan RQ, 2014, J NEUROCHEM, V129, P573, DOI 10.1111/jnc.12656
   Wang D, 2024, BMC ANESTHESIOL, V24, DOI 10.1186/s12871-024-02453-5
   Wang HY, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.705153
   Wang K, 2019, BRIT J ANAESTH, V123, P777, DOI 10.1016/j.bja.2019.07.027
   Wang LZ, 2018, EXP THER MED, V16, P3869, DOI 10.3892/etm.2018.6665
   Wang Y, 2022, FRONT PHYSIOL, V13, DOI 10.3389/fphys.2022.799183
   Wang Z, 2017, EXP THER MED, V14, P5851, DOI 10.3892/etm.2017.5265
   Wang ZD, 2022, CELL SIGNAL, V91, DOI 10.1016/j.cellsig.2021.110227
   Wehrwein EA, 2016, COMPR PHYSIOL, V6, P1239, DOI 10.1002/cphy.c150037
   Werner LM, 2025, AM J EMERG MED, V88, P64, DOI 10.1016/j.ajem.2024.11.029
   Wessler I, 2008, BRIT J PHARMACOL, V154, P1558, DOI 10.1038/bjp.2008.185
   Willows JW, 2023, COMPR PHYSIOL, V13, P4985, DOI [10.1002/j.2040-4603.2023.tb00277.x, 10.1002/cphy.c220030]
   Worek F, 2016, TOXICOL LETT, V249, P22, DOI 10.1016/j.toxlet.2016.03.007
   Xue BH, 2019, REV ASSOC MED BRAS, V65, P1181, DOI 10.1590/1806-9282.65.9.1181
   Yan Y, 2021, CRIT CARE, V25, DOI 10.1186/s13054-021-03793-1
   Yang LQ, 2024, INT J SURG, V110, P5518, DOI 10.1097/JS9.0000000000001669
   Yang T, 2025, ACS SENSORS, V10, P100, DOI 10.1021/acssensors.4c03314
   Yu J, 2021, RESP PHYSIOL NEUROBI, V287, DOI 10.1016/j.resp.2020.103595
   Zahalka AH, 2017, SCIENCE, V358, P321, DOI 10.1126/science.aah5072
   Zhai Q, 2023, BRIT J ANAESTH, V131, P542, DOI 10.1016/j.bja.2023.04.044
   Zhang DF, 2019, ANN SURG, V270, P356, DOI 10.1097/SLA.0000000000002801
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhou Q, 2018, NATURE, V557, P351, DOI 10.1038/s41586-018-0088-0
   Zhu LL, 2023, IEEE J BIOMED HEALTH, V27, P2155, DOI 10.1109/JBHI.2023.3239305
NR 132
TC 1
Z9 2
U1 4
U2 4
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0007-0912
EI 1471-6771
J9 BRIT J ANAESTH
JI Br. J. Anaesth.
PD SEP
PY 2025
VL 135
IS 3
BP 608
EP 622
DI 10.1016/j.bja.2025.06.004
EA AUG 2025
PG 15
WC Anesthesiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Anesthesiology
GA 8MG5N
UT WOS:001592033200007
PM 40615330
OA Green Submitted, hybrid
DA 2026-01-16
ER

PT J
AU Satiamurthy, R
   Shah, NM
   Ab Muin, NF
   Azmi, N
   Ismail, CAN
   Yaakob, NS
AF Satiamurthy, Raajeswari
   Shah, Noraida Mohamed
   Ab Muin, Nur Fa'izah
   Azmi, Norazrina
   Ismail, Che Aishah Nazariah
   Yaakob, Nor Syafinaz
TI Exploring Cancer Patients' Perspectives on Chemotherapy-Induced
   Peripheral Neuropathy Experiences and Its Management: A Qualitative
   Study
SO JOURNAL OF CANCER EDUCATION
LA English
DT Article; Early Access
DE CIPN management; Quality of life; Patient-centred education; Pain
ID COST-EFFECTIVENESS; ACUPUNCTURE; TRIAL
AB Chemotherapy-induced peripheral neuropathy (CIPN) is often an overlooked side effect, affecting cancer patients' quality of life. Improving this requires an in-depth understanding of how patients perceived their CIPN experience, which this study had explored. This study also sought to identify potential barriers to current CIPN management among Malaysian cancer patients. Semi-structured one-to-one interviews were conducted among cancer patients who had a confirmed diagnosis of CIPN from one hospital and a local cancer organization. Interviews were conducted until theme saturation was achieved (N = 22). Interviews were audio-recorded, transcribed verbatim, and analysed using thematic analysis. Three main themes emerged: manageable CIPN experiences impacting activities of daily living despite limited awareness, current conventional treatments of CIPN were partially effective with side effects, and explorative of alternative treatment options for CIPN. The study results indicated that patients experienced CIPN, which was considerably mild and impacted their life activities to a small extent. The limited information provided about CIPN contributed to a sense of uncertainty among patients. They emphasized the importance of more accessible information and education about CIPN and its management. Although the conventional management of CIPN was able to partly control symptoms, patients experienced side effects from the prescribed medications. Interestingly, patients expressed openness to explore new treatments to help them cope better with CIPN. These findings highlighted the need for a comprehensive, patient-centred approach to CIPN management. Insights from patient experiences could guide the development of educational interventions, such as patient's assessment form on CIPN experiences and awareness activities to enhance CIPN care.
C1 [Satiamurthy, Raajeswari; Azmi, Norazrina; Yaakob, Nor Syafinaz] Univ Kebangsaan Malaysia, Fac Pharm, Ctr Drug & Herbal Dev, Kuala Lumpur 50300, Malaysia.
   [Shah, Noraida Mohamed] Univ Kebangsaan Malaysia, Fac Pharm, Ctr Qual Management Med, Kuala Lumpur, Malaysia.
   [Ab Muin, Nur Fa'izah] Univ Kebangsaan Malaysia, Fac Med, Dept Radiotherapy & Oncol, Kuala Lumpur 56000, Malaysia.
   [Ismail, Che Aishah Nazariah] Univ Sains Malaysia, Sch Med Sci, Dept Physiol, Hlth Campus, Kubang Kerian 16150, Kelantan, Malaysia.
C3 Universiti Kebangsaan Malaysia; Universiti Kebangsaan Malaysia;
   Universiti Kebangsaan Malaysia; Universiti Sains Malaysia
RP Yaakob, NS (corresponding author), Univ Kebangsaan Malaysia, Fac Pharm, Ctr Drug & Herbal Dev, Kuala Lumpur 50300, Malaysia.
EM nsy@ukm.edu.my
RI Yaakob, Nor/V-8192-2019; Azmi, Norazrina/AAW-1073-2021; ISMAIL,
   CHE/S-4910-2018
FU Fundamental Research Grant Scheme (FRGS); National Cancer Society of
   Malaysia (NCSM)
FX The authors would like to acknowledge the support of Dr. Murallitharan
   Munisamy from the National Cancer Society of Malaysia (NCSM).
CR Bakitas MA, 2007, NURS RES, V56, P323, DOI 10.1097/01.NNR.0000289503.22414.79
   Banach M, 2017, BRAIN BEHAV, V7, DOI 10.1002/brb3.558
   Bao T, 2021, ONCOLOGIST, V26, pE2070, DOI 10.1002/onco.13933
   Burnight T., 2011, J Pain, V12, P84, DOI [10.1016/j.jpain.2011.02.343, DOI 10.1016/J.JPAIN.2011.02.343]
   Cavaletti G, 2011, CURR TREAT OPTION NE, V13, P180, DOI 10.1007/s11940-010-0108-3
   Cioroiu C, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0757-7
   Jeong Ju Hyeon, 2013, Korean J Women Health Nurs, V19, P201, DOI 10.4069/kjwhn.2013.19.4.201
   Kautio AL, 2009, ANTICANCER RES, V29, P2601
   Khatab NIO, 2017, Cancer incidence and chemotherapy-induced adverse effects in Asia, V16
   Kim EY, 2023, SEMIN ONCOL NURS, V39, DOI 10.1016/j.soncn.2023.151499
   Kim JH, 2013, ASIAN ONCOL NURS, V13, P145, DOI 10.5388/aon.2013.13.3.145
   Loprinzi CL, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01399
   Ma JC, 2018, CANCER-AM CANCER SOC, V124, P2289, DOI 10.1002/cncr.31248
   Ministry of Health Malaysia, 2021, National Strategic Plan for Cancer Control Programme 2021-2025
   Ministry of Health Malaysia National Cancer Registry, 2023, Summary of Malaysia national cancer registry report 2017-2021
   Molassiotis A, 2021, ACUPUNCT MED, V39, P41, DOI 10.1177/0964528420920285
   Njobvu P, 1999, RHEUMATOLOGY, V38, P1184, DOI 10.1093/rheumatology/38.12.1184
   Prager K, 2023, SUPPORT CARE CANCER, V31, DOI 10.1007/s00520-023-07688-5
   Rao RD, 2007, CANCER-AM CANCER SOC, V110, P2110, DOI 10.1002/cncr.23008
   Reinhold T, 2013, ANN ALLERG ASTHMA IM, V111, P56, DOI 10.1016/j.anai.2013.04.008
   Salat K, 2017, NEUROPHARMACOLOGY, V125, P181, DOI 10.1016/j.neuropharm.2017.07.022
   Satiamurthy R, 2023, CURR MOL MED, V23, P341, DOI 10.2174/1566524022666220512122525
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Tanay MA, 2019, EUR J CANCER CARE, V28, DOI 10.1111/ecc.13011
   Tanay MAL, 2022, EUR J CANCER CARE, V31, DOI 10.1111/ecc.13517
NR 25
TC 1
Z9 1
U1 3
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0885-8195
EI 1543-0154
J9 J CANCER EDUC
JI J. Cancer Educ.
PD 2025 APR 11
PY 2025
DI 10.1007/s13187-025-02624-z
EA APR 2025
PG 9
WC Oncology; Education, Scientific Disciplines; Public, Environmental &
   Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Education & Educational Research; Public, Environmental &
   Occupational Health
GA 1GO2U
UT WOS:001464512000001
PM 40214713
DA 2026-01-16
ER

PT J
AU Ferreira, AS
   Lopes, AJ
AF Ferreira, Arthur Sa
   Lopes, Agnaldo Jose
TI Chinese Medicine Pattern Differentiation and Its Implications for
   Clinical Practice
SO CHINESE JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Editorial Material
DE Chinese medicine-syndrome differentiation; Chinese medicine; preventive
   medicine; rehabilitation "health care delivery"
ID CORONARY-HEART-DISEASE; ACUPUNCTURE TREATMENT; BLOOD-STASIS; DIAGNOSIS;
   MANIFESTATIONS; CYSTITIS; WOMEN
AB Chinese medicine practitioners apply the differentiation reasoning for decision-making. The wide scope of Chinese medicine intervention provides coverage of methods and techniques with applications to primary, secondary and tertiary levels of prevention. The rapid evolution of mathematical and computational techniques allowed the implementation of several models for pattern differentiation that were tested for several physiologic systems. Concurrently, it is argued that pattern differentiation might improve the efficacy of either traditional or conventional medical interventions. This article reviewed the influence of pattern differentiation into clinical practice organized by medical field: general pattern differentiation; genitourinary (recurrent cystitis); cardiovascular (coronary heart disease; arterial hypertension; angina pectoris); neurology (stroke); surgery; metabolic (diabetes mellitus); hepatic (cirrhosis); gastrointestinal (chronic superficial gastritis); orthopedic (low back pain; rheumatoid arthritis; cervical spondylosis; elbow arthritis); oncology (gastric mucosal dysplasia; lung cancer); gynecologic and obstetric manifestations (nausea and vomiting). The reviewed studies presented achievements that have contributed to the integration of Chinese medicine and evidence-based medicine in the treatment of many mild and severe diseases. Target diseases considered as major public health problems were also investigated and the results are promising regarding the possibility to treat guided by pattern differentiation.
C1 [Ferreira, Arthur Sa] Augusto Motta Univ, Lab Computat Modeling & Simulat Rehabil, Program Rehabil Sci, Rio De Janeiro, Brazil.
   [Lopes, Agnaldo Jose] Augusto Motta Univ, Lab Cardiopulmonar Anal, Rehabil Sci Postgrad Program, Rio De Janeiro, Brazil.
   [Lopes, Agnaldo Jose] Univ Estado Rio De Janeiro, Physiol Resp Lab, Rio De Janeiro, Brazil.
C3 Centro Universitario Augusto Motta (UNISUAM); Centro Universitario
   Augusto Motta (UNISUAM); Universidade do Estado do Rio de Janeiro
RP Ferreira, AS (corresponding author), Augusto Motta Univ, Lab Computat Modeling & Simulat Rehabil, Program Rehabil Sci, Rio De Janeiro, Brazil.
EM arthur_sf@ig.com.br
RI de Sá Ferreira, Arthur/F-6831-2012; Lopes, Agnaldo José/B-6430-2016
OI de Sá Ferreira, Arthur/0000-0001-7014-2002; Lopes, Agnaldo
   José/0000-0001-8598-4878
CR Alraek T, 2003, J ALTERN COMPLEM MED, V9, P651, DOI 10.1089/107555303322524508
   Alraek T, 2002, AM J PUBLIC HEALTH, V92, P1609, DOI 10.2105/AJPH.92.10.1609
   Alræk T, 2000, COMPLEMENT THER MED, V8, P260, DOI 10.1054/ctim.2000.0399
   [Anonymous], EVID BASED COMPLEMEN
   [Anonymous], 2003, CLIN ACUPUNCT ORIENT
   [Anonymous], J CHIN INTEGR MED CH
   [Anonymous], J CHIN INTEGR MED CH
   [Anonymous], TREATISE SPLEEN STOM
   [Anonymous], J CHIN INTEGR MED CH
   [Anonymous], J CHIN INTEGR MED CH
   [Anonymous], P 2005 C JAP SOC MED
   [Anonymous], MASTER HUAS CLASSIC
   [Anonymous], CLASSIC DIFFICULTIES
   [Anonymous], SYNOPSIS PRESCRIPTIO
   Bossuyt PM, 2003, ANN INTERN MED, V138, P40, DOI 10.7326/0003-4819-138-1-200301070-00010
   Chen YL, 2009, CHIN J INTEGR MED, V15, P341, DOI 10.1007/s11655-009-0341-3
   Chu FY, 2010, CHIN J INTEGR MED, V16, P399, DOI 10.1007/s11655-010-9999-9
   Chuang-Chien Chiu, 2002, Journal of Medical and Biological Engineering, V22, P219
   Feng Y, 2011, CHIN J INTEGR MED, V17, P333, DOI 10.1007/s11655-011-0615-4
   Ferreira AS, 2011, CHIN MED-UK, V6, DOI 10.1186/1749-8546-6-1
   Ferreira Arthur Sa, 2009, Chin Med, V4, P24, DOI 10.1186/1749-8546-4-24
   Flachskampf FA, 2007, CIRCULATION, V115, P3121, DOI 10.1161/CIRCULATIONAHA.106.661140
   Froom P, 2000, PREV MED, V31, P153, DOI 10.1006/pmed.2000.0689
   Fu WB, 2009, CHIN J INTEGR MED, V15, P426, DOI 10.1007/s11655-009-0426-z
   Fu XQ, 2011, CHIN J INTEGR MED, V17, P351, DOI 10.1007/s11655-011-0725-z
   Gu Wan-Li, 2010, Zhong Xi Yi Jie He Xue Bao, V8, P842
   Gu Wan-li, 2007, Zhong Xi Yi Jie He Xue Bao, V5, P255
   Liu GP, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-37
   Lu AP, 2009, CHIN J INTEGR MED, V15, P152, DOI 10.1007/s11655-009-0152-6
   Lu C, 2009, J ALTERN COMPLEM MED, V15, P1021, DOI 10.1089/acm.2009.0065
   Lu Y.-h., 2007, Chin. J. Clin. Pharmacol. Ther, V12, P1144
   Luiz AB, 2011, CHIN MED-UK, V6, DOI 10.1186/1749-8546-6-23
   Lukman S, 2007, COMPUT METH PROG BIO, V88, P283, DOI 10.1016/j.cmpb.2007.09.008
   Maciocia G., 1989, The foundations of Chinese medicine: A comprehensive text for acupuncturists and herbalists
   Macklin EA, 2006, HYPERTENSION, V48, P838, DOI 10.1161/01.HYP.0000241090.28070.4c
   MacPherson H, 2004, COMPLEMENT THER MED, V12, P38, DOI 10.1016/S0965-2299(03)00125-0
   Min ZH, 2010, CHIN J INTEGR MED, V16, P264, DOI 10.1007/s11655-010-0264-z
   Ryu H, 2010, J ALTERN COMPLEM MED, V16, P663, DOI 10.1089/acm.2009.0331
   Sallstrom S., 1996, COMPL THER MED, V4, P193
   Shen SW, 2011, CHIN J INTEGR MED, V17, P346, DOI 10.1007/s11655-011-0616-3
   Smith C, 2002, BIRTH-ISS PERINAT C, V29, P1, DOI 10.1046/j.1523-536X.2002.00149.x
   Su W, 2011, CHIN J INTEGR MED, V17, P272, DOI 10.1007/s11655-011-0702-6
   van Wietmarschen H, 2009, JCR-J CLIN RHEUMATOL, V15, P330, DOI 10.1097/RHU.0b013e3181ba3926
   Wang Y, 2009, COMPUT METH PROG BIO, V95, P249, DOI 10.1016/j.cmpb.2009.03.004
   Wang YL, 2009, CHIN J INTEGR MED, V15, P337, DOI 10.1007/s11655-009-0337-z
   Xu H, 2011, CHIN J INTEGR MED, V17, P163, DOI 10.1007/s11655-011-0661-y
   Yang Shouzhong., 2004, Systematic Classic of Acupuncture and Moxibustion
   Yao KW, 2011, CHIN J INTEGR MED, V17, P200, DOI 10.1007/s11655-011-0667-5
   Zhang XP, 2011, CHIN J INTEGR MED, V17, P307, DOI 10.1007/s11655-011-0699-x
NR 49
TC 66
Z9 74
U1 4
U2 59
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1672-0415
EI 1993-0402
J9 CHIN J INTEGR MED
JI Chin. J. Integr. Med.
PD NOV
PY 2011
VL 17
IS 11
BP 818
EP 823
DI 10.1007/s11655-011-0892-y
PG 6
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA 842QL
UT WOS:000296614000003
PM 22057410
DA 2026-01-16
ER

PT J
AU Narayanan, S
   Reddy, A
   Lopez, G
   Liu, WL
   Ali, S
   Bruera, E
   Cohen, L
   Yennurajalingam, S
AF Narayanan, Santhosshi
   Reddy, Akhila
   Lopez, Gabriel
   Liu, Wenli
   Ali, Sara
   Bruera, Eduardo
   Cohen, Lorenzo
   Yennurajalingam, Sriram
TI Sleep disturbance in cancer patients referred to an ambulatory
   integrative oncology consultation
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Insomnia; Integrative oncology; Complementary medicine; Sleep
   disturbance; Patient-reported outcomes
ID INSOMNIA; PREVALENCE; HEALTH; COMPLEMENTARY; MEDICINE; FATIGUE; QUALITY;
   ADULTS; ASSOCIATIONS; RELAXATION
AB Background Sleep disturbance (SD) is highly prevalent in oncology and negatively affects quality of life and mortality. Evidence supports the use of integrative oncology (IO) practices to treat SD, but there is limited published data on the characteristics of SD and factors associated with SD in IO. We determined the prevalence, severity, and factors associated with SD among cancer patients seen in an ambulatory IO consultation.
   Methods Patients with cancer referred for initial outpatient IO consultation in 2017 were eligible. Patient demographics, clinical characteristics, and patient-reported outcomes (Edmonton Symptom Assessment Scale (ESAS), Measure Yourself Concerns and Wellbeing (MYCaW), PROMIS-10) were retrospectively reviewed.
   Results One thousand five hundred twenty patients were included in the analysis. The majority (70%) were women with breast cancer (42%). Nine hundred seventy-one (64%) patients reported significant SD with ESAS Sleep >= 4, yet only 11% expressed poor sleep as their primary or secondary concern for the IO consultation. The median SD (IQR) was 5 (3,7). ESAS scores for fatigue (adjusted OR 1.16; CI 1.07-1.26, p < 0.001), pain (adjusted OR 1.07; CI 1.00-1.15, p < 0.05), hot flashes (adjusted OR 1.14; CI 1.07-1.22, p < 0.001), well-being (adjusted OR 1.33; CI 1.22-1.46, p < 0.001), and psychological distress score (anxiety and depression) (adjusted OR 1.16; CI 1.01-1.11, p < 0.01) were independently associated with SD in multivariate analysis. Acupuncture was the most frequent intervention prescribed, 175 (35%). Other modalities included oncology massage (15%), health psychology (5%), and meditation (1%).
   Conclusions Although 64% of patients seeking IO consultation reported clinically significant SD, only 11% were seeking integrative approaches for managing SD. ESAS fatigue, hot flashes, well-being, and psychological symptoms were significantly associated with SD.
C1 [Narayanan, Santhosshi; Reddy, Akhila; Lopez, Gabriel; Liu, Wenli; Ali, Sara; Bruera, Eduardo; Cohen, Lorenzo; Yennurajalingam, Sriram] Univ Texas MD Anderson Canc, Dept Palliat Rehabil & Integrat Med, Unit 1414,1515 Holcombe Blvd, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center
RP Narayanan, S (corresponding author), Univ Texas MD Anderson Canc, Dept Palliat Rehabil & Integrat Med, Unit 1414,1515 Holcombe Blvd, Houston, TX 77030 USA.
EM snarayanan2@mdanderson.org
RI Bruera, Eduardo/AAA-1550-2022; liu, wenli/JRW-0517-2023
CR Alfano CM, 2011, BREAST CANCER RES TR, V130, P243, DOI 10.1007/s10549-011-1530-2
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596
   [Anonymous], 2005, AM ACAD SLEEP MED, V2nd, DOI [DOI 10.1007/978-1-4939-6578-6_27, 10.1007/978-1-4939-6578-6_27]
   Blanaru M, 2012, MENT ILLN, V4, P59, DOI 10.4081/mi.2012.e13
   Brauer JA, 2010, J ALTERN COMPLEM MED, V16, P183, DOI 10.1089/acm.2009.0354
   Bruera E, 1991, J Palliat Care, V7, P6
   Cheng KKF, 2013, EUR J CANCER CARE, V22, P70, DOI 10.1111/j.1365-2354.2012.01372.x
   Choi TY, 2017, INTEGR CANCER THER, V16, P135, DOI 10.1177/1534735416664172
   Fiorentino Lavinia, 2011, Drug Discov Today Dis Models, V8, P167
   Garland SN, 2018, SLEEP HEALTH, V4, P160, DOI 10.1016/j.sleh.2018.01.003
   Garland SN, 2014, J CLIN ONCOL, V32, P449, DOI 10.1200/JCO.2012.47.7265
   Hays RD, 2009, QUAL LIFE RES, V18, P873, DOI 10.1007/s11136-009-9496-9
   Hui D, 2015, CANCER-AM CANCER SOC, V121, P3027, DOI 10.1002/cncr.29437
   Hoang HTX, 2020, SLEEP BREATH, V24, P241, DOI 10.1007/s11325-019-01839-x
   Irwin MR, 2016, BIOL PSYCHIAT, V80, P40, DOI 10.1016/j.biopsych.2015.05.014
   Irwin MR, 2015, ANNU REV PSYCHOL, V66, P143, DOI 10.1146/annurev-psych-010213-115205
   Jeon MS, 2021, NEURO-ONCOL PRACT, V8, P48, DOI 10.1093/nop/npaa057
   Kashani Fahimeh, 2014, Iran J Nurs Midwifery Res, V19, P113
   Liou KT, 2019, PAIN MED, V20, P2060, DOI 10.1093/pm/pnz087
   Lopez G, 2017, J CANCER, V8, P395, DOI 10.7150/jca.17506
   Mercier J, 2018, SLEEP, V41, DOI 10.1093/sleep/zsy149
   Mustian Karen M, 2013, Eur Med J Oncol, V1, P106
   Navo MA, 2004, J CLIN ONCOL, V22, P671, DOI 10.1200/JCO.2004.04.162
   Palesh OG, 2010, J CLIN ONCOL, V28, P292, DOI 10.1200/JCO.2009.22.5011
   Parvaneh K, 2014, ASIA PAC J CLIN NUTR, V23, P84, DOI 10.6133/apjcn.2014.23.1.02
   Paterson C, 2007, COMPLEMENT THER MED, V15, P38, DOI 10.1016/j.ctim.2006.03.006
   Qaseem A, 2016, ANN INTERN MED, V165, P125, DOI 10.7326/M15-2175
   Richardson MA, 2000, J CLIN ONCOL, V18, P2505, DOI 10.1200/JCO.2000.18.13.2505
   Rios P, 2019, SYST REV-LONDON, V8, DOI 10.1186/s13643-019-1163-9
   Rosen IM, 2019, J CLIN SLEEP MED, V15, P1671, DOI 10.5664/jcsm.8062
   Rusch HL, 2019, ANN NY ACAD SCI, V1445, P5, DOI 10.1111/nyas.13996
   Sahin ZA, 2015, COMPLEMENT THER CLIN, V21, P277, DOI 10.1016/j.ctcp.2015.10.002
   Savard J, 2001, SLEEP, V24, P583, DOI 10.1093/sleep/24.5.583
   Shinjyo N, 2020, J EVID-BASED INTEGR, V25, DOI 10.1177/2515690X20967323
   Siu PM, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.37199
   Tucker JA, 2021, INT J BEHAV MED, V28, P140, DOI 10.1007/s12529-020-09950-0
   WEYERER S, 1991, SLEEP, V14, P392
   White CM, 2020, ANN PHARMACOTHER, V54, P815, DOI 10.1177/1060028019900504
   Witt Claudia M., 2017, Journal of the National Cancer Institute Monographs, P3, DOI [10.1093/jncimonographs/lgx012, 10.1093/jncimonographs/lgx012]
   Yennurajalingam S, 2021, BMJ SUPPORT PALLIAT, V11, P170, DOI 10.1136/bmjspcare-2019-001877
   Yennurajalingam S, 2017, BMJ SUPPORT PALLIAT, V7, P274, DOI 10.1136/bmjspcare-2015-000847
   Yennurajalingam S, 2016, J PALLIAT MED, V19, P849, DOI 10.1089/jpm.2015.0276
NR 42
TC 7
Z9 9
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD MAR
PY 2022
VL 30
IS 3
BP 2417
EP 2425
DI 10.1007/s00520-021-06668-x
EA NOV 2021
PG 9
WC Oncology; Health Care Sciences & Services; Rehabilitation
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA YQ4FB
UT WOS:000717397300001
PM 34762218
DA 2026-01-16
ER

PT J
AU Xu, RB
   Yu, CH
   Zhang, XY
   Zhang, YP
   Li, MF
   Jia, B
   Yan, SY
   Jiang, M
AF Xu, Runbing
   Yu, Changhe
   Zhang, Xinyu
   Zhang, Yipin
   Li, Mengfei
   Jia, Bei
   Yan, Shiyan
   Jiang, Miao
TI Open REVIEW The Efficacy of Neuromodulation Interventions for
   Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review and Meta
SO JOURNAL OF PAIN RESEARCH
LA English
DT Review
DE chemotherapy; peripheral neuropathy; neuromodulation; systematic review;
   meta -analysis
ID QUALITY-OF-LIFE; CLINICAL IMPORTANCE; PAIN; CANCER; THERAPY;
   QUESTIONNAIRE; ACUPUNCTURE; OXALIPLATIN; INTENSITY; ATTENTION
AB Purpose: To determine the efficacy and safety of a neuromodulation intervention regimen in the treatment of chemotherapy-induced peripheral neuropathy (CIPN).
   Patients and Methods: Systematic searches were conducted in seven English databases. Randomized controlled trials of all neuromodulation interventions (both invasive and non-invasive) for the treatment of CIPN were selected. Group comparisons of differences between interventions and controls were also made. We divided the outcomes into immediate-term effect (<= 3 weeks), short-term effect (3 weeks to <= 3 months), and long-term effect (>3 months).
   Results: Sixteen studies and 946 patients with CIPN were included. Among immediate-term effects, neuromodulation interventions were superior to usual care for improving pain (SMD=-0.77, 95% CI -1.07 similar to 0.47), FACT-Ntx (MD = 5.35, 95% CI 2.84 similar to 7.87), and QOL (SMD = 0.44, 95% CI 0.09 similar to 0.79) (moderate certainty); neuromodulation loaded with usual care was superior to usual care for improving pain (SMD=-0.47, 95% CI -0.71 similar to -0.23), and QOL (SMD = 0.40, 95% CI 0.12 similar to 0.69) (moderate certainty). There were no statistically significant differences between the neuromodulation interventions regimen vs usual care in short- and long-term outcomes and neuromodulation vs sham stimulation from any outcome measure. There were mild adverse events such as pain at the site of stimulation and bruising, and no serious adverse events were reported.
   Conclusion: Neuromodulation interventions had significant immediate-term efficacy in CIPN but had not been shown to be superior to sham stimulation; short-term and long-term efficacy could not be determined because there were too few original RCTs. Moreover, there are no serious adverse effects of this therapy.
C1 [Xu, Runbing; Zhang, Xinyu; Zhang, Yipin; Li, Mengfei; Jia, Bei; Jiang, Miao] Beijing Univ Chinese Med, Affiliated Dongzhimen Hosp, Hematol & Oncol Dept, Beijing, Peoples R China.
   [Yu, Changhe] Beijing Univ Chinese Med, Affiliated Dongzhimen Hosp, Tuina & Pain Management Dept, Beijing, Peoples R China.
   [Yan, Shiyan] Beijing Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, Gongchen St, Beijing, Peoples R China.
   [Jiang, Miao] Beijing Univ Chinese Med, Sch Life Sci, Gongchen St, Beijing, Peoples R China.
C3 Beijing University of Chinese Medicine; Beijing University of Chinese
   Medicine; Beijing University of Chinese Medicine; Beijing University of
   Chinese Medicine
RP Yan, SY (corresponding author), Beijing Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, Gongchen St, Beijing, Peoples R China.; Jiang, M (corresponding author), Beijing Univ Chinese Med, Sch Life Sci, Gongchen St, Beijing, Peoples R China.
EM yanshiyan0927@sina.com; doctorjiang@139.com
RI Yan, Shiyan/J-7224-2013
FU National Natural Science Foundation of China [81973667, 81803956];
   Beijing University of Chinese Medicine Special Funding for Basic
   Research Operating Costs of Central Universities [2022-JYB-JBZR-022]
FX Acknowledgment This review was supported by grants from the National
   Natural Science Foundation of China (No. 81973667 and 81803956) and
   Beijing University of Chinese Medicine Special Funding for Basic
   Research Operating Costs of Central Universities (2022-JYB-JBZR-022) .
CR Aghabozorgi R, 2023, ANTI-CANCER DRUG, V34, P680, DOI 10.1097/CAD.0000000000001429
   Al Onazi MM, 2021, J PAIN SYMPTOM MANAG, V61, P1127, DOI 10.1016/j.jpainsymman.2020.10.028
   Albin B, 2024, ISCIENCE, V27, DOI 10.1016/j.isci.2024.109052
   [Anonymous], 2018, International neuromodulation society neuromodulation, or neuromodulatory effect
   [Anonymous], 2011, Cochrane Handbook for Systematic Reviews of Interventions, V5.1
   Argyriou AA, 2019, J NEUROL NEUROSUR PS, V90, P1361, DOI 10.1136/jnnp-2019-320969
   Ashina M, 2021, LANCET, V397, P1505, DOI 10.1016/S0140-6736(20)32342-4
   Atlas LY, 2023, ANNU REV NEUROSCI, V46, P167, DOI 10.1146/annurev-neuro-101822-122427
   Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015
   Bao T, 2021, ONCOLOGIST, V26, pE2070, DOI 10.1002/onco.13933
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Burgess J, 2021, ONCOL THER, V9, P385, DOI 10.1007/s40487-021-00168-y
   Calhoun EA, 2003, INT J GYNECOL CANCER, V13, P741, DOI 10.1111/j.1525-1438.2003.13603.x
   Caro XJ, 2011, APPL PSYCHOPHYS BIOF, V36, P193, DOI 10.1007/s10484-011-9159-9
   Caylor Jacob, 2019, Bioelectron Med, V5, DOI [10.1186/s42234-019-0023-1, 10.1186/s42234-019-0023-1]
   Chen Y, 2023, FRONT NEUROL, V14, DOI 10.3389/fneur.2023.1093849
   Cheng HL, 2020, HEALTH QUAL LIFE OUT, V18, DOI 10.1186/s12955-020-01493-y
   Chien TJ, 2019, INTEGR CANCER THER, V18, DOI 10.1177/1534735419886662
   Chow R, 2023, BMJ SUPPORT PALLIAT, V13, P27, DOI 10.1136/spcare-2022-003815
   Colloca L, 2019, ANNU REV PHARMACOL, V59, P191, DOI 10.1146/annurev-pharmtox-010818-021542
   D'Alessandro EG, 2022, BMJ SUPPORT PALLIAT, V12, P64, DOI 10.1136/bmjspcare-2018-001542
   D'Souza RS, 2023, CURR PAIN HEADACHE R, V27, P99, DOI 10.1007/s11916-023-01107-4
   D'Souza RS, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10081909
   de Arenas-Arroyo SD, 2023, SCAND J MED SCI SPOR, V33, P1040, DOI 10.1111/sms.14360
   Desforges AD, 2022, BIOMED PHARMACOTHER, V147, DOI 10.1016/j.biopha.2022.112671
   Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005
   Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9
   Feng R, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0382-1
   Flatters SJL, 2017, BRIT J ANAESTH, V119, P737, DOI 10.1093/bja/aex229
   Han XY, 2017, BMC CANCER, V17, DOI 10.1186/s12885-016-3037-z
   Havrilesky LJ, 2015, CRIT REV ONCOL HEMAT, V93, P203, DOI 10.1016/j.critrevonc.2014.10.006
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hesam-Shariati N, 2022, EUR J NEUROL, V29, P921, DOI 10.1111/ene.15189
   Hohenschurz-Schmidt D, 2023, PAIN, V164, P469, DOI 10.1097/j.pain.0000000000002723
   Hsieh YL, 2016, SUPPORT CARE CANCER, V24, P233, DOI 10.1007/s00520-015-2773-y
   Huang CC, 2021, J CLIN MED, V10, DOI 10.3390/jcm10163694
   Huang JF, 2021, GLOB SPINE J, V11, P1248, DOI 10.1177/2192568220962440
   Hwang MS, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000019837
   Iravani S, 2020, PAIN RES MANAG, V2020, DOI 10.1155/2020/2504674
   Jepma M, 2018, NAT HUM BEHAV, V2, P838, DOI 10.1038/s41562-018-0455-8
   Jin MY, 2023, BIOMEDICINES, V11, DOI 10.3390/biomedicines11041145
   Jordan B, 2020, ANN ONCOL, V31, P1306, DOI 10.1016/j.annonc.2020.07.003
   Kim M, 2021, KOREAN J PAIN, V34, P427, DOI 10.3344/kjp.2021.34.4.427
   Knotkova H, 2021, LANCET, V397, P2111, DOI 10.1016/S0140-6736(21)00794-7
   Kroigård T, 2014, EUR J NEUROL, V21, P623, DOI 10.1111/ene.12353
   Li XT, 2023, INTEGR CANCER THER, V22, DOI 10.1177/15347354221149992
   Lindblad K, 2016, SUPPORT CARE CANCER, V24, P2523, DOI 10.1007/s00520-015-3060-7
   Loprinzi CL, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01399
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Luckett T, 2011, ANN ONCOL, V22, P2179, DOI 10.1093/annonc/mdq721
   Magee DJ, 2021, CURR OPIN SUPPORT PA, V15, P77, DOI 10.1097/SPC.0000000000000549
   McCrary JM, 2017, SUPPORT CARE CANCER, V25, P3485, DOI 10.1007/s00520-017-3772-y
   Miltenburg NC, 2014, CANCER TREAT REV, V40, P872, DOI 10.1016/j.ctrv.2014.04.004
   Min YG, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-89667-6
   Molassiotis A, 2019, INTEGR CANCER THER, V18, DOI 10.1177/1534735419836501
   Musoro JZ, 2020, COLORECTAL DIS, V22, P2278, DOI 10.1111/codi.15295
   Omran M, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.693133
   Page MJ, 2021, BMJ-BRIT MED J, V372, DOI [10.1136/bmj.n160, 10.1136/bmj.n71, 10.1038/nchembio.2180, 10.1186/s40900-023-00424-7, 10.3390/jpm13020373]
   Pei LX, 2023, ACUPUNCT MED, V41, P73, DOI 10.1177/09645284221076512
   Postma TJ, 2005, EUR J CANCER, V41, P1135, DOI 10.1016/j.ejca.2005.02.012
   Prady SL, 2015, COMPLEMENT THER MED, V23, P185, DOI 10.1016/j.ctim.2015.01.007
   Prinsloo S, 2017, CANCER-AM CANCER SOC, V123, P1989, DOI 10.1002/cncr.30649
   Rick O, 2017, BIOELECTROMAGNETICS, V38, P85, DOI 10.1002/bem.22005
   Robijns J, 2017, LASER MED SCI, V32, P229, DOI 10.1007/s10103-016-2056-y
   Rossettini G, 2023, J CLIN MED, V12, DOI 10.3390/jcm12124113
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/349653
   Sharpe L, 2012, PAIN, V153, P722, DOI 10.1016/j.pain.2011.12.014
   Smith TJ, 2020, J PALLIAT CARE, V35, P53, DOI 10.1177/0825859719827589
   Song SY, 2020, INTEGR CANCER THER, V19, DOI 10.1177/1534735420925519
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Stringer J, 2022, EUR J ONCOL NURS, V60, DOI 10.1016/j.ejon.2022.102171
   Tella BA, 2022, NEUROMODULATION, V25, P1403, DOI 10.1111/ner.13522
   Teng C, 2023, SUPPORT CARE CANCER, V31, DOI 10.1007/s00520-022-07463-y
   Thompson T, 2021, FRONT NEUROSCI-SWITZ, V15, DOI 10.3389/fnins.2021.746328
   Tonezzer Tania, 2017, J Phys Ther Sci, V29, P685, DOI [10.1589/jpts.29.685, 10.1589/jpts.29.685]
   Traeger AC, 2023, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD014789.pub2
   Uchida H, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-71
   Verville L, 2023, J OCCUP REHABIL, V33, P651, DOI 10.1007/s10926-023-10121-7
   Wang CK, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1080888
   Wang M, 2022, EUR J ONCOL NURS, V58, DOI 10.1016/j.ejon.2022.102124
   Wischnewski M, 2023, TRENDS COGN SCI, V27, P189, DOI 10.1016/j.tics.2022.11.013
   Xu ZH, 2022, FRONT NEUROL, V13, DOI 10.3389/fneur.2022.963358
   Yang XY, 2023, COMPLEMENT THER CLIN, V53, DOI 10.1016/j.ctcp.2023.101797
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zhi JF, 2022, EXPERT REV NEUROTHER, V22, P875, DOI 10.1080/14737175.2022.2137405
NR 85
TC 3
Z9 3
U1 2
U2 4
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-7090
J9 J PAIN RES
JI J. Pain Res.
PY 2024
VL 17
BP 1423
EP 1439
DI 10.2147/JPR.S448528
PG 17
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA NX0U2
UT WOS:001203643200001
PM 38628429
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Kristoffersen, AE
   Wider, B
   Nilsen, JV
   Bjelland, M
   Mora, DC
   Nordberg, JH
   Broderstad, AR
   Nakandi, K
   Stub, T
AF Kristoffersen, Agnete E. E.
   Wider, Barbara
   Nilsen, Jorunn V. V.
   Bjelland, Mona
   Mora, Dana C. C.
   Nordberg, Johanna Hok
   Broderstad, Ann Ragnhild
   Nakandi, Kiwumulo
   Stub, Trine
TI Prevalence of late and long-term effects of cancer (treatment) and use
   of complementary and alternative medicine in Norway
SO BMC COMPLEMENTARY MEDICINE AND THERAPIES
LA English
DT Article
DE Cancer; Late effects; Long-term effects; Complementary therapies;
   Supportive care; CAM
ID INDUCED PERIPHERAL NEUROPATHY; QUALITY-OF-LIFE; BREAST-CANCER;
   CHILDHOOD-CANCER; CHRONIC FATIGUE; MASSAGE THERAPY; HOT FLASHES;
   MANAGEMENT; LYMPHEDEMA; SURVIVORS
AB Background: The increasing number of patients surviving cancer leads to more people experiencing late and long term-effects from the disease and its treatment. Fatigue, sleep disorders, early menopause, pain, and nerve damage are commonly reported. Methods helping people to recover after cancer treatment are therefore essential. The aims of this study were threefold; (1) to determine the level of cancer patients suffering from late and long-term effects of cancer diagnosis and treatment in Norway, (2) explore complementary and alternative medicine (CAM) modalities used for managing these adversities, and (3) describe self-perceived benefits and harms of the CAM interventions. Methods: The study was conducted in cooperation with the Norwegian Cancer Society (NCS) and consisted of an online cross-sectional study among members of the NCS user panel with present or previous cancer (n = 706). The study was carried out in September/October 2021 using a modified cancer-specific version of the International Questionnaire to Measure Use of Complementary and Alternative Medicine (I-CAM-Q). A total of 315 women and 153 men agreed to participate, resulting in a response rate of 67%. Results: Most of the participants (83%) suffered from late and long-term effects of cancer treatment; mostly fatigue (59.2%), sleep disorder (41.5%), hot flashes (39.2%), nerve damage (polyneuropathy, 38.0%), and pain (36.6%) with a mean number of 5.1 different late and long-term effects. Late and long-term effects were positively associated with younger age and college/university education. Nearly half of the participants experiencing late and long-term effects (43%) reported having used CAM to treat these complaints. Most frequently used were self-help practices (26%) such as relaxation therapy (19%), yoga (14%) and meditation (13%), but also visits to CAM providers were reported by 22%. Herbal- and other natural remedies to treat late and long-term effects were used by 13%. A high percentage of CAM users reported self-perceived improvements of their symptoms (86% for self-help practices, 90% for visits to CAM providers). Few experienced adverse effects of the CAM treatment. Conclusion: A large proportion of cancer patients suffered from a wide range of late and long-term effects of cancer diagnosis and treatment, and they use CAM to treat these complaints to a rather high degree. Relaxation therapy, yoga, meditation, massage, and acupuncture were the most frequently used therapies regardless of complaint. The therapies used are generally considered to be both safe and beneficial for the respective complaint, indicating that the participants seem to be well informed about the choices they make.
C1 [Kristoffersen, Agnete E. E.; Wider, Barbara; Mora, Dana C. C.; Nakandi, Kiwumulo; Stub, Trine] UiT Arctic Univ Norway, Natl Res Ctr Complementary & Alternat Med NAFKAM, Dept Community Med, Tromso, Norway.
   [Bjelland, Mona] Norwegian Canc Soc, Oslo, Norway.
   [Nordberg, Johanna Hok] Reg Canc Ctr Stockholm Gotland, Stockholm, Sweden.
   [Nordberg, Johanna Hok] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Div Nursing, Stockholm, Sweden.
   [Nordberg, Johanna Hok] Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden.
   [Broderstad, Ann Ragnhild] UiT Arctic Univ Norway, Ctr Sami Hlth Res, Dept Community Med, Tromso, Norway.
C3 UiT The Arctic University of Tromso; Karolinska Institutet; Karolinska
   Institutet; UiT The Arctic University of Tromso
RP Kristoffersen, AE (corresponding author), UiT Arctic Univ Norway, Natl Res Ctr Complementary & Alternat Med NAFKAM, Dept Community Med, Tromso, Norway.
EM agnete.kristoffersen@uit.no
RI ; Kristoffersen, Agnete Egilsdatter/J-3018-2019; Mora, Dana
   C/HZH-9849-2023
OI Stub, Trine/0000-0002-7053-509X; Kristoffersen, Agnete
   Egilsdatter/0000-0003-4642-0310; Wider, Barbara/0000-0003-1220-1793;
   Mora, Dana C/0000-0003-1209-3526
FU UiTThe Arctic University of Norway
FX Open access funding provided by UiTThe Arctic University of Norway (incl
   University Hospital of North Norway).The publication charges for this
   paper have been funded by a grant from the publication fund of UiTThe
   Arctic University of Norway. No further funding was received.
CR Abuelgasim KA, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-018-2150-8
   Al-naggar R.a., 2013, World Journal of Medical Sciences, V8, P157, DOI DOI 10.5829/IDOSI.WJMS.2013.8.2.7358
   Ando M, 2009, J PALLIAT MED, V12, P1091, DOI 10.1089/jpm.2009.0143
   [Anonymous], 2021, CANC NORW 2020
   [Anonymous], 2022, REL TECHN WHAT YOU N
   [Anonymous], 2003, ACT 64 27 JUNE 2003
   [Anonymous], 2020, SEN ETT KREFTB
   [Anonymous], Lov om helseregistre og behandling av helseopplysninger (helseregisterloven)
   [Anonymous], 2020, CHR LAT EFF CANC TRE
   [Anonymous], 2020, KEY FIG CANC
   [Anonymous], 2013, Declaration of Helsinki. Medical Research Involving Human Subjects
   [Anonymous], 2012, EXAMPL ACT NOT REQ A
   [Anonymous], 2022, LYMFODEM PA GRUNN KR
   [Anonymous], 2021, S3 LEITLINIE KOMPLEM
   [Anonymous], 2018, LEVE MED ETT KREFT U
   Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Bao T, 2018, BREAST CANCER RES TR, V170, P77, DOI 10.1007/s10549-018-4743-9
   Bao YJ, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/170396
   Bissonauth V, 2008, CANCER DETECT PREV, V32, P52, DOI 10.1016/j.cdp.2008.01.005
   Bohn SKH, 2024, J CANCER SURVIV, V18, P375, DOI 10.1007/s11764-022-01202-2
   Boland EG, 2017, CURR OPIN SUPPORT PA, V11, P181, DOI 10.1097/SPC.0000000000000292
   Bower JE, 2014, NAT REV CLIN ONCOL, V11, P597, DOI 10.1038/nrclinonc.2014.127
   Brami C, 2016, CRIT REV ONCOL HEMAT, V98, P325, DOI 10.1016/j.critrevonc.2015.11.014
   Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001
   Brem S, 2011, CLIN J ONCOL NURS, V15, P63, DOI 10.1188/11.CJON.63-71
   CAM Cancer, Complementary and Alternative medicine for Cancer
   Cambron JA, 2007, J ALTERN COMPLEM MED, V13, P793, DOI 10.1089/acm.2006.6401
   Cancer in Norway, 2021, Cancer incidence, mortality, survival and prevalence in Norway
   Carpenter JS, 1998, CANCER-AM CANCER SOC, V82, P1682, DOI 10.1002/(SICI)1097-0142(19980501)82:9<1682::AID-CNCR14>3.0.CO;2-0
   Cassileth BR, 2013, CANCER-AM CANCER SOC, V119, P2455, DOI 10.1002/cncr.28093
   Chao LF, 2009, BREAST CANCER RES TR, V118, P255, DOI 10.1007/s10549-009-0533-8
   Cheuk DKL, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005472.pub3
   Cramer H, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2612-7
   D'Silva S, 2012, PSYCHOSOMATICS, V53, P407, DOI 10.1016/j.psym.2012.04.006
   Dahl AA, 2019, J ADOLESC YOUNG ADUL, V8, P304, DOI 10.1089/jayao.2018.0109
   Davidson JR, 2002, SOC SCI MED, V54, P1309, DOI 10.1016/S0277-9536(01)00043-0
   Davis SR, 2010, MENOPAUSE, V17, P1004, DOI 10.1097/gme.0b013e3181d991dd
   DiSipio T, 2013, LANCET ONCOL, V14, P500, DOI 10.1016/S1470-2045(13)70076-7
   Ebede CC, 2017, MED CLIN N AM, V101, P1085, DOI 10.1016/j.mcna.2017.06.007
   Eikeland SA, 2021, ACTA ONCOL, V60, P911, DOI 10.1080/0284186X.2021.1917776
   Eustachi A, 2009, INTEGR CANCER THER, V8, P56, DOI 10.1177/1534735408327996
   Fabi A, 2020, ANN ONCOL, V31, P713, DOI 10.1016/j.annonc.2020.02.016
   Fallon M, 2018, ANN ONCOL, V29, P166, DOI 10.1093/annonc/mdy152
   Finnegan-John J, 2013, INTEGR CANCER THER, V12, P276, DOI 10.1177/1534735413485816
   Garcia MK, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/1756-8722-7-41
   Gehring K, 2012, EXPERT REV ANTICANC, V12, P255, DOI [10.1586/era.11.202, 10.1586/ERA.11.202]
   Goldberg SB, 2022, PSYCHOTHER RES, V32, P291, DOI 10.1080/10503307.2021.1933646
   Golshan Mehra, 2006, J Support Oncol, V4, P381
   Greco MT, 2014, J CLIN ONCOL, V32, P4149, DOI 10.1200/JCO.2014.56.0383
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Han XY, 2017, BMC CANCER, V17, DOI 10.1186/s12885-016-3037-z
   Hansen F, 2020, ANTHROPOL MED, V27, P330, DOI 10.1080/13648470.2019.1676637
   Harrington CB, 2010, INT J PSYCHIAT MED, V40, P163, DOI 10.2190/PM.40.2.c
   Hayes SC, 2017, GYNECOL ONCOL, V146, P623, DOI 10.1016/j.ygyno.2017.06.004
   Hede K, 2008, J NATL CANCER I, V100, P162, DOI 10.1093/jnci/djn007
   Helsedirektoratet, 2017, NORW DIR HLTH NASJ H
   Henneghan AM, 2015, J HOLIST NURS, V33, P84, DOI 10.1177/0898010114539191
   Herpertz U, 1998, Fortschr Med, V116, P36
   Hess SL, 2018, SENEFFEKTER ETTER KR, P1
   Jacobson JS, 2000, J CLIN ONCOL, V18, P668, DOI 10.1200/JCO.2000.18.3.668
   Jansen CE, 2005, ONCOL NURS FORUM, V32, P329, DOI 10.1188/05.ONF.329-342
   Jaradat NA, 2016, J ETHNOPHARMACOL, V178, P1, DOI 10.1016/j.jep.2015.11.050
   Johannesen TB, 2007, ACTA ONCOL, V46, P60, DOI 10.1080/02841860600774026
   Jordan B, 2020, ANN ONCOL, V31, P1306, DOI 10.1016/j.annonc.2020.07.003
   Kanakura Y, 2002, AM J CHINESE MED, V30, P37, DOI 10.1142/S0192415X02000041
   Keene MR, 2019, COMPLEMENT THER CLIN, V35, P33, DOI 10.1016/j.ctcp.2019.01.004
   Kim YH, 2013, COMPLEMENT THER MED, V21, P379, DOI 10.1016/j.ctim.2013.06.005
   Kirchhoff AC, 2011, CANCER EPIDEM BIOMAR, V20, P1838, DOI 10.1158/1055-9965.EPI-11-0239
   Kirserud C., 2018, KREFTSYKDOMMER EN BA, P148
   Kiserud Cecilie E, 2018, Recent Results Cancer Res, V210, P123, DOI 10.1007/978-3-319-64310-6_8
   Klonoff-Cohen H, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229222
   Kristoffersen AE, 2022, BMC COMPLEMENT MED, V22, DOI 10.1186/s12906-022-03606-0
   Kristoffersen AE, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2762-7
   Lee MS, 2011, ANN ONCOL, V22, P1459, DOI 10.1093/annonc/mdr147
   Lindqvist E, 2017, EUR J OBSTET GYN R B, V211, P112, DOI 10.1016/j.ejogrb.2017.02.021
   Loge JH, 1999, J CLIN ONCOL, V17, P253, DOI 10.1200/JCO.1999.17.1.253
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Mahon Suzanne M, 2021, Clin J Oncol Nurs, V25, P33, DOI [10.1188/21.cjon.s2.33, 10.1188/21.CJON.S2.33]
   Mai QD, 2019, SOC SCI MED, V237, DOI 10.1016/j.socscimed.2019.112424
   Maindet C, 2019, SUPPORT CARE CANCER, V27, P3119, DOI 10.1007/s00520-019-04829-7
   Masmoudi A, 2005, Dermatol Online J, V11, P12
   Melchart D, 2004, ARCH INTERN MED, V164, P104, DOI 10.1001/archinte.164.1.104
   Mellblom AV, 2021, SUPPORT CARE CANCER, V29, P2947, DOI 10.1007/s00520-020-05790-6
   Mitchell AJ, 2013, LANCET ONCOL, V14, P721, DOI 10.1016/S1470-2045(13)70244-4
   Molassiotis A, 2019, INTEGR CANCER THER, V18, DOI 10.1177/1534735419836501
   Mykletun A., 2009, Psykiske lidelser i Norge: Et folkehelseperspektiv
   Nakandi K, 2022, BMC HEALTH SERV RES, V22, DOI 10.1186/s12913-021-07445-6
   Ness KK, 2008, ARCH PHYS MED REHAB, V89, P128, DOI 10.1016/j.apmr.2007.08.123
   Ness KK, 2009, J CLIN ONCOL, V27, P2382, DOI 10.1200/JCO.2008.21.1482
   Ota KS, 2006, J AM OSTEOPATH ASSOC, V106, P110
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Paice JA, 2011, PAIN, V152, pS84, DOI 10.1016/j.pain.2010.10.010
   Pearson NJ, 2006, ARCH INTERN MED, V166, P1775, DOI 10.1001/archinte.166.16.1775
   Pilkington K, 2021, ACUPUNCTURE CANC PAI
   Pilkington K, 2021, ACUPUNCTURE HOT FLUS
   Pinto AC, 2011, MATURITAS, V70, P343, DOI 10.1016/j.maturitas.2011.09.008
   Pitman A, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k1415
   Quandt SA, 2009, J ALTERN COMPLEM MED, V15, P331, DOI 10.1089/acm.2008.0521
   Reinertsen KV, 2017, J PAIN SYMPTOM MANAG, V53, P551, DOI 10.1016/j.jpainsymman.2016.09.011
   Reinertsen Kristin Valborg, 2017, Tidsskr Nor Laegeforen, V137, DOI [10.4045/tidsskr.17.0040, 10.4045/tidsskr.17.0040]
   Reinertsen KV, 2010, J CANCER SURVIV, V4, P405, DOI 10.1007/s11764-010-0145-7
   Rosenberg EI, 2008, PAIN MED, V9, P1065, DOI 10.1111/j.1526-4637.2008.00477.x
   Ryan TJ, 2012, INT J LOW EXTR WOUND, V11, P5, DOI 10.1177/1534734612438548
   Samuel SR, 2021, J CANCER SURVIV, V15, P799, DOI 10.1007/s11764-020-00972-x
   Saquib J, 2011, INTEGR CANCER THER, V10, P138, DOI 10.1177/1534735410392578
   Savard J, 2001, J CLIN ONCOL, V19, P895, DOI 10.1200/JCO.2001.19.3.895
   Seland M, 2015, LEUKEMIA LYMPHOMA, V56, P3306, DOI 10.3109/10428194.2015.1036258
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Solem AG, 2018, PLOT DOKUMENTAR EKSI, V5, P24
   Soo JK, 2008, BRIT J DERMATOL, V158, P1350, DOI 10.1111/j.1365-2133.2007.08423.x
   Stein KD, 2008, CANCER-AM CANCER SOC, V112, P2577, DOI 10.1002/cncr.23448
   Su HI, 2010, BREAST CANCER RES TR, V124, P205, DOI 10.1007/s10549-010-0802-6
   Swain Sandra M, 2008, Clin Adv Hematol Oncol, V6, P455
   Syed Mohammad Salleh Sharifah Nadia, 2021, J Complement Integr Med, V18, P805, DOI [10.1515/jcim-2020-0205, 10.1515/jcim-2020-0205]
   Syse Astri, 2008, J Cancer Surviv, V2, P149, DOI 10.1007/s11764-008-0053-2
   Szabo RA, 2019, CLIMACTERIC, V22, P572, DOI 10.1080/13697137.2019.1646718
   Vistad I, 2007, BJOG-INT J OBSTET GY, V114, P1150, DOI 10.1111/j.1471-0528.2007.01445.x
   White A, 2014, EUR J INTEGR MED, V6, P404, DOI 10.1016/j.eujim.2013.09.006
   Zhang ZJ, 2020, BRAIN BEHAV IMMUN, V88, P88, DOI 10.1016/j.bbi.2020.04.035
NR 120
TC 18
Z9 23
U1 0
U2 23
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2662-7671
J9 BMC COMPLEMENT MED
JI BMC Complement. Med. Ther.
PD DEC 5
PY 2022
VL 22
IS 1
AR 322
DI 10.1186/s12906-022-03790-z
PG 21
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA 6U5UR
UT WOS:000894432100001
PM 36471296
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Amraoui, J
   Pouliquen, C
   Fraisse, J
   Dubourdieu, J
   Guzer, SRD
   Leclerc, G
   de Forges, H
   Jarlier, M
   Gutowski, M
   Bleuse, JP
   Janiszewski, C
   Diaz, J
   Cuvillon, P
AF Amraoui, Jibba
   Pouliquen, Camille
   Fraisse, Julien
   Dubourdieu, Jacques
   Guzer, Sophie Rey Dit
   Leclerc, Gilles
   de Forges, Helene
   Jarlier, Marta
   Gutowski, Marian
   Bleuse, Jean-Pierre
   Janiszewski, Chloe
   Diaz, Jesus
   Cuvillon, Philippe
TI Effects of a Hypnosis Session Before General Anesthesia on Postoperative
   Outcomes in Patients Who Underwent Minor Breast Cancer Surgery The
   HYPNOSEIN Randomized Clinical Trial
SO JAMA NETWORK OPEN
LA English
DT Article
ID AURICULAR ACUPUNCTURE; RECOVERY; QUALITY; BLOCKS
AB IMPORTANCE Hypnosis is now widespread in medical practice and is emerging as an alternative technique for pain management and anxiety. However, its effects on postoperative outcomes remain unclear.
   OBJECTIVE To evaluate the efficacy of a preoperative hypnosis session for reducing postoperative breast pain in patients who underwent minor breast cancer surgery.
   DESIGN, SETTING, AND PARTICIPANTS The HYPNOSEIN prospective randomized clinical trial was conducted from October 7, 2014, to April 5, 2016. In this multicenter study in France, 150 women scheduled for minor breast cancer surgery were randomized between control and hypnosis arms, and 148 (71 control and 77 hypnosis) were included in the intent-to-treat analysis.
   INTERVENTION On the day of surgery, eligible patients were randomly assigned (1:1) to the control arm or the hypnosis arm. Patients (but not the care teams) were blinded to the arm to which they were assigned. A 15-minute hypnosis session before general anesthesia in the operating room was performed in the hypnosis arm.
   MAIN OUTCOMES AND MEASURES The primary end point was breast pain reduction (by 2 on a visual analog scale), assessed immediately before discharge from the postanesthesia care unit (PACU). Secondary end points were nausea/vomiting, fatigue, comfort/well-being, anxiety, and PACU length of stay, assessed at different times until postoperative day 30.
   RESULTS The median patient age was 57 years (range, 33-79 years) in the control arm and 53 years (range, 20-84 years) in the hypnosis arm. Baseline characteristics were similar in the 2 arms. The median duration of the hypnosis session was 6 minutes (range, 2-15 minutes). The use of intraoperative opioids and hypnotics was lower in the hypnosis arm. The mean (SD) breast pain score (range, 0-10) was 1.75 (1.59) in the control arm vs 2.63 (1.62) in the hypnosis arm (P = .004). At PACU discharge and with longer follow-up, no statistically significant difference in breast pain was reported. Fatigue was significantly lower in the hypnosis arm on the evening of surgery (mean [SD] score, 3.81 [2.15] in the control arm vs 2.99 [2.56] in the hypnosis arm; P = .03). The median PACU length of stay was 60 minutes (range, 20-290 minutes) in the control arm vs 46 minutes (range, 5-100 minutes) in the hypnosis arm (P = .002). Exploratory analyses according to patient perception of whether she received hypnosis showed significantly lower fatigue scores in the perceived hypnosis subgroup on the evening of surgery (mean [SD], 4.13[2.26] for no perceived hypnosis vs 2.97 [2.42] for perceived hypnosis; P = .01). Anxiety was also significantly lower on the evening of surgery in the perceived hypnosis subgroup (mean [SD], 0.75 [1.64] for perceived hypnosis vs 1.67 [2.29] for no perceived hypnosis; P = .03).
   CONCLUSIONS AND RELEVANCE The results of this study do not support a benefit of hypnosis on postoperative breast pain in women undergoing minor breast cancer surgery. However, other outcomes seem to be improved, which needs to be confirmed by further studies.
C1 [Amraoui, Jibba; Guzer, Sophie Rey Dit; Leclerc, Gilles; Diaz, Jesus; Cuvillon, Philippe] Univ Montpellier, Montpellier Canc Inst ICM, Dept Anesthesia, 208 Ave Apothicaires, F-34298 Montpellier, France.
   [Pouliquen, Camille] Paoli Calmette Inst, Dept Anesthesia, Marseille, France.
   [Fraisse, Julien; Jarlier, Marta] Univ Montpellier, Biometr Unit, Montpellier Canc Inst ICM, Montpellier, France.
   [Dubourdieu, Jacques] Univ Montpellier, CHU Montpellier, Dept Anesthesia, Montpellier, France.
   [de Forges, Helene; Bleuse, Jean-Pierre; Janiszewski, Chloe] Univ Montpellier, Montpellier Canc Inst ICM, Dept Clin Res, Montpellier, France.
   [Gutowski, Marian] Univ Montpellier, Montpellier Canc Inst ICM, Dept Surg Oncol, Montpellier, France.
   [Cuvillon, Philippe] Univ Montpellier, CHU Nimes, Dept Anesthesia, Nimes, France.
C3 Universite de Montpellier; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Institut National de la Sante et de la
   Recherche Medicale (Inserm); Universite de Montpellier; Universite de
   Montpellier; CHU de Montpellier; Universite de Montpellier; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Universite de
   Montpellier; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universite de Montpellier; CHU de Nimes
RP Amraoui, J (corresponding author), Univ Montpellier, Montpellier Canc Inst ICM, Dept Anesthesia, 208 Ave Apothicaires, F-34298 Montpellier, France.
EM jibba.amraou@icm.unicancer.fr
RI Amraoui, jibba/IWD-9716-2023
FU Montpellier Cancer Institute (ICM)
FX This study was funded by Montpellier Cancer Institute (ICM).
CR Abdallah FW, 2017, ANESTH ANALG, V125, P294, DOI 10.1213/ANE.0000000000001975
   Abdallah FW, 2014, ANESTHESIOLOGY, V120, P703, DOI 10.1097/ALN.0000436117.52143.bc
   ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K
   Apfel CC, 2002, BRIT J ANAESTH, V88, P234, DOI 10.1093/bja/88.2.234
   Bennett S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008144.pub2
   Berger AM, 2012, CANCER-AM CANCER SOC, V118, P2261, DOI 10.1002/cncr.27475
   Bleicher RJ, 2016, JAMA ONCOL, V2, P330, DOI 10.1001/jamaoncol.2015.4508
   Enqvist B, 1997, ACTA ANAESTH SCAND, V41, P1028, DOI 10.1111/j.1399-6576.1997.tb04831.x
   European Medicines Agency, 2016, "Guidance of Good Clinical Practice E6(R2),"
   Hole J, 2015, LANCET, V386, P1659, DOI 10.1016/S0140-6736(15)60169-6
   Karst M, 2007, ANESTH ANALG, V104, P295, DOI 10.1213/01.ane.0000242531.12722.fd
   Kekecs Z, 2014, ANESTH ANALG, V119, P1407, DOI 10.1213/ANE.0000000000000466
   Lang EV, 2000, LANCET, V355, P1486, DOI 10.1016/S0140-6736(00)02162-0
   Machin D, 2008, SAMPLE SIZE TABLES C, P47, DOI [10.1002/9781444300710.ch5, DOI 10.1002/9781444300710.CH5]
   Maurice-Szamburski A, 2015, JAMA-J AM MED ASSOC, V313, P916, DOI 10.1001/jama.2015.1108
   Merrill AY, 2017, AM SURGEON, V83, P887
   Mitchell A, 2012, ANN SURG ONCOL, V19, P3792, DOI 10.1245/s10434-012-2447-7
   Montgomery GH, 2002, ANESTH ANALG, V94, P1639, DOI 10.1097/00000539-200206000-00052
   Montgomery GH, 2007, JNCI-J NATL CANCER I, V99, P1304, DOI 10.1093/jnci/djm106
   Powell R, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008646.pub2
   Wang SM, 2004, ANESTHESIOLOGY, V100, P1399, DOI 10.1097/00000542-200406000-00011
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
   Zhang Q, 2014, ANAESTHESIA, V69, P832, DOI 10.1111/anae.12639
NR 23
TC 46
Z9 48
U1 0
U2 12
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2574-3805
J9 JAMA NETW OPEN
JI JAMA Netw. Open
PD AUG
PY 2018
VL 1
IS 4
AR e181164
DI 10.1001/jamanetworkopen.2018.1164
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HD6JG
UT WOS:000452643200013
PM 30646110
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Suzuki, R
   Small, E
   Makled, M
AF Suzuki, Rie
   Small, Eusebius
   Makled, Melissa
TI Is complementary and alternative medicine use associated with cancer
   screening rates for women with functional disabilities?
SO COMPLEMENTARY THERAPIES IN MEDICINE
LA English
DT Article
DE Complementary and alternative medicine; Disability; Cancer screenings
ID PHYSICAL-DISABILITIES; CHRONIC PAIN; SECONDARY CONDITIONS;
   HEALTH-PROMOTION; ADULTS; BREAST; MAMMOGRAPHY; PEOPLE; BARRIERS; CARE
AB Objectives: The purpose of this study was to examine the associations of complementary and alternative medicine (CAM) use with mammogram and Pap test rates and functional disabilities (FDs).
   Design: Cross-sectional study. Setting: Data were derived from the 2012 National Health Interview Survey (n=6576).
   Analysis: FDs was defined as physical and/or social limitations. The weighted logistic regression models were performed using SAS software. Study covariates were age, race, education, marital status, usual source of care, and insurance.
   Results: Of 6576 women, a majority were Caucasian (87%), with GED or less (40%), married (50%), having usual source of care (96%) and health insurance (91%), and with FDs (56%). The results indicated that some CAM practices were negatively associated with increased mammogram and Pap test rates while other CAM practices were positively associated. The results indicated that CAM practices that contribute to musculoskeletal problems such as acupuncture and massage were associated with the increased mammogram and Pap test rates. Contrary, women who used chiropractic manipulation, biofeedback, guided imagery, and energy hearing therapy were less likely to obtain cancer screenings regularly regardless of having FDs.
   Conclusions: The use of several CAM therapies was more likely to be associated with mammogram and Pap test frequency, indicating that the CAM use may be associated with better screening rates due to the improvement of musculoskeletal problems. It is important to determine how each CAM therapy improves secondary health conditions in clinical trials to increase cancer screening rates for women with FDs. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Suzuki, Rie; Makled, Melissa] Univ Michigan, Sch Hlth Profess & Studies, Flint, MI 48503 USA.
   [Small, Eusebius] Univ Texas Arlington, Sch Social Work, Arlington, TX USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan Flint; University of Texas System; University of Texas
   Arlington
RP Suzuki, R (corresponding author), 3124 William S White Bldg,303 E Kearsley St, Flint, MI 48502 USA.
EM rsuzuki@umflint.edu
RI ; Small, Eusebius/HPG-2328-2023
OI Suzuki, Rie/0000-0003-4969-291X; Small, Eusebius/0000-0001-9027-3632
CR Abrahamsen R, 2011, CLIN J PAIN, V27, P344, DOI 10.1097/AJP.0b013e3181ffbfcb
   Allen JD, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1169
   Andresen EM, 2013, WOMEN HEALTH ISS, V23, pE205, DOI 10.1016/j.whi.2013.04.002
   [Anonymous], 2009, Ann Intern Med, V151, pI, DOI 10.7326/0003-4819-151-9-200911030-00002
   [Anonymous], NAT HLTH INT SURV PU
   [Anonymous], 2001, International classification of functioning, disability and health
   [Anonymous], 2007, The Future of Disability in America, DOI DOI 10.17226/11898
   [Anonymous], HLTH PEOPL 2020
   [Anonymous], 2013, BREAST CANC FACTS FI
   Arnow BA, 2006, PSYCHOSOM MED, V68, P262, DOI 10.1097/01.psy.0000204851.15499.fc
   Barnes Patricia M, 2004, Adv Data, P1
   Barr JK, 2008, AM J HEALTH PROMOT, V22, P381, DOI 10.4278/ajhp.22.6.381
   Bronfort Gert, 2004, Spine J, V4, P335, DOI 10.1016/j.spinee.2003.06.002
   Carlson MJ, 2006, DISABIL REHABIL, V28, P505, DOI 10.1080/09638280500212062
   Centers for Disease Control and Prevention, 2014, WOM DIS BREAST CANC
   Centers for Disease Control and Prevention, 2014, TYP OF DIS
   Courtney-Long E, 2011, J WOMENS HEALTH, V20, P1279, DOI 10.1089/jwh.2010.2609
   DiGianni LM, 2003, CANCER EPIDEM BIOMAR, V12, P321
   Eng Joanna, 2003, Integr Cancer Ther, V2, P212, DOI 10.1177/1534735403256207
   Field KM, 2009, EUR J CANCER, V45, P551, DOI 10.1016/j.ejca.2008.09.023
   Fillingim R B, 2000, Curr Rev Pain, V4, P24
   Gailey R, 2008, J REHABIL RES DEV, V45, P15, DOI 10.1682/JRRD.2006.11.0147
   Garrow D, 2006, DIABETES CARE, V29, P15, DOI 10.2337/diacare.29.01.06.dc05-1448
   Hawk C, 2012, PREV MED, V54, P18, DOI 10.1016/j.ypmed.2011.07.002
   Horner-Johnson W, 2014, WOMEN HEALTH ISS, V24, pE147, DOI 10.1016/j.whi.2013.10.009
   *I MED COMM US COM, 2005, COMPL ALT MED US
   Karlson CW, 2014, J HEALTH PSYCHOL, V19, P427, DOI 10.1177/1359105312471572
   Kinne S, 2004, AM J PUBLIC HEALTH, V94, P443, DOI 10.2105/AJPH.94.3.443
   Kirschner KL, 2007, JAMA-J AM MED ASSOC, V297, P1121, DOI 10.1001/jama.297.10.1121
   Krahn GL, 2015, AM J PUBLIC HEALTH, V105, pS198, DOI 10.2105/AJPH.2014.302182
   Kroll T, 2006, HEALTH SOC CARE COMM, V14, P284, DOI 10.1111/j.1365-2524.2006.00613.x
   Liu SY, 2008, J WOMENS HEALTH, V17, P1321, DOI 10.1089/jwh.2007.0591
   Llewellyn G, 2011, DISABIL REHABIL, V33, P1755, DOI 10.3109/09638288.2010.546935
   MacDonald G, 2005, PSYCHOL BULL, V131, P202, DOI 10.1037/0033-2909.131.2.202
   Marrie Ruth Ann, 2013, Continuum (Minneap Minn), V19, P1046, DOI 10.1212/01.CON.0000433284.07844.6b
   Matsuda PN, 2015, ARCH PHYS MED REHAB, V96, P464, DOI 10.1016/j.apmr.2014.09.034
   Molton I, 2014, CLIN J PAIN, V30, P307, DOI 10.1097/AJP.0b013e31829e9bca
   Morley S, 1999, PAIN, V80, P1, DOI 10.1016/S0304-3959(98)00255-3
   O'Neill S, 2007, EUR J PAIN, V11, P415, DOI 10.1016/j.ejpain.2006.05.009
   Okoro CA, 2012, DISABIL REHABIL, V34, P128, DOI 10.3109/09638288.2011.591887
   Poulos AE, 2006, ARCH PHYS MED REHAB, V87, P304, DOI 10.1016/j.apmr.2005.09.020
   Racine M, 2012, PAIN, V153, P619, DOI 10.1016/j.pain.2011.11.026
   Rakovitch E, 2005, BREAST CANCER RES TR, V90, P139, DOI 10.1007/s10549-004-3779-1
   Ravesloot CH, 2007, HEALTH EDUC RES, V22, P522, DOI 10.1093/her/cyl114
   Reichard A, 2011, DISABIL HEALTH J, V4, P59, DOI 10.1016/j.dhjo.2010.05.003
   Rosenberg DE, 2013, ARCH PHYS MED REHAB, V94, P731, DOI [10.1016/j.apmr.2012.11.014, 10.1016/j.apmr.2012.09.020]
   Rubinstein SM, 2011, SPINE, V36, pE825, DOI 10.1097/BRS.0b013e3182197fe1
   SEEKINS T, 1994, J REHABIL, V60, P47
   Senders A., 2014, Journal of Alternative and Complementary Medicine, V20, pA67, DOI [10.1089/acm.2014.5175.abstract, DOI 10.1089/ACM.2014.5175.ABSTRACT]
   Suzuki R, 2013, AM J HEALTH BEHAV, V37, P711, DOI 10.5993/AJHB.37.5.15
   U.S. Department of Health and Human Services, 2014, CHRON PAIN COMPL HLT
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Wahl AK, 2009, QUAL LIFE RES, V18, P971, DOI 10.1007/s11136-009-9515-x
   Weiner DK, 2006, PAIN MED, V7, P60, DOI 10.1111/j.1526-4637.2006.00091.x
   Wilber N, 2002, MILBANK Q, V80, P393, DOI 10.1111/1468-0009.00009
NR 55
TC 2
Z9 3
U1 0
U2 5
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0965-2299
EI 1873-6963
J9 COMPLEMENT THER MED
JI Complement. Ther. Med.
PD FEB
PY 2016
VL 24
BP 73
EP 79
DI 10.1016/j.ctim.2015.11.008
PG 7
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Integrative & Complementary Medicine
GA DE8NY
UT WOS:000370894100013
PM 26860805
DA 2026-01-16
ER

PT J
AU Teng, C
   Egger, S
   Blinman, PL
   Vardy, JL
AF Teng, Christina
   Egger, Sam
   Blinman, Prunella L.
   Vardy, Janette L.
TI Evaluating laser photobiomodulation for chemotherapy-induced peripheral
   neuropathy: a randomised phase II trial
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Chemotherapy-induced peripheral neuropathy; Photobiomodulation; Laser
   therapy; Survivorship; Neurotoxicity; Patient-reported outcomes
ID QUALITY-OF-LIFE; FUNCTIONAL-ASSESSMENT; CANCER; NEUROTOXICITY;
   ACUPUNCTURE; THERAPY; PAIN; COMPLEMENTARY; QUESTIONNAIRE; EXCITABILITY
AB Purpose This study aims to evaluate the efficacy and safety of laser photobiomodulation (PBM) for treatment of established chemotherapy-induced peripheral neuropathy (CIPN) in cancer survivors. Methods We conducted a randomised phase II, non-comparative, sham-controlled, single-blinded clinical trial in 44 cancer survivors reporting CIPN symptoms at least 3 months following completion of neurotoxic chemotherapy. Participants were randomised 2:1 to either PBM laser or sham control delivered twice weekly for 12 sessions. Assessments were conducted at baseline, the end of intervention (6 weeks), and 6 weeks post intervention (12 weeks). Participants completed neuropathy, quality of life and function questionnaires, and a clinical neurological assessment. The primary outcome was proportion of participants with CIPN response, defined as either symptom resolution or reduction of minimally clinically important difference. Results In the laser and control groups, CIPN response rates were - 48% and 53% at 6 weeks and 45% and 33% at 12 weeks, respectively. The null hypothesis that the true response rate is 5% in the laser arm was rejected at both 6 and 12 weeks (p < 0.001 for both). Compared to baseline, patient-reported CIPN improved in both laser and control groups after the intervention. At 12 weeks, improvement was sustained in the laser group and approaching baseline in the control group. Clinical signs, quality of life, and function remained stable in both groups. Low-grade "side-effects " were observed in both arms. Conclusion PBM may offer clinically meaningful symptom benefit in cancer survivors with established CIPN with improvement potentially continuing beyond completion of the intervention. A larger study is warranted to evaluate this further.
C1 [Teng, Christina; Blinman, Prunella L.; Vardy, Janette L.] Concord Canc Ctr, Concord, NSW, Australia.
   [Teng, Christina; Blinman, Prunella L.; Vardy, Janette L.] Univ Sydney, Fac Med & Hlth, Camperdown, NSW, Australia.
   [Teng, Christina] Cent Coast Canc Ctr, Gosford, NSW, Australia.
   [Egger, Sam] Daffodil Ctr, Canc Council NSW, Kings Cross, NSW, Australia.
   [Egger, Sam] Univ Sydney, Kings Cross, NSW, Australia.
C3 University of Sydney; Cancer Council New South Wales; University of
   Sydney
RP Vardy, JL (corresponding author), Concord Canc Ctr, Concord, NSW, Australia.; Vardy, JL (corresponding author), Univ Sydney, Fac Med & Hlth, Camperdown, NSW, Australia.
EM Janette.vardy@sydney.edu.au
OI Vardy, Janette/0000-0002-5739-5790; Egger, Sam/0000-0003-1808-6909;
   Teng, Christina/0000-0002-3716-8611
FU Concord Cancer Centre Research Grant; Australian Government through a
   National Health Medical Research Council Investigator Grant; 
   [APP1176221]
FX This trial was supported by a Concord Cancer Centre Research Grant. JV
   is supported by the Australian Government through a National Health
   Medical Research Council Investigator Grant (APP1176221).
CR Argenta PA, 2017, GYNECOL ONCOL, V144, P159, DOI 10.1016/j.ygyno.2016.11.013
   Australian and New Zealand Clinical Trials Registry, 2005, US
   Cotler HB, 2015, MOJ Orthopedics & Rheumatology, V2, DOI [10.15406/mojor.2015.02.00068, 10.15406/mojor.2015.02.00068, DOI 10.15406/MOJOR.2015.02.00068]
   Bjordal JM, 2003, AUST J PHYSIOTHER, V49, P107, DOI 10.1016/S0004-9514(14)60127-6
   Boutron I, 2008, ANN INTERN MED, V148, P295, DOI 10.7326/0003-4819-148-4-200802190-00008
   Brami C, 2016, CRIT REV ONCOL HEMAT, V98, P325, DOI 10.1016/j.critrevonc.2015.11.014
   Braun L, 2014, ASIA-PAC J CLIN ONCO, V10, P289, DOI 10.1111/ajco.12227
   Butkovic D, 2005, PEDIATR ANESTH, V15, P37, DOI 10.1111/j.1460-9592.2004.01388.x
   Calhoun EA, 2003, INT J GYNECOL CANCER, V13, P741, DOI 10.1111/j.1525-1438.2003.13603.x
   Cavaletti G, 2007, J PERIPHER NERV SYST, V12, P210, DOI 10.1111/j.1529-8027.2007.00141.x
   CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570
   Cg Shashi Kumar, 2015, Laser Ther, V24, P195, DOI [10.5978/islsm.15-or-12, 10.5978/islsm.15-OR-12]
   Cheng HL, 2020, HEALTH QUAL LIFE OUT, V18, DOI 10.1186/s12955-020-01493-y
   Chow R, 2011, PHOTOMED LASER SURG, V29, P365, DOI 10.1089/pho.2010.2928
   Chung H, 2012, ANN BIOMED ENG, V40, P516, DOI 10.1007/s10439-011-0454-7
   Ellis A, 2013, BRIT J ANAESTH, V111, P26, DOI 10.1093/bja/aet128
   Fujimaki Y, 2003, J CLIN LASER MED SUR, V21, P165, DOI 10.1089/104454703321895635
   Gornstein EL, 2017, EXP NEUROL, V288, P153, DOI 10.1016/j.expneurol.2016.11.015
   Gottschling S, 2008, PAIN, V137, P405, DOI 10.1016/j.pain.2007.10.004
   Grisold W, 2012, NEURO-ONCOLOGY, V14, P45, DOI 10.1093/neuonc/nos203
   Heide R, 2018, CLIN NEUROPHYSIOL, V129, P694, DOI 10.1016/j.clinph.2017.11.015
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Hsieh YL, 2016, ACUPUNCT MED, V34, P398, DOI 10.1136/acupmed-2016-011112
   Joy L, 2022, SUPPORT CARE CANCER, V30, P5509, DOI 10.1007/s00520-022-06975-x
   Khamseh ME, 2011, LASER MED SCI, V26, P831, DOI 10.1007/s10103-011-0977-z
   Klausner G, 2022, SUPPORT CARE CANCER, V30, P13, DOI 10.1007/s00520-021-06518-w
   Kleckner IR, 2018, SUPPORT CARE CANCER, V26, P1019, DOI 10.1007/s00520-017-4013-0
   Lodewijckx J, 2020, PHOTOBIOMOD PHOTOMED, V38, P348, DOI 10.1089/photob.2019.4771
   McCrary JM, 2019, J NATL COMPR CANC NE, V17, P949, DOI 10.6004/jnccn.2019.7290
   Paglioni MD, 2019, ORAL ONCOL, V93, P21, DOI 10.1016/j.oraloncology.2019.04.004
   Park SB, 2013, CA-CANCER J CLIN, V63, P419, DOI 10.3322/caac.21204
   Pereira FC, 2017, LASER SURG MED, V49, P844, DOI 10.1002/lsm.22696
   Postma TJ, 2005, EUR J CANCER, V41, P1135, DOI 10.1016/j.ejca.2005.02.012
   SCHAG CC, 1984, J CLIN ONCOL, V2, P187, DOI 10.1200/JCO.1984.2.3.187
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   SIMON R, 1989, CONTROL CLIN TRIALS, V10, P1, DOI 10.1016/0197-2456(89)90015-9
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Teng CA, 2022, SUPPORT CARE CANCER, V30, P33, DOI 10.1007/s00520-021-06502-4
   Trotti A, 2003, SEMIN RADIAT ONCOL, V13, P176, DOI 10.1016/S1053-4296(03)00031-6
   Winters-Stone KM, 2017, J CLIN ONCOL, V35, P2604, DOI 10.1200/JCO.2016.71.3552
   Yeo F, 2019, SUPPORT CARE CANCER, V27, P4753, DOI 10.1007/s00520-019-04771-8
   Zadik Y, 2019, SUPPORT CARE CANCER, V27, P3969, DOI 10.1007/s00520-019-04890-2
   Zajaczkowska R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061451
   Zhang HJ, 2014, ANESTHESIOLOGY, V120, P1463, DOI 10.1097/ALN.0000000000000176
NR 44
TC 11
Z9 15
U1 4
U2 7
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD JAN
PY 2023
VL 31
IS 1
AR 52
DI 10.1007/s00520-022-07463-y
PG 11
WC Oncology; Health Care Sciences & Services; Rehabilitation
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 7C6ZK
UT WOS:000899958400003
PM 36526802
OA Green Accepted, Bronze
DA 2026-01-16
ER

PT J
AU Wang, MA
   Molassiotis, A
AF Wang, Mian
   Molassiotis, Alex
TI Mapping chemotherapy-induced peripheral neuropathy phenotype and
   health-related quality of life in patients with cancer through
   exploratory analysis of multimodal assessment data
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Chemotherapy; Peripheral neuropathy; Symptom cluster; Health-related
   quality of life; Patients; Cancer
ID SYMPTOMS; PAIN; NEUROTOXICITY; PREVALENCE; VALIDATION; WOMEN; SCORE;
   CIPN
AB Purpose Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of anticancer treatment based on neurotoxic agents, which may affect function and health-related quality of life (HRQoL) in patients with cancer. This exploratory study aimed to identify the phenotype of CIPN and examine the association of CIPN with general symptoms and HRQoL in patients with cancer. Methods A secondary analysis was performed on the baseline multimodal assessment data of 87 patients with cancer who participated in a randomized trial examining the effectiveness of an 8-week acupuncture protocol in managing CIPN. The data used for this study include patient-reported CIPN, general symptoms, and HRQoL, neurological examinations, and clinician-based grading of CIPN. Descriptive statistics, non-parametric tests, and hierarchical cluster analysis were used for data analysis. Results Patients with CIPN experienced a series of symptoms, with numbness, tingling, and discomfort in the hands and feet being the most prominent descriptors pertaining to CIPN. Increased severity of CIPN was associated with higher distress from general symptoms and lower physical well-being. These CIPN-specific and general symptoms formed five independent symptom clusters, including two sensory neuropathy symptom clusters, a sensorimotor neuropathy one, a neuro-psychological one, and an autonomic symptom cluster. Painful CIPN was significantly associated with higher symptom burden, lower physical well-being, and impaired tendon reflex. No significant difference was found between type of neurotoxic agents in symptom burden, neurological signs, and HRQoL. Conclusion Researchers and clinicians should pay attention to the characteristics and impact of CIPN from multiple aspects, so as to develop targeted interventions to meet patients' holistic needs. Painful CIPN warrants particular attention as it is associated with higher symptom burden and lower physical well-being in patients with cancer.
C1 [Wang, Mian; Molassiotis, Alex] Hong Kong Polytech Univ, Sch Nursing, Kowloon, Hong Kong, Peoples R China.
C3 Hong Kong Polytechnic University
RP Molassiotis, A (corresponding author), Hong Kong Polytech Univ, Sch Nursing, Kowloon, Hong Kong, Peoples R China.
EM alex.molasiotis@polyu.edu.hk
RI Molassiotis, Alex/MDS-6695-2025
OI Molassiotis, Alex/0000-0001-6351-9991; Wang, Mian/0000-0002-8935-5021
FU Hong Kong's Health & Medical Research Fund [12131801]
FX The original randomized trial was funded by the Hong Kong's Health &
   Medical Research Fund (Reference Number 12131801). No funding was
   received to assist with the preparation of this manuscript.
CR Bennedsgaard K, 2020, CANCER MED-US, V9, P5114, DOI 10.1002/cam4.3129
   Bonhof CS, 2020, SUPPORT CARE CANCER, V28, P5933, DOI 10.1007/s00520-020-05438-5
   Bonhof CS, 2021, J CANCER SURVIV, V15, P190, DOI 10.1007/s11764-020-00923-6
   Bonhof CS, 2018, GYNECOL ONCOL, V149, P455, DOI 10.1016/j.ygyno.2018.03.052
   Brown TJ, 2019, JAMA ONCOL, V5, P750, DOI 10.1001/jamaoncol.2018.6771
   Cavaletti G, 2007, J PERIPHER NERV SYST, V12, P210, DOI 10.1111/j.1529-8027.2007.00141.x
   CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570
   Dolan ME, 2017, CLIN CANCER RES, V23, P5757, DOI 10.1158/1078-0432.CCR-16-3224
   Dong ST, 2016, J PAIN SYMPTOM MANAG, V51, P88, DOI 10.1016/j.jpainsymman.2015.07.013
   FACIT group, 2003, FACT GOG NTX SCOR GU
   Forstenpointner J, 2021, PAIN, V162, P718, DOI 10.1097/j.pain.0000000000002058
   Frigeni B, 2011, J PERIPHER NERV SYST, V16, P228, DOI 10.1111/j.1529-8027.2011.00351.x
   Geber C, 2013, PAIN, V154, P2877, DOI 10.1016/j.pain.2013.08.028
   Haryani H, 2017, ONCOL NURS FORUM, V44, pE111, DOI 10.1188/17.ONF.E111-E123
   Hong JS, 2014, CURR ONCOL, V21, P174, DOI 10.3747/co.21.1984
   Huang HQ, 2007, INT J GYNECOL CANCER, V17, P387, DOI 10.1111/j.1525-1438.2007.00794.x
   Kerckhove N, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00086
   Kim M, 2021, CANCER NURS, V44, P145, DOI 10.1097/NCC.0000000000000764
   Knoerl R, 2018, PAIN MANAG NURS, V19, P354, DOI 10.1016/j.pmn.2018.01.001
   Kolb NA, 2016, JAMA NEUROL, V73, P860, DOI 10.1001/jamaneurol.2016.0383
   Lakshman A, 2017, CL LYMPH MYELOM LEUK, V17, P513, DOI 10.1016/j.clml.2017.06.035
   Loprinzi CL, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01399
   Lu LC, 2019, CANCER MED-US, V8, P963, DOI 10.1002/cam4.1976
   McCorkle R., 1998, USERS MANUAL SYMPTOM
   McCrary JM, 2017, SUPPORT CARE CANCER, V25, P3485, DOI 10.1007/s00520-017-3772-y
   Miaskowski C, 2019, CLIN J PAIN, V35, P37, DOI 10.1097/AJP.0000000000000649
   Miaskowski C, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw253
   Molassiotis A, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5302-4
   Molassiotis A, 2019, INTEGR CANCER THER, V18, DOI 10.1177/1534735419836501
   Osumi M, 2019, J HAND THER, V32, P41, DOI 10.1016/j.jht.2017.06.003
   Selvy M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082400
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Shah A, 2018, J NEUROL NEUROSUR PS, V89, P636, DOI 10.1136/jnnp-2017-317215
   Sharma KR, 2007, J PERIPHER NERV SYST, V12, P223, DOI 10.1111/j.1529-8027.2007.00143.x
   Simon NB, 2017, QUAL LIFE RES, V26, P2763, DOI 10.1007/s11136-017-1635-0
   Timmins HC, 2020, J PAIN, V21, P44, DOI 10.1016/j.jpain.2019.06.011
   Ventzel L, 2018, PAIN MED, V19, P1813, DOI 10.1093/pm/pnx231
   Ventzel L, 2016, PAIN, V157, P560, DOI 10.1097/j.pain.0000000000000404
   Wang M, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6352-3
   Winters-Stone KM, 2017, J CLIN ONCOL, V35, P2604, DOI 10.1200/JCO.2016.71.3552
   Wolf SL, 2012, SUPPORT CARE CANCER, V20, P625, DOI 10.1007/s00520-011-1141-9
   Zhi WI, 2019, BREAST CANCER RES TR, V178, P587, DOI 10.1007/s10549-019-05416-4
NR 42
TC 5
Z9 6
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD MAY
PY 2022
VL 30
IS 5
BP 4007
EP 4017
DI 10.1007/s00520-022-06821-0
EA JAN 2022
PG 11
WC Oncology; Health Care Sciences & Services; Rehabilitation
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA ZY3CD
UT WOS:000744869400001
PM 35059866
DA 2026-01-16
ER

PT J
AU Lemanne, D
   Maizes, V
AF Lemanne, Dawn
   Maizes, Victoria
TI Advising Women Undergoing Treatment for Breast Cancer: A Narrative
   Review
SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Review
DE cancer; integrative therapies; nutrition; dietary supplements;
   intermittent fasting; stress management
ID FOLLOW-UP; ALL-CAUSE; ADJUVANT CHEMOTHERAPY; INTEGRATIVE THERAPIES;
   COFFEE CONSUMPTION; PHYSICAL-ACTIVITY; CONTROLLED-TRIAL; SUPPLEMENT USE;
   SURVIVORS; EXERCISE
AB A majority of women undergoing conventional treatment for breast cancer also undertake complementary and integrative approaches. Practitioners knowledgeable about the evidence base behind common integrative approaches can help patients attain improved quality of life, and at times, improved survival. Evidence-based recommendations include the following: a plant-based diet for general health after diagnosis, and carbohydrate restriction for patients with estrogen receptor-positive postmenopausal breast cancer may be prudent. Other dietary recommendations include a 13-h daily overnight fast. Carefully selected patients may choose to fast the day before and the day of chemotherapy to decrease side effects. Specific food recommendations include avoidance or limitation of alcohol, and liberal culinary use of cruciferous vegetables, coffee, green tea, soy, and flaxseed. Promising supplements include diindolylmethane and melatonin. Omega 3 fatty acids may help with bone density in patients on aromatase inhibitors, but may increase chemotherapy resistance. Findings regarding the usefulness of multivitamins, vitamin D, vitamin C, and vitamin E are weak and/or mixed different exercise modalities may have different effects and thus play different roles in breast cancer therapy. Aerobic and resistance training combined during breast cancer chemotherapy may confer a survival benefit, while yoga may improve outcome in lymphedema patients. Current evidence suggests that meditation, yoga, breathing, music therapy, guided imagery, and hypnosis may improve mood and quality of life during breast cancer treatment. Acupuncture is useful for treating side effects of breast cancer therapies, including hot flushes, aromatase inhibitor-induced joint pain, chemotherapy-induced peripheral neuropathy, and vulvodynia. Vaginal moisturizers and vaginal rings supplying low-dose estrogen can be useful in the treatment of symptoms of estrogen-deprivation states caused by breast cancer treatments; such symptoms include vaginal dryness, dyspareunia, and sexual dysfunction. Carbon dioxide laser technology can rejuvenate atrophied vaginal mucosa and relieve dyspareunia, allowing avoidance of estrogen therapy. Tertiary sexual health centers are available for referral.
C1 [Lemanne, Dawn; Maizes, Victoria] Univ Arizona, Ctr Integrat Med, 1249N Mt Ave,POB 245153, Tucson, AZ 85724 USA.
   [Lemanne, Dawn] Oregon Integrat Oncol, Ashland, OR USA.
   [Lemanne, Dawn] Natl Inst Integrat Med, Melbourne, Vic, Australia.
C3 University of Arizona; National Institute of Integrative Medicine -
   Australia
RP Maizes, V (corresponding author), Univ Arizona, Ctr Integrat Med, 1249N Mt Ave,POB 245153, Tucson, AZ 85724 USA.
EM vmaizes@email.arizona.edu
CR Ben-Arye E, 2018, J CANCER RES CLIN, V144, P1825, DOI 10.1007/s00432-018-2700-y
   Bloomquist K, 2018, MED SCI SPORT EXER, V50, P187, DOI 10.1249/MSS.0000000000001443
   Buck K, 2011, BRIT J CANCER, V105, P1151, DOI 10.1038/bjc.2011.374
   Chang ST, 2012, INT J MED MUSHROOMS, V14, P95, DOI 10.1615/IntJMedMushr.v14.i2.10
   Chlebowski RT, 2006, JNCI-J NATL CANCER I, V98, P1767, DOI 10.1093/jnci/djj494
   Cormie P, 2017, EPIDEMIOL REV, V39, P71, DOI 10.1093/epirev/mxx007
   Courneya KS, 2007, CANCER EPIDEM BIOMAR, V16, P2572, DOI 10.1158/1055-9965.EPI-07-0413
   Courneya KS, 2007, J CLIN ONCOL, V25, P4396, DOI 10.1200/JCO.2006.08.2024
   Courneya KS, 2014, MED SCI SPORT EXER, V46, P1744, DOI 10.1249/MSS.0000000000000297
   Crew Katherine D, 2007, J Cancer Surviv, V1, P283, DOI 10.1007/s11764-007-0034-x
   Daenen LGM, 2015, JAMA ONCOL, V1, P350, DOI 10.1001/jamaoncol.2015.0388
   de Groot S, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1663-5
   Dorff TB, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2370-6
   Emond JA, 2014, CANCER EPIDEM BIOMAR, V23, P1273, DOI 10.1158/1055-9965.EPI-13-1218
   Fisher MI, 2014, J BODYW MOV THER, V18, P559, DOI 10.1016/j.jbmt.2014.02.006
   Frydenberg H, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0620-1
   Greenlee Heather, 2014, Journal of the National Cancer Institute Monographs, P346, DOI 10.1093/jncimonographs/lgu041
   Guggenheim Alena G, 2014, Integr Med (Encinitas), V13, P32
   Guha N, 2009, BREAST CANCER RES TR, V118, P395, DOI 10.1007/s10549-009-0321-5
   Harvie Michelle, 2014, Am Soc Clin Oncol Educ Book, pe478, DOI 10.14694/EdBook_AM.2014.34.e478
   Holmes MD, 2005, JAMA-J AM MED ASSOC, V293, P2479, DOI 10.1001/jama.293.20.2479
   Howlader N., 2017, SEER Cancer Statistics Review
   Hui E, 2001, J FOOD COMPOS ANAL, V14, P199, DOI 10.1006/jfca.2000.0941
   Hutchins-Wiese HL, 2014, NUTR CANCER, V66, P68, DOI 10.1080/01635581.2014.847964
   Inoue M, 2001, CANCER LETT, V167, P175, DOI 10.1016/S0304-3835(01)00486-4
   Ishitani K, 2008, AM J EPIDEMIOL, V167, P1197, DOI 10.1093/aje/kwn027
   Joseph TP, 2018, INTEGR CANCER THER, V17, P200, DOI 10.1177/1534735417736861
   Kaledkiewicz Emilia, 2018, Rocz Panstw Zakl Hig, V69, P175
   Kendall A, 2006, ANN ONCOL, V17, P584, DOI 10.1093/annonc/mdj127
   Kirkham AA, 2018, ONCOLOGIST, V23, P105, DOI 10.1634/theoncologist.2017-0141
   Ko KP, 2014, ASIAN PAC J CANCER P, V15, P7001, DOI 10.7314/APJCP.2014.15.17.7001
   Kodama Noriko, 2002, Altern Med Rev, V7, P236
   Krause Megan, 2010, Female Pelvic Med Reconstr Surg, V16, P188, DOI 10.1097/SPV.0b013e3181d7e86e
   Kwan ML, 2013, CANCER EPIDEM BIOMAR, V22, P32, DOI 10.1158/1055-9965.EPI-12-1022
   Larsson SC, 2010, AM J CLIN NUTR, V91, P1268, DOI 10.3945/ajcn.2009.28837
   Le CP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10634
   Lee C, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003293
   Lee CH, 2010, CANCER RES, V70, P1564, DOI 10.1158/0008-5472.CAN-09-3228
   Lindau ST, 2016, CA-CANCER J CLIN, V66, P241, DOI 10.3322/caac.21337
   Liu JX, 2013, MAYO CLIN PROC, V88, P1066, DOI 10.1016/j.mayocp.2013.06.020
   Löf M, 2015, EUR J EPIDEMIOL, V30, P1027, DOI 10.1007/s10654-015-0052-3
   Loudon A, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-214
   Lu WD, 2018, HEMATOL ONCOL CLIN N, V32, P519, DOI 10.1016/j.hoc.2018.01.009
   Lyman GH, 2018, J ONCOL PRACT, V14, P495, DOI 10.1200/JOP.18.00283
   de Rezende LFM, 2018, BRIT J SPORT MED, V52, P826, DOI 10.1136/bjsports-2017-098391
   Mao JJ, 2015, J CLIN ONCOL, V33, P3615, DOI 10.1200/JCO.2015.60.9412
   Marinac CR, 2016, JAMA ONCOL, V2, P1049, DOI 10.1001/jamaoncol.2016.0164
   Martínez-Montemayor MM, 2010, CLIN EXP METASTAS, V27, P465, DOI 10.1007/s10585-010-9336-x
   Modica C, 2018, BREAST CARE, V13, P102, DOI 10.1159/000488716
   Morris KT, 2000, AM J SURG, V179, P407, DOI 10.1016/S0002-9610(00)00358-5
   Nakachi K, 1998, JPN J CANCER RES, V89, P254, DOI 10.1111/j.1349-7006.1998.tb00556.x
   Pierce JP, 2007, JAMA-J AM MED ASSOC, V298, P289, DOI 10.1001/jama.298.3.289
   Poole EM, 2013, BREAST CANCER RES TR, V139, P529, DOI 10.1007/s10549-013-2548-4
   Raffaghello L, 2008, P NATL ACAD SCI USA, V105, P8215, DOI 10.1073/pnas.0708100105
   Salvatore S, 2017, SEX MED REV, V5, P486, DOI 10.1016/j.sxmr.2017.07.003
   Schairer C, 2004, JNCI-J NATL CANCER I, V96, P1311, DOI 10.1093/jnci/djh253
   Schlaeger JM, 2015, J SEX MED, V12, P1019, DOI 10.1111/jsm.12830
   Schmitz KH, 2010, JAMA-J AM MED ASSOC, V304, P2699, DOI 10.1001/jama.2010.1837
   Schulz SVW, 2018, DISABIL REHABIL, V40, P1501, DOI 10.1080/09638288.2017.1300688
   Schwartz AL, 2007, ONCOL NURS FORUM, V34, P627, DOI 10.1188/07.ONF.627-633
   Shi YD, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-571
   Simonsson M, 2013, CANCER CAUSE CONTROL, V24, P929, DOI 10.1007/s10552-013-0169-1
   Sloan EK, 2010, CANCER RES, V70, P7042, DOI 10.1158/0008-5472.CAN-10-0522
   Song KB, 2006, J NUTR, V136, P1347, DOI 10.1093/jn/136.5.1347
   Standish Leanna J, 2008, J Soc Integr Oncol, V6, P122
   Suarez-Arroyo Ivette J, 2017, Medicines (Basel), V4, DOI [10.3390/medicines4010015, 10.3390/medicines4010015]
   Thomas RJ, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-096343
   Thompson LU, 2005, CLIN CANCER RES, V11, P3828, DOI 10.1158/1078-0432.CCR-04-2326
   Thomson CA, 2017, BREAST CANCER RES TR, V165, P97, DOI 10.1007/s10549-017-4292-7
   Thomson CA, 2011, BREAST CANCER RES TR, V125, P519, DOI 10.1007/s10549-010-1014-9
   van Waart H, 2015, J CLIN ONCOL, V33, P1918, DOI 10.1200/JCO.2014.59.1081
   Wang YM, 2012, CANCER CHEMOTH PHARM, V69, P1213, DOI 10.1007/s00280-012-1828-8
   Wassertheil-Smoller S, 2013, BREAST CANCER RES TR, V141, P495, DOI 10.1007/s10549-013-2712-x
   Witt CM, 2015, BREAST CANCER RES TR, V149, P449, DOI 10.1007/s10549-014-3249-3
   World Bank, 2018, CONT UPD PROJ EXP RE, P32
   Wu Anna H, 2013, Am Soc Clin Oncol Educ Book, P102, DOI 10.1200/EdBook_AM.2013.33.102
   Yang XJ, 2015, CLIN EXP METASTAS, V32, P323, DOI 10.1007/s10585-015-9709-2
   Zhang FF, 2017, CANCER-AM CANCER SOC, V123, P2070, DOI 10.1002/cncr.30615
   Zheng JL, 2018, CANCER EPIDEM BIOMAR, V27, P454, DOI [10.1158/1055-9965.EPI-17-0569, 10.1158/1055-9965.epi-17-0569]
NR 79
TC 10
Z9 14
U1 0
U2 47
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1075-5535
EI 1557-7708
J9 J ALTERN COMPLEM MED
JI J. Altern. Complement Med.
PD SEP
PY 2018
VL 24
IS 9-10
BP 902
EP 909
DI 10.1089/acm.2018.0150
PG 8
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA GU6VP
UT WOS:000445455600007
PM 30247957
DA 2026-01-16
ER

PT J
AU Pugh, SL
   Wyatt, G
   Wong, RKW
   Sagar, SM
   Yueh, B
   Singh, AK
   Yao, M
   Nguyen-Tan, PF
   Yom, SS
   Cardinale, FS
   Sultanem, K
   Hodson, DI
   Krempl, GA
   Chavez, A
   Yeh, AM
   Bruner, DW
AF Pugh, Stephanie L.
   Wyatt, Gwen
   Wong, Raimond K. W.
   Sagar, Stephen M.
   Yueh, Bevan
   Singh, Anurag K.
   Yao, Min
   Nguyen-Tan, Phuc Felix
   Yom, Sue S.
   Cardinale, Francis S.
   Sultanem, Khalil
   Hodson, D. Ian
   Krempl, Greg A.
   Chavez, Ariel
   Yeh, Alexander M.
   Bruner, Deborah W.
TI Exploratory Factor Analysis of NRG Oncology's University of Washington
   Quality of Life Questionnaire-RTOG Modification
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE Quality of life; factor analysis; xerostomia
ID NECK-CANCER PATIENTS; RADIATION-INDUCED XEROSTOMIA; COLONY-STIMULATING
   FACTOR; ORAL COMPLICATIONS; PHASE-III; UW-QOL; HEAD; PATIENT; IMPACT;
   RADIOTHERAPY
AB Context. The 15-item University of Washington Quality of Life questionnaire-Radiation Therapy Oncology Group (RTOG) modification (UW-QOL-RTOG modification) has been used in several trials of head and neck cancer conducted by NRG Oncology such as RTOG 9709, RTOG 9901, RTOG 0244, and RTOG 0537.
   Objectives. This study is an exploratory factor analysis (EFA) to establish validity and reliability of the instrument subscales.
   Methods. EFA on the UW-QOL-RTOG modification was conducted using baseline data from NRG Oncology's RTOG 0537, a trial of acupuncture-like transcutaneous electrical nerve stimulation in treating radiation-induced xerostomia. Cronbach alpha coefficient was calculated to measure reliability; correlation with the University of Michigan Xerostomia Related Quality of Life Scale was used to evaluate concurrent validity; and correlations between consecutive time points were used to assess test-retest reliability.
   Results. The 15-item EFA of the modified tool resulted in 11 items split into four factors: mucus, eating, pain, and activities. Cronbach alpha ranged from 0.71 to 0.93 for the factors and total score, consisting of all 11 items. There were strong correlations (rho >= 0.60) between consecutive time points and between total score and the Xerostomia Related Quality of Life Scale total score (rho > 0.65).
   Conclusion. The UW-QOLeRTOG modification is a valid tool that can be used to assess symptom burden of head and neck cancer patients receiving radiation therapy or those who have recently completed radiation. The modified tool has acceptable reliability, concurrent validity, and test-retest reliability in this patient population, as well as the advantage of having being shortened from 15 to 11 items. (C) 2016 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
C1 [Pugh, Stephanie L.] NRG Oncol Stat & Data Management Ctr, Philadelphia, PA USA.
   [Wyatt, Gwen] Michigan State Univ, E Lansing, MI 48824 USA.
   [Wong, Raimond K. W.; Sagar, Stephen M.; Hodson, D. Ian] McMaster Univ, Juravinski Canc Ctr, Hamilton, ON, Canada.
   [Yueh, Bevan] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA.
   [Singh, Anurag K.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
   [Yao, Min] Case Western Reserve Univ, Cleveland, OH 44106 USA.
   [Nguyen-Tan, Phuc Felix] Hop Notre Dame De Bon Secours, CHUM, Montreal, PQ, Canada.
   [Yom, Sue S.] UCSF Med Ctr, San Francisco, CA USA.
   [Cardinale, Francis S.] Yale Univ, New Haven, CT USA.
   [Sultanem, Khalil] McGill Univ, Montreal, PQ, Canada.
   [Krempl, Greg A.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
   [Chavez, Ariel] John H Stroger Jr Hosp Cook Cty, Chicago, IL USA.
   [Yeh, Alexander M.] Indiana Univ Hosp, Melvin & Bren Simon Canc Ctr, 550 N Univ Blvd, Indianapolis, IN 46202 USA.
   [Bruner, Deborah W.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
C3 Michigan State University; McMaster University; University of Minnesota
   System; University of Minnesota Twin Cities; Roswell Park Comprehensive
   Cancer Center; University System of Ohio; Case Western Reserve
   University; Universite de Montreal; University of California System;
   University of California San Francisco; UCSF Medical Center; Yale
   University; McGill University; University of Oklahoma System; University
   of Oklahoma Health Sciences Center; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   John H Stroger Junior Hospital Cook County; Indiana University Health;
   IU Health University Hospital; Emory University
RP Pugh, SL (corresponding author), 1818 Market St,Suite 1720, Philadelphia, PA 19103 USA.
EM pughs@nrgoncology.org
OI Sagar, Stephen/0009-0002-9013-1989; Bruner, Deborah/0000-0002-5770-9948;
   Yom, Sue/0000-0002-0779-7476
FU National Cancer Institute (NCI) [U10CA21661, U10CA180868, U10CA180822,
   U10CA37422, UG1CA189867]; National Cancer Institute [U10CA180868,
   U10CA180822, UG1CA190000, UG1CA189867] Funding Source: NIH RePORTER
FX This project was supported by grants U10CA21661 (RTOG-Ops-Stat),
   U10CA180868 (NRG Oncology Operations), U10CA180822 (NRG Oncology SDMC),
   U10CA37422 (CCOP), UG1CA189867 (NCORP) from the National Cancer
   Institute (NCI).
CR Basch E, 2006, LANCET ONCOL, V7, P903, DOI 10.1016/S1470-2045(06)70910-X
   Cleeland CS, 1997, ANN INTERN MED, V127, P813, DOI 10.7326/0003-4819-127-9-199711010-00006
   Cohen J, 1988, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587
   Di Maio M, 2015, J CLIN ONCOL, V33, P910, DOI 10.1200/JCO.2014.57.9334
   Dirix P, 2006, CANCER-AM CANCER SOC, V107, P2525, DOI 10.1002/cncr.22302
   Elting LS, 2008, CANCER-AM CANCER SOC, V113, P2704, DOI 10.1002/cncr.23898
   Epstein JB, 2010, SUPPORT CARE CANCER, V18, P1023, DOI 10.1007/s00520-010-0897-7
   Fisher J, 2003, INT J RADIAT ONCOL, V56, P832, DOI 10.1016/S0360-3016(03)00121-4
   Germano F, 2015, MINERVA STOMATOL, V64, P189
   Goepfert RP, 2015, LARYNGOSCOPE, V125, P869, DOI 10.1002/lary.25023
   HASSAN SJ, 1993, HEAD NECK-J SCI SPEC, V15, P485, DOI 10.1002/hed.2880150603
   Henson BS, 2001, ORAL ONCOL, V37, P84, DOI 10.1016/S1368-8375(00)00063-4
   Hoffman KE, 2014, QUAL LIFE RES, V23, P1841, DOI 10.1007/s11136-014-0628-5
   Hovan AJ, 2010, SUPPORT CARE CANCER, V18, P1081, DOI 10.1007/s00520-010-0902-1
   Jensen SB, 2010, SUPPORT CARE CANCER, V18, P1039, DOI 10.1007/s00520-010-0827-8
   Jha N, 2012, INT J RADIAT ONCOL, V84, P437, DOI 10.1016/j.ijrobp.2012.02.034
   Laraway DC, 2012, BRIT J ORAL MAX SURG, V50, P122, DOI 10.1016/j.bjoms.2010.12.005
   List MA, 2000, CURR OPIN ONCOL, V12, P215, DOI 10.1097/00001622-200005000-00006
   MORTON RP, 1995, J LARYNGOL OTOL, V109, P1029, DOI 10.1017/S0022215100131962
   Movsas B, 2003, SEMIN RADIAT ONCOL, V13, P235, DOI 10.1016/S1053-4296(03)00029-8
   Murphy BA, 2015, J CLIN ONCOL, V33, P3314, DOI 10.1200/JCO.2015.61.3836
   Nunnally J.C., 1978, PSYCHOMETRIC THEORY
   OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014
   Onakoya PA, 2006, J NATL MED ASSOC, V98, P765
   Osborne J.W., 2005, PRACTICAL ASSESSMENT, V10, P1, DOI [10.7275/jyj1-4868, DOI 10.7275/JYJ1-4868, 10.7275/JYJ1-4868]
   Parker PA, 2003, PSYCHO-ONCOLOGY, V12, P183, DOI 10.1002/pon.635
   Petersen MA, 2006, EUR J CANCER, V42, P1159, DOI 10.1016/j.ejca.2006.01.032
   Reeve BB, 2013, HEAD NECK-J SCI SPEC, V35, P1255, DOI 10.1002/hed.23115
   Rogers SN, 2010, ARCH OTOLARYNGOL, V136, P352, DOI 10.1001/archoto.2010.32
   Rogers SN, 2009, ARCH OTOLARYNGOL, V135, P369, DOI 10.1001/archoto.2009.7
   Rogers SN, 2006, ORAL ONCOL, V42, P281, DOI 10.1016/j.oraloncology.2005.08.002
   Rogers SN, 2002, HEAD NECK-J SCI SPEC, V24, P521, DOI 10.1002/hed.10106
   Rogers SN, 2012, J CRANIOMAXILLOFAC S, V30, P125
   Ryu JK, 2007, INT J RADIAT ONCOL, V67, P643, DOI 10.1016/j.ijrobp.2006.09.043
   Scarantino Charles, 2006, J Support Oncol, V4, P252
   Sonis ST, 2002, ONCOLOGY-NY, V16, P680
   Trotti A, 2003, RADIOTHER ONCOL, V66, P253, DOI 10.1016/S0167-8140(02)00404-8
   US Department of Health and Human Services (USDHHS); Guidance for industry, 2009, GUID IND PAT REP OUT
   Weymuller EA, 2001, ARCH OTOLARYNGOL, V127, P489
   Wong RKW, 2015, INT J RADIAT ONCOL, V92, P220, DOI 10.1016/j.ijrobp.2015.01.050
   Wyatt G, 2016, QUAL LIFE RES, V25, P2323, DOI 10.1007/s11136-016-1255-0
   Xiao CH, 2013, CANCER NURS, V36, pE1, DOI 10.1097/NCC.0b013e318269040f
NR 42
TC 5
Z9 8
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD JAN
PY 2017
VL 53
IS 1
BP 139
EP U180
DI 10.1016/j.jpainsymman.2016.11.002
PG 9
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
   Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; General & Internal Medicine;
   Neurosciences & Neurology
GA EO2BW
UT WOS:000396502600018
PM 27899312
OA Green Submitted, Bronze
DA 2026-01-16
ER

PT J
AU Desideri, I
   Lucidi, S
   Francolini, G
   Meattini, I
   Ciccone, LP
   Salvestrini, V
   Valzano, M
   Morelli, I
   Angelini, L
   Scotti, V
   Bonomo, P
   Greto, D
   Terziani, F
   Becherini, C
   Visani, L
   Livi, L
AF Desideri, Isacco
   Lucidi, Sara
   Francolini, Giulio
   Meattini, Icro
   Ciccone, Lucia Pia
   Salvestrini, Viola
   Valzano, Marianna
   Morelli, Ilaria
   Angelini, Lucia
   Scotti, Vieri
   Bonomo, Pierluigi
   Greto, Daniela
   Terziani, Francesca
   Becherini, Carlotta
   Visani, Luca
   Livi, Lorenzo
TI Use of an alfa-lipoic, Methylsulfonylmethane, Boswellia serrata and
   Bromelain dietary supplement (OPERA®) for aromatase inhibitors-related
   arthralgia management (AIA): a prospective phase II trial (NCT04161833)
SO MEDICAL ONCOLOGY
LA English
DT Article
DE Arthralgia; Breast cancer; Aromatase inhibitors; Dietary supplement;
   Quality of life
ID EARLY BREAST-CANCER; MUSCULOSKELETAL SYMPTOMS; POSTMENOPAUSAL WOMEN;
   RANDOMIZED-TRIAL; ADJUVANT TREATMENT; JOINT SYMPTOMS; PAIN; TAMOXIFEN;
   THERAPY; ACUPUNCTURE
AB Aromatase Inhibitors (AIs) are recommended for the adjuvant treatment of hormone receptor positive breast cancer in both high-risk pre-menopausal and post-menopausal population; arthralgia is the main cause of discontinuation of therapy and affects up to 25% of population on AI treatment. The objective of the study was to prospectively evaluate OPERA (R) (GAM-FARMA srl, Milan, Italy), a new dietary supplement where oc-Lipoic acid, Boswellia serrata, Methylsulfonylmethane and Bromelain are combined in a single hard-gelatin capsule to be taken once a day. Fifty-three patients with arthralgia (NCI-CTCAE v4.0 grade >= 1) occurring during AI therapy were enrolled. All patients received OPERA (R) from enrollment (TO) up to sixth months (T3). Patients' AI-related arthralgia was evaluated every two months with VAS Scale, PRAI questionnaire, and CTCAE scale. Primary endpoint was the number of patients with symptom resolution (GO) at T3 if compared to TO, according to CTCAE and VAS scale. Secondary endpoints were decrease in arthralgia intensity measured with PRAI score at T3 compared to baseline, safety of OPERA (R) and rate of AI interruption. Treatment with OPERA (R) supplement was overall well tolerated; no relevant toxicities related to OPERA (R) intake were reported. Seven subjects (13.2%) were not included in the final analysis because of consent withdrawal. 46 participants were eligible for final analysis. According to CTCAE scale, 10 out of 46 patients reported symptoms resolution at 6-month follow-up from the time of enrollment TO (p = 0.0009). According to VAS score, 5 patients reported complete resolution of symptoms at T3 if compared to baseline starting situation TO (p = 0.0222). Analysis of PRAI score showed a significant reduction in arthralgia-related pain perceived (p = 0.0001). OPERA (R) was able to reduce the intensity of arthralgia related to AI therapy. Randomized, double-blind studies are warranted to confirm the effectiveness of this dietary supplement.
C1 [Desideri, Isacco; Francolini, Giulio; Meattini, Icro; Scotti, Vieri; Bonomo, Pierluigi; Greto, Daniela; Becherini, Carlotta] Azienda Osped Univ Careggi, Radiat Oncol Unit, Florence, Italy.
   [Desideri, Isacco; Lucidi, Sara; Meattini, Icro; Ciccone, Lucia Pia; Salvestrini, Viola; Valzano, Marianna; Morelli, Ilaria; Angelini, Lucia; Livi, Lorenzo] Univ Florence, Dept Expt & Clin Biomed Sci Mario Serio, Florence, Italy.
   [Terziani, Francesca] Azienda USL Toscana Sud, Radiotherapy Unit Osped S Donato & Santa Maria Gr, Arezzo, Italy.
   [Visani, Luca] IFCA, Radiotherapy Dept, Florence, Italy.
   [Morelli, Ilaria] Univ Florence, Azienda Osped Univ Careggi, Dept Expt & Clin Biomed Sci, Radiat Oncol Unit, Largo Brambilla 3, I-50134 Florence, Italy.
C3 University of Florence; Azienda Ospedaliero Universitaria Careggi;
   University of Florence; University of Florence; Azienda Ospedaliero
   Universitaria Careggi
RP Morelli, I (corresponding author), Univ Florence, Dept Expt & Clin Biomed Sci Mario Serio, Florence, Italy.; Morelli, I (corresponding author), Univ Florence, Azienda Osped Univ Careggi, Dept Expt & Clin Biomed Sci, Radiat Oncol Unit, Largo Brambilla 3, I-50134 Florence, Italy.
EM ilaria.morelli@unifi.it
RI Meattini, Icro/J-7009-2016; Francolini, Giulio/ACV-9935-2022; Ciccone,
   Lucia Pia/AAD-3056-2022; Becherini, Carlotta/GSI-8127-2022; livi,
   lorenzo/K-8934-2016; Scotti, Vieri/HJG-7364-2022; Desideri,
   Isacco/O-1633-2019
OI Meattini, Icro/0000-0002-1861-2895; Morelli, Ilaria/0000-0002-4787-6902;
   Ciccone, Lucia Pia/0000-0002-7657-7020; Greto,
   Daniela/0000-0002-2667-0841; Desideri, Isacco/0000-0002-9880-8387
CR Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Beckwée D, 2017, SUPPORT CARE CANCER, V25, P1673, DOI 10.1007/s00520-017-3613-z
   Bodai Balazs I, 2015, Perm J, V19, P48, DOI [10.7812/tpp/14-241, 10.7812/TPP/14-241]
   Briot K, 2010, BREAST CANCER RES TR, V120, P127, DOI 10.1007/s10549-009-0692-7
   Burstein HJ, 2007, BREAST, V16, P223, DOI 10.1016/j.breast.2007.01.011
   Castel LD, 2015, PATIENT-RELAT OUTCOM, V6, P205, DOI 10.2147/PROM.S47997
   Chien HC, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020566
   Coombes RC, 2004, NEW ENGL J MED, V350, P1081, DOI 10.1056/NEJMoa040331
   Crew KD, 2007, J CLIN ONCOL, V25, P3877, DOI 10.1200/JCO.2007.10.7573
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Cuzick J, 2010, LANCET ONCOL, V11, P1135, DOI 10.1016/S1470-2045(10)70257-6
   Desideri I, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-0907-4
   Fenlon D, 2013, J PAIN SYMPTOM MANAG, V46, P523, DOI 10.1016/j.jpainsymman.2012.10.282
   Fernandes R, 2018, SUPPORT CARE CANCER, V26, P3073, DOI 10.1007/s00520-018-4161-x
   Fernandes R, 2016, SUPPORT CARE CANCER, V24, P3633, DOI 10.1007/s00520-016-3256-5
   Goss PE, 2005, JNCI-J NATL CANCER I, V97, P1262, DOI 10.1093/jnci/dji250
   Hack CC, 2020, BREAST, V50, P11, DOI 10.1016/j.breast.2019.12.017
   Hawker GA, 2011, ARTHRIT CARE RES, V63, pS240, DOI 10.1002/acr.20543
   Henry NL, 2019, CANCER-AM CANCER SOC, V125, P2123, DOI 10.1002/cncr.32024
   Henry NL, 2018, J CLIN ONCOL, V36, P326, DOI 10.1200/JCO.2017.74.6651
   Henry NL, 2011, CANCER-AM CANCER SOC, V117, P5469, DOI 10.1002/cncr.26230
   Hershman DL, 2015, J CLIN ONCOL, V33, P1910, DOI 10.1200/JCO.2014.59.5595
   Hilditch JR, 1996, MATURITAS, V24, P161, DOI 10.1016/0378-5122(96)01038-9
   Howell A, 2005, LANCET, V365, P60, DOI 10.1016/s0140-6736(04)17666-6
   Ingle JN, 2006, BREAST CANCER RES TR, V99, P295, DOI 10.1007/s10549-006-9207-y
   Jacobsen PB, 2015, PSYCHO-ONCOLOGY, V24, P1578, DOI 10.1002/pon.3756
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010
   Kubo M, 2012, ANTICANCER RES, V32, P2331
   Laroche F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187165
   Lombard JM, 2016, SUPPORT CARE CANCER, V24, P2139, DOI 10.1007/s00520-015-3001-5
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Menas Pamela, 2012, J Oncol Pharm Pract, V18, P387, DOI 10.1177/1078155211434853
   Moscetti L, 2015, TUMORI, V101, P469, DOI 10.5301/tj.5000376
   Nahm N, 2018, ASIA-PAC J CLIN ONCO, V14, P374, DOI 10.1111/ajco.12845
   National Cancer Institute-Common, TOX CRIT ADV EV V4 0
   Niravath P, 2013, ANN ONCOL, V24, P1443, DOI 10.1093/annonc/mdt037
   Oh B, 2013, ACUPUNCT MED, V31, P264, DOI 10.1136/acupmed-2012-010309
   Presant CA, 2007, CLIN BREAST CANCER, V7, P775, DOI 10.3816/CBC.2007.n.038
   Regan MM, 2011, LANCET ONCOL, V12, P1101, DOI 10.1016/S1470-2045(11)70270-4
   Roberts K, 2017, CRIT REV ONCOL HEMAT, V111, P66, DOI 10.1016/j.critrevonc.2017.01.010
   Roberts KE, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012988.pub2
   Saibil S, 2010, CURR ONCOL, V17, P168
   Uhlenbruck G, 2010, IN VIVO, V24, P799
NR 43
TC 4
Z9 4
U1 0
U2 3
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1357-0560
EI 1559-131X
J9 MED ONCOL
JI Med. Oncol.
PD JUN 6
PY 2022
VL 39
IS 8
AR 113
DI 10.1007/s12032-022-01723-x
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 1W5CC
UT WOS:000806790300004
PM 35666314
DA 2026-01-16
ER

PT J
AU Sadek, KM
   Shib, NA
   Taher, ES
   Rashed, F
   Shukry, M
   Atia, GA
   Taymour, N
   El-Nablaway, M
   Ibrahim, AM
   Ramadan, MM
   Abdelkader, A
   Abdo, M
   Imbrea, I
   Pet, E
   Ali, LS
   Abdeen, A
AF Sadek, Kadry M.
   Shib, Naira A.
   Taher, Ehab S.
   Rashed, Fatema
   Shukry, Mustafa
   Atia, Gamal A.
   Taymour, Noha
   El-Nablaway, Mohammad
   Ibrahim, Ateya M.
   Ramadan, Mahmoud M.
   Abdelkader, Afaf
   Abdo, Mohamed
   Imbrea, Ilinca
   Pet, Elena
   Ali, Lashin S.
   Abdeen, Ahmed
TI Harnessing the power of bee venom for therapeutic and regenerative
   medical applications: an updated review
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Review
DE apitherapy; anti-inflammation; anticancer; antimicrobial;
   neuroprotection; wound healing
ID NONALCOHOLIC FATTY LIVER; RHEUMATOID-ARTHRITIS; BREAST-CANCER;
   ANTIOXIDANT ACTIVITY; PARKINSONS-DISEASE; ACID-PHOSPHATASE; POTENTIAL
   USE; MELITTIN; CELL; ACUPUNCTURE
AB Honeybees have been helpful insects since ancient centuries, and this benefit is not limited to being a honey producer only. After the bee stings a person, pain, and swelling occur in this place, due to the effects of bee venom (BV). This is not a poison in the total sense of the word because it has many benefits, and this is due to its composition being rich in proteins, peptides, enzymes, and other types of molecules in low concentrations that show promise in the treatment of numerous diseases and conditions. BV has also demonstrated positive effects against various cancers, antimicrobial activity, and wound healing versus the human immunodeficiency virus (HIV). Even though topical BV therapy is used to varying degrees among countries, localized swelling or itching are common side effects that may occur in some patients. This review provides an in-depth analysis of the complex chemical composition of BV, highlighting the diverse range of bioactive compounds and their therapeutic applications, which extend beyond the well-known anti-inflammatory and pain-relieving effects, showcasing the versatility of BV in modern medicine. A specific search strategy was followed across various databases; Web of sciences, Scopus, Medline, and Google Scholar including in vitro and in vivo clinical studies.to outline an overview of BV composition, methods to use, preparation requirements, and Individual consumption contraindications. Furthermore, this review addresses safety concerns and emerging approaches, such as the use of nanoparticles, to mitigate adverse effects, demonstrating a balanced and holistic perspective. Importantly, the review also incorporates historical context and traditional uses, as well as a unique focus on veterinary applications, setting it apart from previous works and providing a valuable resource for researchers and practitioners in the field.
C1 [Sadek, Kadry M.; Shib, Naira A.] Damanhour Univ, Fac Vet Med, Dept Biochem, Damanhour, Egypt.
   [Taher, Ehab S.; Rashed, Fatema] Zarqa Univ, Fac Dent, Dept Basic Med & Dent Sci, Zarqa, Jordan.
   [Shukry, Mustafa] Kafrelsheikh Univ, Fac Vet Med, Dept Physiol, Kafrelsheikh, Egypt.
   [Atia, Gamal A.] Suez Canal Univ, Fac Dent, Dept Oral Med Periodontol & Diag, Ismailia, Egypt.
   [Taymour, Noha] Imam Abdulrahman Bin Faisal Univ, Coll Dent, Dept Substitut Dent Sci, Dammam, Saudi Arabia.
   [El-Nablaway, Mohammad] AlMaarefa Univ, Coll Med, Dept Basic Med Sci, Riyadh, Saudi Arabia.
   [El-Nablaway, Mohammad] Mansoura Univ, Fac Med, Dept Med Biochem, Mansoura, Egypt.
   [Ibrahim, Ateya M.] Prince Sattam Bin Abdulaziz Univ, Coll Nursing, Dept Adm & Nursing Educ, Al Kharj, Saudi Arabia.
   [Ibrahim, Ateya M.] Port Said Univ, Fac Nursing, Dept Family & Community Hlth Nursing, Port Said, Egypt.
   [Ramadan, Mahmoud M.] Univ Sharjah, Coll Med, Dept Clin Sci, Sharjah, U Arab Emirates.
   [Abdelkader, Afaf] Benha Univ, Fac Med, Dept Forens Med & Clin Toxicol, Banha, Egypt.
   [Abdo, Mohamed] Badr Univ Cairo BUC, Sch Vet Med, Dept Anim Histol & Anat, Badr City, Egypt.
   [Abdo, Mohamed] Univ Sadat City, Fac Vet Med, Dept Anat & Embryol, Sadat City, Egypt.
   [Imbrea, Ilinca] Univ Life Sci King Mihai I Timisoara, Fac Engn & Appl Technol, Dept Forestry, Timisoara, Romania.
   [Pet, Elena] Univ Life Sci King Mihai I Timisoara, Fac Management & Rural Tourism, Dept Management & Rural Dev, Timisoara, Romania.
   [Ali, Lashin S.] Al Ahliyya Amman Univ, Fac Dent, Dept Basic Med Sci, Amman, Jordan.
   [Abdeen, Ahmed] Benha Univ, Fac Vet Med, Dept Forens Med & Toxicol, Toukh, Egypt.
C3 Egyptian Knowledge Bank (EKB); Damanhour University; Zarqa University;
   Egyptian Knowledge Bank (EKB); Kafrelsheikh University; Egyptian
   Knowledge Bank (EKB); Suez Canal University; Imam Abdulrahman Bin Faisal
   University; Almaarefa University; Egyptian Knowledge Bank (EKB);
   Mansoura University; Prince Sattam Bin Abdulaziz University; Egyptian
   Knowledge Bank (EKB); Port Said University; University of Sharjah;
   Egyptian Knowledge Bank (EKB); Benha University; Badr University in
   Cairo; Egyptian Knowledge Bank (EKB); University of Sadat City;
   Al-Ahliyya Amman University; Egyptian Knowledge Bank (EKB); Benha
   University
RP Ibrahim, AM (corresponding author), Prince Sattam Bin Abdulaziz Univ, Coll Nursing, Dept Adm & Nursing Educ, Al Kharj, Saudi Arabia.; Ibrahim, AM (corresponding author), Port Said Univ, Fac Nursing, Dept Family & Community Hlth Nursing, Port Said, Egypt.; Imbrea, I (corresponding author), Univ Life Sci King Mihai I Timisoara, Fac Engn & Appl Technol, Dept Forestry, Timisoara, Romania.; Abdeen, A (corresponding author), Benha Univ, Fac Vet Med, Dept Forens Med & Toxicol, Toukh, Egypt.
EM a.eleglany@psau.edu.sa; ilinca_imbrea@usvt.ro;
   ahmed.abdeen@fvtm.bu.edu.eg
RI アブデン, アハメド/AAI-4849-2020; Imbrea, Ilinca/AAF-3262-2021; Abdelkader,
   Afaf/GQQ-1541-2022; Elnablaway, Mohammad/GRX-9556-2022; Taher,
   Ehab/MZQ-4407-2025; Abdo, Mohamed/N-2377-2019; shukry,
   mustafa/AAB-9324-2019; sadek, kadry/ABE-5737-2021; Ibrahim, Ateya
   megahed/HPF-6878-2023; Taymour, Noha/ABT-1234-2022; Ramadan,
   Mahmoud/KLY-6115-2024
OI Elnablaway, Mohammad/0000-0003-2494-6004; Ibrahim, Ateya
   megahed/0000-0001-8192-0017; Taymour, Noha/0000-0002-1527-638X; Ramadan,
   Mahmoud/0000-0001-8843-0141; Atia, Gamal Abdel
   Nasser/0000-0002-7040-8496
FU Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia
   [PSAU/2023/R/1445]; Zarqa University-Jordan; Mutah University, Jordan;
   AlMaarefa University, Riydah, Saudi Arabia
FX The author(s) declare that financial support was received for the
   research, authorship, and/or publication of this article. This work is
   supported via Prince Sattam bin Abdulaziz University project number
   (PSAU/2023/R/1445), Al-Kharj, Saudi Arabia. This research is also funded
   partially by Zarqa University-Jordan and Mutah University, Jordan. The
   project 6PFE of the University of Life Sciences "King Mihai I" from
   Timisoara and Research Institute for Biosecurity and Bioengineering from
   Timisoara is also appreciated. The authors would also like to thank
   AlMaarefa University, Riydah, Saudi Arabia for supporting this research.
CR El-Aziz AHA, 2020, J ANIM PHYSIOL AN N, V104, P186, DOI 10.1111/jpn.13227
   Abd El-Gawad A, 2023, J DRUG DELIV SCI TEC, V84, DOI 10.1016/j.jddst.2023.104545
   Abd El-Wahed AA, 2018, STUD NAT PROD CHEM, V60, P459, DOI 10.1016/B978-0-444-64181-6.00013-9
   Salem RA, 2024, Kufa Journal for Agricultural Sciences, V16, P177, DOI [10.36077/kjas/2024/v16i1.13633, 10.36077/kjas/2024/v16i1.13633, DOI 10.36077/KJAS/2024/V16I1.13633]
   Ahmed-Farid OA, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-00764-y
   Aksoz E, 2019, PHARMACOL REP, V71, P818, DOI 10.1016/j.pharep.2019.04.015
   Al-Ani I, 2015, PHYTOMEDICINE, V22, P245, DOI 10.1016/j.phymed.2014.11.019
   Al-Sayigh M. A., 2024, Life Sciences
   AL-Shaeli SJJ, 2022, VET WORLD, V15, P2357, DOI 10.14202/vetworld.2022.2357-2364
   Alalawy AI, 2020, INT J POLYM SCI, V2020, DOI 10.1155/2020/2785304
   Ali AMH, 2024, ADV LIFE SCI-PAK, V11, P49
   Ali EM, 2014, J APICULT RES, V53, P441, DOI 10.3896/IBRA.1.53.4.13
   Ali M.A., 2012, Int. J. Adv. Res. Technol, V1, P69
   Alkhursani SA, 2022, POLYMERS-BASEL, V14, DOI 10.3390/polym14183791
   Alonezi S, 2017, METABOLITES, V7, DOI 10.3390/metabo7020014
   Alonezi S, 2016, METABOLITES, V6, DOI 10.3390/metabo6040035
   Alvarez-Fischer D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061700
   Amin MA, 2014, ARCH PHARM RES, V37, P1016
   An HJ, 2018, BRIT J PHARMACOL, V175, P4310, DOI 10.1111/bph.14487
   An HJ, 2014, INT J MOL MED, V34, P1341, DOI 10.3892/ijmm.2014.1933
   Annila IT, 1996, ANN ALLERG ASTHMA IM, V77, P423, DOI 10.1016/S1081-1206(10)63342-X
   dos Santos-Pinto JRA, 2018, TOXICON, V148, P172, DOI 10.1016/j.toxicon.2018.04.029
   Aparna N., 2020, Econ. Entomol, P115
   Atia GA, 2023, DRUG DES DEV THER, V17, P2985, DOI 10.2147/DDDT.S419361
   Atia GAN, 2024, CERAM INT, V50, P22184, DOI 10.1016/j.ceramint.2024.04.035
   Atia GAN, 2023, PHARMACEUTICALS-BASE, V16, DOI 10.3390/ph16050702
   Atia GAN, 2022, ACS OMEGA, V7, P44532, DOI 10.1021/acsomega.2c05596
   Atia GAN, 2022, POLYMERS-BASEL, V14, DOI 10.3390/polym14153192
   Atia GAN, 2022, POLYMERS-BASEL, V14, DOI 10.3390/polym14142964
   Avalo Z, 2022, TOXINS, V14, DOI 10.3390/toxins14050344
   Bae Young Hyeon, 2015, Journal of Acupuncture Research, V32, P127, DOI 10.13045/acupunct.2015045
   Baek H, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35030-1
   BANKS BEC, 1990, BRIT J PHARMACOL, V99, P350, DOI 10.1111/j.1476-5381.1990.tb14707.x
   Barreto-Núñez R, 2024, GLIA, V72, P1319, DOI 10.1002/glia.24531
   Bava R, 2023, VET SCI, V10, DOI 10.3390/vetsci10020119
   Bellik Yuva, 2015, Anti-Infective Agents, V13, P3, DOI 10.2174/2211352513666150318234624
   Berhe H, 2024, PHARMACEUTICS, V16, DOI 10.3390/pharmaceutics16020227
   Bilò MB, 2019, J INVEST ALLERG CLIN, V29, P180, DOI 10.18176/jiaci.0310
   Bindlish A, 2024, CUREUS J MED SCIENCE, V16, DOI 10.7759/cureus.54855
   Blank S, 2010, J IMMUNOL, V184, P5403, DOI 10.4049/jimmunol.0803709
   Borojeni SK, 2020, J PHARMACOPUNCT, V23, P212, DOI 10.3831/KPI.2020.23.4.212
   Cai HY, 2021, NPJ PARKINSONS DIS, V7, DOI 10.1038/s41531-021-00233-3
   Cai M, 2015, TOXINS, V7, P846, DOI 10.3390/toxins7030846
   Carpena M, 2020, NUTRIENTS, V12, DOI 10.3390/nu12113360
   Cekici A, 2014, PERIODONTOL 2000, V64, P57, DOI 10.1111/prd.12002
   Ceremuga M, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10020247
   ChaChunNam, 2012, Journal of Biomedical and Translational Research, V13, P65
   Chen M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16130-w
   Cherniack EP, 2018, TOXICON, V154, P74, DOI 10.1016/j.toxicon.2018.09.013
   Choi GM, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82298-x
   Choi J, 2017, TOXINS, V9, DOI 10.3390/toxins9110351
   Chu ST, 2007, LIFE SCI, V80, P364, DOI 10.1016/j.lfs.2006.09.024
   Cummings Jeffrey, 2018, Alzheimers Dement (N Y), V4, P195, DOI [10.1016/j.trci.2018.03.009, 10.1016/j.trci.2018.03.009]
   Dadar M, 2019, INFLAMM RES, V68, P125, DOI 10.1007/s00011-018-1208-x
   Darwish SF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079284
   De Graaf DC, 2021, J APICULT RES, V60, DOI 10.1080/00218839.2020.1801073
   de Roodt AR, 2020, TOXICON, V188, P27, DOI 10.1016/j.toxicon.2020.09.014
   de Souza RN, 2017, J ACUPUNCT MERIDIAN, V10, P204, DOI 10.1016/j.jams.2017.04.003
   Değer O, 2023, Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi, V12, P167, DOI [10.37989/gumussagbil.1095925, 10.37989/gumussagbil.1095925]
   Dinu M, 2024, LIFE-BASEL, V14, DOI 10.3390/life14040492
   Djahonkulovna S. L., 2023, Tex. J. Eng. Technol, V20, P38
   Doo AR, 2010, NEUROL RES, V32, pS88, DOI 10.1179/016164109X12537002794282
   Doo KH, 2015, J ALTERN COMPLEM MED, V21, P598, DOI 10.1089/acm.2015.0078
   Duché G, 2024, CHEM REV, V124, P3284, DOI 10.1021/acs.chemrev.3c00608
   Duda GN, 2023, NAT REV RHEUMATOL, V19, P78, DOI 10.1038/s41584-022-00887-0
   El Bakary NM, 2020, INTEGR CANCER THER, V19, DOI 10.1177/1534735420944476
   El Mehdi I, 2022, J ADV PHARM TECHNOL, V13, P154, DOI 10.4103/japtr.japtr_166_21
   El-Beltagy AFBM, 2021, BREAST CANCER-TARGET, V13, P431, DOI 10.2147/BCTT.S306971
   El-Didamony SE, 2022, WORLD J MICROB BIOT, V38, DOI 10.1007/s11274-022-03425-y
   El-Didamony SE, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-17391-w
   El-Gendy A., 2017, Journal of Applied Pharmaceutical Science, V7, P168, DOI 10.7324/japs.2017.70823
   El-Hanoun A, 2020, PHYSIOL BEHAV, V223, DOI 10.1016/j.physbeh.2020.112987
   El-Nablaway M, 2024, LIFE SCI, V349, DOI 10.1016/j.lfs.2024.122671
   El-Seedi H, 2020, TOXINS, V12, DOI 10.3390/toxins12070451
   El-Tedawy DM, 2020, BIOMED REP, V13, DOI 10.3892/br.2020.1327
   Eleiwa NZH, 2023, ENVIRON SCI POLLUT R, V30, P88685, DOI 10.1007/s11356-023-28538-1
   Elenany YE, 2025, J APICULT RES, V64, P908, DOI 10.1080/00218839.2024.2328473
   Elkomy A, 2021, J ANIM PHYSIOL AN N, V105, P975, DOI 10.1111/jpn.13552
   Elnosary ME, 2023, INT J BIOL MACROMOL, V224, P871, DOI 10.1016/j.ijbiomac.2022.10.173
   Eltaher S, 2015, J DERMATOL TREAT, V26, P335, DOI 10.3109/09546634.2014.990411
   Er-Rouassi H, 2023, BIOMOLECULES, V13, DOI 10.3390/biom13040680
   Erkoc P, 2022, TOXINS, V14, DOI 10.3390/toxins14120818
   Fan XG, 2021, ACTA PHARMACOL SIN, V42, P1256, DOI 10.1038/s41401-020-00516-0
   Farook U. B., 2024, Honey Bees, Beekeeping and Bee Products, P189
   Feng NJ, 2023, INT J BIOL MACROMOL, V249, DOI 10.1016/j.ijbiomac.2023.125814
   Frangieh J, 2019, TOXINS, V11, DOI 10.3390/toxins11040191
   Gajski G, 2024, TOXINS, V16, DOI 10.3390/toxins16030117
   Gajski G, 2016, CYTOTECHNOLOGY, V68, P1197, DOI 10.1007/s10616-015-9879-4
   Galante P, 2023, SCI REP-UK, V13, DOI 10.1038/s41598-023-38828-w
   Gao C, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392-023-01588-0
   Gasanoff E, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222011122
   Ghadiri N, 2024, FRONT IMMUNOL, V15, DOI 10.3389/fimmu.2024.1310443
   Ghasemi N, 2017, CELL J, V19, P1
   Giannenas I, 2020, FEED ADDITIVES: AROMATIC PLANTS AND HERBS IN ANIMAL NUTRITION AND HEALTH, P1, DOI 10.1016/B978-0-12-814700-9.00001-7
   Giribaldi J, 2021, BIOTECHNOL ADV, V50, DOI 10.1016/j.biotechadv.2021.107769
   GMACHL M, 1993, P NATL ACAD SCI USA, V90, P3569, DOI 10.1073/pnas.90.8.3569
   Golubnitschaja O, 2016, TUMOR BIOL, V37, P12941, DOI 10.1007/s13277-016-5168-x
   Gong HN, 2023, J COLLOID INTERF SCI, V637, P182, DOI 10.1016/j.jcis.2023.01.051
   Govindasamy B, 2023, INT J BIOL MACROMOL, V253, DOI 10.1016/j.ijbiomac.2023.127162
   Grawish Mohammed E, 2020, Cancer Treat Res Commun, V25, P100242, DOI [10.1016/j.ctarc.2020.100242, 10.1016/j.ctarc.2020.100242]
   Grunwald T, 2006, J ALLERGY CLIN IMMUN, V117, P848, DOI 10.1016/j.jaci.2005.12.1331
   Gu H, 2020, TOXINS, V12, DOI 10.3390/toxins12030195
   Gu H, 2019, FOOD CHEM TOXICOL, V129, P344, DOI 10.1016/j.fct.2019.05.001
   Guo QY, 2018, BAMBOO SILK, V1, P1, DOI [10.1163/24689246-00101001, 10.1038/s41413-018-0016-9]
   Gwon MG, 2021, J MOL MED, V99, P1265, DOI 10.1007/s00109-021-02087-x
   Hamza RG, 2019, ARAB J NUCL SCI APPL, V52, P178, DOI 10.21608/ajnsa.2018.3107.1071
   Han SM, 2017, J COSMET DERMATOL-US, V16, pE68, DOI 10.1111/jocd.12350
   Han SM, 2015, CLIN INTERV AGING, V10, DOI 10.2147/CIA.S84940
   Han SM, 2013, J INTEGR MED-JIM, V11, P320, DOI 10.3736/jintegrmed2013043
   Han S, 2011, J PLAST RECONSTR AES, V64, pE67, DOI 10.1016/j.bjps.2010.08.022
   Hanafi MY, 2018, EXP THER MED, V15, P5091, DOI 10.3892/etm.2018.6028
   Haque S, 2023, J CANCER RES CLIN, V149, P17709, DOI 10.1007/s00432-023-05458-8
   Haque TT, 2024, SCI IMMUNOL, V9, DOI 10.1126/sciimmunol.adg8691
   Hartmann A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158235
   Hasan N, 2023, CANCER BIOMARK, V38, P61, DOI 10.3233/CBM-220268
   Hassani S, 2024, AGEING RES REV, V97, DOI 10.1016/j.arr.2024.102299
   Hegazi A. G., 2013, Int Res J Med Med Sci, V1, P27
   Heron M., 2021, Deaths: Leading Causes for 2019
   Hossen M. S., 2017, Melittin, a potential natural toxin of crude bee venom: probable future arsenal in the treatment of diabetes mellitus
   Hossen MS, 2017, J CHEM-NY, V2017, DOI 10.1155/2017/4035626
   Hossen MS, 2017, MOLECULES, V22, DOI 10.3390/molecules22010025
   How KY, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00053
   Hozzeinab WN, 2018, MOL IMMUNOL, V103, P322, DOI 10.1016/j.molimm.2018.10.016
   Huang JY, 2021, BIOSCI BIOTECH BIOCH, V85, P2250, DOI 10.1093/bbb/zbab153
   Hwang YN, 2022, J PHARMACOPUNCT, V25, P390, DOI 10.3831/KPI.2022.25.4.390
   Isidorov V, 2023, MOLECULES, V28, DOI 10.3390/molecules28104135
   Ivanov E, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24032045
   Izhar MP, 2023, J CLUST SCI, V34, P2257, DOI 10.1007/s10876-023-02423-w
   Jafari Z, 2024, ARCH PHARM, V357, DOI 10.1002/ardp.202300569
   Jafarzadeh A, 2023, CELL IMMUNOL, V393, DOI 10.1016/j.cellimm.2023.104778
   Jamasbi E, 2016, CURR TOP MED CHEM, V16, P40, DOI 10.2174/1568026615666150703115919
   Jang S, 2020, TOXINS, V12, DOI 10.3390/toxins12090558
   Jeon S, 2007, EXP MOL MED, V39, P603, DOI 10.1038/emm.2007.66
   Jeong CH, 2017, J MICROBIOL BIOTECHN, V27, P1827, DOI 10.4014/jmb.1706.06003
   Jia L, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00262
   Jung GB, 2018, BIOMED OPT EXPRESS, V9, P5703, DOI 10.1364/BOE.9.005703
   Kallarackal AJ, 2013, BEHAV BRAIN RES, V237, P71, DOI 10.1016/j.bbr.2012.09.009
   Kamran MR, 2020, INT J PEPT RES THER, V26, P1819, DOI 10.1007/s10989-019-09979-0
   Khalil A, 2021, MOLECULES, V26, DOI 10.3390/molecules26164941
   Khaliq R., 2022, IGI Glob, P119
   Khan N, 2018, PROTEIN PEPTIDE LETT, V25, P663, DOI 10.2174/0929866525666180629121823
   Kharroubi AT, 2015, WORLD J DIABETES, V6, P850, DOI 10.4239/wjd.v6.i6.850
   Khateeb S, 2024, INT J RADIAT BIOL, V100, P940, DOI 10.1080/09553002.2024.2338515
   Khulan TS, 2015, J DIABETES METAB, V6, DOI 10.4172/2155-6156.1000507
   Kim BY, 2016, J ASIA-PAC ENTOMOL, V19, P793, DOI 10.1016/j.aspen.2016.07.013
   Kim DH, 2018, BRIT POULTRY SCI, V59, P435, DOI 10.1080/00071668.2018.1476675
   Kim DH, 2020, BMB REP, V53, P419, DOI 10.5483/BMBRep.2020.53.8.031
   Kim DaHye Kim DaHye, 2019, Korean Journal of Poultry Science, V46, P39, DOI [10.5536/kjps.2019.46.1.39, 10.5536/KJPS.2019.46.1.39, 10.5536/kjps.2019.46.1.39]
   Kim H, 2019, TOXINS, V11, DOI 10.3390/toxins11070374
   Kim H, 2021, TOXINS, V13, DOI 10.3390/toxins13090603
   Kim H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114726
   Kim JY, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9080992
   Kim JY, 2020, MOLECULES, V25, DOI 10.3390/molecules25235717
   Kim JY, 2017, INT J MOL MED, V39, P1188, DOI 10.3892/ijmm.2017.2922
   Kim JY, 2015, VASC PHARMACOL, V70, P8, DOI 10.1016/j.vph.2014.12.004
   Kim JY, 2015, INT J MOL MED, V35, P1651, DOI 10.3892/ijmm.2015.2180
   Kim Jungyeon K. J., 2015, Apamin inhibits PDGF-BB-induced vascular smooth muscle cell proliferation and migration through suppressions of activated Akt and Erk signaling pathway
   Kim KH, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00080
   Kim SJ, 2012, EXP MOL PATHOL, V93, P129, DOI 10.1016/j.yexmp.2012.04.003
   Kim W. K. W., 2016, Combined effects of bee venom acupuncture and morphine on oxaliplatin-induced neuropathic pain in mice
   Kim YW, 2015, ONCOL REP, V33, P1675, DOI 10.3892/or.2015.3760
   KOBUROVA K L, 1985, Acta Physiologica et Pharmacologica Bulgarica, V11, P50
   Komi DEA, 2018, CLIN REV ALLERG IMMU, V54, P386, DOI 10.1007/s12016-017-8597-4
   Kurek-Górecka A, 2021, MOLECULES, V26, DOI 10.3390/molecules26010148
   Kuzmenkov AI, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.977440
   Kwon YB, 2001, NEUROSCI LETT, V308, P133, DOI 10.1016/S0304-3940(01)01989-9
   Lamptey RNL, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031851
   Lebel AA, 2021, CHEM-BIOL INTERACT, V347, DOI 10.1016/j.cbi.2021.109622
   Lee C. H., 2019, A retrospective study on the clinical safety of bee venom pharmacopuncture at craniofacial acupuncture points for the treatment of facial disorders
   Lee C, 2017, ONCOTARGET, V8, P54951, DOI 10.18632/oncotarget.18627
   Lee G, 2019, MOL CELL TOXICOL, V15, P307, DOI 10.1007/s13273-019-0034-8
   Lee G, 2016, MOLECULES, V21, DOI 10.3390/molecules21050616
   Lee G, 2016, TOXINS, V8, DOI 10.3390/toxins8020048
   Lee HS, 2021, APPL BIOCHEM BIOTECH, V193, P4068, DOI 10.1007/s12010-021-03653-2
   Lee JA, 2020, CUREUS J MED SCIENCE, V12, DOI 10.7759/cureus.8078
   Lee JD, 2005, EVID-BASED COMPL ALT, V2, P79, DOI 10.1093/ecam/neh070
   Lee JD, 2004, AM J CHINESE MED, V32, P361, DOI 10.1142/S0192415X04002016
   Lee JH, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-471
   Lee Kwang Sik, 2023, Journal of Apiculture, V38, P391, DOI 10.17519/apiculture.2023.11.38.4.391
   Lee KS, 2016, DEV COMP IMMUNOL, V63, P27, DOI 10.1016/j.dci.2016.05.011
   Lee MJ, 2016, MOL NEUROBIOL, V53, P1419, DOI 10.1007/s12035-014-9012-2
   Lee Sun-Hwa, 2014, Exp Neurobiol, V23, P86, DOI 10.5607/en.2014.23.1.86
   Li BW, 2023, CHEMBIOCHEM, DOI 10.1002/cbic.202300002
   Li JH, 2010, AM J CHINESE MED, V38, P1039, DOI 10.1142/S0192415X10008457
   Li X, 2022, FREE RADICAL RES, V56, P398, DOI 10.1080/10715762.2022.2131551
   Lim HN, 2019, MOLECULES, V24, DOI 10.3390/molecules24050929
   Lin TY, 2020, TOXINS, V12, DOI 10.3390/toxins12100618
   Liu FF, 2023, QUANT IMAG MED SURG, V13, P5996, DOI 10.21037/qims-23-254
   Liu H, 2023, BIOMOLECULES, V13, DOI 10.3390/biom13010184
   Liu X, 2003, J CONTROL RELEASE, V93, P293, DOI 10.1016/j.jconrel.2003.08.019
   López-Incera A, 2021, BMC BIOL, V19, DOI 10.1186/s12915-021-01028-x
   Lv C, 2023, TOXICON, V222, DOI 10.1016/j.toxicon.2022.106996
   Malek A, 2023, CANCERS, V15, DOI 10.3390/cancers15143714
   Malek A, 2022, FRONT NEUROSCI-SWITZ, V16, DOI 10.3389/fnins.2022.792970
   Mansour GH, 2021, BIOORG CHEM, V116, DOI 10.1016/j.bioorg.2021.105329
   Pereira AFM, 2020, MICROB PATHOGENESIS, V141, DOI 10.1016/j.micpath.2020.104011
   Martinello M, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10010071
   Meligi NM, 2020, TOXICOL RES-UK, V9, P693, DOI 10.1093/toxres/tfaa077
   Memariani H, 2021, AMB EXPRESS, V11, DOI 10.1186/s13568-021-01229-1
   Memariani H, 2020, EUR J CLIN MICROBIOL, V39, P5, DOI 10.1007/s10096-019-03674-0
   Memariani H, 2019, APPL MICROBIOL BIOT, V103, P3265, DOI 10.1007/s00253-019-09698-y
   Mi WJ, 2024, COMPLEMENT THER MED, V82, DOI 10.1016/j.ctim.2024.103044
   Mohammadi-Rad M, 2019, RES PHARM SCI, V14, P424, DOI 10.4103/1735-5362.268203
   Mohanty M. C., 2023, Anti-Viral Metabolites from Medicinal Plants, P429
   Montoro A., 2023, Radiobiology textbook, P571, DOI DOI 10.1007/978-3-031-18810-7_11
   Moon DO, 2007, INT IMMUNOPHARMACOL, V7, P1092, DOI 10.1016/j.intimp.2007.04.005
   Moreno M, 2015, TOXINS, V7, P1126, DOI 10.3390/toxins7041126
   Morgan E, 2023, GUT, V72, P338, DOI 10.1136/gutjnl-2022-327736
   Morin Jr P., 2024, Natural molecules in neuroprotection and neurotoxicity, P405
   Murakami M, 2017, CRIT REV IMMUNOL, V37, P121, DOI 10.1615/CritRevImmunol.v37.i2-6.20
   Nainu F, 2021, ANTIBIOTICS-BASEL, V10, DOI 10.3390/antibiotics10070822
   Nassan M, 2022, NAT REV NEUROL, V18, P7, DOI 10.1038/s41582-021-00577-7
   Nitecka-Buchta A, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/296053
   Ojha S, 2023, LETT DRUG DES DISCOV, V20, P1437, DOI 10.2174/1570180819666220901093732
   Orsi RO, 2024, J TOXICOL ENV HEAL B, V27, P73, DOI 10.1080/10937404.2023.2300786
   Otreba M, 2021, LIFE-BASEL, V11, DOI 10.3390/life11121311
   Palm NW, 2013, IMMUNITY, V39, P976, DOI 10.1016/j.immuni.2013.10.006
   Pandey P, 2023, NUTRIENTS, V15, DOI 10.3390/nu15143111
   Park Heegeun P. H., 2018, Honeybee (Apis cerana) vitellogenin acts as an antimicrobial and antioxidant agent in the body and venom
   Park HJ, 2004, ARTHRITIS RHEUM-US, V50, P3504, DOI 10.1002/art.20626
   Park JE, 2019, EUR J INTEGR MED, V27, P121, DOI 10.1016/j.eujim.2019.03.001
   Park JH, 2011, EXP BIOL MED, V236, P1306, DOI 10.1258/ebm.2011.011127
   Park J, 2018, ANN DERMATOL, V30, P202, DOI 10.5021/ad.2018.30.2.202
   Park S, 2016, BIOL PHARM BULL, V39, P1060, DOI 10.1248/bpb.b16-00158
   Pavel CI, 2014, J APICULT RES, V53, P116, DOI 10.3896/IBRA.1.53.1.12
   Peng Y, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1294966
   Peralta F, 2023, IBRO NEUROSCI REP, V15, pS707, DOI [10.1016/j.ibneur.2023.08.1432, 10.1016/j.ibneur.2023.08.1432, DOI 10.1016/J.IBNEUR.2023.08.1432]
   Petronek MS, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10091458
   Piek T., 2013, Venoms of the Hymenoptera: biochemical, pharmacological and behavioural aspects
   Pinmanee P, 2023, BIOMOLECULES, V13, DOI 10.3390/biom13071156
   Portelli P., 2020, Insects and other invertebrates in Maltese culture and tradition
   Proulx É, 2020, CEREB CORTEX, V30, P563, DOI 10.1093/cercor/bhz107
   Pucca MB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02090
   Qi XB, 2024, APPL BIOCHEM BIOTECH, V196, P3441, DOI 10.1007/s12010-023-04677-6
   Quatorze M., 2024, Amyotrophic lateral sclerosis: when nerve cells run out of power
   Rady I, 2017, CANCER LETT, V402, P16, DOI 10.1016/j.canlet.2017.05.010
   Rasinar Adrian-Dan, 2023, Scientific Papers: Animal Science and Biotechnologies, V56, P104
   Regeai SO, 2020, OPEN VET J, V11, P70, DOI 10.4314/ovj.v11i1.11
   Reuter S, 2024, RESP RES, V25, DOI 10.1186/s12931-023-02660-7
   Rocha MM, 2022, J VENOM ANIM TOXINS, V28, DOI [10.1590/1678-9199-JVATITD-2021-0067, 10.1590/1678-9199-jvatitd-2021-0067]
   Rosenblum MD, 2015, J CLIN INVEST, V125, P2228, DOI 10.1172/JCI78088
   Rouhi A, 2024, LWT-FOOD SCI TECHNOL, V199, DOI 10.1016/j.lwt.2024.116083
   Roversi D, 2023, BIOPHYS CHEM, V300, DOI 10.1016/j.bpc.2023.107060
   Roy D, 2023, INDIAN J BIOCHEM BIO, V60, P365, DOI 10.56042/ijbb.v60i5.552
   Rzetecka N, 2024, J FOOD COMPOS ANAL, V126, DOI 10.1016/j.jfca.2023.105860
   Sadek M., 2023, The sting that cures: Bee venom and its therapeautic future (Apis mellifera)
   Salama Mohamed A, 2020, J Complement Integr Med, V18, P75, DOI [10.1515/jcim-2019-0182, 10.1515/jcim-2019-0182]
   Salimo ZM, 2023, BIOMOLECULES, V13, DOI 10.3390/biom13030403
   Sangboonruang S, 2020, ANTIBIOTICS-BASEL, V9, DOI 10.3390/antibiotics9080517
   Saravanan D, 2023, Archives of Clinical Toxicology, V5, P22, DOI [10.46439/toxicology.5.021, 10.46439/toxicology.5.021, DOI 10.46439/TOXICOLOGY.5.021, DOI 10.46439/TOXICOLOGY.5021]
   Sarhan WA, 2017, NANOMEDICINE-UK, V12, P2055, DOI 10.2217/nnm-2017-0151
   Sawicka B., 2024, Antidotes to toxins and drugs, P37
   Schmidt JO, 2018, TOXICON, V150, P96, DOI 10.1016/j.toxicon.2018.05.013
   Sevin S, 2023, APPL BIOCHEM BIOTECH, V195, P3194, DOI 10.1007/s12010-022-04284-x
   Shaik RA, 2023, SAUDI PHARM J, V31, P736, DOI 10.1016/j.jsps.2023.03.014
   Sharaf M, 2024, FRONT MICROBIOL, V15, DOI 10.3389/fmicb.2024.1345478
   Sharif K, 2018, CLIN ANAT, V31, P216, DOI 10.1002/ca.22980
   Sharma A, 2024, INT J PHARMACEUT, V656, DOI 10.1016/j.ijpharm.2024.124099
   Sharma P, 2024, LANGMUIR, V40, P7791, DOI 10.1021/acs.langmuir.3c03474
   Shen L, 2020, J PHARMACOPUNCT, V23, P44, DOI 10.3831/KPI.2020.23.008
   Shi PY, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1001553
   Shi W, 2016, APPL MICROBIOL BIOT, V100, P5059, DOI 10.1007/s00253-016-7400-4
   Shin D, 2018, TOXINS, V10, DOI 10.3390/toxins10040146
   Shin SH, 2017, TOXINS, V9, DOI 10.3390/toxins9110348
   Silva J, 2015, TOXINS, V7, P3179, DOI 10.3390/toxins7083179
   Silva LN, 2019, CURR TOP MED CHEM, V19, P495, DOI 10.2174/156802661907190531093808
   Singh AK, 2023, PHARMACEUTICALS-BASE, V16, DOI 10.3390/ph16060899
   Smith BD, 2019, CANCER CELL, V35, P738, DOI 10.1016/j.ccell.2019.04.006
   Soares P, 2023, AGEING RES REV, V83, DOI 10.1016/j.arr.2022.101790
   Sobral F, 2016, FOOD CHEM TOXICOL, V94, P172, DOI 10.1016/j.fct.2016.06.008
   Soliman C, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224028
   Somwongin S, 2018, TOXICON, V145, P32, DOI 10.1016/j.toxicon.2018.02.049
   Son DJ, 2007, PHARMACOL THERAPEUT, V115, P246, DOI 10.1016/j.pharmthera.2007.04.004
   Stahelin R.V., 2016, Biochem. Lipids, VSixth, P237, DOI DOI 10.1016/B978-0-444-63438-2.00008-0
   Starkl P, 2022, ALLERGY, V77, P499, DOI 10.1111/all.14852
   Stepanova Maria, 2017, Clin Diabetes, V35, P79, DOI [10.2337/cd16-0018, 10.2337/cd16-0018]
   Sturm GJ, 2018, ALLERGY, V73, P744, DOI 10.1111/all.13262
   Suleiman JB, 2021, MOLECULES, V26, DOI 10.3390/molecules26113421
   Sung WS, 2022, BMJ OPEN, V12, DOI 10.1136/bmjopen-2021-056545
   Sur B, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1019-y
   Swiatly-Blaszkiewicz A, 2020, METABOLITES, V10, DOI 10.3390/metabo10050191
   Tae-Han Y, 2008, J PHARMACOPUNCT, V11, P41, DOI 10.3831/KPI.2008.11.1.041
   Tanner CM, 2011, ENVIRON HEALTH PERSP, V119, P866, DOI 10.1289/ehp.1002839
   Tanuwidjaja I, 2021, MOLECULES, V26, DOI 10.3390/molecules26103049
   Thawabteh A, 2019, TOXINS, V11, DOI 10.3390/toxins11110656
   Tiwari R, 2022, NAT PROD J, V12, DOI 10.2174/2210315510999201210143035
   Tsai LC, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/363801
   Tusiimire J, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4020011
   Twarowski B, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24076518
   Uddin M, 2016, J MICROBIOL, V54, P853
   Ullah A, 2023, SAUDI PHARM J, V31, P96, DOI 10.1016/j.jsps.2022.11.008
   Varol A, 2022, TOXIN REV, V41, P1382, DOI 10.1080/15569543.2021.2024576
   Vickers NJ, 2017, CURR BIOL, V27, pR713, DOI 10.1016/j.cub.2017.05.064
   Villa C, 2020, MECH AGEING DEV, V185, DOI 10.1016/j.mad.2019.111197
   Virk MS, 2024, NUTRIENTS, V16, DOI 10.3390/nu16040546
   Wachinger M, 1998, J GEN VIROL, V79, P731, DOI 10.1099/0022-1317-79-4-731
   Wang Q, 2021, ACTA PHARM SIN B, V11, P1158, DOI 10.1016/j.apsb.2021.03.013
   Wang TJ, 2016, BIOCHEM BIOPH RES CO, V480, P126, DOI 10.1016/j.bbrc.2016.09.135
   Wang WY, 2018, EUR J MED CHEM, V158, P502, DOI 10.1016/j.ejmech.2018.09.027
   Wang XM, 2021, BIOENGINEERED, V12, P117, DOI 10.1080/21655979.2020.1860491
   Wehbe R, 2019, MOLECULES, V24, DOI 10.3390/molecules24162997
   Xing X, 2024, NEUROCHEM RES, V49, P348, DOI 10.1007/s11064-023-04030-7
   Xu WZ, 2020, ADV PROTEIN CHEM STR, V120, P45, DOI 10.1016/bs.apcsb.2019.12.001
   Yaacoub C, 2023, PATHOGENS, V12, DOI 10.3390/pathogens12111354
   Yang EJ, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-69
   Yang LF, 2023, MEDICINE, V102, DOI 10.1097/MD.0000000000034728
   Ye M, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.49
   Ye M, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0476-z
   Yin DC, 2017, CIRC-ARRHYTHMIA ELEC, V10, DOI 10.1161/CIRCEP.116.004434
   Yoon Heera Y. H., 2015, Nicotinic acetylcholine receptors mediate the suppressive effect of an injection of diluted bee venom into the GV3 acupoint on oxaliplatin-induced neuropathic cold allodynia in rats
   Yoon J, 2012, J ACUPUNCT MERIDIAN, V5, P156, DOI [10.1016/j.jams.2012.05.003, 10.106/j.jams.2012.05.003]
   Yoon SY, 2013, BIOL PHARM BULL, V36, P1787, DOI 10.1248/bpb.b13-00469
   You CE, 2016, ANN DERMATOL, V28, P593, DOI 10.5021/ad.2016.28.5.593
   Younossi Z. M., 2023, The global burden of liver disease. Clinical Gastroenterology and Hepatology
   Younossi Z, 2016, GASTROENTEROLOGY, V150, P1778, DOI 10.1053/j.gastro.2016.03.005
   Yu JJ, 2024, CURR RES TOXICOL, V6, DOI 10.1016/j.crtox.2024.100171
   Yu X, 2023, J NANOBIOTECHNOL, V21, DOI 10.1186/s12951-023-02223-4
   Zarei Sara, 2015, Surg Neurol Int, V6, P171, DOI [10.4103/2152-7806.169561, 10.4103/2152-7806.169561]
   Zarrinnahad H, 2018, INT J PEPT RES THER, V24, P563, DOI 10.1007/s10989-017-9641-1
   Zein N, 2024, Biochemistry Letters, V20, P12, DOI [10.21608/blj.2024.340261, 10.21608/blj.2024.340261, DOI 10.21608/BLJ.2024.340261]
   zgen, 2023, Veteriner Hekimler Dernei Derg, V94, P59, DOI [10.33188/vetheder.1183380, DOI 10.33188/VETHEDER.1183380]
   Zhang HQ, 2024, FRONT IMMUNOL, V15, DOI 10.3389/fimmu.2024.1326033
   Zhang JJ, 2015, J THORAC ONCOL, V10, P682, DOI 10.1097/JTO.0000000000000456
   Zhang SF, 2017, MOL MED REP, V16, P3581, DOI 10.3892/mmr.2017.6970
   Zhao J, 2022, J GASTROINTEST ONCOL, V13, P847, DOI 10.21037/jgo-22-222
   Zhao RL, 2024, WOUND REPAIR REGEN, V32, P90, DOI 10.1111/wrr.13148
   Zhou YJ, 2023, ACTA PHARM SIN B, V13, P577, DOI 10.1016/j.apsb.2022.07.019
   Zuazo-Gaztelu I, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00248
NR 328
TC 31
Z9 33
U1 5
U2 34
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUL 18
PY 2024
VL 15
AR 1412245
DI 10.3389/fphar.2024.1412245
PG 33
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA A2W9I
UT WOS:001281194800001
PM 39092234
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Steinhorn, DM
   Din, J
   Johnson, A
AF Steinhorn, David M.
   Din, Jana
   Johnson, Angela
TI Healing, spirituality and integrative medicine
SO ANNALS OF PALLIATIVE MEDICINE
LA English
DT Review
DE Suffering; spiritual healing; complementary medicine; shamanism;
   acupuncture
ID ALTERNATIVE MEDICINE; SYMPTOM MANAGEMENT; PALLIATIVE CARE; HERBAL
   MEDICINE; PASTORAL CARE; CANCER CARE; COMPLEMENTARY; THERAPY;
   ACUPUNCTURE; SAFETY
AB Spirituality plays a prominent role in the lives of most palliative patients whether or not they formally adhere to a specific religion and belief. As a result, the palliative care team is frequently called upon to support families who are experiencing their "dark night of the soul" and struggling to make sense of their lives during a healthcare crisis. While conventional religious practices provide a source of comfort and guidance for many of our patients, a significant number of our patients do not have a strong religious community to which to turn. Over the last two decades, more people in Western countries identify themselves as spiritual but not religious and do not belong to an organized faith community. For those patients who express a strong spiritual connection or sense of 'something greater' or 'a higher power', encouraging the exploration of those feelings and beliefs through chaplains, clergypersons, or members of the interdisciplinary palliative care team can help provide context, meaning and purpose in their lives impacted by serious illness. One of the goals of effective palliative care is the facilitation of personal growth and psychological resilience in dealing with one's health challenges. Integrative medicine, also referred to as complementary and alternative medicine, provides a set of tools and philosophies intended to enhance wellness and a sense of wellbeing. Many of the modalities are derived from disciplines such as massage, acupuncture, Rei Ki, aromatherapy, and dietary supplements. The use of integrative medicine in North America is widespread and frequently not shared with one's clinician due to many patients' concerns that clinicians will disapprove of the patient's use of them. In addition to its efficacy in reducing symptoms commonly experienced by patients receiving palliative care (e.g., nausea, pain, depression, and existential suffering), integrative medicine offers non-verbal, non-cognitive avenues for many to achieve a peaceful and calm inner state. The calm state often achieved during integrative medicine treatments is similar to that seen during deep prayer or meditation. In such a transcendent or non-ordinary state of consciousness, many people experience new insights or understanding of their lives and choices they must make. Thus, integrative approaches facilitate patients attaining greater self-awareness and may meet their spiritual needs without the religious overtones that accompany traditional prayer. In so doing, patients may gain greater insight and find inner peace through simple, non-verbal approaches.
C1 [Steinhorn, David M.] Childrens Natl Med Ctr, PANDA Palliat Care Program, Washington, DC 20010 USA.
   [Din, Jana] Tao Ctr Healing, Sacramento, CA USA.
   [Johnson, Angela] Rush Presbyterian St Lukes Med Ctr, Canc Integrat Med Program, Chicago, IL USA.
C3 Children's National Health System; Rush University
RP Steinhorn, DM (corresponding author), Childrens Natl Med Ctr, Pediat, 111 Michigan Ave NW, Washington, DC 20010 USA.; Steinhorn, DM (corresponding author), Childrens Natl Med Ctr, PANDA Palliat Care Program, Div Crit Care, 111 Michigan Ave NW, Washington, DC 20010 USA.
EM dsteinhorn@childrensnational.org
RI Steinhorn, David/JHT-1209-2023
OI Steinhorn, David/0000-0002-1081-891X
CR Agdal R, 2011, FORSCH KOMPLEMENTMED, V18, P146, DOI 10.1159/000329316
   Alcorn R, 2010, HEALING STORIES MY J
   Alsanad SM, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1372-x
   [Anonymous], 2013, FULL CATASTROPHE LIV
   [Anonymous], 2015, TRENDS USE COMPLEMEN
   [Anonymous], NY TIMES
   Barnes Patricia M, 2004, Adv Data, P1
   Barrie-Anthony S., 2014, ATLANTIC
   Ben-Arye E, 2016, CANCER-AM CANCER SOC, V122, P598, DOI 10.1002/cncr.29796
   Blumberg A., 2016, HUFFINGTON POST
   Botha Elmarie, 2015, JBI Database System Rev Implement Rep, V13, P21, DOI [10.11124/jbisrir-2015-2380, 10.11124/jbisrir-2015-2380]
   Braden G., 2008, The divine matrix: Bridging time, space, miracles and belief
   Burden B, 2005, INT J PALLIAT NURS, V11, P248, DOI 10.12968/ijpn.2005.11.5.248
   Carey LB, 2015, J RELIG HEALTH, V54, P1772, DOI 10.1007/s10943-014-9938-8
   Carson C, 2013, SPIRITED MED SHAMANI
   CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104
   Chang KH, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-196
   Chung VCH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002793
   Conrad AC, 2014, J CANCER RES CLIN, V140, P1229, DOI 10.1007/s00432-014-1656-9
   de Aguiar PR, 2016, J RELIG HLTH
   Duncan G, 2000, J MED PHILOS, V25, P485, DOI 10.1076/0360-5310(200008)25:4;1-A;FT485
   Ernst E, 2009, SUPPORT CARE CANCER, V17, P333, DOI 10.1007/s00520-008-0569-z
   Fadiman A., 1997, SPIRIT CATCHES YOU Y
   Falkensteiner Maria, 2011, ISRN Nurs, V2011, P929868, DOI 10.5402/2011/929868
   Gouveia LO, 2009, SPINE, V34, pE405, DOI 10.1097/BRS.0b013e3181a16d63
   Grant SJ, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-299
   Harding SR, 2008, J HEALTH CARE CHAPL, V14, P99, DOI 10.1080/08854720802129067
   Isaac KS, 2016, J RELIG HEALTH, V55, P1065, DOI 10.1007/s10943-016-0190-2
   Jeuland J, 2017, J PALLIAT MED, V20, P502, DOI 10.1089/jpm.2016.0308
   Johnson A, 2012, OXFORD TXB PALLIATIV
   Jou J, 2016, JAMA INTERN MED, V176, P545, DOI 10.1001/jamainternmed.2015.8593
   Kemper KJ, 2016, AUTHENTIC HEALING
   Koenig H.G., 2008, MED RELIG HLTH
   Koenig Harold G, 2012, ISRN Psychiatry, V2012, P278730, DOI 10.5402/2012/278730
   Koenig HG., 2012, Handbook of religion and health (2nd Edition)
   Ladas EJ, 2010, SUPPORT CARE CANCER, V18, P1487, DOI 10.1007/s00520-010-0926-6
   Lau CHY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002901
   Loquai C, 2016, MED ONCOL, V33, DOI 10.1007/s12032-016-0764-6
   Luzzatto RM, 2009, WAY GOD DERECH HASHE
   Maschi D, 2016, AM MAY BE GETTING LE
   NG JY, 2016, BMC COMPLEM ALTERN M, V16
   PDQ Integrative Alternative and Complementary Therapies Editorial Board. Medicinal Mushrooms, 2002, PDQ CANC INF SUMM
   Proserpio T, 2011, TUMORI, V97, P666, DOI 10.1700/989.10729
   Puchalski C, 2009, J PALLIAT MED, V12, P885, DOI 10.1089/jpm.2009.0142
   Quest H, SHAMANS IN THE ICU
   Roberts L, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000368.pub3
   Shin ES, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009873.pub3
   Singh D, 2012, CRIT REV FOOD SCI, V52, P876, DOI 10.1080/10408398.2010.512426
   Uhlig T, 2012, BEST PRACT RES CL RH, V26, P387, DOI 10.1016/j.berh.2012.05.006
   Weber SR, 2012, J RELIG HEALTH, V51, P72, DOI 10.1007/s10943-011-9541-1
   Weeks L., 2014, OPEN MED-WARSAW, V8, pE54
NR 51
TC 62
Z9 80
U1 1
U2 54
PU AME PUBLISHING COMPANY
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2224-5820
EI 2224-5839
J9 ANN PALLIAT MED
JI Ann. Pallliat. Med.
PD JUL
PY 2017
VL 6
IS 3
BP 237
EP 247
DI 10.21037/apm.2017.05.01
PG 11
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services
GA FC5TC
UT WOS:000406903600007
PM 28595441
OA hybrid
DA 2026-01-16
ER

PT J
AU Li, D
   Lee, Y
   Kim, W
   Lee, K
   Bae, H
   Kim, SK
AF Li, Dongxing
   Lee, Younju
   Kim, Woojin
   Lee, Kyungjin
   Bae, Hyunsu
   Kim, Sun Kwang
TI Analgesic Effects of Bee Venom Derived Phospholipase A2 in a
   Mouse Model of Oxaliplatin-Induced Neuropathic Pain
SO TOXINS
LA English
DT Article
DE phospholipase A(2); Bee Venom; oxaliplatin; neuropathic pain;
   noradrenergic
ID REGULATORY T-CELLS; ADRENERGIC SENSITIVITY; RAT MODEL; ACUPUNCTURE
   APIPUNCTURE; THERMAL HYPERALGESIA; SAFETY PROFILE; SPINAL-CORD;
   INVOLVEMENT; MODULATION; MECHANISM
AB A single infusion of oxaliplatin, which is widely used to treat metastatic colorectal cancer, induces specific sensory neurotoxicity signs that are triggered or aggravated when exposed to cold or mechanical stimuli. Bee Venom (BV) has been traditionally used in Korea to treat various pain symptoms. Our recent study demonstrated that BV alleviates oxaliplatin-induced cold allodynia in rats, via noradrenergic and serotonergic analgesic pathways. In this study, we have further investigated whether BV derived phospholipase A(2) (bvPLA(2)) attenuates oxaliplatin-induced cold and mechanical allodynia in mice and its mechanism. The behavioral signs of cold and mechanical allodynia were evaluated by acetone and a von Frey hair test on the hind paw, respectively. The significant allodynia signs were observed from one day after an oxaliplatin injection (6 mg/kg, i.p.). Daily administration of bvPLA(2) (0.2 mg/kg, i.p.) for five consecutive days markedly attenuated cold and mechanical allodynia, which was more potent than the effect of BV (1 mg/kg, i.p.). The depletion of noradrenaline by an injection of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride (DSP4, 50 mg/kg, i.p.) blocked the analgesic effect of bvPLA(2), whereas the depletion of serotonin by injecting DL-p-chlorophenylalanine (PCPA, 150 mg/kg, i.p.) for three successive days did not. Furthermore, idazoxan (2-adrenegic receptor antagonist, 1 mg/kg, i.p.) completely blocked bvPLA(2)-induced anti-allodynic action, whereas prazosin (1-adrenegic antagonist, 10 mg/kg, i.p.) did not. These results suggest that bvPLA(2) treatment strongly alleviates oxaliplatin-induced acute cold and mechanical allodynia in mice through the activation of the noradrenergic system, via 2-adrenegic receptors, but not via the serotonergic system.
C1 [Li, Dongxing; Lee, Younju; Bae, Hyunsu; Kim, Sun Kwang] Kyung Hee Univ, Coll Korean Med, Dept Physiol, Seoul 130701, South Korea.
   [Kim, Woojin; Kim, Sun Kwang] Kyung Hee Univ, Grad Sch, Dept East West Med, Seoul 130701, South Korea.
   [Lee, Kyungjin] Kyung Hee Univ, Coll Korean Med, Dept Herbol, Seoul 130701, South Korea.
C3 Kyung Hee University; Kyung Hee University; Kyung Hee University
RP Kim, SK (corresponding author), Kyung Hee Univ, Coll Korean Med, Dept Physiol, 26 Kyungheedae Ro, Seoul 130701, South Korea.
EM leedongxing@naver.com; eyounju@naver.com; thasnow@gmail.com;
   niceday@khu.ac.kr; hbae@khu.ac.kr; skkim77@khu.ac.kr
RI Kim, Sun Kwang/AAM-1289-2020; Kim, Woojin/AAK-2464-2020
OI Kim, Sun Kwang/0000-0002-2649-6652; Kim, Woojin/0000-0001-8494-4524;
   Bae, Hyunsu/0000-0002-0299-3582
FU Korea Health Industry Development Institute (KHIDI) - Ministry of Health
   & Welfare, Republic of Korea [HI14 C0738]
FX This research was supported by a grant of the Korea Health Technology
   R&D Project through the Korea Health Industry Development Institute
   (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea
   (grant number: HI14 C0738).
CR Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709
   Austin PJ, 2012, PAIN, V153, P1916, DOI 10.1016/j.pain.2012.06.005
   Back SK, 2002, NEUROSCI LETT, V322, P153, DOI 10.1016/S0304-3940(02)00067-8
   Baek YH, 2006, BRAIN RES, V1073, P305, DOI 10.1016/j.brainres.2005.12.086
   BILLINGHAM ME, 1973, NATURE, V245, P163, DOI 10.1038/245163a0
   Binder A, 2007, EUR J CANCER, V43, P2658, DOI 10.1016/j.ejca.2007.07.030
   Burrage PS, 2006, FRONT BIOSCI-LANDMRK, V11, P529, DOI 10.2741/1817
   Cassidy J, 2002, SEMIN ONCOL, V29, P11, DOI 10.1053/sonc.2002.35524
   Choi MS, 2013, CYTOKINE, V61, P256, DOI 10.1016/j.cyto.2012.10.005
   Crespi F, 2009, BRAIN RES, V1281, P35, DOI 10.1016/j.brainres.2009.05.021
   De Felipe C, 1998, NATURE, V392, P394, DOI 10.1038/32904
   de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938
   Desoize B, 2002, CRIT REV ONCOL HEMAT, V42, P317, DOI 10.1016/S1040-8428(01)00219-0
   Extra JM, 1998, SEMIN ONCOL, V25, P13
   Farquhar-Smith Paul, 2011, Curr Opin Support Palliat Care, V5, P1, DOI 10.1097/SPC.0b013e328342f9cc
   Flatters SJL, 2004, PAIN, V109, P150, DOI 10.1016/j.pain.2004.01.029
   Grothey A, 2003, SEMIN ONCOL, V30, P5, DOI 10.1016/S0093-7754(03)00399-3
   Honore P, 2000, NEUROSCIENCE, V98, P585, DOI 10.1016/S0306-4522(00)00110-X
   Hord AH, 2001, ANESTH ANALG, V92, P1558, DOI 10.1097/00000539-200106000-00042
   Jeong JK, 2011, INT J MOL MED, V28, P867, DOI 10.3892/ijmm.2011.730
   Johnson JD, 2005, NEUROSCIENCE, V135, P1295, DOI 10.1016/j.neuroscience.2005.06.090
   Joseph EK, 2009, J PAIN, V10, P534, DOI 10.1016/j.jpain.2008.12.003
   Kang SY, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/784713
   Kang SY, 2012, J PAIN, V13, P155, DOI 10.1016/j.jpain.2011.10.012
   Kannarkat G, 2007, CURR OPIN NEUROL, V20, P719
   Kim HW, 2005, PHARMACOL RES, V51, P183, DOI 10.1016/j.phrs.2004.07.011
   Kim H, 2015, KIDNEY INT, V88, P550, DOI 10.1038/ki.2015.147
   Kim H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114726
   KORENMAN EMD, 1981, EXP NEUROL, V72, P63, DOI 10.1016/0014-4886(81)90127-8
   Kudo T, 2011, NEUROSCI LETT, V503, P20, DOI 10.1016/j.neulet.2011.07.056
   Kwon YB, 2001, NEUROSCI LETT, V308, P133, DOI 10.1016/S0304-3940(01)01989-9
   Lamont LA, 2000, VET CLIN N AM-SMALL, V30, P703, DOI 10.1016/S0195-5616(08)70003-2
   Lee DH, 1999, J NEUROPHYSIOL, V81, P2226, DOI 10.1152/jn.1999.81.5.2226
   Lee JH, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-471
   Leem JW, 1997, NEUROSCI LETT, V234, P39, DOI 10.1016/S0304-3940(97)00658-7
   Lehky RJ, 2004, MUSCLE NERVE, V29, P387, DOI 10.1002/mus.10559
   Lim BS, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/369324
   Ling B, 2008, NEUROPHARMACOLOGY, V55, P724, DOI 10.1016/j.neuropharm.2008.06.007
   Ling B, 2007, TOXICOLOGY, V234, P176, DOI 10.1016/j.tox.2007.02.013
   López-Vales R, 2011, FASEB J, V25, P4240, DOI 10.1096/fj.11-183186
   Maleki N, 2005, INT IMMUNOPHARMACOL, V5, P1723, DOI 10.1016/j.intimp.2005.05.012
   Millan MJ, 2002, PROG NEUROBIOL, V66, P355, DOI 10.1016/S0301-0082(02)00009-6
   Monti MC, 2006, CHEMBIOCHEM, V7, P971, DOI 10.1002/cbic.200500454
   Nelson LE, 2003, ANESTHESIOLOGY, V98, P428, DOI 10.1097/00000542-200302000-00024
   Ossipov MH, 2014, CURR OPIN SUPPORT PA, V8, P143, DOI 10.1097/SPC.0000000000000055
   Pasetto LM, 2006, CRIT REV ONCOL HEMAT, V59, P159, DOI 10.1016/j.critrevonc.2006.01.001
   Roh DH, 2004, J PAIN, V5, P297, DOI 10.1016/j.jpain.2004.05.003
   Scullion GA, 2009, NEUROSCIENCE, V164, P415, DOI 10.1016/j.neuroscience.2009.08.046
   Shibata K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023510
   SOMERFIELD SD, 1988, J RHEUMATOL, V15, P1878
   TRACEY DJ, 1995, PAIN, V60, P317, DOI 10.1016/0304-3959(94)00141-Z
   Yoon SY, 2013, BIOL PHARM BULL, V36, P1787, DOI 10.1248/bpb.b13-00469
   Zarrindast MR, 2002, BEHAV PHARMACOL, V13, P117, DOI 10.1097/00008877-200203000-00003
   Zhang JM, 1997, PAIN, V72, P51, DOI 10.1016/S0304-3959(97)00013-4
   Zhao HX, 2003, ANTIMICROB AGENTS CH, V47, P965, DOI 10.1128/AAC.47.3.965-971.2003
   Zhu JX, 2001, J PHYSIOL-LONDON, V530, P431, DOI 10.1111/j.1469-7793.2001.0431k.x
NR 56
TC 41
Z9 45
U1 3
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2072-6651
J9 TOXINS
JI Toxins
PD JUL
PY 2015
VL 7
IS 7
BP 2422
EP 2434
DI 10.3390/toxins7072422
PG 13
WC Food Science & Technology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Toxicology
GA CO5HW
UT WOS:000359191200006
PM 26131771
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Stie, M
   Delmar, C
   Norgaard, B
   Jensen, LH
AF Stie, Mette
   Delmar, Charlotte
   Norgaard, Birgitte
   Jensen, Lars Henrik
TI Impact of Open Dialogue about Complementary Alternative Medicine-A Phase
   II Randomized Controlled Trial
SO CANCERS
LA English
DT Article
DE complementary alternative medicine; communication; integrative;
   oncology; patient safety; quality of life
ID CANCER-PATIENTS; INTEGRATIVE MEDICINE; DISCUSSING COMPLEMENTARY;
   COMMUNICATION; CARE; BREAST; INTERVENTION; PERCEPTIONS; PREDICTORS;
   DEPRESSION
AB Simple Summary A large number of patients with cancer use complementary alternative medicine (CAM), such as diet supplements, massage and acupuncture, as an adjunct to conventional cancer treatment and care. Some types of CAM reduce nausea and vomiting, pain, fear, fatigue and depression, but CAM may also cause new symptoms and side effects. Therefore, it is crucial that cancer patients receive professional guidance on how to use CAM in a safe and healthy manner. Open dialogue about CAM between patients and health professionals is, however, not an integrated part of cancer treatment and care. Therefore, the aim of our study was to assess how open dialogue, including guidance about CAM, affected patients' safety and health when it was an integrated part of the cancer treatment and care. We found that open dialogue about CAM does not compromise patient safety and that it may improve patients' quality of life, self-care and survival. Complementary alternative medicine (CAM) may reduce the symptom burden of side effects to antineoplastic treatment but also cause new side effects and non-adherence to conventional treatment. The aim of this RCT was to investigate the impact of open dialogue about complementary alternative medicine (OD-CAM) on cancer patients' safety, health and quality of life (QoL). Patients undergoing antineoplastic treatment were randomly assigned to standard care (SC) plus OD-CAM or SC alone. The primary endpoint was frequency of grade 3-4 adverse events (AE) eight weeks after enrollment. Secondary endpoints were frequency of grade 1-4 AE, QoL, psychological distress, perceived information, attitude towards and use of CAM 12 and 24 weeks after enrollment. Survival was analyzed post hoc. Fifty-seven patients were randomized to the OD-CAM group and fifty-five to the SC group. No significant difference in frequency of grade 3-4 AEs was shown. The same applied to grade 1-4 AEs and QoL, psychological distress and perceived information. A tendency towards better QoL, improved survival and a lower level of anxiety was found in the OD-CAM group. OD-CAM is not superior to SC in reducing the frequency of AEs in patients undergoing antineoplastic treatment. OD-CAM does not compromise patient safety; it may reduce psychological stress and improve QoL and overall survival.
C1 [Stie, Mette; Jensen, Lars Henrik] Univ Hosp Southern Denmark, Dept Oncol, DK-7100 Vejle, Denmark.
   [Stie, Mette] Univ Hosp Southern Denmark, Fac Hlth Sci, Dept Reg Hlth Res, DK-5000 Odense, Denmark.
   [Delmar, Charlotte] Aarhus Univ, Dept Publ Hlth, Res Unit Nursing & Hlth Care, DK-8000 Aarhus, Denmark.
   [Norgaard, Birgitte] Univ Southern Denmark, Dept Publ Hlth, DK-5000 Odense, Denmark.
C3 University of Southern Denmark; Lillebaelt Hospital; University of
   Southern Denmark; Odense University Hospital; Aarhus University;
   University of Southern Denmark
RP Stie, M (corresponding author), Univ Hosp Southern Denmark, Dept Oncol, DK-7100 Vejle, Denmark.; Stie, M (corresponding author), Univ Hosp Southern Denmark, Fac Hlth Sci, Dept Reg Hlth Res, DK-5000 Odense, Denmark.
EM mette.stie@rsyd.dk; cd@ph.au.dk; binorgaard@health.sdu.dk;
   lars.henrik.jensen@rsyd.dk
RI Jensen, Lars Henrik/P-6252-2018; Noergaard, Birgitte/L-3061-2017
OI Jensen, Lars Henrik/0000-0002-0020-1537; Noergaard,
   Birgitte/0000-0002-2284-2335
FU Fondation Idella [N/A] Funding Source: Medline
CR Baarts C, 2009, SOCIOL HEALTH ILL, V31, P719, DOI 10.1111/j.1467-9566.2009.01163.x
   Bahall M, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1853-6
   Bar-Sela G, 2015, SUPPORT CARE CANCER, V23, P1979, DOI 10.1007/s00520-014-2560-1
   Basch E, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju244
   Ben-Arye E, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0511-1
   Bossi P, 2018, ANN ONCOL, V29, P126, DOI 10.1093/annonc/mdy145
   Broom A, 2009, HEALTH, V13, P317, DOI 10.1177/1363459308101806
   Chong Ooi-Thye, 2006, Clin J Oncol Nurs, V10, P83, DOI 10.1188/06.CJON.83-88
   Cramer H, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010802.pub2
   Davis EL, 2012, ONCOLOGIST, V17, P1475, DOI 10.1634/theoncologist.2012-0223
   de Jong FA, 2008, EUR J CANCER, V44, P374, DOI 10.1016/j.ejca.2007.12.012
   Ebel MD, 2015, J CANCER RES CLIN, V141, P1449, DOI 10.1007/s00432-015-1940-3
   European Organisation for Research and Treatment of Cancer, 2001, Eur Organ Res Treat Cancer, V3rd
   Fremd C, 2017, ARCH GYNECOL OBSTET, V295, P1239, DOI 10.1007/s00404-017-4348-2
   Frenkel M, 2014, J ALTERN COMPLEM MED, V20, P12, DOI 10.1089/acm.2012.0533
   Frenkel M, 2010, INTEGR CANCER THER, V9, P276, DOI 10.1177/1534735410378663
   Frenkel M, 2010, INTEGR CANCER THER, V9, P177, DOI 10.1177/1534735410363706
   Greenlee H, 2016, JAMA ONCOL, V2, P1170, DOI 10.1001/jamaoncol.2016.0685
   Grossarth-Maticek R, 2007, ARZNEIMITTELFORSCH, V57, P665
   Horneber M, 2018, INTEGR CANCER THER, V17, P1172, DOI 10.1177/1534735418808597
   Horneber M, 2012, INTEGR CANCER THER, V11, P187, DOI 10.1177/1534735411423920
   Arraras JI, 2010, EUR J CANCER, V46, P2726, DOI 10.1016/j.ejca.2010.06.118
   Johnson SB, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx145
   Juraskova I, 2010, INTEGR CANCER THER, V9, P168, DOI 10.1177/1534735410365712
   Keshet Y, 2015, PSYCHO-ONCOLOGY, V24, P169, DOI 10.1002/pon.3621
   Keyhanmehr AS, 2018, COMPLEMENT THER CLIN, V31, P175, DOI 10.1016/j.ctcp.2018.02.009
   Klafke N, 2019, CANCER MED-US, V8, P3666, DOI 10.1002/cam4.2196
   Klafke N, 2016, SUPPORT CARE CANCER, V24, P2341, DOI 10.1007/s00520-015-3038-5
   Koithan M, 2007, INTEGR CANCER THER, V6, P174, DOI 10.1177/1534735407301992
   Kust D, 2016, ACTA CLIN CROAT, V55, P585, DOI 10.20471/acc.2016.55.04.08
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Molassiotis A, 2017, SUPPORT CARE CANCER, V25, P267, DOI 10.1007/s00520-016-3324-x
   Münstedt K, 2014, BREAST CARE, V9, P416, DOI 10.1159/000368428
   Nissen N, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-388
   Radwin L, 2000, RES NURS HEALTH, V23, P179, DOI 10.1002/1098-240X(200006)23:3<179::AID-NUR2>3.3.CO;2-K
   Roter DL, 2016, PATIENT EDUC COUNS, V99, P1519, DOI 10.1016/j.pec.2016.06.002
   Rubinstein LV, 2005, J CLIN ONCOL, V23, P7199, DOI 10.1200/JCO.2005.01.149
   Schofield P, 2010, PATIENT EDUC COUNS, V79, P143, DOI 10.1016/j.pec.2009.07.038
   Schulz KF, 2010, BMJ-BRIT MED J, V340, DOI [10.1136/bmj.c869, 10.1136/bmj.c332]
   Segev Y, 2021, SUPPORT CARE CANCER, V29, P4055, DOI 10.1007/s00520-020-05961-5
   Shalom-Sharabi I, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-1016-0
   Stie M, 2020, PATIENT EDUC COUNS, V103, P2224, DOI 10.1016/j.pec.2020.06.003
   Toledano A, 2021, INTEGR CANCER THER, V20, DOI 10.1177/15347354211004730
   Towler P, 2013, SUPPORT CARE CANCER, V21, P2913, DOI 10.1007/s00520-013-1882-8
   Wanchai A, 2010, CLIN J ONCOL NURS, V14, P431, DOI 10.1188/10.CJON.E45-E55
   Werthmann Paul G, 2018, Perm J, V23, P18, DOI [10.7812/tpp/18-025, 10.7812/TPP/18-025]
   Witt Claudia M., 2017, Journal of the National Cancer Institute Monographs, P3, DOI [10.1093/jncimonographs/lgx012, 10.1093/jncimonographs/lgx012]
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
   Zwingmann J, 2017, CANCER-AM CANCER SOC, V123, P3167, DOI 10.1002/cncr.30694
NR 49
TC 7
Z9 7
U1 1
U2 14
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD FEB
PY 2022
VL 14
IS 4
AR 952
DI 10.3390/cancers14040952
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Oncology
GA ZH7YR
UT WOS:000761149900001
PM 35205698
OA Green Submitted, Green Published, gold
DA 2026-01-16
ER

PT J
AU Lindblad, K
   Bergkvist, L
   Johansson, AC
AF Lindblad, Katarina
   Bergkvist, Leif
   Johansson, Ann-Christin
TI Evaluation of the treatment of chronic chemotherapy-induced peripheral
   neuropathy using long-wave diathermy and interferential currents: a
   randomized controlled trial
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Physical therapy; Electrotherapy; Diathermy; Interferential current;
   Cancer
ID TEST-RETEST RELIABILITY; SCRAMBLER THERAPY; PAIN; CANCER; ACUPUNCTURE;
   MANAGEMENT; BALANCE; CIPN
AB Purpose The purpose was to investigate the effects of long-wave diathermy in combination with interferential currents (interferential therapy and long-wave diathermy at high power (ITH)) in comparison with long-wave diathermy at a power below the active treatment dose (long-wave diathermy at low power (LDL), control group) on sensory and motor symptoms in patients with chronic chemotherapy-induced peripheral neuropathy (CIPN) in the lower extremities.
   Methods Sixty-seven patients with chronic CIPN were randomized to 12 weeks of either ITH or LDL. Follow-up assessments were performed after the treatment period and at 37 weeks after randomization. The primary outcome was pain (Numeric Rating Scale (NRS)), and the secondary outcomes were discomfort, nerve symptoms, subjective measurement of dizziness (Dizziness Handicap Inventory), and balance. Differences within and between groups were analyzed.
   Results Pain intensity decreased significantly only in the LDL group directly after the treatment period from NRS median 25 to median 12.5 (P = 0.017). At the 37-week follow-up, no changes were detected, irrespective of group (NRS 13 vs. 20, P = 0.885). Discomfort decreased significantly in both groups at both 12 and 37 weeks after the baseline (P < 0.05). Balance disability showed significant declines in both groups at 12 and 37 weeks (P = 0.001/0.025 in the ITH group vs P = 0.001/<0.001 in the LDL group). Balance ability (tightened Romberg test) increased significantly at both 12 and 37 weeks in both groups (P = 0.004/<0.040 in the ITH group) but did not improve in the LDL group at any of the follow-up time points (P = 0.203 vs P = 0.383). The one-legged stance test was unchanged in the ITH group after 12 weeks but improved 37 weeks after baseline (P = 0.03). No significant changes were observed in the LDL group at any of the follow-up time points.
   Conclusion This study provides no support for the use of a combination of long-wave diathermy and ITH as a treatment option for patients with chronic CIPN. However, the chronic CIPN symptoms decreased with time irrespective of the treatment.
C1 [Lindblad, Katarina] Vastmanland Cty Hosp, Dept Surg, S-72189 Vasteras, Sweden.
   [Bergkvist, Leif] Uppsala Univ, Vastmanland Cty Hosp, Clin Res Ctr, Dept Surg, S-72189 Vasteras, Sweden.
   [Johansson, Ann-Christin] Malardalen Univ, Clin Res Ctr, Vastmanland Cty Hosp, Dept Physiotherapy,Sch Hlth Care & Social Welf, S-72189 Vasteras, Sweden.
C3 Uppsala University; Malardalen University
RP Lindblad, K (corresponding author), Vastmanland Cty Hosp, Dept Surg, S-72189 Vasteras, Sweden.
EM katarinalindblad@hotmail.com
FU Vastmanland County Hospital, Vasteras, Sweden
FX The study was supported by research grants from the Vastmanland County
   Hospital, Vasteras, Sweden. We are grateful for the support provided by
   physical therapists Jenny Ulmestedt and Karin Tissier Knutsgard, for
   helping with the assessment and evaluation of the patients. We also
   acknowledge Berit Werner-Erichsen, Head of Physical Therapy, Surgical
   Department, Vastmanland County Hospital, Vasteras, who gave permission
   for performing the study.
CR [Anonymous], EVID BASED COMPLEMEN
   BRIGGS RC, 1989, PHYS THER, V69, P748, DOI 10.1093/ptj/69.9.748
   Cavaletti G, 2011, CURR TREAT OPTION NE, V13, P180, DOI 10.1007/s11940-010-0108-3
   Coyne Patrick J, 2013, J Pain Palliat Care Pharmacother, V27, P359, DOI 10.3109/15360288.2013.847519
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9
   Ferrier J, 2013, CURR PAIN HEADACHE R, V17, DOI 10.1007/s11916-013-0364-5
   Giorgi F, 1996, AM J CLIN ONCOL-CANC, V19, P394, DOI 10.1097/00000421-199608000-00016
   Grisold W, 2012, NEURO-ONCOLOGY, V14, P45, DOI 10.1093/neuonc/nos203
   ITO Physiotherapy & Rehabilitation, EL ES 520 VAK DEV MA
   JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424
   Jarlsater S., 2003, Adv Physiother, V5, P137, DOI 10.1080/14038190310004385
   Jensen MP, 2003, J PAIN, V4, P2, DOI 10.1054/jpai.2003.1
   Johnson M.I., 1997, PHYSIOTHERAPY, V83, P461
   Johnson MI, 2003, PHYS THER, V83, P208, DOI 10.1093/ptj/83.3.208
   MARGOLIS RB, 1988, PAIN, V33, P49, DOI 10.1016/0304-3959(88)90202-3
   Molin B, 2010, OM SMARTA FYSIOLOGIS
   Ohlund C, 1996, SPINE, V21, P1021, DOI 10.1097/00007632-199605010-00005
   Pachman DR, 2015, J CLIN ONCOL, V33, P3416, DOI 10.1200/JCO.2014.58.8533
   Pachman DR, 2015, SUPPORT CARE CANCER, V23, P943, DOI 10.1007/s00520-014-2424-8
   Rao RD, 2008, CANCER, V112, P2802, DOI 10.1002/cncr.23482
   Schloss JM, 2013, CLIN NUTR, V32, P888, DOI 10.1016/j.clnu.2013.04.007
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Sluka KA, 2009, TRANSCUTANEOUS ELECT, P166
   Smith TJ, 2010, J PAIN SYMPTOM MANAG, V40, P883, DOI 10.1016/j.jpainsymman.2010.03.022
   Steffen T, 2008, PHYS THER, V88, P733, DOI 10.2522/ptj.20070214
   Stephenson Richard, 1995, Physiotherapy Theory and Practice, V11, P89, DOI 10.3109/09593989509022405
   Stillman Mark, 2006, Curr Pain Headache Rep, V10, P279
   Visovsky Constance, 2007, Clin J Oncol Nurs, V11, P901
   Wall P.D., 1999, TXB PAIN
   Wolf S, 2008, EUR J CANCER, V44, P1507, DOI 10.1016/j.ejca.2008.04.018
NR 31
TC 13
Z9 16
U1 3
U2 19
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD JUN
PY 2016
VL 24
IS 6
BP 2523
EP 2531
DI 10.1007/s00520-015-3060-7
PG 9
WC Oncology; Health Care Sciences & Services; Rehabilitation
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA DK5TL
UT WOS:000374983300017
PM 26687020
DA 2026-01-16
ER

PT J
AU Ben-Arye, E
   Biron-Shental, T
   Rosa, WE
   Samuels, N
   Levy, O
   Keshet, Y
   Armon, S
   Gressel, O
   Kedar, R
   Messinger, A
   Ari, RL
   Lavie, A
   Atzil, N
   Ben Zohar, B
   Sokolovski, CF
   Solt, I
   Yaffe, H
   Maor, GS
   Levy, M
   Maor-Sagie, E
   Shtern, DK
   Stoffman, G
   Ben Ze'ev, R
   Sher, ML
   Zidenberg, B
   Sagi, S
   Schiff, E
AF Ben-Arye, Eran
   Biron-Shental, Tal
   Rosa, William E.
   Samuels, Noah
   Levy, Oz
   Keshet, Yael
   Armon, Shunit
   Gressel, Orit
   Kedar, Reuven
   Messinger, Aviv
   Ari, Revital Lev
   Lavie, Anat
   Atzil, Neta
   Ben Zohar, Bosmat
   Sokolovski, Cara Ferrer
   Solt, Ido
   Yaffe, Hila
   Maor, Gil Shechter
   Levy, Moti
   Maor-Sagie, Esther
   Shtern, Danit Katz
   Stoffman, Gali
   Ben Ze'ev, Reut
   Sher, Maayan Lahav
   Zidenberg, Betty
   Sagi, Shlomi
   Schiff, Elad
TI Acupuncture in <bold>obstetrics</bold>: <bold>delivery room integrative
   medicine for anxiety and pain</bold>
SO BMJ SUPPORTIVE & PALLIATIVE CARE
LA English
DT Article
DE Integrative Medicine; Complementary therapy
ID ALTERNATIVE MEDICINE; COMPLEMENTARY; PREGNANCY; PERIOD; WOMEN
AB Objectives Supportive and palliative care include non-oncology settings where patients suffer from pain and quality of life-related concerns. Integrative medicine plays important roles in supportive care and symptom management, including Integrative Obstetric (IOb) programmes within peri-partum settings. Multidisciplinary approaches may help nurse-midwives and obstetricians improve patient care and associated outcomes. This study presents a national perspective on IOb programmes in Israel.Methods A qualitative research methodology was codesigned by the Society for Complementary Medicine and Society of Maternal-Fetal Medicine, Israel Medical Association. A questionnaire with 17 open-ended questions was distributed throughout obstetrics and gynaecology departments across Israel. Respondent narratives were qualitatively analysed using ATLAS.Ti software for systematic coding.Results 22 senior obstetricians and IOb directors across 11 centres with IOb programmes completed the questionnaire. Core themes considered essential for the design and operation of IOb programmes included (1) determining major goals and indications for referral, primarily pain and anxiety; (2) targeting patients most likely to benefit; (3) identifying barriers and enablers to implementation and communication with the obstetric team; (4) designing the referral process and (5) documenting outcomes and safety of the IOb intervention in electronic medical files.Conclusions Designing and implementing IOb models of care that effectively support holistic symptom management within obstetric settings requires identifying barriers and enablers and establishing effective communication between obstetric and integrative medical teams. Further research should explore other multidisciplinary models of IOb care and structured referral development and testing while assessing risks and effectiveness.
C1 [Ben-Arye, Eran] LIN Med Ctr, Integrat Oncol Program, Oncol Serv, Clalit Hlth Serv, Haifa, Israel.
   [Biron-Shental, Tal; Maor, Gil Shechter] Meir Med Ctr, Kefar Sava, Israel.
   [Rosa, William E.] Mem Sloan Kettering Canc Ctr, Psychiat & Behav Sci, New York, NY USA.
   [Samuels, Noah] Shaare Zedek Med Ctr, Ctr Integrat Complementary Med, Jerusalem, Israel.
   [Levy, Oz; Armon, Shunit] Shaare Zedek Med Ctr, Jerusalem, Israel.
   [Keshet, Yael] Western Galilee Coll, Akko, Israel.
   [Gressel, Orit] Carmel Hosp, Integrat Obstet Program, Haifa, Israel.
   [Kedar, Reuven; Sher, Maayan Lahav] Carmel Hosp, Haifa, Israel.
   [Messinger, Aviv] Sheba Med Ctr, Tel Hashomer, Israel.
   [Ari, Revital Lev; Lavie, Anat] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel.
   [Atzil, Neta; Ben Zohar, Bosmat] Hadassah Mt Scopus Univ Hosp, Jerusalem, Israel.
   [Sokolovski, Cara Ferrer; Solt, Ido] Rambam Hlth Care Campus, Haifa, Israel.
   [Yaffe, Hila] Hadassah Univ, Div Obstet & Gynecol, Med Ctr, Jerusalem, Israel.
   [Levy, Moti] Clalit Hlth Serv, Tel Aviv, Israel.
   [Maor-Sagie, Esther; Shtern, Danit Katz] Hillel Yaffe Med Ctr, Hadera, Israel.
   [Stoffman, Gali] Barzilai Univ, Med Ctr, Ashqelon, Israel.
   [Ben Ze'ev, Reut] Barzilai Govt Hosp, Ashqelon, Israel.
   [Zidenberg, Betty; Sagi, Shlomi] Bnai Zion Med Ctr, Haifa, Israel.
   [Schiff, Elad] Bnai Zion Hosp, Dept Internal Med, Haifa, Israel.
C3 Clalit Health Services; Tel Aviv University; Sackler Faculty of
   Medicine; Memorial Sloan Kettering Cancer Center; Hebrew University of
   Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem;
   Shaare Zedek Medical Center; Western Galilee Academic College; Clalit
   Health Services; Carmel Medical Center; Clalit Health Services; Carmel
   Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Tel
   Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical
   Center; Hebrew University of Jerusalem; Hadassah University Hospital;
   Rambam Health Care Campus; Hebrew University of Jerusalem; Hadassah
   University Medical Center; Clalit Health Services; Ben-Gurion University
   of the Negev; Barzilai Medical Center; Ben-Gurion University of the
   Negev; Barzilai Medical Center; Bnai Zion Medical Center; Bnai Zion
   Medical Center
RP Ben-Arye, E (corresponding author), LIN Med Ctr, Integrat Oncol Program, Oncol Serv, Clalit Hlth Serv, Haifa, Israel.
EM eranben@netvision.net.il; Tal.Biron-Shental@clalit.org.il;
   rosaw@mskcc.org; noahs@szmc.org.il; ozlevy@szmc.org.il;
   yaelk@wgalil.ac.il; shunita@szmc.org.il; oritgresselraz@gmail.com;
   Reuven.kedar@gmail.com; aviv@briat.co.il; revlev@gmail.com;
   anatlavier@gmail.com; Neta.atzil@gmail.com; Bosmatbosmat100@gmail.com;
   CARA.TCM@GMAIL.COM; Ido.solt@gmail.com; yaffehila@gmail.com;
   gilshec@gmail.com; motil@clalit.org.il; estimaorsagie@gmail.com;
   Danit.k.s11@gmail.com; gali@pandaclinic.co.il; reutb@bmc.gov.il;
   maayanlahavsher@gmail.com; Betty.ziden@gmail.com; Mdsagi.s@gmail.com;
   elad.schiff@b-zion.org.il
RI ; Stoffman, Gali/PGL-7016-2026; Biron-Shental, Tal/L-6035-2019
OI Rosa, William/0000-0002-0680-8911; Gressel, Orit/0000-0002-0184-0453
FU Department of Obstetrics and Gynecology, Sheba Medical Center
FX We are grateful to Dr. Orit Moran from the Department of Obstetrics and
   Gynecology, Sheba Medical Center and Dr. Reem Yassin from the Department
   of Obstetrics and Gynecology, Ziv Medical Center, Zfat, Israel.
CR Abadi F, 2017, J ACUPUNCT MERIDIAN, V10, P114, DOI 10.1016/j.jams.2016.11.008
   Ben-Arye E, 2023, CANCER-AM CANCER SOC, V129, P908, DOI 10.1002/cncr.34542
   Ben-Arye E, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0511-1
   Birdee GS, 2014, J WOMENS HEALTH, V23, P824, DOI 10.1089/jwh.2013.4568
   Carr DJ, 2015, ACUPUNCT MED, V33, P413, DOI 10.1136/acupmed-2015-010936
   Emiru Yohannes Kelifa, 2021, Int J Reprod Med, V2021, P8829313, DOI [10.1155/2021/8829313, 10.1155/2021/8829313]
   Fok D, 2016, BIRTH-ISS PERINAT C, V43, P247, DOI 10.1111/birt.12233
   Jodie F, 2025, J PAIN SYMPTOM MANAG, V69, P102, DOI 10.1016/j.jpainsymman.2024.07.024
   Johnson PJ, 2016, WOMEN HEALTH ISS, V26, P40, DOI 10.1016/j.whi.2015.08.009
   Keshet Y, 2015, PSYCHO-ONCOLOGY, V24, P169, DOI 10.1002/pon.3621
   Lokugamage AU, 2020, J OBSTET GYNAECOL, V40, P1096, DOI 10.1080/01443615.2019.1694878
   Madden K, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009356.pub2
   Marc I, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007559.pub2
   Michel J, 2007, J ETHNOPHARMACOL, V114, P92, DOI 10.1016/j.jep.2007.07.033
   Mollart LJ, 2015, WOMEN BIRTH, V28, P199, DOI 10.1016/j.wombi.2015.03.007
   Pallivalapila AR, 2015, OBSTET GYNECOL, V125, P204, DOI 10.1097/AOG.0000000000000596
   Peeters R, 2023, MED CARE RES REV, V80, P266, DOI [10.1177/10775587221118156, 10.1111/eva.13711]
   Schürger N, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-018-2249-y
   Schytt E, 2011, ACTA OBSTET GYN SCAN, V90, P77, DOI 10.1111/j.1600-0412.2010.01027.x
   Shalom-Sharabi I, 2018, INTEGR CANCER THER, V17, P697, DOI 10.1177/1534735418764839
   Skouteris H, 2008, AUST NZ J OBSTET GYN, V48, P384, DOI 10.1111/j.1479-828X.2008.00865.x
   Smith C, 2002, COMPLEMENT THER MED, V10, P78, DOI 10.1054/ctim.2002.0523
   Smith CA, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009232.pub2
   Smith CA, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009290.pub2
   Smith CA, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009514
   Tan MY, 2023, FRONT PUBLIC HEALTH, V11, DOI 10.3389/fpubh.2023.1108756
   Usichenko TI, 2022, JAMA NETW OPEN, V5, DOI 10.1001/jamanetworkopen.2022.0517
   Zamawe C, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022499
   Zeng YC, 2014, COMPLEMENT THER MED, V22, P1047, DOI 10.1016/j.ctim.2014.10.009
   Zhang N H, 1988, Midwives Chron, V101, P100
   Zhou DD, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/7341920
   Zimpel SA, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011216.pub2
NR 32
TC 0
Z9 0
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2045-435X
EI 2045-4368
J9 BMJ SUPPORT PALLIAT
JI BMJ Support. Palliat. Care
PD JUL
PY 2025
VL 15
IS 4
BP 535
EP 541
DI 10.1136/spcare-2025-005512
EA APR 2025
PG 7
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services
GA 4PS8Q
UT WOS:001468809800001
PM 40240122
OA Green Submitted
DA 2026-01-16
ER

PT J
AU Li, DX
   Wu, Y
   Chang, LR
   Song, YZ
   Du, XQ
   Xue, FQ
   Liu, Y
   Wu, J
   Wang, TL
AF Li, Daxian
   Wu, Yan
   Chang, Lirong
   Song, Yizhi
   Du, Xiaoqiang
   Xue, Fenqin
   Liu, Yang
   Wu, Jie
   Wang, Tianlong
TI Therapeutic effects of melittin on paclitaxel-induced peripheral
   neuropathic pain and spinal neuronal hyperactivity in male rats
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Article
DE chemotherapy-induced peripheral neuropathy; bee venom; acupuncture;
   analgesia; wide dynamic range neuron; electrophysiological recording;
   noradrenergic system
ID SUBSTANTIA-GELATINOSA NEURONS; MOUSE MODEL; MECHANISMS; INHIBITION;
   MANAGEMENT; ALLODYNIA; STIMULI; SYSTEM; ADULT
AB Introduction As a taxane-based cytostatic agent, paclitaxel holds a broad spectrum of life-saving properties. However, its use is frequently limited by painful neuropathy in the extremities, which severely hinders the ultimate prognosis of cancer survivors. While bee venom therapy has shown promise in alleviating chemotherapy-induced neuropathic pain, the analgesic potential of its primary bioactive components, such as melittin and phospholipase A2 (bvPLA2), remains uncharacterized. This study investigated the ameliorative effects of melittin against paclitaxel-induced peripheral neuropathy in rats through integrated behavioral, in vivo electrophysiological, and neuropharmacological approaches.Methods Paclitaxel was administered intraperitoneally (i.p.) at a total dose of 8 mg/kg. Cold and mechanical allodynia and hyperalgesia were quantified using the acetone drop and von Frey filament tests. To compare the therapeutic properties of bee venom ingredients, either melittin (0.5 mg/kg) or bvPLA2 (0.12 mg/kg) was administered subcutaneously at ST36 (Zusanli acupoint). In vivo extracellular recordings of wide dynamic range (WDR) neurons were performed in the spinal dorsal horn. Noradrenaline depletion was induced by the i.p. treatment with N-(2-Chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4, 50 mg/kg), and serotonin depletion was conducted by the i.p. administration of para-chlorophenylalanine (PCPA, 450 mg/kg).Results ST36 treatment with melittin, but not bvPLA2, markedly impeded mechanical and cold hypersensitivity. Electrophysiological analysis revealed that paclitaxel induced spontaneous and stimulus-evoked hyperexcitation of spinal WDR neurons. Melittin selectively suppressed evoked neuronal activities (i.e., acute responses and after-discharges) without modulating the spontaneous firing of WDR neurons. Neuropharmacological investigation demonstrated that the effects of melittin were fully reversed by noradrenaline depletion, whereas serotonin depletion had no effect.Discussion Our findings establish that melittin treatment at ST36 could ease paclitaxel-induced neuropathic pain by partially attenuating the hyperexcitable state of spinal WDR neurons. Furthermore, these ameliorative actions were mediated by the specific recruitment of the endogenous noradrenergic system. This study provides novel evidence supporting melittin as a targeted symptomatic agent for paclitaxel-induced peripheral neuropathy, which would advance the development of promising analgesic strategies in oncological care.
C1 [Li, Daxian; Liu, Yang; Wu, Jie; Wang, Tianlong] Capital Med Univ, Xuanwu Hosp, Dept Anesthesiol, Beijing, Peoples R China.
   [Li, Daxian; Liu, Yang; Wu, Jie; Wang, Tianlong] Natl Clin Res Ctr Geriatr Dis, Beijing, Peoples R China.
   [Wu, Yan; Chang, Lirong; Song, Yizhi; Du, Xiaoqiang] Capital Med Univ, Beijing Inst Brain Disorders, Beijing Key Lab Neural Regenerat & Repair, Dept Anat,Sch Basic Med Sci, Beijing, Peoples R China.
   [Wu, Yan] Beijing Agr Univ, Coll Vet Med, Beijing, Peoples R China.
   [Xue, Fenqin] Capital Med Univ, Core Facil Ctr, Beijing, Peoples R China.
C3 Capital Medical University; Capital Medical University; Beijing
   University of Agriculture; Capital Medical University
RP Wang, TL (corresponding author), Capital Med Univ, Xuanwu Hosp, Dept Anesthesiol, Beijing, Peoples R China.; Wang, TL (corresponding author), Natl Clin Res Ctr Geriatr Dis, Beijing, Peoples R China.
EM w_tl5595@hotmail.com
RI song, yizhi/W-2374-2019
OI Li, Daxian/0000-0003-1327-5866
FU National Natural Science Foundation of China [82204932]
FX The author(s) declare that financial support was received for the
   research and/or publication of this article. This work was supported by
   grants from the National Natural Science Foundation of China (82204932).
CR Baron R, 2010, LANCET NEUROL, V9, P807, DOI 10.1016/S1474-4422(10)70143-5
   Beh ST, 2019, PAIN, V160, P1505, DOI 10.1097/j.pain.0000000000001547
   Boyette-Davis JA, 2018, PAIN MANAG, V8, P363, DOI 10.2217/pmt-2018-0020
   Boyette-Davis JA, 2015, PAIN MANAG, V5, P285, DOI [10.2217/PMT.15.19, 10.2217/pmt.15.19]
   Cavaletti G, 2015, CURR OPIN NEUROL, V28, P500, DOI 10.1097/WCO.0000000000000234
   Chae HK, 2019, NUTRIENTS, V11, DOI 10.3390/nu11020432
   Chen YP, 2005, J PHARMACOL EXP THER, V315, P696, DOI 10.1124/jpet.105.091314
   Choi S, 2019, TOXINS, V11, DOI 10.3390/toxins11070396
   Choi S, 2017, J PHYSIOL SCI, V67, P431, DOI 10.1007/s12576-016-0505-9
   CHOI Y, 1994, PAIN, V59, P369, DOI 10.1016/0304-3959(94)90023-X
   Flatters SJL, 2006, NEUROSCI LETT, V397, P219, DOI 10.1016/j.neulet.2005.12.013
   Flatters SJL, 2004, PAIN, V109, P150, DOI 10.1016/j.pain.2004.01.029
   Furue H, 1999, J PHYSIOL-LONDON, V521, P529, DOI 10.1111/j.1469-7793.1999.00529.x
   Gajski G, 2024, TOXINS, V16, DOI 10.3390/toxins16030117
   Gilron I, 2013, LANCET NEUROL, V12, P1084, DOI 10.1016/S1474-4422(13)70193-5
   HAIT WN, 1985, CANCER CHEMOTH PHARM, V14, P202, DOI 10.1007/BF00258116
   Hershman DL, 2014, J ONCOL PRACT, V10, pE421, DOI 10.1200/JOP.2014.001776
   Hickey L, 2014, J NEUROSCI, V34, P4148, DOI 10.1523/JNEUROSCI.4835-13.2014
   JAIMETCHEVERRY G, 1980, BRAIN RES, V188, P513, DOI 10.1016/0006-8993(80)90049-9
   Kawashiri T, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168733
   Kim HW, 2005, PHARMACOL RES, V51, P183, DOI 10.1016/j.phrs.2004.07.011
   Kim N, 2023, PLANTS-BASEL, V12, DOI 10.3390/plants12122283
   Kim W, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122626
   Kim W, 2016, TOXINS, V8, DOI 10.3390/toxins8020033
   Kwon YB, 2001, PAIN, V90, P271, DOI 10.1016/S0304-3959(00)00412-7
   Latremoliere A, 2009, J PAIN, V10, P895, DOI 10.1016/j.jpain.2009.06.012
   Lee JH, 2001, J VET MED SCI, V63, P251, DOI 10.1292/jvms.63.251
   Lee JH, 2022, CURR ISSUES MOL BIOL, V44, P718, DOI 10.3390/cimb44020050
   Li DX, 2021, KOREAN J PHYSIOL PHA, V25, P489, DOI 10.4196/kjpp.2021.25.5.489
   Li DX, 2020, TOXINS, V12, DOI 10.3390/toxins12120775
   Li DX, 2020, TOXINS, V12, DOI 10.3390/toxins12100620
   Li DX, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071652
   Li D, 2015, TOXINS, V7, P2422, DOI 10.3390/toxins7072422
   Lin TY, 2020, TOXINS, V12, DOI 10.3390/toxins12100618
   Lu KW, 2016, SCI REP-UK, V6, DOI 10.1038/srep22123
   Maleki N, 2005, INT IMMUNOPHARMACOL, V5, P1723, DOI 10.1016/j.intimp.2005.05.012
   Marupudi NI, 2007, EXPERT OPIN DRUG SAF, V6, P609, DOI 10.1517/14740338.6.5.609
   McGgaraughty S, 2018, J NEUROPHYSIOL, V120, P1893, DOI 10.1152/jn.00325.2018
   Millan MJ, 2002, PROG NEUROBIOL, V66, P355, DOI 10.1016/S0301-0082(02)00009-6
   Morisset V, 1998, EUR J NEUROSCI, V10, P3642, DOI 10.1046/j.1460-9568.1998.00370.x
   Park JW, 2012, INTEGR CANCER THER, V11, P166, DOI 10.1177/1534735411413265
   PERTOVAARA A, 1993, PROG NEUROBIOL, V40, P691, DOI 10.1016/0301-0082(93)90011-G
   Polomano RC, 2001, PAIN, V94, P293, DOI 10.1016/S0304-3959(01)00363-3
   Reddi Danielle, 2013, Br J Hosp Med (Lond), V74 Suppl 12, pC188
   Seo BK, 2017, TOXINS, V9, DOI 10.3390/toxins9110361
   Shim HS, 2019, MOL PAIN, V15, DOI 10.1177/1744806919840098
   Siau C, 2006, EXP NEUROL, V201, P507, DOI 10.1016/j.expneurol.2006.05.007
   Sikandar S, 2017, PHYSIOL REP, V5, DOI 10.14814/phy2.13323
   Sisignano M, 2014, NAT REV NEUROL, V10, P694, DOI 10.1038/nrneurol.2014.211
   Stela M, 2024, PHARMACEUTICALS-BASE, V17, DOI 10.3390/ph17091211
   Sun XW, 2022, NAT SCI SLEEP, V14, P335, DOI 10.2147/NSS.S352035
   Sung SH, 2021, TOXINS, V13, DOI 10.3390/toxins13090608
   Tasmuth T, 2002, EUR J PAIN-LONDON, V6, P17, DOI 10.1053/eujp.2001.0266
   Todd AJ, 2010, NAT REV NEUROSCI, V11, P823, DOI 10.1038/nrn2947
   Tsai CH, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179257
   Woo S, 2019, TOXINS, V11, DOI 10.3390/toxins11080477
   Yamada A, 2018, MOL PAIN, V14, DOI 10.1177/1744806918817969
   Yin CS, 2008, RES VET SCI, V84, P159, DOI 10.1016/j.rvsc.2007.04.004
   Yoon J, 2012, J ACUPUNCT MERIDIAN, V5, P156, DOI [10.1016/j.jams.2012.05.003, 10.106/j.jams.2012.05.003]
   YOSHIMURA M, 1989, J NEUROPHYSIOL, V62, P96, DOI 10.1152/jn.1989.62.1.96
   Yoshimura M, 2006, J PHARMACOL SCI, V101, P107, DOI 10.1254/jphs.CRJ06008X
   Yu DL, 2022, INT IMMUNOPHARMACOL, V105, DOI 10.1016/j.intimp.2022.108555
   Zain M, 2019, PAIN, V160, P2199, DOI 10.1097/j.pain.0000000000001632
   Zajaczkowska R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061451
   Zeng YJ, 2018, LASER MED SCI, V33, P295, DOI 10.1007/s10103-017-2367-7
   Zhang S, 2018, TOXICON, V148, P64, DOI 10.1016/j.toxicon.2018.04.012
   Zhang ZY, 2024, J PAIN RES, V17, P441, DOI 10.2147/JPR.S446803
   Zheng FY, 2011, NEUROSCIENCE, V176, P447, DOI 10.1016/j.neuroscience.2010.12.052
   ZHU HG, 1991, J BIOL REG HOMEOS AG, V5, P52
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
NR 70
TC 0
Z9 0
U1 4
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PD JUL 2
PY 2025
VL 19
AR 1622553
DI 10.3389/fnins.2025.1622553
PG 13
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 4XZ0Q
UT WOS:001529336300001
PM 40672870
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Ding, ZW
   Wang, XH
   Han, DD
   Zhang, C
   Xie, KJ
   Zhou, HD
   Yuan, XH
   Mao, XC
   Yu, WF
   Huang, ZX
AF Ding, Zewu
   Wang, Xihui
   Han, Dongdong
   Zhang, Can
   Xie, Kangjie
   Zhou, Huidan
   Yuan, Xiaohong
   Mao, Xiaochun
   Yu, Weifeng
   Huang, Zhangxiang
TI Comparison of the analgesic efficacy of ultrasound-guided retrolaminar
   block with serratus anterior plane block in patients undergoing radical
   mastectomy
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Postoperative pain; nerve block; retrolaminar block; serratus anterior
   plane block; radical mastectomy
ID PARAVERTEBRAL BLOCK; CANCER-SURGERY; BREAST SURGERY; PAIN
AB Objectives: The newly introduced retrolaminar block (RLB) offers anesthesiologists an alternative regional anesthetic technique for radical mastectomy. However, few clinical studies have compared the efficacy of RLB with that of serratus anterior plane block (SAPB). This study aimed to investigate the postoperative analgesia efficacy between ultrasound-guided RLB and SAPB in patients undergoing radical mastectomy. Methods: Seventy patients were included in this prospective, randomized controlled trial. Patients were assigned to receive either ultrasoundguided RLB or SAPB. The primary outcome was the visual analogue scale (VAS) score during coughing at 6 hours postoperatively. The secondary indicators included dermatomal spread of sensory block (from T2 to T6 at the medial and lateral nipple lines assessed by acupuncture), intraoperative hemodynamic changes, and analgesia-related adverse reactions. Results: The median VAS scores during coughing at 6 hours postoperatively were 2 (IQ1-IQ3: 1-3; P = 0.39) in both groups, indicating no significant difference. Similar analgesic effects were observed at other time points within 48 hours post-surgery. RLB provided broader sensory coverage on the medial side of the nipple compared to SAPB (median [IQR]: 3 (3-4) and 2 (1-2)) (P = 0.006). No significant differences in mean arterial pressure (MAP) or heart rate (HR) were observed immediately or 5 minutes after skin incision. The incidence of adverse events did not differ significantly between the two groups. Conclusions: Retrolaminar block and Serratus anterior plane block provide comparable postoperative analgesia following radical mastectomy. However, RLB offers a broader sensory block range, particularly over the medial chest wall.
C1 [Ding, Zewu; Xie, Kangjie; Zhou, Huidan; Yuan, Xiaohong] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med HIM, Dept Anesthesiol, Hangzhou 310005, Zhejiang, Peoples R China.
   [Wang, Xihui] Shaoxing Peoples Hosp, Dept Anesthesiol, Shaoxing 312300, Zhejiang, Peoples R China.
   [Han, Dongdong; Zhang, Can] Wenzhou Med Univ, Zhejiang Canc Hosp, Postgrad Training Base Alliance, Hangzhou 310005, Zhejiang, Peoples R China.
   [Mao, Xiaochun] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med HIM, Dept Thyroid Surg, Hangzhou 310005, Zhejiang, Peoples R China.
   [Yu, Weifeng] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Anesthesiol, 145 Shandong Middle Rd, Shanghai 200001, Peoples R China.
   [Huang, Zhangxiang] Kunming Med Univ, Affiliated Hosp 1, Dept Pain, 295 Xichang Rd, Kunming 650000, Yunnan, Peoples R China.
C3 Zhejiang Cancer Hospital; Chinese Academy of Sciences; Hangzhou
   Institute of Medicine, CAS; Zhejiang Cancer Hospital; Wenzhou Medical
   University; Zhejiang Cancer Hospital; Chinese Academy of Sciences;
   Hangzhou Institute of Medicine, CAS; Shanghai Jiao Tong University;
   Kunming Medical University
RP Yu, WF (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Anesthesiol, 145 Shandong Middle Rd, Shanghai 200001, Peoples R China.; Huang, ZX (corresponding author), Kunming Med Univ, Affiliated Hosp 1, Dept Pain, 295 Xichang Rd, Kunming 650000, Yunnan, Peoples R China.
EM ywf808@yeah.net; adams7777@163.com
RI Zhou, Huidan/JPX-5174-2023; Yu, Wei/OGP-5721-2025
FU Zhejiang Provincial Health Science and Technology Program Young
   Innovative Talents Project [2022RC015]; Zhejiang Traditional Chinese
   Medicine Science and Technology Plan [2023ZL302]; Zhejiang Medical
   Science and Technology Plan [2020-KY482]; National Natural Science
   Foundation of China [82160229]
FX This work was supported by Zhejiang Provincial Health Science and
   Technology Program Young Innovative Talents Project (grant number
   2022RC015) , Zhejiang Traditional Chinese Medicine Science and
   Technology Plan (grant number 2023ZL302) , Zhejiang Medical Science and
   Technology Plan (grant number 2020-KY482) and National Natural Science
   Foundation of China (grant number 82160229) .
CR Abdallah FW, 2021, ANAESTHESIA, V76, P1190, DOI 10.1111/anae.15373
   Alseoudy MM, 2021, J CLIN ANESTH, V74, DOI 10.1016/j.jclinane.2021.110421
   Ball L, 2016, CURR OPIN CRIT CARE, V22, P379, DOI 10.1097/MCC.0000000000000312
   Bennett GJ, 2000, J PAIN SYMPTOM MANAG, V19, pS2
   Bican O, 2013, NEUROL CLIN, V31, P1, DOI 10.1016/j.ncl.2012.09.009
   Boezaart AP, 2009, CURR OPIN ANESTHESIO, V22, P637, DOI 10.1097/ACO.0b013e32832f3277
   Cho TH, 2021, REGION ANESTH PAIN M, V46, P699, DOI 10.1136/rapm-2021-102588
   Damjanovska M, 2018, J PAIN RES, V11, P293, DOI 10.2147/JPR.S153660
   Dubowitz J, 2021, CURR OPIN ANESTHESIO, V34, P317, DOI 10.1097/ACO.0000000000001002
   Ekinci M, 2022, PAIN MED, V23, P870, DOI 10.1093/pm/pnac004
   Elsharkawy H, 2020, KOREAN J ANESTHESIOL, V73, P550
   Heller GZ, 2016, SCAND J PAIN, V13, P67, DOI 10.1016/j.sjpain.2016.06.012
   Hwang BY, 2020, KOREAN J PAIN, V33, P378, DOI 10.3344/kjp.2020.33.4.378
   Jacobs A, 2020, ANAESTHESIA, V75, P664, DOI 10.1111/anae.14964
   Jayadeep I, 2022, CUREUS J MED SCIENCE, V14, DOI 10.7759/cureus.30828
   Jüttner T, 2011, J CLIN ANESTH, V23, P443, DOI 10.1016/j.jclinane.2010.12.015
   Kamel AAF, 2022, PAIN PHYSICIAN, V25, pE795
   Marshall K, 2020, THORAC SURG CLIN, V30, P339, DOI 10.1016/j.thorsurg.2020.03.001
   Massard G, 1998, Chest Surg Clin N Am, V8, P503
   Mayes J, 2016, ANAESTHESIA, V71, P1064, DOI 10.1111/anae.13549
   O'Neill Archana, 2022, Anesthesiol Clin, V40, P455, DOI [10.1016/j.anclin.2022.04.002, 10.1016/j.anclin.2022.04.002]
   Onishi E, 2018, TOHOKU J EXP MED, V245, P179, DOI 10.1620/tjem.245.179
   Pfeiffer G, 2006, ANAESTHESIST, V55, P423, DOI 10.1007/s00101-005-0969-0
   Qian B, 2021, J CLIN ANESTH, V74, DOI 10.1016/j.jclinane.2021.110410
   Ross JDW, 2021, HEART LUNG CIRC, V30, P1244, DOI 10.1016/j.hlc.2020.12.001
   Sabouri AS, 2018, REGION ANESTH PAIN M, V43, P864, DOI 10.1097/AAP.0000000000000828
   Shi KJ, 2021, ANN PALLIAT MED, V10, P6104, DOI 10.21037/apm-21-199
   Shibata Y, 2009, ANESTH ANALG, V109, P996, DOI 10.1213/ane.0b013e3181af7e7b
   Singariya G, 2023, INDIAN J ANAESTH, V67, pS12, DOI 10.4103/ija.ija_90_23
   Sotome S, 2021, J ANESTH, V35, P27, DOI 10.1007/s00540-020-02855-y
   Voscopoulos C, 2013, CAN J ANESTH, V60, P888, DOI 10.1007/s12630-013-9983-x
   Zhao YP, 2022, BRAZ J ANESTHESIOL, V72, P115, DOI 10.1016/j.bjane.2021.04.004
NR 32
TC 0
Z9 0
U1 0
U2 0
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2025
VL 17
IS 7
BP 5090
EP 5099
DI 10.62347/PUCP3777
PG 10
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA 5RB2M
UT WOS:001542299900016
PM 40821082
OA Green Submitted, Bronze
DA 2026-01-16
ER

PT J
AU Guo, S
   Lin, XP
   Jin, XR
   Tuo, KX
   Li, P
   Yang, WW
   Wang, Q
AF Guo, Shuai
   Lin, Xiang-Ping
   Jin, Xiang-Ren
   Tuo, Kang-Xiu
   Li, Pei
   Yang, Wei-Wei
   Wang, Qian
TI Effect of the thumbtack needle on gastrointestinal function recovery
   after laparoscopic radical gastrectomy for gastric cancer with the
   concept of enhanced recovery after surgery: a randomized controlled
   trial
SO FRONTIERS IN SURGERY
LA English
DT Article
DE thumbtack needle; gastric cancer; GI function recovery; laparoscopic
   radical gastrectomy; ERAS
ID ACUPOINTS
AB Objectives: Postoperative gastrointestinal (GI) dysfunction is a common complication in patients undergoing gastric cancer surgery. This study aimed to evaluate the effect of thumbtack needle therapy on GI function recovery after laparoscopic radical gastrectomy. Methods: Participants were randomly assigned to either the treatment or control group. Both groups received perioperative enhanced recovery after surgery management. Participants in the treatment group received thumbtack needle therapy at bilateral Neiguan (PC6), Zusanli (ST36), Shangjuxu (ST37), Hegu (LI4), and Sanyinjiao (SP6). Primary outcomes included the time to bowel sound recovery and time to first flatus (all measured in hours). Secondary outcomes included the time to first defecation, time to removal of the nasogastric tube and intra-abdominal drains (all measured in hours), postoperative pain scores, nausea and vomiting scores, abdominal distension scores (all measured in points), length of hospital stay (days), incidence of complications (%), safety evaluation, and overall response rate (%). Results: A total of 103 participants were screened, and 80 were enrolled (40 per group). Baseline characteristics were similar between groups. Compared with the control group, the treatment group showed significantly shorter times to bowel sound recovery (difference, -4.0 h, 95% CI: -7.0 to -1.0, P = 0.010), first flatus (-11.0 h, 95% CI: -19.0 to -2.0, P = 0.017), first defecation (-8.0 h, 95% CI: -16.0 to -1.0, P = 0.026), nasogastric tube removal (-12.0 h, 95% CI: -27.0 to -2.0 P = 0.023), and intra-abdominal drain removal (-10.0 h, 95% CI: -21.0 to -1.0, P = 0.038). Pain scores were significantly lower in the treatment group on postoperative day (POD) 1 (-1, 95% CI: -1 to 0, P = 0.031), POD 2 (-1, 95% CI: -2 to -1, P < 0.001), and POD 3 (-1, 95% CI: -2 to 0, P < 0.001). Similar improvements were observed in nausea, vomiting, and abdominal distension scores on POD 1-3 (all showing a median difference of -1, all P < 0.05). The treatment group also had a significantly shorter hospital stay (difference, -1.7 days, 95% CI: -3.0 to -0.3, P = 0.015). There was no significant difference in the incidence of postoperative complications (difference, -5.0%, 95% CI: -18.6 to 8.0, P = 0.396), and no adverse reactions occurred in the treatment group. The overall response rate was significantly higher in the treatment group (difference, 17.5%, 95% CI: 0.18-34.0, P = 0.046). Conclusion: Thumbtack needle therapy at bilateral Neiguan (PC6), Zusanli (ST36), Shangjuxu (ST37), Hegu (LI4), and Sanyinjiao (SP6) is a safe and effective intervention that promotes early recovery of GI function after laparoscopic radical gastrectomy for gastric cancer. Clinical Trial Registration: http://www.chictr.org.cn, ChiCTR2400084712.
C1 [Guo, Shuai; Lin, Xiang-Ping; Tuo, Kang-Xiu; Yang, Wei-Wei] Guizhou Med Univ, Dept Pharm, Affiliated Hosp, Guiyang, Guizhou, Peoples R China.
   [Jin, Xiang-Ren; Li, Pei; Wang, Qian] Guizhou Med Univ, Affiliated Hosp, Dept Gastroenterol, Guiyang, Guizhou, Peoples R China.
C3 Guizhou Medical University; Guizhou Medical University
RP Guo, S (corresponding author), Guizhou Med Univ, Dept Pharm, Affiliated Hosp, Guiyang, Guizhou, Peoples R China.; Wang, Q (corresponding author), Guizhou Med Univ, Affiliated Hosp, Dept Gastroenterol, Guiyang, Guizhou, Peoples R China.
EM guoshuai@gmc.edu.cn; wq5969@sina.com
FU Guizhou Administration of Traditional Chinese Medicine of China; 
   [QZYY-2024-061]
FX The author(s) declare that financial support was received for the
   research and/or publication of this article. SG was supported by the
   Guizhou Administration of Traditional Chinese Medicine of China (Grant
   No. QZYY-2024-061).
CR Blanke EN, 2021, NEURAL REGEN RES, V16, P254, DOI 10.4103/1673-5374.290883
   Buchanan L, 2025, StatPearls
   Chen HY, 2019, AM J CHINESE MED, V47, P1, DOI 10.1142/S0192415X19500010
   Chinese ERAS Expert Group, 2016, Asian J. Surg, V15, P527
   Fleming MA, 2020, GASTROENT RES PRACT, V2020, DOI 10.1155/2020/8024171
   Gottfried-Blackmore A, 2020, NEUROGASTROENT MOTIL, V32, DOI 10.1111/nmo.13769
   Guo M, 2022, WORLD J CLIN CASES, V10, P11427, DOI 10.12998/wjcc.v10.i31.11427
   Hughes J, 2021, COMPLEMENT THER CLIN, V43, DOI 10.1016/j.ctcp.2021.101372
   Kannan V, 2025, PATIENT SAF SURG, V19, DOI 10.1186/s13037-024-00425-9
   Kong Q, 2024, INT J SURG, V110, P5713, DOI 10.1097/JS9.0000000000001641
   Lin B., 2019, Zhongguo Shi Yong Yi Yao, V14, P192
   Ljungqvist O, 2023, JAMA SURG, V158, P28, DOI 10.1001/jamasurg.2022.5683
   Ljungqvist O, 2017, JAMA SURG, V152, P292, DOI 10.1001/jamasurg.2016.4952
   Lubbers T, 2010, WORLD J GASTROENTERO, V16, P1683, DOI 10.3748/wjg.v16.i14.1683
   Maisiyiti A, 2023, FRONT NEUROSCI-SWITZ, V17, DOI 10.3389/fnins.2023.1188781
   Mortensen K, 2014, BRIT J SURG, V101, P1209, DOI 10.1002/bjs.9582
   Ou YX, 2024, FRONT MED-LAUSANNE, V11, DOI 10.3389/fmed.2024.1464749
   Painovich J, 2012, EVID-BASED COMPL ALT, V2012, P1, DOI 10.1155/2012/309762
   Qiang CZ., 2013, Zhongguo Zhong Xi Yi Jie He Za Zhi, V33, P149
   Ren L, 2012, WORLD J SURG, V36, P407, DOI 10.1007/s00268-011-1348-4
   Schwenk W, 2021, CHIRURG, V92, P405, DOI 10.1007/s00104-020-01328-y
   Standardization Administration of the People's Republic of China, 2021, National Standard of the People's Republic of China: Nomenclature and Location of Meridian Points (GB/T 12346-2021)
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tian M, 2020, OBES SURG, V30, P2980, DOI 10.1007/s11695-020-04626-w
   Urman RD., 2020, Enhanced Recovery After Surgery: A Complete Guide to Optimizing Outcomes
   Xv Y, 2025, FRONT MED-LAUSANNE, V11, DOI 10.3389/fmed.2024.1494693
   Yu Xiang F., 2022, Clinical Study of Electro-Acupuncture Promoting Early Gastrointestinal Function Recovery After Laparoscopic Gastric Cancer Surgery
   Zhang ZY, 2024, J NEUROINFLAMM, V21, DOI 10.1186/s12974-024-03285-3
   Zhu HM, 2014, MED ACUPUNCT, V26, P264, DOI 10.1089/acu.2014.1057
NR 29
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-875X
J9 FRONT SURG
JI Front. Surg.
PD SEP 18
PY 2025
VL 12
AR 1612766
DI 10.3389/fsurg.2025.1612766
PG 13
WC Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Surgery
GA 8EG5S
UT WOS:001586594300001
PM 41050349
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Ben-Arye, E
   Zohar, S
   Keshet, Y
   Gressel, O
   Samuels, N
   Eden, A
   Vagedes, J
   Kassem, S
AF Ben-Arye, Eran
   Zohar, Shaked
   Keshet, Yael
   Gressel, Orit
   Samuels, Noah
   Eden, Arieh
   Vagedes, Jan
   Kassem, Sameer
TI Sensing the lightness: a narrative analysis of an integrative medicine
   program for healthcare providers in the COVID-19 department
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE COVID-19; Integrative medicine; Pain; Burnout; Palliative care;
   Narrative-based medicine
ID WELL-BEING MYCAW; YOURSELF CONCERNS; BURNOUT; PROFESSIONALS; ANXIETY;
   STRESS
AB Objectives The research addressing physical and emotional exhaustion among healthcare providers (HCPs) in COVID-19 departments is limited. We examined the impact of integrative medicine (IM) intervention for HCPs working in isolated COVID-19 in-patient departments, addressing concerns and well-being.
   Methods HCPs working in 3 isolated COVID-19 in-patient departments underwent 40-min IM treatment sessions (including acupuncture, manual movement, and/or mind-body modalities) provided by integrative oncology practitioners. The MYCAW (Measure Yourself Concerns and Well-being) questionnaire examined HCP concerns and free-text narratives following IM treatments. Data were qualitatively analyzed using ATLAS.Ti software for systematic coding.
   Results A total of 181 HCPs underwent 305 IM treatments. Narrative themes focused on physical symptoms (primarily pain and fatigue) and emotional concerns, including perceived communication barriers with patients, and reflections on well-being and insights following IM treatments. HCPs reported feeling a sense of "relief" which was likely related to the 3 main effects of the IM intervention: a sense of "being cared for" and treated; experiencing emotional, sometimes spiritual effects of the treatment; and the feeling of relaxation, combined with the relief of pain. Qualitative analysis identified clusters of emotional and spiritual-related keywords such as "calming," "release," "relaxation," and "disengagement" following the first IM session (119 of 181 narratives, 65.7%).
   Conclusions HCPs working in isolated COVID-19 departments reported improved well-being and the addressing of their concerns following IM treatment sessions provided during their work shift. Further research is needed to explore the impact of IM on HCP burnout and resilience in palliative care settings.
C1 [Ben-Arye, Eran; Gressel, Orit] Clalit Hlth Serv, Lin Carmel & Zebulun Med Ctr, Integrat Oncol Program, 35 Rothschild St, Haifa, Israel.
   [Ben-Arye, Eran; Zohar, Shaked; Gressel, Orit; Eden, Arieh; Kassem, Sameer] Technion Israel Inst Technol, Ruth & Bruch Rappaport Fac Med, Haifa, Israel.
   [Keshet, Yael] Western Galilee Acad Coll, Dept Sociol, Galilee, Israel.
   [Samuels, Noah] Hebrew Univ Jerusalem, Fac Med, Ctr Integrat Complementary Med, Shaarei Zedek Med Ctr, Jerusalem, Israel.
   [Eden, Arieh] Lady Davis Carmel Med Ctr, Dept Anesthesiol Crit Care & Pain Med, Haifa, Israel.
   [Vagedes, Jan] ARCIM Inst, Res Inst, Filderstadt, Germany.
   [Vagedes, Jan] Univ Tubingen, Univ Hosp Tuebingen, Dept Neonatol, Tubingen, Germany.
   [Kassem, Sameer] Lady Davis Carmel Med Ctr, Dept Internal Med, Haifa, Israel.
C3 Clalit Health Services; Technion Israel Institute of Technology; Western
   Galilee Academic College; Hebrew University of Jerusalem; Shaare Zedek
   Medical Center; Clalit Health Services; Carmel Medical Center; Eberhard
   Karls University of Tubingen; Eberhard Karls University Hospital; Clalit
   Health Services; Carmel Medical Center
RP Ben-Arye, E (corresponding author), Clalit Hlth Serv, Lin Carmel & Zebulun Med Ctr, Integrat Oncol Program, 35 Rothschild St, Haifa, Israel.; Ben-Arye, E (corresponding author), Technion Israel Inst Technol, Ruth & Bruch Rappaport Fac Med, Haifa, Israel.
EM eranben@netvision.net.il
RI Kassem, Sameer/HNI-4559-2023; Vagedes, Jan/NIS-6048-2025
CR Asghar MS, 2021, AM J TROP MED HYG, V104, P2185, DOI 10.4269/ajtmh.21-0141
   Ben-Arye E, 2021, J CANCER RES CLIN, V147, P2361, DOI 10.1007/s00432-020-03506-1
   Ben-Arye E, 2018, SUPPORT CARE CANCER, V26, P4039, DOI 10.1007/s00520-018-4271-5
   Buran F, 2021, LEGAL MED-TOKYO, V51, DOI 10.1016/j.legalmed.2021.101881
   Damico Vincenzo, 2020, Prof Inferm, V73, P250, DOI 10.7429/pi.2020.734250
   Denning M, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0238666
   Dincer B, 2021, EXPLORE-NY, V17, P109, DOI 10.1016/j.explore.2020.11.012
   Georger F, 2020, Ann Cardiol Angeiol (Paris), V69, P227, DOI 10.1016/j.ancard.2020.09.005
   Gonzales Morgan, 2017, J Adv Pract Oncol, V8, P453, DOI 10.6004/jadpro.2017.8.5.1
   Ibar C, 2021, PSYCHONEUROENDOCRINO, V128, DOI 10.1016/j.psyneuen.2021.105213
   Jalili M, 2021, INT ARCH OCC ENV HEA, V94, P1345, DOI 10.1007/s00420-021-01695-x
   Jolliffe R, 2015, INTEGR CANCER THER, V14, P26, DOI 10.1177/1534735414555809
   Keshet Y, 2015, PSYCHO-ONCOLOGY, V24, P169, DOI 10.1002/pon.3621
   Koh MYH, 2020, J PAIN SYMPTOM MANAG, V59, P105, DOI 10.1016/j.jpainsymman.2019.08.008
   Kok N, 2021, CRIT CARE MED, V49, P419, DOI 10.1097/CCM.0000000000004865
   Lou NM, 2021, EVAL HEALTH PROF, V44, P319, DOI 10.1177/01632787211012742
   Marton G, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.588762
   Naldi A, 2021, BJPSYCH OPEN, V7, DOI 10.1192/bjo.2020.161
   Nawaz MW, 2020, PSYCHIAT DANUB, V32, P557, DOI 10.24869/psyd.2020.557
   Ng QX, 2020, ASIAN J PSYCHIATR, V54, DOI 10.1016/j.ajp.2020.102258
   Norful AA, 2021, GEN HOSP PSYCHIAT, V69, P20, DOI 10.1016/j.genhosppsych.2021.01.001
   Norkiene I, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18052660
   Paterson C, 2007, COMPLEMENT THER MED, V15, P38, DOI 10.1016/j.ctim.2006.03.006
   Peeters R, 2023, MED CARE RES REV, V80, P266, DOI [10.1177/10775587221118156, 10.1111/eva.13711]
   Ripp J, 2020, ACAD MED, V95, P1136, DOI 10.1097/ACM.0000000000003414
   Siddiqui I, 2021, CLIN MED, V21, P66, DOI 10.7861/clinmed.2020-0502
   Stewart NH, 2021, J MED INTERNET RES, V23, DOI 10.2196/27331
   Thimmapuram J, 2021, HOSP PRACT, V49, P194, DOI [10.1080/21548331.2021.1896858, 10.1080/21548331.2021.1896858]
   Vajpeyee M, 2022, INT J SOC PSYCHIATR, V68, P798, DOI 10.1177/00207640211006742
   Zhang XD, 2021, INT ARCH OCC ENV HEA, V94, P1441, DOI 10.1007/s00420-021-01657-3
   Zhang XN, 2021, INT J MENT HEALTH NU, V30, P939, DOI 10.1111/inm.12847
NR 31
TC 6
Z9 7
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD FEB
PY 2022
VL 30
IS 2
BP 1419
EP 1426
DI 10.1007/s00520-021-06546-6
EA SEP 2021
PG 8
WC Oncology; Health Care Sciences & Services; Rehabilitation
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA YB0VG
UT WOS:000696140100002
PM 34528124
OA Green Submitted, Bronze
DA 2026-01-16
ER

PT J
AU Ren, X
   Qu, YP
   Xia, T
   Tang, XF
AF Ren, Xu
   Qu, Yong-Ping
   Xia, Tian
   Tang, Xiu-Fen
TI Technical success, clinical efficacy, and safety of endoscopic minor
   papilla interventions for symptomatic pancreatic diseases
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Endoscopic minor papilla intervention; Symptomatic pancreatic diseases;
   Obstructive chronic pancreatitis; Pancreas division; Abdominal pain
   improvement
ID SHOCK-WAVE LITHOTRIPSY; GUIDED ELECTROHYDRAULIC LITHOTRIPSY; DUCT
   STONES; BALLOON SPHINCTEROPLASTY; THERAPY; DIAGNOSIS
AB BACKGROUND Endoscopic minor papilla intervention (EMPI) is an option for diagnosing or treating symptomatic pancreatic diseases in cases with failed pancreatic duct deep cannulation via the major papilla, pancreas divisum with obstruction of the minor papilla, or an abnormal patulous orifice of the minor papilla during endoscopic retrograde cholangiopancreatography (ERCP). However, the relatively low patency and small opening of the minor papillae pose technical challenges. AIM To evaluate the technical success, clinical success, stone clearance, and safety profile of EMPI for diagnosis and treatment of symptomatic pancreatic diseases. METHODS Patients diagnosed with symptomatic pancreatic diseases and EMPI between February 1996 and February 2023 were included. The primary outcomes were the initial technical success, defined as successful deep cannulation via the minor papilla (DCMP; access of the guidewire to the upstream pancreatic duct via the minor papilla) alone, overall technical success, defined as successful DCMP alone and successful DCMP with additional needle-knife precut minor papillotomy (NKPMP), and immediate clinical success, defined as > 50% improvement in abdominal pain after therapeutic EMPI. Secondary outcomes included long-term clinical success at 1, 3, and 7 years, pancreatic stone clearance, and procedure-related early and late adverse events (AEs). RESULTS Overall, 43 patients, 32 with obstructive chronic pancreatitis, 8 with pancreatic divisum, and 3 with intraductal papillary mucinous neoplasm were included. The initial and overall technical success rates were 74.4% (32/43) and 88.4% (38/43), respectively. The immediate clinical success rate was 79.1% (34/43), and the long-term clinical success rates at 1, 3, and 7 years were 74.7%, 55.3%, and 41.5%, respectively, among the 22 patients with a follow-up period of 57.5 (7-266) months. Complete and partial success of pancreatic stone clearance was achieved in 53.9% (7/13) and 15.4% (2/13), respectively. Early AEs included post-ERCP pancreatitis (PEP, n = 5) and self-limiting bleeding (n = 1); surgery therapy was required for 1 case with severe PEP and conservative management for the other 4 with mild PEP. Late AEs included minor papilla stricture (n = 1) after endoscopic minor papillotomy and pancreatic duct stricture (n = 1) after double pancreatic stent placement; no specific treatment was implemented for these events. CONCLUSION EMPI is feasible, effective, and safe for symptomatic pancreatic diseases, in terms of the technical and clinical success, stone clearance, and incidence and severity of AEs. NKPMP appears to enhance technical success. However, potential risks of developing PEP and late AEs should be kept in mind.
C1 [Ren, Xu; Xia, Tian] Heilongjiang Prov Hosp, Heilongjiang Prov Clin Med Res Ctr Minimally Invas, Digest Hosp, 405 Guogeli St, Harbin 150001, Heilongjiang, Peoples R China.
   [Qu, Yong-Ping] Heilongjiang Prov Hosp, Heilongjiang Prov Clin Med Res Ctr Minimally Invas, Digest Endoscopy Ctr, Harbin 150001, Heilongjiang, Peoples R China.
   [Tang, Xiu-Fen] Heilongjiang Prov Hosp, Heilongjiang Prov Clin Med Res Ctr Minimally Invas, Dept Gastroenterol 1, Digest Hosp, Harbin 150001, Heilongjiang, Peoples R China.
RP Ren, X (corresponding author), Heilongjiang Prov Hosp, Heilongjiang Prov Clin Med Res Ctr Minimally Invas, Digest Hosp, 405 Guogeli St, Harbin 150001, Heilongjiang, Peoples R China.
EM hljxhy2001@126.com
RI QU, Yongping/GQZ-6935-2022
FU Heilongjiang Provincial Natural Science Foundation Team Project
   [TD2020H002]
FX Supported by Heilongjiang Provincial Natural Science Foundation Team
   Project, No. TD2020H002.
CR Bansal RK, 2017, ENDOSC INT OPEN, V5, pE1229, DOI 10.1055/s-0043-119752
   Basturk O., 2019, WHO Classification of Tumours Editorial Board. Digestive system tumours, V1, P310
   Bellocchi MCC, 2021, PANCREATOLOGY, V21, P805, DOI 10.1016/j.pan.2021.01.019
   Bhurwal A, 2021, PANCREATOLOGY, V21, P990, DOI 10.1016/j.pan.2021.03.021
   Boninsegna E, 2015, EUR RADIOL, V25, P2437, DOI 10.1007/s00330-015-3644-0
   Brauer BC, 2013, GASTROINTEST ENDOSC, V78, P545, DOI 10.1016/j.gie.2013.05.005
   Brown NG, 2017, GASTROINTEST ENDOSC, V85, P365, DOI 10.1016/j.gie.2016.07.066
   de Rijk FEM, 2023, ENDOSC INT OPEN, V11, pE296, DOI 10.1055/a-2035-8969
   Dickson ZA, 2020, GASTROINTEST ENDOSC, V91, P1396, DOI 10.1016/j.gie.2020.01.005
   Dirweesh A, 2022, DIGEST DIS SCI, V67, P1624, DOI 10.1007/s10620-022-07391-1
   Dumonceau JM, 2019, ENDOSCOPY, V51, P179, DOI 10.1055/a-0822-0832
   Ertan A, 2000, GASTROINTEST ENDOSC, V52, P9, DOI 10.1067/mge.2000.106311
   Gardner TB, 2020, AM J GASTROENTEROL, V115, P322, DOI 10.14309/ajg.0000000000000535
   Gonoi W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037652
   Gonoi W, 2011, GUT, V60, P1103, DOI 10.1136/gut.2010.230011
   Gourgiotis S, 2007, EJSO-EUR J SURG ONC, V33, P678, DOI 10.1016/j.ejso.2006.11.031
   Han S, 2022, PANCREATOLOGY, V22, P1120, DOI 10.1016/j.pan.2022.09.245
   Han S, 2019, DIGEST DIS SCI, V64, P1059, DOI 10.1007/s10620-019-05502-z
   Inamdar Sumant, 2023, Gastrointest Endosc Clin N Am, V33, P789, DOI [10.1016/j.giec.2023.04.012, 10.1016/j.giec.2023.04.012]
   Iwano K, 2020, ENDOSCOPY, V52, pE213, DOI 10.1055/a-1071-7649
   Jagtap SV, 2018, Annals of Pathology and Laboratory Medicine, V5, pC82, DOI [10.21276/apalm.1809, 10.21276/APALM.1809, DOI 10.21276/APALM.1809]
   James TW, 2018, ENDOSC INT OPEN, V6, pE735, DOI 10.1055/a-0607-2484
   Kamisawa T, 2007, PANCREAS, V34, P96
   Kamisawa Terumi, 2004, JOP, V5, P107
   Kondo H, 2014, DIGEST LIVER DIS, V46, P639, DOI 10.1016/j.dld.2014.02.017
   Korpela T, 2016, SCAND J GASTROENTERO, V51, P866, DOI 10.3109/00365521.2016.1150502
   Kwon CI, 2017, ENDOSCOPY, V49, P371, DOI 10.1055/s-0042-120996
   Löhr JM, 2017, UNITED EUR GASTROENT, V5, P153, DOI 10.1177/2050640616684695
   Machado NO, 2015, N AM J MED SCI, V7, P160, DOI 10.4103/1947-2714.157477
   Mandai K, 2022, ENDOSCOPY, V54, pE1051, DOI 10.1055/a-1913-7425
   Maydeo A, 2009, GASTROINTEST ENDOSC, V70, P798, DOI 10.1016/j.gie.2009.05.004
   Meldrum JT, 2020, J CLIN IMAG SCI, V10, DOI 10.25259/JCIS_17_2020
   Michailidis L, 2017, ANN GASTROENTEROL, V30, P550, DOI 10.20524/aog.2017.0159
   Moole H, 2016, PANCREAS, V45, P651, DOI 10.1097/MPA.0000000000000512
   Müller PC, 2017, SURG LAPARO ENDO PER, V27, pE44, DOI 10.1097/SLE.0000000000000414
   Mukai H, 1998, Endoscopy, V30 Suppl 1, pA99, DOI 10.1055/s-2007-1001486
   Muramoto Yuya, 2021, VideoGIE, V6, P419, DOI [10.1016/j.vgie.2021.05.014, 10.1016/j.vgie.2021.05.014]
   Okamoto Takeshi, 2021, VideoGIE, V6, P512, DOI [10.1016/j.vgie.2021.08.004, 10.1016/j.vgie.2021.08.004]
   Pancreatology Speciality Committee of Chinese Medical Doctor Association, 2018, Zhonghua Yixianbing Zazhi, V35, P814
   Ren X., 2000, Zhonghua Xiaohuaneijing Zazhi, V17, P271
   Ren X, 2019, WORLD J CLIN CASES, V7, P102, DOI 10.12998/wjcc.v7.i1.102
   Shintani Shuhei, 2020, VideoGIE, V5, P673, DOI [10.1016/j.vgie.2020.07.004, 10.1016/j.vgie.2020.07.004]
   Siddappa PK, 2021, GASTROENTEROL REP, V9, P105, DOI 10.1093/gastro/goab001
   Singh A, 2023, PANCREATOLOGY, V23, P858, DOI 10.1016/j.pan.2023.09.141
   Song MH, 2004, GASTROINTEST ENDOSC, V59, P901, DOI 10.1016/S0016-5107(04)00457-2
   Takeshita K, 2020, DIGEST ENDOSC, V32, pE98, DOI 10.1111/den.13697
   Tandan M, 2019, PANCREATOLOGY, V19, P916, DOI 10.1016/j.pan.2019.08.001
   Tringali A, 2019, SCAND J GASTROENTERO, V54, P359, DOI 10.1080/00365521.2019.1584640
   van der Wiel SE, 2022, GASTROINTEST ENDOSC, V95, P905, DOI 10.1016/j.gie.2021.11.047
   Zhang PY., 1993, Zhonghua Xiaohua Zazhi, V13, P14
NR 50
TC 0
Z9 0
U1 0
U2 0
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD MAY 28
PY 2025
VL 31
IS 20
AR 100192
DI 10.3748/wjg.v31.i20.100192
PG 16
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 3IW8T
UT WOS:001501422800011
PM 40495942
OA Green Accepted
DA 2026-01-16
ER

PT J
AU Carpena, M
   Nuñez-Estevez, B
   Soria-Lopez, A
   Simal-Gandara, J
AF Carpena, Maria
   Nunez-Estevez, Bernabe
   Soria-Lopez, Anton
   Simal-Gandara, Jesus
TI Bee Venom: An Updating Review of Its Bioactive Molecules and Its Health
   Applications
SO NUTRIENTS
LA English
DT Review
DE bee venom; biological properties; health applications; peptides; enzymes
ID CELL DEGRANULATING PEPTIDE; APIS-MELLIFERA VENOM; NF-KAPPA-B;
   PHOSPHOLIPASE A(2); SIGNALING PATHWAY; MOUSE MODEL; IN-VITRO;
   NEUROINFLAMMATORY RESPONSES; CANCER CELLS; MCD PEPTIDE
AB Bee venom (BV) is usually associated with pain since, when humans are stung by bees, local inflammation and even an allergic reaction can be produced. BV has been traditionally used in ancient medicine and in acupuncture. It consists of a mixture of substances, principally of proteins and peptides, including enzymes as well as other types of molecules in a very low concentration. Melittin and phospholipase A2 (PLA2) are the most abundant and studied compounds of BV. Literature of the main biological activities exerted by BV shows that most studies focuses on the comprehension and test of anti-inflammatory effects and its mechanisms of action. Other properties such as antioxidant, antimicrobial, neuroprotective or antitumor effects have also been assessed, both in vitro and in vivo. Moreover, human trials are necessary to confirm those clinical applications. However, notwithstanding the therapeutic potential of BV, there are certain problems regarding its safety and the possible appearance of adverse effects. On this perspective, new approaches have been developed to avoid these complications. This manuscript is aimed at reviewing the actual knowledge on BV components and its associated biological activities as well as the latest advances on this subject.
C1 [Carpena, Maria; Nunez-Estevez, Bernabe; Soria-Lopez, Anton; Simal-Gandara, Jesus] Univ Vigo, Fac Food Sci & Technol, Analyt & Food Chem Dept, Nutr & Bromatol Grp, Ourense Campus, E-32004 Orense, Spain.
C3 Universidade de Vigo
RP Simal-Gandara, J (corresponding author), Univ Vigo, Fac Food Sci & Technol, Analyt & Food Chem Dept, Nutr & Bromatol Grp, Ourense Campus, E-32004 Orense, Spain.
EM maria.carpena.rodriguez@uvigo.es; bernabenunez16@gmail.com;
   antonsoria@hotmail.es; jsimal@uvigo.es
RI ; Carpena Rodríguez, María/JGD-8937-2023; Simal-Gandara,
   Jesus/A-9533-2009; Rodríguez, María/JGD-8937-2023
OI Núñez Estévez, Bernabé/0000-0002-6435-7952; Carpena Rodríguez,
   María/0000-0002-4819-7856; , IIS Galicia Sur/0000-0003-3812-7413;
   Simal-Gandara, Jesus/0000-0001-9215-9737; 
FU Programa de Cooperacion Interreg V-A Espana-Portugal (POCTEP) 2014-2020
   [0181_NANOEATERS_01_E, 0377_IBERPHENOL_6_E]; Xunta de Galicia [IN852A
   2018/58]; EcoChestnut Project (Erasmus + KA202); Ibero-American Program
   on Science and Technology (CYTED-AQUA-CIBUS) [P317RT0003]; European
   Union's Horizon 2020 and Based Industries Joint Undertaking (JU)
   [888003]
FX The research leading to these results received financial support from:
   Programa de Cooperacion Interreg V-A Espana-Portugal (POCTEP) 2014-2020
   (projects Ref.: 0181_NANOEATERS_01_E and Ref: 0377_IBERPHENOL_6_E);
   Xunta de Galicia for the Axudas Conecta Peme supporting the IN852A
   2018/58 NeuroFood Project; EcoChestnut Project (Erasmus + KA202); to
   Ibero-American Program on Science and Technology (CYTED-AQUA-CIBUS,
   P317RT0003); European Union's Horizon 2020 and Based Industries Joint
   Undertaking (JU) under grant agreement No 888003 UP4HEALTH Project
   (H2020-BBI-JTI-2019).
CR Abd El-Wahed AA, 2018, STUD NAT PROD CHEM, V60, P459, DOI 10.1016/B978-0-444-64181-6.00013-9
   Ahn YJ, 2016, J ETHNOPHARMACOL, V194, P774, DOI 10.1016/j.jep.2016.11.012
   Al-Ani I, 2015, PHYTOMEDICINE, V22, P245, DOI 10.1016/j.phymed.2014.11.019
   Al-Samie M.A.M.A., 2012, INT J ADV RES TECHNO, V1, P1
   dos Santos-Pinto JRA, 2018, TOXICON, V148, P172, DOI 10.1016/j.toxicon.2018.04.029
   Badshah H, 2016, SCI REP-UK, V6, DOI 10.1038/srep24493
   Bae YH, 2020, ADV DRUG DELIVER REV, V158, P4, DOI 10.1016/j.addr.2020.06.018
   Baek H, 2020, TOXINS, V12, DOI 10.3390/toxins12030198
   Baek H, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00179
   Baek YH, 2006, BRAIN RES, V1073, P305, DOI 10.1016/j.brainres.2005.12.086
   BANKS BEC, 1990, BRIT J PHARMACOL, V99, P350, DOI 10.1111/j.1476-5381.1990.tb14707.x
   BENTON AW, 1963, SCIENCE, V142, P228, DOI 10.1126/science.142.3589.228
   Bidaud I, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66673-8
   Blank S, 2010, J IMMUNOL, V184, P5403, DOI 10.4049/jimmunol.0803709
   Boutrin MCF, 2008, EXP PARASITOL, V119, P246, DOI 10.1016/j.exppara.2008.02.002
   Buku A, 1999, PEPTIDES, V20, P415, DOI 10.1016/S0196-9781(98)00167-3
   Buku A, 2004, J PEPT SCI, V10, P313, DOI 10.1002/psc.532
   Buku A, 2001, PEPTIDES, V22, P1987, DOI 10.1016/S0196-9781(01)00538-1
   Buku A, 2001, PEPTIDES, V22, P1993, DOI 10.1016/S0196-9781(01)00542-3
   Cai M, 2015, TOXINS, V7, P846, DOI 10.3390/toxins7030846
   Silva LFCD, 2010, EUR J PHARMACOL, V626, P239, DOI 10.1016/j.ejphar.2009.09.064
   Chen J, 2010, PROG NEUROBIOL, V92, P151, DOI 10.1016/j.pneurobio.2010.06.006
   Chen M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16130-w
   Cherniack EP, 2018, TOXICON, V154, P74, DOI 10.1016/j.toxicon.2018.09.013
   Cho SY, 2012, PARKINSONISM RELAT D, V18, P948, DOI 10.1016/j.parkreldis.2012.04.030
   Choi S, 2019, TOXINS, V11, DOI 10.3390/toxins11070396
   Chung ES, 2015, J IMMUNOL, V195, P4853, DOI 10.4049/jimmunol.1500386
   Chung ES, 2012, BRAIN BEHAV IMMUN, V26, P1322, DOI 10.1016/j.bbi.2012.08.013
   Cornara L, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00412
   Corthésy B, 2016, ALLERGY, V71, P957, DOI 10.1111/all.12859
   Csoka AB, 2001, MATRIX BIOL, V20, P499, DOI 10.1016/S0945-053X(01)00172-X
   Dacheux M, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00556-19
   Davies J, 2019, THER ADV MUSCULOSKEL, V11, DOI 10.1177/1759720X19844429
   de Alnneida-Muradian LB, 2020, J APICULT RES, V59, P1, DOI 10.1080/00218839.2020.1738135
   de Lau LML, 2004, NEUROLOGY, V63, P1240, DOI 10.1212/01.WNL.0000140706.52798.BE
   Dennis EA, 2011, CHEM REV, V111, P6130, DOI 10.1021/cr200085w
   Duchez AC, 2019, PROSTAG OTH LIPID M, V143, DOI 10.1016/j.prostaglandins.2019.106340
   El-Hanoun A, 2020, PHYSIOL BEHAV, V223, DOI 10.1016/j.physbeh.2020.112987
   Fenard D, 2001, MOL PHARMACOL, V60, P341, DOI 10.1124/mol.60.2.341
   Gajski G, 2013, ENVIRON TOXICOL PHAR, V36, P697, DOI 10.1016/j.etap.2013.06.009
   Grange PA, 2009, J DERMATOL SCI, V56, P106, DOI 10.1016/j.jdermsci.2009.08.001
   Grassberger M., 2013, Biotherapy-History, Principles and Practice: A Practical Quide to the Diagnosis and Treatment of Disease Using Living Organisms
   Grunwald T, 2006, J ALLERGY CLIN IMMUN, V117, P848, DOI 10.1016/j.jaci.2005.12.1331
   Gu H, 2020, TOXINS, V12, DOI 10.3390/toxins12030195
   HAIT WN, 1985, CANCER CHEMOTH PHARM, V14, P202, DOI 10.1007/BF00258116
   Ham HJ, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00287
   Hartmann A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158235
   Hellner M, 2008, EVID-BASED COMPL ALT, V5, P475, DOI 10.1093/ecam/nem052
   Heppner FL, 2015, NAT REV NEUROSCI, V16, P358, DOI 10.1038/nrn3880
   Hincha DK, 1996, BBA-BIOMEMBRANES, V1284, P162, DOI 10.1016/S0005-2736(96)00122-8
   Ho JN, 2010, MOL CANCER THER, V9, P825, DOI 10.1158/1535-7163.MCT-09-0904
   Hood JL, 2013, ANTIVIR THER, V18, P95, DOI 10.3851/IMP2346
   Hossen MS, 2017, MOLECULES, V22, DOI 10.3390/molecules22010025
   Hou CS, 2014, MOL BIOL REP, V41, P8081, DOI 10.1007/s11033-014-3706-4
   Hu HY, 2006, J PHARM PHARMACOL, V58, P83, DOI 10.1211/jpp.58.1.0010
   Jakob T., 2017, Allergo Journal, V26, P33, DOI [DOI 10.1007/S15007-017-1315-Y, 10.1007/s15007-017-1315-y]
   Jang MH, 2003, J PHARMACOL SCI, V91, P95, DOI 10.1254/jphs.91.95
   Jeong YJ, 2015, INT IMMUNOPHARMACOL, V25, P400, DOI 10.1016/j.intimp.2015.02.021
   Jin WL, 1999, BIOCHEMISTRY-US, V38, P14294, DOI 10.1021/bi991206j
   Jo M, 2012, TOXICOL APPL PHARM, V258, P72, DOI 10.1016/j.taap.2011.10.009
   Jung KH, 2017, TOXINS, V9, DOI 10.3390/toxins9020068
   Jung SY, 2015, TOXINS, V7, P3715, DOI 10.3390/toxins7093715
   Khalil WKB, 2015, NEUROCHEM INT, V80, P79, DOI 10.1016/j.neuint.2014.11.008
   Khulan TS, 2015, J DIABETES METAB, V6, DOI 10.4172/2155-6156.1000507
   Kim H, 2015, KIDNEY INT, V88, P550, DOI 10.1038/ki.2015.147
   Kim JY, 2017, INT J MOL MED, V39, P1188, DOI 10.3892/ijmm.2017.2922
   Kim KH, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00080
   Kim SJ, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/305454
   Kim SJ, 2012, EXP MOL PATHOL, V93, P129, DOI 10.1016/j.yexmp.2012.04.003
   Kim SJ, 2011, J ATHEROSCLER THROMB, V18, P1117, DOI 10.5551/jat.8474
   Kim WH, 2017, PHARMACOL REP, V69, P1030, DOI 10.1016/j.pharep.2017.04.006
   Kitamura H, 2000, J PHARMACOL EXP THER, V293, P196
   Klocek G, 2009, BIOCHEMISTRY-US, V48, P2586, DOI 10.1021/bi802127h
   Kocyigit A, 2019, TOXICON, V161, P4, DOI 10.1016/j.toxicon.2019.02.016
   Komi DEA, 2018, CLIN REV ALLERG IMMU, V54, P386, DOI 10.1007/s12016-017-8597-4
   Kong GM, 2016, WORLD J GASTROENTERO, V22, P3186, DOI 10.3748/wjg.v22.i11.3186
   Krell R., 1996, FAO AGR SERVER B, V124
   Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5
   Kumar A, 2004, J MOL MED, V82, P434, DOI 10.1007/s00109-004-0555-y
   Kwon YB, 2001, PAIN, V90, P271, DOI 10.1016/S0304-3959(00)00412-7
   LAMBEAU G, 1990, J BIOL CHEM, V265, P9526
   LAMBEAU G, 1989, J BIOL CHEM, V264, P11503
   Lamy C, 2010, J BIOL CHEM, V285, P27067, DOI 10.1074/jbc.M110.110072
   Landucci ECT, 2000, TOXICON, V38, P199, DOI 10.1016/S0041-0101(99)00143-9
   Leandro LF, 2015, AN ACAD BRAS CIENC, V87, P147, DOI 10.1590/0001-3765201520130511
   Lee C, 2017, ONCOTARGET, V8, P54951, DOI 10.18632/oncotarget.18627
   Lee G, 2016, MOLECULES, V21, DOI 10.3390/molecules21050616
   Lee G, 2016, TOXINS, V8, DOI 10.3390/toxins8020048
   Lee JE, 2019, J PHARMACOL SCI, V140, P26, DOI 10.1016/j.jphs.2019.03.009
   Lee J, 2018, VET IMMUNOL IMMUNOP, V200, P40, DOI 10.1016/j.vetimm.2018.04.006
   Lee JY, 2005, IN VIVO, V19, P801
   Lee KS, 2016, DEV COMP IMMUNOL, V63, P27, DOI 10.1016/j.dci.2016.05.011
   Lee MT, 2013, P NATL ACAD SCI USA, V110, P14243, DOI 10.1073/pnas.1307010110
   Lee WR, 2014, J INVEST DERMATOL, V134, P1922, DOI 10.1038/jid.2014.75
   Lee WR, 2011, TOXICOL APPL PHARM, V256, P209, DOI 10.1016/j.taap.2011.08.012
   Lee YJ, 2020, INFLAMMOPHARMACOLOGY, V28, P253, DOI 10.1007/s10787-019-00646-w
   Lee YM, 2020, J ETHNOPHARMACOL, V257, DOI 10.1016/j.jep.2020.112860
   Li L, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.117893
   Lim HN, 2019, MOLECULES, V24, DOI 10.3390/molecules24050929
   Lin L, 2017, BIOMED PHARMACOTHER, V90, P921, DOI 10.1016/j.biopha.2017.04.055
   Liu JJ, 2018, BBA-BIOMEMBRANES, V1860, P2234, DOI 10.1016/j.bbamem.2018.09.007
   Liu X, 2003, J CONTROL RELEASE, V93, P293, DOI 10.1016/j.jconrel.2003.08.019
   LOWY PH, 1971, ARCH BIOCHEM BIOPHYS, V145, P338, DOI 10.1016/0003-9861(71)90044-0
   Marcos JF, 1995, P NATL ACAD SCI USA, V92, P12466, DOI 10.1073/pnas.92.26.12466
   Markovic-Housley Z, 2000, STRUCTURE, V8, P1025, DOI 10.1016/S0969-2126(00)00511-6
   Pereira AFM, 2020, MICROB PATHOGENESIS, V141, DOI 10.1016/j.micpath.2020.104011
   Matysiak J, 2011, J PHARMACEUT BIOMED, V54, P273, DOI 10.1016/j.jpba.2010.08.020
   Mcf C., 1870, MATERIALS, V13, P90
   Memariani H, 2020, APPL MICROBIOL BIOT, V104, P6513, DOI 10.1007/s00253-020-10701-0
   Memariani H, 2020, EUR J CLIN MICROBIOL, V39, P5, DOI 10.1007/s10096-019-03674-0
   Meng Y, 2012, CHINESE CHEM LETT, V23, P1161, DOI 10.1016/j.cclet.2012.09.003
   Rubio-Perez JM, 2012, SCI WORLD J, DOI 10.1100/2012/756357
   Moga MA, 2018, MOLECULES, V23, DOI 10.3390/molecules23030692
   Mohamed WA, 2019, TOXICOLOGY, V419, P11, DOI 10.1016/j.tox.2019.03.003
   Mohammadi-Rad M, 2019, RES PHARM SCI, V14, P424, DOI 10.4103/1735-5362.268203
   Mourelle D, 2014, PEPTIDES, V59, P42, DOI 10.1016/j.peptides.2014.07.004
   Mourre C, 1997, BRAIN RES, V778, P405, DOI 10.1016/S0006-8993(97)01165-7
   Nicolas JP, 1997, J BIOL CHEM, V272, P7173, DOI 10.1074/jbc.272.11.7173
   Orsolic N, 2012, CANCER METAST REV, V31, P173, DOI 10.1007/s10555-011-9339-3
   Otón T, 2019, BEST PRACT RES CL RH, V33, DOI 10.1016/j.berh.2019.101477
   Ozturk AB, 2017, ALLERGOL IMMUNOPATH, V45, P473, DOI 10.1016/j.aller.2016.10.015
   PACAKOVA V, 1995, J CHROMATOGR A, V700, P187, DOI 10.1016/0021-9673(94)01170-J
   Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239
   Palm NW, 2013, IMMUNITY, V39, P976, DOI 10.1016/j.immuni.2013.10.006
   Palma M.S., 2013, Handbook of BiologicallyActive Peptides, Vsecond, P416
   Park HG, 2018, DEV COMP IMMUNOL, V85, P51, DOI 10.1016/j.dci.2018.04.001
   Park JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126971
   Park JH, 2010, MOL CELLS, V29, P209, DOI 10.1007/s10059-010-0028-9
   Park MH, 2011, PROSTATE, V71, P801, DOI 10.1002/pros.21296
   Park SU, 2017, J NEUROL SCI, V381, P724, DOI 10.1016/j.jns.2017.08.2041
   Pascoal A, 2019, FOOD CHEM TOXICOL, V134, DOI 10.1016/j.fct.2019.110864
   PECK ML, 1974, J AGR FOOD CHEM, V22, P51, DOI 10.1021/jf60191a002
   Peeler DJ, 2019, BIOMATERIALS, V192, P235, DOI 10.1016/j.biomaterials.2018.11.004
   Pucca MB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01598
   Putz T, 2007, CANCER IMMUNOL IMMUN, V56, P627, DOI 10.1007/s00262-006-0220-0
   Qiao MX, 2007, INT J PHARMACEUT, V345, P116, DOI 10.1016/j.ijpharm.2007.05.056
   Qin G, 2016, MOL MED REP, V14, P57, DOI 10.3892/mmr.2016.5215
   Rady I, 2017, CANCER LETT, V402, P16, DOI 10.1016/j.canlet.2017.05.010
   Raghuraman H, 2007, BIOSCIENCE REP, V27, P189, DOI 10.1007/s10540-006-9030-z
   Samy RP, 2007, J APPL MICROBIOL, V102, P650, DOI 10.1111/j.1365-2672.2006.03161.x
   SCHUMACHER MJ, 1989, NATURE, V337, P413, DOI 10.1038/337413a0
   Shin JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069380
   Shin SH, 2018, MOL MED REP, V17, P6632, DOI 10.3892/mmr.2018.8720
   Shin SH, 2017, TOXINS, V9, DOI 10.3390/toxins9110348
   SHKENDEROV S, 1982, TOXICON, V20, P317, DOI 10.1016/0041-0101(82)90234-3
   Sobral F, 2016, FOOD CHEM TOXICOL, V94, P172, DOI 10.1016/j.fct.2016.06.008
   Soliman C, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224028
   Somwongin S, 2018, TOXICON, V145, P32, DOI 10.1016/j.toxicon.2018.02.049
   Son DJ, 2007, PHARMACOL THERAPEUT, V115, P246, DOI 10.1016/j.pharmthera.2007.04.004
   Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284
   Sun XJ, 2005, PEPTIDES, V26, P369, DOI 10.1016/j.peptides.2004.10.004
   Taketomi Y, 2013, NAT IMMUNOL, V14, P554, DOI 10.1038/ni.2586
   Tighilet B, 2019, NEUROPHARMACOLOGY, V144, P133, DOI 10.1016/j.neuropharm.2018.10.029
   Uddin M, 2016, J MICROBIOL, V54, P853
   Van Vaerenbergh M, 2013, INSECT MOL BIOL, V22, P199, DOI 10.1111/imb.12013
   Van Vaerenbergh M, 2014, J PROTEOMICS, V99, P169, DOI 10.1016/j.jprot.2013.04.039
   Vazquez-Revuelta P, 2018, J INVEST ALLERG CLIN, V28, P45, DOI 10.18176/jiaci.0202
   VICK JA, 1974, TOXICON, V12, P139, DOI 10.1016/0041-0101(74)90237-2
   VLASAK R, 1984, EUR J BIOCHEM, V145, P279, DOI 10.1111/j.1432-1033.1984.tb08549.x
   WACHINGER M, 1992, FEBS LETT, V309, P235, DOI 10.1016/0014-5793(92)80780-K
   Wang QQ, 2015, TRANSL NEURODEGENER, V4, DOI 10.1186/s40035-015-0042-0
   Wehbe R, 2019, MOLECULES, V24, DOI 10.3390/molecules24162997
   Welker S, 2011, BIOCHIMIE, V93, P195, DOI 10.1016/j.biochi.2010.09.012
   Yalcin M, 2009, PROSTAG LEUKOTR ESS, V81, P341, DOI 10.1016/j.plefa.2009.10.001
   Yang X, 2014, TUMOR BIOL, V35, P10443, DOI 10.1007/s13277-014-2218-0
   Ye M, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.49
   Ye M, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0476-z
   Yin DC, 2018, HEART RHYTHM, V15, P761, DOI 10.1016/j.hrthm.2018.01.016
   Yu X, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08538-x
   Zhang H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095520
   Zhang S, 2018, TOXICON, V148, P64, DOI 10.1016/j.toxicon.2018.04.012
   ZIAI MR, 1990, J PHARM PHARMACOL, V42, P457, DOI 10.1111/j.2042-7158.1990.tb06595.x
NR 172
TC 125
Z9 143
U1 1
U2 50
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD NOV
PY 2020
VL 12
IS 11
AR 3360
DI 10.3390/nu12113360
PG 27
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA OX6TN
UT WOS:000593694600001
PM 33142794
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Bishop, FL
   Coghlan, B
   Geraghty, AWA
   Everitt, H
   Little, P
   Holmes, MM
   Seretis, D
   Lewith, G
AF Bishop, Felicity L.
   Coghlan, Beverly
   Geraghty, Adam W. A.
   Everitt, Hazel
   Little, Paul
   Holmes, Michelle M.
   Seretis, Dionysis
   Lewith, George
TI What techniques might be used to harness placebo effects in
   non-malignant pain? A literature review and survey to develop a taxonomy
SO BMJ OPEN
LA English
DT Review
ID RANDOMIZED CONTROLLED-TRIAL; OPEN-LABEL USE; CLINICAL-PRACTICE;
   INTERVENTIONS; NOCEBO; METAANALYSIS; EXPECTANCY; OSTEOARTHRITIS;
   COMMUNICATION; ACUPUNCTURE
AB Objectives Placebo effects can be clinically meaningful but are seldom fully exploited in clinical practice. This review aimed to facilitate translational research by producing a taxonomy of techniques that could augment placebo analgesia in clinical practice.
   Design Literature review and survey.
   Methods We systematically analysed methods which could plausibly be used to elicit placebo effects in 169 clinical and laboratory-based studies involving nonmalignant pain, drawn from seven systematic reviews. In a validation exercise, we surveyed 33 leading placebo researchers (mean 12 year sa  pound (TM) research experience, SD 9.8), who were asked to comment on and add to the draft taxonomy derived from the literature.
   Results The final taxonomy defines 30 procedures that may contribute to placebo effects in clinical and experimental research, proposes 60 possible clinical applications and classifies procedures into five domains: the patienta  pound (TM) s characteristics and belief (5 procedures and 11 clinical applications), the practitionera  pound (TM) s characteristics and beliefs (2 procedures and 4 clinical applications), the healthcare setting (8 procedures and 13 clinical applications), treatment characteristics (8 procedures and 14 clinical applications) and the patienta " pound practitioner interaction (7 procedures and 18 clinical applications).
   Conclusion The taxonomy provides a preliminary and novel tool with potential to guide translational research aiming to harness placebo effects for patient benefit in practice.
C1 [Bishop, Felicity L.; Holmes, Michelle M.; Seretis, Dionysis] Univ Southampton, Fac Social Human & Math Sci, Dept Psychol, Southampton, Hants, England.
   [Coghlan, Beverly; Geraghty, Adam W. A.; Everitt, Hazel; Little, Paul; Lewith, George] Univ Southampton, Aldermoor Hlth Ctr, Primary Care & Populat Sci, Southampton, Hants, England.
C3 University of Southampton; University of Southampton
RP Bishop, FL (corresponding author), Univ Southampton, Fac Social Human & Math Sci, Dept Psychol, Southampton, Hants, England.
EM F.L.Bishop@southampton.ac.uk
RI ; Holmes, Michelle/I-2622-2016; Bishop, Felicity/AFW-1840-2022
OI Little, Paul/0000-0003-3664-1873; Everitt, Hazel/0000-0001-7362-8403;
   Holmes, Michelle/0000-0002-6018-2235; Geraghty,
   Adam/0000-0001-7984-8351; Bishop, Felicity/0000-0002-8737-6662; Seretis,
   Dionysis/0000-0002-1116-4305
FU National Institute of Health Research (NIHR) School for Primary Care
   Research (SPCR) [161]; NIHR; Solent NHS Trust
FX The project "Creating a Taxonomy to Harness the Placebo effect in UK
   primary care" was funded by the National Institute of Health Research
   (NIHR) School for Primary Care Research (SPCR) (project number 161).
   This paper presents independent research funded by the NIHR. Additional
   funding for BC was provided by Solent NHS Trust.
CR [Anonymous], PHARMACOLOGY OF PAIN
   Barnhill A, 2015, J MED ETHICS, V41, P673, DOI 10.1136/medethics-2014-102651
   Bélanger L, 2007, J SLEEP RES, V16, P77, DOI 10.1111/j.1365-2869.2007.00566.x
   Benedetti F, 2003, J NEUROSCI, V23, P4315
   Benedetti F., 2003, PREVENTION TREATMENT, V6
   Benedetti F, 2016, LANCET NEUROL, V15, P736, DOI [10.1016/S1474-4422(16)00066-1, 10.1016/s1474-4422(16)00066-1]
   Benedetti F, 2013, PHYSIOL REV, V93, P1207, DOI 10.1152/physrev.00043.2012
   Benedetti F, 2011, PATIENT EDUC COUNS, V84, P413, DOI 10.1016/j.pec.2011.04.034
   Bensing JM, 2010, PATIENT EDUC COUNS, V80, P293, DOI 10.1016/j.pec.2010.05.033
   Bingel U, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001244
   Bishop FL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101822
   Bishop FL, 2014, FAM PRACT, V31, P357, DOI 10.1093/fampra/cmu016
   Blease C, 2016, BIOETHICS, V30, P407, DOI 10.1111/bioe.12245
   Brody H, 2000, J FAM PRACTICE, V49, P649
   Colloca L, 2013, PAIN, V154, P511, DOI 10.1016/j.pain.2013.02.002
   Colloca L, 2012, JAMA-J AM MED ASSOC, V307, P567, DOI 10.1001/jama.2012.115
   Colloca L, 2011, PHILOS T R SOC B, V366, P1922, DOI 10.1098/rstb.2010.0399
   Colloca L, 2011, PHILOS T R SOC B, V366, P1859, DOI 10.1098/rstb.2010.0398
   Di Blasi Z, 2001, LANCET, V357, P757, DOI 10.1016/S0140-6736(00)04169-6
   Dijkstra K, 2006, J ADV NURS, V56, P166, DOI 10.1111/j.1365-2648.2006.03990.x
   Doherty M, 2009, OSTEOARTHR CARTILAGE, V17, P1255, DOI 10.1016/j.joca.2009.03.023
   Dowell Deborah, 2016, JAMA, V315, P1624, DOI [10.15585/mmwr.rr6501e1, 10.1001/jama.2016.1464]
   Drahota A, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005315.pub2
   Enck P, 2013, NAT REV DRUG DISCOV, V12, P191, DOI 10.1038/nrd3923
   Fässler M, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-144
   Faria V, 2008, EUR NEUROPSYCHOPHARM, V18, P473, DOI 10.1016/j.euroneuro.2008.03.002
   Feffer K, 2016, GEN HOSP PSYCHIAT, V41, P53, DOI 10.1016/j.genhosppsych.2016.05.004
   Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2
   Ford AC, 2010, ALIMENT PHARM THER, V32, P144, DOI 10.1111/j.1365-2036.2010.04328.x
   Greville-Harris M, 2015, AM J MED, V128, P126, DOI 10.1016/j.amjmed.2014.08.031
   Howick J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062599
   Howick J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058247
   Hróbjartsson A, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003974.pub3
   Hyland ME, 2008, J PSYCHOSOM RES, V65, P405, DOI 10.1016/j.jpsychores.2008.02.006
   Jubb J, 2013, NEUROSCI BIOBEHAV R, V37, P2709, DOI 10.1016/j.neubiorev.2013.09.006
   Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25
   Kaptchuk TJ, 2015, NEW ENGL J MED, V373, P8, DOI 10.1056/NEJMp1504023
   Kaptchuk TJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015591
   Kaptchuk TJ, 2006, BMJ-BRIT MED J, V332, P391, DOI 10.1136/bmj.38726.603310.55
   Kelley JM, 2012, PSYCHOTHER PSYCHOSOM, V81, P312, DOI 10.1159/000337053
   Kirsch I, 2005, J CLIN PSYCHOL, V61, P791, DOI 10.1002/jclp.20126
   Kirsch I, 2004, PSYCHOL BULL, V130, P341, DOI 10.1037/0033-2909.130.2.341
   Kirsch I, 1997, APPL PREV PSYCHOL, V6, P69, DOI 10.1016/S0962-1849(05)80012-5
   Kirsch I., 1998, Prevention Treatment, V1, DOI DOI 10.1037/1522-3736.1.1.12A
   Klinger R, 2014, PAIN, V155, P1055, DOI 10.1016/j.pain.2013.12.007
   Lichtenberg P, 2004, J MED ETHICS, V30, P551, DOI 10.1136/jme.2002.002832
   Linde K, 2011, PHILOS T R SOC B, V366, P1905, DOI 10.1098/rstb.2010.0383
   Manchikanti L, 2011, PAIN PHYSICIAN, V14, pE157
   Meissner K, 2011, PHILOS T R SOC B, V366, P1783, DOI 10.1098/rstb.2010.0414
   Michie S, 2009, HEALTH PSYCHOL, V28, P690, DOI 10.1037/a0016136
   Mistiaen P, 2016, EUR J PAIN, V20, P675, DOI 10.1002/ejp.797
   Moerman DE, 2002, ANN INTERN MED, V136, P471, DOI 10.7326/0003-4819-136-6-200203190-00011
   Ortiz R, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-011012
   Patel SM, 2005, NEUROGASTROENT MOTIL, V17, P332, DOI 10.1111/j.1365-2982.2005.00650.x
   Peerdeman KJ, 2016, PAIN, V157, P1179, DOI 10.1097/j.pain.0000000000000540
   Planès S, 2016, PHARMACOL RES PERSPE, V4, DOI 10.1002/prp2.208
   Price D.D., 2005, SEMINARS PAIN MED, V3, P15
   Price DD, 2008, ANNU REV PSYCHOL, V59, P565, DOI 10.1146/annurev.psych.59.113006.095941
   Puhl AA, 2011, PAIN RES MANAG, V16, P45, DOI 10.1155/2011/625315
   Rice T, 2010, J MAT CULT, V15, P287, DOI 10.1177/1359183510373985
   Sandler A, 2008, CHILD CARE HLTH DEV, V34, P111, DOI 10.1111/j.1365-2214.2007.00743.x
   Sandler AD, 2008, CHILD CARE HLTH DEV, V34, P104, DOI 10.1111/j.1365-2214.2007.00797.x
   Snyder CF, 2012, QUAL LIFE RES, V21, P1305, DOI 10.1007/s11136-011-0054-x
   Stewart-Williams S, 2004, PSYCHOL BULL, V130, P324, DOI 10.1037/0033-2909.130.2.324
   Strauss E, 1998, CLIN ORTHOP RELAT R, P2
   Street RL, 2009, PATIENT EDUC COUNS, V74, P295, DOI 10.1016/j.pec.2008.11.015
   Suarez-Almazor ME, 2010, ARTHRIT CARE RES, V62, P1229, DOI 10.1002/acr.20225
   Vase L, 2002, PAIN, V99, P443, DOI 10.1016/S0304-3959(02)00205-1
   Vase L, 2013, PAIN, V154, P1659, DOI 10.1016/j.pain.2013.05.008
   Vase L, 2009, PAIN, V145, P36, DOI 10.1016/j.pain.2009.04.008
   White P, 2012, PAIN, V153, P455, DOI 10.1016/j.pain.2011.11.007
   Witt CM, 2012, EUR J PAIN, V16, P1455, DOI 10.1002/j.1532-2149.2012.00152.x
   Zhang W, 2008, ANN RHEUM DIS, V67, P1716, DOI 10.1136/ard.2008.092015
NR 73
TC 31
Z9 35
U1 1
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD JUN
PY 2017
VL 7
IS 6
AR e015516
DI 10.1136/bmjopen-2016-015516
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC General & Internal Medicine
GA FB8LT
UT WOS:000406391200163
PM 28667217
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Rossi, E
   Vita, A
   Baccetti, S
   Di Stefano, M
   Voller, F
   Zanobini, A
AF Rossi, Elio
   Vita, Alessandra
   Baccetti, Sonia
   Di Stefano, Mariella
   Voller, Fabio
   Zanobini, Alberto
TI Complementary and alternative medicine for cancer patients: results of
   the EPAAC survey on integrative oncology centres in Europe
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Complementary and alternative medicine; Integrative oncology; European
   centres; Cancer patients; EPAAC survey
ID PREVALENCE; CARE
AB The Region of Tuscany Health Department was included as an associated member in WP7 "Healthcare" of the European Partnership for Action Against Cancer (EPAAC), initiated by the EU Commission in 2009.
   The principal aim was to map centres across Europe prioritizing those that provide public health services and operating within the national health system in integrative oncology (IO).
   A cross-sectional descriptive survey design was used to collect data. A questionnaire was elaborated concerning integrative oncology therapies to be administered to all the national health system oncology centres or hospitals in each European country. These institutes were identified by convenience sampling, searching on oncology websites and forums. The official websites of these structures were analysed to obtain more information about their activities and contacts.
   Information was received from 123 (52.1 %) out of the 236 centres contacted until 31 December 2013. Forty-seven out of 99 responding centres meeting inclusion criteria (47.5 %) provided integrative oncology treatments, 24 from Italy and 23 from other European countries. The number of patients seen per year was on average 301.2 +/- 337. Among the centres providing these kinds of therapies, 33 (70.2 %) use fixed protocols and 35 (74.5 %) use systems for the evaluation of results. Thirty-two centres (68.1 %) had research in progress or carried out until the deadline of the survey. The complementary and alternative medicines (CAMs) more frequently provided to cancer patients were acupuncture 26 (55.3 %), homeopathy 19 (40.4 %), herbal medicine 18 (38.3 %) and traditional Chinese medicine 17 (36.2 %); anthroposophic medicine 10 (21.3 %); homotoxicology 6 (12.8 %); and other therapies 30 (63.8 %). Treatments are mainly directed to reduce adverse reactions to chemo-radiotherapy (23.9 %), in particular nausea and vomiting (13.4 %) and leucopenia (5 %). The CAMs were also used to reduce pain and fatigue (10.9 %), to reduce side effects of iatrogenic menopause (8.8 %) and to improve anxiety and depression (5.9 %), gastrointestinal disorders (5 %), sleep disturbances and neuropathy (3.8 %).
   Mapping of the centres across Europe is an essential step in the process of creating a European network of centres, experts and professionals constantly engaged in the field of integrative oncology, in order to increase, share and disseminate the knowledge in this field and provide evidence-based practice.
C1 [Rossi, Elio; Vita, Alessandra; Baccetti, Sonia; Di Stefano, Mariella] Tuscan Network Integrat Med, Reg Hlth Minist Reg Tuscany Italy, Dept Res Innovat & Human Resources, I-50100 Florence, Italy.
   [Voller, Fabio] Tuscan Reg Agcy Healthcare, Operat Unit Epidemiol, Florence, Italy.
   [Zanobini, Alberto] Reg Hlth Minist Reg Tuscany, Dept Res Innovat & Human Resources, Florence, Italy.
RP Rossi, E (corresponding author), Tuscan Network Integrat Med, Reg Hlth Minist Reg Tuscany Italy, Dept Res Innovat & Human Resources, Via T Alderotti 26 N, I-50100 Florence, Italy.
EM retemedicinaintegrata@regione.toscana.it
RI Voller, Fabio/K-5809-2016; rossi, elio/AAS-5047-2020
OI Voller, Fabio/0000-0002-1063-415X; rossi, elio/0000-0003-2515-9416
FU European Union through the Executive Agency for Health and Consumers of
   the European Commission
FX This publication arises from the European Partnership for Action Against
   Cancer (EPAAC), which has received funding from the European Union
   through the Executive Agency for Health and Consumers of the European
   Commission, in the framework of the Health Programme 2008-2013.
CR Ben-Arye E, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0511-1
   Boon H, 2004, BMC HEALTH SERV RES, V4, DOI 10.1186/1472-6963-4-15
   CASSILETH BR, 2005, INTEGRATIVE ONCOLOGY
   Cramer H, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/383142
   Deng Gary E, 2009, J Soc Integr Oncol, V7, P85
   Egan Bernadette, 2012, Complement Ther Clin Pract, V18, P75, DOI 10.1016/j.ctcp.2011.11.003
   Ernst E, 2000, COMPLEMENT THER MED, V8, P32, DOI 10.1016/S0965-2299(00)90833-1
   Ernst E, 1998, CANCER-AM CANCER SOC, V83, P777, DOI 10.1002/(SICI)1097-0142(19980815)83:4<777::AID-CNCR22>3.0.CO;2-O
   Gansler T, 2008, CANCER-AM CANCER SOC, V113, P1048, DOI 10.1002/cncr.23659
   Horneber M, 2012, INTEGR CANCER THER, V11, P187, DOI 10.1177/1534735411423920
   Johannessen H, 2008, TUMORI, V94, P406
   Mittring N, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/316950
   Molassiotis A, 2005, ANN ONCOL, V16, P655, DOI 10.1093/annonc/mdi110
   Sagar SM, 2008, CURR ONCOL, V15, P166
   Sagar Stephen M, 2006, J Soc Integr Oncol, V4, P27
   Salomonsen LJ, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-4
   Scott J A, 2005, Eur J Oncol Nurs, V9, P131, DOI 10.1016/j.ejon.2005.03.012
NR 17
TC 75
Z9 84
U1 2
U2 38
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD JUN
PY 2015
VL 23
IS 6
BP 1795
EP 1806
DI 10.1007/s00520-014-2517-4
PG 12
WC Oncology; Health Care Sciences & Services; Rehabilitation
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA CH1ON
UT WOS:000353791200038
PM 25471177
DA 2026-01-16
ER

PT J
AU Öztürk, FG
   Sencan, I
   Özkara, A
   Yapar, A
   Engin, EE
   Öztürk, R
AF Ozturk, Fatma Gokcenur
   Sencan, Irfan
   Ozkara, Adem
   Yapar, Aliekber
   Engin, Eray Erturk
   Ozturk, Recep
TI Knowledge and experiences of complementary and alternative medical
   practices among patients presenting to an orthopedic clinic: A
   cross-sectional study
SO EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Article
DE Traditional medicine; Conventional therapy; Acupuncture; Leech therapy;
   Cupping; Joint pain; Cross-sectional study; Complementary medicine
AB Introduction: This study aimed to determine the level of knowledge about complementary and alternative medicine (CAM) practices and the frequency of CAM use and treatment among patients who presented to an orthopedic outpatient clinic.& nbsp;Methods: Patients who presented to the orthopedics outpatient clinic of Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital between February 1 and April 1, 2020, were invited to participate in this study. A questionnaire containing 11 questions about 14 different CAM approaches, designed to determine patients' knowledge of and attitudes toward each of these practices, was administered by the responsible physician through face-to-face interviews.& nbsp;Results: A total of 359 patients were included in the study, the mean age was 49.0 +/- 16.1 years and 240 (66.9%) were women. Of the 455 individuals who were considered eligible for the study, 96 refused to participate. The majority of the participants (78.8%) stated that they knew of at least one CAM approach. The most common sources of information were families or friends (54.1%). Of the participants, 30.6% had previously received at least one CAM treatment. About half of the participants (52.6%) stated that they would consider using the methods that they had heard of. The three most commonly known and applied methods were cupping, leech therapy, and acupuncture, respectively. Only 36.4% of the treatments were applied by health professionals.& nbsp;Conclusion: Almost all patients presenting to the orthopedics outpatient clinic had some knowledge of CAM approaches and more than half of them stated that they received such treatments. Health professionals should be aware that society is interested in these practices, regardless of professional support or opposition. All patients presenting to outpatient clinics should be asked about their usage of CAM methods, and the potential interactions of patients' treatments with CAM practices should be considered.
C1 [Ozturk, Fatma Gokcenur; Sencan, Irfan; Ozkara, Adem] Ankara Bilkent City Hosp, Dept Family Med, Ankara, Turkey.
   [Yapar, Aliekber; Engin, Eray Erturk; Ozturk, Recep] Dr Abdurrahman Yurtaslan Ankara Oncol Training &, Dept Orthoped & Traumatol, Ankara, Turkey.
C3 Dr. Abdurrahman Yurtaslan Oncology Hospital
RP Öztürk, R (corresponding author), Dr Abdurrahman Yurtaslan Ankara Oncol Training &, Dept Orthoped & Traumatol, Ankara, Turkey.
EM ozturk_recep@windowslive.com
RI Şencan, İrfan/AAG-5653-2019; Özkara, Adem/AAP-5416-2020; öztürk,
   recep/N-7086-2017; Yapar, Aliekber/NWH-3129-2025
OI Şencan, İrfan/0000-0003-2008-8700; öztürk, recep/0000-0002-6753-9321; 
CR [Anonymous], 1994, TURKIYE KLIN J MED E
   [Anonymous], 2004, WHO MED STRAT COUNTR
   Ernst E, 2012, J PAIN SYMPTOM MANAG, V43, pE11, DOI 10.1016/j.jpainsymman.2011.11.001
   Ernst E, 2009, MED J AUSTRALIA, V191, P263, DOI 10.5694/j.1326-5377.2009.tb02780.x
   Gonen E., 2022, REPORT TRADITIONAL C
   Kilper A, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-037192
   Leach MJ, 2018, COMPLEMENT THER CLIN, V31, P38, DOI 10.1016/j.ctcp.2018.01.011
   Mollahaliloğlu S, 2015, Ankara Medical Journal, V15, DOI [10.17098/amj.44789, 10.17098/amj.44789]
   Ozturk R, 2018, ULUTAS MEDIC J, V4, P152, DOI [10.5455/umj.20171124110044, 10.5455/ umj.20171124110044, DOI 10.5455/UMJ.20171124110044]
   Park HL, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/429103
   Qi Z., 2013, WHO Traditional Medicine Strategy. 2014-2023
   Resmi Gazete, 2014, RESMI GAZETE 1027
   Resmi Gazete, 2018, RESMI GAZETE 0710
   Shang AJ, 2005, LANCET, V366, P726, DOI 10.1016/S0140-6736(05)67177-2
   Simsek B, 2017, EUR J INTEGR MED, V15, P68, DOI 10.1016/j.eujim.2017.09.006
   Tutuianu S, 2017, TORN BETWEEN EAST AND WEST: EUROPE'S BORDER STATES, P1
   WHO, 2000, TRM20001 WHO EDM
NR 17
TC 2
Z9 2
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1876-3820
EI 1876-3839
J9 EUR J INTEGR MED
JI Eur. J. Integr. Med.
PD APR
PY 2022
VL 51
AR 102117
DI 10.1016/j.eujim.2022.102117
EA MAR 2022
PG 7
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA 0O9WA
UT WOS:000783873000001
DA 2026-01-16
ER

PT J
AU Omura, Y
   Chen, YM
   Lermand, O
   Jones, M
   Duvvi, H
   Shimotsuura, Y
AF Omura, Yoshiaki
   Chen, Yemeng
   Lermand, Olivia
   Jones, Marilyn
   Duvvi, Harsha
   Shimotsuura, Yasuhiro
TI Effects of Transcutaneous Electrical Stimulation (1 pulse/sec) Through
   Custom-made Disposable Surface Electrodes Covering Omura's ST36 Area of
   Both Legs on Normal Cell Telomeres, Oncogen C-fosAb2, Integrin
   α5β1, Chlamydia Trachomatis, etc. in Breast Cancer
   & Alzheimer Patients
SO ACUPUNCTURE & ELECTRO-THERAPEUTICS RESEARCH
LA English
DT Article
DE Electrical stimulation; Transcutaneous Electrical Stimulation; Breast
   cancer; Alzheimer's Disease, beta-Amyloid (1-42); Diabetic gangrene of
   lower extremities; Telomere; Chlamydia trachomatis; Oncogen C-fosAb2;
   Integrin alpha(5)beta(1); Pain
ID O-RING TEST; TEST MOLECULAR-IDENTIFICATION; CARDIAC TROPONIN-I; INTERNAL
   ORGANS; ACUPUNCTURE POINTS; CIRCULATORY DISTURBANCES; CEPHALIC
   HYPERTENSION; HYPOTENSION SYNDROMES; CLINICAL-APPLICATIONS; VIRAL
   TRANSFORMATION
AB Our previous study indicated that when extremely reduced normal cell (NC) telomeres in various cancer patients are increased over 500ng BDORT units, abnormally high cancer cell telomeres and cancer-related markers such as Oncogen C-fosAb2 (Onco.) & Integrin alpha(5)beta(1) (Integ.), & 8-OH-dG as well as bacterial & viral infections, mercury, asbestos, chromium, & beta-amyloid (1-42) markedly reduced due to improved circulation & excretion of these substances in urine. Since 1995, we have been using press-needle stimulation of Omura's ST36 with 200x press-release procedure 4x a day, with significant improvements in various cancer patients. In this study, Transcutaneous Electrical Stimulation (TES) at 60 pulses/min, which is close to patient's heart rate, was given between Omura's ST36 of both legs of the breast cancer & Alzheimer's patients. After about 10 minutes of TES, NC telomeres increased from 1yg (=10(-24)g) to 500 similar to 525ng; Integ. reduced from 85 similar to 75ng to 0.5ng & Chlamydia trachomatis (CT) reduced from 4500 similar to 3500ng to 0.5ng. An additional 10 minutes TES increased NC telomeres to 800-875ng, while Integ. reduced to 0.5yg & CT became less than 0.1yg. After a total 30 minutes of TES, NC telomeres increased to 1000-1200ng BDORT units, with decreases in Integ. and Onco. to less than 0.1yg. CT reduced to <<0.1yg. About 24 hours later, NC telomeres were still 300ng & both Integ. and Onco. were 2.5ng. CT was similar to 20ng. In Alzheimer patient, abnormally high beta-Amyloid (1-42) of 7-12ng markedly reduced to within normal value of less than 1.5ng by 20 similar to 30 min TES. Stimulation beyond 30 minutes gradually reduced NC telomeres. TES pulse rate of 4 pulses/sec for the same patient initially increased NC telomere up to 750-950ng BDORT units within 20 minutes, but when stimulation continued more than 20 min, NC telomeres rapidly reduced to similar to 150ng in less than 10 min of TES with reduced beneficial effects.
C1 [Duvvi, Harsha] New York Med Coll, Dept Family & Community Med, Valhalla, NY 10595 USA.
   [Omura, Yoshiaki] Manhattan Coll, Dept Elect Engn, New York, NY USA.
   [Omura, Yoshiaki] Univ Paris, Univ Paris 05, Paris, France.
   [Chen, Yemeng] New York Coll Tradit Chinese Med, New York, NY USA.
   [Chen, Yemeng] New York State Board Acupuncture, New York, NY USA.
   [Chen, Yemeng] Shanghai Med Univ, Acupuncture Clin, Shanghai, Peoples R China.
   [Lermand, Olivia] St Lukes Roosevelt Hosp, New York, NY USA.
   [Jones, Marilyn] Wholist Dent Ctr Houston, Houston, TX USA.
   [Jones, Marilyn] Univ Houston, Houston, TX 77004 USA.
   [Shimotsuura, Yasuhiro] Japan Bi Digital O Ring Test Assoc, Kurume, Fukuoka, Japan.
C3 New York Medical College; Manhattan University; Universite Paris Cite;
   Fudan University; Mount Sinai Morningside; Mount Sinai West; University
   of Houston System; University of Houston
RP Omura, Y (corresponding author), 800 Riverside Dr 8-I, New York, NY 10032 USA.
EM icaet@yahoo.com
RI Chen, Yemeng/AAK-4979-2021
OI Chen, Yemeng/0000-0001-7746-6253; Shimotsuura,
   Yasuhiro/0000-0003-2245-8162
CR [Anonymous], WHAT IS LIFE NEXT 10
   [Anonymous], HDB MED ACUPUNCTURE
   [Anonymous], PRACTICE BI DIGITAL
   [Anonymous], PROPHYLACTIC APPROAC
   [Anonymous], JAPANESE J ACUPUNCTU
   [Anonymous], P 10 ANN JAP IMM DIS
   [Anonymous], FUTURE MED O RING TE
   CASTO BC, 1976, P AM ASSOC CANC RES, V17, P12
   Charlton J.E., 2005, Core Curriculum for Professional Education in Pain, P1
   DiPaolo J A, 1978, Natl Cancer Inst Monogr, P245
   FORNACE AJ, 1981, CHEM-BIOL INTERACT, V36, P345, DOI 10.1016/0009-2797(81)90077-6
   FUKUDA S, 2000, ACUPUNCTURE ELECTRO, V25, P221
   Gibb HJ, 2000, AM J IND MED, V38, P115, DOI 10.1002/1097-0274(200008)38:2<115::AID-AJIM1>3.0.CO;2-Y
   HATCH GG, 1983, CANCER RES, V43, P1945
   Hayes RB, 1997, CANCER CAUSE CONTROL, V8, P371, DOI 10.1023/A:1018457305212
   Kaye Vladimir, TRANSCUTANEOUS ELECT
   LEVIN MF, 1993, ARCH PHYS MED REHAB, V74, P54
   MILLER FR, 1979, JNCI-J NATL CANCER I, V63, P1457
   OMURA Y, 1985, ACUPUNCTURE ELECTRO, V10, P139, DOI 10.3727/036012985816714469
   OMURA Y, 1981, ACUPUNCTURE ELECTRO, V6, P109, DOI 10.3727/036012981816952234
   OMURA Y, 1980, ACUPUNCTURE ELECTRO, V5, P1
   OMURA Y, 1978, ACUPUNCTURE ELECTRO, V3, P223
   Omura Y, 2005, ACUPUNCTURE ELECTRO, V30, P219, DOI 10.3727/036012905815901226
   OMURA Y, 1986, ACUPUNCTURE ELECTRO, V11, P219, DOI 10.3727/036012986816359003
   Omura Y, 2004, ACUPUNCTURE ELECTRO, V29, P1
   OMURA Y, 1986, ACUPUNCTURE ELECTRO, V11, P65, DOI 10.3727/036012986816359201
   OMURA Y, 1988, ACUPUNCTURE ELECTRO, V13, P153, DOI 10.3727/036012988816358606
   OMURA Y, 1995, ACUPUNCTURE ELECTRO, V20, P21
   OMURA Y, 1985, ACUPUNCTURE ELECTRO, V10, P255, DOI 10.3727/036012985816714423
   OMURA Y, 1982, ACUPUNCTURE ELECTRO, V7, P209, DOI 10.3727/036012982816952026
   OMURA Y, 1978, ACUPUNCTURE ELECTRO, V3, P1
   OMURA Y, 1985, ACUPUNCTURE ELECTRO, V10, P335, DOI 10.3727/036012985816714405
   OMURA Y, 1977, Acupuncture and Electro-Therapeutics Research, V2, P161
   OMURA Y, 1994, ACUPUNCTURE ELECTRO, V19, P39, DOI 10.3727/036012994816357394
   OMURA Y, 1986, ACUPUNCTURE ELECTRO, V11, P127, DOI 10.3727/036012986816359193
   Omura Y, 1998, ACUPUNCTURE ELECTRO, V23, P185, DOI 10.3727/036012998816356472
   OMURA Y, 1989, ACUPUNCTURE ELECTRO, V14, P155, DOI 10.3727/036012989816358470
   OMURA Y, 1975, Acupuncture and Electro-Therapeutics Research, V1, P157
   OMURA Y, 1975, Acupuncture and Electro-Therapeutics Research, V1, P231
   OMURA Y, 1983, ACUPUNCTURE ELECTRO, V8, P177
   OMURA Y, 1984, ACUPUNCTURE ELECTRO, V9, P187
   OMURA Y, 1987, ACUPUNCTURE ELECTRO, V12, P201, DOI 10.3727/036012987816358788
   OMURA Y, 1989, ACUPUNCTURE ELECTRO, V14, P61, DOI 10.3727/036012989816358506
   OMURA Y, 1993, ACUPUNCTURE ELECTRO, V18, P33, DOI 10.3727/036012993816357601
   OMURA Y, 1979, P NAT S AC MOX AC AN
   OMURA Y, 2008, ACUPUNCTURE ELECTRO, V33, P78
   OMURA Y, 2000, ACUPUNCTURE ELECT TH, V25, P208
   OMURA Y, 2000, PRATICA TESTE ANEL B
   Omura Y., 1993, ACUPUNCTURE ELECTRO, V19, P248
   Omura Y., 1975, Acupunct. Electro-Ther. Res, V1, P51
   OMURA Y, 1978, S PHYS MECH AC MOX 5, P81
   Omura Y., 1985, ACUPUNCTURE ELECTRO, V10, P1
   OMURA Y, 2002, P BRIDG WORLDS FILL, P150
   Omura Y., 2009, 19 ANN S JAP BI DIG, P15
   Omura Y., 1990, 4 WORLD C SCI AC ICM, P42
   OMURA Y, 1979, J JAPAN ACUPUNCTURE, V27, P310
   Omura Y, 1999, 10 ANN S BI DIG O RI, P32
   OMURA Y, 2005, 15 ANN SCI M JAP BI
   OMURA Y, 1980, PAIN BASIC RES TREAT, P360
   OMURA Y, 2002, JAPANESE J ACUPUNCTU, V61, P143
   Omura Y, 2000, 4 INT S BID O RING T, V25, p[126, 230]
   Omura Y., 1997, FUTURE MED O RING TE, P341
   Omura Y, 2001, ACUPUNCTURE ELECTRO, V26, P77
   OMURA Y, 2000, 4 INT S BI DIG O RIN, P204
   OMURA Y, 1997, PRACTICE BI DIGITAL
   Omura Y., 2001, JAPANESE J ACUPUNCTU, V692, P129
   OMURA Y, 2002, ACUPUNCTURE ELECTRO, V27, P237
   OMURA Y, 1993, ACUPUNCTURE ELECTRO, V19, P234
   Omura Y., 2008, ACUPUNCTURE ELECTRO, V33, P231
   Omura Y., 1983, ELECTROACUPUNTURA Y
   Omura Y., 2008, ACUPUNCTURE ELECTRO, V33, P227
   Omura Y, 2007, ACUPUNCTURE ELECTRO, V32, P235, DOI 10.3727/036012907815844066
   Omura Y, 2007, ACUPUNCTURE ELECTRO, V32, P31, DOI 10.3727/036012907815844174
   Omura Y, 2006, ACUPUNCTURE ELECTRO, V31, P247
   Omura Y, 2006, ACUPUNCTURE ELECTRO, V31, P61, DOI 10.3727/036012906815844300
   Omura Y, 2010, ACUPUNCTURE ELECTRO, V35, P45, DOI 10.3727/036012910803860977
   Omura Y, 2009, ACUPUNCTURE ELECTRO, V34, P41, DOI 10.3727/036012909803861059
   TSAPAKOS MJ, 1983, CANCER RES, V43, P5662
NR 78
TC 14
Z9 14
U1 0
U2 12
PU COGNIZANT COMMUNICATION CORP
PI PUTNAM VALLEY
PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA
SN 0360-1293
EI 2167-9010
J9 ACUPUNCTURE ELECTRO
JI Acupunct. Electro-Ther. Res.
PY 2010
VL 35
IS 3-4
BP 147
EP 185
DI 10.3727/036012910803860922
PG 39
WC Integrative & Complementary Medicine; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine; Neurosciences & Neurology
GA 704UU
UT WOS:000286081900003
PM 21319603
DA 2026-01-16
ER

PT J
AU Kalder, M
   Knoblauch, K
   Hrgovic, I
   Münstedt, K
AF Kalder, Matthias
   Knoblauch, Katrin
   Hrgovic, Igor
   Muenstedt, Karsten
TI Use of complementary and alternative medicine during pregnancy and
   delivery
SO ARCHIVES OF GYNECOLOGY AND OBSTETRICS
LA English
DT Article
DE Complementary and alternative medicine (CAM); Obstetrics; Pregnancy;
   Birth
ID OBSTETRICS; THERAPIES; KNOWLEDGE; ATTITUDES; MIDWIVES; PAIN
AB To assess the use of complementary and alternative medicine (CAM) during pregnancy and birth and the reasons behind it from the patient's perspective.
   In a prospective study, we assessed the use of CAM before and during pregnancy as well as during delivery in women by means of a self-report questionnaire.
   Some 205 patients completed the questionnaire at a response rate of 43.2% (205/475) and 104 women used CAM during pregnancy, especially homoeopathy, acupuncture, and phytotherapy. Stepwise regression analysis identified CAM use prior to pregnancy, greater income, and nationality as the most important predictors of CAM use.
   In accordance with earlier studies from Germany, we determined the most important methods used in the field of obstetrics. Interestingly, these are not evidence-based and those methods which are evidence-based are not now used. Also, the predictors of CAM use in pregnancy were similar to those in oncology. Future studies should focus on the safety and efficacy of CAM in pregnancy.
C1 [Knoblauch, Katrin; Hrgovic, Igor; Muenstedt, Karsten] Univ Giessen, Dept Obstet & Gynaecol, D-35385 Giessen, Germany.
   [Kalder, Matthias] Univ Marburg, Dept Gynaecol Gynaecol Endocrinol & Oncol, Marburg, Germany.
C3 Justus Liebig University Giessen; Philipps University Marburg
RP Münstedt, K (corresponding author), Univ Giessen, Dept Obstet & Gynaecol, Klinikstr 32, D-35385 Giessen, Germany.
EM karsten.muenstedt@gyn.med.uni-giessen.de
CR Adams Jon, 2006, Complement Ther Clin Pract, V12, P40, DOI 10.1016/j.ctcp.2005.09.003
   Adams J, 2009, BIRTH-ISS PERINAT C, V36, P237, DOI 10.1111/j.1523-536X.2009.00328.x
   Allaire AD, 2000, OBSTET GYNECOL, V95, P19, DOI 10.1016/S0029-7844(99)00481-0
   Bayles BP, 2007, J MIDWIFERY WOM HEAL, V52, P473, DOI 10.1016/j.jmwh.2007.03.023
   BISHOP FL, 2008, EVID BASED COMPLEMEN
   Boivin J, 2009, HUM REPROD, V24, P1626, DOI 10.1093/humrep/dep077
   Dog TL, 2009, ALTERN THER HEALTH M, V15, P54
   Field T, 2008, ALTERN THER HEALTH M, V14, P28
   Gaffney L, 2004, AUST NZ J OBSTET GYN, V44, P24, DOI 10.1111/j.1479-828X.2004.00161.x
   Hammarberg K, 2008, HUM REPROD UPDATE, V14, P395, DOI 10.1093/humupd/dmn030
   Hodgson DM, 2007, FORSCH KOMP KLAS NAT, V14, P92, DOI 10.1159/000100958
   Hofberg K, 2003, POSTGRAD MED J, V79, P505, DOI 10.1136/pmj.79.935.505
   Holst L, 2009, J ALTERN COMPLEM MED, V15, P787, DOI 10.1089/acm.2008.0467
   Kalder M, 2009, GEBURTSH FRAUENHEILK, V69, P687, DOI 10.1055/s-0029-1185975
   Kappauf H, 2000, SUPPORT CARE CANCER, V8, P314, DOI 10.1007/s005209900111
   Mårtensson L, 2008, J MIDWIFERY WOM HEAL, V53, P115, DOI 10.1016/j.jmwh.2007.09.008
   Münstedt K, 2009, EUR J OBSTET GYN R B, V146, P50, DOI 10.1016/j.ejogrb.2009.05.013
   Münstedt K, 2009, FORSCH KOMPLEMENTMED, V16, P111, DOI 10.1159/000208918
   Munstedt K, 1996, ARCH GYNECOL OBSTET, V258, P81
   Newell S, 2000, MED J AUSTRALIA, V172, P110, DOI 10.5694/j.1326-5377.2000.tb127933.x
   Nordeng H, 2005, ACTA OBSTET GYN SCAN, V84, P26, DOI 10.1111/j.0001-6349.2005.00648.x
   Nordeng H, 2004, PHARMACOEPIDEM DR S, V13, P371, DOI 10.1002/pds.945
   Skouteris H, 2008, AUST NZ J OBSTET GYN, V48, P384, DOI 10.1111/j.1479-828X.2008.00865.x
   Smith C., 2003, COCHRANE DB SYST REV, V4, pCD003399, DOI [DOI 10.1002/14651858.CD003399, 10.1002/14651858.CD003399.]
   Smith CA, 2009, BIRTH-ISS PERINAT C, V36, P246, DOI 10.1111/j.1523-536X.2009.00329.x
   Tournaire M, 2007, EVID-BASED COMPL ALT, V4, P409, DOI 10.1093/ecam/nem012
   Wang SM, 2005, J ALTERN COMPLEM MED, V11, P459, DOI 10.1089/acm.2005.11.459
NR 27
TC 60
Z9 70
U1 0
U2 16
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0932-0067
EI 1432-0711
J9 ARCH GYNECOL OBSTET
JI Arch. Gynecol. Obstet.
PD MAR
PY 2011
VL 283
IS 3
BP 475
EP 482
DI 10.1007/s00404-010-1388-2
PG 8
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Obstetrics & Gynecology
GA 718RV
UT WOS:000287144700011
PM 20177901
DA 2026-01-16
ER

PT J
AU Yu, C
   Zhang, N
   Zhu, WK
   Zhang, YY
   Yang, J
   Wang, Y
   Song, XG
   Hu, L
   Wu, ZJ
   Liu, Q
   Tang, Y
   Wu, QF
   Yu, SG
AF Yu, Chang
   Zhang, Ning
   Zhu, Weikang
   Zhang, Yueyue
   Yang, Jiao
   Wang, Yong
   Song, Xiaoge
   Hu, Ling
   Wu, Zijian
   Liu, Qi
   Tang, Yong
   Wu, Qiaofeng
   Yu, Shuguang
TI Does Moxa Smoke Have Significant Effect on the Acupuncturist's
   Respiratory System? A Population-Based Study
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID MOXIBUSTION; HEALTH; EXPOSURE; SYMPTOMS; MEDICINE; CANCER; SAFETY; PAIN
AB Objectives. To evaluate the safety of moxa smoke, especially to provide quantitative information and details for the occupational prevention of acupuncturists. Methods. We combined the questionnaire-based cross-sectional survey and lung function testing-based historical retrospective cohort research to investigate the safety of moxa smoke exposure (MSE) among acupuncturists. A mathematical regression model was established to quantitatively evaluate the relationship between moxa smoke exposure and the respiratory health of the acupuncturist. The smoke exposure time of the acupuncturist and the prevalence of abnormal respiratory symptoms or diseases were also evaluated. Results. (1) The cross-sectional research showed that the incidence of expectoration (18.7%) and rhinitis (22.7%) was the most common respiratory symptom and disease after MSE. No statistical difference was found between smoke exposure time of the acupuncturist and the prevalence of abnormal respiratory symptoms or diseases, except the prevalence of rhinitis and shortness of breath (P<0.01). Regression model for the incidence of first three symptoms (expectoration, shortness of breath, and wheezing) from the cross-sectional survey indicated that the weight coefficients of factors associated with moxa smoke were lower than those of factors unrelated to moxa smoke, such as gender and personal history of respiratory diseases. (2) Historical retrospective cohort research showed that there was no significant difference in the % predicted PEF. No statistic difference was found between the exposed and nonexposed group in large airway function indexes (% predicted FEV1, % predicted FVC, and % predicted FEV1/FVC) and small airway function indexes (% predicted FEF25, % predicted FEF50, % predicted FEF75, and % predicted MMEF), either. Especially, the % predicted MVV among males (106.23 +/- 2.92 vs. 95.56 +/- 1.92, P<0.01 and % predicted VC among females (100.70 +/- 1.59 vs. 95.91 +/- 1.61, P<0.05) between the two groups had statistical significance, but did not cause pulmonary ventilation dysfunction. Conclusions. MSE has no significant effect on the respiratory health of acupuncturists.
C1 [Yu, Chang; Zhang, Ning; Zhang, Yueyue; Yang, Jiao; Tang, Yong; Wu, Qiaofeng; Yu, Shuguang] Chengdu Univ Tradit Chinese Med, Acupuncture & Moxibust Coll, Chengdu 610075, Sichuan, Peoples R China.
   [Zhu, Weikang; Wang, Yong] Chinese Acad Sci, Acad Math & Syst Sci, MDIS, CEMS,NCMIS, Beijing 100080, Peoples R China.
   [Song, Xiaoge; Hu, Ling; Wu, Zijian] Anhui Univ Tradit Chinese Med, Acupuncture & Moxibust Coll, Hefei 230000, Anhui, Peoples R China.
   [Liu, Qi] Shaanxi Univ Tradit Chinese Med, Acupuncture & Moxibust Coll, Xian 712046, Shaanxi, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Chinese Academy of
   Sciences; Anhui University of Chinese Medicine; Shaanxi University of
   Chinese Medicine
RP Wu, QF; Yu, SG (corresponding author), Chengdu Univ Tradit Chinese Med, Acupuncture & Moxibust Coll, Chengdu 610075, Sichuan, Peoples R China.
EM 20052023@cdutcm.edu.cn; ysg@cdutcm.edu.cn
RI WU, QIAOFENG/AAE-5945-2019; Yang, Jiao/JTV-6688-2023
OI Zhang, Ning/0000-0002-2452-9289; WU, Zijian/0000-0002-6291-5404
FU National Basic Research Program of China [2015CB554504]; National
   Natural Science Foundation of China [81873383, 81873386, 81330087,
   81704160]; fund of Science and Technology Department of Sichuan
   Province, China [18YYJC0095]; fund of Sichuan Provincial Department of
   Education, China [18TD0018]; fund of Science and Technology Innovation
   and Cultivation Project of Sichuan Province, China [2019042]
FX This work was supported by the National Basic Research Program of China
   (no. 2015CB554504), National Natural Science Foundation of China (nos.
   81873383, 81873386, 81330087, and 81704160), fund of Science and
   Technology Department of Sichuan Province, China (no. 18YYJC0095), fund
   of Sichuan Provincial Department of Education, China (no. 18TD0018), and
   fund of Science and Technology Innovation and Cultivation Project of
   Sichuan Province, China (no. 2019042).
CR Anastasi JK, 2009, GASTROENTEROL NURS, V32, P243, DOI 10.1097/SGA.0b013e3181b2c920
   [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792
   [Anonymous], 2014, WORLD CHINESE MED
   [Anonymous], J CHENGDU U TRADIT C
   BECKETT WS, 1994, OCCUP ENVIRON MED, V51, P14, DOI 10.1136/oem.51.1.14
   Cardini F, 1998, JAMA-J AM MED ASSOC, V280, P1580, DOI 10.1001/jama.280.18.1580
   Choi TY, 2017, MATURITAS, V100, P33, DOI 10.1016/j.maturitas.2017.03.314
   Cui YX, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/510318
   Duan Wen-Xiu, 2018, Zhen Ci Yan Jiu, V43, P98, DOI 10.13702/j.1000-0607.170854
   Duan Wenxiu, 2016, Zhongguo Zhen Jiu, V36, P637, DOI 10.13703/j.0255-2930.2016.06.022
   Han Li, 2016, Zhongguo Zhen Jiu, V36, P499
   He R, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/9236742
   Huanfang X., 2013, EVID-BASED COMPL ALT, V2013, P6, DOI 10.1155/2013/178067
   Kwon OS, 2017, ACUPUNCT MED, V35, P93, DOI 10.1136/acupmed-2016-011105
   Lee MS, 2010, AM J CHINESE MED, V38, P829, DOI 10.1142/S0192415X10008275
   Li H., 2012, INVESTIGATION MED WO
   Lui KH, 2016, ENVIRON POLLUT, V213, P524, DOI 10.1016/j.envpol.2016.02.053
   Mao HJ, 2016, CANCER-AM CANCER SOC, V122, P3667, DOI 10.1002/cncr.30189
   Matsumoto T, 2016, EUR J INTEGR MED, V8, P414, DOI 10.1016/j.eujim.2016.03.005
   Peters J, 1996, INT J EPIDEMIOL, V25, P821, DOI 10.1093/ije/28.5.859
   Ping L., 2013, CHINESE ACUPUNCTURE, V33, P145
   Shu Q., 2016, AKUPUNKTUR AURIKULOM, V42, P11, DOI [10.1007/s15009-016-5429-1, DOI 10.1007/S15009-016-5429-1]
   Stein DJ, 2017, GASTROENTEROL CLIN N, V46, P875, DOI 10.1016/j.gtc.2017.08.015
   STEVENS RG, 1984, AM J EPIDEMIOL, V119, P624, DOI 10.1093/oxfordjournals.aje.a113779
   Sun YJ, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1179-9
   Vas J, 2013, ACUPUNCT MED, V31, P31, DOI 10.1136/acupmed-2012-010261
   Wang JY, 2015, ARCH ENVIRON OCCUP H, V70, P225, DOI 10.1080/19338244.2013.872077
   Wang XM, 2015, ACSR ADV COMPUT, V34, P1055
   Wang X, 2018, J TRADIT CHIN MED, V38, P132
   Wheeler J, 2009, ACUPUNCT MED, V27, P16, DOI 10.1136/aim.2009.000422
   Wu HG, 2013, WORLD CHIN MED, V8, P845
   Xu DM, 2018, MED SCI MONITOR, V24, P2937, DOI 10.12659/MSM.909725
   Xu Ji, 2014, Evid Based Complement Alternat Med, V2014, P783704, DOI 10.1155/2014/783704
   Yamaguchi Satoru, 2012, Rinsho Shinkeigaku, V52, P1287
   Yang MX, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170952
   Yu Chang, 2018, Zhen Ci Yan Jiu, V43, P103, DOI 10.13702/j.1000-0607.170840
   Zhao JM, 2014, WORLD J GASTROENTERO, V20, P13563, DOI 10.3748/wjg.v20.i37.13563
NR 37
TC 10
Z9 10
U1 0
U2 24
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD SEP 16
PY 2019
VL 2019
AR 4873235
DI 10.1155/2019/4873235
PG 10
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA JB3LS
UT WOS:000488459400001
PM 31636685
OA Green Submitted, hybrid
DA 2026-01-16
ER

PT J
AU Gregory, R
   Gilles, C
   Aude, A
   Laurie, L
   Leila, B
   Jean-Cyr, Y
   Jean-Christophe, M
AF Gregory, Reychler
   Gilles, Caty
   Aude, Arcq
   Laurie, Lebrun
   Leila, Belkhir
   Jean-Cyr, Yombi
   Jean-Christophe, Marot
TI Effects of massage therapy on anxiety, depression, hyperventilation and
   quality of life in HIV infected patients: A randomized controlled trial
SO COMPLEMENTARY THERAPIES IN MEDICINE
LA English
DT Article
DE Massage; Anxiety; Depression; HIV
ID ANTIRETROVIRAL THERAPY; CANCER-PATIENTS; HEALTH; ACUPUNCTURE;
   MANAGEMENT; DISORDERS; ADHERENCE; SYMPTOMS; SERVICES; SAMPLE
AB Introduction: HIV infection is often preceded or accompanied by psychiatric comorbidities. These disorders improve with complementary therapies. The aim of this study was to measure the effect of massage therapy on anxiety, depression, hyperventilation and quality of life in HIV infected patients.
   Method: Adult HIV-infected patients were randomized (n = 29) in massage therapy group (one hour a week during four weeks) and control group. Anxiety and depression (HADS-A and HADS-D), hyperventilation (Nijmegen questionnaire) and quality of life (WHOQOL-HIV) were evaluated at inclusion and after 4 weeks.
   Results: At inclusion, 51% and 17% of the patients had a positive HADS-A and HADS-D score respectively. Two facets from WHOQOL-HIV ("Home environment" and "Death and dying" (p = 0.04)) were different between groups. After the four week massage therapy, a significant improvement was observed only for Nijmegen questionnaire (p = 0.01) and HADS-A (p = 0.04) contrarily to WHOQOL-HIV and HADS-D. Domains of the WHOQOL-HIV did not improve following the massage therapy. Only "Pain and discomfort" facet improved after massage therapy (p = 0.04).
   Conclusion: This study highlights the positive impact of a four week massage therapy on anxiety and hyperventilation in HIV infected patients. However, neither benefit of this program was observed on depression and quality of life.
C1 [Gregory, Reychler] Catholic Univ Louvain, Pole Pneumol ORL &Dermatol, IREC, Brussels, Belgium.
   [Gregory, Reychler; Gilles, Caty] Clin Univ St Luc, Serv Med Phys & Readaptat, Brussels, Belgium.
   [Gregory, Reychler; Aude, Arcq; Laurie, Lebrun] Clin Univ St Luc, Serv Pneumol, Brussels, Belgium.
   [Leila, Belkhir; Jean-Cyr, Yombi] Clin Univ St Luc, Serv Med Interne, AIDS Reference Ctr, Brussels, Belgium.
   [Jean-Christophe, Marot] Clin St Pierre, Serv Infectiol, Ottignies, Belgium.
C3 Universite Catholique Louvain; Universite Catholique Louvain; Cliniques
   Universitaires Saint-Luc; Universite Catholique Louvain; Cliniques
   Universitaires Saint-Luc; Universite Catholique Louvain; Cliniques
   Universitaires Saint-Luc
RP Gregory, R (corresponding author), Clin Univ St Luc UCL, Serv Pneumol, Ave Hippocrate 10, B-1200 Brussels, Belgium.
EM Gregory.reychler@uclouvain.be; gilles.caty@uclouvain.be;
   aude.arcq@student.uclouvain.be; laurie.lebrun@student.uclouvain.be;
   leila.belkhir@uclouvain.be; jean.yombi@uclouvain.be;
   Jean-Christophe.MAROT@cspo.be
OI Reychler, Gregory/0000-0002-7674-1150; Belkhir,
   Leila/0000-0002-1701-7584
CR Andrinopoulos K, 2011, AIDS EDUC PREV, V23, P367, DOI 10.1521/aeap.2011.23.4.367
   Babaee Sima, 2012, Iran J Nurs Midwifery Res, V17, pS120
   Bauer Brent A, 2010, Complement Ther Clin Pract, V16, P70, DOI 10.1016/j.ctcp.2009.06.012
   Blom EH, 2014, PSYCHOPHYSIOLOGY, V51, P412, DOI 10.1111/psyp.12188
   Campsmith Michael L, 2003, Health Qual Life Outcomes, V1, P12, DOI 10.1186/1477-7525-1-12
   Canavarro MC, 2011, AIDS CARE, V23, P187, DOI 10.1080/09540121.2010.498870
   Chauhan V S, 2013, Ind Psychiatry J, V22, P125, DOI 10.4103/0972-6748.132925
   Chin JJ, 2009, AIDS CARE, V21, P1289, DOI 10.1080/09540120902732019
   Ciesla JA, 2001, AM J PSYCHIAT, V158, P725, DOI 10.1176/appi.ajp.158.5.725
   Crane JD, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002882
   Crawford JR, 2003, BRIT J CLIN PSYCHOL, V42, P111, DOI 10.1348/014466503321903544
   DeLorenze GN, 2010, AIDS PATIENT CARE ST, V24, P705, DOI 10.1089/apc.2010.0139
   Diego MA, 2001, INT J NEUROSCI, V106, P35, DOI 10.3109/00207450109149736
   Falkensteiner Maria, 2011, ISRN Nurs, V2011, P929868, DOI 10.5402/2011/929868
   Ford N, 2015, LANCET HIV, V2, pE438, DOI 10.1016/S2352-3018(15)00137-X
   Gibson D, 2007, J ALTERN COMPLEM MED, V13, P39, DOI 10.1089/acm.2006.5283
   Hays RD, 2000, AM J MED, V108, P714, DOI 10.1016/S0002-9343(00)00387-9
   Hernandez-Reif M, 2008, EVID-BASED COMPL ALT, V5, P345, DOI 10.1093/ecam/nem032
   Hillier SL, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007502.pub2
   Hinz A, 2010, EUR J CANCER CARE, V19, P522, DOI 10.1111/j.1365-2354.2009.01088.x
   Hou WH, 2010, J CLIN PSYCHIAT, V71, P894, DOI 10.4088/JCP.09r05009blu
   Hsiung PC, 2005, QUAL LIFE RES, V14, P141, DOI 10.1007/s11136-004-6252-z
   Institut scientifique de Sante publique, 2014, EPIDEMIOLOGIE SID IN
   Jörngården A, 2007, EUR J CANCER, V43, P1952, DOI 10.1016/j.ejca.2007.05.031
   Kagee A, 2010, AIDS CARE, V22, P159, DOI 10.1080/09540120903111445
   Kemppainen JK, 2006, AIDS CARE, V18, P597, DOI 10.1080/09540120500275726
   Li YG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111707
   Liu CL, 2006, QUAL LIFE RES, V15, P941, DOI 10.1007/s11136-005-5913-x
   Liu SL, 2015, EUR REV MED PHARMACO, V19, P3843
   Mills E, 2005, INT J STD AIDS, V16, P395, DOI 10.1258/0956462054093962
   Moir S, 2010, BLOOD, V116, P5571, DOI 10.1182/blood-2010-05-285528
   Morrison MF, 2002, AM J PSYCHIAT, V159, P789, DOI 10.1176/appi.ajp.159.5.789
   Mrus JM, 2006, QUAL LIFE RES, V15, P503, DOI 10.1007/s11136-005-1946-4
   Naoroibam Rosy, 2016, Int J Yoga, V9, P57, DOI [10.4103/0973-6131.171723, 10.4103/0973-6131.171723]
   Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004
   Paxton RJ, 2007, J SCHOOL HEALTH, V77, P180, DOI 10.1111/j.1746-1561.2007.00189.x
   Poland RE, 2013, J ALTERN COMPLEM MED, V19, P334, DOI 10.1089/acm.2012.0058
   Puhan MA, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-46
   Razavi P, 2012, AIDS RES TREAT, V2012, DOI 10.1155/2012/849406
   Reda AA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016049
   Reychler G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073180
   Robertson K, 2014, AIDS CARE, V26, P1555, DOI 10.1080/09540121.2014.936813
   Roux P, 2009, J CLIN PSYCHIAT, V70, P1328, DOI 10.4088/JCP.08l04885
   Shacham Enbal, 2016, J Int Assoc Provid AIDS Care, V15, P126, DOI 10.1177/2325957414553846
   Sherbourne CD, 2000, AM J PSYCHIAT, V157, P248, DOI 10.1176/appi.ajp.157.2.248
   Sin NL, 2014, ANN BEHAV MED, V47, P259, DOI 10.1007/s12160-013-9559-6
   Slot M, 2015, HIV MED, V16, P393, DOI 10.1111/hiv.12223
   Tao WW, 2016, J PAIN SYMPTOM MANAG, V51, P728, DOI 10.1016/j.jpainsymman.2015.11.027
   Thomas Mike, 2005, Prim Care Respir J, V14, P78, DOI 10.1016/j.pcrj.2004.10.007
   UNAIDS, 2015, AIDS CHANG EV UNAIDS
   VANDIXHOORN J, 1985, J PSYCHOSOM RES, V29, P199, DOI 10.1016/0022-3999(85)90042-X
   VANSTEENKISTE J, 1991, EUR RESPIR J, V4, P393
   Wong V T C, 2013, East Asian Arch Psychiatry, V23, P6
   Wouters E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034881
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 55
TC 6
Z9 14
U1 0
U2 10
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0965-2299
EI 1873-6963
J9 COMPLEMENT THER MED
JI Complement. Ther. Med.
PD JUN
PY 2017
VL 32
BP 109
EP 114
DI 10.1016/j.ctim.2017.05.002
PG 6
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Integrative & Complementary Medicine
GA EZ4RQ
UT WOS:000404700600017
PM 28619295
DA 2026-01-16
ER

PT J
AU Zhang, X
   Wang, A
   Wang, MW
   Li, G
   Wei, Q
AF Zhang, Xia
   Wang, Ao
   Wang, Miaowei
   Li, Guo
   Wei, Quan
TI Non-pharmacological therapy for chemotherapy-induced peripheral
   neurotoxicity: a network meta-analysis of randomized controlled trials
SO BMC NEUROLOGY
LA English
DT Article
DE Chemotherapy; Adjuvant; Peripheral nervous system diseases; Randomized
   controlled trial
ID COLORECTAL-CANCER; NEUROPATHY; PREVENTION; MASSAGE
AB BackgroundChemotherapy-induced peripheral neurotoxicity (CIPN) is the most common adverse effect in patients undergoing chemotherapy, and no effective interventions are currently available for its prevention and treatment. Non-pharmacological therapies appear to be beneficial for the prevention and treatment of CIPN, but it remains unclear which therapy is most effective. The aim of this study was to identify the most effective non-pharmacological therapy for CIPN patients.MethodsPubMed, Web of Science, Embase, and Cochrane Library were searched for randomized controlled trials on non-pharmacological therapies for CIPN. The primary outcomes included pain and peripheral neuropathological symptoms, and the secondary outcomes included quality of life, sensory and motor symptoms. The pairwise analysis and a network meta-analysis were performed using a random effects model.ResultsA total of 46 articles were included in this study, involving 2,878 participants. Our study showed that massage was more effective in pain-alleviating compared with acupuncture [SMD = 0.81, 95%CI (0.04, 1.57)], vitamin and gabapentin [SMD = 2.56, 95%CI (1.39, 3.74)], and usual care and placebo [SMD = 0.9, 95%CI (0.31, 1.49)]. As for attenuating peripheral neuropathological symptoms, massage was more effective than usual care and placebo [SMD = 0.75, 95%CI (0.33, 1.17)], sensorimotor training [SMD = 1.17, 95%CI (0.24, 2.10)], electrostimulation [SMD=-1.18, 95%CI (-2.14, -0.21)], multimodal exercise [SMD=-0.82, 95%CI (-1.57, -0.08)], and resistance training [SMD = 1.03, 95%CI (0.11, 1.95)]. Massage was also more effective than other non-pharmacological therapies in improving quality of life, sensory and motor symptoms.ConclusionsAccording to our study, massage has advantages in alleviating pain, improving quality of life, and improving peripheral neuropathological symptoms and has better effect than other non-pharmacological interventions, representing certain clinical significance. However, the results of this study should be interpreted with caution due to the limitations of the included studies. In the future, more high-quality multi arm randomized controlled trials can be attempted to provide direct comparisons of the relative effects of non-pharmacological interventions.
C1 [Zhang, Xia; Wang, Ao; Wang, Miaowei; Li, Guo; Wei, Quan] Sichuan Univ, West China Hosp, Inst Rehabil Med, Rehabil Med Ctr, Chengdu, Sichuan, Peoples R China.
   [Zhang, Xia; Wang, Ao; Wang, Miaowei; Li, Guo; Wei, Quan] Key Lab Rehabil Med Sichuan Prov, Chengdu, Sichuan, Peoples R China.
C3 Sichuan University
RP Wei, Q (corresponding author), Sichuan Univ, West China Hosp, Inst Rehabil Med, Rehabil Med Ctr, Chengdu, Sichuan, Peoples R China.; Wei, Q (corresponding author), Key Lab Rehabil Med Sichuan Prov, Chengdu, Sichuan, Peoples R China.
EM weiquan@scu.edu.cn
RI Wang, Miaowei/NLO-5199-2025; Wei, Quan/AAV-4474-2021; Xia,
   Zhang/KCJ-5316-2024
CR Al Onazi MM, 2021, J PAIN SYMPTOM MANAG, V61, P1127, DOI 10.1016/j.jpainsymman.2020.10.028
   Bao T, 2021, ONCOLOGIST, V26, pE2070, DOI 10.1002/onco.13933
   Bao T, 2020, JNCI CANCER SPECT, V4, DOI 10.1093/jncics/pkaa048
   Bao T, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.0681
   Bland KA, 2019, CLIN BREAST CANCER, V19, P411, DOI 10.1016/j.clbc.2019.05.013
   Cao A, 2023, JAMA NETW OPEN, V6, DOI 10.1001/jamanetworkopen.2023.26463
   Chan KY, 2023, ACUPUNCT MED, V41, P268, DOI 10.1177/09645284221125421
   Chien TJ, 2019, INTEGR CANCER THER, V18, DOI 10.1177/1534735419886662
   Chitkumarn P, 2022, SUPPORT CARE CANCER, V30, P4835, DOI 10.1007/s00520-022-06890-1
   Cornell JE, 2015, ANN INTERN MED, V162, P797, DOI 10.7326/M15-0930
   Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142
   Cunningham JE, 2011, SUPPORT CARE CANCER, V19, P1473, DOI 10.1007/s00520-011-1231-8
   D'Alessandro EG, 2022, BMJ SUPPORT PALLIAT, V12, P64, DOI 10.1136/bmjspcare-2018-001542
   Dalal K, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/843036
   Flatters SJL, 2017, BRIT J ANAESTH, V119, P737, DOI 10.1093/bja/aex229
   Friedemann T, 2022, PHYTOMEDICINE, V104, DOI 10.1016/j.phymed.2022.154294
   GHOLAMZADEH H, 2023, TURKISH J Oncol, V38
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Hammond EA, 2020, NEUROREHAB NEURAL RE, V34, P235, DOI 10.1177/1545968319899918
   Huang CC, 2021, J Clin Med, V10
   Huang MC, 2023, ONCOLOGIST, V28, pE436, DOI 10.1093/oncolo/oyad065
   Ikio Y, 2022, SUPPORT CARE CANCER, V30, P4981, DOI 10.1007/s00520-022-06846-5
   Iravani S, 2020, PAIN RES MANAG, V2020, DOI 10.1155/2020/2504674
   Izgu N, 2019, EUR J ONCOL NURS, V40, P36, DOI 10.1016/j.ejon.2019.03.002
   Izgu N, 2019, CANCER NURS, V42, P139, DOI 10.1097/NCC.0000000000000577
   Joy L, 2022, SUPPORT CARE CANCER, V30, P5509, DOI 10.1007/s00520-022-06975-x
   Jung MS, 2023, Cancer nursing
   Kanda K, 2023, ASIA-PAC J ONCOL NUR, V10, DOI 10.1016/j.apjon.2023.100198
   Kanzawa-Lee GA, 2022, CANCER NURS, V45, pE531, DOI 10.1097/NCC.0000000000001003
   Kim SY, 2021, ASIAN ONCOL NURS, V21, P129, DOI 10.5388/aon.2021.21.3.129
   Kneis S, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5522-7
   Knoerl R, 2022, J CANCER SURVIV, V16, P882, DOI 10.1007/s11764-021-01081-z
   Knoerl R, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-5093-z
   Knoerl R, 2018, J PAIN, V19, P382, DOI 10.1016/j.jpain.2017.11.009
   Kurt S, 2018, EUR J ONCOL NURS, V32, P12, DOI 10.1016/j.ejon.2017.11.001
   Lai XB, 2019, CANCER NURS, V42, P20, DOI 10.1097/NCC.0000000000000539
   Loprinzi CL, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01399
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Molassiotis A, 2019, INTEGR CANCER THER, V18, DOI 10.1177/1534735419836501
   Moyer CA, 2004, PSYCHOL BULL, V130, P3, DOI 10.1037/0033-2909.130.1.3
   Müller J, 2021, BRIT J CANCER, V125, P955, DOI 10.1038/s41416-021-01471-1
   Noh GO, 2019, EUR J ONCOL NURS, V42, P82, DOI 10.1016/j.ejon.2019.08.007
   Oh PJ, 2018, J KOREAN ACAD NURS, V48, P123, DOI 10.4040/jkan.2018.48.2.123
   Park SB, 2013, CA-CANCER J CLIN, V63, P419, DOI 10.3322/caac.21204
   Prinsloo S, 2018, J PAIN SYMPTOM MANAG, V55, P1276, DOI 10.1016/j.jpainsymman.2018.01.010
   Rahmati M, 2023, J MED VIROL, V95, DOI 10.1002/jmv.28325
   Rahmati M, 2023, J MED VIROL, V95, DOI 10.1002/jmv.28298
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/349653
   Saraboon C, 2021, J BODYW MOV THER, V28, P164, DOI 10.1016/j.jbmt.2021.07.013
   Schönsteiner SS, 2017, EXP HEMATOL ONCOL, V5, DOI 10.1186/s40164-017-0065-6
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Shigematsu H, 2020, SUPPORT CARE CANCER, V28, P5005, DOI 10.1007/s00520-020-05345-9
   Smith TJ, 2020, J PALLIAT CARE, V35, P53, DOI 10.1177/0825859719827589
   Song SY, 2020, INTEGR CANCER THER, V19, DOI 10.1177/1534735420925519
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Streckmann F, 2022, SPORTS MED, V52, P1043, DOI 10.1007/s40279-021-01596-6
   Streckmann F, 2019, SUPPORT CARE CANCER, V27, P2471, DOI 10.1007/s00520-018-4531-4
   Stringer J, 2022, EUR J ONCOL NURS, V60, DOI 10.1016/j.ejon.2022.102171
   Teng C, 2023, SUPPORT CARE CANCER, V31, DOI 10.1007/s00520-022-07463-y
   Waibel S, 2021, ANN CLIN TRANSL NEUR, V8, P1680, DOI 10.1002/acn3.51426
   Zajaczkowska R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061451
   Zimmer P, 2018, SUPPORT CARE CANCER, V26, P615, DOI 10.1007/s00520-017-3875-5
NR 62
TC 8
Z9 8
U1 2
U2 22
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2377
J9 BMC NEUROL
JI BMC Neurol.
PD DEC 11
PY 2023
VL 23
IS 1
AR 433
DI 10.1186/s12883-023-03485-z
PG 14
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA CF1W0
UT WOS:001123754100006
PM 38082216
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Tender, T
   Rahangdale, RR
   Balireddy, S
   Nampoothiri, M
   Sharma, KK
   Chandrashekar, HR
AF Tender, Tenzin
   Rahangdale, Rakesh Ravishankar
   Balireddy, Sridevi
   Nampoothiri, Madhavan
   Sharma, K. Krishna
   Raghu Chandrashekar, Hariharapura
TI Melittin, a honeybee venom derived peptide for the treatment of
   chemotherapy-induced peripheral neuropathy
SO MEDICAL ONCOLOGY
LA English
DT Review
DE Chemotherapy; Peripheral neuropathy; Melittin; Haemolysis;
   alpha-Crystallin
ID QUALITY-OF-LIFE; ACUPOINT STIMULATION; ARAB BREAST; PAIN; PREVALENCE;
   CANCER; ACUPUNCTURE; THALIDOMIDE; ACTIVATION; PACLITAXEL
AB Chemotherapy-induced peripheral neuropathy (CIPN) is the most prevalent neurological complication of cancer treatment which involves sensory and motor nerve dysfunction. Severe CIPN has been reported in around 5% of patients treated with single and up to 38% of patients treated with multiple chemotherapeutic agents. Present medications available for CIPN are the use of opioids, nonsteroidal anti-inflammatory agents, and tricyclic antidepressants, which are only marginally effective in treating neuropathic symptoms. In reality, symptom reappears after these drugs are discontinued. The pathogenesis of CIPN has not been sufficiently recognized and methods for the prevention and treatment of CIPN remain vulnerable to therapeutic problems. It has witnessed that the present medicines available for the disease offer only symptomatic relief for the short term and have severe adverse side effects. There is no standard treatment protocol for preventing, reducing, and treating CIPN. Therefore, there is a need to develop curative therapy that can be used to treat this complication. Melittin is the main pharmacological active constituent of honeybee venom and has therapeutic values including in chemotherapeutic-induced peripheral neuropathy. It has been shown that melittin and whole honey bee venom are effective in treating paclitaxel and oxaliplatin-induced peripheral neuropathy. The use of melittin against peripheral neuropathy caused by chemotherapy has been limited despite having strong therapeutic efficacy against the disease. Melittin mediated haemolysis is the key reason to restrict its use. In our study, it is found that alpha-Crystallin (an eye lens protein) is capable of inhibiting melittin-induced haemolysis which gives hope of using an appropriate combination of melittin and alpha-Crystallin in the treatment of CIPN. The review summarizes the efforts made by different research groups to address the concern with melittin in the treatment of chemotherapeutic-induced neuropathy. It also focuses on the possible approaches to overcome melittin-induced haemolysis. Graphic
C1 [Tender, Tenzin; Rahangdale, Rakesh Ravishankar; Balireddy, Sridevi; Raghu Chandrashekar, Hariharapura] Manipal Acad Higher Educ, Dept Pharmaceut Biotechnol, Manipal Coll Pharmaceut Sci, Manipal 576104, Karnataka, India.
   [Nampoothiri, Madhavan] Manipal Acad Higher Educ, Dept Pharmacol, Manipal Coll Pharmaceut Sci, Manipal 576104, Karnataka, India.
   [Sharma, K. Krishna] Univ Missouri, Dept Ophthalmol & Biochem, Columbia Sch Med, Columbia, MO 65211 USA.
C3 Manipal Academy of Higher Education (MAHE); Manipal Academy of Higher
   Education (MAHE); University of Missouri System; University of Missouri
   Columbia
RP Chandrashekar, HR (corresponding author), Manipal Acad Higher Educ, Dept Pharmaceut Biotechnol, Manipal Coll Pharmaceut Sci, Manipal 576104, Karnataka, India.
EM raghu.c@manipal.edu
RI ; Tender, Tenzin/OAL-0418-2025; Hariharapura, Raghu
   Chanashekhar/AGG-9879-2022
OI Rahangdale, Rakesh/0000-0003-2105-7551; Tender,
   Tenzin/0000-0003-0639-9537; Hariharapura, Raghu
   Chanashekhar/0000-0002-6538-7758
FU Manipal Academy of Higher Education, Manipal
FX Open access funding provided by Manipal Academy of Higher Education,
   Manipal. This work did not receive any specific grant.
CR Alhuqail A, 2018, BREAST CANCER RES TR, V168, P695, DOI 10.1007/s10549-017-4635-4
   Augusteyn Robert C, 2004, Clin Exp Optom, V87, P356
   Banach M, 2017, BRAIN BEHAV, V7, DOI 10.1002/brb3.558
   Barton DL, 2011, SUPPORT CARE CANCER, V19, P833, DOI 10.1007/s00520-010-0911-0
   Bhat SP, 2003, PROG DRUG RES, V60, P205
   Cheng B, 2015, J MATER CHEM B, V3, P25, DOI [10.1039/c4tb01401d, 10.1039/C4TB01401D]
   Choi J, 2017, TOXINS, V9, DOI 10.3390/toxins9110351
   Choi S, 2019, TOXINS, V11, DOI 10.3390/toxins11070396
   Cioroiu C, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0757-7
   Fallon MT, 2013, BRIT J ANAESTH, V111, P105, DOI 10.1093/bja/aet208
   Fernyhough P, 2005, J NEUROSCI, V25, P1682, DOI 10.1523/JNEUROSCI.3127-04.2005
   Ghafoor M, 2003, Med J Malaysia, V58, P712
   Gornstein EL, 2017, EXP NEUROL, V288, P153, DOI 10.1016/j.expneurol.2016.11.015
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Hilal L, 2015, CLIN GENITOURIN CANC, V13, P505, DOI 10.1016/j.clgc.2015.05.010
   HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449
   Jester JV, 2008, SEMIN CELL DEV BIOL, V19, P82, DOI 10.1016/j.semcdb.2007.09.015
   Jones D, 2015, J CANCER SURVIV, V9, P1, DOI 10.1007/s11764-014-0379-x
   Jones MR, 2020, CURR CLIN PHARMACOL, V15, P38, DOI 10.2174/1574884714666190121154813
   JONES SL, 1991, PROG BRAIN RES, V88, P381
   Karakas B, 2013, CANCER BIOL THER, V14, P888, DOI 10.4161/cbt.25945
   Kim HW, 2003, J VET MED SCI, V65, P349, DOI 10.1292/jvms.65.349
   Kim W, 2016, TOXINS, V8, DOI 10.3390/toxins8020033
   KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652
   Kwon YB, 2001, NEUROSCI LETT, V308, P133, DOI 10.1016/S0304-3940(01)01989-9
   Kwon YB, 2006, NEUROSCI RES, V55, P197, DOI 10.1016/j.neures.2006.03.003
   Lee JE, 2019, J PHARMACOL SCI, V140, P26, DOI 10.1016/j.jphs.2019.03.009
   Lee JS, 2006, J PHARMACOPUNCT, V9, P61
   Lopus M, 2015, CANCER CHEMOTH PHARM, V76, P1013, DOI 10.1007/s00280-015-2863-z
   Ma JC, 2018, CANCER-AM CANCER SOC, V124, P2289, DOI 10.1002/cncr.31248
   McKeage MJ, 2001, BRIT J CANCER, V85, P1219, DOI 10.1054/bjoc.2001.2024
   Mohty B, 2010, HAEMATOL-HEMATOL J, V95, P311, DOI 10.3324/haematol.2009.012674
   Pan H, 2011, WIRES NANOMED NANOBI, V3, P318, DOI 10.1002/wnan.126
   Park JW, 2012, INTEGR CANCER THER, V11, P166, DOI 10.1177/1534735411413265
   Peiren N, 2005, BBA-PROTEINS PROTEOM, V1752, P1, DOI 10.1016/j.bbapap.2005.07.017
   Richardson P, 2002, BIOMED PHARMACOTHER, V56, P115, DOI 10.1016/S0753-3322(02)00168-3
   Roh DH, 2004, J PAIN, V5, P297, DOI 10.1016/j.jpain.2004.05.003
   Rok KK, 2006, J PHARMACOPUNCT, V9, P79
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Sharma KK, 2000, J BIOL CHEM, V275, P3767, DOI 10.1074/jbc.275.6.3767
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Soman NR, 2009, J CLIN INVEST, V119, P2830, DOI 10.1172/JCI38842
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   THOMSON JA, 1985, EXP EYE RES, V40, P393, DOI 10.1016/0014-4835(85)90152-6
   WALL PD, 1974, EXP NEUROL, V43, P580, DOI 10.1016/0014-4886(74)90197-6
   Wani TH, 2017, CHEM RES TOXICOL, V30, P1622, DOI 10.1021/acs.chemrestox.7b00127
   Winters-Stone KM, 2017, J CLIN ONCOL, V35, P2604, DOI 10.1200/JCO.2016.71.3552
   Wolf S, 2008, EUR J CANCER, V44, P1507, DOI 10.1016/j.ejca.2008.04.018
   Xiao WH, 2012, NEUROSCIENCE, V203, P194, DOI 10.1016/j.neuroscience.2011.12.023
   Yang EJ, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-69
   Yoon SY, 2009, J PAIN, V10, P253, DOI 10.1016/j.jpain.2008.09.002
   Zajaczkowska R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061451
NR 52
TC 22
Z9 22
U1 2
U2 23
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1357-0560
EI 1559-131X
J9 MED ONCOL
JI Med. Oncol.
PD MAY
PY 2021
VL 38
IS 5
AR 52
DI 10.1007/s12032-021-01496-9
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA RH0WW
UT WOS:000635949500001
PM 33796975
OA Green Submitted, hybrid
DA 2026-01-16
ER

PT J
AU Gjeorgjievski, M
   Manickam, P
   Ghaith, G
   Cappell, MS
AF Gjeorgjievski, Mihajlo
   Manickam, Palaniappan
   Ghaith, Gehad
   Cappell, Mitchell S.
TI Safety and Efficacy of Endoscopic Therapy for Nonmalignant Duodenal
   Duplication Cysts Case Report and Comprehensive Review of 28 Cases
   Reported in the Literature
SO MEDICINE
LA English
DT Review
ID ACUTE RECURRENT PANCREATITIS; GASTROINTESTINAL-TRACT; MANAGEMENT;
   DIAGNOSIS; RESECTION; RARE; EUS; COMPLICATIONS; ULTRASOUND; FREQUENCY
AB Analyze efficacy, safety of endoscopic therapy for duodenal duplication cysts (DDC) by comprehensively reviewing case reports.
   Tandem, independent, systematic, computerized, literature searches were performed via PubMed using medical subject headings or Keywords "cyst" and "duodenal" and "duplication"; or "cyst", and "endoscopy" or "endoscopic", and "therapy" or "decompression"; with reconciliation of generated references by two experts. Case report followed CARE guidelines.
   Literature review revealed 28 cases (mean = 1.3 +/- 1.2 cases/report). Endoscopic therapy is increasingly reported recently (1984-1999: 3 cases, 2000-2015: 25 cases, P = 0.003, OR = 8.33, 95%-CI: 1.77-44.5). Fourteen (54%) of 26 patients were men (unknown-sex = 2). Mean age = 32.2 +/- 18.3 years old. Procedure indications: acute pancreatitis-16, abdominal pain-8, jaundice-2, gastrointestinal (GI) obstruction-1, asymptomatic cyst-1. Mean maximal DDC dimension = 3.20 +/- 1.53 cm (range, 1-6.5 cm). Endoscopic techniques included cyst puncture via needle knife papillotomy (NKP)/papillotome-18, snare resection of cyst-7, cystotome-2, and cyst needle aspiration/ligation-1. Endoscopic therapy was successful in all cases. Among 24 initially symptomatic patients, all remained asymptomatic post-therapy without relapses (mean follow-up = 36.5 +/- 48.6 months, 3 others reported asymptomatic at follow-up of unknown duration; 1 initially asymptomatic patient remained asymptomatic 3 years post-therapy). Two complications occurred: mild intraprocedural duodenal bleeding related to NKP and treated locally endoscopically.
   A patient is reported who presented with vomiting, 15-kg-weight-loss, and profound dehydration for 1 month from extrinsic compression of duodenum by 14 x 6 cm DDC, underwent successful endosonographic cyst decompression with large fenestration of cyst and endoscopic aspiration of 1 L of fluid from cyst with rapid relief of symptoms. At endoscopy the DDC was intubated and visualized and random endoscopic mucosal biopsies were obtained to help exclude malignant or dysplastic DDC.
   Study limitations include retrospective literature review, potential reporting bias, limited patient number, variable follow-up.
   In conclusion, endoscopic therapy for DDC was efficacious in all 29 reported patients including current case, including patients presenting acutely with acute pancreatitis, or GI obstruction. Complications were rare and minor, suggesting that endoscopic therapy may be a useful alternative to surgery for nonmalignant DDC when performed by expert endoscopists.
C1 [Gjeorgjievski, Mihajlo; Manickam, Palaniappan; Ghaith, Gehad; Cappell, Mitchell S.] William Beaumont Hosp, Div Gastroenterol & Hepatol, MOB 602,3535 West Thirteen Mile Rd, Royal Oak, MI 48073 USA.
   [Ghaith, Gehad; Cappell, Mitchell S.] Oakland Univ, William Beaumont Sch Med, Royal Oak, MI USA.
C3 Beaumont Health; Corewell Health William Beaumont University Hospital;
   Oakland University
RP Cappell, MS (corresponding author), William Beaumont Hosp, Div Gastroenterol & Hepatol, MOB 602,3535 West Thirteen Mile Rd, Royal Oak, MI 48073 USA.
EM mscappell@yahoo.com
CR Al-Harake A, 2013, INT J SURG CASE REP, V4, P296, DOI 10.1016/j.ijscr.2013.01.004
   ALTRAIF I, 1992, GASTROINTEST ENDOSC, V38, P64
   Annigeri Venkatesh M, 2012, J Indian Assoc Pediatr Surg, V17, P80, DOI 10.4103/0971-9261.93973
   Antaki F, 2008, GASTROINTEST ENDOSC, V67, P163, DOI 10.1016/j.gie.2007.08.006
   Antaki N, 2013, CLIN RES HEPATOL GAS, V37, DOI 10.1016/j.clinre.2012.05.001
   Arantes V, 2012, ENDOSCOPY, V44, pE117, DOI 10.1055/s-0031-1291674
   Arbell Dan, 2002, J Pediatr Surg, V37, pE8, DOI 10.1053/jpsu.2002.32294
   Bhutani MS, 1996, ENDOSCOPY, V28, P396, DOI 10.1055/s-2007-1005489
   Carbognin G, 2000, EUR RADIOL, V10, P1277, DOI 10.1007/s003309900286
   Chen JJ, 2010, J PEDIATR SURG, V45, P1598, DOI 10.1016/j.jpedsurg.2010.01.010
   Chong VY, 2014, ANZ J SURG
   Chryssostalis Ariane, 2007, Clin Gastroenterol Hepatol, V5, pe31, DOI 10.1016/j.cgh.2007.05.028
   Coumaros D, 2010, GASTROINTEST ENDOSC, V71, P827, DOI 10.1016/j.gie.2009.12.011
   Criblez D, 2011, GASTROENTEROLOGY, V140, P783, DOI 10.1053/j.gastro.2010.02.063
   DAVE P, 1984, ENDOSCOPY, V16, P75, DOI 10.1055/s-2007-1018537
   Deesomsak M, 2013, WORLD J GASTROENTERO, V19, P8445, DOI 10.3748/wjg.v19.i45.8445
   Destruys L, 2014, ARCH PEDIATRIE, V21, P532, DOI 10.1016/j.arcped.2014.02.009
   Eloubeidi MA, 2006, GASTROINTEST ENDOSC, V63, P622, DOI 10.1016/j.gie.2005.05.024
   Eom Jung Seop, 2011, Korean J Gastroenterol, V58, P346
   Faigel DO, 1997, GASTROINTEST ENDOSC, V45, P99, DOI 10.1016/S0016-5107(97)70315-8
   FALK GL, 1991, AUST NZ J SURG, V61, P551, DOI 10.1111/j.1445-2197.1991.tb00289.x
   GELLER A, 1995, GASTROENTEROLOGY, V109, P838, DOI 10.1016/0016-5085(95)90392-5
   GROSS RE, 1952, PEDIATRICS, V9, P449
   Guarise A, 2006, WORLD J GASTROENTERO, V12, P1630, DOI 10.3748/wjg.v12.i10.1630
   Gyökeres T, 2008, GASTROINTEST ENDOSC, V68, P1244, DOI 10.1016/j.gie.2008.04.019
   Gyökeres T, 2002, ENDOSCOPY, V34, P503, DOI 10.1055/s-2002-31990
   Hata H, 2006, PATHOL INT, V56, P272, DOI 10.1111/j.1440-1827.2006.01957.x
   INOUE M, 1979, Gastroenterologia Japonica, V14, P233
   Ivekovic H, 2012, Endoscopy, V44 Suppl 2 UCTN, pE404, DOI 10.1055/s-0032-1310144
   Janssen J, 2004, GASTROINTEST ENDOSC, V59, P339, DOI 10.1016/S0016-5107(03)02707-X
   Jo YC, 2004, J KOREAN MED SCI, V19, P604, DOI 10.3346/jkms.2004.19.4.604
   JOHANSON JF, 1992, GASTROINTEST ENDOSC, V38, P60, DOI 10.1016/S0016-5107(92)70335-6
   Johnson EA, 2015, GASTROINTEST ENDOSC, V82, P172, DOI 10.1016/j.gie.2015.02.001
   Joyce AM, 2006, GASTROINTEST ENDOSC, V64, P288, DOI 10.1016/j.gie.2006.04.046
   Jung MK, 2009, GUT LIVER, V3, P356, DOI 10.5009/gnl.2009.3.4.356
   Khanna PC, 2004, PRENATAL DIAG, V24, P312, DOI 10.1002/pd.864
   Klair JS, 2015, CLIN GASTROENTEROL H, V13, pE161, DOI 10.1016/j.cgh.2015.04.017
   Ko SY, 2013, WORLD J GASTROENTERO, V19, P6490, DOI 10.3748/wjg.v19.i38.6490
   Kobara H, 2016, DIGEST ENDOSC, V28, P223, DOI 10.1111/den.12595
   Kochhar R, 2006, ENDOSCOPY, V38, P424, DOI 10.1055/s-2006-925023
   Kumar A, 2015, INT J SURG CASE REP, V9, P123, DOI 10.1016/j.ijscr.2015.02.045
   Kurien RT, 2014, ENDOSCOPY, V46, pE583, DOI 10.1055/s-0034-1377551
   Lad RJ, 2000, CAN J GASTROENTEROL, V14, P341, DOI 10.1155/2000/152809
   Lam WWM, 2002, PEDIATR RADIOL, V32, P126, DOI 10.1007/s00247-001-0616-0
   Laskowska K, 2014, POL J RADIOL, V79, P243, DOI 10.12659/PJR.890443
   Lee NK, 2010, RADIOGRAPHICS, V30, P1489, DOI 10.1148/rg.306105504
   Lee YC, 2011, GASTROINTEST ENDOSC, V73, P1039, DOI 10.1016/j.gie.2010.11.038
   Liu R, 2014, ENDOSC ULTRASOUND, V3, P152, DOI 10.4103/2303-9027.138783
   García FMA, 2014, GASTROENT HEPAT-BARC, V37, P274, DOI 10.1016/j.gastrohep.2013.11.003
   Meier AH, 2012, J PEDIATR SURG, V47, pE33, DOI 10.1016/j.jpedsurg.2012.07.035
   Merrot T, 2006, EUR J PEDIATR SURG, V16, P18, DOI 10.1055/s-2006-923798
   Moreno P, 2002, DIGEST DIS SCI, V47, P304, DOI 10.1023/A:1013709819896
   Mou Y, 2015, ENDOSCOPY, V47, pE348, DOI 10.1055/s-0034-1392502
   Narlawar RS, 2002, J CLIN ULTRASOUND, V30, P566, DOI 10.1002/jcu.10117
   Rai Binod Kumar, 2012, APSP J Case Rep, V3, P15
   Redondo-Cerezo E, 2010, WORLD J GASTRO ENDOS, V2, P318, DOI 10.4253/wjge.v2.i9.318
   Rockx MAJ, 2007, J PANCREAS, V8, P795
   Rotondo A, 1999, EUR RADIOL, V9, P890, DOI 10.1007/s003300050762
   RUBIN RB, 1995, J CLIN GASTROENTEROL, V21, P72
   Seeliger B, 2012, ANN SURG ONCOL, V19, P3753, DOI 10.1245/s10434-012-2502-4
   Sefa T, 2015, INT J SURG CASE REP, V10, P252, DOI 10.1016/j.ijscr.2015.02.022
   SEGAL SR, 1994, J ULTRAS MED, V13, P863, DOI 10.7863/jum.1994.13.11.863
   Sezgin O, 2001, J CLIN GASTROENTEROL, V32, P353, DOI 10.1097/00004836-200104000-00017
   Simone M, 2004, ANN SURG, V240, P82, DOI 10.1097/01.sla.0000129493.22157.b7
   Stecevic V, 2003, GASTROINTEST ENDOSC, V57, P615, DOI 10.1067/mge.2003.167
   STOUPIS C, 1994, RADIOGRAPHICS, V14, P729, DOI 10.1148/radiographics.14.4.7938764
   STRINGER MD, 1995, BRIT J SURG, V82, P74, DOI 10.1002/bjs.1800820126
   Tekin F, 2009, ENDOSCOPY, V41, pE32, DOI 10.1055/s-2008-1077337
   Troebs RB, 2013, EUR J PEDIATR SURG, V23, P505, DOI 10.1055/s-0033-1360459
   VANDAM J, 1992, AM J GASTROENTEROL, V87, P762
   Vandenbroucke F, 2005, ENDOSCOPY, V37, P601, DOI 10.1055/s-2005-861328
   Wada S, 2001, ENDOSCOPY, V33, P808, DOI 10.1055/s-2001-16528
   Wildi SM, 2003, GASTROINTEST ENDOSC, V58, P362, DOI 10.1016/S0016-5107(03)00009-9
   Will U, 2005, SCAND J GASTROENTERO, V40, P995, DOI 10.1080/00365520510023125
   Woolfolk GM, 1998, GASTROINTEST ENDOSC, V47, P76, DOI 10.1016/S0016-5107(98)70304-9
   You HS, 2012, CLIN ENDOSC, V45, P425, DOI 10.5946/ce.2012.45.4.425
NR 76
TC 15
Z9 22
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD MAY
PY 2016
VL 95
IS 22
AR e3799
DI 10.1097/MD.0000000000003799
PG 17
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA DO8QV
UT WOS:000378049400029
PM 27258515
OA gold
DA 2026-01-16
ER

PT J
AU Youn, I
   Cheong, MJ
   Kim, J
   Kim, SI
   Kim, HK
   Kwon, M
   Seo, J
   Nam, D
   Leem, J
AF Youn, Inae
   Cheong, Moon Joo
   Kim, Jinwon
   Kim, Soo Im
   Kim, Hye Kyung
   Kwon, Miri
   Seo, Joohee
   Nam, Dongwoo
   Leem, Jungtae
TI Understanding the experiences and perception of people living with HIV
   on integrative traditional East Asian medicine management in Korea: an
   interview protocol for qualitative research
SO BMJ OPEN
LA English
DT Article
ID ALTERNATIVE MEDICINE; IMMUNE RECONSTITUTION; HIV/AIDS; COMPLEMENTARY;
   ACUPUNCTURE; PAIN; INFORMATION; SURVIVAL; CANCER; AIDS
AB Introduction Patients with HIV/AIDS have been able to experience the average life expectancy of the general population due to medical advancements. However, they face physical, emotional and social difficulties that worsen their quality of life. The pharmacological approach is often the first choice to address these issues, but it involves some limitations. Integrative traditional East Asian medicine (ITEAM) can compensate for the limitations of drugs and can be applied to treat physiological and psychiatric problems. In Korea, ITEAM interventions are easily accessible under the government insurance. However, the experiences, perceptions and barriers to the use of ITEAM in patients with HIV/AIDS are less studied. Therefore, we will interview them to explore their experiences and examine the strengths, limitations, barriers and improvements in the use of ITEAM.
   Methods and analysis This is a qualitative study using a phenomenological framework. We will conduct one-to-one interviews with 3-10 patients with HIV/AIDS who have been treated with ITEAM from March 2021 to January 2022. We will present semistructured open-ended questions and analyse them using experiential phenomenological research methods. The results will be reported in accordance with the Consolidated Criteria for Reporting Qualitative Studies.
   Ethics and dissemination This research was approved by the Institutional Review Board of the National Medical Center (IRB number, NMC-2101-008). The results of this study will be disseminated through journal articles, newspapers and conference proceedings.
C1 [Youn, Inae; Kwon, Miri] Kyung Hee Univ, Clin Korean Med, Seoul, South Korea.
   [Youn, Inae] Natl Med Ctr, Dept Acupuncture & Moxibust, Seoul, South Korea.
   [Cheong, Moon Joo] Wankwang Univ, Jangheung Integrat Med Hosp, Rare Dis Integrated Treatment Res Ctr, Jeonju, South Korea.
   [Kim, Jinwon] Natl Med Ctr, Dept Internal Korean Med, Seoul, South Korea.
   [Kim, Soo Im] Dankook Univ, Dept Counseling, Gyeonggi, South Korea.
   [Kim, Hye Kyung] Psychol Counseling Off, LG Elect Gasan Res & Dev Campus, Seoul, South Korea.
   [Seo, Joohee] Natl Med Ctr, Dept Korean Neuropsychiatry, Seoul, South Korea.
   [Nam, Dongwoo] Kyung Hee Univ, Coll Korean Med, Dept Acupuncture & Moxibust, Seoul, South Korea.
   [Leem, Jungtae] Wonkwang Univ, Res Ctr Tradit Korean Med, Jeollabuk, South Korea.
C3 Kyung Hee University; National Medical Center - Korea; National Medical
   Center - Korea; Dankook University; National Medical Center - Korea;
   Kyung Hee University; Wonkwang University
RP Nam, D (corresponding author), Kyung Hee Univ, Coll Korean Med, Dept Acupuncture & Moxibust, Seoul, South Korea.; Leem, J (corresponding author), Wonkwang Univ, Res Ctr Tradit Korean Med, Jeollabuk, South Korea.
EM hanisanam@daum.net; julcho@naver.com
RI Leem, Jungtae/LGY-7782-2024; Nam, Dongwoo/AAH-5090-2020
OI Leem, Jungtae/0000-0003-3300-5556; Youn, Inae/0000-0002-1463-2178
FU National Medical Center, Republic of Korea [NMC2020-PR-007]
FX This work was supported by a grant of National Medical Center, Republic
   of Korea (Grant number: NMC2020-PR-007).
CR Amorim D, 2018, COMPLEMENT THER CLIN, V31, P31, DOI 10.1016/j.ctcp.2018.01.008
   Anastasi Joyce K, 2010, EJOM, V6, P40
   Anastasi JK, 2013, J ASSOC NURSE AIDS C, V24, P268, DOI 10.1016/j.jana.2012.09.006
   Arias-Colmenero T, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17020639
   Barbier F, 2020, INTENS CARE MED, V46, P329, DOI 10.1007/s00134-020-05945-3
   Brandt CP, 2016, AIDS CARE, V28, P432, DOI 10.1080/09540121.2015.1100704
   Chang BH, 2011, ACUPUNCT MED, V29, P180, DOI 10.1136/acupmed-2011-010026
   Cho HY, 2017, APPL CLIN INFORM, V8, P348, DOI 10.4338/ACI-2016-10-R-0175
   Cooper V, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-017-0778-6
   Deng G, 2019, CANCER J, V25, P343, DOI 10.1097/PPO.0000000000000399
   Drewes Jochen, 2013, J Int Assoc Provid AIDS Care, V12, P18, DOI 10.1177/1545109712456429
   DUKES S, 1984, J RELIG HEALTH, V23, P197, DOI 10.1007/BF00990785
   Ezeamama AE, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002525
   Finkelstein JL, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.19033
   Gallo RC, 2003, NEW ENGL J MED, V349, P2283, DOI 10.1056/NEJMp038194
   Gardner AT, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005021
   Garner BK, 2018, MED ACUPUNCT, V30, P262, DOI 10.1089/acu.2018.1294
   Halpin SN, 2018, AIDS BEHAV, V22, P848, DOI 10.1007/s10461-017-1866-7
   Harris TG, 2018, AIDS, V32, P1563, DOI 10.1097/QAD.0000000000001870
   Jin YT, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/282819
   Leem J, 2021, INTEGR MED RES, V10, DOI 10.1016/j.imr.2020.100430
   Li MX, 2020, COMPLEMENT THER MED, V50, DOI 10.1016/j.ctim.2019.102202
   Lim B, 2013, INTEGR MED RES, V2, P81, DOI 10.1016/j.imr.2013.06.004
   Liu ZB, 2015, INFECT DIS POVERTY, V4, DOI 10.1186/s40249-015-0093-6
   Liu ZB, 2015, J TRADIT CHIN MED, V35, P473, DOI 10.1016/S0254-6272(15)30127-8
   Lorenc A, 2013, AIDS PATIENT CARE ST, V27, P503, DOI 10.1089/apc.2013.0175
   Milan FB, 2008, AIDS PATIENT CARE ST, V22, P811, DOI 10.1089/apc.2007.0159
   Namuleme RK, 2015, HEALTH INFO LIBR J, V32, P61, DOI 10.1111/hir.12090
   Navarrete-Dechent C, 2015, REV CHIL INFECTOL, V32, pS57, DOI [10.4067/s0716-10182015000100005, 10.4067/S0716-10182015000100005]
   Nguyen AL, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008495
   Ofotokun I, 2011, DISCOV MED, V11, P385
   Palinkas LA, 2015, ADM POLICY MENT HLTH, V42, P533, DOI 10.1007/s10488-013-0528-y
   Rueda S, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011453
   Sadler GR, 2010, NURS HEALTH SCI, V12, P369, DOI 10.1111/j.1442-2018.2010.00541.x
   Shiflett SC, 2011, EXPLORE-NY, V7, P148, DOI 10.1016/j.explore.2011.02.004
   Solano JP, 2006, J PAIN SYMPTOM MANAG, V31, P58, DOI 10.1016/j.jpainsymman.2005.06.007
   Suphanchaimat R, 2014, HIV AIDS-RES PALLIAT, V6, P19, DOI 10.2147/HIV.S56277
   Swanson B, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/908538
   Takemura Y, 2005, TOHOKU J EXP MED, V206, P151, DOI 10.1620/tjem.206.151
   Tenny S., 2022, STATPEARLS
   Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042
   Torres RA, 2014, LAB INVEST, V94, P120, DOI 10.1038/labinvest.2013.142
   van Manen M., 1990, Theory intoPractice, V29, P152, DOI DOI 10.1080/00405849009543448
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Vreeman RC, 2019, J INT ASSOC PRO AIDS, V18, DOI 10.1177/2325958219880570
   Wang J, 2013, CHIN J INTEGR MED, V19, P340, DOI 10.1007/s11655-013-1449-z
   Wang J, 2010, CHIN J INTEGR MED, V16, P557, DOI 10.1007/s11655-010-0573-2
   Wang XY, 2018, J AM MED INFORM ASSN, V25, P931, DOI 10.1093/jamia/ocy012
   Wu XL, 2015, SCI REP-UK, V5, DOI [10.1038/srep11728, 10.1038/srep16776]
   Yang J, 2003, QUAL RES, V4, P87
   Yoo M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66314-0
   Zhao HL, 2014, AM J CHINESE MED, V42, P261, DOI 10.1142/S0192415X14500177
   Zhu QS, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000023638
NR 53
TC 0
Z9 2
U1 0
U2 17
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD DEC
PY 2021
VL 11
IS 12
AR e051880
DI 10.1136/bmjopen-2021-051880
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC General & Internal Medicine
GA XN5WT
UT WOS:000729575800016
PM 34887276
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Lee, JE
   Shah, VK
   Lee, EJ
   Oh, MS
   Choi, JJ
AF Lee, Jae Eun
   Shah, Vikash Kumar
   Lee, Eun-Jung
   Oh, Min-Seok
   Choi, Jeong June
TI Melittin - A bee venom component - Enhances muscle regeneration factors
   expression in a mouse model of skeletal muscle contusion
SO JOURNAL OF PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Melittin; Sweet bee venom; Muscle contusion; Muscle regeneration;
   Anti-inflammatory effects
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; PAIN; ACUPUNCTURE; INHIBITION;
   INDUCTION; RECOVERY
AB Melittin is a major peptide component of sweet bee venom that possesses anti-allergic, anti-inflammatory, anti-arthritis, anti-cancer, and neuroprotective properties. However, the therapeutic effects of melittin on muscle injury have not been elucidated. We investigated the therapeutic effects of melittin on muscle injury in a mouse model of muscle contusion. The biceps femoris muscle of the mice was injured using drop mass method, and the animals were treated with melittin (4, 20, or 100 mu g/kg) for 7 days. Melittin significantly increased: locomotor activity in open field test, and treadmill running activity in a dose-dependent manner to level comparable to the positive control, diclofenac (30 mg/kg). Melittin treatment attenuated the pro-inflammatory cytokine MCP-1, TNF-alpha and IL-6. The expression of muscle regeneration biomarkers, including MyoD (muscle differentiation marker), myogenin, smooth muscle actin, and myosin heavy chain was markedly increased in the injured muscle tissue of melittin-treated mice, as determined by western blotting and quantitative real-time polymerase chain reaction. These results demonstrate that melittin inhibits inflammatory response and improves muscle damage by regenerating muscles in a mouse model of muscle contusion. Taken together, the results of present study suggest that melittin is a promising candidate for the muscle injury treatment. (C) 2019 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.
C1 [Lee, Jae Eun] Daejeon Univ, Cheonan Korean Med Hosp, Dept Korean Rehabil Med, Cheonan 31099, South Korea.
   [Shah, Vikash Kumar; Choi, Jeong June] Daejeon Univ, Coll Korean Med, Lab Mol Med, 62 Daehak Ro, Daejeon 34520, South Korea.
   [Lee, Eun-Jung; Oh, Min-Seok] Daejeon Univ, Coll Korean Med, Dept Korean Rehabil Med, 1136 Dunsan Dong, Daejeon 34520, South Korea.
C3 Daejeon University; Daejeon University; Daejeon University
RP Choi, JJ (corresponding author), Daejeon Univ, Coll Korean Med, Lab Mol Med, 62 Daehak Ro, Daejeon 34520, South Korea.; Oh, MS (corresponding author), Daejeon Univ, Coll Korean Med, Dept Korean Rehabil Med, 1136 Dunsan Dong, Daejeon 34520, South Korea.
EM ohmin@dju.ac.kr; c27022@dju.ac.kr
OI Lee, Eun-Jung/0000-0001-9468-9694
FU Daejeon University fund
FX This research was supported by the Daejeon University fund (2015).
CR Alvarez P, 2014, PAIN, V155, P1161, DOI 10.1016/j.pain.2014.03.004
   [Anonymous], J ASTHMA ALLERGY CLI
   Bryant AE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172486
   Ceafalan LC, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/957014
   Delos D, 2013, SPORTS HEALTH, V5, P346, DOI 10.1177/1941738113480934
   Jarvinen T. A., 2014, MUSCLES LIGAMENTS TE, V3, P337
   Jo M, 2012, TOXICOL APPL PHARM, V258, P72, DOI 10.1016/j.taap.2011.10.009
   Kang H, 2014, J PHARMACOPUNCT, V17, P73
   Kang SY, 2012, J PAIN, V13, P155, DOI 10.1016/j.jpain.2011.10.012
   Kim YJ, 2009, J PHARMACOPUNCT, V12, P5, DOI 10.3831/KPI.2009.12.4.005
   Launay T, 2001, J HISTOCHEM CYTOCHEM, V49, P887, DOI 10.1177/002215540104900709
   Lee JA, 2014, BMJ OPEN, V4
   Lee JD, 2005, EVID-BASED COMPL ALT, V2, P79, DOI 10.1093/ecam/neh070
   Lee MS, 2008, J PAIN, V9, P289, DOI 10.1016/j.jpain.2007.11.012
   Mann CJ, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-21
   Morelli KM, 2018, AM J SPORT MED, V46, P224, DOI 10.1177/0363546517697957
   Park JH, 2012, APOPTOSIS, V17, P61, DOI 10.1007/s10495-011-0659-0
   Plackett TP, 2015, ADV WOUND CARE, V4, P92, DOI 10.1089/wound.2014.0597
   Seo BK, 2017, TOXINS, V9, DOI 10.3390/toxins9110361
   TOSTESON MT, 1981, BIOPHYS J, V36, P109, DOI 10.1016/S0006-3495(81)84719-4
   Vignaud A, 2005, EXP PHYSIOL, V90, P487, DOI 10.1113/expphysiol.2005.029835
   Volans G, 2015, IBUPROFEN: DISCOVERY, DEVELOPMENT AND THERAPEUTICS, P498
   Wolfe RR, 2006, AM J CLIN NUTR, V84, P475, DOI 10.1093/ajcn/84.3.475
   Zádor E, 2002, BBA-MOL CELL RES, V1590, P52, DOI 10.1016/S0167-4889(02)00198-2
NR 24
TC 18
Z9 20
U1 2
U2 9
PU JAPANESE PHARMACOLOGICAL SOC
PI KYOTO
PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI-EBISUGAWA NAKAGYO-KU, KYOTO, 604,
   JAPAN
SN 1347-8613
EI 1347-8648
J9 J PHARMACOL SCI
JI J. Pharmacol. Sci.
PD MAY
PY 2019
VL 140
IS 1
BP 26
EP 32
DI 10.1016/j.jphs.2019.03.009
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA ID7SN
UT WOS:000471882900005
PM 31113730
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Liu, ZM
   Lu, H
   Zhang, XJ
   Tang, S
   Lin, AT
   Han, S
   Ma, XX
AF Liu, Zhiming
   Lu, Hui
   Zhang, Xianjuan
   Tang, Shuai
   Lin, Antao
   Han, Shuo
   Ma, Xuexiao
TI NOXA exacerbates endoplasmic-reticulum-stress-induced intervertebral
   disc degeneration by activating apoptosis and ECM degradation
SO CELL DEATH DISCOVERY
LA English
DT Article
ID NUCLEUS PULPOSUS CELLS; GLOBAL BURDEN; THERAPY; EXPRESSION; SURVIVAL;
   REVEALS; DISEASE; CANCER; INJURY; DEATH
AB Intervertebral disc degeneration (IVDD) is a prevalent condition leading to low back pain. Endoplasmic reticulum stress (ERS) is strongly linked to IVDD progression, although the underlying mechanisms remain unclear. In this study, we investigated the effects of NOXA on ERS-induced IVDD. Primary nucleus pulposus cells (NPCs) were stimulated with Thapsigargin to mimic the ERS microenvironment in IVDD. Western blot analysis, PCR, immunofluorescence, and immunohistochemistry assay were performed to measure the expression levels of PERK, NOXA, and cell apoptosis- and extracellular-matrix-degradation-relevant proteins. JC-1 fluorescent probes, terminal deoxynucleotidyl transferase dUTP nick end labeling staining, and flow cytometry were used to measure mitochondrial function and apoptosis in NPCs under ERS conditions. Magnetic resonance imaging, Safranin O staining, alcian blue staining, and immunohistochemistry were performed to estimate the effects of NOXA knockdown on acupuncture-mediated IVDD in rats at both imaging and histological levels. The results showed that ERS induced and activated the PERK pathway during IVDD development. Mechanically, ERS induced NPC apoptosis and ECM degradation by upregulating PERK expression and activating NOXA expression. The genetic overexpression of NOXA inhibited cell proliferation and increased apoptosis, whereas its knockdown decreased MCL-1 expression and alleviated IVDD degeneration in human NPCs and rat models. NOXA plays a crucial role in the PERK/NOXA/MCL-1 axis, mediating the link between ERS and IVDD. Targeting NOXA expression may be an effective method for treating IVDD, laying the foundation for future research on molecular mechanisms and the development of new therapies.
C1 [Liu, Zhiming; Lu, Hui; Tang, Shuai; Lin, Antao; Han, Shuo; Ma, Xuexiao] Qingdao Univ, Dept Spinal Surg, Affiliated Hosp, Qingdao, Shandong, Peoples R China.
   [Zhang, Xianjuan] Qingdao Univ, Affiliated Hosp, Dept Clin Lab, Qingdao, Shandong, Peoples R China.
C3 Qingdao University; Qingdao University
RP Han, S; Ma, XX (corresponding author), Qingdao Univ, Dept Spinal Surg, Affiliated Hosp, Qingdao, Shandong, Peoples R China.
EM 576110131@qq.com; maxuexiaospinal@163.com
FU Taishan Scholar Foundation of Shandong Province
FX We would like to thank all the participants in this study.
CR Alcorta-Sevillano N, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9122630
   [Anonymous], **DATA OBJECT**
   Carlton JG, 2020, NAT REV MOL CELL BIO, V21, P151, DOI 10.1038/s41580-019-0208-1
   Cazzanelli P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103601
   Cheng XF, 2018, ANN RHEUM DIS, V77, P770, DOI 10.1136/annrheumdis-2017-212056
   Diallo JS, 2007, CLIN CANCER RES, V13, P7044, DOI 10.1158/1078-0432.CCR-07-1224
   Fujii T, 2018, J ORTHOP RES, V36, P1334, DOI 10.1002/jor.23787
   GBD 2015 Disease and Injury Incidence and Prevalence Collaborators, 2016, Lancet, V388, P1545, DOI 10.1016/S0140-6736(16)31678-6
   Ghiotto F, 2009, CANCER BIOL THER, V8, P263, DOI 10.4161/cbt.8.3.7424
   Gonen N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38705-5
   Gupta A, 2015, SCI REP-UK, V5, DOI 10.1038/srep18304
   Hauck P, 2009, MOL CANCER THER, V8, P883, DOI 10.1158/1535-7163.MCT-08-1118
   Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270
   Kang HL, 2022, BIOCHEM PHARMACOL, V197, DOI 10.1016/j.bcp.2022.114932
   Kelly KR, 2015, ONCOTARGET, V6, P41275, DOI 10.18632/oncotarget.5753
   Kepler CK, 2013, SPINE J, V13, P318, DOI 10.1016/j.spinee.2012.12.003
   Le Maitre CL, 2007, BIOCHEM SOC T, V35, P652, DOI 10.1042/BST0350652
   Lee EF, 2008, J CELL BIOL, V180, P341, DOI 10.1083/jcb.200708096
   Liang HZ, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031715
   Liao ZW, 2019, THERANOSTICS, V9, P4084, DOI 10.7150/thno.33638
   Lin H, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/8810698
   Lin JH, 2007, SCIENCE, V318, P944, DOI 10.1126/science.1146361
   Luo RJ, 2019, FEBS J, V286, P4356, DOI 10.1111/febs.14972
   Luo RJ, 2019, LIFE SCI, V228, P85, DOI 10.1016/j.lfs.2019.04.064
   Majumder M, 2012, MOL CELL BIOL, V32, P992, DOI 10.1128/MCB.06665-11
   Marshall AD, 2013, NEOPLASIA, V15, P738, DOI 10.1593/neo.121888
   Masuda K, 2005, SPINE, V30, P5, DOI 10.1097/01.brs.0000148152.04401.20
   Matsuhashi T, 2017, EBIOMEDICINE, V20, P27, DOI 10.1016/j.ebiom.2017.05.016
   Meroni R, 2021, DISABIL REHABIL, V43, P1029, DOI 10.1080/09638288.2019.1645888
   Morsi RZ, 2018, CURR CANCER DRUG TAR, V18, P914, DOI 10.2174/1568009618666180308105048
   Mukherjee N, 2017, ONCOTARGET, V8, P46801, DOI 10.18632/oncotarget.8695
   Nakajima W, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.6
   O'Keeffe M, 2020, LANCET, V396, P1560, DOI [10.1016/s0140-6736(20)32325-4, 10.1016/S0140-6736(20)32325-4]
   Ochoa CD, 2018, MOL ASPECTS MED, V63, P18, DOI 10.1016/j.mam.2018.03.002
   Ong G, 2024, CELL DEATH DIS, V15, DOI 10.1038/s41419-024-06663-0
   Pattappa G, 2012, J ANAT, V221, P480, DOI 10.1111/j.1469-7580.2012.01521.x
   Pietkiewicz S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061438
   Qiu XB, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1886-3
   Raj P Prithvi, 2008, Pain Pract, V8, P18, DOI 10.1111/j.1533-2500.2007.00171.x
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Sakai D, 2015, ADV DRUG DELIVER REV, V84, P159, DOI 10.1016/j.addr.2014.06.009
   Sampara P, 2018, GENE THER, V25, P67, DOI 10.1038/s41434-018-0004-0
   Shpilka T, 2018, NAT REV MOL CELL BIO, V19, P109, DOI 10.1038/nrm.2017.110
   Simonin K, 2013, APOPTOSIS, V18, P492, DOI 10.1007/s10495-012-0799-x
   Smith E, 2014, ANN RHEUM DIS, V73, P1462, DOI 10.1136/annrheumdis-2013-204680
   Stewart ML, 2010, NAT CHEM BIOL, V6, P595, DOI [10.1038/nchembio.391, 10.1038/NCHEMBIO.391]
   Teng C, 2024, PHYTOTHER RES, V38, P2114, DOI 10.1002/ptr.8057
   Theocharis AD, 2016, ADV DRUG DELIVER REV, V97, P4, DOI 10.1016/j.addr.2015.11.001
   van Galen P, 2014, NATURE, V510, P268, DOI 10.1038/nature13228
   Verhaegen M, 2006, CANCER RES, V66, P11348, DOI 10.1158/0008-5472.CAN-06-1748
   Vo NV, 2013, SPINE J, V13, P331, DOI 10.1016/j.spinee.2012.02.027
   Wang D, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.819139
   Wang WJ, 2015, CLIN CHIM ACTA, V448, P238, DOI 10.1016/j.cca.2015.06.023
   Wang WZ, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/6719460
   Wen ZQ, 2023, MILITARY MED RES, V10, DOI 10.1186/s40779-023-00485-5
   Xi YM, 2020, CELL BIOL INT, V44, P583, DOI 10.1002/cbin.11258
   Xu DL, 2017, PHARMACOL RES, V117, P357, DOI 10.1016/j.phrs.2017.01.005
   Xu M, 2016, STEM CELL TRANSL MED, V5, P1171, DOI 10.5966/sctm.2015-0384
   Yang CH, 2020, EUR REV MED PHARMACO, V24, P11295, DOI 10.26355/eurrev_202011_23619
   Yao DB, 2024, CELL SIGNAL, V114, DOI 10.1016/j.cellsig.2023.110986
   Zhang LN, 2013, CANCER GENE THER, V20, P1, DOI 10.1038/cgt.2012.84
   Zhang M, 2017, CELL HOST MICROBE, V22, P766, DOI 10.1016/j.chom.2017.11.005
   Zhang S, 2022, CELL TISSUE RES, V390, P1, DOI 10.1007/s00441-022-03662-5
   Zhang XB, 2021, INT J MED SCI, V18, P2799, DOI 10.7150/ijms.59171
   Zhao CQ, 2010, AGE, V32, P161, DOI 10.1007/s11357-009-9121-4
   ,, 2018, Lancet (British edition), V392, P1789, DOI 10.1016/s0140-6736(18)32279-7
NR 66
TC 2
Z9 2
U1 2
U2 2
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
EI 2058-7716
J9 CELL DEATH DISCOV
JI Cell Death Discov.
PD MAY 28
PY 2025
VL 11
IS 1
AR 257
DI 10.1038/s41420-025-02539-0
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 3DY7J
UT WOS:001498057700001
PM 40436859
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Mohanty, S
   Panigrahi, MK
   Turuk, J
   Dhal, S
AF Mohanty, Srujana
   Panigrahi, Manas Kumar
   Turuk, Jyotirmayee
   Dhal, Sagarika
TI Liver Abscess due to Streptococcus constellatus in an
   Immunocompetent Adult: A Less Known Entity
SO JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION
LA English
DT Article
DE Liver abscess; Hepatic abscess; Pyogenic liver abscess; Streptococcus
   constellatus
ID ANGINOSUS; MILLERI; TRENDS
AB Background: Pyogenic liver abscesses (PLAs) are an uncommon, but potentially life threatening infection. We report a case of PLA due to Streptococcus constellatus, a member of the Streptococcus anginosus group (SAG) bacteria. commonly found as commensals of the oropharyngeal, gastrointestinal and genitourinary flora.
   Case: The patient, a 42-year-old man with no premorbidities, non-smoker and non-alcoholic, presented to our hospital with high-grade fever associated with chills and rigors and right upper quadrant pain of one month duration. Culture of the ultrasound-guided liver aspirate yielded a pure growth of S. constellatus subspecies constellatus identified by conventional biochemical tests. In a standard antimicrobial disk-diffusion test, the isolate was susceptible to cefepime, cefotaxime, ceftriaxone, vancomcyin, levofioxacin, clindamycin and linezolid. Treatment with parenteral ceftriaxone alongwith appropriate surgical management led to resolution of the abscess with no recurrence of infection at three months follow-up.
   Conclusions: The pathogenic potential of SAG has generally been disregarded because of the commensal nature of these microorganisms: however, streptococci belonging to this group have been increasingly reported as relevant pathogens in abscesses and blood cultures. An underlying condition, such as diabetes, cirrhosis or cancer or some medical manipulation, such as dental extraction, acupuncture, or hemorrhoidectomy is associated with the majority of patients with SAG abscess. However, the present case highlights the need to include S. constellatus and other members of the SAG while investigating for etiology of PLA, even in immunocompetent adults.
C1 [Mohanty, Srujana; Turuk, Jyotirmayee; Dhal, Sagarika] All India Inst Med Sci, Dept Microbiol, Bhubaneswar 751019, Odisha, India.
   [Panigrahi, Manas Kumar] All India Inst Med Sci, Dept Gastroenterol, Bhubaneswar 751019, Odisha, India.
C3 All India Institute of Medical Sciences (AIIMS) Bhubaneswar; All India
   Institute of Medical Sciences (AIIMS) Bhubaneswar
RP Mohanty, S (corresponding author), All India Inst Med Sci, Dept Microbiol, Bhubaneswar 751019, Odisha, India.
EM srujana_micro@yahoo.co.in
CR [Anonymous], 2016, Clinical Practice Guideline: Postpartum Haemorrhage, P1
   Asam D, 2014, MOL ORAL MICROBIOL, V29, P145, DOI 10.1111/omi.12056
   BATEMAN NT, 1975, LANCET, V1, P657
   Belko J, 2002, PEDIATR INFECT DIS J, V21, P715, DOI 10.1097/00006454-200208000-00002
   Bonenfant F, 2013, CAN J INFECT DIS MED, V24, pE45, DOI 10.1155/2013/802545
   Chang AC, 2015, ANZ J SURG, V85, P179, DOI 10.1111/ans.12411
   Cherian J, 2016, J INVEST MED HIGH IM, V4, DOI 10.1177/2324709616660576
   Choi EJ, 2013, KOREAN J FAM MED, V34, P364, DOI 10.4082/kjfm.2013.34.5.364
   Corredoira J, 1998, EUR J CLIN MICROBIOL, V17, P556, DOI 10.1007/BF01708618
   Giuliano Simone, 2012, Infez Med, V20, P145
   Heneghan Helen M, 2011, BMC Res Notes, V4, P80, DOI 10.1186/1756-0500-4-80
   Iwashita Hideyuki, 2015, Nihon Shokakibyo Gakkai Zasshi, V112, P1525, DOI 10.11405/nisshoshi.112.1525
   Kaplan GG, 2004, CLIN GASTROENTEROL H, V2, P1032, DOI 10.1016/S1542-3565(04)00459-8
   Lefort A, 2002, ARCH INTERN MED, V162, P2450, DOI 10.1001/archinte.162.21.2450
   Livingston LV, 2014, CASE REP INFECT DIS, V2014, DOI 10.1155/2014/954046
   Lok KH, 2008, J MICROBIOL IMMUNOL, V41, P483
   Masood Umair, 2016, Case Rep Gastroenterol, V10, P769, DOI [10.1159/000452757, 10.1159/000452757]
   Mohammedi I, 1996, ANN FR ANESTH, V15, P1090, DOI 10.1016/S0750-7658(96)89480-9
   MOOREGILLON JC, 1981, BMJ-BRIT MED J, V283, P819, DOI 10.1136/bmj.283.6295.819
   Murarka S, 2011, J GLOB INFECT DIS, V3, P79, DOI 10.4103/0974-777X.77300
   Pang TCY, 2011, WORLD J GASTROENTERO, V17, P1622, DOI [10.3748/wjg.v17.i12.1622, 10.3748/wjg.v17.i12. 1622]
   Rahimian J, 2004, CLIN INFECT DIS, V39, P1654, DOI 10.1086/425616
   Rusman Jan, 2013, BMJ Case Rep, V2013, DOI 10.1136/bcr-2013-009455
   Whiley RA, 1999, INT J SYST BACTERIOL, V49, P1443, DOI 10.1099/00207713-49-4-1443
   Winn W., 2006, Konemans color atlas and Textbook of Diagnostic Microbiology, V6th, P672
   Yeh TS, 1998, CLIN INFECT DIS, V26, P1224, DOI 10.1086/520290
NR 26
TC 17
Z9 21
U1 0
U2 3
PU NATL MED ASSOC
PI WASHINGON
PA 1012 10TH ST, N W, WASHINGON, DC 20001 USA
SN 0027-9684
EI 1943-4693
J9 J NATL MED ASSOC
JI J. Natl. Med. Assoc.
PD DEC
PY 2018
VL 110
IS 6
BP 591
EP 595
DI 10.1016/j.jnma.2018.03.006
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HA2SB
UT WOS:000450091500014
PM 30129495
DA 2026-01-16
ER

PT J
AU Stussman, BJ
   Nahin, RL
   Barnes, PM
   Scott, R
   Feinburg, T
   Ward, BW
AF Stussman, Barbara J.
   Nahin, Richard L.
   Barnes, Patricia M.
   Scott, Remle
   Feinburg, Termeh
   Ward, Brian W.
TI Reasons Office-Based Physicians in the United States Recommend Common
   Complementary Health Approaches to Patients: An Exploratory Study Using
   a National Survey
SO JOURNAL OF INTEGRATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
DE U; S; physicians; National Ambulatory Medical Care Survey; chiropractic;
   acupuncture; dietary supplements; mind and body
ID ALTERNATIVE MEDICINE USE; BREAST-CANCER; CARE; PAIN; ATTITUDES;
   COMMUNICATION; EXPERIENCE; CLINICIAN; PATTERNS; WOMEN
AB Objective: To examine the reasons why office-based physicians do or do not recommend four selected complementary health approaches to their patients in the context of the Andersen Behavioral Model.Design: Descriptive estimates of physician-level data from the 2012 National Ambulatory Medical Care Survey (NAMCS) Physician Induction Interview, a nationally representative survey of office-based physicians (N = 5622, weighted response rate = 59.7%).Setting/Location: The United States.Outcome measures: Reasons for the recommendation or lack thereof to patients for: herbs and other non-vitamin supplements, chiropractic/osteopathic manipulation, acupuncture, and mind-body therapies (including meditation, guided imagery, and progressive relaxation). Differences by physician sex and medical specialty were described.Results: For each of the four complementary health approaches, more than half of the physicians who made recommendations indicated that they were influenced by scientific evidence in peer-reviewed journals (ranging from 52.0% for chiropractic/osteopathic manipulation [95% confidence interval, CI = 47.6-56.3] to 71.3% for herbs and other non-vitamin supplements [95% CI = 66.9-75.4]). More than 60% of all physicians recommended each of the four complementary health approaches because of patient requests. A higher percentage of female physicians reported evidence in peer-reviewed journals as a rationale for recommending herbs and non-vitamin supplements or chiropractic/osteopathic manipulation when compared with male physicians (herbs and non-vitamin supplements: 78.8% [95% CI = 72.4-84.3] vs. 66.6% [95% CI = 60.8-72.2]; chiropractic/osteopathic manipulation: 62.3% [95% CI = 54.7-69.4] vs. 47.5% [95% CI = 42.3-52.7]). For each of the four complementary health approaches, a lack of perceived benefit was the most frequently reported reason by both sexes for not recommending. Lack of information sources was reported more often by female versus male physicians as a reason to not recommend herbs and non-vitamin supplements (31.4% [95% CI = 26.8-36.3] vs. 23.4% [95% CI = 21.0-25.9]).Conclusions: There are limited nationally representative data on the reasons as to why office-based physicians decide to recommend complementary health approaches to patients. Developing a more nuanced understanding of influencing factors in physicians' decision making regarding complementary health approaches may better inform researchers and educators, and aid physicians in making evidence-based recommendations for patients.
C1 [Stussman, Barbara J.; Nahin, Richard L.] NCCIH, NIH, Bethesda, MD USA.
   [Barnes, Patricia M.; Ward, Brian W.] Natl Ctr Hlth Stat, Hyattsville, MD USA.
   [Scott, Remle] Uniformed Serv Univ Hlth Sci, Sch Med, Dept Prevent Med & Biostat, Bethesda, MD USA.
   [Feinburg, Termeh] Kelly Govt Solut, Rockville, MD USA.
   [Stussman, Barbara J.] NCCIH, NIH, 6707 Democracy Blvd,Suite 401, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; Centers for Disease Control &
   Prevention - USA; CDC National Center for Health Statistics (NCHS);
   Uniformed Services University of the Health Sciences - USA; National
   Institutes of Health (NIH) - USA
RP Stussman, BJ (corresponding author), NCCIH, NIH, Bethesda, MD USA.; Stussman, BJ (corresponding author), NCCIH, NIH, 6707 Democracy Blvd,Suite 401, Bethesda, MD 20892 USA.
EM stussmanbj@mail.nih.gov
OI Scott, Remle/0000-0002-6423-459X; Feinberg, Termeh/0000-0003-2567-1567
CR ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284
   [Anonymous], 2012, VITAL HLTH STAT
   [Anonymous], 2019, Pain Management Best Practices Inter-Agency Task Force Report: Updates, Gaps, Inconsistencies, and Recommendations
   Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548
   Aveni E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184979
   Barnes PM., 2002, ADV DATA, V2004, P1, DOI DOI 10.1016/J.SIGM.2004.07.003
   Barnes PM., 2008, NATL HLTH STAT REPOR, DOI DOI 10.1037/E623942009-001
   Berman BM, 2002, ARCH INTERN MED, V162, P766, DOI 10.1001/archinte.162.7.766
   Bethell C., 2011, UNPUB
   Bonnie RJ, 2017, PAIN MANAGEMENT AND THE OPIOID EPIDEMIC: BALANCING SOCIETAL AND INDIVIDUAL BENEFITS AND RISKS OF PRESCRIPTION OPIOID USE, P1, DOI 10.17226/24781
   Brown C, 2009, J ALTERN COMPLEM MED, V15, P911, DOI 10.1089/acm.2008.0561
   Casbarro N, 2021, COMPLEMENT THER MED, V58, DOI 10.1016/j.ctim.2021.102693
   Clarke Tainya C, 2015, Natl Health Stat Report, P1
   Cowan AE, 2018, NUTRIENTS, V10, P11
   Curlin FA, 2009, J ALTERN COMPLEM MED, V15, P987, DOI 10.1089/acm.2008.0512
   Davis MA, 2013, HEALTH AFFAIR, V32, P45, DOI 10.1377/hlthaff.2011.0321
   Dennis JA, 2020, J ALTERN COMPLEM MED, V26, P1080, DOI 10.1089/acm.2020.0237
   Doyle C, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-001570
   EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406
   Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569
   Foley H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38279-8
   Furlow ML, 2008, BMC COMPLEM ALTERN M, V8, DOI 10.1186/1472-6882-8-35
   Grainger R, 2014, CLIN RHEUMATOL, V33, P3, DOI 10.1007/s10067-013-2379-z
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P527, DOI 10.1007/s10549-016-3740-0
   Groden SR, 2017, AM J GERIAT PSYCHIAT, V25, P1393, DOI 10.1016/j.jagp.2017.08.001
   Groenewald CB, 2017, ACAD PEDIATR, V17, P785, DOI 10.1016/j.acap.2017.02.008
   Guzman Jennifer R, 2019, J Fam Med Dis Prev, V5, DOI [10.23937/2469-5793/1510109, 10.23937/2469-5793/1510109]
   Hirschkorn KA, 2005, SOC SCI MED, V61, P157, DOI 10.1016/j.socscimed.2004.11.048
   Huston P, 2021, J ALTERN COMPLEM MED, V27, P434, DOI 10.1089/acm.2020.0418
   Jain N, 2001, J ALTERN COMPLEM MED, V7, P689, DOI 10.1089/10755530152755243
   Kennedy J, 2005, CLIN THER, V27, P1847, DOI 10.1016/j.clinthera.2005.11.004
   Koenig CJ, 2012, PATIENT EDUC COUNS, V89, P368, DOI 10.1016/j.pec.2012.02.020
   Lambe CE, 2013, J CHRIST NURS, V30, P218
   Lee YS, 2015, ACUPUNCT MED, V33, P129, DOI 10.1136/acupmed-2014-010661
   Levine SM, 2003, J AM BOARD FAM PRACT, V16, P318, DOI 10.3122/jabfm.16.4.318
   Macinko J, 2019, J ALTERN COMPLEM MED, V25, P920, DOI 10.1089/acm.2019.0206
   Manek NJ, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-5
   Mbizo J, 2018, BMC COMPLEM ALTERN M, V18, P281
   Milden SP, 2004, BEHAV MED, V30, P73, DOI 10.3200/BMED.30.2.73-84
   Nahin R.L., 2012, Natl. Health Stat. Rep, V95, P1
   Nahin RL, 2016, MAYO CLIN PROC, V91, P1292, DOI 10.1016/j.mayocp.2016.06.007
   Nahin RL, 2015, J PAIN, V16, P1147, DOI 10.1016/j.jpain.2015.07.013
   National Center for Complementary and Integrative Health, NCCIH STRAT PLAN FY
   National Center for Complementary and Integrative Health (NCCIH), 2021, PIL STUD COMM US MIS
   National Center for Health Statistics, 2015, 2012 NAMCS MIRC FIL
   Ndao-Brumblay SK, 2010, PAIN MED, V11, P16, DOI 10.1111/j.1526-4637.2009.00767.x
   Oskoui M, 2020, CAN J NEUROL SCI, V28, P1
   Parker Jennifer D, 2017, Vital Health Stat 2, P1
   Qaseem Amir, 2017, Ann Intern Med, V166, P514, DOI 10.7326/M16-2367
   Research Triangle Institute, 2018, SUDAAN REL 11 0 COMP
   Sawni Anju, 2007, BMC Complement Altern Med, V7, P18, DOI 10.1186/1472-6882-7-18
   Shelley BM, 2009, ANN FAM MED, V7, P139, DOI 10.1370/afm.947
   Siedlecki SL, 2021, COMPLEMENT THER CLIN, V43, DOI 10.1016/j.ctcp.2021.101327
   Sikand A, 1998, ARCH PEDIAT ADOL MED, V152, P1059
   Smith SR, 1999, ANN PHARMACOTHER, V33, P294, DOI 10.1345/aph.18320
   Spencer CN, 2016, CANCER-AM CANCER SOC, V122, P1552, DOI 10.1002/cncr.29819
   Stussman BJ, 2020, J ALTERN COMPLEM MED, V26, P25, DOI 10.1089/acm.2019.0303
   Tick H, 2018, EXPLORE-NY, V14, P177, DOI 10.1016/j.explore.2018.02.001
   Tilburt JC, 2010, MED CARE, V48, P341, DOI 10.1097/MLR.0b013e3181ca3ee2
   Tovey Philip, 2002, Complement Ther Nurs Midwifery, V8, P12
   Upchurch D. M., 2013, J EVIDENCE BASED COM, V18, P100
   Upchurch DM, 2007, J WOMENS HEALTH, V16, P102, DOI 10.1089/jwh.2006.M074
   von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013
   Whedon JM, 2020, J ALTERN COMPLEM MED, V26, P966, DOI 10.1089/acm.2020.0078
   Winslow LC, 2002, ARCH INTERN MED, V162, P1176
   Zhang Y, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/413173
NR 66
TC 2
Z9 3
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2768-3605
EI 2768-3613
J9 J INTEGR COMPLEMENT
JI J. Integr. Complement. Med.
PD AUG
PY 2022
VL 28
IS 8
BP 651
EP 663
DI 10.1089/jicm.2022.0493
EA MAY 2022
PG 13
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA S6JB5
UT WOS:000794032700001
PM 35549394
OA Green Accepted
DA 2026-01-16
ER

PT J
AU Ismail, NFF
   Neoh, CF
   Lim, SM
   Abdullah, AH
   Mastuki, MF
   Ramasamy, K
   Zainuddin, N
   Saim, L
   Ming, LC
AF Ismail, Nor Faizatul Fatikah
   Neoh, Chin Fen
   Lim, Siong Meng
   Abdullah, Amir Heberd
   Mastuki, Mohd Fahmi
   Ramasamy, Kalavathy
   Zainuddin, Nazli
   Saim, Lokman
   Ming, Long Chiau
TI The immediate effect of facial candling on inflammatory mediators,
   substance P, symptoms severity, and quality of life in allergic rhinitis
   patients Study protocol for a randomized controlled trial
SO MEDICINE
LA English
DT Article
DE complementary therapies; ethnomedicine; folk medicine; immune system
   diseases; otorhinolaryngologic diseases; respiratory hypersensitivity;
   traditional medicine
ID DNA MICROARRAY ANALYSIS; ASTHMA; POPULATION; MANAGEMENT; PAIN;
   ACUPUNCTURE; DIAGNOSIS; MASSAGE; DISEASE; IMPACT
AB Introduction: Asian countries have a variety of ethnic groups and culture that provide their own traditional treatment in health care. Facial candling appears to be one of the popular traditional treatments in Southeast Asian. The complementary medicine practitioners promote that the facial candling treatment would help in reducing the symptoms of allergic rhinitis and other problems related to sinus. Due to the lack of evidence available, the effectiveness of this treatment method and its mechanism, however, remains unknown. The objective of this research is therefore to study impact of facial candling on inflammatory mediators, substance P (SP), symptoms severity, and quality of life (QoL) in allergic rhinitis patients.
   Method and analysis: A randomized, nonblinded, controlled trial will be carried out by recruiting a total of 66 eligible allergic rhinitis patients who fulfill the inclusion criteria from a university health center. The subjects will be randomly assigned into 2 groups: intervention group receiving facial candling treatment and control group (no treatment given). Samples of blood and nasal mucus will be collected right before and after intervention. Samples collected will be analyzed. The primary outcomes are the changes in the level of SP in both blood and mucus samples between both groups. The secondary outcomes include the levels of inflammatory mediators (ie, tumor necrosis factor alpha, interleukin (IL)-3, IL-5, IL-6, IL-10, and IL-13) and the severity of allergic rhinitis symptoms as measured by a visual analogous scale and QoL using the Rhinitis Quality of Life Questionnaire (RQLQ).
   Ethical and trial registration: The study protocols are approved from the Ethical and Research Committee of the Universiti Teknologi MARA (REC/113/15). The trial is registered under the Australia New Zealand Clinical Trial Registry (ACTRN12616000299404). The trial was registered on 03/07/2016 and the first patient was enrolled on 10/12/2016.
   Conclusion: Facial candling is one of the unique treatments using candles to reduce the severity of symptoms and inflammation. This is the first ever study conducted on facial candling that will give rise to new knowledge underlying the effects of facial candling on severity of symptoms and inflammation relief mechanism mediated by substance P and inflammatory mediators.
C1 [Ismail, Nor Faizatul Fatikah; Neoh, Chin Fen; Lim, Siong Meng; Ramasamy, Kalavathy; Ming, Long Chiau] Univ Teknol MARA UiTM, Fac Pharm, Puncak Alam, Malaysia.
   [Neoh, Chin Fen; Lim, Siong Meng; Ramasamy, Kalavathy] Univ Teknol MARA, Collaborat Drug Discovery Res CDDR Grp, Pharmaceut & Life Sci CoRe, Shah Alam, Selangor, Malaysia.
   [Abdullah, Amir Heberd] Univ Teknol MARA, Fac Hlth Sci, Environmetal Hlth Dept, Bertam, Penang, Malaysia.
   [Abdullah, Amir Heberd] Univ Teknol MARA, Pharmaceut & Life Sci CoRe, Vector Borne Dis Res Grp VERDI, Shah Alam, Selangor, Malaysia.
   [Mastuki, Mohd Fahmi] Univ Teknol MARA, Fac Hlth Sci, Med Lab Dept, Puncak Alam, Johor, Malaysia.
   [Zainuddin, Nazli] Univ Teknol MARA, Fac Med, Puncak Alam, Selangor, Malaysia.
   [Saim, Lokman; Ming, Long Chiau] KPJ Healthcare Univ Coll, Sch Pharm, Lot PT 17010 Persiaran Seriemas, Nilai 71800, Negeri Sembilan, Malaysia.
C3 Universiti Teknologi MARA; Universiti Teknologi MARA; Universiti
   Teknologi MARA; Universiti Teknologi MARA; Universiti Teknologi MARA
RP Ming, LC (corresponding author), KPJ Healthcare Univ Coll, Sch Pharm, Lot PT 17010 Persiaran Seriemas, Nilai 71800, Negeri Sembilan, Malaysia.
EM longchiauming@gmail.com
RI Mastuki, Mohd Fahmi/GPF-9942-2022; Ramasamy, Kalavathy/ABA-8532-2021;
   Ming, Long Chiau/J-5210-2015; Neoh, Chin Fen/AFV-9536-2022; Lim, Siong
   Meng/I-5697-2015
OI Ramasamy, Kalavathy/0000-0002-1666-9230; Ming, Long
   Chiau/0000-0002-6971-1383; Neoh, Chin Fen/0000-0003-2462-2958; Lim,
   Siong Meng/0000-0003-1905-6584
FU Research Entity Initiative: UiTM, Ministry of Higher Education
   [600-IRMI/DANA5/3/REI (0004/2016)]; KPJ Healthcare University College
FX The current study is funded by Research Entity Initiative:
   600-IRMI/DANA5/3/REI (0004/2016), UiTM, Ministry of Higher Education and
   KPJ Healthcare University College.
CR Accordini S, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0008-0
   Amadesi S, 2012, CIRCULATION, V125, P1774, DOI 10.1161/CIRCULATIONAHA.111.089763
   Asha'ari ZA, 2010, ANN ACAD MED SINGAP, V39, P619
   Benson M, 2002, CYTOKINE, V18, P20, DOI 10.1006/cyto.2002.1012
   Benson M, 2001, CLIN EXP ALLERGY, V31, P361, DOI 10.1046/j.1365-2222.2001.01045.x
   Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x
   Callebaut I, 2014, AM J RHINOL ALLERGY, V28, P290, DOI 10.2500/ajra.2014.28.4052
   Cardell LO, 2016, NPJ PRIM CARE RESP M, V26, DOI 10.1038/npjpcrm.2015.82
   Choi SM, 2013, ALLERGY, V68, P365, DOI 10.1111/all.12053
   CHUNG KF, 1990, EUR RESPIR J, V3, P329
   Crossley KM, 2004, ARCH PHYS MED REHAB, V85, P815, DOI 10.1016/S0003-9993(03)00613-0
   Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755
   Gould HJ, 2012, ESSENTIALS OF REGIONAL ANESTHESIA, P83, DOI 10.1007/978-1-4614-1013-3_4
   Jackie Clark P, 2010, EAR CANDLES CANDLING
   Kushnir NM, 2005, DEPTH REV ALLERGIC R
   Lisowska B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139206
   Lourenço EA, 2016, INT ARCH OTORHINOLAR, V20, P6, DOI 10.1055/s-0035-1564437
   Mackawan S, 2007, J BODYW MOV THER, V11, P9, DOI 10.1016/j.jbmt.2005.11.001
   Manuel AM, 2012, TROP BIOMED, V29, P360
   McDonald JL, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/591796
   Molina-Ortega F, 2014, MAN THER, V19
   Nee RJ, 2006, PHYS THER SPORT, V7, P36, DOI 10.1016/j.ptsp.2005.10.002
   O'Connor TM, 2004, J CELL PHYSIOL, V201, P167, DOI 10.1002/jcp.20061
   Packard KA, 2003, INT IMMUNOPHARMACOL, V3, P909, DOI 10.1016/S1567-5769(02)00235-7
   Petti Filomena Bangrazi, 2002, J Tradit Chin Med, V22, P104
   Pols DHJ, 2016, SCAND J PRIM HEALTH, V34, P143, DOI 10.3109/02813432.2016.1160629
   Prepageran N, 2014, ASIA PAC ALLERGY, V4, P142, DOI 10.5415/apallergy.2014.4.3.142
   Rafferty J, 2007, CAN FAM PHYSICIAN, V53, P2121
   Seidman MD, 2015, OTOLARYNG HEAD NECK, V152, pS1, DOI 10.1177/0194599814561600
   Sejari N, 2014, ARCH PHARM PRACT, V5, P144, DOI 10.4103/2045-080X.142048
   Sejari N, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-0988-1
   Shiue HS, 2008, J ALTERN COMPLEM MED, V14, P689, DOI 10.1089/acm.2007.0669
   Shiue HS, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1418-0
   Skoner DR, 2001, J ALLERGY CLIN IMMUN, V108, pS2, DOI 10.1067/mai.2001.115569
   Taylor MB, 2012, RHINOLOGY, V50, P139, DOI 10.4193/Rhino10.140
   Verhoef MJ, 2006, BMC COMPLEM ALTERN M, V6, P1
   Wallace DV, 2008, J ALLERGY CLIN IMMUN, V122, pS1, DOI 10.1016/j.jaci.2008.06.003
NR 37
TC 3
Z9 3
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JUL
PY 2017
VL 96
IS 30
AR e7511
DI 10.1097/MD.0000000000007511
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FB9SY
UT WOS:000406480500026
PM 28746195
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Church, D
   Stapleton, P
   Vasudevan, A
   O'Keefe, T
AF Church, Dawson
   Stapleton, Peta
   Vasudevan, Anitha
   O'Keefe, Tom
TI Clinical EFT as an evidence-based practice for the treatment of
   psychological and physiological conditions: A systematic review
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Review
DE emotional freedom techniques (EFT); anxiety; depression; PTSD; somatic
   symptoms; pain; insomnia; obesity
ID EMOTIONAL FREEDOM TECHNIQUES; POSTTRAUMATIC-STRESS-DISORDER;
   COGNITIVE-BEHAVIORAL THERAPY; MERIDIAN-BASED INTERVENTION; PTSD
   REMEDIATION; CONTROLLED-TRIAL; ANXIETY; VETERANS; METAANALYSIS; SYMPTOMS
AB Background: Since the turn of the century, Emotional Freedom Techniques (EFT) has come into widespread use in medical and psychological treatment settings. It is also used as self-help by tens of millions of people each year. Clinical EFT, the manualized form of the method, has been validated as an "evidence-based " practice using criteria published by the American Psychological Association (APA) Division 12 Task Force on Empirically Validated Therapies. Its three essential ingredients are exposure, cognitive framing, and acupressure. Objectives: In 2013 we published a paper defining Clinical EFT and reviewing published research. It has been viewed or downloaded over 36,000 times, indicating widespread interest in this treatment modality. Here we update our findings based on subsequently published literature and propose directions for future research. Method: We performed a systematic review of the literature to identify randomized controlled trials (RCTs) and meta-analyses. Retrieval of 4,167 results resulted in the identification of 56 RCTs (n = 2,013), 41 of which were published subsequent to our earlier review, as well as eight meta-analyses. Results: RCTs have found EFT treatment to be effective for (a) psychological conditions such as anxiety, depression, phobias, and posttraumatic stress disorder (PTSD); (b) physiological issues such as pain, insomnia, and autoimmune conditions; (c) professional and sports performance; and (d) biological markers of stress. Meta-analyses evaluating the effect of EFT treatment have found it to be "moderate " to "large. " Successful independent replication studies have been carried out for anxiety, depression, PTSD, phobias, sports performance, and cortisol levels. We outline the next steps in EFT research. These include determining its impact on cancer, heart disease, diabetes, and cognitive impairment; analysis of the large-scale datasets made possible by mobile apps; and delivery through channels such as virtual practitioner sessions, artificial intelligence agents, online courses, apps, virtual reality platforms, and standardized group therapy. Conclusions: Subsequent research has confirmed the conclusions of earlier studies. These find Clinical EFT to be efficacious for a range of psychological and physiological conditions. Comparatively few treatment sessions are required, treatment is effective whether delivered in person or virtually, and symptom improvements persist over time. Treatment is associated with measurable biological effects in the dimensions of gene expression, brain synchrony, hormonal synthesis, and a wide range of biomarkers. Clinical EFT is a stable and mature method with an extensive evidence base. Its use in primary care settings as a safe, rapid, reliable, and effective treatment for both psychological and medical diagnoses continues to grow.
C1 [Church, Dawson; Vasudevan, Anitha] Natl Inst Integrat Healthcare, Petaluma, CA 95404 USA.
   [Stapleton, Peta; O'Keefe, Tom] Bond Univ, Dept Soc & Design, Gold Coast, Qld, Australia.
C3 Bond University
RP Church, D (corresponding author), Natl Inst Integrat Healthcare, Petaluma, CA 95404 USA.
EM dawsonchurch@gmail.com
RI Church, Dawson/HKO-8152-2023
OI Church, Dawson/0000-0001-7324-3140; O'Keefe, Tom
   Donald/0000-0001-5072-534X
CR Abdi M.R., 2015, APPL MATH ENG MANAGE, V3, P476
   AlHadethe A, 2015, Journal of Traumatic Stress Disorders & Treatment, V04, DOI [10.4172/2324-8947.1000145, DOI 10.4172/2324-8947.1000145]
   American Psychological Association (APA), 2021, PSYCH TREATM
   Anderson K, 2019, Energy Psychology, V11, P31, DOI [10.9769/epj.2019.11.2.ka, 10.9769/EPJ.2019.11.2.KA, DOI 10.9769/EPJ.2019.11.2.KA, 10.9769/epj.2019.11.2.ka]
   [Anonymous], 2017, ELIFE, V6, DOI 10.7554/eLife.23693
   [Anonymous], 2007, SHOCK AWE HITS HOME
   [Anonymous], 2015, Science, V349, DOI DOI 10.1126/SCIENCE.AAC4716
   [Anonymous], Complementary and Integrative Health - Whole Health
   [Anonymous], 2006, EVIDENCE BASED PRACT
   [Anonymous], 2012, ENERGY PSYCHOL THEOR, DOI DOI 10.9769/EPJ.2012.4.1.PS.TS.BP
   [Anonymous], 2008, Treatment of posttraumatic stress disorder: An assessment of the evidence
   [Anonymous], 2009, ENERGY PSYCHOL THEOR, DOI DOI 10.9769/EPJ.2009.1.1.KS
   [Anonymous], 2017, Clinical practice guideline for the treatment of posttraumatic stress disorder (PTSD) in adults
   Babamahmoodi A, 2015, IRAN J ALLERGY ASTHM, V14, P37
   Bach D, 2019, J EVID-BASED INTEGR, V24, DOI 10.1177/2515690X18823691
   Baghini AA, 2020, V13, P625
   Baker A.H., 2010, Energy Psychol, V2, P13, DOI [DOI 10.9769/EPJ.2010.2.2, 10.9769/EPJ.2010.2.2.AHB.LSS, DOI 10.9769/EPJ.2010.2.2.AHB.LSS]
   Baker BS, 2015, EUR J INTEGR MED, V7, P136, DOI 10.1016/j.eujim.2014.10.004
   Baker M, 2016, NATURE, V533, P452, DOI 10.1038/533452a
   Bakir N, 2022, PERSPECT PSYCHIATR C, V58, P1502, DOI 10.1111/ppc.12957
   Balha S M., 2020, International Journal of Novel Research in Healthcare and Nursing, V7, P30
   Begley CG, 2012, NATURE, V483, P531, DOI 10.1038/483531a
   Beutler L.E., 2005, EVIDENCE BASED PRACT
   Boath E., 2014, Current Research in Psychology, V5, P64, DOI [10.3844/crpsp.2014.64.72, DOI 10.3844/CRPSP.2014.64.72]
   Boath E, 2014, EURO J INTEGR MED, V6, P614, DOI DOI 10.1016/J.EUJIM.2014.07.011
   Boath E., 2013, INNOVATIVE PRACTICE, V1, P1
   Boath E, 2017, SOC WORK EDUC, V36, P715, DOI 10.1080/02615479.2017.1297394
   Bougea AM, 2013, EXPLORE-NY, V9, P91, DOI 10.1016/j.explore.2012.12.005
   Brattberg G., 2008, Integrative Medicine: A Clinician's Journal, V7, P30
   Callahan R., 1985, Five minute phobia cure
   Chambless D., 1996, The Clinical Psychologist, V51, P5
   Chambless D.L., 1998, CLIN PSYCHOL-UK, V51, P3
   Chambless DL, 1998, J CONSULT CLIN PSYCH, V66, P7, DOI 10.1037/0022-006X.66.1.7
   Chatwin Hannah, 2016, Integr Med (Encinitas), V15, P27
   Church D., 2009, Open Sports Sci. J, V2, P94, DOI [DOI 10.2174/1875399X00902010094, 10.2174/1875399X00902010094]
   Church D., 2009, EFT MINI MANUAL
   Church D., 2018, The EFT Manual, V3rd
   Church D., 2012, Traumatology, V18, P73, DOI DOI 10.1177/1534765611426788
   Church D., 2012, SPORT J, P1
   Church D., 2019, Psychology, V10, P941, DOI 10.4236/psych.2019.107061
   Church D., 2010, Anti Aging Ther, V13, P35
   Church D., 2010, INTEGRATIVE MED, V9, P40
   Church D., 2013, INT J SCI RES REP, V2, P315, DOI DOI 10.9734/JSRR/2013/3500
   Church D., 2014, Traumatology, V20, P172, DOI [DOI 10.1037/H0099831, 10.1037/h0099831]
   Church D., 2013, The EFT Manual, V3rd
   Church D., 2009, INT J HEALING CARING, V9, P1
   Church D., 2013, Psychology, V4, P645, DOI [DOI 10.4236/PSYCH.2013.48092, 10.4236/psych.2013.48092]
   Church D., 2017, HUFFINGTON POST
   Church Dawson, 2022, Adv Mind Body Med, V36, P13
   Church D, 2020, JMIR MHEALTH UHEALTH, V8, DOI 10.2196/18545
   Church D, 2020, J NERV MENT DIS, V208, P632, DOI 10.1097/NMD.0000000000001222
   Church D, 2019, J NERV MENT DIS, V207, P315, DOI 10.1097/NMD.0000000000000975
   Church D, 2018, J NERV MENT DIS, V206, P783, DOI 10.1097/NMD.0000000000000878
   Church D, 2018, EXPLORE-NY, V14, P131, DOI 10.1016/j.explore.2017.10.009
   Church D, 2018, J EVID-BASED INTEGR, V23, DOI 10.1177/2156587218756510
   Church D, 2018, AM J HEALTH PROMOT, V32, P112, DOI 10.1177/0890117116661154
   Church Dawson, 2017, Perm J, V21, P16, DOI [10.7812/tpp/16-100, 10.7812/TPP/16-100]
   Church D, 2016, Archives of Scientific Psychology, V4, P38, DOI [10.1037/arc0000028, DOI 10.1037/ARC0000028, 10.1037/arc0000028]
   Church D, 2016, EXPLORE-NY, V12, P355, DOI 10.1016/j.explore.2016.06.012
   Church Dawson, 2012, Depress Res Treat, V2012, P257172, DOI 10.1155/2012/257172
   Church D, 2014, EXPLORE-NY, V10, P162, DOI 10.1016/j.explore.2014.02.005
   Church D, 2014, EXPLORE-NY, V10, P24, DOI 10.1016/j.explore.2013.10.006
   Church D, 2013, J NERV MENT DIS, V201, P153, DOI 10.1097/NMD.0b013e31827f6351
   Church D, 2012, J NERV MENT DIS, V200, P891, DOI 10.1097/NMD.0b013e31826b9fc1
   Cici R, 2022, ALTERN THER HEALTH M, V28, P20
   Clond M, 2016, J NERV MENT DIS, V204, P388, DOI 10.1097/NMD.0000000000000483
   Craig G., 2008, THE EFT MANUAL
   Craig G., 1995, Emotional freedom techniques: The manual
   Craig G., 2009, International Journal of Healing and Caring, V9, P1
   Curtin KB, 2017, SCAND J PAIN, V17, P156, DOI 10.1016/j.sjpain.2017.08.006
    CD, 2016, Journal of Sleep Disorders Treatment & Care, V05, DOI [10.4172/2325-9639.1000171, 10.4172/2325-9639.1000171, DOI 10.4172/2325-9639.1000171]
   Department of Applied Psychology Akamai University Hilo HI, 2016, Energy Psychology, V8, P17, DOI [10.9769/epj.2016.8.1.mm, DOI 10.9769/EPJ.2016.8.1.MM, 10.9769/EPJ.2016.8.1.MM]
   DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102
   Di Rienzo F, 2019, PsyArXiv, DOI [10.31234/osf.io/s3hce, 10.31234/osf.io/s3hce, DOI 10.31234/OSF.IO/S3HCE]
   Diamandis P.H., 2020, FUTURE IS FASTER YOU
   Diamond John., 1985, Life Energy
   Dincer B, 2020, EXPLORE-NY, DOI [10.1016/j.explore.2020.11.006, DOI 10.1016/J.EXPLORE.2020.11.006]
   Dincer B, 2021, EXPLORE-NY, V17, P109, DOI 10.1016/j.explore.2020.11.012
   Dominguez SK, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.01425
   Eley TC, 1997, CURR OPIN NEUROBIOL, V7, P279, DOI 10.1016/S0959-4388(97)80017-7
   Energy Psychology, 2017, WORK PAP AUTH REV EN
   Fang JL, 2009, HUM BRAIN MAPP, V30, P1196, DOI 10.1002/hbm.20583
   Feinstein D., 2009, Energy Psychology: Theory, Research, Treatment, V1, P45, DOI [10.9769/EPJ.2009.1.1.DF, DOI 10.9769/EPJ.2009.1.1.DF]
   Feinstein D, 2022, FRONT PSYCHOL, V13, DOI 10.3389/fpsyg.2022.856209
   Feinstein David, 2021, Adv Mind Body Med, V35, P17
   Feinstein D, 2015, The Neuropsychotherapist, P38, DOI [10.12744/tnpt(10)038-049, 10.12744/tnpt(10)038-049]
   Feinstein D, 2010, REV GEN PSYCHOL, V14, P283, DOI 10.1037/a0021252
   Fernandez E, 2021, CLIN PSYCHOL PSYCHOT, V28, P1535, DOI 10.1002/cpp.2594
   Flint G.A., 2005, TRAUMA TREATMENT TEC, P125
   Food and Drug Administration (FDA), 1998, GUID IND E9 STAT PRI
   Fox L., 2013, Energy Psychol Theory Res Treat, V5, P15, DOI [DOI 10.9769/EPJ.2013.5.2, 10.9769/EPJ.2013.5.2]
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Gaesser A.H., 2020, PROMOTING MIND BODY, P283, DOI 10.1037/0000157-020
   Gaesser AH, 2017, J ALTERN COMPLEM MED, V23, P102, DOI 10.1089/acm.2015.0316
   Gamble A, 2020, ASLIB J INFORM MANAG, V72, P509, DOI 10.1108/AJIM-11-2019-0316
   Gaudiano BA, 2012, RES SOCIAL WORK PRAC, V22, P647, DOI 10.1177/1049731512448468
   Geronilla L, 2016, Energy Psychology, V8, P29, DOI [10.9769/epj.2016.8.2.lg, 10.9769/EPJ.2016.8.2, DOI 10.9769/EPJ.2016.8.2, DOI 10.9769/EPJ.2016.8.2.LG]
   Ghaderi Z, 2021, IRAN J NURS MIDWIFE, V26, P531, DOI 10.4103/ijnmr.IJNMR_188_19
   Gilomen SA, 2015, J BEHAV THER EXP PSY, V48, P140, DOI 10.1016/j.jbtep.2015.03.012
   Glisenti K, 2021, J EAT DISORD, V9, DOI 10.1186/s40337-020-00358-5
   Goodheart G.J., 1987, Youll be better
   Gorman J M, 1996, Depress Anxiety, V4, P160, DOI 10.1002/(SICI)1520-6394(1996)4:4<160::AID-DA2>3.0.CO;2-J
   Gurret J.M., 2012, Energy Psychology, V4, P26, DOI [10.9769/EPJ.2012.4.2.JPH, DOI 10.9769/EPJ.2012.4.2.JPH]
   Hartung J., 2012, Energy Psychology, V4, P33, DOI DOI 10.9769/EPJ.2012.4.1.JH
   Hodge P., 2011, Energy Psychology Journal, V3, P13, DOI [https://doi.org/10.9769/EPJ.2011.3.2.PMH.CYJ, DOI 10.9769/EPJ.2011.3.2.PMH.CYJ]
   Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037
   Inangil D, 2020, EUR J INTEGR MED, V33, DOI 10.1016/j.eujim.2019.101041
   Jain S., 2012, ENERGY PSYCHOL THEOR, V4, P13, DOI DOI 10.9769/EPJ.2012.4.2.SJ
   Jasubhai DS, 2018, International Journal of Emergency Mental Health and Human Resilience, V20, DOI [10.4172/1522-4821.1000403, DOI 10.4172/1522-4821.1000403, 10.4172/1522-4821.1000403]
   Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045
   Jones S., 2011, Energy Psychology: Theory, Research, Treatment, V3, P19
   Kaiser Jocelyn., 2012, Science, DOI DOI 10.1126/SCIENCE.AAL0628
   Karatzias T, 2011, J NERV MENT DIS, V199, P372, DOI 10.1097/NMD.0b013e31821cd262
   König N, 2019, BRAIN SCI, V9, DOI 10.3390/brainsci9080206
   Kornstein SG, 2019, J CLIN PSYCHIAT, V80, DOI 10.4088/JCP.18m12378
   Kwak HY, 2020, EXPLORE-NY, V16, P170, DOI 10.1016/j.explore.2019.08.006
   Lambrou P., 2003, Subtle Energ. Energy Med, V14, P239
   Lane J., 2009, EPJ, V1, P31, DOI DOI 10.9769/EPJ.2009.1.1.JRL
   Ledger K.E., 2019, INT J HEAL CARING, V19, P3
   Lee JH, 2013, PSYCHOTHER PSYCHOSOM, V82, P55
   Lee J.-H., 2011, J Orient Neuropsychiatry, V22, P101, DOI [10.7231/JON.2011.22.4.101, DOI 10.7231/JON.2011.22.4.101]
   Lee JH, 2015, Energy Psychology, V7, P22, DOI [10.9769/epj.2015.7.1.jhl, DOI 10.9769/EPJ.2015.7.1.JHL]
   Llewellyn-Edwards T., 2012, Journal for the National Council of Psychotherapists, V1, P14
   Llewellyn-Edwards T., 2013, CLIN EFT HDB, V2, P2
   Madoni E R., 2018, J. Bimbingan Konseling, P28
   Mavranezouli I, 2020, PSYCHOL MED, V50, P542, DOI 10.1017/S0033291720000070
   Mavranezouli I, 2020, J CHILD PSYCHOL PSYC, V61, P18, DOI 10.1111/jcpp.13094
   McCallion F., 2012, ENERGY PSYCHOL THEOR, V4, P35, DOI [10.9769/EPJ.2012.4.2.FM, DOI 10.9769/EPJ.2012.4.2.FM]
   Mehdipour Asieh, 2022, J Complement Integr Med, V19, P737, DOI [10.1515/jcim-2020-0245, 10.1515/jcim-2020-0245]
   Mishkind MC, 2017, CURR PSYCHIAT REP, V19, DOI 10.1007/s11920-017-0836-0
   Mollon P, 2007, PRIMARY CARE COMMUN, V12, P123, DOI 10.1080/17468840701750836
   Napadow V, 2007, PAIN, V130, P254, DOI 10.1016/j.pain.2006.12.003
   National Institute for Health Clinical Excellence (NICE), 2009, END CLIN GUID 2008 2
   Nelms JA, 2016, EXPLORE-NY, V12, P416, DOI 10.1016/j.explore.2016.08.001
   Noble C., 2021, B PSYCHOL, V1, P100022, DOI [10.1016/j.etdah.2021.100022, DOI 10.3917/BUPSY.515.0471]
   Norcross JC, 2019, PSYCHOTHERAPY, V56, P391, DOI 10.1037/pst0000228
   North Carolina State University, 2015, Energy Psychology, V7, P13, DOI [10.9769/epj.2015.11.01.an, 10.9769/EPJ.2015.7.2.AN, DOI 10.9769/EPJ.2015.7.2.AN]
   Ortner N., 2014, Energy Psychology: Theory, Research, and Treatment, V6, P14, DOI [10.9769/EPJ.2014.6.2.NO.JH.MC, DOI 10.9769/EPJ.2014.6.2.NO.JH.MC]
   PalmerHoffman J., 2011, ENERGY PSYCHOL, V3, P1, DOI [10.9769/EPJ.2011.3.1.JPH, DOI 10.9769/EPJ.2011.3.1.JPH]
   Pasahow R., 2010, Energy Psychology Journal, V2, P57, DOI [10.9769/EPJ.2010.2.2.RP, DOI 10.9769/EPJ.2010.2.2.RP]
   Patterson SL, 2016, NURS EDUC TODAY, V40, P104, DOI 10.1016/j.nedt.2016.02.003
   Popescu A, 2021, ENERGY PSYCHOL THEOR, V13, P12, DOI [10.9769/EPJ.2021.13.1.AP, DOI 10.9769/EPJ.2021.13.1.AP]
   Rahmi T., 2012, Pedagogi, V12, P107, DOI [10.24036/pedagogi.v12i2.2212, DOI 10.24036/PEDAGOGI.V12I2.2212]
   Rizzo A, 2017, EUR J PSYCHOTRAUMATO, V8, DOI 10.1080/20008198.2017.1414560
   Rogers R, 2015, Energy Psychology, V7, P26, DOI [10.9769/epj.2015.7.2.rr, 10.9769/EPJ.2015.7.2.RR, DOI 10.9769/EPJ.2015.7.2.RR, DOI 10.9769/EPJ.2015.11.1.RR, 10.9769/EPJ.2015.11.01.RR, DOI 10.9769/EPJ.2015.11.01.RR]
   Rotheram M, 2012, SPORT PSYCHOL, V26, P551, DOI 10.1123/tsp.26.4.551
   Rowe J.E., 2005, COUNSELING CLIN PSYC, V2, P104, DOI DOI 10.1002/JCLP.10189
   Salas MM, 2011, EXPLORE-NY, V7, P155, DOI 10.1016/j.explore.2011.02.005
   Samueli Institute, 2015, Energy Psychology, V7, P33, DOI [10.9769/epj.2015.7.2.sl, 10.9769/EPJ.2015.7.2.SL, DOI 10.9769/EPJ.2015.7.2.SL, DOI 10.9769/EPJ.2015.11.01.SL]
   Santa Rosa CA, 2022, Energy Psychology, V14, P22, DOI [10.9769/epj.2022.14.1.jf, 10.9769/EPJ.2022.14.1.JF, DOI 10.9769/EPJ.2022.14.1.JF]
   School of Psychology Bond University Gold Coast Queensland 4229 Australia, 2019, OBM Integrative and Complementary Medicine, V4, P1, DOI [10.21926/obm.icm.1904065, 10.21926/obm.icm.1904065, DOI 10.21926/OBM.ICM.1904065]
   School of Psychology Bond University Gold Coast Queensland 4229 Australia, 2018, OBM Integrative and Complementary Medicine, V4, P1, DOI [10.21926/obm.icm.1901010, 10.21926/obm.icm.1901010, DOI 10.21926/OBM.ICM.1901010]
   School of Psychology Bond University Queensland Australia, 2016, Energy Psychology, V8, P18, DOI [10.9769/epj.2016.8.2.ps, 10.9769/EPJ.2016.8.2.PS, DOI 10.9769/EPJ.2016.8.2.PS]
   School of Psychology Bond University Queensland Australia, 2018, OBM Integrative and Complementary Medicine, V3, P1, DOI [10.21926/obm.icm.1803014, 10.21926/obm.icm.1803014, DOI 10.21926/OBM.ICM.1803014]
   Sebastian B, 2017, EXPLORE-NY, V13, P16, DOI 10.1016/j.explore.2016.10.001
   SELIGMAN MEP, 1995, AM PSYCHOL, V50, P965, DOI 10.1037/0003-066X.50.12.965
   Sezgin N., 2009, Energy Psychology: Theory, Research, and Treatment, V1, P23, DOI [10.9769/EPJ.2009.1.1.NS, DOI 10.9769/EPJ.2009.1.1.NS]
   Smith T.G., 1989, IND TRUJILLO    0829, V25, P93
   Song S.-Y., 2014, J ORIENTAL NEUROPSYC, V25, P29, DOI [10.7231/jon.2014.25.1.029, DOI 10.7231/JON.2014.25.1.029]
   Souilm N, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-10456-w
   Spielmans GI, 2020, J NERV MENT DIS, V208, P628, DOI 10.1097/NMD.0000000000001181
   Stapleton P, 2020, Open Journal of Social Sciences, V08, P158, DOI [10.4236/jss.2020.82014, 10.4236/jss.2020.82014, DOI 10.4236/JSS.2020.82014]
   Stapleton P., 2022, C PRESENTATION 11 AN
   Stapleton P., 2021, C HELD OM I RHIN NEW
   Stapleton P, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e04058
   Stapleton P, 2020, PSYCHOL TRAUMA-US, V12, P869, DOI 10.1037/tra0000563
   Stapleton P, 2020, J ALTERN COMPLEM MED, V26, P98, DOI 10.1089/acm.2019.0309
   Stapleton P, 2017, COMPLEMENT THER CLIN, V28, P136, DOI 10.1016/j.ctcp.2017.06.004
   Stapleton P, 2016, APPL PSYCHOL-HLTH WE, V8, P232, DOI 10.1111/aphw.12070
   Stapleton P, 2016, EXPLORE-NY, V12, P113, DOI 10.1016/j.explore.2015.12.001
   Stapleton Peta, 2013, ISRN Psychiatry, V2013, P573532, DOI 10.1155/2013/573532
   Stapleton P, 2011, BEHAV CHANGE, V28, P1, DOI 10.1375/bech.28.1.1
   Stein P.K., 2011, Energy Psychology: Theory, Research, and Treatment, V3, P11, DOI DOI 10.9769/EPJ.2011.3.1.PKS.AJB
   Swingle P G., 2004, Subtle Energies Energy Medicine, V15, P75
   Swingle P.G., 2010, Energy Psychology: Theory, Research, Treatment, V2, P27, DOI [10.9769/epj.2010.2.1.pgs, DOI 10.9769/EPJ.2010.2.1.PGS]
   Tack L, 2021, ECLINICALMEDICINE, V39, DOI 10.1016/j.eclinm.2021.101081
   Thomas RM, 2017, Energy Psychology, V9, P26, DOI [10.9769/epj.2017.9.1.rt, 10.9769/EPJ.2017.9.1.RT, DOI 10.9769/EPJ.2017.9.1.RT]
   Thompson Mark, 2015, Time, V185, P40
   Tolin DF, 2015, CLIN PSYCHOL-SCI PR, V22, P317, DOI 10.1111/cpsp.12122
   Vural PI, 2019, COMPLEMENT THER CLIN, V35, P224, DOI 10.1016/j.ctcp.2019.02.011
   Waite W.L., 2003, The Scientific Review of Mental Health Practice: Objective Investigations of Controversial and Unorthodox Claims in Clinical Psychology, Psychiatry, and Social Work, V2, P20
   Wampold BE, 2005, J CONSULT CLIN PSYCH, V73, P914, DOI 10.1037/0022-006X.73.5.914
   Wells S, 2003, J CLIN PSYCHOL, V59, P943, DOI 10.1002/jclp.10189
   Wittfoth D, 2022, NEUROIMAGE-CLIN, V34, DOI 10.1016/j.nicl.2022.102996
   Wittfoth D, 2020, BMC NEUROSCI, V21, DOI 10.1186/s12868-020-00597-x
   Yount Garret, 2019, Glob Adv Health Med, V8, p2164956119832500, DOI [10.1177/2164956119832500, 10.1177/2164956119832500]
NR 186
TC 34
Z9 43
U1 1
U2 37
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD NOV 10
PY 2022
VL 13
AR 951451
DI 10.3389/fpsyg.2022.951451
PG 40
WC Psychology, Multidisciplinary
WE Social Science Citation Index (SSCI)
SC Psychology
GA 6P2VG
UT WOS:000890791800001
PM 36438382
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Xiong, XJ
   Li, SJ
   Zhang, YQ
AF Xiong, X. J.
   Li, S. J.
   Zhang, Y. Q.
TI Massage therapy for essential hypertension: a systematic review
SO JOURNAL OF HUMAN HYPERTENSION
LA English
DT Review
ID TRADITIONAL CHINESE MEDICINE; BLOOD-PRESSURE; ALTERNATIVE THERAPIES;
   RANDOMIZED-TRIAL; TISSUE MASSAGE; BREAST-CANCER; GLOBAL BURDEN;
   COMPLEMENTARY; ACUPUNCTURE; PERSPECTIVE
AB Massage, an ancient Chinese healing art, is widely practiced for symptom relief in hypertensive patients with anxiety, depression, headache, vertigo, chronic pain in neck, shoulder and back. A large number of case series and clinical trials have been published. However, it is still unclear whether massage can be recommended as an effective therapy for essential hypertension (EH). We estimated the current clinical evidence of massage for EH. Articles published before 10 December 2013 were searched using Cochrane Library, PubMed, EMBASE, Chinese Scientific Journal Database (VIP), Chinese Biomedical Literature Database, Wanfang data and Chinese National Knowledge Infrastructure. Randomized controlled trials comparing massage with any type of control intervention were included. Trials testing massage combined with antihypertensive drugs versus antihypertensive drugs were included as well. Meta-analysis was performed on the effects on blood pressure (BP). Twenty-four articles involving 1962 patients with EH were selected. Methodological quality of most trials was evaluated as generally low. Meta-analyses demonstrated that massage combined with antihypertensive drugs may be more effective than antihypertensive drugs alone in lowering both systolic BP (SBP; mean difference (MD): - 6.92 (- 10.05, - 3.80); P<0.0001) and diastolic BP (MD: - 3.63 (- 6.18, - 1.09); P = 0.005); massage appears beneficial for reducing SBP (MD: - 3.47 (- 5.39, - 1.56); P = 0.0004) for hypertensive patients as compared with antihypertensive drugs. Safety of massage is still unclear. There is some encouraging evidence of massage for EH. However, because of poor methodological quality, the evidence remains weak. Rigorously designed trials are needed to validate the use of massage in future.
C1 [Xiong, X. J.] China Acad Chinese Med Sci, Guanganmen Hosp, Dept Cardiol, Beijing 100053, Peoples R China.
   [Li, S. J.] Tsinghua Univ, Sch Life Sci, Dept Biol Sci & Technol, Beijing 100084, Peoples R China.
   [Zhang, Y. Q.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada.
C3 China Academy of Chinese Medical Sciences; Guang'anmen Hospital, CACMS;
   Tsinghua University; McMaster University
RP Xiong, XJ (corresponding author), China Acad Chinese Med Sci, Guanganmen Hosp, Dept Cardiol, Beixiange 5, Beijing 100053, Peoples R China.
EM xiongxingjiangtcm@163.com
RI Xiong, Xingjiang/Q-8626-2019; li, shengjie/GQH-1789-2022
CR [Anonymous], CHINA J TRADIT CHIN
   [Anonymous], CHIN MANIPULATION QI
   [Anonymous], J NURS
   [Anonymous], ZHEJIANG J TRADIT CH
   [Anonymous], J BODYWORK MOVEMENT
   [Anonymous], J CLIN ACUPUNCT MOXI
   [Anonymous], J AUST TRADIT MED SO
   [Anonymous], CHANGCHUN U CHIN MED
   [Anonymous], MED J QILU
   [Anonymous], MED INFORM
   [Anonymous], TRADIT CHIN MED RES
   [Anonymous], COCHRANE HDB SYSTEMA
   [Anonymous], CHANGCHUN U CHIN MED
   [Anonymous], THESIS U S FLORIDA
   [Anonymous], ACTA ACAD MED QINGDA
   [Anonymous], 2005, SEQUENCE STRATIGRAPH
   [Anonymous], J HUNAN COLL TRADIT
   [Anonymous], CHINESE MANIPULATION
   [Anonymous], BMJ BRIT MED J
   [Anonymous], J YICHUN COLL
   [Anonymous], J PR MED
   [Anonymous], GLOBAL TRADIT CHIN M
   [Anonymous], TRADIT CHIN MED RES
   [Anonymous], SHANGHAI MED PHARM J
   Aourell Moa, 2005, Complement Ther Clin Pract, V11, P242, DOI 10.1016/j.ctcp.2005.02.008
   Bramlage P, 2010, J CLIN HYPERTENS, V12, P666, DOI 10.1111/j.1751-7176.2010.00322.x
   Brattberg G, 1999, EUR J PAIN, V3, P235, DOI 10.1016/S1090-3801(99)90050-2
   Braun LA, 2012, J THORAC CARDIOV SUR, V144, P1453, DOI 10.1016/j.jtcvs.2012.04.027
   Brook RD, 2013, HYPERTENSION, V61, P1360, DOI 10.1161/HYP.0b013e318293645f
   CAFARELLI E, 1992, SPORTS MED, V14, P1, DOI 10.2165/00007256-199214010-00001
   Cambron JA, 2006, J ALTERN COMPLEM MED, V12, P65, DOI 10.1089/acm.2006.12.65
   Cassileth BR, 2004, J PAIN SYMPTOM MANAG, V28, P244, DOI 10.1016/j.jpainsymman.2003.12.016
   [陈军 Chen Jun], 2010, [中华中医药杂志, China Journal of Traditional Chinese Medicine and Pharmacy], V25, P1708
   Cherkin DC, 2003, ANN INTERN MED, V138, P898, DOI 10.7326/0003-4819-138-11-200306030-00011
   Cherkin DC, 2001, ARCH INTERN MED, V161, P1081, DOI 10.1001/archinte.161.8.1081
   Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2
   Day A L, 2009, G Ital Med Lav Ergon, V31, pB25
   Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569
   Ernst E, 2003, RHEUMATOLOGY, V42, P1101, DOI 10.1093/rheumatology/keg306
   Ezzati Majid, 2002, Lancet (North American Edition), V360, P1347, DOI 10.1016/S0140-6736(02)11403-6
   Fellowes D., 2004, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858, 10.1002/14651858.CD002287.pub2, DOI 10.1002/14651858.CD002287.PUB2]
   Field TM, 1998, AM PSYCHOL, V53, P1270, DOI 10.1037/0003-066X.53.12.1270
   Fisher JW, 1914, J AMER MED ASSOC, V63, P1752
   Flachskampf FA, 2007, CIRCULATION, V115, P3121, DOI 10.1161/CIRCULATIONAHA.106.661140
   Gagnier JJ, 2006, ANN INTERN MED, V144, P364, DOI 10.7326/0003-4819-144-5-200603070-00013
   GOATS GC, 1994, BRIT J SPORT MED, V28, P153, DOI 10.1136/bjsm.28.3.153
   Hansen NV, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004989.pub2
   Hernandez-Reif M, 1998, INT J NEUROSCI, V96, P1
   Hu J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028696
   Hu Jun, 2005, Zhong Xi Yi Jie He Xue Bao, V3, P429
   Hur MH, 2007, INT J NEUROSCI, V117, P1281, DOI 10.1080/00207450600936650
   IRNICH D., 2001, British Medical Journal, V322, P1
   Jiang WY, 2005, TRENDS PHARMACOL SCI, V26, P558, DOI 10.1016/j.tips.2005.09.006
   Ju MS, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/403251
   Kangas M, 2008, PSYCHOL BULL, V134, P700, DOI 10.1037/a0012825
   Kaplan NM, 2006, HYPERTENSION, V48, P815, DOI 10.1161/01.HYP.0000241069.80574.76
   Kaye AD, 2008, J ALTERN COMPLEM MED, V14, P125, DOI 10.1089/acm.2007.0665
   Kearney PM, 2005, LANCET, V365, P217, DOI 10.1016/S0140-6736(05)70151-3
   Kutner JS, 2008, ANN INTERN MED, V149, P369, DOI 10.7326/0003-4819-149-6-200809160-00003
   Lawes CMM, 2008, LANCET, V371, P1513, DOI 10.1016/S0140-6736(08)60655-8
   Lee MS, 2007, J HYPERTENS, V25, P1525, DOI 10.1097/HJH.0b013e328092ee18
   Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8
   Liberati Alessandro, 2009, PLoS Med, V6, pe1000100, DOI 10.1371/journal.pmed.1000100
   Lin MC, 2001, CIRCULATION, V103, P2038
   Liu JP, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002968
   Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9
   Mansoor GA, 2001, AM J HYPERTENS, V14, P971, DOI 10.1016/S0895-7061(01)02172-0
   Mashour NH, 1998, ARCH INTERN MED, V158, P2225, DOI 10.1001/archinte.158.20.2225
   Moeini Mahin, 2011, Iran J Nurs Midwifery Res, V16, P61
   Moraska A, 2010, EVID-BASED COMPL ALT, V7, P409, DOI 10.1093/ecam/nen029
   Morris KT, 2000, AM J SURG, V179, P407, DOI 10.1016/S0002-9610(00)00358-5
   Moyer CA, 2004, PSYCHOL BULL, V130, P3, DOI 10.1037/0033-2909.130.1.3
   Olney CM, 2005, BIOL RES NURS, V7, P98, DOI 10.1177/1099800405280827
   Perlman AI, 2006, ARCH INTERN MED, V166, P2533, DOI 10.1001/archinte.166.22.2533
   Plaugher G, 2002, J MANIP PHYSIOL THER, V25, P221, DOI 10.1067/mmt.2002.123171
   Rees RW, 2000, EUR J CANCER, V36, P1359, DOI 10.1016/S0959-8049(00)00099-X
   REISSLAND N, 1987, SOC SCI MED, V25, P231, DOI 10.1016/0277-9536(87)90226-7
   Schulz KF, 2010, ANN INTERN MED, V152, P726, DOI 10.7326/0003-4819-152-11-201006010-00232
   Scott M, 2009, J EQUINE VET SCI, V29, P687, DOI 10.1016/j.jevs.2009.07.017
   Supa'at I, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/171852
   Vickers A, 1999, BRIT MED J, V319, P1254, DOI 10.1136/bmj.319.7219.1254
   Vickers A., 2004, Cochrane Database of Systematic Reviews, DOI [DOI 10.1002/14651858.CD000390.PUB2, 10.1002/14651858.CD000390.pub2]
   Vora CK, 2005, CURR HYPERTENS REP, V7, P275, DOI 10.1007/s11906-005-0025-0
   Wandell P E, 2013, Diabetes Metab, V39, P411, DOI 10.1016/j.diabet.2013.02.002
   Wang JX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082745
   Wang J, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/215254
   Wang J, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/978398
   Wang J, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/706125
   Wang J, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/268542
   Weerapong P, 2005, SPORTS MED, V35, P235, DOI 10.2165/00007256-200535030-00004
   Wu XY, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/812179
   Xiong XJ, 2014, COMPLEMENT THER MED, V22, P187, DOI 10.1016/j.ctim.2013.11.005
   Xiong XJ, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/275279
   Xiong XJ, 2013, HYPERTENS RES, V36, P570, DOI 10.1038/hr.2013.18
   Zeitlin D, 2000, PSYCHOSOM MED, V62, P83, DOI 10.1097/00006842-200001000-00012
NR 95
TC 32
Z9 41
U1 1
U2 50
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-9240
EI 1476-5527
J9 J HUM HYPERTENS
JI J. Hum. Hypertens.
PD MAR
PY 2015
VL 29
IS 3
BP 143
EP 151
DI 10.1038/jhh.2014.52
PG 9
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Cardiovascular System & Cardiology
GA CB5MM
UT WOS:000349671500002
PM 24990417
DA 2026-01-16
ER

PT J
AU Ge, WB
   Qu, Y
   Hou, TT
   Zhang, JY
   Li, QJ
   Yang, LL
   Cao, LQ
   Li, JD
   Zhang, SY
AF Ge, Wanbao
   Qu, Yuan
   Hou, Tingting
   Zhang, Jiayin
   Li, Qiuju
   Yang, Lili
   Cao, Lanqing
   Li, Jindong
   Zhang, Shanyong
TI Case report: Surgical treatment of a primary giant epithelioid
   hemangioendothelioma of the spine with total en-bloc spondylectomy
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE epithelioid hemangioendothelioma; total en-bloc spondylectomy; vertebral
   lesion; vascular neoplasm; giant
AB BackgroundEpithelioid hemangioendothelioma (EHE) is an extremely uncommon malignant neoplasm that originates from vascular endothelial or pre-endothelial cells. In this report, we present the case of patient who was diagnosed with a primary giant EHE of the spine and underwent treatment with total en-bloc spondylectomy (TES). Case presentationA 43-year-old male patient with a history of he presented to our hospital with chronic and progressive back pain. Physical examination revealed weakened sensation of acupuncture and touch on the left costal arch, while relatively normal neurological functions were preserved. Radiological examinations identified a giant destructive soft tissue lesion occupying the T8 vertebral region, with moderate destruction of the pedicle and lamina, as well as the 7(th) left rib. A preoperative biopsy of the 8th vertebra resulted in a diagnosis of epithelioid hemangioendothelioma(EHE). Postoperative immunohistochemical and pathological reports confirmed the presence of EHE in the left ribs and T8 ribs. The patient underwent resection of the 7th left rib and posterior pedicle screw fixation with 8 pairs of screws and a titanium mesh cage. Subsequently, thoracic en bloc spondylectomy was performed on the T8 vertebra. The patient did not receive radiation or chemotherapy following surgery. Over a period of 3 years, the patient remained free of disease and relapse. ConclusionThe use of transarterial embolization with spherical embolic agents (TES) has been demonstrated to be a safe, effective, and reliable treatment option for hepatic epithelioid hemangioendothelioma (EHE). Nevertheless, it is crucial to conduct long-term follow-up of this patient in order to assess their clinical outcome.
C1 [Ge, Wanbao; Qu, Yuan; Hou, Tingting; Zhang, Jiayin; Li, Qiuju; Yang, Lili; Zhang, Shanyong] Jilin Univ, Affiliated Hosp 2, Dept Spine Surg, Changchun, Jilin, Peoples R China.
   [Cao, Lanqing] Jilin Univ, Affiliated Hosp 2, Dept Pathol, Changchun, Jilin, Peoples R China.
   [Li, Jindong] Jilin Univ, Affiliated Hosp 2, Dept Thorac Surg, Changchun, Jilin, Peoples R China.
C3 Jilin University; Jilin University; Jilin University
RP Zhang, SY (corresponding author), Jilin Univ, Affiliated Hosp 2, Dept Spine Surg, Changchun, Jilin, Peoples R China.
EM jzhangshanyong@yeah.net
RI Hou, Tingting/LMN-6690-2024
FU Natural Science Foundation of Science and Technology Department of Jilin
   Province [20200201551JC]
FX Acknowledgments The authors would like to acknowledge the financial
   support from the Natural Science Foundation of Science and Technology
   Department of Jilin Province (20200201551JC).
CR Aflatoon K, 2004, CLIN ORTHOP RELAT R, P191
   Agulnik M, 2013, ANN ONCOL, V24, P257, DOI 10.1093/annonc/mds237
   Chevreau C, 2013, CANCER-AM CANCER SOC, V119, P2639, DOI 10.1002/cncr.28109
   Deyrup AT, 2008, AM J SURG PATHOL, V32A, P924, DOI 10.1097/PAS.0b013e31815bf8e6
   Doyle LA, 2016, AM J SURG PATHOL, V40, P94, DOI 10.1097/PAS.0000000000000511
   Flucke U, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-131
   Kerry G, 2012, CASE REP ONCOL, V5, P91, DOI 10.1159/000336947
   Kitaichi M, 1998, EUR RESPIR J, V12, P89, DOI 10.1183/09031936.98.12010089
   Lee SS, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000019859
   Luzzati A, 2015, EUR SPINE J, V24, P2156, DOI 10.1007/s00586-014-3510-9
   Ma JM, 2011, EUR SPINE J, V20, P1371, DOI 10.1007/s00586-011-1798-2
   Mendlick MR, 2001, AM J SURG PATHOL, V25, P684, DOI 10.1097/00000478-200105000-00019
   Mentzel T, 1997, AM J SURG PATHOL, V21, P363, DOI 10.1097/00000478-199704000-00001
   Munier O, 2017, CANCER RADIOTHER, V21, P222, DOI 10.1016/j.canrad.2016.11.006
   O'Shea Bendan M, 2014, Radiol Case Rep, V9, P984, DOI 10.2484/rcr.v9i4.984
   Riley DS, 2017, J CLIN EPIDEMIOL, V89, P218, DOI 10.1016/j.jclinepi.2017.04.026
   Rosenbaum E, 2020, MODERN PATHOL, V33, P591, DOI 10.1038/s41379-019-0368-8
   Sardaro A, 2014, ONCOL REV, V8, P82, DOI 10.4081/oncol.2014.259
   Shiba S, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4934-0
NR 19
TC 6
Z9 9
U1 0
U2 11
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD MAR 28
PY 2023
VL 13
AR 1109643
DI 10.3389/fonc.2023.1109643
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA D2FX9
UT WOS:000966943100001
PM 37056332
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Nagraj, SK
   George, RP
   Shetty, N
   Levenson, D
   Ferraiolo, DM
   Shrestha, A
AF Nagraj, Sumanth Kumbargere
   George, Renjith P.
   Shetty, Naresh
   Levenson, David
   Ferraiolo, Debra M.
   Shrestha, Ashish
TI Interventions for managing taste disturbances
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE *Acupuncture Therapy; Quality of Life; Randomized ControlledTrials as
   Topic; TasteDisorders [diagnosis; *therapy]; Taste Perception; Zinc
   Compounds [adverse effects; *therapeutic use]; Adolescent; Adult; Child;
   Humans
ID PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; ZINC SUPPLEMENTATION;
   CANCER-PATIENTS; PILOCARPINE TREATMENT; GUSTATORY FUNCTION; SMELL
   DYSFUNCTION; UREMIC HYPOGEUSIA; ORAL ZINC; ACUITY
AB Background
   The sense of taste is very much essential to the overall health of an individual. It is a necessary component to enjoy one's food, which in turn provides nutrition to an individual. Any disturbance in taste perception can hamper quality of life in such patients by influencing their appetite, body weight and psychological well-being. Taste disorders have been treated using different modalities of treatment and there is no consensus for the best intervention. Hence this Cochrane Review was undertaken. This is an update of the Cochrane Review first published in November 2014.
   Objective
   To assess the effects of interventions for the management of patients with taste disturbances. S e a r c h m e t h o d s Cochrane Oral Health's Information Specialist searched the following databases: Cochrane Oral Health's Trials Register (to 4 July 2017); the Cochrane Central Register of Controlled Trials (CENTRAL; 2017 Issue 6) in the Cochrane Library (searched 4 July 2017); MEDLINE Ovid (1946 to 4 July 2017); Embase Ovid (1980 to 4 July 2017); CINAHL EBSCO (1937 to 4 July 2017); and AMED Ovid (1985 to 4 July 2017). The US National Institutes of Health Ongoing Trials Register ClinicalTrials. gov (www. clinicaltrials. gov) and the World Health Organization International Clinical Trials Registry Platform were searched for trials. Abstracts from scientific meetings and conferences were searched on 25 September 2017. No restrictions were placed on the language or date of publication when searching the electronic databases.
   Selection criteria
   We included all randomised controlled trials (RCTs) comparing any pharmacological agent with a control intervention or any nonpharmacological agent with a control intervention. We also included cross-over trials in the review.
   Data collection and analysis
   Two pairs of review authors independently, and in duplicate, assessed the quality of trials and extracted data. Wherever possible, we contacted trial authors for additional information. We collected adverse events information from the trials.
   Main results
   We included 10 trials (581 participants), nine of which we were able to include in the quantitative analyses (566 participants). We assessed three trials (30%) as having a low risk of bias, four trials (40%) at high risk of bias and three trials (30%) as having an unclear risk of bias. We only included studies on taste disorders in this review that were either idiopathic, or resulting from zinc deficiency or chronic renal failure.
   Of these, nine trials with 544 people compared zinc supplements to placebo for patients with taste disorders. The participants in two trials were children and adolescents with respective mean ages of 10 and 11.2 years and the other seven trials had adult participants. Out of these nine, two trials assessed the patient-reported outcome for improvement in taste acuity using zinc supplements (risk ratio (RR) 1.40, 95% confidence interval (CI) 0.94 to 2.09; 119 participants, very low-quality evidence). We meta-analysed for taste acuity improvement using objective outcome (continuous data) in idiopathic and zinc-deficient taste disorder patients (standardised mean difference (SMD) 0.44, 95% CI 0.23 to 0.65; 366 participants, three trials, very low-quality evidence). We also analysed one cross-over trial separately using the first half of the results for taste detection (mean difference (MD) 2.50, 95% CI 0.93 to 4.07; 14 participants, very low-quality evidence), and taste recognition (MD3.00, 95% CI 0.66 to 5.34; 14 participants, very low-quality evidence). Wemetaanalysed taste acuity improvement using objective outcome (dichotomous data) in idiopathic and zinc-deficient taste disorder patients (RR 1.42, 95% 1.09 to 1.84; 292 participants, two trials, very low-quality evidence). Out of the nine trials using zinc supplementation, four reported adverse events like eczema, nausea, abdominal pain, diarrhoea, constipation, decrease in blood iron, increase in blood alkaline phosphatase, and minor increase in blood triglycerides.
   One trial tested taste discrimination using acupuncture (MD 2.80, 95% CI -1.18 to 6.78; 37 participants, very low-quality evidence). No adverse events were reported in the acupuncture trial. None of the included trials could be included in the meta-analysis for health-related quality of life in taste disorder patients.
   Authors' conclusions
   We found very low-quality evidence that was insufficient to conclude on the role of zinc supplements to improve taste acuity reported by patients and very low-quality evidence that zinc supplements improve taste acuity in patients with zinc deficiency/ idiopathic taste disorders. We did not find any evidence to conclude the role of zinc supplements for improving taste discrimination, or any evidence addressing health-related quality of life due to taste disorders.
   We found very low-quality evidence that is not sufficient to conclude on the role of acupuncture for improving taste discrimination in cases of idiopathic dysgeusia (distortion of taste) and hypogeusia (reduced ability to taste). We were unable to draw any conclusions regarding the superiority of zinc supplements or acupuncture as none of the trials compared these interventions.
C1 [Nagraj, Sumanth Kumbargere] Melaka Manipal Med Coll, Dept Oral Med & Oral Radiol, Fac Dent, Jalan Batu Hampar, Bukit Baru 75150, Melaka, Malaysia.
   [George, Renjith P.] Melaka Manipal Med Coll, Dept Oral Pathol, Fac Dent, Melaka, Malaysia.
   [Shetty, Naresh] IMU, Sch Dent Oral & Maxillofacial Surg, Bukit Jalil, Malaysia.
   [Levenson, David; Ferraiolo, Debra M.] NYU, Coll Dent, Dept Oral & Maxillofacial Pathol Radiol & Med, New York, NY USA.
   [Shrestha, Ashish] BP Koirala Inst Hlth Sci, Coll Dent, Community Dent, Dharan, Nepal.
C3 Manipal Academy of Higher Education (MAHE); Manipal University College
   Malaysia; Manipal Academy of Higher Education (MAHE); Manipal University
   College Malaysia; New York University; B.P. Koirala Institute of Health
   Sciences
RP Nagraj, SK (corresponding author), Melaka Manipal Med Coll, Dept Oral Med & Oral Radiol, Fac Dent, Jalan Batu Hampar, Bukit Baru 75150, Melaka, Malaysia.
EM sumikn@rediffmail.com
RI Kumbargere Nagraj, Sumanth/L-6740-2019; GEORGE, RENJITH/X-2394-2019
OI Kumbargere Nagraj, Sumanth/0000-0003-1798-3245; SHETTY,
   NARESH/0000-0003-1130-0802; Shrestha, Ashish/0000-0003-3449-7134; 
FU Faculty of Dentistry, Melaka-Manipal Medical College, Manipal
   University, Melaka Campus, Malaysia; Faculty of Dentistry, International
   Medical University, Kuala Lumpur, Malaysia; National Institute for
   Health Research (NIHR), UK; NIHR, via Cochrane Infrastructure funding;
   Cochrane Oral Health Global Alliance; Global Alliance; Professor BV
   Moses Centre for Research & Training in Evidence-Informed Healthcare,
   ICMR Advanced Centre for Evidence-Based Medicine, Cochrane South Asia,
   Christian Medical College, Vellore, India
FX Internal sourcesFaculty of Dentistry, Melaka-Manipal Medical College,
   Manipal University, Melaka Campus, Malaysia.Faculty of Dentistry,
   International Medical University, Kuala Lumpur, Malaysia.External
   sourcesNational Institute for Health Research (NIHR), UK.This project
   was supported by the NIHR, via Cochrane Infrastructure funding to
   Cochrane Oral Health. The views and opinions expressed herein are those
   of the review authors and do not necessarily reflect those of the
   Systematic Reviews Programme, the NIHR, the NHS or the Department of
   HealthCochrane Oral Health Global Alliance, Other.The production of
   Cochrane Oral Health reviews has been supported financially by our
   Global Alliance since 2011 (oralhealth. cochrane.
   org/partnerships-alliances). Contributors over the past year have been
   the American Association of Public Health Dentistry, USA; the British
   Association for the Study of Community Dentistry, UK; the British
   Society of Paediatric Dentistry, UK; the Canadian Dental Hygienists
   Association, Canada; the Centre for Dental Education and Research at All
   India Institute of Medical Sciences, India; the National Center for
   Dental Hygiene Research & Practice, USA; New York University College of
   Dentistry, USA; NHS Education for Scotland, UK; and the Swiss Society
   for Endodontology, SwitzerlandProfessor BV Moses Centre for Research &
   Training in Evidence-Informed Healthcare, ICMR Advanced Centre for
   Evidence-Based Medicine, Cochrane South Asia, Christian Medical College,
   Vellore, India.
CR Aframian DJ, 2007, ORAL DIS, V13, P88, DOI 10.1111/j.1601-0825.2006.01252.x
   [Anonymous], 2011, COCHRANE HDB SYSTEMA
   [Anonymous], REV MAN 5 REVMAN 5 V
   ATKINTHOR E, 1978, AM J CLIN NUTR, V31, P1948, DOI 10.1093/ajcn/31.10.1948
   BARRIE SA, 1987, AGENTS ACTIONS, V21, P222, DOI 10.1007/BF01974946
   BARTOSHUK LM, 1994, PHYSIOL BEHAV, V56, P1165, DOI 10.1016/0031-9384(94)90361-1
   BICKNELL JM, 1988, WESTERN J MED, V149, P457
   Birks J, 2009, COCHRANE DB SYST REV, DOI [10.1002/l4651858.CD003120.pub3, DOI 10.1002/L4651858.CD003120.PUB3]
   Brandt H, 2008, DTSCH Z AKUPUNKT, V51, P24, DOI 10.1016/j.dza.2008.01.003
   Brandt H HB., 2008, REV INT ACUPUNTURA, V2, P155
   Brisbois TD, 2011, ANN ONCOL, V22, P2086, DOI 10.1093/annonc/mdq727
   Bromley SM, 2000, AM FAM PHYSICIAN, V61, P427
   DAHL H, 1984, ACTA OPHTHALMOL, V62, P739
   de Moraes M, 2012, J ORAL PATHOL MED, V41, P281, DOI 10.1111/j.1600-0714.2011.01100.x
   DEEMS DA, 1991, ARCH OTOLARYNGOL, V117, P519
   Deniz F, 2016, EXP CLIN ENDOCR DIAB, V124, P562, DOI 10.1055/s-0042-108446
   EGGERT JV, 1982, INT J PED NEPHROL, V3, P21
   Femiano F, 2002, INT J ORAL MAX SURG, V31, P625, DOI 10.1054/ijom.2002.0276
   FIKENTSCHER R, 1987, LARYNGO RHINO OTOL, V66, P355, DOI 10.1055/s-2007-998675
   Fujiyama R, 2010, ODONTOLOGY, V98, P82, DOI 10.1007/s10266-009-0110-y
   Gardiner J, 2008, BIOSCIENCE HYPOTHESE, V1, P251
   Gondivkar SM, 2009, ORAL SURG ORAL MED O, V108, P876, DOI 10.1016/j.tripleo.2009.08.015
   Green A, 2013, J PSYCHOPHARMACOL, V27, P265, DOI 10.1177/0269881112472567
   Greenway FL, 2011, J AM COLL NUTR, V30, P178, DOI 10.1080/07315724.2011.10719958
   Halyard MY, 2007, INT J RADIAT ONCOL, V67, P1318, DOI 10.1016/j.ijrobp.2006.10.046
   Hartman-Petrycka M, 2016, APPETITE, V107, P159, DOI 10.1016/j.appet.2016.08.004
   Hawkes CH., 2002, The Most Common Complaints: Smell and Taste Complaints, V2nd ed
   Heckmann SM, 2005, J DENT RES, V84, P35, DOI 10.1177/154405910508400105
   Henkin RI, 2000, J COMPUT ASSIST TOMO, V24, P106, DOI 10.1097/00004728-200001000-00022
   HENKIN RI, 1976, AM J MED SCI, V272, P285, DOI 10.1097/00000441-197611000-00006
   HENKIN RI, 1963, J CLIN INVEST, V42, P727, DOI 10.1172/JCI104765
   Henkin RI, 1999, AM J MED SCI, V318, P392, DOI 10.1097/00000441-199912000-00006
   Henkin RI, 2007, AM J MED SCI, V334, P431, DOI 10.1097/MAJ.0b013e3180de4d97
   Henkin RI, 2014, NUTRITION, V30, P690, DOI 10.1016/j.nut.2013.11.003
   Henkin RI, 2013, AM J OTOLARYNG, V34, P477, DOI 10.1016/j.amjoto.2013.04.006
   Henkin RI, 2012, ARCH OTOLARYNGOL, V138, P1064, DOI 10.1001/2013.jamaoto.342
   Henkin RI, 2011, AM J OTOLARYNG, V32, P38, DOI 10.1016/j.amjoto.2009.10.001
   Henkin RI, 2011, AM J OTOLARYNG, V32, P178, DOI 10.1016/j.amjoto.2010.05.005
   Henkin RI, 2010, AM J MED SCI, V339, P249, DOI 10.1097/MAJ.0b013e3181cda0e3
   Henkin RI, 2009, METABOLISM, V58, P1717, DOI 10.1016/j.metabol.2009.05.027
   Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049
   Hovan AJ, 2010, SUPPORT CARE CANCER, V18, P1081, DOI 10.1007/s00520-010-0902-1
   Ikeda M, 2005, ACTA OTO-LARYNGOL, V125, P1203, DOI 10.1080/00016480510040173
   Ikeda Minoru, 2013, Nihon Jibiinkoka Gakkai Kaiho, V116, P17
   Imoscopi A, 2012, AGING CLIN EXP RES, V24, P570, DOI 10.3275/8520
   Ishimaru T, 2001, CHEM SENSES, V26, P91, DOI 10.1093/chemse/26.1.91
   Iwatsuki K, 2012, J PHARMACOL SCI, V118, P123, DOI 10.1254/jphs.11R08CP
   Jham Bruno C, 2009, J Oral Sci, V51, P565
   Kamphuis MMJW, 2003, BRIT J NUTR, V90, P199, DOI 10.1079/BJN2003858
   Kashihara K, 2011, INTERNAL MED, V50, P2311, DOI 10.2169/internalmedicine.50.5935
   Kinnamon SC, 2012, ACTA PHYSIOL, V204, P158, DOI 10.1111/j.1748-1716.2011.02308.x
   Leek H, 2002, MICRON, V33, P153, DOI 10.1016/S0968-4328(01)00004-X
   Lyckholm Laurel, 2012, J Pain Palliat Care Pharmacother, V26, P111, DOI 10.3109/15360288.2012.676618
   MAHAJAN S K, 1992, Journal of Trace Elements in Experimental Medicine, V5, P33
   MAHAJAN SK, 1980, AM J CLIN NUTR, V33, P1517, DOI 10.1093/ajcn/33.7.1517
   MAHAJAN SK, 1982, AM J CLIN NUTR, V36, P1177, DOI 10.1093/ajcn/36.6.1177
   MAHAJAN SK, 1979, T AM SOC ART INT ORG, V25, P443
   Matson A, 2003, J RENAL NUTR, V13, P224, DOI 10.1016/S1051-2276(03)00072-4
   Mattes RD, 2004, HUM PSYCHOPHARM CLIN, V19, P81, DOI 10.1002/hup.562
   Mattes RD, 2009, ANNU REV NUTR, V29, P305, DOI 10.1146/annurev-nutr-080508-141108
   McLaughlin L, 2014, ONCOL NURS FORUM, V41, pE194, DOI 10.1188/14.ONF.E194-E202
   Miller IJ., 1995, NEUROL DIS, P521
   MISTRETTA CM, 1984, J ANAT, V138, P323
   MOSSMAN KL, 1978, INT J RADIAT ONCOL, V4, P663, DOI 10.1016/0360-3016(78)90190-6
   Mueller C, 2003, RHINOLOGY, V41, P2
   Nagao Y, 2010, MED SCI MONITOR, V16, pPI7
   Nagraj SK, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010470.pub2
   Najafizade N, 2013, J RES MED SCI, V18, P123
   National Institute on Deafness and other Communication Disorders, NIDCD FACT SHEET TAS
   National Institute on Deafness and other Communication Disorders, QUICK STAT TAST SMEL
   Ohno Tomohisa, 2003, Journal of Medical and Dental Sciences, V50, P101
   Ohnuki M, 2014, BMC ORAL HEALTH, V14, DOI 10.1186/1472-6831-14-36
   Padala Kalpana P, 2006, Prim Care Companion J Clin Psychiatry, V8, P178
   Porter SR, 2010, ORAL ONCOL, V46, P457, DOI 10.1016/j.oraloncology.2010.03.011
   Rawal S, 2016, CHEM SENSES, V41, P69, DOI 10.1093/chemse/bjv057
   Ripamonti C, 1998, CANCER-AM CANCER SOC, V82, P1938, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1938::AID-CNCR18>3.0.CO;2-U
   RUSSELL RM, 1980, AM J CLIN NUTR, V33, P2741, DOI 10.1093/ajcn/33.12.2741
   Sakagami M, 2009, ACTA OTO-LARYNGOL, V129, P1115, DOI 10.1080/00016480802552550
   Sakai C, 2017, 77 SCI SESS AM DIAB
   Sakai F, 2002, ACTA OTO-LARYNGOL, V122, P129, DOI 10.1080/00016480260046517
   Sakai F, 1995, Nihon Jibiinkoka Gakkai Kaiho, V98, P1135
   Sanchez Nebra J, 1993, Nutr Hosp, V8, P561
   Sasano T, 2010, BIOL PHARM BULL, V33, P1791, DOI 10.1248/bpb.33.1791
   Sergi G, 2017, CRIT REV FOOD SCI, V57, P3684, DOI 10.1080/10408398.2016.1160208
   Silverman J E, 1983, J Oral Med, V38, P14
   Smutzer G, 2008, LARYNGOSCOPE, V118, P1411, DOI 10.1097/MLG.0b013e31817709a0
   SOLOMONS N, 1974, CLIN RES, V22, P582
   Soter A, 2008, LARYNGOSCOPE, V118, P611, DOI 10.1097/MLG.0b013e318161e53a
   SPIELMAN AI, 1992, CHEM SENSES, V17, P451, DOI 10.1093/chemse/17.4.451
   Sprenger K B, 1983, Kidney Int Suppl, V16, pS315
   Stewart-Knox BJ, 2008, BRIT J NUTR, V99, P129, DOI 10.1017/S0007114507781485
   Strasser F, 2008, ONCOLOGIST, V13, P337, DOI 10.1634/theoncologist.2007-0217
   Sturniolo GC, 1985, J HEPATOL         S1, V1, psl36
   Tomita H, 1986, Auris Nasus Larynx, V13 Suppl 1, pS1
   Treldal C, 2016, ORAL DIS, V22, P123, DOI 10.1111/odi.12386
   Tupe RP, 2009, J AM COLL NUTR, V28, P388, DOI 10.1080/07315724.2009.10718101
   Velargo PA, SYNSEPALUM DULCIFICU
   Vent J, 2010, OTOLARYNG HEAD NECK, V142, P505, DOI 10.1016/j.otohns.2010.01.012
   WATSON AR, 1983, HUM NUTR-CLIN NUTR, V37, P219
   Wickham R S, 1999, Oncol Nurs Forum, V26, P697
   Wilken Marlene K, 2012, Clin J Oncol Nurs, V16, pE173
   Winkler S, 1999, J AM DENT ASSOC, V130, P1759, DOI 10.14219/jada.archive.1999.0133
   YOSHIDA S, 1991, Auris Nasus Larynx, V18, P153
NR 103
TC 41
Z9 53
U1 0
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2017
IS 12
AR CD010470
DI 10.1002/14651858.CD010470.pub3
PG 79
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FR5JG
UT WOS:000419102200040
PM 29260510
OA Green Submitted, Bronze
DA 2026-01-16
ER

PT J
AU Wang, J
   Li, DL
   Tang, W
   Guo, J
   Chen, WT
   Yong, Y
   Song, W
   Yu, GJ
   Feng, R
   Yuan, L
   Fu, GQ
   Song, JG
   Fan, LH
AF Wang, Jian
   Li, Dongli
   Tang, Wei
   Guo, Jun
   Chen, Wenting
   Yong, Yue
   Song, Wei
   Yu, Guijie
   Feng, Rui
   Yuan, Lan
   Fu, Guoqiang
   Song, Jiangang
   Fan, Lihua
TI Pretreatment with transcutaneous electrical acupoint stimulation to
   prevent postoperative ileus in patients undergoing laparoscopic colon
   surgery: study protocol for a randomised controlled trial
SO BMJ OPEN
LA English
DT Article
DE transcutaneous electrical acupoint stimulation (TEAS); postoperative
   ileus (POI); pretreatment
ID TYPE-1 MEMORY CELLS; RADICAL CYSTECTOMY; ECONOMIC BURDEN; ACUPUNCTURE;
   REDUCTION; INHIBITION; ALVIMOPAN; RECOVERY; DURATION; CANCER
AB Introduction Postoperative ileus (POI), a common complication after surgery, severely affects postoperative recovery. It is unclear whether pretreatment with transcutaneous electrical acupoint stimulation (TEAS) can improve recovery from POI. This trial will evaluate the effects of pretreatment with TEAS on POI. Methods and analysis This will be a prospective, randomised controlled trial. American Society of Anesthesiologists (ASA) physical status classification I-III level patients, aged 18-75 years and scheduled for laparoscopic colon surgery, will be included in the study. It is planned that 146 subjects will be randomised to the TEAS and sham TEAS (STEAS) groups. The groups will undergo two sessions of TEAS/STEAS daily for 3 days before surgery, with a final TEAS/STEAS treatment 30 min before anaesthesia. The primary endpoint of the study will be time to first defaecation. Secondary endpoints will include time to first flatus, time to tolerance of oral diet, GI-2 (composite outcome of time to first defaecation and time to tolerance of oral diet), time to independent walking, length of hospital stay, postoperative pain Visual Analogue Scale score on the first 3 days after surgery, analgesic requirements, complications and plasma concentrations of interferon-beta (IFN-beta), IFN-gamma, interleukin-6 (IL-6) and IL-1 beta. Multiple linear regression will be used to identify independent predictors of outcome measures. Ethics and dissemination This study has been approved by the Chinese Registered Clinical Trial Ethics Review Committee (No. ChiECRCT-20170084). The results of the trial will be published in an international peer-reviewed journal. Trial status The study was in the recruitment phase at the time of manuscript submission.
C1 [Wang, Jian; Tang, Wei; Guo, Jun; Chen, Wenting; Song, Wei; Yu, Guijie; Feng, Rui; Yuan, Lan; Fu, Guoqiang; Song, Jiangang] Shanghai Univ Tradit Chinese Med, Anesthesiol, Shuguang Hosp, Shanghai, Peoples R China.
   [Li, Dongli; Fan, Lihua] Wenzhou Med Univ, Affiliated Hosp 6, Anesthesiol, Lishui, Peoples R China.
   [Yong, Yue] Shanghai Univ Tradit Chinese Med, Res Inst Acupuncture Anesthesia, Shuguang Hosp, Shanghai, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Wenzhou Medical
   University; Shanghai University of Traditional Chinese Medicine
RP Fan, LH (corresponding author), Wenzhou Med Univ, Affiliated Hosp 6, Anesthesiol, Lishui, Peoples R China.
EM fanlihua_ls@126.com
RI Fan, Lihua/KOD-7046-2024; li, dongli/IWE-0692-2023; Tang,
   Wei/IZQ-1283-2023
FU National Natural Science Foundation of China [81703898, 81603702,
   81603700, 81774108]; SINCH Pharmaceuticals Tech.
FX The present study is supported by the project of the National Natural
   Science Foundation of China (Nos. 81703898, 81603702, 81603700 and
   81774108) and the commercial sponsorship of SINCH Pharmaceuticals Tech.
CR Adding LC, 2001, CARDIOVASC DRUG REV, V19, P41
   [Anonymous], 2008, CHIN J INTEGR MED, V14, P61, DOI 10.1007/s11655-007-9006
   Balogun JA, 1998, DISABIL REHABIL, V20, P41, DOI 10.3109/09638289809166052
   Boelens PG, 2014, ANN SURG, V259, P649, DOI 10.1097/SLA.0000000000000288
   Bragg D, 2015, CLIN NUTR, V34, P367, DOI 10.1016/j.clnu.2015.01.016
   Bungard TJ, 1999, PHARMACOTHERAPY, V19, P416, DOI 10.1592/phco.19.6.416.31040
   Chae HD, 2016, J ALTERN COMPLEM MED, V22, P465, DOI 10.1089/acm.2015.0161
   Deng G, 2013, ANN SURG ONCOL, V20, P1164, DOI 10.1245/s10434-012-2759-7
   Dindo D, 2004, ANN SURG, V240, P205, DOI [10.17116/hirurgia2018090162, 10.1097/01.sla.0000133083.54934.ae]
   Engel DR, 2010, NAT MED, V16, P1407, DOI 10.1038/nm.2255
   Goldstein JL., 2007, P & T, V32, P82
   Hilton WM, 2013, BJU INT, V111, P1054, DOI 10.1111/j.1464-410X.2012.11499.x
   Huang LP, 2017, TURK J MED SCI, V47, P1267, DOI 10.3906/sag-1611-35
   Iyer S, 2009, J MANAGE CARE PHARM, V15, P485, DOI 10.18553/jmcp.2009.15.6.485
   Jiang YQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065756
   Koscielny A, 2011, CURR OPIN GASTROEN, V27, P509, DOI 10.1097/MOG.0b013e32834bb7d7
   Maffezzini M, 2008, SURG ONCOL, V17, P41, DOI 10.1016/j.suronc.2007.09.003
   Melis M, 2006, ARCH SURG-CHICAGO, V141, P701, DOI 10.1001/archsurg.141.7.701
   Mikkelsen HB, 1999, CELL TISSUE RES, V295, P485, DOI 10.1007/s004410051254
   Moghadamyeghaneh Z, 2016, SURG ENDOSC, V30, P603, DOI 10.1007/s00464-015-4247-1
   Ng SSM, 2013, GASTROENTEROLOGY, V144, P307, DOI 10.1053/j.gastro.2012.10.050
   Nguyen DL, 2015, ANN GASTROENTEROL, V28, P475
   Rakel B, 2010, J PAIN, V11, P230, DOI 10.1016/j.jpain.2009.07.007
   Schwarz NT, 2001, GASTROENTEROLOGY, V121, P1354, DOI 10.1053/gast.2001.29605
   Song JG, 2012, ANESTHESIOLOGY, V116, P406, DOI 10.1097/ALN.0b013e3182426ebd
   Stakenborg N, 2019, GUT, V68, P1406, DOI 10.1136/gutjnl-2018-317263
   van Bree SHW, 2014, ANN SURG, V259, P708, DOI 10.1097/SLA.0b013e318293ee55
   van Bree SHW, 2012, NAT REV GASTRO HEPAT, V9, P675, DOI 10.1038/nrgastro.2012.134
   Vather R, 2013, J GASTROINTEST SURG, V17, P962, DOI 10.1007/s11605-013-2148-y
   Vilz TO, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-011014
   Wehner S, 2007, GUT, V56, P176, DOI 10.1136/gut.2005.089615
   Wehner S, 2009, GASTROENTEROLOGY, V136, P619, DOI 10.1053/j.gastro.2008.10.017
   Wolthuis AM, 2016, COLORECTAL DIS, V18, pO1, DOI 10.1111/codi.13210
   Wu ZQ, 2015, EUR SURG RES, V54, P127, DOI 10.1159/000369529
   You XM, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001968
   Zhang J, 2015, SCI REP-UK, V5, DOI 10.1038/srep15503
   Zhang Q, 2014, ANAESTHESIA, V69, P832, DOI 10.1111/anae.12639
NR 37
TC 2
Z9 2
U1 2
U2 14
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2020
VL 10
IS 8
AR e030694
DI 10.1136/bmjopen-2019-030694
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA NH0DY
UT WOS:000564351500026
PM 32819923
OA Green Submitted, Green Accepted, gold
DA 2026-01-16
ER

PT J
AU Zhang, YP
   Hu, RX
   Han, M
   Lai, BY
   Liang, SB
   Chen, BJ
   Robinson, N
   Chen, K
   Liu, JP
AF Zhang, Ya-Peng
   Hu, Rui-Xue
   Han, Mei
   Lai, Bao-Yong
   Liang, Shi-Bing
   Chen, Bing-Jie
   Robinson, Nicola
   Chen, Kevin
   Liu, Jian-Ping
TI Evidence Base of Clinical Studies on Qi Gong: A Bibliometric Analysis
SO COMPLEMENTARY THERAPIES IN MEDICINE
LA English
DT Article
DE Qigong; Ba Duan Jin; Bibliometric Analysis; Clinical Study; Non-drug
   therapy
ID QUALITY-OF-LIFE; QIGONG; INDIVIDUALS; EXERCISES; DISEASE; ADULTS; IMPACT
AB Objective: This bibliometric study aimed to systematically and comprehensively summarize the volume, breadth and evidence for clinical research on Qigong. And this bibliometric analysis also can provide the evidence of this field. Design: Bibliometric analysis.
   Methods: All types of primary and secondary studies on humans were included: systematic reviews, randomized clinical trials, non-randomized controlled clinical studies, case series and case reports. Chinese Biomedical Literature Database, China National Knowledge Infrastructure, Chinese Scientific Journal Database, Chinese Academic Conference Papers Database and Chinese Dissertation Database, PubMed and the Cochrane Library were searched from the date of inception to December 10, 2018. Bibliometric information, such as publication information, disease/condition, Qigong intervention and research results were extracted and analyzed.
   Results: A total of 886 clinical studies were identified: including 47 systematic reviews, 705 randomized clinical trials, 116 non-randomized controlled clinical studies, 12 case series and 6 case reports. The studies were conducted in 14 countries. The top 15 diseases/conditions studied were: diabetes, chronic obstructive pulmonary disease, hypertension, stroke, cervical spondylosis, lumbar disc herniation, insomnia, knee osteoarthritis, low back pain, and osteoporosis, Coronary heart disease, breast cancer, periarthritis of shoulder, depression, metabolic syndrome. Of the various Qigong exercises reported in these 886 clinical studies, Ba Duan Jin was the most frequently researched in 492 (55.5%) studies, followed by Health Qigong 107 (12.1%), Dao Yin Shu 85 (9.6%), Wu Qin Xi 67 (7.6%) and Yi Jin Jing 66 (7.4%). The most frequently used comparisons in randomized trials were maintaining normal way of life unchanged 149 (18.1%), the remaining controls included conventional treatment, mainly western medicine, Chinese herbal medicine, acupuncture, health education, psychological therapy, Yoga, Tai Chi and other non-drug therapy. The most frequently reported outcomes were physical function, quality of life, symptoms, pain and mental health indicators. Beneficial results from practicing Qigong were reported in 97% of studies.
   Conclusions: Qigong research publications have been increasing gradually. Reports on study types, participants, Qigong Intervention, and outcomes are diverse and inconsistent. There is an urgent need to develop a set of reporting standards for various interventions of Qigong. Further trials of high methodological quality with sufficient sample size and real world studies are needed to verify the effects of Qigong in health and disease management.
C1 [Zhang, Ya-Peng; Hu, Rui-Xue; Han, Mei; Liang, Shi-Bing; Robinson, Nicola; Liu, Jian-Ping] Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing 100029, Peoples R China.
   [Hu, Rui-Xue] China Acad Chinese Med Sci, Ctr Evidence Based Tradit Chinese Med, Inst Basic Res Clin Med, Beijing, Peoples R China.
   [Lai, Bao-Yong] Beijing Universal Chinese Med, Affiliated Hosp 3, Beijing 100029, Peoples R China.
   [Liang, Shi-Bing] Shanxi Univ Tradit Chinese Med, Coll Basic Med Sci, Taiyuan 030000, Peoples R China.
   [Chen, Bing-Jie] Beijing Univ Chinese Med, Coll Tradit Chinese Med, Beijing 100029, Peoples R China.
   [Robinson, Nicola] London South Bank Univ, Sch Hlth & Social Care, London SE1 0AA, England.
   [Chen, Kevin] Univ Maryland, Sch Med, Ctr Integrat Med, College Pk, MD 20742 USA.
   [Chen, Kevin] ShenZhen Univ, Fac Phys Educ, Shenzhen, Peoples R China.
   [Zhang, Ya-Peng; Hu, Rui-Xue; Han, Mei; Lai, Bao-Yong; Liang, Shi-Bing; Chen, Bing-Jie; Robinson, Nicola; Chen, Kevin; Liu, Jian-Ping] Guangzhou Med Univ, Inst Integrated Tradit Chinese Med & Western Med, Guangzhou, Peoples R China.
C3 Beijing University of Chinese Medicine; Institute of Basic Research In
   Clinical Medicine, CACMS; China Academy of Chinese Medical Sciences;
   Beijing University of Chinese Medicine; London South Bank University;
   University System of Maryland; University of Maryland College Park;
   Shenzhen University; Guangzhou Medical University
RP Liu, JP (corresponding author), Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing 100029, Peoples R China.; Liu, JP (corresponding author), Guangzhou Med Univ, Inst Integrated Tradit Chinese Med & Western Med, Guangzhou, Peoples R China.
EM zhangyapeng@bucm.edu.cn; ruixue_hu@bucm.edu.cn; hanmeizoujin@163.com;
   by_lai@126.com; zyi20126185@163.com; tian8388@163.com;
   nicky.robinson@lsbu.ac.uk; KChen@som.umaryland.edu; Liujp@bucm.edu.cn
RI Hu, Rui-xue/AAC-3527-2019
OI Hu, Rui-xue/0000-0002-1333-0485
FU key program of the National Natural Science Foundation of China
   [81830115]; Beijing University of Chinese Medicine [2016-ZXFZJJ-011];
   Overseas Expertise Project, Ministry of Education of China [MS20080009]
FX This work was supported by the key program of the National Natural
   Science Foundation of China (No. 81830115), and by Beijing University of
   Chinese Medicine funding project for the research and development of
   evidence base medicine of TCM clinical scientific research ability and
   international development (No.2016-ZXFZJJ-011); Prof. Nicola Robinson
   (visiting professor of Beijing UniUversity of Chinese Medicine) is
   funded by Overseas Expertise Project, Ministry of Education of
   China(MS20080009).
CR [Anonymous], 2003, MANAGEMENT CANC CHIN
   [Anonymous], 2017, RES EVOLUTION HYDROL
   [Anonymous], 2010, International statistical classifications of diseases and related health problems. 10th Revision Vol 2 Instruction Manual
   Bai ZG, 2015, AM J CHINESE MED, V43, P1525, DOI 10.1142/S0192415X15500871
   Bongi SM, 2012, CLIN EXP RHEUMATOL, V30, pS51
   Chen DZ, 2016, J AM GERIATR SOC, V64, P1513, DOI 10.1111/jgs.14218
   Chen Kevin, 2002, Integr Cancer Ther, V1, P345, DOI 10.1177/1534735402238187
   Chen Z, 2013, CANCER-AM CANCER SOC, V119, P1690, DOI 10.1002/cncr.27904
   Hartley L, 2015, COCHRANE DATABASE SY
   Kemp Carol A, 2004, J Holist Nurs, V22, P351, DOI 10.1177/0898010104269313
   Kuan SC, 2012, BIOL RES NURS, V14, P139, DOI 10.1177/1099800411399645
   Li M, 2016, CHINESE MED MODERN D, V14, P49
   Li X.S., 2008, THESIS
   Li Y., 2011, 9 NAT SPORTS SCI C 2, P2
   Liu J. Y., 2006, J HLTH MANAGEMENT, V4, P1
   Liu TJ, 2016, TRADITIONAL CHINESE, P2
   Liu TJ, 2005, QIGONG STUDY CHINESE
   Lynch M, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3931
   Oh B, 2010, ANN ONCOL, V21, P608, DOI 10.1093/annonc/mdp479
   Song R, 2017, PARKINSONISM RELAT D, V41, P3, DOI 10.1016/j.parkreldis.2017.05.019
   Tang N, 2016, CHINESE MED MODERN D, V14, P111
   Tao J, 2017, SCI REP-UK, V7, DOI 10.1038/srep41581
   Teut M, 2016, J PAIN, V17, P796, DOI 10.1016/j.jpain.2016.03.003
   Wang CX., 1994, Chin J Gerontol, P90
   Wang CX, 1984, J TRADITIONAL CHINES, P27
   Wang L., 2009, THESIS
   Wei X, 2015, MATURITAS, V82, P346, DOI 10.1016/j.maturitas.2015.08.013
   Xiao CM, 2015, J AM GERIATR SOC, V63, P1420, DOI 10.1111/jgs.13478
   Yang XM, 2009, J JIANGXI U TRADITIO, V21, P32
   [杨莹骊 Yang Yingli], 2019, [中医杂志, Journal of Traditional Chinese Medicine], V60, P664
   Yu J., 2018, CHINESE MED MODERN D, V16, P56
   Zhang F, 2014, J PHYS THER SCI, V26, P881, DOI 10.1589/jpts.26.881
   ZHU GM, 2012, SHANGHAI J TRADITION, V46, P10
NR 33
TC 61
Z9 66
U1 16
U2 207
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0965-2299
EI 1873-6963
J9 COMPLEMENT THER MED
JI Complement. Ther. Med.
PD MAY
PY 2020
VL 50
AR 102392
DI 10.1016/j.ctim.2020.102392
PG 8
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA LR4ZL
UT WOS:000535704900005
PM 32444061
OA Green Accepted, hybrid
DA 2026-01-16
ER

PT J
AU Nagraj, SK
   Naresh, S
   Srinivas, K
   George, PR
   Shrestha, A
   Levenson, D
   Ferraiolo, DM
AF Nagraj, Sumanth Kumbargere
   Naresh, Shetty
   Srinivas, Kandula
   George, P. Renjith
   Shrestha, Ashish
   Levenson, David
   Ferraiolo, Debra M.
TI Interventions for the management of taste disturbances
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; ZINC SUPPLEMENTATION;
   CANCER-PATIENTS; PILOCARPINE TREATMENT; GUSTATORY FUNCTION; UREMIC
   HYPOGEUSIA; ORAL ZINC; SMELL; ACUITY
AB Background
   The sense of taste is very much essential to the overall health of the individual. It is a necessary component to enjoying one's food, which in turn provides nutrition to an individual. Any disturbance in taste perception can hamper the quality of life in such patients by influencing their appetite, body weight and psychological well-being. Taste disorders have been treated using different modalities of treatment and there is no consensus for the best intervention. Hence this Cochrane systematic review was undertaken.
   Objectives
   To assess the effects of interventions for the management of patients with taste disturbances.
   Search methods
   We searched the Cochrane Oral Health Group Trials Register (to 5 March 2014), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2014), MEDLINE via OVID (1948 to 5 March 2014), EMBASE via OVID (1980 to 5 March 2014), CINAHL via EBSCO (1980 to 5 March 2014) and AMED via OVID (1985 to 5 March 2014). We also searched the relevant clinical trial registries and conference proceedings from the International Association of Dental Research/American Association of Dental Research (to 5 March 2014), Association for Research in Otolaryngology (to 5 March 2014), the US National Institutes of Health Trials Register (to 5 March 2014), metaRegister of Controlled Trials (mRCT) (to 5 March 2014), World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP) (to 5 March 2014) and International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Clinical Trials Portal (to 5 March 2014).
   Selection criteria
   We included all randomised controlled trials (RCTs) comparing any pharmacological agent with a control intervention or any non-pharmacological agent with a control intervention. We also included cross-over trials in the review.
   Data collection and analysis
   Two authors independently, and in duplicate, assessed the quality of trials and extracted data. Wherever possible, we contacted study authors for additional information. We collected adverse events information from the trials.
   Main results
   We included nine trials (seven parallel and two cross-over RCTs) with 566 participants. We assessed three trials (33.3%) as having a low risk of bias, four trials (44.5%) at high risk of bias and two trials (22.2%) as having an unclear risk of bias. We only included studies on taste disorders in this review that were either idiopathic, or resulting from zinc deficiency or chronic renal failure.
   Of these, eight trials with 529 people compared zinc supplements to placebo for patients with taste disorders. The participants in two trials were children and adolescents with respective mean ages of 10 and 11.2 years and the other six trials had adult participants. Out of these eight, two trials assessed the patient reported outcome for improvement in taste acuity using zinc supplements (RR 1.45, 95% CI 1.0 to 2.1; very low quality evidence). We included three trials in the meta-analysis for overall taste improvement (effect size 0.44, 95% CI 0.23 to 0.65; moderate quality evidence). Two other trials described the results as taste acuity improvement and we conducted subgroup analyses due to clinical heterogeneity. One trial described the results as taste recognition improvement for each taste sensation and we analysed this separately. We also analysed one cross-over trial separately using the first half of the results. None of the zinc trials tested taste discrimination. Only one trial tested taste discrimination using acupuncture (effect size 2.80, 95% CI -1.18 to 6.78; low quality evidence).
   Out of the eight trials using zinc supplementation, four reported adverse events like eczema, nausea, abdominal pain, diarrhoea, constipation, decrease in blood iron, increase in blood alkaline phosphatase, and minor increase in blood triglycerides. No adverse events were reported in the acupuncture trial.
   None of the included trials could be included in the meta-analysis for health-related quality of life in taste disorder patients.
   Authors' conclusions
   We found very low quality evidence that was insufficient to conclude on the role of zinc supplements to improve taste perception by patients, however we found moderate quality evidence that zinc supplements improve overall taste improvement in patients with zinc deficiency/idiopathic taste disorders. We also found low quality evidence that zinc supplements improve taste acuity in zinc deficient/idiopathic taste disorders and very low quality evidence for taste recognition improvement in children with taste disorders secondary to chronic renal failure. We did not find any evidence to conclude the role of zinc supplements for improving taste discrimination, or any evidence addressing health-related quality of life due to taste disorders.
   We found low quality evidence that is not sufficient to conclude on the role of acupuncture for improving taste discrimination in cases of idiopathic dysgeusia (distortion of taste) and hypogeusia (reduced ability to taste). We were unable to draw any conclusions regarding the superiority of zinc supplements or acupuncture as none of the trials compared these interventions.
C1 [Nagraj, Sumanth Kumbargere] Melaka Manipal Med Coll, Fac Dent, Dept Oral Med & Oral Radiol, Bukit Baru 75150, Melaka, Malaysia.
   [Naresh, Shetty] Int Med Univ, Sch Dent Oral & Maxillofacial Surg, Bukit Jalil, Malaysia.
   [Srinivas, Kandula] Manipal Hosp, Bangalore, Karnataka, India.
   [George, P. Renjith] Melaka Manipal Med Coll, Fac Dent, Dept Oral Pathol, Bukit Baru 75150, Melaka, Malaysia.
   [Shrestha, Ashish] BP Koirala Inst Hlth Sci, Coll Dent, Dharan, Nepal.
   [Levenson, David; Ferraiolo, Debra M.] NYU, Coll Dent, Dept Oral & Maxillofacial Pathol, New York, NY USA.
C3 Manipal Academy of Higher Education (MAHE); Manipal University College
   Malaysia; IMU University; Manipal Academy of Higher Education (MAHE);
   Manipal University College Malaysia; B.P. Koirala Institute of Health
   Sciences; New York University
RP Nagraj, SK (corresponding author), Melaka Manipal Med Coll, Fac Dent, Dept Oral Med & Oral Radiol, Jalan Batu Hampar, Bukit Baru 75150, Melaka, Malaysia.
EM sumikn@rediffmail.com
RI Kumbargere Nagraj, Sumanth/L-6740-2019; GEORGE, RENJITH/X-2394-2019
OI Kumbargere Nagraj, Sumanth/0000-0003-1798-3245; Shrestha,
   Ashish/0000-0003-3449-7134; 
FU Faculty of Dentistry, Melaka Manipal Medical College, Manipal
   University, Melaka Campus, Malaysia; Faculty of Dentistry, International
   Medical University, Kuala Lumpur, Malaysia; National Institute for
   Health Research (NIHR), UK; NIHR; Cochrane Oral Health Group Global
   Alliance, UK; British Orthodontic Society, UK; British Society of
   Paediatric Dentistry, UK; Canadian Dental Hygienists Association,
   Canada; National Center for Dental Hygiene Research Practice, USA; New
   York University College of Dentistry, USA
FX Internal sourcesFaculty of Dentistry, Melaka Manipal Medical College,
   Manipal University, Melaka Campus, Malaysia.Faculty of Dentistry,
   International Medical University, Kuala Lumpur, Malaysia.External
   sourcesNational Institute for Health Research (NIHR), UK.CRG funding
   acknowledgement:The NIHR is the largest single funder of the Cochrane
   Oral Health GroupCochrane Oral Health Group Global Alliance, UK.All
   reviews in the Cochrane Oral Health Group are supported by Global
   Alliance member organisations (British Orthodontic Society, UK; British
   Society of Paediatric Dentistry, UK; Canadian Dental Hygienists
   Association, Canada; National Center for Dental Hygiene Research &
   Practice, USA; and New York University College of Dentistry, USA)
   providing funding for the editorial process (http://ohg.cochrane.org)
CR Aframian DJ, 2007, ORAL DIS, V13, P88, DOI 10.1111/j.1601-0825.2006.01252.x
   [Anonymous], 2012, Z 103 PHASE 3 CLIN S
   [Anonymous], THE COCHRANE COLLABO
   ATKINTHOR E, 1978, AM J CLIN NUTR, V31, P1948, DOI 10.1093/ajcn/31.10.1948
   BARRIE SA, 1987, AGENTS ACTIONS, V21, P222, DOI 10.1007/BF01974946
   BARTOSHUK LM, 1994, PHYSIOL BEHAV, V56, P1165, DOI 10.1016/0031-9384(94)90361-1
   BICKNELL JM, 1988, WESTERN J MED, V149, P457
   Birks J, 2009, COCHRANE DATABASE OF, DOI [10.1002/14651858.CD003120.pub3, DOI 10.1002/14651858.CD003120.PUB3]]
   Brandt H, 2008, DTSCH Z AKUPUNKT, V51, P24, DOI 10.1016/j.dza.2008.01.003
   Brandt H HB., 2008, REV INT ACUPUNTURA, V2, P155
   Brisbois TD, 2011, ANN ONCOL, V22, P2086, DOI 10.1093/annonc/mdq727
   Bromley SM, 2000, AM FAM PHYSICIAN, V61, P427
   Christopher H Hawkes, 2002, THE MOST COMMON COMP
   DAHL H, 1984, ACTA OPHTHALMOL, V62, P739
   de Moraes M, 2012, J ORAL PATHOL MED, V41, P281, DOI 10.1111/j.1600-0714.2011.01100.x
   Doty RL, 1995, HANDBOOK OF OLFACTIO, P521
   EGGERT JV, 1982, INT J PED NEPHROL, V3, P21
   Femiano F, 2002, INT J ORAL MAX SURG, V31, P625, DOI 10.1054/ijom.2002.0276
   FIKENTSCHER R, 1987, LARYNGO RHINO OTOL, V66, P355, DOI 10.1055/s-2007-998675
   Fujiyama R, 2010, ODONTOLOGY, V98, P82, DOI 10.1007/s10266-009-0110-y
   Gardiner J, 2008, BIOSCIENCE HYPOTHESE, V1, P251
   Gondivkar SM, 2009, ORAL SURG ORAL MED O, V108, P876, DOI 10.1016/j.tripleo.2009.08.015
   Green A, 2013, J PSYCHOPHARMACOL, V27, P265, DOI 10.1177/0269881112472567
   Greenway FL, 2011, J AM COLL NUTR, V30, P178, DOI 10.1080/07315724.2011.10719958
   Halyard MY, 2007, INT J RADIAT ONCOL, V67, P1318, DOI 10.1016/j.ijrobp.2006.10.046
   Hebuterne Xaviere, 2013, IMPACT OF EARLY AND
   Heckmann SM, 2005, J DENT RES, V84, P35, DOI 10.1177/154405910508400105
   Henkin RI, 2000, J COMPUT ASSIST TOMO, V24, P106, DOI 10.1097/00004728-200001000-00022
   HENKIN RI, 1976, AM J MED SCI, V272, P285, DOI 10.1097/00000441-197611000-00006
   HENKIN RI, 1963, J CLIN INVEST, V42, P727, DOI 10.1172/JCI104765
   Henkin RI, 1999, AM J MED SCI, V318, P392, DOI 10.1097/00000441-199912000-00006
   Henkin RI, 2013, NUTRITION
   Henkin RI, 2007, AM J MED SCI, V334, P431, DOI 10.1097/MAJ.0b013e3180de4d97
   Henkin RI, 2012, ARCH OTOLARYNGOL, V138, P1064, DOI 10.1001/2013.jamaoto.342
   Henkin RI, 2011, AM J OTOLARYNG, V32, P38, DOI 10.1016/j.amjoto.2009.10.001
   Henkin RI, 2011, AM J OTOLARYNG, V32, P178, DOI 10.1016/j.amjoto.2010.05.005
   Henkin RI, 2010, AM J MED SCI, V339, P249, DOI 10.1097/MAJ.0b013e3181cda0e3
   Henkin RI, 2009, METABOLISM, V58, P1717, DOI 10.1016/j.metabol.2009.05.027
   Higgins J., 2011, COCHRANE COLLABORATI
   Hovan AJ, 2010, SUPPORT CARE CANCER, V18, P1081, DOI 10.1007/s00520-010-0902-1
   Ikeda M, 2005, ACTA OTO-LARYNGOL, V125, P1203, DOI 10.1080/00016480510040173
   Ikeda Minoru, 2013, Nihon Jibiinkoka Gakkai Kaiho, V116, P17
   Ishimaru T, 2001, CHEM SENSES, V26, P91, DOI 10.1093/chemse/26.1.91
   Iwatsuki K, 2012, J PHARMACOL SCI, V118, P123, DOI 10.1254/jphs.11R08CP
   Jham Bruno C, 2009, J Oral Sci, V51, P565
   Kamphuis MMJW, 2003, BRIT J NUTR, V90, P199, DOI 10.1079/BJN2003858
   Kashihara K, 2011, INTERNAL MED, V50, P2311, DOI 10.2169/internalmedicine.50.5935
   Kinnamon SC, 2012, ACTA PHYSIOL, V204, P158, DOI 10.1111/j.1748-1716.2011.02308.x
   Leek H, 2002, MICRON, V33, P153, DOI 10.1016/S0968-4328(01)00004-X
   Lyckholm Laurel, 2012, J Pain Palliat Care Pharmacother, V26, P111, DOI 10.3109/15360288.2012.676618
   MAHAJAN S K, 1992, Journal of Trace Elements in Experimental Medicine, V5, P33
   MAHAJAN SK, 1980, AM J CLIN NUTR, V33, P1517, DOI 10.1093/ajcn/33.7.1517
   MAHAJAN SK, 1982, AM J CLIN NUTR, V36, P1177, DOI 10.1093/ajcn/36.6.1177
   MAHAJAN SK, 1979, T AM SOC ART INT ORG, V25, P443
   Mattes RD, 2004, HUM PSYCHOPHARM CLIN, V19, P81, DOI 10.1002/hup.562
   Mattes RD, 2009, ANNU REV NUTR, V29, P305, DOI 10.1146/annurev-nutr-080508-141108
   MISTRETTA CM, 1984, J ANAT, V138, P323
   MOSSMAN KL, 1978, INT J RADIAT ONCOL, V4, P663, DOI 10.1016/0360-3016(78)90190-6
   Mueller C, 2003, RHINOLOGY, V41, P2
   Nagao Y, 2010, MEDICAL SCIENCE MONI, V16, pPI7
   Najafizade N, 2013, J RES MED SCI, V18, P123
   National Institute on Deafness and other Communication Disorders, QUICK STATISTICS ABO
   National Institute on Deafness and other Communication Disorders, TASTE DISORDERS
   Ohno Tomohisa, 2003, Journal of Medical and Dental Sciences, V50, P101
   Padala Kalpana P, 2006, Prim Care Companion J Clin Psychiatry, V8, P178
   Porter SR, 2010, ORAL ONCOL, V46, P457, DOI 10.1016/j.oraloncology.2010.03.011
   Ripamonti C, 1998, CANCER-AM CANCER SOC, V82, P1938, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1938::AID-CNCR18>3.0.CO;2-U
   RUSSELL RM, 1980, AM J CLIN NUTR, V33, P2741, DOI 10.1093/ajcn/33.12.2741
   Sakagami M, 2009, ACTA OTO-LARYNGOL, V129, P1115, DOI 10.1080/00016480802552550
   Sakai F, 2002, ACTA OTO-LARYNGOL, V122, P129, DOI 10.1080/00016480260046517
   Sakai F, 1995, Nihon Jibiinkoka Gakkai Kaiho, V98, P1135
   Sanchez Nebra J, 1993, Nutr Hosp, V8, P561
   Sasano T, 2010, BIOL PHARM BULL, V33, P1791, DOI 10.1248/bpb.33.1791
   Silverman J E, 1983, J Oral Med, V38, P14
   Smutzer G, 2008, LARYNGOSCOPE, V118, P1411, DOI 10.1097/MLG.0b013e31817709a0
   SOLOMONS N, 1974, CLIN RES, V22, P582
   Soter A, 2008, LARYNGOSCOPE, V118, P611, DOI 10.1097/MLG.0b013e318161e53a
   SPIELMAN AI, 1992, CHEM SENSES, V17, P451, DOI 10.1093/chemse/17.4.451
   Sprenger K B, 1983, Kidney Int Suppl, V16, pS315
   Stewart-Knox BJ, 2008, BRIT J NUTR, V99, P129, DOI 10.1017/S0007114507781485
   Strasser F, 2008, ONCOLOGIST, V13, P337, DOI 10.1634/theoncologist.2007-0217
   Sturniolo GC, 1985, JOURNAL OF HEPATOLOG, V1, ps136
   Tomita H, 1986, Auris Nasus Larynx, V13 Suppl 1, pS1
   Tupe RP, 2009, J AM COLL NUTR, V28, P388, DOI 10.1080/07315724.2009.10718101
   Velargo PA, SYNSEPALUM DULCIFICU
   Vent J, 2010, OTOLARYNG HEAD NECK, V142, P505, DOI 10.1016/j.otohns.2010.01.012
   WATSON AR, 1983, HUM NUTR-CLIN NUTR, V37, P219
   Wickham R S, 1999, Oncol Nurs Forum, V26, P697
   Wilken Marlene K, 2012, Clin J Oncol Nurs, V16, pE173
   Winkler S, 1999, J AM DENT ASSOC, V130, P1759, DOI 10.14219/jada.archive.1999.0133
   YOSHIDA S, 1991, Auris Nasus Larynx, V18, P153
NR 91
TC 20
Z9 23
U1 0
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2014
IS 11
AR CD010470
DI 10.1002/14651858.CD010470.pub2
PG 71
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA AY5YY
UT WOS:000347646200055
PM 25425011
DA 2026-01-16
ER

PT J
AU McVicar, A
   Greenwood, C
   Ellis, C
   LeForis, C
AF McVicar, Andrew
   Greenwood, Christina
   Ellis, Carol
   LeForis, Chantelle
TI Influence of Study Design on Outcomes Following Reflexology Massage: An
   Integrative and Critical Review of Interventional Studies
SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Review
ID RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; FOOT REFLEXOLOGY;
   MULTIPLE-SCLEROSIS; CLINICAL-TRIALS; BREAST-CANCER; PAIN; COMPLEMENTARY;
   EFFICACY; ACUPUNCTURE
AB Background: Interpretation of the efficacy of reflexology is hindered by inconsistent research designs and complicated by professional views that criteria of randomized controlled trials (RCTs) are not ideal to research holistic complementary and alternative medicine practice. The influence of research designs on study outcomes is not known. This integrative review sought to evaluate this possibility.
   Materials and Methods: Thirty-seven interventional studies (2000-2014) were identified; they had RCT or non-RCT design and compared reflexology outcomes against a control/comparison group. Viability of integrating RCT and non-RCT studies into a single database was first evaluated by appraisal of 16 reporting fields related to study setting and objectives, sample demographics, methodologic design, and treatment fidelity and assessment against Jadad score quality criteria for RCTs. For appraisal, the database was stratified into RCT/non-RCT or Jadad score of 3 or more or less than 3. Deficits in reporting were identified for blind assignment of participants, dropout/completion rate, and School of Reflexology. For comparison purposes, these fields were excluded from subsequent analysis for evidence of association between design fields and of fields with study outcomes.
   Results: Thirty-one studies applied psychometric tools and 20 applied biometric tools (14 applied both). A total of 116 measures were used. Type of measure was associated with study objectives (p < 0.001; chi-square), in particular of psychometric measures with a collated "behavioral/cognitive" objective. Significant outcomes were more likely (p < 0.001; chi-square) for psychometric than for biometric measures. Neither type of outcome was associated with choice of RCT or non-RCT method, but psychometric responses were associated (p = 0.007) with a nonmassage control strategy.
   Conclusions: The review supports psychometric responses to reflexology when study design uses a nonmassage control strategy. Findings suggest that an evaluation of outcomes against sham reflexology massage and other forms of massage, as well as a narrower focus of study objective, may clarify whether there is a relationship between study design and efficacy of reflexology.
C1 [McVicar, Andrew; LeForis, Chantelle] Anglia Ruskin Univ, Fac Hlth Social Care & Educ, Bishop Hall Lane, Chelmsford CM1 15Q, Essex, England.
   [Greenwood, Christina; Ellis, Carol] Anglia Ruskin Univ, Fac Med Sci, Chelmsford, Essex, England.
C3 Anglia Ruskin University; Anglia Ruskin University
RP McVicar, A (corresponding author), Anglia Ruskin Univ, Fac Hlth Social Care & Educ, Bishop Hall Lane, Chelmsford CM1 15Q, Essex, England.
EM Andy.McVicar@anglia.ac.uk
OI Greenwood, Christina/0000-0003-2238-5397; McVicar,
   Anew/0000-0001-8743-5629
FU Anglia Ruskin University, United Kingdom
FX This article arose after completion of an RCT involving
   reflexology21 that was supported by funds allocated to
   authors C.G. and C.E. by Anglia Ruskin University, United Kingdom. A
   detailed paper of that study is in preparation. Authors A.M., C.G., and
   C.E. are academic staff members of Anglia Ruskin University and further
   acknowledge a faculty undergraduate studentship awarded to author C.L.
   in the undertaking of this review.
CR [Anonymous], J KOREAN ACAD NURS
   Asltoghiri M, 2012, PROCD SOC BEHV, V31, P242, DOI 10.1016/j.sbspro.2011.12.049
   Bagheri-Nesami M, 2014, COMPLEMENT THER CLIN, V20, P42, DOI 10.1016/j.ctcp.2013.10.006
   Birch S, 2004, J ALTERN COMPLEM MED, V10, P481, DOI 10.1089/1075553041323911
   Boutron I, 2008, ANN INTERN MED, V148, P295, DOI 10.7326/0003-4819-148-4-200802190-00008
   Brown P, 2013, J NURS MANAGE, V21, P459, DOI 10.1111/j.1365-2834.2012.01352.x
   Brygge T, 2001, RESP MED, V95, P173, DOI 10.1053/rmed.2000.0975
   Carter Bernie, 2003, Complement Ther Nurs Midwifery, V9, P133, DOI 10.1016/S1353-6117(03)00042-8
   Caspar F, 2005, PSYCHOTHER RES, V15, P91, DOI 10.1080/10503300512331327074
   Dolatian M, 2011, IRAN RED CRESCENT ME, V13, P475
   Eghbali Maryam, 2012, Iran J Nurs Midwifery Res, V17, P239
   Ellis C, 2014, EUR J INTEGR MED, V6, P611
   Ernst E, 2011, MATURITAS, V68, P116, DOI 10.1016/j.maturitas.2010.10.011
   Ernst E, 2009, MED J AUSTRALIA, V191, P263, DOI 10.5694/j.1326-5377.2009.tb02780.x
   Green VL, 2010, EXP THER MED, V1, P97, DOI 10.3892/etm_00000018
   Hodgson H, 2000, Nurs Stand, V14, P33
   Hodgson NA, 2008, J ALTERN COMPLEM MED, V14, P269, DOI 10.1089/acm.2007.0577
   Hodgson NA, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/456897
   Holt J, 2009, FERTIL STERIL, V91, P2514, DOI 10.1016/j.fertnstert.2008.04.016
   Hughes CM, 2011, ALTERN THER HEALTH M, V17, P32
   Hughes CM, 2009, MULT SCLER J, V15, P1229, DOI 10.1177/1352458509345916
   Hughes CM, 2009, ACUPUNCT MED, V27, P163, DOI 10.1136/aim.2009.000760
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Johns Christopher, 2010, Complement Ther Clin Pract, V16, P96, DOI 10.1016/j.ctcp.2009.10.003
   Jones J, 2013, COMPLEMENT THER CLIN, V19, P133, DOI 10.1016/j.ctcp.2013.03.004
   Jones Jenny, 2012, Complement Ther Clin Pract, V18, P204, DOI 10.1016/j.ctcp.2012.03.006
   Kim JI, 2010, INTEGR CANCER THER, V9, P326, DOI 10.1177/1534735410387423
   Leach Matthew J, 2005, Complement Ther Clin Pract, V11, P262, DOI 10.1016/j.ctcp.2005.05.005
   Li CY, 2011, MIDWIFERY, V27, P181, DOI 10.1016/j.midw.2009.04.005
   Liu R, 2016, J ALTERN COMPLEM MED, V22, P160, DOI 10.1089/acm.2015.0061
   Mackereth Peter A, 2009, Complement Ther Clin Pract, V15, P14, DOI 10.1016/j.ctcp.2008.07.002
   MacPherson H, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3335
   Mak HLJ, 2007, INT UROGYNECOL J, V18, P653, DOI 10.1007/s00192-006-0222-7
   McCullough JEM, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/502123
   McVicar A J, 2007, Complement Ther Clin Pract, V13, P137, DOI 10.1016/j.ctcp.2006.11.001
   Miller L, 2013, CLIN REHABIL, V27, P591, DOI 10.1177/0269215512469383
   Mollart L, 2003, COMPLEMENT THER NURS, V9, P2013
   Özdemir G, 2013, INT J NURS PRACT, V19, P265, DOI 10.1111/ijn.12066
   Paterson C, 2005, BMJ-BRIT MED J, V330, P1202, DOI 10.1136/bmj.330.7501.1202
   Poole H, 2007, EUR J PAIN, V11, P878, DOI 10.1016/j.ejpain.2007.01.006
   Quattrin R, 2006, J Nurs Manag, V14, P96, DOI 10.1111/j.1365-2934.2006.00557.x
   Ross CSK, 2002, PALLIATIVE MED, V16, P544, DOI 10.1191/0269216302pm597xx
   Samuel CA, 2013, COMPLEMENT THER CLIN, V19, P57, DOI 10.1016/j.ctcp.2013.02.005
   Sharp DM, 2010, EUR J CANCER, V46, P312, DOI 10.1016/j.ejca.2009.10.006
   Siev-Ner I, 2003, MULT SCLER J, V9, P356, DOI 10.1191/1352458503ms925oa
   Steenkamp E, 2012, HEALTH SA GESONDHEID, V17, DOI 10.4102/hsag.v17i1.567
   Stephenson N, 2003, APPL NURS RES, V16, P284, DOI 10.1016/j.apnr.2003.08.003
   Stephenson N L, 2000, Oncol Nurs Forum, V27, P67
   Stephenson NLN, 2007, ONCOL NURS FORUM, V34, P127, DOI 10.1188/07.ONF.127-132
   Tovey P, 2002, BRIT J GEN PRACT, V52, P19
   Verhoef MJ, 2005, COMPLEMENT THER MED, V13, P206, DOI 10.1016/j.ctim.2005.05.001
   Wang MY, 2008, J ADV NURS, V62, P512, DOI 10.1111/j.1365-2648.2008.04606.x
   Whittemore R, 2005, J ADV NURS, V52, P546, DOI 10.1111/j.1365-2648.2005.03621.x
   Wilkinson Iain S A, 2006, Complement Ther Clin Pract, V12, P141, DOI 10.1016/j.ctcp.2005.10.004
   Williamson J, 2002, BJOG-INT J OBSTET GY, V109, P1050, DOI 10.1111/j.1471-0528.2002.01504.x
   Wyatt G, 2012, ONCOL NURS FORUM, V39, P568, DOI 10.1188/12.ONF.568-577
   Wyatt G, 2010, CANCER NURS, V33, P331, DOI 10.1097/NCC.0b013e3181d0b4b7
   Yeung WF, 2012, SLEEP MED, V13, P971, DOI 10.1016/j.sleep.2012.06.003
   Zhang WP, 2010, J ACUPUNCT MERIDIAN, V3, P43, DOI 10.1016/S2005-2901(10)60007-6
NR 59
TC 5
Z9 7
U1 0
U2 14
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1075-5535
EI 1557-7708
J9 J ALTERN COMPLEM MED
JI J. Altern. Complement Med.
PD SEP
PY 2016
VL 22
IS 9
BP 739
EP 750
DI 10.1089/acm.2016.0015
PG 12
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Integrative & Complementary Medicine
GA DW9SL
UT WOS:000384002900010
PM 27463943
DA 2026-01-16
ER

PT J
AU Du, WQ
   Wang, LD
   Jia, M
   Liang, X
   Li, B
   Zhang, YL
   Liao, X
AF Du Wanqing
   Wang Liuding
   Jia Min
   Liang Xiao
   Li Bo
   Zhang Yunling
   Liao Xing
TI Mixed methods research in complementary and alternative medicine: a
   scoping review
SO JOURNAL OF TRADITIONAL CHINESE MEDICINE
LA English
DT Review
DE complementary therapies; review; biomedical research; pilot projects;
   mixed methods
ID DATA-COLLECTION; HEALTH; INTEGRATION; PRINCIPLES; SYSTEMS; DESIGN
AB OBJECTIVE: To update the current characteristics about the scope and quality of mixed methods research (MMR) in complementary and alternative medicine (CAM) after nearly 10 years. METHODS: A 5-stage approach for conducting a scoping review was adopted. Articles published on the top 10 journals in CAM with the highest impact factor in 2020 were screened for MMR. Information of included articles were extracted, and then synthesized to illustrate the current state. Methodological quality was evaluated according to the Mixed Method Appraisal Tool (MMAT) 2018 version. mixed methods were retrieved, including 17 medical studies and 38 ethnobotanical studies. We performed an in-depth analysis on the 17 medical studies, which studied cancer, stress, pain, fatigue, exercises, mindfulness intervention, herbal medicine use, art and acupuncture. Thirteen pilot studies applied MMR to evaluate the feasibility of interventions or programs (13/17, 76%); phenomenology was inferred as the most common philosophical assumptions (13/17, 76%); the most applied type of MMR was convergent design (16/17, 94%); integration often took place at integration (12/17, 71%). Among the 16 eligible studies for quality appraisal, majority were rated as good (14/16, 88%), whereas two studies were rated as poorly described. Primarily, a poor rating was due to incomplete reporting of data analysis and citations in qualitative components; lack of confounder controlling and the sampling strategy in quantitative components; poor description of integration and justification for mixed methods. Comparing with the previous review, fewer MMR were published in 2020 in CAM, but the proportion of studies that clearly reported MMR has increased by 4 times (4%-> 15%). CONCLUSION: CAM researchers need to realize the benefits that MMR can have on conducting further health care research. Our findings highlight that applying MMR will be helpful to understand the complex dynamics and interdisciplinary nature of complex intervention. In addition, addressing a standardized reporting criteria for MMR is recommended. (c) 2022 JTCM. All rights reserved.
C1 [Du Wanqing; Wang Liuding; Jia Min; Liang Xiao; Zhang Yunling] China Acad Chinese Med Sci, Xiyuan Hosp, Dept Neurol, Beijing 100091, Peoples R China.
   [Du Wanqing; Liao Xing] China Acad Chinese Med Sci, Ctr Evidence Based Chinese Med, Inst Basic Res Clin Med, Beijing 100700, Peoples R China.
   [Du Wanqing] Beijing Univ Chinese Med, Xiyuan Sch Clin Med, Beijing 100029, Peoples R China.
   [Li Bo] Capital Med Univ, Beijing Tradit Chinese Med Hosp, Beijing Inst Tradit Chinese Med, Dept Clin Epidemiol, Beijing 100010, Peoples R China.
C3 Xiyuan Hospital, CACMS; China Academy of Chinese Medical Sciences; China
   Academy of Chinese Medical Sciences; Institute of Basic Research In
   Clinical Medicine, CACMS; Beijing University of Chinese Medicine;
   Capital Medical University
RP Zhang, YL (corresponding author), China Acad Chinese Med Sci, Xiyuan Hosp, Dept Neurol, Beijing 100091, Peoples R China.; Liao, X (corresponding author), China Acad Chinese Med Sci, Ctr Evidence Based Chinese Med, Inst Basic Res Clin Med, Beijing 100700, Peoples R China.
EM yunlingzhang2004@126.com; okfrom2008@hotmail.com
RI Li, Bo/AAA-8968-2020
FU Scientific and Technological Innovation Project of China Academy of
   Chinese Medical Sciences: Design and Application of Mixed Method
   Research in Traditional Chinese Medicine [CI2021B003]; Special Project
   of China Center for Evidence Based Traditional Chinese Medicine:
   Integrated Innovation and Application of Traditional Trial and
   Real-World Study of Chinese Medicine in Integrated Chinese and Western
   Medicine Setting [2020YJSZX-3]; Fundamental Research Funds for the
   Central Public Welfare Research Institutes: the Optimal Subject Setting
   and Design of Evidence-Based Research Implementation in the Area of
   Brain Diseases of Traditional Chinese Medicine [ZZ13-024-3]
FX Supported by the Scientific and Technological Innovation Project of
   China Academy of Chinese Medical Sciences: Design and Application of
   Mixed Method Research in Traditional Chinese Medicine (No. CI2021B003);
   Special Project of China Center for Evidence Based Traditional Chinese
   Medicine: Integrated Innovation and Application of Traditional Trial and
   Real-World Study of Chinese Medicine in Integrated Chinese and Western
   Medicine Setting (No. 2020YJSZX-3); the Fundamental Research Funds for
   the Central Public Welfare Research Institutes: the Optimal Subject
   Setting and Design of Evidence-Based Research Implementation in the Area
   of Brain Diseases of Traditional Chinese Medicine (No. ZZ13-024-3)
CR Abdusalam A, 2020, J ETHNOPHARMACOL, V260, DOI 10.1016/j.jep.2020.113012
   Adam S, 2021, SUPPORT CARE CANCER, V29, P6259, DOI 10.1007/s00520-021-06132-w
   Ahn AC, 2010, J ALTERN COMPLEM MED, V16, P1015, DOI 10.1089/acm.2009.0593
   Ahoyo CC, 2021, J ETHNOPHARMACOL, V265, DOI 10.1016/j.jep.2020.113417
   Alqethami A, 2020, J ETHNOPHARMACOL, V257, DOI 10.1016/j.jep.2020.112899
   [Anonymous], 2019, Who, (REPORT), P10
   Carabajal MPA, 2020, J ETHNOPHARMACOL, V247, DOI 10.1016/j.jep.2019.112258
   Anywara G, 2020, J ETHNOPHARMACOL, V246, DOI 10.1016/j.jep.2019.112205
   Arden-Close E, 2020, INTEGR CANCER THER, V19, DOI 10.1177/1534735420908341
   Arksey H., 2005, INT J SOC RES METHOD, V8, P19, DOI [DOI 10.1080/1364557032000119616, 10.1080/1364557032000119616, DOI 10.1080/136.455.7032000119616]
   Arnold DM, 2009, CRIT CARE MED, V37, pS69, DOI 10.1097/CCM.0b013e3181920e33
   Ataba E, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906-020-03008-0
   Attia M, 2017, OPEN REV EDUC RES, V4, P33, DOI 10.1080/23265507.2017.1300068
   Baldé MA, 2020, J ETHNOPHARMACOL, V263, DOI 10.1016/j.jep.2020.113232
   Barbosa F, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906-019-2809-9
   Bishop FL, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/187365
   Bloom-Foster J, 2020, J ALTERN COMPLEM MED, V26, P34, DOI 10.1089/acm.2019.0242
   Broom A, 2005, COMPLEMENT THER MED, V13, P65, DOI 10.1016/j.ctim.2005.01.001
   Campbell DJT, 2017, CIRC-CARDIOVASC QUAL, V10, DOI 10.1161/CIRCOUTCOMES.116.003310
   Cargo M, 2018, MIXED METHODS APPRAI
   Chamorro MF, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906-020-02952-1
   Clark VLP, 2010, QUAL INQ, V16, P428, DOI 10.1177/1077800410364609
   Conte E, 2020, INTEGR CANCER THER, V19, DOI 10.1177/1534735420983472
   Creswell JW, 2018, QUAL INQ, V4th, P30
   Creswell JW, 2017, DESIGNING CONDUCTING, V3rd, P34
   Curry LA, 2013, CIRC-CARDIOVASC QUAL, V6, P119, DOI 10.1161/CIRCOUTCOMES.112.967885
   Curry LA, 2009, CIRCULATION, V119, P1442, DOI 10.1161/CIRCULATIONAHA.107.742775
   Dassou GH, 2020, J ETHNOPHARMACOL, V261, DOI 10.1016/j.jep.2020.113107
   De Allegri M, 2018, HEALTH POLICY PLANN, V33, P445, DOI 10.1093/heapol/czx182
   Dhakal P, 2020, J ETHNOPHARMACOL, V249, DOI 10.1016/j.jep.2019.112386
   Dowding D, 2013, QUAL SOC WORK, V12, P541, DOI 10.1177/1473325013493540a
   Fàbregues S, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17113853
   Farquhar MC, 2011, PALLIATIVE MED, V25, P748, DOI 10.1177/0269216311417919
   Fetters MD, 2013, HEALTH SERV RES, V48, P2134, DOI 10.1111/1475-6773.12117
   Fielding NG, 2012, J MIX METHOD RES, V6, P124, DOI 10.1177/1558689812437101
   Gaglio B, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4435
   Hirschberg R, 2020, J ALTERN COMPLEM MED, V26, P198, DOI 10.1089/acm.2019.0368
   In J, 2017, KOREAN J ANESTHESIOL, V70, P601, DOI 10.4097/kjae.2017.70.6.601
   Irvine FE, 2020, J ADV NURS, V76, P2798, DOI 10.1111/jan.14479
   Kaimal G, 2020, INTEGR CANCER THER, V19, DOI 10.1177/1534735420912835
   Lewin S, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3496
   Low MY, 2020, J ALTERN COMPLEM MED, V26, P113, DOI 10.1089/acm.2019.0249
   Maudsley G, 2011, MED TEACH, V33, pe92, DOI 10.3109/0142159X.2011.542523
   McDonnell KK, 2020, INTEGR CANCER THER, V19, DOI 10.1177/1534735420969829
   Mehl A, 2020, INTEGR CANCER THER, V19, DOI 10.1177/1534735420935618
   Nsibirwa S, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906-020-02959-8
   Nunez-Smith M., 2014, MIXED METHODS HLTH S
   O'Cathain A, 2008, J HEALTH SERV RES PO, V13, P92, DOI 10.1258/jhsrp.2007.007074
   Osypiuk K, 2020, INTEGR CANCER THER, V19, DOI 10.1177/1534735419893766
   Palinkas LA, 2019, ANNU REV PUBL HEALTH, V40, P423, DOI 10.1146/annurev-publhealth-040218-044215
   Peters BC, 2020, J ALTERN COMPLEM MED, V26, P743, DOI 10.1089/acm.2020.0039
   Pluye P, 2014, ANNU REV PUBL HEALTH, V35, P29, DOI 10.1146/annurev-publhealth-032013-182440
   Rahayu YYS, 2020, J ETHNOPHARMACOL, V260, DOI 10.1016/j.jep.2020.112974
   Reporting the results of the MMAT, MIXED METHODS APPRAI
   ROSENFIELD PL, 1992, SOC SCI MED, V35, P1343, DOI 10.1016/0277-9536(92)90038-R
   Rothman JM, 2020, J ALTERN COMPLEM MED, V26, P636, DOI 10.1089/acm.2020.0063
   Sandelowski M, 2000, RES NURS HEALTH, V23, P246, DOI 10.1002/1098-240X(200006)23:3<246::AID-NUR9>3.0.CO;2-H
   Schultes RichardEvans., 1995, ETHNOBOTANY EVOLUTIO
   Sharma S, 2020, INT J NURS STUD, V110, DOI 10.1016/j.ijnurstu.2020.103709
   Shewamene Z, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906-020-2852-6
   Stritter W, 2020, INTEGR CANCER THER, V19, DOI 10.1177/1534735420928393
   Sylvia L, 2020, J INTEGR MED-JIM, V18, P169, DOI 10.1016/j.joim.2020.01.005
   Tariq Shema, 2013, JRSM Short Rep, V4, p2042533313479197, DOI 10.1177/2042533313479197
   Tashakkori A., 1989, Mixed Methodology: Combining Qualitative and Quantitative Approaches
   Thangaraj P, 2016, PROG DRUG RES, V71, P1, DOI 10.1007/978-3-319-26811-8
   Veziari Y, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1660-0
   Wisdom JP, 2012, HEALTH SERV RES, V47, P721, DOI 10.1111/j.1475-6773.2011.01344.x
   Yan H, 2020, NEUROSURGERY, V86, P325, DOI 10.1093/neuros/nyz509
   Zhao Q, 2020, INTEGR CANCER THER, V19, DOI 10.1177/1534735420976579
   Zörgo S, 2020, INTEGR CANCER THER, V19, DOI 10.1177/1534735420910472
NR 70
TC 4
Z9 4
U1 1
U2 14
PU JOURNAL TRADITIONAL CHINESE MED
PI BEIJING
PA 16 NANXIAOJIE, DONGZHIMEN NEI, BEIJING, 100700, PEOPLES R CHINA
SN 0255-2922
EI 1577-7014
J9 J TRADIT CHIN MED
JI J. Tradit. Chin. Med.
PD AUG
PY 2022
VL 42
IS 4
BP 652
EP 666
DI 10.19852/j.cnki.jtcm.20220602.002
PG 15
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA 3D2EC
UT WOS:000829120500001
PM 35848983
DA 2026-01-16
ER

PT J
AU Wang, B
   Li, WL
   Su, SJ
AF Wang, Bo
   Li, Weilin
   Su, Shengjie
TI Changes of serum miR-21-5p level in patients with acute spinal cord
   injury treated with ganglioside and methylprednisolone pulse therapy and
   its correlation with therapeutic effect
SO NEUROLOGY ASIA
LA English
DT Article
DE Acute spinal cord injury; ganglioside; methylprednisolone; inflammatory
   factors; miR-21-5p
ID GENE-EXPRESSION; PLASTICITY; ISCHEMIA; BETA; IL-6; PCR
AB Background: Acute spinal cord injury (ASCI) is a serious central nervous system condition that carries a high rate of disability and mortality, making it a primary focus of clinical research. The commonly used drugs for ASCI are ganglioside (GM-1) and methylprednisolone (MP). There are few studies available on the impact of GM-1 combined with MP pulse therapy on the clinical outcomes of patients with ASCI and the underlying mechanisms involved. Methods: In a randomized controlled trial, the 100 patients with ASCI who were treated at our hospital from 2021 to 2024 were selected for this study. They were arbitrarily separated into two equal cohorts, a control cohort and an observation cohort, each containing 50 patients. While the control cohort underwent treatment solely with GM-1, the observation cohort additionally received MP pulse therapy, both treatments administered over a span of six months. The general information of patients was recorded. The motor score, acupuncture pain score, light touch score, Barthel Index (BI) for evaluating daily living capabilities, American Spinal Injury Association (ASIA) neurological function score, and visual analogue scale (VAS) score were analyzed between the two groups before and after treatment to evaluate the recovery of neurological function. Additionally, quantitative real-time PCR (qRT-PCR) was used to assess the serum levels of miR-21-5p in both groups. Moreover, the concentrations of serum inflammatory markers, such as C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), along with nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), were quantified using ELISA. The Pearson method was employed to evaluate the correlation between miR-21-5p and the levels of CRP, TNF-alpha, IL-6, NGF, and BDNF. The receiver operating characteristic (ROC) curve was employed to evaluate the predictive ability of serum miR-21-5p regarding treatment effectiveness in patients with ASCI. Results: Three patients dropped out of the control group, and no patient dropped out of the observation group. There were no significant variations in the baseline data, index scores, or factor levels between the two groups prior to treatment (P > 0.05). After undergoing therapy, the observation group exhibited significantly higher BI index, ASIA motor and sensory scores, as well as increased in serum miR-21-5p levels, BDNF, and NGF compared to the reference group (P < 0.05). Furthermore, the observation group exhibited marked decreases in VAS ratings as well as serum CRP, TNF-alpha, and IL-6 levels, in stark contrast to the control group (P < 0.05). Furthermore, the level of miR-21-5p exhibited a negative correlation with the levels of CRP, TNF-alpha, and IL-6 (P < 0.05), while showing a positive correlation with the levels of BDNF and NGF (P < 0.05). The ROC curve analysis indicated that miR-21-5p possesses strong diagnostic potential for assessing ASCI efficacy, with an area under the curve (AUC) of 0.987, a sensitivity rate of 91.49%, and a specificity rate of 100.00%. Conclusions: The combination of GM-1 and MP pulse therapy can significantly enhance neurological symptoms and facilitate the restoration of neurological function in patients with ASCI. This effect may be ascribed to the increased levels of miR-21-5p, BDNF, and NGF, along with a reduction in serum inflammatory factors.
C1 [Wang, Bo] Hainan Med Univ, Hainan Affiliated Hosp, Hainan Gen Hosp, Dept Joint Surg, Haikou, Hainan, Peoples R China.
   [Li, Weilin] Southeast Univ, Nanjing Pukou Peoples Hosp, Liangjiang Hosp, Dept Spine, Nanjing, Jiangsu, Peoples R China.
   [Su, Shengjie] Baoji City Tradit Chinese Med Hosp, Shaanxi Prov Baoji City Orthoped Hosp, Orthoped Ctr Ward 3, Baoji, Shaanxi, Peoples R China.
C3 Hainan Medical University; Southeast University - China
RP Su, SJ (corresponding author), 43 Baofu Rd, Baoji 721001, Shaanxi, Peoples R China.
EM wbo129129@hotmail.com
CR Al Mamun A, 2021, IMMUNOBIOLOGY, V226, DOI 10.1016/j.imbio.2020.152033
   Alizadeh A, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00282
   Alves MA, 2023, SPINAL CORD SER CASE, V9, DOI 10.1038/s41394-023-00571-9
   Baichurina I, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23010114
   Chen C, 2021, AM J TRANSL RES, V13, P14005
   Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011
   Cui YJ, 2024, SCI REP-UK, V14, DOI 10.1038/s41598-024-52080-w
   de Laorden EH, 2023, FRONT CELL DEV BIOL, V11, DOI 10.3389/fcell.2023.1328261
   Dolci S, 2022, PHARMACOL RES, V178, DOI 10.1016/j.phrs.2022.106149
   Fabbri Isabella, 2023, eNeurologicalSci, V31, P100467, DOI [10.1016/j.ensci.2023.100467, 10.1016/j.ensci.2023.100467]
   Fan BY, 2022, BONE RES, V10, DOI 10.1038/s41413-022-00199-9
   Garcia E, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/9476020
   Gheorghe RO, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms242115831
   Guo ZW, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24119558
   Hellenbrand DJ, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02337-2
   Ho PTB, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23137167
   Huang HY, 2020, J ORTHOP TRANSL, V20, P14, DOI 10.1016/j.jot.2019.10.006
   Jiang L, 2021, BRAZ J MED BIOL RES, V54, DOI [10.1590/1414-431X2021e11530, 10.1590/1414-431x2021e11530]
   Jin W, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010257
   Kim YT, 2009, BIOMATERIALS, V30, P2582, DOI 10.1016/j.biomaterials.2008.12.077
   Lau D, 2019, NEUROSURG FOCUS, V46, DOI 10.3171/2018.12.FOCUS18555
   Li YY, 2022, FRONT AGING NEUROSCI, V14, DOI 10.3389/fnagi.2022.986443
   Li Z, 2024, MOL NEUROBIOL, V61, P2197, DOI 10.1007/s12035-023-03702-3
   Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029
   LINDSAY RM, 1985, J CELL SCI, P115
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lv X, 2020, Panminerva Med, V66, P256, DOI [10.23736/S0031-0808, DOI 10.23736/S0031-0808]
   MAHADIK SP, 1993, NEUROCHEM INT, V23, P163, DOI 10.1016/0197-0186(93)90094-L
   MAHADIK SP, 1989, J NEUROSCI RES, V24, P402, DOI 10.1002/jnr.490240310
   Ngwa DN, 2022, MOL IMMUNOL, V146, P50, DOI 10.1016/j.molimm.2022.04.003
   Nieto-Diaz M, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00053
   Park DY, 2013, GLOB SPINE J, V3, P1, DOI 10.1055/s-0033-1337118
   Pattwell SS, 2012, J NEUROSCI, V32, P2410, DOI 10.1523/JNEUROSCI.5205-11.2012
   Plebani M, 2023, CLIN CHEM LAB MED, V61, P1540, DOI 10.1515/cclm-2023-0086
   Razzouk J, 2023, SPINE, V48, pE302, DOI 10.1097/BRS.0000000000004708
   Rizo-Téllez SA, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1237729
   Roberts TT, 2017, CLIN ORTHOP RELAT R, V475, P1499, DOI 10.1007/s11999-016-5133-4
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Siddiqui AM, 2015, PROG BRAIN RES, V218, P15, DOI 10.1016/bs.pbr.2014.12.007
   Sproston NR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00754
   Tsitsiou E, 2009, CURR OPIN PHARMACOL, V9, P514, DOI 10.1016/j.coph.2009.05.003
   Tsutsumi S, 2006, SPINE, V31, P2992, DOI 10.1097/01.brs.0000250273.28483.5c
   Vaccaro AR, 2016, EUR SPINE J, V25, P2173, DOI 10.1007/s00586-015-3831-3
   Wang JC, 2021, AM J TRANSL RES, V13, P646
   Wang Wenzhao, 2020, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V34, P213, DOI 10.7507/1002-1892.201905079
   Wang WZ, 2018, INT J BIOL SCI, V14, P178, DOI 10.7150/ijbs.24074
   Yang ZH, 2018, MOL NEUROBIOL, V55, P2174, DOI 10.1007/s12035-017-0424-7
   Yoshii A, 2010, DEV NEUROBIOL, V70, P304, DOI 10.1002/dneu.20765
   Zhang HY, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-130
   Zhou YJ, 2023, INT J SPINE SURG, V17, P678, DOI 10.14444/8527
NR 50
TC 0
Z9 0
U1 4
U2 4
PU ASEAN NEUROLOGICAL ASSOC
PI KUALA LUMPUR
PA UNIV MALAYA MEDICAL CENTRE, NEUROLOGY LABORATORY, KUALA LUMPUR, 59100,
   MALAYSIA
SN 1823-6138
J9 NEUROL ASIA
JI Neurol. Asia
PD SEP
PY 2025
VL 30
IS 3
BP 881
EP 891
DI 10.54029/2025xwv
PG 11
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 9ET2P
UT WOS:001604605400001
OA Bronze
DA 2026-01-16
ER

PT J
AU Montross-Thomas, LP
   Meier, EA
   Reynolds-Norolahi, K
   Raskin, EE
   Slater, D
   Mills, PJ
   MacElhern, L
   Kallenberg, G
AF Montross-Thomas, Lori P.
   Meier, Emily A.
   Reynolds-Norolahi, Kimberly
   Raskin, Erin E.
   Slater, Daniel
   Mills, Paul J.
   MacElhern, Lauray
   Kallenberg, Gene
TI Inpatients' Preferences, Beliefs, and Stated Willingness to Pay for
   Complementary and Alternative Medicine Treatments
SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
DE complementary and alternative medicine; inpatients; holistic care;
   integrative medicine; patient satisfaction; patient preferences
ID INTEGRATIVE MEDICINE; PATIENT SATISFACTION; MASSAGE THERAPY; PAIN;
   ANXIETY; CARE; ONCOLOGY
AB Objectives: Research demonstrates the benefits of complementary and alternative medicine (CAM) in myriad environments. Yet, the majority of CAM services are offered in outpatient settings. Incorporating CAM into hospital settings may lead to increased patient comfort, well-being, and overall satisfaction with hospital admissions. Few studies have examined CAM services among inpatients. Therefore, this study assessed inpatients' preferences and beliefs regarding CAM, as well as their stated willingness to pay for these services. Design: Adult patients (n=100), ranging in age from 19-95 years (M=53 years; SD=19.2 years), were recruited during their hospitalization in the University of California, San Diego, Healthcare System. The inpatients completed a brief individual interview to gather their perspectives on common CAM services, including acupuncture, aromatherapy, art therapy, guided imagery, healthy food, humor therapy, massage therapy, music therapy, pet therapy, Reiki, and stress management. Inpatients were asked which CAM therapies they perceived as being potentially the most helpful, their willingness to pay for those therapies, and their perceived beliefs regarding the use of those therapies. Results: Inpatients most commonly perceived healthy food (85%), massage therapy (82%), and humor therapy (70%) to be the most helpful, and were most willing to pay for healthy food (71%), massage therapy (70%), and stress management (48%). Inpatients most commonly believed CAM treatments would provide relaxation (88%), increase well-being (86%), and increase their overall satisfaction with the hospitalization (85%). Conclusions: This study suggests that CAM services may be a beneficial addition to hospitals, as demonstrated by inpatients' interest and stated willingness to pay for these services. These findings may help organizational leaders when making choices regarding the development of CAM services within hospitals, particularly since a significant percentage of inpatients reported that CAM services would increase their overall satisfaction with the hospitalization. These results merit further attention given the need to increase cost savings while enhancing the overall patient experience in today's medical marketplace.
C1 [Montross-Thomas, Lori P.; Meier, Emily A.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
   [Montross-Thomas, Lori P.; Meier, Emily A.] Univ Calif San Diego, Moores Canc Ctr, Patient & Family Support Serv, Psychiat & Psychosocial Serv, San Diego, CA 92103 USA.
   [Montross-Thomas, Lori P.; Reynolds-Norolahi, Kimberly; Raskin, Erin E.; Slater, Daniel; Mills, Paul J.; Kallenberg, Gene] Univ Calif San Diego, Dept Family Med & Publ Hlth, San Diego, CA 92103 USA.
   [Raskin, Erin E.; Mills, Paul J.; MacElhern, Lauray; Kallenberg, Gene] Univ Calif San Diego, Ctr Integrat Med, San Diego, CA 92103 USA.
   [Reynolds-Norolahi, Kimberly] True Wellness Acupuncture, San Diego, CA USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego
RP Montross-Thomas, LP (corresponding author), Univ Calif San Diego, 9500 Gilman Dr 0664, La Jolla, CA 92093 USA.
EM lpmontross@ucsd.edu
FU Westreich Foundation
FX The authors wish to thank the University of California, San Diego,
   Center for Integrative Medicine Executive Team, and the inpatients who
   graciously participated in this study during their hospital admission.
   We further acknowledge the additional support of Sabina Rea and Tania
   Cisneros in preparation of this article. The Westreich Foundation
   provided funding for this study.
CR Ahles TA, 1999, J PAIN SYMPTOM MANAG, V18, P157, DOI 10.1016/S0885-3924(99)00061-5
   [Anonymous], 2010, 2010 COMPLEMENTARY A
   Boulding W, 2011, AM J MANAG CARE, V17, P41
   Dreyer NE, 2015, COMPLEMENT THER CLIN, V21, P154, DOI 10.1016/j.ctcp.2015.06.004
   Dusek Jeffery A, 2010, J Patient Saf, V6, P48, DOI 10.1097/PTS.0b013e3181d10ad5
   Gardiner P, 2013, J HEALTH COMMUN, V18, P290, DOI 10.1080/10810730.2013.830663
   Horrigan B., 2012, Integrative Medicine in America: How integrative medicine is being practiced in clinical settings across the United States
   Johnson JR, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-486
   Johnson Jill R., 2014, Journal of the National Cancer Institute Monographs, P330, DOI 10.1093/jncimonographs/lgu030
   Kligler B, 2011, AM J MANAG CARE, V17, P779
   Kutner M, 2006, HLTH LITERACY AM ADU
   Lewis Charles R, 2003, Am J Hosp Palliat Care, V20, P221, DOI 10.1177/104990910302000312
   Li L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156076
   Maizes V, 2009, EXPLORE-NY, V5, P277, DOI 10.1016/j.explore.2009.06.008
   Mandel Susan E, 2014, Hosp Top, V92, P28, DOI 10.1080/00185868.2014.906830
   Mann JD., 2004, Integrating Complementary Alternative Therapies with Conventional Care The Convergence of Complementary, Alternative Conventional Health Care
   Newshan Gayle, 2004, Complement Ther Nurs Midwifery, V10, P168, DOI 10.1016/j.ctnm.2004.01.003
   Rhee TG, 2016, COMPLEMENT THER MED, V24, P7, DOI 10.1016/j.ctim.2015.11.002
NR 18
TC 14
Z9 19
U1 1
U2 20
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1075-5535
EI 1557-7708
J9 J ALTERN COMPLEM MED
JI J. Altern. Complement Med.
PD APR
PY 2017
VL 23
IS 4
BP 259
EP 263
DI 10.1089/acm.2016.0288
PG 5
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA ER7ZB
UT WOS:000399033400006
PM 28112554
DA 2026-01-16
ER

PT J
AU Fan, MY
   Liu, AL
   Lu, TY
   Zhou, XW
   Tian, C
   Liu, BQ
   Xie, QW
   Cai, JX
   Yin, LJ
   Ge, L
   Wu, DR
AF Fan, Mingyue
   Liu, Aolin
   Lu, Taoying
   Zhou, Xiaowen
   Tian, Chen
   Liu, Bingqing
   Xie, Qianwen
   Cai, Jianxiong
   Yin, Lingjia
   Ge, Long
   Wu, Darong
TI Quality appraisal of clinical practice guidelines addressing massage
   interventions using the AGREE II instrument
SO SYSTEMATIC REVIEWS
LA English
DT Article
DE Massage; Practice guideline; Consensus; Recommendation; Quality
   assessment; AGREE II
ID CHIROPRACTIC TREATMENT; INTEGRATIVE MEDICINE; THERAPEUTIC MASSAGE;
   MANAGEMENT; PAIN; CANCER; ADULTS; TOOLS
AB Objective The purpose of this study was to systematically evaluate the methodological quality of massage-related clinical practice guidelines (CPGs)/consensus on massage using the Appraisal of Guidelines Research and Evaluation (AGREE II) instrument and to summarize the current status of recommendations in the CPGs.
   Methods The Chinese National Knowledge Infrastructure (CNKI), WanFang Data, China Science and Technology Journal Database (VIP), China Biology Medicine disc (CBM), PubMed, Embase, and guideline websites (such as the Chinese Medical Ace Base, the China Association of Chinese Medicine, the World Health Organization, Guideline International Network, National Institute for Health and Care Excellence, Scottish Intercollegiate Guidelines Network) were searched from inception to October 31, 2022. In addition, the reference lists of relevant studies were reviewed to identify domestic and overseas massage CPGs/consensus. The search terms adopted a combination of subject words and free words, mainly including traditional Chinese medicine, complementary therapies, Tuina, massage, manipulation, chiropractic/osteopathic, spinal, acupressure, guideline, and consensus. Two researchers independently completed the eligible records and extracted the data. Before the formal research, calibrations were performed twice on AGREE II, and all reviewers completed the pilot test three times until they understood and reached an agreement on the assessment items. Three researchers appraised the methodological quality of the included guidelines using the AGREE II instrument and calculated the overall intraclass correlation coefficient (ICC) of agreement.
   Results The evaluation results showed that among the 49 eligible CPGs/consensus, 4 (8.2%) CPGs/consensus were considered "recommended", 15 (30.6%) CPGs/consensus were considered "recommended with modifications", and 30 (61.2%) CPGs/consensus were considered "not recommended", while the consensus was considered "not recommended". Generally, the scores in the six domains of the guidelines were all higher than the consensus. Evaluation results for the overall quality of 36 CPGs showed that 4 (11%) were "good quality", 15 (42%) were "sufficient quality" and 17 (47%) were "lower quality". The AGREE II quality scores of domains ranged from 0.30 to 0.75 ([ICC = 0.993, 95% CI (0.992, 0.995)]). The domain of scope and purpose (domain 1), with a median score of 0.75 (0.52 similar to 0.91), performed best in the guidelines with AGREE II, and stakeholder involvement (domain 2) [median 0.39 (0.31 similar to 0.56)] and application (domain 5) [median 0.30 (0.17 similar to 0.47] obtained lower scores. The consensus score of domain 1 was better at 26.0 (21.6 similar to 44.8), followed by rigor of development (domain 3) with a score of 18.0 (10.0 similar to 28.9). A total of 119 massage-related recommendations were extracted from 49 guidelines/consensuses, including "in favor" (102, 85.7%), "against" (9, 7.6%), and "did not make recommendations" (8, 6.7%).
   Conclusion The overall quality of the included guidelines was low, and most of the guidelines were not "recommended". In future guideline updates, the existing evidence should be used, the professional composition of members of the expert group should be enriched, and patients' values and preferences should be fully considered. It is necessary to clearly propose recognizable recommendations and strengthen the rigor and standardization of guideline formulation. Thus, clear standard guidelines can be formulated to better guide clinical practice.
C1 [Fan, Mingyue; Liu, Aolin; Zhou, Xiaowen; Liu, Bingqing] Guangzhou Univ Chinese Med, Clin Med Coll 2, Guangzhou, Peoples R China.
   [Lu, Taoying; Cai, Jianxiong; Wu, Darong] Guangzhou Univ Chinese Med, State Key Lab Dampness Syndrome Chinese Med, Affiliated Hosp 2, Guangzhou, Peoples R China.
   [Lu, Taoying; Xie, Qianwen; Cai, Jianxiong; Yin, Lingjia; Wu, Darong] Guangdong Prov Hosp Chinese Med, Outcome Assessment Res Team Chinese Med, Guangzhou, Peoples R China.
   [Tian, Chen; Ge, Long] Lanzhou Univ, Sch Publ Hlth, Dept Social Sci & Hlth Management, Lanzhou, Peoples R China.
   [Yin, Lingjia] Karolinska Inst, Stockholm, Sweden.
   [Ge, Long] Key Lab Evidence Based Med & Knowledge Translat Ga, Lanzhou, Peoples R China.
   [Wu, Darong] Guangzhou Univ Chinese Med, Affiliated Hosp 2, Guangdong Prov Key Lab Clin Res Tradit Chinese Med, Guangzhou, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine; Guangzhou University of Chinese Medicine; Lanzhou
   University; Karolinska Institutet; Guangzhou University of Chinese
   Medicine
RP Wu, DR (corresponding author), Guangzhou Univ Chinese Med, State Key Lab Dampness Syndrome Chinese Med, Affiliated Hosp 2, Guangzhou, Peoples R China.; Wu, DR (corresponding author), Guangdong Prov Hosp Chinese Med, Outcome Assessment Res Team Chinese Med, Guangzhou, Peoples R China.; Wu, DR (corresponding author), Guangzhou Univ Chinese Med, Affiliated Hosp 2, Guangdong Prov Key Lab Clin Res Tradit Chinese Med, Guangzhou, Peoples R China.
EM darongwu@gzucm.edu.cn
RI Fang, Mingyue/JWA-3746-2024; Cai, Jianxiong/HTM-3448-2023; Liu,
   Bingqing/E-6932-2015; Ge, Long/G-8876-2017; Tian, Chen/IUN-7982-2023
OI Tian, Chen/0000-0002-2434-4743
FU State Key Laboratory of Dampness Syndrome of Chinese Medicine
   [SZ2021ZZ30/SZ2021ZZ3004]; Guangdong Provincial Key Laboratory of
   Clinical Research on Traditional Chinese Medicine Syndrome [ZH2019ZZ04];
   Wang Lixin Academic Experience Inheritance Studio of Guangdong
   Provincial Hospital of Chinese Medicine
FX This study was supported by the State Key Laboratory of Dampness
   Syndrome of Chinese Medicine (No. SZ2021ZZ30/SZ2021ZZ3004); the
   Guangdong Provincial Key Laboratory of Clinical Research on Traditional
   Chinese Medicine Syndrome (No. ZH2019ZZ04); Wang Lixin Academic
   Experience Inheritance Studio of Guangdong Provincial Hospital of
   Chinese Medicine.
CR Abdulla A, 2013, AGE AGEING, V42, pI1, DOI 10.1093/ageing/afs200
   Airaksinen O, 2006, EUR SPINE J, V15, pS192, DOI 10.1007/s00586-006-1072-1
   Amri MM, 2023, Mesopotamian Journal of Big Data, P70, DOI [10.58496/mjbd/2023/010, 10.58496/MJBD/2023/010, DOI 10.58496/MJBD/2023/010]
   Andrade R, 2020, BRIT J SPORT MED, V54, P512, DOI 10.1136/bjsports-2018-100310
   [Anonymous], 2016, Low Back Pain and Sciatica in Over 16s: Assessment and Management
   Armstrong JJ, 2016, ARCH OSTEOPOROS, V11, DOI 10.1007/s11657-016-0260-9
   Barnes Patricia M, 2008, Natl Health Stat Report, P1
   Beider S, 2007, PEDIATR CLIN N AM, V54, P1025, DOI 10.1016/j.pcl.2007.10.001
   Benjamin P.J., 2005, Tappan's handbook of healing massage techniques, V4th
   Brosseau L, 2012, J BODYW MOV THER, V16, P424, DOI 10.1016/j.jbmt.2012.04.002
   Brosseau L, 2012, J BODYW MOV THER, V16, P300, DOI 10.1016/j.jbmt.2012.04.001
   Brouwers MC, 2019, SEMIN NUCL MED, V49, P145, DOI 10.1053/j.semnuclmed.2018.11.001
   Brouwers MC, 2010, CAN MED ASSOC J, V182, pE839, DOI 10.1503/cmaj.090449
   Brouwers MC, 2010, CAN MED ASSOC J, V182, pE472, DOI 10.1503/cmaj.091716
   Brouwers MC, 2010, CAN MED ASSOC J, V182, P1045, DOI 10.1503/cmaj.091714
   Bryans R, 2014, J MANIP PHYSIOL THER, V37, P42, DOI 10.1016/j.jmpt.2013.08.010
   Bryans R, 2011, J MANIP PHYSIOL THER, V34, P274, DOI 10.1016/j.jmpt.2011.04.008
   Burnett M, 2017, J OBSTET GYNAECOL CA, V39, P585, DOI 10.1016/j.jogc.2016.12.023
   Bussières AE, 2018, J MANIP PHYSIOL THER, V41, P265, DOI 10.1016/j.jmpt.2017.12.004
   Cordeiro Santos Maria Luisa, 2022, World J Clin Pediatr, V11, P105, DOI [10.5409/wjcp.v11.i2.105, 10.5409/wjcp.v11.i2.105]
   Côté P, 2019, EUR J PAIN, V23, P1051, DOI 10.1002/ejp.1374
   Côté P, 2016, EUR SPINE J, V25, P2000, DOI 10.1007/s00586-016-4467-7
   Deng GE, 2013, CHEST, V143, pE420, DOI 10.1378/chest.12-2364
   Devlin J, 2019, CRIT CARE MED, V47
   Pereira PADD, 2021, COMPLEMENT THER MED, V61, DOI 10.1016/j.ctim.2021.102774
   Feehan J, 2022, INT J OSTEOPATH MED, V43, P53, DOI 10.1016/j.ijosm.2021.12.003
   Field TM, 1998, AM PSYCHOL, V53, P1270, DOI 10.1037/0003-066X.53.12.1270
   [葛龙 Ge Long], 2021, [中国循证医学杂志, Chinese Journal of Evidence-Based Medicine], V21, P745
   Globe G, 2016, J MANIP PHYSIOL THER, V39, P1, DOI 10.1016/j.jmpt.2015.10.006
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Guy SD, 2016, SPINAL CORD, V54, pS14, DOI 10.1038/sc.2016.90
   Hawk C, 2020, J ALTERN COMPLEM MED, V26, P884, DOI 10.1089/acm.2020.0181
   Hui D, 2021, J CLIN ONCOL, V39, P1389, DOI 10.1200/JCO.20.03465
   International Traditional Chinese Medicine Rapid Guideline Working Group, 2022, J TRADIT CHIN MED, V63, P1295, DOI [10.13288/j.11-2166/r.2022.13.018, DOI 10.13288/J.11-2166/R.2022.13.018]
   Johnston A, 2019, J CLIN EPIDEMIOL, V108, P64, DOI 10.1016/j.jclinepi.2018.11.030
   Kopf D, 2021, Z GERONTOL GERIATR, V54, P753, DOI 10.1007/s00391-021-01995-4
   Li XL, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-3200
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Messina C, 2017, INSIGHTS IMAGING, V8, P311, DOI 10.1007/s13244-017-0553-6
   National Institute for Health and Care Excellence, Low back pain and sciatica in over 16s: assessment and management (NG59).2016
   National Institute for Health and Care Excellence, ATOPIC ECZEMA 12S DI
   Ng JY, 2023, INTEGR MED RES, V12
   Ng JY, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1410-8
   Professional Committee of Spine Medicine of Chinese Association of Integrated Traditional and Western Medicine, 2020, Zhongguo Gu Shang, V33, P27, DOI 10.3969/j.issn.1003-0034.2020.01.006
   Qaseem A, 2021, ANN INTERN MED, V174, pW116, DOI 10.7326/L21-0607
   Shirado O, 2022, J ORTHOP SCI, V27, P3, DOI 10.1016/j.jos.2021.06.024
   SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420
   Tan JY, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.866284
   Wang G, 2022, COMPLEMENT THER MED, V70, DOI 10.1016/j.ctim.2022.102861
   Wang Y.G., 2013, J. Guangzhou Univ. Tradit. Chin. Med., V15, P60, DOI DOI 10.13194/J.JLUNIVTCM.2013.08.62.WANGYG.051
   Wickham H., 2016, ggplot2: elegant graphics for data analysis, DOI [DOI 10.1007/978-3-319-24277-4, 10.1007/978-3-319-24277-4]
   Xie Li-min, 2012, Zhong Xi Yi Jie He Xue Bao, V10, P160
NR 64
TC 2
Z9 2
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2046-4053
J9 SYST REV-LONDON
JI Syst. Rev.
PD MAR 8
PY 2024
VL 13
IS 1
AR 83
DI 10.1186/s13643-024-02503-6
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA KP4V2
UT WOS:001181166100001
PM 38459534
OA Green Submitted, gold
DA 2026-01-16
ER

PT J
AU Turawa, EB
   Musekiwa, A
   Rohwer, AC
AF Turawa, Eunice B.
   Musekiwa, Alfred
   Rohwer, Anke C.
TI Interventions for preventing postpartum constipation
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE Constipation [*prevention & control]; Dietary Fiber [*therapeutic use];
   Laxatives [*therapeutic use]; Perineum [injuries]; *Postpartum Period;
   Randomized Controlled Trials as Topic; Adult; Female; Humans
ID MATERNAL HEALTH; CLINICAL-TRIAL; PRIMARY REPAIR; EPIDEMIOLOGY;
   PREVALENCE; SYMPTOMS; WOMEN
AB Background
   Postpartum constipation, with symptoms, such as pain or discomfort, straining, and hard stool, is a common condition affecting mothers. Haemorrhoids, pain at the episiotomy site, effects of pregnancy hormones, and haematinics used in pregnancy can increase the risk of postpartum constipation. Eating a high-fibre diet and increasing fluid intake are usually encouraged. Although laxatives are commonly used in relieving constipation, the effectiveness and safety of available interventions for preventing postpartum constipation should be ascertained. This is an update of a review first published in 2015.
   Objectives
   To evaluate the effectiveness and safety of interventions for preventing postpartum constipation.
   Search methods
   We searched Cochrane Pregnancy and Childbirth's Trials Register, and two trials registers ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP) (7 October 2019), and screened reference lists of retrieved trials.
   Selection criteria
   We considered all randomised controlled trials (RCTs) comparing any intervention for preventing postpartum constipation versus another intervention, placebo, or no intervention in postpartum women. Interventions could include pharmacological (e.g. laxatives) and non-pharmacological interventions (e.g. acupuncture, educational and behavioural interventions). Quasi-randomised trials and cluster-RCTs were eligible for inclusion; none were identified. Trials using a cross-over design were not eligible.
   Data collection and analysis
   Two review authors independently screened the results of the search to select potentially relevant trials, extracted data, assessed risk of bias, and the certainty of the evidence, using the GRADE approach. We did not pool results in a meta-analysis, but reported them per study.
   Main results
   We included five trials (1208 postpartum mothers); three RCTs and two quasi-RCTs. Four trials compared a laxative with placebo; one compared a laxative plus a bulking agent versus the same laxative alone, in women who underwent surgical repair of third degree perineal tears. Trials were poorly reported, and four of the five trials were published over 40 years ago. We judged the risk of bias to be unclear for most domains. Overall, we found a high risk of selection and attrition bias.
   Laxative versus placebo
   We included four triaLs in this comparison. Two of the trials examined the effects of Laxatives that are no Longer used; one has been found to have carcinogenic properties (Danthron), and the other is not recommended for lactating women (Bisoxatin acetate); therefore, we did not include their results in our main findings.
   None of the trials included in this comparison assessed our primary outcomes: pain or straining on defecation, incidence of postpartum constipation, or quality of life; or many of our secondary outcomes.
   A laxative (senna) may increase the number of women having their first bowel movement within 24 hours after delivery (risk ratio (RR) 2.90, 95% confidence interval (CI) 2.24 to 3.75; 1 trial, 471 women; low-certainty evidence); may have little or no effect on the number of women having their first bowel movement on day one after delivery (RR 0.94, 95% CI 0.72 to 1.22; 1 trial, 471 women; very low-certainty evidence); may reduce the number of women having their first bowel movement on day two (RR 0.23, 95% CI 0.11 to 0.45; 1 trial, 471 women; low-certainty evidence); and day three (RR 0.05, 95% CI 0.00 to 0.89; 1 trial, 471 women; low-certainty evidence); and may have litte or no effect on the number of women having their first bowel movement on day four after delivery (RR 0.22, 95% CI 0.03 to 1.87; 1 trial, 471 women; very low-certainty evidence), but some of the evidence is very uncertain.
   Adverse effects were poorly reported. Low-certainty evidence suggests that the laxative (senna) may increase the number of women experiencing abdominal cramps (RR 4.23, 95% CI 1.75 to 10.19; 1 trial, 471 women). Very low-certainty evidence suggests that laxatives taken by the mother may have little or no effect on Loose stooLs in the baby (RR 0.62, 95% CI 0.16 to 2.41; 1 triaL, 281 babies); or diarrhoea (RR 2.46, 95% CI 0.23 to 26.82; 1 trial, 281 babies).
   Laxative plus bulking agent versus laxative only
   Very Low-certainty evidence from one trial (147 women) suggests no evidence of a difference between these two groups of women who underwent surgical repair of third degree perineal tears; only median and range data were reported. The trial also reported no evidence of a difference in the incidence of postpartum constipation (data not reported), but did not report on quality of life. Time to first bowel movement was reported as a median (range); very low-certainty evidence suggests little or no difference between the two groups. A laxative plus bulking agent may increase the number of women having any episode of faecal incontinence during the first 10 days postpartum (RR 1.81, 95% CI 1.01 to 3.23; 1 trial, 147 women; very low-certainty evidence). The trial did not report on adverse effects of the intervention on babies, or many of our secondary outcomes.
   Authors' conclusions
   There is insufficient evidence to make general conclusions about the effectiveness and safety of laxatives for preventing postpartum constipation. The evidence in this review was assessed as low to very low-certainty evidence, with downgrading decisions based on limitations in study design, indirectness and imprecision.
   We did not identify any trials assessing educational or behavioural interventions. We identified four trials that examined laxatives versus placebo, and one that examined laxatives versus laxatives plus stool bulking agents.
   Further, rigorous trials are needed to assess the effectiveness and safety of laxatives during the postpartum period for preventing constipation. Trials shouLd assess educationaL and behavioural interventions, and positions that enhance defecation. They should report on the primary outcomes from this review: pain or straining on defecation, incidence of postpartum constipation, quality of life, time to first bowel movement after delivery, and adverse effects caused by the intervention, such as: nausea or vomiting, pain, and flatus.
C1 [Turawa, Eunice B.] Stellenbosch Univ, Fac Med & Hlth Sci, Dept Global Hlth, Div Hlth Syst & Publ Hlth, Cape Town, South Africa.
   [Turawa, Eunice B.] South African Med Res Council, Burden Dis Res Unit, Cape Town, South Africa.
   [Musekiwa, Alfred] Stellenbosch Univ, Fac Med & Hlth Sci, Ctr Evidence Based Hlth Care, Div Epidemiol & Biostat, Cape Town, South Africa.
   [Rohwer, Anke C.] Stellenbosch Univ, Fac Med & Hlth Sci, Ctr Evidence Based Hlth Care, Cape Town, South Africa.
C3 Stellenbosch University; South African Medical Research Council;
   Stellenbosch University; Stellenbosch University
RP Turawa, EB (corresponding author), Stellenbosch Univ, Fac Med & Hlth Sci, Dept Global Hlth, Div Hlth Syst & Publ Hlth, Cape Town, South Africa.; Turawa, EB (corresponding author), South African Med Res Council, Burden Dis Res Unit, Cape Town, South Africa.
EM kbolanle@gmail.com
RI ; Musekiwa, Alfred/IUP-3659-2023; Turawa, Eunice/GSN-2063-2022
OI Rohwer, Anke/0000-0002-1092-5942; Musekiwa, Alfred/0000-0001-5880-3680; 
FU National Institute for Health Research (NIHR) Cochrane Review Incentive
   Scheme award, UK [14/175/47]; Research, Evidence and Development
   Initiative (READ-It) project, UK
FX National Institute for Health Research (NIHR) Cochrane Review Incentive
   Scheme award, UKAward number 14/175/47Research, Evidence and Development
   Initiative (READ-It) project, UK
CR Aksu S, 2017, CONTEMP NURSE, V53, P167, DOI 10.1080/10376178.2016.1258315
   Alonso-Coello P, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004649.pub2
   Andrews Christopher N, 2011, Can J Gastroenterol, V25 Suppl B, p16B
   [Anonymous], MED J MALAYSIA
   [Anonymous], 2009, BMJ-BRIT MED J, V6, pe1000097, DOI [DOI 10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, DOI 10.1371/JOURNAL.PMED.1000097]
   [Anonymous], 2014, DIOCTYL SULFOSUCCINA
   [Anonymous], 2015, GRADEPRO GDT
   [Anonymous], 2014, Review Manager (RevMan) Version 5.3
   [Anonymous], 1998, Maternal and Newborn Health/Safe Motherhood Unit: Postpartum Care of the Mother and Newborn: A Practical Guide: Report of a Technical Working Group
   [Anonymous], 2002, BREASTF MAT MED REC
   [Anonymous], J GASTROENTEROLOGY H
   Balch P.A., 2010, Prescription for Nutritional Healing
   BARTH JH, 1984, CLIN EXP DERMATOL, V9, P95, DOI 10.1111/j.1365-2230.1984.tb00763.x
   Borders N, 2006, J MIDWIFERY WOM HEAL, V51, P242, DOI 10.1016/j.jmwh.2005.10.014
   Brown S, 1998, BRIT J OBSTET GYNAEC, V105, P156, DOI 10.1111/j.1471-0528.1998.tb10045.x
   Candy B, 2011, SAO PAULO MED J, V129, P277, DOI 10.1002/14651858.CD003448.pub3
   Cappell J, 2017, MIDWIFERY, V50, P125, DOI 10.1016/j.midw.2017.04.002
   Cheng CY, 2006, J PERINAT EDUC, V15, P34, DOI 10.1624/105812406X119002
   Davies GAL, 2003, CAN J APPL PHYSIOL, V28, P329, DOI 10.1139/h03-024
   De Groot N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202960
   DIAMOND RA, 1968, J LANCET, V88, P16
   Drossman DA, 2016, GASTROENTEROLOGY, V150, P1262, DOI 10.1053/j.gastro.2016.02.032
   Eogan M, 2007, BJOG-INT J OBSTET GY, V114, P736, DOI 10.1111/j.1471-0528.2007.01331.x
   Fakheri RJ, 2019, J HOSP MED, V14, P110, DOI 10.12788/jhm.3124
   Gordon M, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009118.pub2
   Gözüm S, 2005, MIDWIFERY, V21, P371, DOI 10.1016/j.midw.2005.02.005
   Higgins JP GS., 2011, COCHRANE HDB SYSTEMA, V4, p9.5.2, DOI DOI 10.1002/9780470712184
   Higgins PDR, 2004, AM J GASTROENTEROL, V99, P750, DOI 10.1111/j.1572-0241.2004.04114.x
   Kabakian-Khasholian T, 2014, WOMEN BIRTH, V27, P15, DOI 10.1016/j.wombi.2013.02.002
   Lee-Robichaud H, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007570.pub2
   Lewis SJ, 1997, SCAND J GASTROENTERO, V32, P920, DOI 10.3109/00365529709011203
   Lin LW, 2009, J ALTERN COMPLEM MED, V15, P1335, DOI 10.1089/acm.2008.0373
   Liu N, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-45
   MACARTHUR C, 1991, BRIT J OBSTET GYNAEC, V98, P1193, DOI 10.1111/j.1471-0528.1991.tb15386.x
   MacMillan TE, 2016, AM J MED, V129, DOI 10.1016/j.amjmed.2016.04.008
   Mahony R, 2004, DIS COLON RECTUM, V47, P12, DOI 10.1007/s10350-003-0009-6
   Mahony Rhona, 2002, American Journal of Obstetrics and Gynecology, V187, pS166
   Mottola Michelle F, 2002, Curr Sports Med Rep, V1, P362, DOI 10.1249/00149619-200212000-00010
   Mugie SM, 2011, BEST PRACT RES CL GA, V25, P3, DOI 10.1016/j.bpg.2010.12.010
   MUNDOW L, 1975, BRIT J CLIN PRACT, V29, P95
   National Institute of Health: National Institute of Diabetes and Digestive and Kidney Diseases (NIH-NIDDK), 2018, CONSTIPATION
   National Toxicology Program, REP CARC DANTHR 14 R
   Omega Pharma Blegium NV. Wylaxine, 2016, SUMMARY PRODUCT CHAR
   Peppas G, 2008, BMC GASTROENTEROL, V8, DOI 10.1186/1471-230X-8-5
   Schmidt FMQ, 2014, J WOUND OSTOMY CONT, V41, P70, DOI 10.1097/01.WON.0000438019.21229.b7
   Ramkumar D, 2005, AM J GASTROENTEROL, V100, P936, DOI 10.1111/j.1572-0241.2005.40925.x
   Romano Mattea, 2010, J Prenat Med, V4, P22
   Rungsiprakarn Phassawan, 2015, Cochrane Database Syst Rev, pCD011448, DOI 10.1002/14651858.CD011448.pub2
   Sakai T, 2015, BENEF MICROBES, V6, P253, DOI 10.3920/BM2014.0076
   Schunemann H., 2013, HDB GRADING QUALITY
   SHELTON MG, 1980, S AFR MED J, V57, P78
   Sunitha D, 2016, Asian Journal of Pharmaceutical Research, V6, P205, DOI [10.5958/2231-5691.2016.00029.0, 10.5958/2231-5691.2016.00029.0, DOI 10.5958/2231-5691.2016.00029.0]
   Turawa EB, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010273.pub2
   van Brummen HJ, 2006, INT UROGYNECOL J, V17, P224, DOI 10.1007/s00192-005-1351-0
   World Health Organization, WHO technical consultation on postpartum and postnatal care
   Xing JH, 2001, DIS COLON RECTUM, V44, P1201, DOI 10.1007/BF02234645
   ZUSPAN FP, 1960, AM J OBSTET GYNECOL, V80, P548
NR 57
TC 10
Z9 13
U1 4
U2 39
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2020
IS 8
AR CD011625
DI 10.1002/14651858.CD011625.pub3
PG 46
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA NN3IF
UT WOS:000568684200041
PM 32761813
DA 2026-01-16
ER

PT J
AU Schiller, DS
   Parikh, A
AF Schiller, Daryl S.
   Parikh, Ashish
TI Identification, Pharmacologic Considerations, and Management of
   Prostatitis
SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY
LA English
DT Review
DE Bacterial prostatitis; chronic prostatitis; NIH-CPSI; prostatitis
ID PELVIC PAIN SYNDROME; INSTITUTES-OF-HEALTH; COMMUNITY-BASED COHORT;
   DOUBLE-BLIND; NONBACTERIAL PROSTATITIS; SYMPTOM INDEX; MEN; THERAPY;
   CIPROFLOXACIN; PREVALENCE
AB Background: Prostatitis is a collection of signs and symptoms that occur as a result of inflammation or swelling of the prostate gland. There are many different causes for prostatitis, including infection; occasionally no clear etiology for the inflammation is found. Effective treatment often depends on identification of the cause, but a microbiologic organism is not always detectable, especially in cases of chronic prostatitis.
   Objective: The aim of this article was to review identification and treatment options for prostatitis, including pharmacologic and nonpharmacologic interventions.
   Methods: Relevant information was identified through a search of MEDLINE (1966 June 2010), International Pharmaceutical Abstracts (1970 June 2010), and EMBASE (1947 June 2010). Randomized, controlled trials that examined prostate cancer, benign prostatic hypertrophy, or procedures related to the prostate (ie, biopsies) were excluded.
   Results: A working classification system for prostatitis was developed in 1999, but there are few randomized controlled trials that distinguish between the various treatment options. Bacterial prostatitis can be acute or chronic but always requires some degree of antimicrobial therapy. Pharmacologic features of fluoroquinolones make them the preferred agents for most patients. These antibiotics can become trapped in a chronically inflamed prostate due to pH differences between prostatic tissue and serum. Many fluoroquinolones have penetration ratios (prostate level:serum level) of up to 4:1. A study in European men (N = 117) who received levofloxacin 500 mg/d with a diagnosis of chronic bacterial prostatitis demonstrated clinical success rates of 92% (95% CI 84.8%-96.5%), 77.4% (95% CI, 68.2-84.9%), 66.0% (95% CI, 56.2%-75.0%), and 61.9% (95% CI, 51.9%-71.2%) at 5-12 days, 1 month, 3 months, and 6 months after treatment. Additionally, there have been numerous randomized, placebo-controlled trials in patients with chronic prostatitis that have studied alpha-blockers, steroid inhibitors, anti-inflammatory agents, and bioflavonoids. Treatment responses to a-blockers appear to be greater with longer durations of therapy in a-blocker nave patients (National Institutes of Health-Chronic Prostatitis Symptom Index [NIH-CPSI] score reduction of at least 3.6 points after 6 weeks of tamsulosin therapy [P = 0.04] and up to 14.3 and 9.9 point NIH-CPSI score reductions with 14 weeks of terazosin and 24 weeks of alfuzosin therapy, respectively [P = 0.01 for both]). Combination therapy with an a-blocker, an anti-inflammatory, and a muscle relaxant does not appear to offer significant advantages over monotherapy (12.7 vs 12.4 point reduction in NIH-CPSI scores) and a stepwise approach to therapy involving antibiotics followed by bioflavonoids and then a-blockers appears to effectively reduce symptoms for up to 1 year in patients with chronic prostatitis (mean NIH-CPSI point reduction of 9.5 points compared with baseline, P < 0.0001). Patients who have had multiple unsuccessful treatment regimens may benefit from direct stimulation of the pelvic muscles through electromagnetic or electroacupuncture therapy.
   Conclusions: Prostatitis can resemble various other medical conditions but proper classification and an understanding of the pharmacologic features and expectations of the medications used to treat it can help identify effective treatment strategies. Fluoroquinolones are the preferred agents for treating bacterial causes of prostatitis and have demonstrated efficacy in some cases of chronic prostatitis when an organism has not been identified. However, the use of agents with anti-inflammatory or antiadrenergic properties may be necessary in combination with or after trying antimicrobial agents. (Am J Geriatr Pharmacother. 2011;9:37-48) (C) 2011 Elsevier HS Journals, Inc. All rights reserved.
C1 [Schiller, Daryl S.] St Barnabas Hosp, Dept Pharm, BCPS ID, Livingston, NJ 07039 USA.
   [Parikh, Ashish] St Barnabas Hosp, Dept Med, Livingston, NJ 07039 USA.
RP Schiller, DS (corresponding author), St Barnabas Hosp, Dept Pharm, BCPS ID, 94 Old Short Hills Rd, Livingston, NJ 07039 USA.
EM dschiller@sbhcs.com
CR Alexander RB, 2004, ANN INTERN MED, V141, P581, DOI 10.7326/0003-4819-141-8-200410190-00005
   Barbalias G A, 1998, Int J Urol, V5, P157, DOI 10.1111/j.1442-2042.1998.tb00267.x
   BARZA M, 1984, EUR J CLIN MICROBIOL, V3, P503, DOI 10.1007/BF02013607
   Bundrick W, 2003, UROLOGY, V62, P537, DOI 10.1016/S0090-4295(03)00565-X
   Charalabopoulos K, 2003, CHEMOTHERAPY, V49, P269, DOI 10.1159/000074526
   Cheah PY, 2003, J UROLOGY, V169, P592, DOI 10.1016/S0022-5347(05)63960-2
   Cheah PY, 2003, UROLOGY, V61, P60, DOI 10.1016/S0090-4295(02)02081-2
   Chen R, 2003, UROLOGY, V61, P1156, DOI 10.1016/S0090-4295(03)00141-9
   Cho YH, 2002, INT J ANTIMICROB AG, V19, P576, DOI 10.1016/S0924-8579(02)00115-2
   Clemens JQ, 2007, J UROLOGY, V178, P1333, DOI 10.1016/j.juro.2007.05.140
   Clemens JQ, 2006, J UROLOGY, V176, P593, DOI 10.1016/j.juro.2006.03.089
   Collins MM, 1998, J UROLOGY, V159, P1224, DOI 10.1016/S0022-5347(01)63564-X
   CUNHA BA, 1983, B NEW YORK ACAD MED, V59, P443
   Daniels NA, 2005, UROLOGY, V66, P964, DOI 10.1016/j.urology.2005.05.034
   Drusano GL, 2000, ANTIMICROB AGENTS CH, V44, P2046, DOI 10.1128/AAC.44.8.2046-2051.2000
   Etienne M, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-12
   FitzGerald MP, 2009, J UROLOGY, V182, P570, DOI 10.1016/j.juro.2009.04.022
   GOURTSOYIANNIS N, 1990, AM J ROENTGENOL, V155, P541, DOI 10.2214/ajr.155.3.2117353
   KIRBY RS, 1982, BRIT J UROL, V54, P729, DOI 10.1111/j.1464-410X.1982.tb13635.x
   KRIEGER JN, 1984, SEX TRANSM DIS, V11, P100, DOI 10.1097/00007435-198404000-00011
   Krieger JN, 1999, JAMA-J AM MED ASSOC, V282, P236, DOI 10.1001/jama.282.3.236
   Krieger JN, 2008, INT J ANTIMICROB AG, V31, pS85, DOI 10.1016/j.ijantimicag.2007.08.028
   Le BV, 2009, UROL CLIN N AM, V36, P527, DOI 10.1016/j.ucl.2009.08.005
   Lee SH, 2009, UROLOGY, V73, P1036, DOI 10.1016/j.urology.2008.10.047
   Lipsky BA, 2010, CLIN INFECT DIS, V50, P1641, DOI 10.1086/652861
   Litwin MS, 1999, J UROLOGY, V162, P369, DOI 10.1016/S0022-5347(05)68562-X
   Litwin MS, 2002, UROLOGY, V60, P6
   Lugg J, 2008, J CHEMOTHERAPY, V20, P213, DOI 10.1179/joc.2008.20.2.213
   Mehik A, 2000, BJU INT, V86, P443, DOI 10.1046/j.1464-410X.2000.00836.x
   Mehik A, 2003, UROLOGY, V62, P425, DOI 10.1016/S0090-4295(03)00466-7
   MONTORSI F, 1995, J ENDOUROL, V9, P333, DOI 10.1089/end.1995.9.333
   Naber KG, 2008, INT J ANTIMICROB AG, V32, P145, DOI 10.1016/j.ijantimicag.2008.03.014
   Nadler RB, 2002, UROLOGY, V60, P42, DOI 10.1016/S0090-4295(02)02390-7
   Netter F.H., 2010, ATLAS HUMAN ANATOMY
   Nickel J C, 1997, Tech Urol, V3, P38
   Nickel J Curtis, 2005, Rev Urol, V7, P65
   Nickel JC, 2008, NEW ENGL J MED, V359, P2663, DOI 10.1056/NEJMoa0803240
   Nickel JC, 2004, BJU INT, V93, P991, DOI 10.1111/j.1464-410X.2003.04766.x
   Nickel JC, 2004, J UROLOGY, V171, P1594, DOI 10.1097/01.ju.0000117811.40279.19
   Nickel JC, 2003, J UROLOGY, V169, P1401, DOI 10.1097/01.ju.0000054983.45096.16
   Nickel JC, 1996, J UROLOGY, V155, P1950, DOI 10.1016/S0022-5347(01)66056-7
   Olyaei AJ, 2009, CLIN GERIATR MED, V25, P459, DOI 10.1016/j.cger.2009.04.004
   Özden E, 2009, UROLOGY, V74, P119, DOI 10.1016/j.urology.2008.12.067
   Persson BE, 1996, J UROLOGY, V155, P958, DOI 10.1016/S0022-5347(01)66357-2
   Pontari MA, 2007, J UROLOGY, V177, P2050, DOI 10.1016/j.juro.2007.01.128
   Potts Jeannette, 2007, Cleve Clin J Med, V74 Suppl 3, pS63
   Propert KJ, 2006, QUAL LIFE RES, V15, P299, DOI 10.1007/s11136-005-1317-1
   Roberts RO, 2002, J UROLOGY, V168, P2467, DOI 10.1016/S0022-5347(05)64170-5
   ROSS DL, 1990, INT J PHARMACEUT, V63, P237, DOI 10.1016/0378-5173(90)90130-V
   Rowe E, 2005, J UROLOGY, V173, P2044, DOI 10.1097/01.ju.0000158445.68149.38
   Shoskes D A, 2001, Can J Urol, V8 Suppl 1, P24
   Shoskes DA, 1999, UROLOGY, V54, P960, DOI 10.1016/S0090-4295(99)00358-1
   Shoskes DA, 2003, J UROLOGY, V169, P1406, DOI 10.1097/01.ju.0000055549.95490.3c
   Skerk V, 2003, INT J ANTIMICROB AG, V21, P457, DOI 10.1016/S0924-8579(03)00056-6
   Stahlmann R, 2010, DRUG AGING, V27, P193, DOI 10.2165/11531490-000000000-00000
   Taylor BC, 2008, AM J MED, V121, P444, DOI 10.1016/j.amjmed.2008.01.043
   THIN RNT, 1974, BRIT J VENER DIS, V50, P370
   Tugcu V, 2007, EUR UROL, V51, P1113, DOI 10.1016/j.eururo.2006.09.036
   Tunuguntla HSGR, 2002, PROSTATE CANCER P D, V5, P172, DOI 10.1038/sj.pcan.4500604
   Turner JA, 2004, J UROLOGY, V172, P538, DOI 10.1097/01.ju.0000132797.63480.44
   Vykhovanets EV, 2009, PROSTATE, V69, P633, DOI 10.1002/pros.20916
   Wagenlehner FME, 2006, J CHEMOTHERAPY, V18, P485, DOI 10.1179/joc.2006.18.5.485
   Wagenlehner FME, 2007, EXPERT OPIN PHARMACO, V8, P1667, DOI 10.1517/14656566.8.11.1667
   WISEMAN LR, 1994, DRUG AGING, V4, P145, DOI 10.2165/00002512-199404020-00007
   Yavasçaoglu I, 1999, INT J UROL, V6, P130, DOI 10.1046/j.1442-2042.1999.06338.x
   Ye ZQ, 2003, ASIAN J ANDROL, V5, P155
   Zhao WP, 2009, BRAZ J MED BIOL RES, V42, P963, DOI 10.1590/S0100-879X2009005000021
NR 67
TC 9
Z9 11
U1 0
U2 20
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 1543-5946
J9 AM J GERIATR PHARMAC
JI Am. J. Geriatr. Pharmacother.
PD FEB
PY 2011
VL 9
IS 1
BP 37
EP 48
DI 10.1016/j.amjopharm.2011.02.005
PG 12
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 754PA
UT WOS:000289866600004
PM 21459307
DA 2026-01-16
ER

EF